BBF11_Profiles_O-Z_P..
BBF11_Profiles_O-Z_P..
BBF11_Profiles_O-Z_P..
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
NOTES<br />
The information in this book was obtained from the attending companies. The<br />
Biotechnology Industry Organization (BIO) does not guarantee that the information is<br />
complete or accurate, and does not warrant the information for a particular use or purpose.<br />
A number of the Presenting Companies may be clients of the Conference Sponsors or may be<br />
members of BIO.<br />
<strong>Profiles</strong> of all companies participating in the Business Forum may be accessed online at the<br />
computers located in the Business Forum. The online set of profiles may contain additional<br />
profiles and data that were not available at press time for this book.<br />
BIO Business Forum 2011 i Participating Company <strong>Profiles</strong>
TABLE OF CONTENTS<br />
OCT Group LLC .......................................................................... 1<br />
OctoPlus N.V. ............................................................................ 2<br />
Odan Laboratories Ltd ........................................................... 3<br />
Odyssey Thera, Inc ................................................................... 4<br />
Omeros Corporation .............................................................. 6<br />
Omnia Molecular S.L. ............................................................. 7<br />
OMT, Inc. .................................................................................... 8<br />
Oncodesign SA ......................................................................... 9<br />
Oncolytics Biotech Inc. ......................................................... 10<br />
Oncomedics ............................................................................ 12<br />
One Nucleus Ltd..................................................................... 13<br />
One Way Liver Genomics (OWL) ....................................... 14<br />
Ono Pharmaceutical Co. Ltd. .............................................. 15<br />
Ontario Institute for Cancer Research (OICR) ............... 16<br />
Opexa Therapeutics ............................................................. 17<br />
Ora ............................................................................................ 19<br />
Oramed Pharmaceuticals ................................................... 20<br />
Orasi Medical.......................................................................... 21<br />
Orbis Biosciences ................................................................... 23<br />
ORCA Therapeutics ............................................................... 24<br />
Orchid Chemicals & Pharmaceuticals Ltd ...................... 25<br />
Organovo, Inc. ........................................................................ 27<br />
OriGene Technologies, Inc .................................................. 28<br />
Orion Corporation ................................................................. 30<br />
Orphagen Pharmaceuticals, Inc ........................................ 31<br />
Orphan Europe ...................................................................... 32<br />
Oryzon Genomics, S.A. ......................................................... 33<br />
Osaka Bio Headquarters - Osaka Prefectural<br />
Government .................................................................... 35<br />
Osaka University ................................................................... 36<br />
Oscotec Inc. ............................................................................. 38<br />
Otago Innovation Limited .................................................. 39<br />
Otsuka Pharmaceutical Co., Ltd. ....................................... 40<br />
Ovizio Imaging Systems ...................................................... 41<br />
Oxeltis ....................................................................................... 42<br />
Oxford Finance LLC ............................................................... 43<br />
Oxford Gene Technology..................................................... 44<br />
Ozmosis Research Inc. .......................................................... 45<br />
Pacific Biomarkers, Inc. ........................................................ 46<br />
Pacific Biosciences ................................................................. 47<br />
Pacific Edge Ltd ...................................................................... 48<br />
PACT & PARTNERS Executive Search In Life Sciences .. 50<br />
PAION AG ................................................................................. 51<br />
Paladin Biosciences .............................................................. 52<br />
PALAU PHARMA, S.A. ............................................................. 53<br />
Palobiofarma .......................................................................... 55<br />
Pamlico Pharmaceutical, Inc ............................................. 56<br />
Paragon Bioservices, Inc ...................................................... 57<br />
Paratek Pharmaceuticals, Inc ............................................ 58<br />
Parco Tecnologico Padano Foundation .......................... 59<br />
Paris Region Economic Development Agency ............... 60<br />
Partner International ........................................................... 61<br />
Partners HealthCare System, Inc ...................................... 62<br />
Partners In Pharma LLC ........................................................ 63<br />
PATH .......................................................................................... 64<br />
Patheon, Inc ............................................................................ 65<br />
Pathway Therapeutics, Inc.................................................. 66<br />
PATRADE A/S ........................................................................... 67<br />
Paul Capital ............................................................................. 68<br />
PCI Biotech ............................................................................... 69<br />
Pearl Therapeutics, Inc ......................................................... 70<br />
Pearne & Gordon LLP ............................................................ 71<br />
Peira .......................................................................................... 72<br />
Pepscan Therapeutics NV ................................................... 73<br />
Peptisyntha SA ....................................................................... 74<br />
Peregrine Pharmaceuticals, Inc ......................................... 75<br />
Pergamum AB ........................................................................ 77<br />
Pervasis Therapeutics .......................................................... 78<br />
Pfizer Inc ................................................................................... 79<br />
PHACT ....................................................................................... 80<br />
Pharmaceutics International, Inc ..................................... 81<br />
Pharmacision LLC .................................................................. 82<br />
PharmacoFore, Inc ................................................................. 83<br />
PharmaDirections, Inc. ........................................................ 85<br />
PharmaHungary .................................................................... 86<br />
PharmaMar ............................................................................. 88<br />
PharmaNet Inc ....................................................................... 90<br />
Pharmascience ....................................................................... 91<br />
Pharmatek Laboratories, Inc. ............................................. 92<br />
PharmaVentures, Ltd ........................................................... 93<br />
Pharmaxon .............................................................................. 94<br />
Pharming Group N.V. ........................................................... 96<br />
Phasebio Pharmaceuticals Inc. .......................................... 97<br />
PhaseRx, Inc. ........................................................................... 98<br />
Phenopro Sas .......................................................................... 99<br />
Phigenix, Inc. ........................................................................ 100<br />
Philogen S.p.A. ..................................................................... 101<br />
Phoenix Pharmalabs, Inc .................................................. 102<br />
Phrixus Pharmaceuticals, Inc .......................................... 104<br />
Phylogica Ltd ........................................................................ 106<br />
PHYSIOMICS PLC.................................................................. 107<br />
Pieris AG ................................................................................ 108<br />
PIERRE FABRE MEDICAMENT ............................................ 109<br />
Pipeline Biotech A/s ........................................................... 110<br />
PLANTFORM ......................................................................... 111<br />
Plasticell Limited ................................................................ 113<br />
Pluristem Therapeutics, Inc ............................................ 114<br />
Polaris Technology Inc. ..................................................... 116<br />
Polybatics .............................................................................. 117<br />
PolyMedix, Inc ..................................................................... 118<br />
PolyPeptide Group ............................................................. 120<br />
Polyphor Ltd ......................................................................... 121<br />
Polyplus Transfection........................................................ 123<br />
POLYTHERICS LIMITED ....................................................... 125<br />
Population Genetics Technologies ................................ 126<br />
Porsolt .................................................................................... 128<br />
BIO Business Forum 2011 iii Participating Company <strong>Profiles</strong>
Positively Minnesota ......................................................... 129<br />
POXEL ..................................................................................... 131<br />
PPM Oost NV ........................................................................ 132<br />
Precision Antibody ............................................................. 133<br />
Precision Biosciences ......................................................... 134<br />
Preclin Biosystems AG ....................................................... 135<br />
Premacure AB ...................................................................... 136<br />
Prestwick Chemical ............................................................ 137<br />
PRMA Consulting ................................................................ 138<br />
ProBioGen AG ...................................................................... 139<br />
Procognia .............................................................................. 141<br />
PROGE FARM S.r.L. .............................................................. 143<br />
ProGenosis ........................................................................... 144<br />
Progenra, Inc ........................................................................ 145<br />
ProImmune Limited .......................................................... 147<br />
PROLOR Biotech, Inc ........................................................... 148<br />
Promosome, LLC .................................................................. 150<br />
ProPharma Partners Ltd ................................................... 151<br />
Pro-Pharmaceuticals, Inc ................................................. 152<br />
Prosensa Therapeutics ...................................................... 153<br />
ProStrakan Group plc ........................................................ 154<br />
Protaffin Biotechnologie Ag ............................................ 155<br />
Protagen AG ......................................................................... 156<br />
Protagonist Therapeutics, Inc ......................................... 158<br />
Protalix Biotherapeutics Inc. ........................................... 160<br />
Protect Pharmaceutical Corporation ........................... 162<br />
Proteologics LTD. ................................................................ 163<br />
ProteoNic BV ........................................................................ 164<br />
Provence Promotion .......................................................... 165<br />
Provid Pharmaceuticals, Inc ............................................ 166<br />
Psioxus Therapeutics, Ltd. ............................................... 168<br />
Psyadon Pharmaceuticals, Inc ........................................ 170<br />
PsychoGenics, Inc ............................................................... 171<br />
Pulmotect, Inc. ..................................................................... 172<br />
Purdue Pharma, LP ............................................................. 174<br />
Px'Therapeutics .................................................................. 175<br />
Pyxant Labs, Inc ................................................................... 176<br />
Q-Chip Ltd ............................................................................. 177<br />
QCTR Ltd ................................................................................ 178<br />
QLT, Inc .................................................................................. 179<br />
Q-Pharm Pty Limited ......................................................... 180<br />
Qu Biologics Inc................................................................... 181<br />
Quality Assistance SA ........................................................ 183<br />
QUANTUM GENOMICS ...................................................... 184<br />
QUEEN MARY INNOVATION LTD ..................................... 185<br />
Queensland Alliance for Agriculture & Food<br />
Innovation (QAAFI) ..................................................... 186<br />
Quinten ................................................................................. 187<br />
Quro Science ........................................................................ 188<br />
R&D Focus Drug News ...................................................... 189<br />
RadMD, LLC ........................................................................... 190<br />
Rafa Laboratories ............................................................... 191<br />
Randox Pharma Services .................................................. 192<br />
Ratio, Inc. .............................................................................. 193<br />
RBC Capital Markets .......................................................... 194<br />
RD Consulting ..................................................................... 195<br />
RecipharmCobra Biologics ............................................... 196<br />
Recordati ............................................................................... 197<br />
Redx Pharma Ltd................................................................. 198<br />
ReGenX Biosciences, LLC ................................................... 199<br />
REGiMMUNE Corporation ................................................ 201<br />
Regulatory Pharma Net S.R.L. ......................................... 202<br />
Regulatory Pharma Net, S.L. ............................................ 203<br />
Rentschler Biotechnologie GmbH ................................. 204<br />
RepliGen Corporation ....................................................... 205<br />
ReqMed Company, Ltd ...................................................... 206<br />
Research & Diagnostic Antibodies ................................ 207<br />
Research Corporation Technologies, Inc ..................... 208<br />
ResVerlogix Corporation .................................................. 209<br />
Rexahn Pharmaceuticals, Inc .......................................... 211<br />
Rhenovia Pharma ............................................................... 213<br />
RHEONIX, INC ....................................................................... 215<br />
Rib-X Pharmaceuticals, Inc .............................................. 217<br />
Richter-Helm Biotec Gmbh & Co. KG ............................ 218<br />
Rigel Pharmaceuticals, Inc ............................................... 219<br />
Riken ...................................................................................... 221<br />
Roche ...................................................................................... 222<br />
Roche Applied Science/Custom Biotech ...................... 224<br />
Rochester Area Economic Development Inc ............... 225<br />
Rondaxe Pharma, LLC ........................................................ 226<br />
Royal Danish Embassy ...................................................... 227<br />
RSA ......................................................................................... 228<br />
R-Tech Ueno, Ltd. ................................................................ 229<br />
Russian Venture Company Seed Fund, Ltd ................. 230<br />
Rutgers, The State University of New Jersey .............. 231<br />
RVC Biofund, Ltd ................................................................. 232<br />
RXi Pharmaceuticals Corporation ................................. 233<br />
SAFC Pharma ....................................................................... 234<br />
Sage Group ........................................................................... 235<br />
SAIC ......................................................................................... 236<br />
Salupharma Biosimilars SA ............................................. 237<br />
SAMIL PHARM CO, LTD ...................................................... 238<br />
Samyang Corporation ....................................................... 239<br />
San Raffaele Scientific Institute ..................................... 241<br />
SanBio, Inc ............................................................................ 243<br />
Sandoz Austria .................................................................... 245<br />
Sandoz Canada ................................................................... 247<br />
Sangamo BioSciences, Inc ................................................ 248<br />
Sanofi ..................................................................................... 250<br />
Sanofi Pasteur ..................................................................... 251<br />
Santaris Pharma, AS .......................................................... 253<br />
Santen Pharmaceutical Co., Ltd. .................................... 255<br />
Sanwa Kagaku Kenkyusho Co., Ltd. .............................. 256<br />
Sareum Ltd. .......................................................................... 257<br />
Sarmont, LLC ........................................................................ 258<br />
Savic Patentanwälte .......................................................... 259<br />
Savira Pharmaceuticals Gmbh ....................................... 260<br />
SBW Corp Ltd ....................................................................... 261<br />
Scancell .................................................................................. 263<br />
Scarab Genomics ................................................................ 264<br />
SciClone Pharmaceuticals, Inc ........................................ 266<br />
Scil Technology .................................................................... 267<br />
Scottish Biomedical ........................................................... 268<br />
Scottish Development International ............................ 269<br />
BIO Business Forum 2011 iv Participating Company <strong>Profiles</strong>
Seattle Genetics, Inc .......................................................... 270<br />
SE-CURE PHARMACEUTICALS .......................................... 272<br />
Selcia Limited ...................................................................... 273<br />
Selexis SA .............................................................................. 275<br />
Selvita S.A. ............................................................................ 277<br />
Semler Research Center Pvt. Ltd. ................................... 279<br />
Senju USA, Inc...................................................................... 280<br />
Senri Life Science Foundation ........................................ 281<br />
SENTINEL ONCOLOGY LIMITED ....................................... 282<br />
Sentry Biopharma Services .............................................. 283<br />
Sequella, Inc ......................................................................... 284<br />
Servier .................................................................................... 286<br />
Shanghai Medicilon Inc. ................................................... 287<br />
Shanghai Newsummit Biopharma R&D Co., Ltd ...... 288<br />
Sheba Medical Center ....................................................... 289<br />
Shenyang Everbright Pharma ........................................ 290<br />
SHEPHERD RESEARCH LLC ................................................. 291<br />
SHI Consulting .................................................................... 292<br />
Shield Therapeutics ........................................................... 293<br />
Shionogi & Co., Ltd. ............................................................ 294<br />
Shire Pharmaceuticals, Inc .............................................. 295<br />
Sichenzia Ross Friedman Ference LLP ........................... 297<br />
Sigma-Aldrich Corporation ............................................. 298<br />
Silence Therapeutics PLC .................................................. 299<br />
Simcere Pharmaceutical Group ..................................... 301<br />
Sinoveda Canada Inc. ........................................................ 302<br />
Sirga Advanced Biopharma, Inc ..................................... 304<br />
Sirona Biochem Corporation .......................................... 305<br />
Sistemic Ltd .......................................................................... 307<br />
SK biopharmaceuticals ..................................................... 308<br />
Skannex ................................................................................. 309<br />
SkyePharma PLC ................................................................. 311<br />
Smerud Medical Research UK Ltd .................................. 312<br />
SNBL, Ltd. .............................................................................. 313<br />
SOCPRA .................................................................................. 314<br />
Solstice Neurosciences, Inc .............................................. 315<br />
Soluble Therapeutics......................................................... 316<br />
Solvotrin Therapeutics Ltd .............................................. 318<br />
SONN & PARTNER Patentanwälte ................................. 319<br />
Sorbent Therapeutics, Inc ................................................ 320<br />
Sorrento Therapeutics, Inc .............................................. 322<br />
Speedx ................................................................................... 323<br />
SPharm Inc. .......................................................................... 324<br />
Spherix, Inc ........................................................................... 325<br />
Splicos .................................................................................... 327<br />
Springleaf Therapeutics ................................................... 328<br />
SRC BioManufacturing ..................................................... 329<br />
Staatz Business Development & Strategy .................. 330<br />
Stabilitech Ltd ..................................................................... 331<br />
Starpharma .......................................................................... 332<br />
Statking Consulting Inc. ................................................... 334<br />
Stendhal ................................................................................ 335<br />
Stiris Research Inc. ............................................................. 336<br />
Stonearch Creative ............................................................ 337<br />
Stony Brook University ..................................................... 338<br />
Stratatech Corporation .................................................... 339<br />
Strativa Pharmaceuticals ................................................. 340<br />
Stromedix ............................................................................. 341<br />
Sun Pharmaceutical Industries Ltd ............................... 342<br />
Sundman Business Development Gmbh .................... 344<br />
Sunstein Kann Murphy & Timbers LLP ........................ 345<br />
Sunten Phytotech Co., Ltd. ............................................... 346<br />
Super Religare Laboratories ............................................ 348<br />
SuperGen, Inc ...................................................................... 350<br />
Supernus Pharmaceuticals, Inc ...................................... 351<br />
SuppreMol, GmbH ............................................................. 352<br />
SurModics Pharmaceuticals ........................................... 354<br />
Sutro Biopharma, Inc ........................................................ 355<br />
Swedish Orphan Biovitrum ............................................. 356<br />
Swiss Precision Diagnostics ............................................ 357<br />
Swissaustral Biotech SA ................................................... 358<br />
Symbiosis Pharmaceutical Services .............................. 359<br />
Symphogen, A/S ................................................................. 360<br />
Synco Bio Partners B.V. ..................................................... 362<br />
Syngene International Ltd ............................................... 364<br />
Syntab Therapeutics.......................................................... 365<br />
Synthelis ............................................................................... 366<br />
Tactic Pharma, LLC ............................................................. 367<br />
Taejoon Pharm .................................................................... 368<br />
TaiGen Biotechnology Company, Ltd ........................... 370<br />
Taisho Pharmaceutical Co., Ltd. ..................................... 372<br />
Taiwan Liposome Company Co., Ltd. (TLC) .................. 374<br />
Takeda Pharmaceutical Company ................................ 375<br />
Takeda San Francisco ........................................................ 376<br />
Talon Therapeutics, Inc .................................................... 377<br />
Targacept, Inc ...................................................................... 378<br />
Targepeutics ........................................................................ 380<br />
Target Discovery, Inc ......................................................... 381<br />
TC Scientific, Inc. ................................................................. 383<br />
TCD Pharma ......................................................................... 384<br />
TCG Lifesciences Limited .................................................. 385<br />
Team Cote D'Azur ............................................................... 386<br />
Technical University of Catalonia ................................. 387<br />
Technion Technology Transfer Company ................... 388<br />
Technology Vision Group, LLC ........................................ 389<br />
TechnoPhage, SA ................................................................ 390<br />
Techorizon Srl ...................................................................... 391<br />
Techsol Corporation .......................................................... 392<br />
Teijin Pharma Limited ...................................................... 393<br />
Tekmira Pharmaceuticals Corp. ..................................... 394<br />
TELORMEDIX SA ................................................................... 395<br />
Telstar .................................................................................... 396<br />
Tembua: The Precision Language Solution ................ 397<br />
Tengion, Inc .......................................................................... 398<br />
Terrapinn Ltd. ...................................................................... 399<br />
TetraQ .................................................................................... 400<br />
Teva Innovative Ventures ................................................ 402<br />
Teva Pharmaceuticals-Global Branded Products ...... 403<br />
Texas A&M Institute for Preclinical Studies ............... 404<br />
TFS Trial Form Support International .......................... 405<br />
Tgen Drug Development (TD2) ...................................... 406<br />
The Clearity Foundation ................................................... 407<br />
The Founders Club ............................................................. 408<br />
The Hospital for Sick Children ........................................ 409<br />
BIO Business Forum 2011 v Participating Company <strong>Profiles</strong>
The Institute of Cancer Research ................................... 410<br />
The Jackson Laboratory .................................................... 411<br />
The Leukemia & Lymphoma Society ........................... 412<br />
The Michael J. Fox Foundation ....................................... 413<br />
The Royal National Institute for Deaf People ............. 414<br />
The Salk Institute for Biological Studies ...................... 415<br />
The Salter Group................................................................. 416<br />
The University of Chicago ................................................ 417<br />
The University of Sydney .................................................. 418<br />
Theraclone Sciences, Inc ................................................... 419<br />
Theralpha SAS ..................................................................... 421<br />
Theranostics Health .......................................................... 422<br />
Theravance, Inc ................................................................... 423<br />
Theron Pharmaceuticals Inc ........................................... 424<br />
THOMSON REUTERS ........................................................... 425<br />
Thrombotargets Europe SL .............................................. 426<br />
Tillotts Pharma AG ............................................................. 428<br />
Tioga Pharmaceuticals ..................................................... 429<br />
TISSUE SOLUTIONS LTD ..................................................... 430<br />
Titan Pharmaceuticals, Inc .............................................. 431<br />
TNO Life Sciences, Inc. ....................................................... 432<br />
Tobira Therapeutics, Inc ................................................... 433<br />
Tocagen, Inc ......................................................................... 434<br />
TODAI TLO, Ltd. .................................................................... 435<br />
Tohoku Techno Arch Co., Ltd ........................................... 436<br />
Tohoku University .............................................................. 437<br />
Tokyo University of Science ............................................. 438<br />
Torrey Pines Investment .................................................. 440<br />
Toscana Life Sciences Foundation ................................. 441<br />
Toscana Promozione - Invest In Tuscany ..................... 442<br />
TOYOTA MOTOR CORPORATION .................................... 443<br />
Tracon Pharmaceuticals, Inc ........................................... 444<br />
Tradition Center For Innovation .................................... 445<br />
Transition Therapeutics, Inc ........................................... 446<br />
Transposagen Biopharmaceuticals, Inc....................... 447<br />
TransTech Pharma, Inc ..................................................... 449<br />
Tranzyme, Inc ...................................................................... 450<br />
Trevena, Inc .......................................................................... 451<br />
Trillium Therapeutics, Inc ................................................ 453<br />
TRUDEAU INSTITUTE .......................................................... 454<br />
TSRL, Inc. ................................................................................ 455<br />
TTFactor ................................................................................. 457<br />
Turku Science Park Ltd ...................................................... 459<br />
TWi Biotechnology, Inc. .................................................... 460<br />
Tytonis Bv ............................................................................. 462<br />
UAB Research Foundation ............................................... 463<br />
UAM Global .......................................................................... 464<br />
UC San Diego ....................................................................... 465<br />
UCL Business PLC ................................................................ 466<br />
UGent Tech Transfer ......................................................... 467<br />
UK Trade & Investment .................................................... 468<br />
UMAN PHARMA Inc. ........................................................... 469<br />
Unhwa Corporation ........................................................... 470<br />
Unigene Laboratories, Inc ................................................ 472<br />
UniQuest Pty Limited ........................................................ 474<br />
Universitat Autònoma De Barcelona ........................... 476<br />
Université de Lyon ............................................................. 477<br />
University of Alberta ......................................................... 478<br />
University of Amsterdam ................................................. 479<br />
University of California, Irvine,<br />
Office of Corporate Relations ................................. 480<br />
University of Colorado ...................................................... 481<br />
University of Illinois at Chicago ..................................... 482<br />
University of Illinois at Urbana-Champaign .............. 483<br />
University of Manitoba .................................................... 484<br />
University of Michigan ..................................................... 485<br />
University of North Dakota ............................................. 486<br />
University of Otago ............................................................ 487<br />
University of Pittsburgh ................................................... 488<br />
University of Pittsburgh,<br />
Center for Biotechnology & Bioengineering ...... 489<br />
University of Rochester ..................................................... 490<br />
University of São Paulo ..................................................... 491<br />
University of South Florida Research Foundation .... 493<br />
University of Szeged .......................................................... 494<br />
University of Victoria ........................................................ 495<br />
University System of Maryland ...................................... 496<br />
University Technologies International Inc. ................. 497<br />
UoM Commercial Ltd. ....................................................... 498<br />
Upsher-Smith Laboratories, Inc. .................................... 499<br />
Upstate Medical University ............................................. 500<br />
URL Pharma .......................................................................... 501<br />
Vakzine Projekt Management, GmbH ......................... 503<br />
Valeant Pharmaceuticals International, Inc .............. 505<br />
Valens Therapeutics, Inc. ................................................. 506<br />
Valeo Management, L.P. ................................................... 507<br />
Vanda Pharmaceuticals Inc ............................................. 508<br />
Vanthys Pharmaceutical Dev Pvt Ltd ............................ 509<br />
Vapogenix, Inc ..................................................................... 510<br />
vasopharm GmbH .............................................................. 511<br />
Västerbotten Investment Agency .................................. 512<br />
VBI Vaccines ......................................................................... 513<br />
Vectron Biosolutions AS ................................................... 514<br />
Vectura Group Plc .............................................................. 515<br />
Ventria Bioscience.............................................................. 517<br />
Venture Valuation ............................................................. 518<br />
Ventures West Capital ...................................................... 519<br />
Vernalis plc ........................................................................... 520<br />
Verseon Corporation ......................................................... 521<br />
Vetter Pharma International GmbH ............................. 522<br />
VGXI, Inc. ............................................................................... 524<br />
VIB ......................................................................................... 525<br />
Vibalogics GmbH ................................................................ 526<br />
Victory Pharma, Inc ............................................................ 527<br />
Vidara Therapeutics .......................................................... 528<br />
Viking Healthcare Solutions, Inc .................................... 529<br />
Viralytics Ltd ........................................................................ 530<br />
VIRBAC LABORATORIES ...................................................... 531<br />
ViroMed Co., Ltd. ................................................................. 532<br />
Vitae Pharmaceuticals, Inc .............................................. 533<br />
VitamFero ............................................................................. 535<br />
Vivia Biotech ........................................................................ 537<br />
VIVUS, Inc .............................................................................. 539<br />
VLST Corporation ................................................................ 541<br />
BIO Business Forum 2011 vi Participating Company <strong>Profiles</strong>
Vossius & Partner .............................................................. 542<br />
VTT Technical Research Centre of Finland .................. 543<br />
VTU Technology .................................................................. 544<br />
Wacker Biotech AG ............................................................ 545<br />
Waypoint Holdings, LLC ................................................... 546<br />
West Holland Foreign Investment Agency ................. 547<br />
Wexford Science & Technology, LLC ............................. 548<br />
Wiborg ApS .......................................................................... 549<br />
Wilson, Sonsini, Goodrich & Rosati, LLP ...................... 550<br />
Winered Chemical Corporation ..................................... 551<br />
WOMBAT CAPITAL, LTD. .................................................... 553<br />
Worldiscoveries .................................................................. 554<br />
WuXi AppTec, Inc ............................................................... 555<br />
Xcovery, Inc .......................................................................... 556<br />
Xencor, Inc ............................................................................ 557<br />
Xenon Pharmaceuticals, Inc ............................................ 559<br />
XenoPort, Inc ........................................................................ 560<br />
XOMA Ltd. ............................................................................. 561<br />
Xplico A/S ............................................................................. 563<br />
Yangji Chemical .................................................................. 564<br />
Yissum ................................................................................... 565<br />
YM BioSciences Inc. ............................................................ 566<br />
Ypsomed AG ......................................................................... 568<br />
Yuhan Corporation ............................................................ 569<br />
ZAB Brandenburg Economic Development Board .... 570<br />
Zalicus Inc ............................................................................. 571<br />
Zealand Pharma A/S.......................................................... 572<br />
Zebra Ventures S.r.L. .......................................................... 573<br />
Zenyaku Kogyo Co., Ltd. .................................................... 574<br />
ZF BIOTOX ............................................................................. 575<br />
ZIOPHARM Oncology, Inc ................................................. 576<br />
Zirus, Inc. ............................................................................... 577<br />
Zophis .................................................................................... 579<br />
Zosano Pharmaceutical, Inc ............................................ 580<br />
Zymeworks Inc .................................................................... 581<br />
Zyngenia, Inc ....................................................................... 583<br />
Zytoprotec Gmbh ............................................................... 584<br />
BIO Business Forum 2011 vii Participating Company <strong>Profiles</strong>
Dmitry Sharov<br />
Chief Executive Officer<br />
845 Third Avenue<br />
New York, NY 10022<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Julia Nedokusheva<br />
Ekaterina Mochalova, Business Development Manager, IR<br />
HIGHLIGHTS<br />
Recent<br />
OCT Group LLC<br />
www.oct-clinicaltrials.com<br />
Phone: 1-212-449-8634<br />
OCT is going to become a leading contract research organization in Russia and CEE<br />
OCT is providing investment opportunities to its' Partners and Clients<br />
CORPORATE MISSION<br />
Incorporated: 2005<br />
Employees: 65<br />
Ownership: Private<br />
OCT is based in St. Petersburg, with infrastructure in Russia and a number of other countries: Ukraine, Belarus, Bulgaria, Latvia, Lithuania<br />
and Estonia, that covers a significant patient population of over 200 MM persons. We believe that OCT geographical presence is a strategic<br />
advantage; in addition to having access to a large population, it is also a population that is drug naïve in several therapeutic areas, at least<br />
they have not been exposed to many new western drugs, and disease prevalence is similar to other European countries and is higher in<br />
some indications. This translates into some key advantages for placing trials in these territories, including fast recruitment, yet offering<br />
the potential for significant cost savings. However, while it is well recognized that patient recruitment is important to a successful trial,<br />
also crucial is that trials are well run and well monitored. Having been in business for several years OCT is experienced in wide range of<br />
therapeutic areas. Moreover, we have a record of successful trial completion, and of course have all of the necessary qualifications and<br />
experience in ICH GCP, and other quality systems. Many of these completed trials have resulted in repeat business opportunities.<br />
Therefore, OCT is well positioned as a boutique CRO of choice to place strategic trials in this region, as well as being able to provide a<br />
number of other clinical development services. Therefore, OCT is well positioned as a boutique CRO of choice to place strategic trials in this<br />
region, as well as being able to provide a number of other clinical development services.<br />
OCT provides investment opportunities in exchange for clinical trials (please contact Ekaterina Mochalova at +7 921 9152317 and look<br />
through http://www.oct-clinicaltrials.com/?q=content/oct-consulting-co-financing-clinical-trials).<br />
FINANCING HISTORY<br />
Investors: Dmitry Sharov (100 %)<br />
SENIOR MANAGEMENT<br />
Dmitry Sharov, Chief Executive Officer • Irina Petrova, Director • Julia Nedokusheva, Business Development • Ekaterina Mochalova,<br />
Business Development<br />
BIO Business Forum 2011 1 Participating Company <strong>Profiles</strong>
Jan Egberts<br />
Chief Executive Officer<br />
Zernikedreef 12<br />
2333 CL Leiden<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Gerben Moolhuizen<br />
Andy Lewin, Senior Business Development Manager<br />
Erik-Jan Klok, Senior Manager Business Development<br />
OctoPlus N.V.<br />
Clinical Foci: Drug Development • Drug Delivery • Biopharmaceuticals<br />
www.octoplus.nl<br />
Phone: 31-71-5244044<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
During 2010 and 2011, successful clinical Phase IIb results for Locteron® were presented,<br />
which further validate the potential of our PolyActive® controlled release drug delivery<br />
technology.<br />
In October 2008 OctoPlus announced an exclusive license and manufacturing<br />
agreement for Locteron with Biolex allowing for revenues in excess of 100 million euro.<br />
Positive topline results for the ongoing Phase IIb study will be presented in April.<br />
In 2008 OctoPlus adapted its strategy to utilise its proprietary drug delivery technology<br />
for the controlled release of injectable products, in particular proteins, on behalf of a<br />
growing client base.<br />
Incorporated: 1995<br />
Employees: 100<br />
Ownership: Public<br />
Market Cap: $46.00 million<br />
AMSTERDAM STOCK EXCHANGE: OCTO<br />
In 2011 OctoPlus will further expand its<br />
pipeline of projects evaluating the feasibility<br />
of a controlled release formulation that<br />
combines the active ingredient of the client<br />
with OctoPlus’ proprietary drug delivery<br />
technology.<br />
CORPORATE MISSION<br />
OctoPlus is a drug product development company that is globally renowned as a center of excellence in pharmaceutical development and<br />
drug delivery. We offer proven and reliable services in formulation development, analytical development, process development and GMP<br />
manufacturing. Our expertise is focused on formulation of biotech-derived compounds and small chemical molecules. In addition, we<br />
offer clients our expertise in combination with our drug delivery technology for the development of controlled release formulations of<br />
injectable compounds. Such depot formulation products have demonstrated strong improvement of side effect profiles, greatly increased<br />
patient compliance and better efficacy.<br />
PROPRIETARY TECHNOLOGY<br />
OctoPlus' clinical-stage proprietary drug delivery technology is PolyActive. Our technologies consist of biodegradable polymer-based drug<br />
delivery platforms for controlled parenteral release of proteins, peptides and small molecules. OctoPlus’ drug delivery technologies offer<br />
unsurpassed flexibility to achieve the desired release profile (release over days/weeks/months; zero-order or pulsed-release). They elicit no<br />
high initial release upon injection (so-called burst) as seen with other technologies. The manufacturing process is simple and the patent<br />
position is well established and solid.<br />
CORPORATE ALLIANCES<br />
OctoPlus’ clinical-stage PolyActive-based product, Locteron, was licensed to Biolex Therapeutics on 6 October 2008. The agreement secures<br />
an upfront fee for OctoPlus of € 8 million, and allows for revenues of up to € 100 million. This product has completed Phase IIb clinical<br />
studies and OctoPlus will be involved in process development and clinical manufacturing for future studies.<br />
In addition to this agreement, OctoPlus has worked for multiple clients to develop a controlled release formulation of their product. We<br />
commercialise our technology on a product-by-product basis and are open to partnerships with companies producing pharmaceutical<br />
compounds that might benefit from controlled release using OctoPlus’ technologies. For further information, please contact us during the<br />
conference.<br />
INTELLECTUAL PROPERTY<br />
OctoPlus’ products and technologies are all patent protected with Freedom to Operate. A complete overview of patents is available upon<br />
request.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Locteron Phase II, IIa, IIb Hepatitis C Initiation of Phase III<br />
OP-145 Phase II, IIa, IIb Chronic middle ear infection Ready for licensing<br />
SENIOR MANAGEMENT<br />
Jan Egberts, Chief Executive Officer • Susan Swarte, Chief Financial Officer • Gerben Moolhuizen, Chief Business Officer<br />
BOARD OF DIRECTORS<br />
Hans Stellingsma, Quintel • Rene Kuijten, Life Sciences Partners • Frans Eelkman Rooda, Wessanen • Nancy de Ruiter, ACEE B.V. •<br />
Jim Gale, Signet Healthcare Partners<br />
BIO Business Forum 2011 2 Participating Company <strong>Profiles</strong>
Howard Kaminsky<br />
Business Development<br />
325 Stillview<br />
Pointe Claire, QC H9R 2Y6<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Howard Kaminsky<br />
Odan Laboratories Ltd<br />
Clinical Foci: Specialty Pharmaceutical • Gastroenterology • CNS<br />
www.odanlab.com<br />
Phone: 1-514-428-1628<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
For 2010 the company realized growth of 35% compared to 2009.<br />
This growth pattern has been constant for the past number of<br />
years.<br />
Incorporated: 1974<br />
Employees: 150<br />
Ownership: Private<br />
The company anticipates continued growth and in 2011 is<br />
searching for partners to acquire and/or in-licence drugs for the<br />
Canadian and/or US market.<br />
CORPORATE MISSION<br />
Odan Laboratories Ltd. is an established Canadian specialty pharmaceutical company which develops, acquires and in-licenses<br />
pharmaceutical products for Canadian and/or US markets.<br />
CORPORATE ALLIANCES<br />
Sanofi-Aventis, International Pharmaceutical Generics, Kamins Dermatologics, etc.<br />
PRODUCTS<br />
Name Phase Indication<br />
Ni-OdanTM On Market extended-release niacin<br />
Purg-OdanTM On Market bowel cleansing purgative<br />
AlertonicTM On Market treatment of functional fatigue<br />
Odan K-20 Potassium Chloride Extended<br />
Release<br />
SENIOR MANAGEMENT<br />
On Market hypokalemia<br />
Howard Kaminsky, Business Development • Ben Kaminsky, President & CEO<br />
BIO Business Forum 2011 3 Participating Company <strong>Profiles</strong>
John K. Westwick, PhD<br />
President & CEO<br />
4550 Norris Canyon Road<br />
San Ramon, CA 94583<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
John K. Westwick, PhD, President and CEO<br />
Odyssey Thera, Inc<br />
Presenting Company<br />
Clinical Foci: Drug Discovery • Oncology • Systems Biology<br />
www.odysseythera.com<br />
Phone: 1-925-242-5000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
2009: R&D alliance with Mitsubishi-Tanabe Pharma Co., multiple milestones under Pfizer<br />
alliance, closed equity financing led by Merck and Pfizer; Japanese patent issuance and US<br />
patent on key GPCR screening strategies<br />
2010: Option, License and Service Agreement with Lonza; alliance with US EPA ToxCast<br />
program; co-publication of manuscript with Pfizer<br />
2011: Significant expansion of EPA ToxCast alliance; license agreement with Lonza<br />
Corporation, multiple drug profiling programs with major pharma and biotech; US patent<br />
issues on drug screening and re-purposing technologies<br />
Incorporated: 2000<br />
Employees: 20<br />
Ownership: Private<br />
significant alliances signed with major<br />
pharma companies; significant revenue<br />
from environmental monitoring<br />
program with US EPA and from Lonza<br />
alliance; profitable 2011<br />
license agreement for in vivo imaging<br />
with PCA<br />
license agreements in agbio field<br />
CORPORATE MISSION<br />
Odyssey Thera, Inc. is a privately held drug discovery technology company focused on improving the success rate of therapeutic<br />
development. Proprietary assay technologies measure targets and pathways in their native biological context in living human cells. Over<br />
ten years of concerted development has generated the largest collection of high-content assays in the world, enabling therapeutic<br />
discovery around “un-drugable” targets as well as systems biology- based discovery strategies. Utilizing arrays of diverse and contextual<br />
cell-based assays, Odyssey scientists define global patterns of drug activity. These “signatures” identify the most promising drug<br />
candidates at an early stage in the development process. These global strategies have been validated in partnerships with pharmaceutical<br />
companies and government agencies. Technology development has also been supported by three rounds of equity investment from Pfizer,<br />
Inc., Merck and Co., Lonza, HBM Partners, Burrill & Company, HealthCap, and other investors. Patents owned by Odyssey also cover the use<br />
of the technology in live animals, plants, for diagnostic and bioprocess applications, for biodefense and environmental applications.<br />
PROPRIETARY TECHNOLOGY<br />
The company’s proprietary molecular technology, known as PCA (Protein-fragment Complementation Assay), spans all known pathways<br />
and target classes. Assays performed in living human cells quantify the existence of and dynamic changes in protein complexes. Utilizing a<br />
fully integrated platform and relational database, hundreds of assays are utilized in high-throughput parallel arrays to profile drug<br />
activities. This unprecedented data acquisition capability has created a database of activity signatures for over 10,000 known drugs,<br />
toxicants, and proprietary chemical compounds across cellular pathways. The screening capability and drug signature database have been<br />
validated to expedite the development of drugs with desired mechanisms and lacking undesired, off-pathway effects.<br />
CORPORATE ALLIANCES<br />
Odyssey Thera is actively engaging with biotech and pharmaceutical companies to expedite target and drug discovery and preclinical drug<br />
development in oncology and other therapeutic areas. Partners benefit from Odyssey’s assay design, engineering, and performance<br />
capabilities to identify targets and drug candidates. Odyssey’s validated drug profiling capability and proprietary drug activity database<br />
are used in research alliances to improve decision making, to expedite the process of preclinical development and to identify optimal leads<br />
and potential biomarkers to facilitate development. In addition to work with premier pharmaceutical companies, Odyssey has a major<br />
alliance with the US EPA ToxCast program and a license and service agreement with Lonza.<br />
INTELLECTUAL PROPERTY<br />
19 issued US, European and Japanese patents and over 60 patents in prosecution support the contextual assay technologies and diverse<br />
applications. These include protein- and enzyme fragmentation strategies around any protein including inherently fluorescent proteins,<br />
luminescent protiens, enzymes, and other proteins. IP also protects the use of these technologies for cellular analysis, target and siRNA<br />
analysis, drug discovery and profiling, in vivo imaging, agricultural applications, biomarker and diagnostic applications, bioprocess and<br />
biodefense applications.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Assay technologies for drug<br />
discovery<br />
Preclinical drug discovery fully validated technologies<br />
Assay technologies for target<br />
discovery<br />
Pre-Target Validation target discovery and validation fully validated technologies<br />
BIO Business Forum 2011 4 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Compound profiing for<br />
mechanism determination and<br />
drug re-purposing<br />
Assay technologies for<br />
development of homogeneous<br />
diagnostic assays<br />
Preclinical drug profiling validated; multiple milestones<br />
achieved in major pharma<br />
alliances<br />
Diagnostics Dengue fever, HIV proof-of-concept assays<br />
engineered and optimized<br />
FINANCING HISTORY<br />
Investors: Burrill & Company (20 %) • HBM Bioventures (Cayman) (16 %) • Pfizer (14 %) • Healthcap (9 %) •<br />
Merck (9 %) • Incyte (8 %) • Bayer CropScience (7 %) • Lonza (6 %) • Royal Bank of Canada (1 %)<br />
SENIOR MANAGEMENT<br />
John K. Westwick, PhD, President & CEO • Jane E. Lamerdin, PhD, Director<br />
BOARD OF DIRECTORS<br />
Hugh Rienhoff, MD, President, CEO and Chairman, Ferrokin Biosciences • John K. Westwick, PhD, President and CEO, Odyssey Thera, Inc.<br />
• Bryant Fong, Principal, Burrill and Co. • Alan Sachs, MD, Vice President, RNA Therapeutics, Merck and Co.<br />
BIO Business Forum 2011 5 Participating Company <strong>Profiles</strong>
Gregory A. Demopulos, MD (Chairman)<br />
Chief Executive Officer<br />
1420 Fifth Avenue<br />
Seattle, WA 98101<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Timothy M. Duffy, Vice President, Business Development<br />
HIGHLIGHTS<br />
Recent<br />
Omeros Corporation<br />
Clinical Foci: CNS • Metabolic Disease • Hematology<br />
www.omeros.com<br />
Phone: 1-206-676 5037<br />
Incorporated: 1994<br />
Employees: 75<br />
Ownership: Public<br />
Market Cap: $120.00 million<br />
NASDAQ: OMER<br />
Omeros identified and confirmed functional compounds that interact selectively with five orphan GPCRs linked to squamous cell<br />
carcinoma (GPR87), pancreatic cancer (GPR182), obesity (GPR85), appetite control (GPR101) and cognitive disorders (GPR12).<br />
A Phase 2b study of OMS302 demonstrated statistically significant (p
Raphael Gernot Klingmann<br />
Chief Executive Officer<br />
Baldiri Reixac 15<br />
08028 Barcelona<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Ralph Klingmann, CEO<br />
Lluís Ribas, Founder and Chief Scientific Officer<br />
Omnia Molecular S.L.<br />
Clinical Foci: Infectious Disease • Drug Discovery • Drug Development<br />
www.omniamol.com<br />
Phone: 1-202-657 4327<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Omnia Molecular closes $3 Mio round of funding. The round was<br />
led by Caixa Capital Risc, and includes backing from Empresa<br />
Nacional de Innovación (ENISA), private investors and the<br />
incorporation of experience management from industry.<br />
CORPORATE MISSION<br />
Incorporated: 2008<br />
Employees: 15<br />
Ownership: Private<br />
Omnia Molecular concludes co-development agreement for MRSA<br />
program with pharma industry partner after demonstrating<br />
positive results in a highly-predictive animal infection model.<br />
Omnia Molecular designs and develops novel anti-infectives targeted at difficult-to-treat infections. Our MRSA program will deliver<br />
preclinical candidates for co-development in Q4 2011. Lead compounds are synthesized and optimized using a proprietary technology (in-<br />
Omnia platform) and proven effective in standardized biological assays. Final proof of concept on lead compounds is validated in animal<br />
infection models.<br />
In-Omnia Platform: Time-lines and costs are reduced, while probabilities of success in clinic are increased through rich information on<br />
biological activity generated against pathogenic target (aaRS) in human cell.<br />
Aminoacyl-tRNA Synthetases (aaRS): Universal family of enzymes playing a central role in protein biosynthesis. The extremely high fitness<br />
cost makes the appearance of resistances due to punctual mutations on the catalytic core unlikely. aaRS Inhibition is a proven mode of<br />
action for antiinfectives and validated in the marketplace by the registration of Mupirocin (Bactroban®).<br />
PROPRIETARY TECHNOLOGY<br />
In-Omnia assay is a multi-parametric human-cell-based screening methodology that is acting as a stringent filter. Selected hits are clean<br />
molecular entities much closer to the candidate status.<br />
Omnia's advantage is the obtaining of rich multi-parametric information about biological activity, selectivity, toxicity, permeability and<br />
stability in just one step, coupled with a deep understanding of the target associated structure and specialised chemistry design.<br />
Thanks to Omnia's proprietary technology, candidate compounds are substantially de-risked in the pre-clinical phase.<br />
CORPORATE ALLIANCES<br />
Omnia currently has alliances targeting aaRS to develop antiinfectivess against MRSA, Tuberculosis and Mycosis. Of these, the MRSA<br />
program is most advanced and will deliver preclinical candidates for co-development in Q4 2011.<br />
INTELLECTUAL PROPERTY<br />
Patents on Platform Technology:<br />
-Ribas de Pouplana Lluís; Bori Sanz Teresa: A screening method for identifying new drugs: WO 2008/000785.<br />
-Ribas de Pouplana Lluís; Bori Sanz Teresa; Castro de Moura Manuel; Geslain Renaud: A screening method for identifying new aminoacyltrna<br />
synthetase inhibitors: WO 2008/028862.<br />
Patents pending on Aminoacyl-tRNA Synthetases (aaRS) inhibitors.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
OM-A/E Lead Series MRSA Nosocomial Infections PoC in Animal (mice)<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Seed Round: 01/01/2008 (US $0.80 million)<br />
Round A: 01/01/2011 (US $3.00 million)<br />
SENIOR MANAGEMENT<br />
Raphael Gernot Klingmann, Chief Executive Officer • Lluis Ribas de Pouplana, Chief Scientific Officer<br />
BIO Business Forum 2011 7 Participating Company <strong>Profiles</strong>
Roland Buelow<br />
Chief Executive Officer<br />
2747 Ross Road<br />
Palo Alto, CA 94303<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Roland Buelow, PhD, Chief Executive Officer<br />
HIGHLIGHTS<br />
Recent<br />
OMT, Inc.<br />
Clinical Foci: Oncology • AutoImmune • Infectious Disease<br />
www.omtinc.net<br />
Phone: 1-650-224-6835<br />
Incorporated: 2007<br />
Ownership: Private<br />
In December 2010, Open Monoclonal Technology, Inc. announced its new human antibody platform using the first genetically engineered<br />
rats expressing a human antibody repertoire.<br />
CORPORATE MISSION<br />
Open Monoclonal Technology, Inc. (“OMT”) is a private, California-based biotechnology company with a new, fully human monoclonal<br />
antibody (mAb) platform based on genetically engineered rats. OMT’s antibody platform has freedom to operate and unrestricted<br />
development options.<br />
For more information, visit: www.omtinc.net.<br />
PROPRIETARY TECHNOLOGY<br />
OMT’s antibody platform derives fully human antibodies from genetically engineered rats. The technology is the result of breakthroughs<br />
in the understanding of B-cell development and a novel approach to the inactivation of endogenous rat antibody expression. OMT’s<br />
platform has broad freedom to operate and uses technology protected by new patent applications.<br />
CORPORATE ALLIANCES<br />
Confidential<br />
INTELLECTUAL PROPERTY<br />
OMT has developed a new genetic engineering approach using transgenic rats. The technology will provide potential partners freedom to<br />
operate.<br />
OMT has filed a patent application covering its platform technology, including OMT's animals, its methods, the transgenes used to make<br />
the animals, and the antibodies and novel immunoglobulin compositions from the animals. The company also has a worldwide nonexclusive<br />
license from Sangamo BioSciences, Inc. for the use of ZFNs. OMT has exclusive commercial rights for the ZFN-mediated<br />
inactivation of rat immunoglobulin genes.<br />
SENIOR MANAGEMENT<br />
Roland Buelow, Chief Executive Officer • Richard Murdock, Chairman • Sandra Cavanah Tucher, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Richard Murdock, None • Ron Eastman, Essex Woodland Health Ventures • Tom D. Kiley, None<br />
SCIENTIFIC ADVISORY BOARD<br />
Marianne Bruggemann, Recombinant Antibody Technology, Ltd., Cambridge, UK • Michael Neuberger, MRC, Cambridge, UK • C.<br />
Geoffrey Davis, Angelica Therapeutics, Inc., Emeryville, CA • Ignacio Anegon, INSERM, Nantes, France • Andrew Scharenberg,<br />
University of Washington, Seattle, WA<br />
BIO Business Forum 2011 8 Participating Company <strong>Profiles</strong>
Dr. Philippe Genne<br />
Chief Executive Officer<br />
20 rue Jean MAZEN<br />
21076 Dijon Cedex<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Philippe Genne, Chief Executive Officer<br />
Jonathan Ewing, Business Development Director<br />
Oncodesign SA<br />
Clinical Foci: Oncology • Drug Discovery • Service<br />
www.oncodesign.com<br />
Phone: 33-3-8078 8260<br />
Incorporated: 1995<br />
Employees: 55<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Licensing agreement with Janssen Pharmaceutica NV (Johnson & Johnson) related to Worldwide distribution partnership<br />
the Nanocyclix® chemistry technology.<br />
VC fundraising in 2011<br />
IMAkinib: launch of the $30 million PET biomarker program.<br />
Drug discovery collaboration<br />
Chi-mice®: Oncodesign has acquired exclusive commercialization rights to distribute<br />
the world’s most comprehensive collection of human colorectal cancer models<br />
directly developed from patient’s tumors ($7 million program).<br />
CORPORATE MISSION<br />
Oncodesign® is a pioneer in the preclinical assessment of anti-cancer therapy, a market that it has led for many years now. Today, the<br />
company has more than 400 customers worldwide. Its reputation is built on its innovative approach and the thoroughness and<br />
engagement of its scientific teams. Recently, Oncodesign® has launched its own research programs in close cooperation with multiple<br />
partners, and in particular IMAkinib®, a discovery program of new PET radiotracers capable of detecting targets and pathways and<br />
monitoring their changes during treatment.<br />
Oncodesign’s mission consists of discovering effective anti-cancer therapies. Its scientific expertise in pharmacology, imaging and<br />
medicinal chemistry, in addition to strong project management skills, support the company’s two strategic activities of experimentation<br />
and discovery, conducted in partnership with pharmaceutical and biotechnology companies.<br />
The experimentation activity is organized in three technological modules: Chi-mice®, PharmImage® and PREDICT®.<br />
On the basis of these three modules, Oncodesign markets a broad range of products and services (fee for service), for the assessment,<br />
validation, targeting and diagnostic linking of anti-cancer therapies (small molecules, natural products, antibodies, gene therapy,<br />
vaccination, hormone therapy, radiotherapy, etc.).<br />
In 2010, Oncodesign has incorporated a medicinal chemistry technology, Nanocyclix®, into its discovery activity. Nanocyclix® consists of<br />
potent and selective inhibitors for currently unexplored kinases used as pharmacological tools on novel areas.<br />
The combination of these four technological modules enables Oncodesign to offer its partners a unique and innovative translational<br />
research platform, from bench to bedside, in a risk-sharing approach between partners.<br />
PROPRIETARY TECHNOLOGY<br />
- Nanocyclix®: which is dedicated to the synthesis and optimization of new compounds used for therapeutic and diagnostic purposes. This<br />
technology is currently applied to the synthesis of highly potent and specific novel kinase inhibitors. Oncodesign has initiated multiple<br />
drug discovery programs as well as the IMAkinib® PET biomarker program.<br />
- Chi-mice® focuses on the development of in vivo chimeric experimental models (patient derived models, humanized mice; new disease<br />
relevant models)<br />
- PharmImage® is dedicated to multi-modal, non-invasive pharmaco-imaging (SPECT, MRI, PET, pre-clinical and Phase 0: imaging<br />
biomarkers)<br />
- PREDICT® specializes in conventional in vitro and in vivo pharmacology (ADMET, toxicology, combinations, PK/PD, xenograft, syngeneic<br />
models; proof of concept)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Flt-3 mutant inhibitor Optimized Lead oncology in vivo activity<br />
Haspin inhibitor Optimized Lead oncology<br />
TrkA inhibitor Optimized Lead oncology, pain<br />
PET tracer development Optimized Lead oncology<br />
SENIOR MANAGEMENT<br />
Dr. Philippe Genne, Chief Executive Officer • Dr. Francis Bichat, Director • Dr. Jan Hoflack, Chief Scientific Officer • Mr. Jonathan<br />
Ewing, Business Development • Mr. Laurent Gonthiez, Chief Financial Officer • Mr. Olivier Duchamp, Chief Technology Officer<br />
BIO Business Forum 2011 9 Participating Company <strong>Profiles</strong>
Brad Thompson, PhD<br />
President & CEO<br />
1167 Kensington Crescent NW<br />
Calgary, AB T2N 1X7<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Brad Thompson, PhD<br />
Oncolytics Biotech Inc.<br />
Presenting Company<br />
Clinical Foci: Oncology • Drug Development<br />
www.oncolyticsbiotech.com<br />
Phone: 1-403-670-7377<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Announced entry into commercial supply agreement with SAFC, a Division of Sigma-Aldrich<br />
Corporation, for the commercial manufacture of REOLYSIN.<br />
Completed patient enrollment in its U.S. Phase 2 clinical trial using intravenous administration of<br />
REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and<br />
neck cancers.<br />
Start of patient enrollment in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus<br />
REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with<br />
recurrent or metastatic pancreatic cancer.<br />
Incorporated: 1998<br />
Employees: 21<br />
Ownership: Public<br />
Market Cap: $407.30 million<br />
TORONTO STOCK EXCHANGE: ONC<br />
Results from ongoing Phase II clinical<br />
trials.<br />
Start of enrolment in additional<br />
clinical trials.<br />
Completion of enrolment in first 80patient<br />
stage of Phase 3 trial in head<br />
and neck cancer.<br />
CORPORATE MISSION<br />
Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of<br />
human cancers. Headquartered in Calgary, Alberta, Canada, the company was formed in 1998 to explore the oncolytic capability of the<br />
reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects<br />
leading to cancer.<br />
The company’s technologies are based on discoveries made in the 1990s in the Department of Microbiology and Infectious Diseases at the<br />
University of Calgary. The potential products are being developed using the naturally occurring reovirus for treatment of cancers in<br />
humans. The reovirus, or Respiratory Enteric Orphan virus, has been demonstrated to replicate specifically in tumour cells that have a<br />
constitutively activated Ras pathway. Activating mutations of Ras and mutations along the Ras pathway occur in approximately twothirds<br />
of all tumours. Tumours bearing an activated Ras pathway are deficient in their ability to activate an anti-viral response mediated<br />
by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumour cells lacking the activity of PKR are<br />
susceptible to reovirus infection and eventual cell death. As normal cells do not possess Ras activation, these cells are able to thwart<br />
reovirus infection by the activity of PKR. In a tumour cell with an activated Ras pathway, the reovirus is able to freely replicate and kill the<br />
host tumour cell. Progeny virus particles are then able to infect and kill surrounding cancer cells. This cycle of infection, replication and cell<br />
death is believed to be repeated until there are no longer any tumour cells carrying an activated Ras pathway available.<br />
PROPRIETARY TECHNOLOGY<br />
REOLYSIN, the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells<br />
bearing an activated Ras pathway. Activating mutations of Ras and upstream elements of Ras may play a role in greater than two thirds of<br />
all human cancers. REOLYSIN may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders.<br />
Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans.<br />
Reovirus is found naturally in sewage and water supplies. By age 12, half of all children show evidence of reovirus exposure and by<br />
adulthood, most people have been exposed. However, the disease is non-pathogenic, meaning there are typically no symptoms.<br />
CORPORATE ALLIANCES<br />
Clinical Trial Agreements with the U.S. NCI, the University of Leeds, and the Cancer Therapy & Research Center at the University of Texas<br />
Health Science Center to conduct multiple clinical trials with REOLYSIN.<br />
INTELLECTUAL PROPERTY<br />
More than 250 patents issued worldwide, including 41 U.S. patents and 11 Canadian patents.<br />
Reovirus issued patent claims cover: compositions of matter comprising reovirus; pharmaceutical use of reoviruses to treat neoplasia and<br />
cellular proliferative diseases; combination therapy with radiation, chemotherapy and/or immune suppressants; methods for<br />
manufacturing reovirus and screening for susceptibility to reovirus; pharmaceutical use of reoviruses in transplantation procedures.<br />
The company has more than 200 pending applications worldwide.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
REOLYSIN Phase III Head & neck cancer in combination with paclitaxel/carboplatin Enrollment ongoing<br />
BIO Business Forum 2011 10 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
REOLYSIN Phase II, IIa, IIb NSCLC with KRAS or EGFR mutations in combination with<br />
paclitaxel/carboplatin<br />
REOLYSIN Phase II, IIa, IIb Squamous Cell Carcinoma of the Lung in combination with<br />
paclitaxel/carboplatin<br />
Enrollment ongoing<br />
Enrollment ongoing<br />
REOLYSIN Phase II, IIa, IIb Pancreatic cancer in combination with gemcitabine Enrollment ongoing<br />
REOLYSIN Phase II, IIa, IIb Metastatic melanoma in combination with<br />
paclitaxel/carboplatin<br />
REOLYSIN Phase II, IIa, IIb Peristent or recurrent ovarian cancer in combination with<br />
paclitaxel<br />
REOLYSIN Phase II, IIa, IIb Recurrent or metastatic pancreatic cancer in combination with<br />
paclitaxel/carboplatin<br />
Enrollment ongoing<br />
With NCI - enrollment started in<br />
2011<br />
With NCI - randomized -<br />
enrollment ongoing<br />
REOLYSIN Phase I Colorectal cancer in combination with FOLFIRI Enrollment ongoing<br />
REOLYSIN Phase I Pediatric patients with relapsed or refractory solid tumours in<br />
combination with cyclophosphamide<br />
SENIOR MANAGEMENT<br />
With NCI - study announced<br />
Brad Thompson, PhD, President & CEO • Doug Ball, CA, Chief Financial Officer • Matt Coffey, PhD, Chief Operating Officer • Karl<br />
Mettinger, MD, PhD, Chief Medical Officer • George Gill, MD, Senior Vice President • Mary Ann Dillahunty, JD, MBA, Vice President<br />
BOARD OF DIRECTORS<br />
Brad Thompson, PhD, President and CEO, Oncolytics Biotech Inc. • Doug Ball, CA, Chief Financial Officer, Oncolytics Biotech Inc. • Ger<br />
van Amersfoort, Biotech Consultant • William A. Cochrane, OC, MD, Biotech Consultant • Jim Dinning, Chairman, Western Financial<br />
Group • Ed Levy, PhD, Adjunct Professor, University of British Columbia • J. Mark Lievonen, FCA, President, Sanofi Pasteur Limited •<br />
Bob Schultz, FCA, Corporate Director • Fred A. Stewart, QC, President, Fred Stewart and Associates Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
Ramon Alemany, PhD • Richard Gorlick, MD • Alan Tuchman, MD • Frank Tufaro, PhD<br />
BIO Business Forum 2011 11 Participating Company <strong>Profiles</strong>
Christophe Lautrette (Ph.D)<br />
Chief Executive Officer<br />
1 Avenue d'ester<br />
87069 Limoges<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Christophe Lautrette, CEO<br />
HIGHLIGHTS<br />
Recent<br />
Oncomedics<br />
Clinical Foci: Oncology • Drug Development • Diagnostics<br />
www.oncomedics.com/index.php?page=hom<br />
e&hl=en_US<br />
Phone: 33-5-5533 8525<br />
Incorporated: 2006<br />
Employees: 5<br />
Ownership: Private<br />
Publication in international scientific revues:<br />
- Oncogramme, a new promising method for individualized breast tumour response testing for cancer treatment. Anticancer Res.<br />
2011 Jan;31(1):139-45.<br />
Publication in international scientific revues:<br />
- Oncogramme, a new individualized tumor response testing method: application to colon cancer. Cytotechnology. 2010 Oct;62(5):381-8<br />
CORPORATE MISSION<br />
Oncomedics is a preclinical CRO providing products & services in the field of oncology and assists biotechnology and pharmaceutical<br />
companies in lead optimization and personalized medicine<br />
Oncomedics has developed an innovative technique called Oncogramme, based on primary cell cultures of tumors, from biopsies or<br />
surgeries, in defined medium (which has been validated and published in international scientific revues for best cancer modeling)<br />
allowing:<br />
- Collection & conservation<br />
- Preparation<br />
- Primary cell culture<br />
The “Oncogramme” can be used to evaluate experimental drug efficiency on a panel of tumoral cells allowing the study of patient<br />
heterogeneity in oncology.<br />
PROPRIETARY TECHNOLOGY<br />
Products:<br />
- living human primary tumor cells<br />
- defined medium for their collection, preparation, and culture<br />
Services:<br />
- ex vivo cancer models (colon, prostate, breast ovaries, glyoblastome)<br />
- research and validation of drug-candidate/biomarker<br />
- biomarker screening assay<br />
- customized models<br />
CORPORATE ALLIANCES<br />
Collaborations with several clinical centers and academic research laboratories. Customers include middle pharma, biotech companies<br />
and academic research laboratories<br />
PRODUCTS<br />
Name Phase Indication<br />
Chemically defined medium On Market Tumor cell preparation, conservation or primary culture<br />
Living human tumor cell On Market Cancer research<br />
SENIOR MANAGEMENT<br />
Christophe Lautrette (Ph.D), Chief Executive Officer<br />
BIO Business Forum 2011 12 Participating Company <strong>Profiles</strong>
Harriet Fear<br />
Chief Executive Officer<br />
The Portway<br />
Cambridge<br />
CB21 6LS<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Tony Jones, PhD<br />
CORPORATE MISSION<br />
One Nucleus Ltd<br />
www.erbi.co.uk<br />
Phone: 44-1223-896 463<br />
Incorporated: 1999<br />
Employees: 10<br />
Ownership: Private<br />
About One Nucleus<br />
One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and<br />
London UK, the heart of Europe’s largest life science and healthcare cluster.<br />
Vision: For One Nucleus and our members to be the top European life science and healthcare network.<br />
Mission: We will achieve this by maximising the global competitiveness of our members.<br />
The merger, driven by requests from ERBI and LBN members, results in several member benefits including:<br />
•A large pool of companies to support business-to-business interaction<br />
•Membership of a cluster of international size, relevance and visibility<br />
•One membership providing discounted entry to events in London and Cambridge<br />
•Economies of scale supporting our group purchasing scheme<br />
•An expanded training programme focused on the needs of members<br />
SENIOR MANAGEMENT<br />
Harriet Fear, Chief Executive Officer • Tony Jones, Director • Richard Dickinson, Director • Jean Verney, Director<br />
BIO Business Forum 2011 13 Participating Company <strong>Profiles</strong>
Julian Sanchez Alegria<br />
Chief Executive Officer<br />
Parque Tecnológico de Bizkaia<br />
48160 Derio<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Teresa Porto, Business Deveolpment Manager<br />
HIGHLIGHTS<br />
Recent<br />
One Way Liver Genomics (OWL)<br />
Clinical Foci: Metabolic Disease • CNS • Diagnostics<br />
www.owlgenomics.com<br />
Phone: 3-494-431 8540<br />
Incorporated: 2002<br />
Employees: 16<br />
Ownership: Private<br />
OWL Genomics strives to provide a top quality service for cutting-edge research, using strictly controlled analytical procedures and state of<br />
the art facilities under expert supervision.<br />
From a multi-technological approach, becoming a leader in metabolomics. Applying this technology not only to hepatic diseases but also<br />
to other complex pathologies.<br />
Going from biotechnological research to commercialize new products and services.<br />
CORPORATE MISSION<br />
OWL Genomics is a biotechnology company whose primary objective is to develop new diagnosis and treatment solutions for complex<br />
disease scenarios. The company has focused on the application on metabolomics technology to biomarker discovery.<br />
PROPRIETARY TECHNOLOGY<br />
OWL Genomics has developed an industry leading metabolomic profiling platform for biomarkers discovery. The Metabolomics<br />
department uses mass spectrometry as its technology base. The company has acquired /state of the art mass spectrometers (UPLC/MS),<br />
that interface to ultra performance liquid chromatography system (UPLC) capable of separating large numbers of metabolites found in<br />
complex biological samples.<br />
CORPORATE ALLIANCES<br />
Owl Genomics has settled an agreement with Grupo Ferrer Internacional S.A for Spain except for Basque Country. Also with CIC bioGUNE<br />
for hepatic diseases research and with the well known Fundació Clínic at Barcelone.<br />
INTELLECTUAL PROPERTY<br />
EP05780314.0<br />
“Method for the in vitro diagnosis of non-alcoholic steatohepatitis”<br />
American patent US11/572.562<br />
EP05077320.9<br />
“SP1 as a marker in diagnosis and prognosis of non-alcoholic steatohepatitis (NASH) and target in drug screening for NASH”<br />
American patent US 11/370068<br />
EP 08380249.6<br />
“Method for the diagnosis of Non Alcoholic steatohepatitis (NASH) using metabolic profiles”<br />
EP 08380196.9<br />
“Proteomic fingerprint for the diagnosis of Non Alcoholic steatohepatitis (NASH) and/or steatosis”<br />
?EP 08380249.6<br />
“5 Methilthioadenosina (MTA) as a marker of liver injury”<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Owl liver On Market Owl liver is the first serum based test to be used for Steatosis and NASH diagnosis. It is an<br />
innovative non-invasive method that allows the diagnosis through.<br />
R&D Projects On Market OWL Genomics offers metabolomic services to pharmaceutical and biotechnology<br />
companies in key areas such as biomarkers discovery, clinical studies, diagnostics and<br />
toxicology.<br />
SENIOR MANAGEMENT<br />
Julian Sanchez Alegria, Chief Executive Officer • Azucena Castro Espido, Managing Director<br />
BOARD OF DIRECTORS<br />
Jose Maria Mato, Chief Scientific Officer<br />
SCIENTIFIC ADVISORY BOARD<br />
Jose Maria Mato, Chief Scientific Officer<br />
BIO Business Forum 2011 14 Participating Company <strong>Profiles</strong><br />
2009<br />
2005
Gyo Sagara<br />
President & CEO<br />
8-2, Kyutaromachi 1-Chome, Chuo-ku<br />
Osaka 541-8526<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Daisuke Nakayama<br />
Ryota Udagawa<br />
Susumu Yamamoto<br />
Shinji Shinoda<br />
Saiko Matsuda<br />
Nobusuke Kojima<br />
Ono Pharmaceutical Co. Ltd.<br />
www.ono.co.jp/eng/default.htm<br />
Phone: 81-06-6222-5551<br />
Incorporated: 1717<br />
Employees: 2500<br />
Ownership: Public<br />
Market Cap: $5500.00 million<br />
TOKYO STOCK EXCHANGE: 4528<br />
CORPORATE MISSION<br />
The Ono Pharmaceutical Group, in keeping with our philosophy of "Dedicated to Man's Fight against Disease and Pain," has always striven<br />
to serve as an R&D-oriented international pharmaceutical company. In this endeavor we have placed our emphasis on creating innovative<br />
medicines that meet international requirements. In addition to its own original research and development efforts, Ono has been very<br />
activly seeking a in-licensing opportunity from companies inside and outside Japan.<br />
SENIOR MANAGEMENT<br />
Gyo Sagara, President & CEO<br />
BIO Business Forum 2011 15 Participating Company <strong>Profiles</strong>
Thomas Hudson, MD<br />
President<br />
101 College Street<br />
Toronto, ON M5G 0A3<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Dawn Richards, Senior Business Development Officer<br />
Frank D. Stonebanks, Chief Commercial Officer<br />
Ontario Institute for Cancer Research (OICR)<br />
Clinical Foci: Oncology • Biology • Chemistry<br />
www.oicr.on.ca<br />
Phone: 1-866-678-6427<br />
Incorporated: 2005<br />
Employees: 250<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
International Cancer Genome Consortium announces $20 million Canadian research project to decode the prostate cancer genome<br />
January 13, 2010. OICR Appoints Two Former Biotechnology and Pharmaceutical Industry Executives as Chief Commercial Officer and as<br />
Deputy Director.<br />
July 15, 2009. Pfizer Global Research and Development joins forces with Ontario cancer researchers and contributes $6 million to discover<br />
and validate new targets for the diagnosis, prognosis and treatment of colorectal cancer.<br />
CORPORATE MISSION<br />
The Ontario Institute for Cancer Research (OICR) is a new, innovative cancer research & development institute dedicated to research in<br />
prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the<br />
Government of Ontario through the Ministry of Research and Innovation, with 200 people in research and development and a $100 mm<br />
annual operating budget. It is located in the heart of the innovation district in downtown Toronto, proximal to over 5000 scientists,<br />
physicians and health professionals and more than 10 teaching hospitals. It has key research efforts underway in small molecules,<br />
biologics, stem cells, imaging, genomics, informatics and bio-computing.<br />
CORPORATE ALLIANCES<br />
International Cancer Genome Consortium; The Canada-California Cancer Stem Cell Consortium; The Broad Institute RNAi Consortium; The<br />
Terry Fox Research Institute; Cancer Care Ontario; Canadian Partnership Against Cancer<br />
INTELLECTUAL PROPERTY<br />
The OICR has an "institution owns" IP policy.<br />
SENIOR MANAGEMENT<br />
Thomas Hudson, MD, President • Nicole Onetto, MD, Director • Frank Stonebanks, MBA, Vice President • Rima Al-awar, PhD,<br />
Academic • John McPherson, PhD, Academic • Lincoln Stein, PhD, Academic • Janet Dancey, MD, Academic<br />
BOARD OF DIRECTORS<br />
Calvin Stiller, Professor Emeritus, University of Western Ontario • Elizabeth Eisenhauer, Director, Investigational New Drug Program,<br />
NCIC Clinical Trials Group • Benjamin G. Neel, Director, Ontario Cancer Institute; Research Director, The Campbell Family Cancer Research<br />
Institute • Michael Power, Vice-President, Regional Cancer and Diagnostic Services, Thunder Bay Regional Health Services Centre • Mark<br />
Lievonen, President, Sanofi Pasteur Limited • John Morrison, Former Group President, Healthcare, MDS Inc. • Allan Rock, President and<br />
Vice-Chancellor, University of Ottawa • David Parkinson, President and CEO of Nodality Inc. • Joseph Pater, VP of Clinical and<br />
Translational Research, Cancer Care Ontario • Graham Scott, Senior Partner, McMillan Binch Mendelsohn LLP<br />
SCIENTIFIC ADVISORY BOARD<br />
Elizabeth Eisenhauer, MD, Co-Chair, Director, Investigational New Drug Program, NCIC Clinical Trials Group • Eric S. Lander, PhD, Co-<br />
Chair, Founding Director of the Broad Institute • Lewis Cantley, PhD, Chief, Division of Signal Transduction, Department of Medicine,<br />
Beth Israel Deaconess Medical Center • Tak Mak, PhD, Director, Advanced Medical Discovery Institute, Ontario Cancer Institute • David<br />
Mankoff, MD, PhD, Professor Radiology, Medicine and Bioengineering, University of Washington • Homer Pearce, PhD, Director, Sunesis<br />
Pharmaceuticals, Inc., Board of Directors; Eli Lilly and Co. (retired) • Richard Schilsky, MD, Professor of Medicine and Associate Dean for<br />
Clinical Research, University of Chicago • Jane Weeks, MD, Professor, Department of Medicine, Harvard Medical School • Arul<br />
Chinnaiyan, MD, PhD, Director of Cancer Bioinformatics, University of Michigan Medical School<br />
BIO Business Forum 2011 16 Participating Company <strong>Profiles</strong>
Neil K. Warma<br />
President & CEO<br />
2635 Technology Forest Blvd<br />
The Woodlands, TX 77381<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Neil K. Warma, President & CEO<br />
Opexa Therapeutics<br />
Clinical Foci: CNS • Neurology • Gene/Cell Therapy<br />
www.opexatherapeutics.com<br />
Phone: 1-281-775-0600<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successfully completed two separate meetings with the FDA. Based on positive<br />
FDA feedback, Opexa believes it is now positioned from a regulatory perspective<br />
to advance with a pivotal Phase III clinical study of Tovaxin in patients with MS.<br />
Executed a strategic service agreement with the American Red Cross to provide<br />
blood procurement services to support Opexa's upcoming Phase III study of<br />
Tovaxin in patients with MS.<br />
Closed a public offering for gross proceeds of $8.5 million, to support in part<br />
Opexa's preparation for and process toward the initiation of a pivotal Phase III<br />
clinical study in the U.S. of Tovaxin in patients with MS.<br />
Incorporated: 2004<br />
Ownership: Public<br />
Market Cap: $40.00 million<br />
NASDAQ: OPXA<br />
Preparation is underway for the pivotal Phase III<br />
clinical study of Tovaxin in patients with Relapsing<br />
Remitting Multiple Sclerosis. The U.S.-based clinical<br />
study is expected to commence during the second half<br />
of 2011.<br />
Preparation is also underway for a second pivotal<br />
Phase III clinical study to occur in Europe, potentially<br />
during the second half of 2012.<br />
CORPORATE MISSION<br />
Opexa Therapeutics, Inc. is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment<br />
of autoimmune diseases. The company’s leading product candidate has the potential to address the significant unmet medical needs of<br />
the large multiple sclerosis (MS) patient population.<br />
Opexa Therapeutics, Inc. was established in 2004 through the merger of two independent companies – PharmaFrontiers and Opexa<br />
Pharmaceuticals. PharmaFrontiers had licensed novel stem cell technology from the University of Chicago and Opexa Pharmaceuticals had<br />
licensed novel T-cell technology from the University of Baylor. These two novel and independent platforms propelled Opexa Therapeutics,<br />
Inc. to the forefront of cell therapy where it remains a leading force today.<br />
Opexa’s lead therapy, Tovaxin®, is a cellular immunotherapy having completed a Phase IIb clinical study for the treatment of MS that is<br />
specifically tailored to each patient’s disease profile. Opexa believes the potential combination of efficacy, superior safety, improved<br />
tolerability and administration may position Tovaxin as the MS treatment of choice as compared to existing therapeutics.<br />
Positive results from the Phase IIb Tovaxin for Early Relapsing Multiple Sclerosis (TERMS) study demonstrated key indications of<br />
therapeutic activity, as well as an excellent safety profile.<br />
Planning is underway for a pivotal Phase III clinical study of Tovaxin in Relapsing Remitting Multiple Sclerosis patients. Partnering<br />
discussions are proceeding in parallel.<br />
PROPRIETARY TECHNOLOGY<br />
Opexa’s initial disease targets are autoimmune diseases amenable to T-cell based therapies, such as MS. Opexa has developed a<br />
proprietary T-cell technology platform that allows for the production of patient-specific T-cell therapies that induce therapeutic immune<br />
responses to combat a variety of autoimmune diseases. Tovaxin, Opexa’s lead therapeutic candidate for the treatment of MS is based on<br />
this platform. Tovaxin is a personalized autologous immunotherapy that is not only manufactured for every individual patient but also is<br />
tailored to match each patient’s evolving disease profile. Tovaxin consists of attenuated, patient-specific myelin reactive T-cells against<br />
peptides from the three primary myelin proteins that have been implicated in T-cell pathogenesis of MS.<br />
CORPORATE ALLIANCES<br />
Opexa owns all world wide rights for all indications with ability to sublicense. The Tovaxin platform asset is currently not partnered (100%<br />
owned by Opexa), but potential partnering discussions are ongoing with several companies.<br />
INTELLECTUAL PROPERTY<br />
The current patent portfolio which was initiated in 1998 recognizes the complex interactions of the T cells, B cells, and antibodies<br />
instrumental in autoimmune diseases. The company’s patent portfolio tracks its scientific development programs in autoimmune disease<br />
treatments, with an initial focus on Multiple Sclerosis. The scientific platform is adaptable in that any disease with known specific<br />
antigens, such as Rheumatoid Arthritis, may be a candidate for treatment, and the company’s patent strategy is readily extendable to<br />
encompass these new indications. Currently, Opexa has numerous issued patents and several pending patent applications which it is<br />
pursuing worldwide in key territories.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Tovaxin Phase II, IIa, IIb Multiple Sclerosis Completed Phase IIb TERMS clinical<br />
study<br />
BIO Business Forum 2011 17 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Neil K. Warma, President & CEO • Jaye Thompson, Senior Vice President • Donna Rill, Senior Vice President • Don Healey, Vice<br />
President • John Ginzler, Vice President<br />
BOARD OF DIRECTORS<br />
David Hung, MD, President & CEO, Medivation, Inc. • Michael Richman, President & CEO, Amplimmune, Inc. • David E. Jorden,<br />
Executive Director, Cytomedix, Inc. • Scott B. Seaman, Executive Director, Albert and Margaret Alkek Foundation • Neil K. Warma,<br />
President & CEO, Opexa Therapeutics, Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
Dawn McGuire, MD, Acting CMO, Opexa Therapeutics, Inc. • Hans-Peter Hartung, MD, Chair of Neurology, Heinrich-Heine University,<br />
Dusseldorf • Paul O'Conner, MD, MS Clinic Director at St. Michael's Hospital, University of Toronto • Arthur Vandenbark, PhD, Co-<br />
Director, Neuroimmunology Research Laboratory, Portland Veterans Affairs Medical Center, Portland, OR • Clyde Markowitz, MD,<br />
Director, Multiple Sclerosis Center, University of Pennsylvania • Doug Arnold, MD, Professor of Neurology and Neurosurgery, Montreal<br />
Neurological Institute • Edward Fox, MD, PhD, Director, Multiple Sclerosis Clinic of Central Texas<br />
BIO Business Forum 2011 18 Participating Company <strong>Profiles</strong>
Stuart Abelson<br />
Chief Executive Officer<br />
300 Brickstone Square<br />
Andover, MA 01810<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Brian Campion, Director, Business Development<br />
HIGHLIGHTS<br />
Recent<br />
Ora<br />
Clinical Foci: Ophthalmic • Service • Drug Development<br />
www.oraclinical.com<br />
Phone: 1-978-332-9560<br />
Ownership: Private<br />
iCo Therapeutics Inc. Engages Ora for Ophthalmic Clinical & Regulatory Guidance<br />
05/13/2011<br />
http://www.oraclinical.com/medical_professionals/about_us/media.aspx?id=722<br />
RegeneRx Reports New Statistically Significant Data Confirming Repair of Corneal Damage in Ora's Dry Eye Model<br />
04/13/2011<br />
http://www.oraclinical.com/medical_professionals/about_us/media.aspx?id=692<br />
CORPORATE MISSION<br />
Ora stands committed to working with collaborators and partners to identify and advance the next generation of ophthalmic therapies<br />
and devices.<br />
For over 30 years, Ora has been at the forefront of ophthalmic clinical research. Ora's domain expertise and drug development experience<br />
has made it the preferred ophthalmic drug development partner for many of the top ophthalmic pharmaceutical companies in the world.<br />
Ora has conducted over 1,300 clinical studies and consulting projects, and has built a proven track record that includes 32 FDA approvals<br />
in the ophthalmic space.”<br />
Ora stands apart from all other research groups in that we have conducted over 1,300 clinical trials and consulting projects within the<br />
ophthalmology category. This deep knowledge and expertise has made Ora the preferred ophthalmic drug development partner for many<br />
of the top ophthalmic pharmaceutical companies in the world.<br />
Ora functions as a virtual R&D unit that has helped countless pharmaceutical companies develop new ophthalmic products from<br />
molecule to marketplace. Over the past three decades, we have provided turnkey operations for ophthalmic start-ups, mid-sized<br />
companies, publicly traded companies, and large multinationals.<br />
Our reputation has been built upon a solid foundation of scientific rigor and research excellence. Since our founding, we have developed a<br />
series of proprietary clinical models that have consistently generated accurate and reliable data to support regulatory approvals, both in<br />
the US and around the world.<br />
We design, execute, and innovate the most efficient ophthalmic clinical development programs in the industry. We dedicate considerable<br />
resources towards internal research and development to advance ophthalmic clinical research design, including model innovation and<br />
evolution, endpoint development and evaluation, and clinical trial processes and management strategies.<br />
PROPRIETARY TECHNOLOGY<br />
Ora has developed numerous proprietary clinical study models, methodologies, scales and clinical endpoints for the study of ophthalmic<br />
drugs and devices.<br />
For example, Ora's validated models for conducting allergy studies, the Conjunctival Allergen Challenge (CACSM) and the Enviro-CAC®, are<br />
accepted by regulatory agencies as a standard test system for clinical trials to evaluate ophthalmic anti-allergic agents in the US, Europe,<br />
and Japan.<br />
CORPORATE ALLIANCES<br />
We provide support to companies with established infrastructure and products, as well as companies in need of a complete virtual R&D<br />
unit. We also assist with strategic pipeline building for companies that do not currently have ophthalmic products but wish to enter this<br />
rapidly expanding market. To pragmatically accelerate development, ORA collaborates and creates innovative partnerships.<br />
For media releases about ongoing development activities with select partners:<br />
http://www.oraclinical.com/medical_professionals/about_us/media.aspx?id=51<br />
SENIOR MANAGEMENT<br />
Stuart Abelson, Chief Executive Officer • Mark Abelson, MD, CM, FRCSC, Chief Scientific Officer<br />
BIO Business Forum 2011 19 Participating Company <strong>Profiles</strong>
Nadav Kidron<br />
President & CEO<br />
Kefar Hi-tech 2/5<br />
91390 Jerusalem<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Nadav Kidron<br />
Oramed Pharmaceuticals<br />
Clinical Foci: Drug Delivery • Metabolic Disease • Drug Development<br />
www.oramed.com<br />
Phone: 972-02-566-0001<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
.Oramed Successfully Completes Toxicity Study for ORMD-0801<br />
Oramed Pharmaceuticals Announces Completion of $3.4 Million Private Placement Round<br />
Oramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to<br />
Invest $250,000 in Oramed<br />
CORPORATE MISSION<br />
Incorporated: 2006<br />
Employees: 10<br />
Ownership: Public<br />
Market Cap: $22.00 million<br />
OTC BB: ORMP<br />
Submission of IND to the FDA<br />
Start of Phase 2 FDA approved clinical trial<br />
Founded by scientists after 30 years of groundbreaking research at Hadassah Medical Center in Jerusalem, Oramed Pharmaceuticals<br />
(ORMP.OB) has developed an innovative technology allowing for the oral delivery of drugs currently available via injection only. Oramed’s<br />
flagship product is an oral insulin capsule which has the potential to revolutionize the treatment of diabetes.<br />
Our staff includes many renowned scientists, all of whom are actively involved in the company's strategizing and implementation phases.<br />
To name a few, Professor Avram Hershko, 2004 Noble Prize laureate, Dr. Michael Berelowitz, Senior Vice President at Pfizer, Inc., Professor<br />
Ele Ferrannini, former President of the EASD, and Professor John Amatruda, former Senior Vice President of Merck and Co., Inc who all<br />
significantly contribute to Oramed's progress.<br />
Our plans for 2011 include initiation of Phase 2 FDA approved clinical trials.<br />
The exciting validations of the Oramed oral insulin capsules promise further advancements based on the company’s revolutionary<br />
proprietary technology. In addition to ORMD-0801, Oramed’s pipeline currently consists of an oral method for delivery of GLP 1-Analog<br />
(ORMD-0901).<br />
PROPRIETARY TECHNOLOGY<br />
Oramed’s unique drug delivery technology allows peptides to travel from the<br />
gastrointestinal tract via the portal vein to the bloodstream, enabling passage in a more physiological manner. This technology can also<br />
be utilized for other drugs and vaccines.<br />
CORPORATE ALLIANCES<br />
Oramed has an agreement with Swiss Caps for the production on the capsules.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Oral Insulin Phase II, IIa, IIb Type 2 Diabetes Submit IND in Q4 2011<br />
Oral GLP1 Analog Phase I Type 2 Diabetes Phase 1 clinical trial results<br />
SENIOR MANAGEMENT<br />
Nadav Kidron, President & CEO • Michael Berelowitz, Director • Miriam Kidron, Chief Scientific Officer • Harold Jacobs, Director •<br />
Ehud Arbit, Other<br />
BOARD OF DIRECTORS<br />
Michael Berelowitz • Len Sank • Nadav Kidron • Miriam Kidron • Harold Jacob<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Derek LeRoith, Mt. Sinai School of Medicine, • John Amatruda • Prof. Avraham Hershko, Technion • Prof. Nir Barzillai, Albert<br />
Einstein College of Medicine. • Ele Ferrannini, MD PhD<br />
BIO Business Forum 2011 20 Participating Company <strong>Profiles</strong>
Rajiv Khosla, PhD<br />
Chief Executive Officer<br />
6465 Wayzata Blvd<br />
Minneapolis, MN 55426<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sarah Haecker , PHD, Vice President, Business Development<br />
Orasi Medical<br />
Presenting Company<br />
Clinical Foci: CNS • Diagnostics • Neurology<br />
www.orasimedical.com<br />
Phone: 1-763-951-8001<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
February 2010: Launched first commercial CNS biomarker using MEG measure dose<br />
response, pharmacodynamics and drug mechanism<br />
September 2011 Partnership with Novartis<br />
April 2011 Partnership with Biogen Idec<br />
May 2011 CEO Rajiv Khosla joins Orasi Med<br />
March 2011: Largest commercial database of MEG scans. Scan #2000 processed by Orasi.<br />
2009: Completed Alzheimer's disease, multiple sclerosis and acute drug effect studies.<br />
Achieved > 90% accuracy for Alzheimer's disease classification and multiple sclerosis<br />
classification as compared to healthy aged matched controls<br />
Incorporated: 2007<br />
Employees: 8<br />
Ownership: Private<br />
Publish study results on the use of MEG to<br />
measure the dose response of CNS drugs.<br />
Publish Alzheimer's Disease longitudinal<br />
results.<br />
Announce additional Top 10 pharma<br />
customer deals in 2011<br />
Announce results of Alzheimer's disease<br />
progression and diagnostic study<br />
CORPORATE MISSION<br />
Orasi Medical develops neurological diagnostic products that use electrical brain activity data to measure the effect of neurological and<br />
psychiatric drugs. The Orasi Index, the company’s flagship product, provides pharmaceutical companies invaluable insight into dose<br />
selection, drug mechanism and disease progression. The Orasi Index accurately measures neurological drug effects earlier and<br />
throughout the drug development process to help improve clinical outcomes and reduce costs.<br />
93% of neurological and psychiatric drugs entering clinical trials will fail to reach the market. Most of these failures result from one of the<br />
following: i) Utilizing incorrect drug dose, ii) Inclusion of wrong patients in the trial, iii) Inability to replicate the drug effect found in<br />
animals in humans, and iv) Existing tools for measuring drug effect are inadequate.<br />
The current standard for measuring drug effect in clinical trials is neuropsychological assessment, which is subjective, time consuming<br />
and generally disliked by patients. These challenges result in neurological and psychiatric drug development that on average takes 12-13<br />
years (6 years longer than cardiovascular drugs) with the cost of bringing a drug to market now approaching $1 billion.<br />
Orasi accelerates neurological and psychiatric drug development, reduces costs and improves outcomes by providing pharmaceutical<br />
companies invaluable insight throughout the drug development process by: i) Confirming the drug reaches the brain, ii) Indentifying the<br />
most effective dose, iii) Selecting the best patients, and iv) Measuring drug effect earlier and more accurately.<br />
PROPRIETARY TECHNOLOGY<br />
Using the patent pending Orasi SNI Test, The Orasi Index analyzes a patient’s electrical brain activity scan and enables comparison of<br />
magnetoencephalography (MEG) scan data to assess patient response to drug treatment and patient disease severity. Orasi has the<br />
largest commercial database of MEG brain scans, biomarkers and supporting clinical data for an expanding range of CNS drugs and CNS<br />
disease signatures.<br />
Orasi Index is available online using OrasView. OrasiView is a web based analysis and reporting tool that enables researchers to make<br />
critical, informed decisions regarding drug mechanism, dose selection, patient selection and ongoing treatment effect.<br />
CORPORATE ALLIANCES<br />
Novartis Pharmaceuticals<br />
Biogen Idec<br />
INTELLECTUAL PROPERTY<br />
Orasi's intellectual property was initially developed over five years at the University of Minnesota and Minneapolis VA Hospital. In 2007,<br />
Orasi Medical secured an exclusive world-wide commercial license to the copyrights, data and patents for this technology. Orasi continues<br />
to update its intellectual property portfolio in conjunction with ongoing research and development.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Orasi Index Diagnostics Dose selection, drug mechanism,<br />
pharmacodynamics, pharmacokinetics<br />
Orasi Index Diagnostics Alzheimer's disease progression<br />
Clinical study completed that supports the<br />
use of MEG in measure acute drug effect<br />
and dose selection.<br />
BIO Business Forum 2011 21 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round A: 08/01/2007 (US $2.50 million)<br />
Round B: 04/01/2009 (US $3.50 million)<br />
SENIOR MANAGEMENT<br />
Rajiv Khosla, PhD, Chief Executive Officer • Steve Lebow MD, Chief Medical Officer • Todd Vedroorn PhD, Chief Scientific Officer •<br />
Dallas Steiner, Chief Financial Officer • Sarah Haecker PhD, Business Development<br />
BOARD OF DIRECTORS<br />
Mark Wagner, Founder • Rajiv Khosla, CEO • Ken Heithoff MD, Founder & President of Center for Diagnostic Imaging (CDI) • Michael<br />
Jerstad, PrairieGold Venture Partners • Marcus Enns, CentreStone Ventures • Doug Johnson, University of Minnesota • Chris Fibiger,<br />
PhD, former Biovail • Bob Butz, former Biovail<br />
SCIENTIFIC ADVISORY BOARD<br />
Bill Potter MD PhD, Previously VP Translational Neuroscience Merck • Chris Fibiger PhD, CSO Biovail • Wes Ashford MD PhD,<br />
Stanford/VA Aging Clinical Research Center, Palo Alto • Dick Golden MD, Noran Clinic • Steve Lebow MD, Noran Clinic • Randy<br />
Schapiro MD, Minneapolis Clinic of Neurology<br />
BIO Business Forum 2011 22 Participating Company <strong>Profiles</strong>
Bo Fishback<br />
Chief Executive Officer<br />
2002 West 39th Avenue<br />
Kansas City, KS 66160<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Maria Stecklein Flynn, Chief Operating Officer<br />
CORPORATE MISSION<br />
Orbis Biosciences<br />
Clinical Foci: Drug Delivery<br />
www.orbisbio.com<br />
Phone: 1-913-945-6754<br />
Incorporated: 2007<br />
Ownership: Private<br />
Orbis revolutionizes the delivery, efficacy, and safety of drugs and biologics through unprecedented control of particles. Orbis provides a<br />
new level of control of particle size and architecture, which translates into delivery solutions that enable improved release profiles, provide<br />
drug format flexibility, and reset product exclusivity clocks.<br />
Using Precision Particle Fabrication (PPF) technology, Orbis improves drugs and biologics for desired drug delivery rates and differentiated<br />
products. This patented, scalable solution for controlled release and delivery of drugs is a flexible, single-step process that easily fits with<br />
existing processes.<br />
Controlling particle size and shell thickness gives control of delivery to consistently improve release profiles, safety and efficacy, and taste<br />
masking. Working with pharmaceutical and biotech companies looking to reinvent their products, Orbis develops customized<br />
formulations and the intellectual property for their manufacture. Orbis holds the exclusive license for commercialization. Beyond the life<br />
sciences industry, companies get access to this technology through licensing arrangements and third-party manufacturing partnerships.<br />
PROPRIETARY TECHNOLOGY<br />
Precision Particle Fabrication (PPF) is a robust, affordable, and scalable solution for controlled release and delivery of active ingredients.<br />
PPF produces uniform microparticles or microcapsules with a narrow size distribution and precise control over morphology (e.g. porosity,<br />
coating thickness) to consistently improve:<br />
1) Release profiles – create releases (sustained, pulsatile, staged) to improve compliance,<br />
2) Safety and efficacy – increase time in the therapeutic range,<br />
3) Protection of active ingredient – improve delivery to defined sites,<br />
4) Taste masking – taste mask oral drugs, and<br />
5) Size tolerance – create new routes of administration.<br />
PPF is successful with many materials and sizes (2μ-2mm) in a scalable, flexible, single step process.<br />
CORPORATE ALLIANCES<br />
Working with pharmaceutical and biotechnology companies looking to reinvent their products, Orbis develops customized formulations<br />
and the intellectual property for their manufacture. Beyond the life sciences industry, companies get access to this technology through<br />
licensing arrangements and third-party manufacturing partnerships.<br />
INTELLECTUAL PROPERTY<br />
The PPF technology is patent-protected, and Orbis holds the exclusive license for commercialization. Patents include US Patent No.<br />
6,669,961 titled "Microparticles" TF00058-US. Complete list of patents available upon request.<br />
PRODUCTS<br />
Name Phase Indication<br />
Precision Particle Fabrication (PPF) Other Many<br />
SENIOR MANAGEMENT<br />
Bo Fishback, Chief Executive Officer • Cory Berkland, PhD, Chief Scientific Officer • Maria Stecklein Flynn, Chief Operating Officer •<br />
Milind Singh, PhD, Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Scott Weir, PharmD, PhD, Institute for Advancing Medical Innovation • Valentino Stella, PhD, The University of Kansas • Michael<br />
Beckloff, Beckloff Associates, Inc.<br />
BIO Business Forum 2011 23 Participating Company <strong>Profiles</strong>
Janneke Meulenberg<br />
Chief Executive Officer<br />
de Boelelaan 1118<br />
1081 HZ Amsterdam<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Janneke Meulenberg<br />
CORPORATE MISSION<br />
ORCA Therapeutics<br />
Clinical Foci: Oncology • Biopharmaceuticals<br />
www.orca-therapeutics.com<br />
Phone: 31-20-444 1826<br />
Incorporated: 2005<br />
Ownership: Private<br />
ORCA Therapeutics develops effective anticancer treatments using Oncolytic Replication Competent Agents (ORCA). Oncolytic viruses<br />
represent a promising new departure for treatment of cancer. Multiple preclinical and clinical studies have proven the concept: oncolytic<br />
viruses can seek out and destroy cancer cells while leaving normal cells undisturbed. Owing to their ability to self-replicate within the<br />
cancer cell, oncolytic viruses have unique pharmacokinetic properties that set them apart from conventional small molecule or<br />
monoclonal antibody-based therapeutics. Oncolytic viruses are programmed to specifically replicate in and ultimately kill tumor cells,<br />
while healthy cells are left unharmed thereby minimizing side effects. Since the mode of action of oncolytic viruses is different from<br />
currently available therapies, ORCA’s oncolytic virus approaches offer the potential for novel and powerful therapies to treat cancer, both<br />
in the standalone and especially in the combination or adjuvant setting.<br />
PROPRIETARY TECHNOLOGY<br />
ORCA has a broad and versatile multi-modal oncolytic virus technology platform.<br />
CORPORATE ALLIANCES<br />
ORCA has partnerships with the Department of Medical Oncology at the VU University Medical Center in Amsterdam, The Netherlands,<br />
and the the Catalan Institute of Oncology (ICO), Barcelona, Spain.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ORCA-010 Preclinical Prostate cancer Start Phase I/II trial<br />
SENIOR MANAGEMENT<br />
Janneke Meulenberg, Chief Executive Officer • Victor van Beusechem, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Karl Rothweiler, Aglaia BioMedical Ventures • Mark Krul, Aglaia BioMedical Ventures<br />
SCIENTIFIC ADVISORY BOARD<br />
Franck Mc Cormick, Helen Diller Family Comprehensive Cancer Center & Cancer Research Institute of the University of California, San<br />
Francis • Ramon Alemany, Catalan Institute of Oncology (ICO), Barcelona, Spain • Winald Gerritsen, VUmc Cancer Center Amsterdam,<br />
The Netherlands<br />
BIO Business Forum 2011 24 Participating Company <strong>Profiles</strong>
K Raghavendra Rao<br />
Chief Executive Officer<br />
#313, Valluvar Kottam High Road<br />
Chennai 600 034<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Prasad S. Patala<br />
Orchid Chemicals & Pharmaceuticals Ltd<br />
Clinical Foci: Drug Discovery • Drug Development • Generics<br />
www.orchidpharma.com<br />
Phone: 91-44-28211000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Presented NCE pipeline: BLX-1002: EASL, International Liver<br />
Congress, Berlin, 2011, ADA, San Diego, 2011, OCID 4681: AAPS,<br />
2010, TAT, 2011, OCID 2987: World Inflammation Congress, 2011,<br />
Paris<br />
Phase 1 for OCID 2987, DP-4088 and await IND for OCID 4681<br />
ORCHID makes progress in Merck anti-infective collaboration,<br />
involves in established product development and manufacturing<br />
as part of MSA with Pfizer, continues to support new product<br />
development & NDA filing for an global innovator pharmacetical.<br />
ORCHID at a group level, acquired US-based marketing company<br />
Karalex Pharma, to strengthen its presence in the front-end US<br />
market and to reach its generic products to the US customers<br />
directly.<br />
Incorporated: 1993<br />
Ownership: Public<br />
Market Cap: $500.00 million<br />
NATIONAL STOCK EXCHANGE OF INDIA:<br />
ORCCHEM<br />
Complete Phase 1 clinical trial studies of OCID 2987, PDE4 inhibitor,<br />
while pursuing select out-licensing opportunities, Complete<br />
bridging phase 1 studies for DP -4088, a direct thrombin inhibitor,<br />
while pursuing select out-licensing opportunitie<br />
Initiate OCID 4681, novel HDAC inhibitor Phase 1 trials following<br />
approval of submitted IND package, while pursuing collaborative<br />
efforts for further development, Out-license BLX-1002 for NAFLD,<br />
while seeking co-development options.<br />
Out license and co-develop OCID5090 as combination product with<br />
new or old antibiotics (betalactums).<br />
Also, ORCHID seeks to in-license or collaborate on opportunities to<br />
enhance its NCE/product pipeline.<br />
CORPORATE MISSION<br />
Orchid Chemicals & Pharmaceuticals Ltd (ORCHID) is a leading Indian Pharmaceutical company, which has attained status of a global<br />
pharmaceutical player and is fuelling further growth with its innovation driven strategy to embark on R & D of novel small molecules and<br />
new products through its scientific, technical and manufacturing competencies backed by global intellectual property management. .<br />
ORCHID’s global footprint has advanced over the last decade by its expertise of operating in the domains of active pharmaceutical<br />
ingredients (APIs), finished dosage forms (FDFs – GENERICS), New Drug Discovery, Custom Research and Manufacturing Services (CRAMS).<br />
As an on-going effort, Orchid continues to expand its geographical presence, product and service-offering portfolio through acquisitions<br />
and co-marketing alliances.<br />
Innovation plays a strategic role in the growth of the company, wherein ORCHID through its drug discovery subsidiaries: Bexel<br />
Pharmaceuticals Inc in USA, Orchid Research Laboratories Ltd in India, and affiliate Diakron Pharmaceuticals Inc in USA, has ongoing New<br />
Drug Discovery Programs in therapeutic areas of metabolic disorders, cardio-vascular, oncology, inflammation and anti-infectives on<br />
validated and undisclosed targets.<br />
In a partnership based business approach:<br />
1. Focused proprietary drug discovery and development on validated/undisclosed target and novel mechanisms brings forth a rich<br />
pipeline of NCE’s for out-licensing to Innovator Pharmaceutical companies.<br />
2. Collaborative Drug Discovery and Development with select Big Pharmaceutical and Bio-Technology enables joint effort to synergise<br />
plans either in early discovery or late drug development leading to NCE/Product pipeline expansion for global markets and specific<br />
patient needs<br />
PROPRIETARY TECHNOLOGY<br />
ORCHID’s Proprietary NCE Pipeline:<br />
BLX-1002: Oral amino-acid conjugate molecule in Clinical Phase 2 for NASH/NAFLD<br />
OCID 2987: Selective PDE4 inhibitor in Clinical Phase 1 for inflammatory conditions.<br />
OCID-4681: Class I selective HDAC inhibitor in Clinical Phase 1 for oncology.<br />
OCID 5090: Beta-lactamase inhibitor in late preclinical with potent KPC 2 & 3 activity envisaged as a novel combination with current or<br />
new antibiotics (Beta-lactums).<br />
DPOC-4088: Oral direct thrombin inhibitor in Clinical Phase1 studies.<br />
OCID 5005: STAT3 inhibitor in late Preclinical studies<br />
BIO Business Forum 2011 25 Participating Company <strong>Profiles</strong>
CORPORATE ALLIANCES<br />
ORCHID’s Collaboration:<br />
An on-going new drug discovery and development collaboration with MERCK in undisclosed areas of anti-infectives.<br />
Master Research & Manufacturing Services Agreement with Pfizer, other undisclosed Innovator, Speciality and Biotech companies.<br />
Manufacturing and Distribution Alliances: Orchid’s quality manufacturing competence and international regulatory focus has resulted in<br />
exclusive marketing and distribution alliances with several global pharmaceutical corporations including Apotex, Actavis, Hospira and<br />
Dava among others.<br />
China JV - NCPC-Orchid Pharmaceuticals Ltd: Orchid has a manufacturing and marketing joint venture with the North China<br />
Pharmaceutical Corporation (NCPC), the largest pharmaceutical group in China.<br />
INTELLECTUAL PROPERTY<br />
One of leading and top 5 Global Intellectual Property filers from India and backed by sound Intellectual Property and Management(IPM)<br />
Policy<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
BLX-1002 Phase II, IIa, IIb Metabolic Disorders - NAFLD/NASH<br />
DPOC-4088 Phase I Cardio-Vascular (Direct Thrombin Inhibitor) Oral direct thrombin inhibitor, in<br />
Bioequivalence Clinical Phase1 studies<br />
OCID 2987 Phase I Inflammation- PDE4 inhibitor Selective PDE4 inhibitor in Clinical Phase 1 for<br />
inflammatory/dermatological indications.<br />
OCID-4681-S-01 Phase I Cancer - Pan/Specific HDAC inhibitors Class I selective HDAC inhibitor, in Clinical<br />
Phase 1 for oncology<br />
OCID 5090 Preclinical Anti-infectives (Beta-lactamase inhibitor) Beta-lactamase inhibitor in late preclinical<br />
SENIOR MANAGEMENT<br />
K Raghavendra Rao, Chief Executive Officer • Dr B Gopalan, Chief Scientific Officer • Dr Shridhar Narayanan, Senior Vice President •<br />
Dr Prasad S Patala, Executive Vice President<br />
BOARD OF DIRECTORS<br />
K Raghavendra Rao<br />
BIO Business Forum 2011 26 Participating Company <strong>Profiles</strong>
Keith Murphy<br />
Chief Executive Officer<br />
5871 Oberlin Dr.<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Organovo, Inc.<br />
Clinical Foci: Drug Discovery • Oncology • Metabolic Disease<br />
www.organovo.com<br />
Phone: 1-858-550-9994<br />
Keith Murphy Sharon Presnell, EVP, R&D<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Signed major deal with Pfizer for discovery in two therapeutic areas using platform 3D<br />
bioprinting technology<br />
Demonstrated vasculariazed 3D tissue enabling specific investigation of pathology of<br />
multiple diseases where 3D cellular orientation is relevent (Oncology, diabetes, fibrosis,<br />
PAH)<br />
Demonstrated that 3D bioprinted tissues can be made from primary human cells robustly<br />
for better applicability of research results<br />
Incorporated: 2008<br />
Employees: 25<br />
Ownership: Private<br />
Delivery of fully human perfused ex vivo<br />
tumor constructs utilizing 3D bioprinting<br />
platform<br />
Delivery of fully human perfused ex vivo<br />
pancreatic constructs that allow beta cells to<br />
be interrogated and persist ex vivo utilizing<br />
3D bioprinting platform<br />
CORPORATE MISSION<br />
Organovo utilizes its proprietary cellular 3D Bioprinting technology to create best in class research and commercial opportunities for<br />
pharmaceutical development partners. 3D Bioprinting was invented by Organovo’s scientific founder, Gabor Forgacs, at the University of<br />
Missouri-Columbia under a $5M National Science Foundation grant. The company has utilized initial private funding and multiple grants<br />
from the National Institutes of Health SBIR program to transform Dr. Forgacs’ initial achievements in cellular printing into a drug<br />
discovery platform that can produce functional 3D human tissue with highly conserved native structure for accurate disease modeling.<br />
Headquartered in San Diego, California, Organovo has partnered with the Harvard Medical School and the Sanford Consortium for<br />
Regenerative Medicine, a collection of San Diego’s leading research institutions, to further leverage the capabilities of the 3D Bioprinting<br />
platform.<br />
PROPRIETARY TECHNOLOGY<br />
Patent pending 3D Bioprinting technology creates unique and powerful ways to investigate multiple in vivo systems of interest,<br />
elucidating the true biology of specific cells in 3D and their roles in human conditions and disease. Organovo’s partners commercialize<br />
first to market opportunities. The 3D bioprinter is being utilized by partners today institutions to develop solutions in creating useful 3D<br />
tissue. Organovo’s discovery platform can quickly produce constructs that can be utilized for drug development, such as a small perfused<br />
tissue construct that allows study of human vasculature in human parenchyma and one that creates appropriate in vivo conditions to<br />
study pharmacologic signal transduction across an endothelial or epithelial cell lining<br />
CORPORATE ALLIANCES<br />
Pfizer - two therapeutic area deal for creation of useful constructs for drug discovery research<br />
Undisclosed - PAH platform development<br />
INTELLECTUAL PROPERTY<br />
Patent pending<br />
Broad coverage of underlying cellular combination methods and final composition of matter<br />
Coverage in multiple therapeutic areas<br />
Licenses available in specific therapeutic areas<br />
PRODUCTS<br />
Name Phase Indication<br />
Diabetes Discovery Platform Research Bioprinting 3D Diabetes Research Constructs<br />
Fibrosis Discovery Platform Research Bioprinting 3D Fibrosis Research Constructs<br />
Cardiovascular Discovery Platform Research Bioprinting 3D CV Research Constructs<br />
PAH Discovery Platform Research Bioprinting 3D PAH Research Constructs<br />
Oncology Discovery Platform Research Bioprinting 3D Oncology Research Constructs<br />
SENIOR MANAGEMENT<br />
Keith Murphy, Chief Executive Officer • Sharon Presnell, Executive Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
David Mooney, Harvard University • Gordana Vunjak-Novokovic, Columbia University • Glenn Prestwich, University of Utah • Craig<br />
Kent, Chief of Surgery, Univ Wisconsin • Gabor Forgacs, Univ of Missouri<br />
BIO Business Forum 2011 27 Participating Company <strong>Profiles</strong>
Wei-wu He, PhD<br />
Chief Executive Officer<br />
9620 Medical Center Drive<br />
Rockville, MD 20850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
OriGene Technologies, Inc<br />
Clinical Foci: Diagnostics • Immunology • Oncology<br />
www.origene.com<br />
Phone: 1-301-340-3188<br />
Mark Watson, Sr. Director, Business & Corporate Development<br />
HIGHLIGHTS<br />
Recent<br />
Incorporated: 1996<br />
Employees: 250<br />
Ownership: Private<br />
OriGene Releases 2,000 TrueMAB Monoclonal Antibodies<br />
Extensively Validated mAbs Made Against Native Protein Antigens for Superior IHC, IF, ELISA and Flow Applications<br />
Each TrueMAB Ab is specifically developed with full-length human proteins.<br />
OriGene Technologies Acquires Blue Heron Biotechnology, A Leading Gene Synthesis Company<br />
One of the most successful gene synthesis companies, providing customers with solutions for complex DNA synthesis, Blue Heron is now<br />
part of OriGene Tech.<br />
OriGene Releases Bioactive Full-Length Human MTOR Protein<br />
Release of the first commercially available full-length human MTOR protein with superior biological activity. Produced in mammalian<br />
cells, the MTOR protein is desirable in screening assays.<br />
CORPORATE MISSION<br />
OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies<br />
in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow<br />
researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone<br />
collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB), 100,000 highly validated human tissues,<br />
and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genomewide<br />
tagged antigen standards and extensive IHC slides derived from our tissue collection.<br />
PROPRIETARY TECHNOLOGY<br />
- Proprietary +10,000 protein microarray for autoantibody studies, antibody decoding and determination of antibody specificity<br />
- Highly validated monoclonal antibodies for immunoassay development and diagnostics<br />
- Purified Human Proteins Expressed in Mammalian Expression Systems<br />
- Gene Synthesis (Antibody variant libraries and protein codon optimization)<br />
- >100,000 human tissue samples of human cancer and normal tissue origin, each collected under strict collection protocol and IRB<br />
methodologies<br />
CORPORATE ALLIANCES<br />
- Institute for Systems Biology (ISB)<br />
- Royal Institute of Technology (Sweden)<br />
- Hitachi Software Engineering America Ltd.<br />
- Various Top 20 Global Pharmaceuticals Companies<br />
- Global Diagnostic Instrument & Reagent Providers<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TrueMAB Monoclonal<br />
Antibodies<br />
Purified Human Proteins<br />
from HEK293T<br />
(Mammalian) Cells<br />
Preclinical Various Hybridoma Cell Lines<br />
& Purified Monoclonal<br />
Antibodies for Research &<br />
Diagnostic Use<br />
High-throughput Hybridoma Development Leading to the<br />
Release >2,000 Fully Validated Monoclonal Antibodies in<br />
Early 2011<br />
Research Various OriGene now offers >5,000 full-length human proteins<br />
expressed in HEK293 cells and purified with affinity<br />
column.Optimal preservation of protein structure, posttranslational<br />
modifications and functions. >80% purity<br />
through affinity purification.<br />
BIO Business Forum 2011 28 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Gene Synthesis<br />
Capabilities through<br />
Blue Heron<br />
Biotechnology<br />
TrueORF Gold -<br />
Expression-validated<br />
cDNA Clones<br />
Multiplexed<br />
Immunoassay<br />
Development for the<br />
Luminex xMAP Platform<br />
Human Cancer and<br />
Normal Tissue Products<br />
Heavy Labeled Full-<br />
Length Proteins as MRM/<br />
MS Standards<br />
Preclinical Gene Synthesis Leading Gene Synthesis Company to Large Pharma<br />
Supplying Synthetic DNA. Blue Heron Was the Supplier of<br />
Synthetic DNA Fragments to Develop the First Synthetic Cell<br />
for the J. Craig Venter Institute. Offering Includes Services<br />
for Protein & Ab Optimization.<br />
Research Tested Individually by Western,<br />
Sequence Verified, Next Day<br />
Shipment, Transfection Ready,<br />
and Easily Shuttled Into Over<br />
60 Vectors<br />
Preclinical OriGene is a Certified Luminex<br />
Developer And Provides<br />
Custom Multiplexed<br />
Immunoassay Development<br />
Services for Various Research<br />
And Commercial<br />
Organizations<br />
Preclinical Primarily Cancer and Normal<br />
Tissues for use in Biomarker<br />
Validation; Other Areas of<br />
Research are Available<br />
Diagnostics For Accurate Quantification of<br />
Human Protein Biomarkers<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round B: 03/17/2010 (US $16,000,000.00 million)<br />
SENIOR MANAGEMENT<br />
TrueORF Gold is OriGene’s collection of premium cDNA<br />
clones that have passed the ultimate tests: sequence<br />
verification and protein expression validation.<br />
The Assay Development Team At OriGene Possesses<br />
Extensive Development Expertise Using Luminex and<br />
Various Platforms. Whether its Assays for Research or Drug<br />
Development, OriGene Can Ensure Success.<br />
OriGene has assembled a comprehensive collection of<br />
>140,000 high quality human tissues collected under strict<br />
guidelines and IRB practices<br />
Each MRM/ MS Standards is Thoroughly Tested and<br />
Validated By MS Through a Collaboration with The Institute<br />
for Systems Biology (ISB)<br />
Wei-wu He, PhD, Chief Executive Officer • James Hu, General Counsel • Mark Watson, Business Development • Dr. Walter Tian, Vice<br />
President • Gene Dove, Vice President • Jim Lazar, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Jim Lazar, PhD, Vice President, Assay Development • Donghui Ma, PhD, Director of Immunology • Youmin Shu, PhD, Vice President,<br />
Gene Synthesis Services<br />
BIO Business Forum 2011 29 Participating Company <strong>Profiles</strong>
Timo Lappalainen<br />
President & CEO<br />
P.O. Box 65<br />
02101 Espoo<br />
Finland<br />
CONFERENCE PARTICIPANTS<br />
Reijo Salonen<br />
Pekka Kallio, Head of Oncology and Critical Care Research<br />
Juha Rouru<br />
Ilkka Larma<br />
Arto Toivonen, Business Development Director<br />
Jukka Muhonen<br />
Orion Corporation<br />
Clinical Foci: CNS • Oncology • Specialty Pharmaceutical<br />
www.orionpharma.com<br />
Phone: 358-10-4261<br />
Incorporated: 1917<br />
Employees: 3100<br />
Ownership: Public<br />
Market Cap: $3500.00 million<br />
HELSINKI STOCK EXCHANGE: ORNAV/BV<br />
CORPORATE MISSION<br />
Orion is an innovative European R&D-based pharmaceuticals and diagnostics company with an emphasis on developing medicinal<br />
treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals,<br />
active pharmaceutical ingredients as well as diagnostic tests.<br />
CORPORATE ALLIANCES<br />
Novartis, Hospira, Pfizer, Endo Pharmaceuticals, Takeda, Aurigene Discovery Technologies, Recordati, Upsher-Smith Limited<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Stalevo®, Comtess® and<br />
Comtan®<br />
On Market Parkinsonson's disease<br />
Simdax® (levosimendan) On Market Acute decompensated heart failure<br />
Easyhaler® product family On Market Asthma, COPD<br />
Precedex® (dexmedetomidine) On Market Intensive care sedation Dexmedetomidine MAA<br />
submitted in Europe<br />
Dexdomitor®, Domitor®,<br />
Domosedan® and Antisedan®<br />
On Market Animal sedation<br />
Enanton® On Market Prostate cancer<br />
Fareston® On Market Breast cancer<br />
Alpha-2C adrenoceptor<br />
antagonist<br />
SENIOR MANAGEMENT<br />
Timo Lappalainen, President & CEO<br />
Phase II, IIa, IIb Alzheimer’s disease and Raynaud’s<br />
phenomenon<br />
BIO Business Forum 2011 30 Participating Company <strong>Profiles</strong>
Scott Thacher<br />
Chief Executive Officer<br />
11494 Sorrento Valley Road<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Scott M. Thacher, PhD, Chief Executive Officer<br />
Judy Blakemore, Business Development<br />
Orphagen Pharmaceuticals, Inc<br />
Clinical Foci: Drug Discovery • AutoImmune • Oncology<br />
www.orphagen.com<br />
Phone: 1-858-481-6191<br />
Employees: 7<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Awarded $622,971 in Qualified Therapeutic Discovery Program grant funding that was provided for in the Health Care and Education<br />
Reconciliation Act of 2010.<br />
Awarded Phase 1 SBIR funding for adrenocortical and prostate cancer drug discovery research.<br />
Awarded Phase 2 SBIR funding to investigate a novel drug class for CNS disorders.<br />
CORPORATE MISSION<br />
Orphagen is focused on the discovery of first-in-class drugs targeting orphan nuclear receptors. Our technology and expertise enable us to<br />
pursue a first-to-ligand approach in which we rapidly discover and validate ligands for these orphan targets. Our programs span a range<br />
of therapeutic areas, including oncology (adrenocortical cancer, castration-resistant prostate cancer), ophthalmological diseases (retinitis<br />
pigmentosa, dry age-related macular degeneration), autoimmune diseases and CNS disorders.<br />
Our strategy is to partner our novel discovery programs for newly validated targets at the lead stage. We partnered our autoimmune<br />
discovery program with Japan Tobacco in 2008. We now have three other programs in various stages of discovery. We are seeking funding<br />
from pharmaceutical companies, corporate venture groups or other investors to advance these discovery programs to the stage at which<br />
they can be partnered.<br />
Founded in 2003, Orphagen been funded entirely by non-dilutive sources, including partnering revenue and more than $5 million in<br />
federal grants.<br />
PROPRIETARY TECHNOLOGY<br />
Expertise in orphan screening methods to identify operational ligands to selected orphan nuclear receptors. Once these ligands are<br />
obtained, we employ diverse resources, including internal research and external collaboration, to further elucidate the role of these<br />
receptors and validate their relevance to disease states triggered by inappropriate receptor activity.<br />
CORPORATE ALLIANCES<br />
Japan Tobacco<br />
INTELLECTUAL PROPERTY<br />
Patent applications filed.<br />
PRODUCTS<br />
Name Phase Indication<br />
SF-1 Discovery Program Lead Series Adrenocortical cancer, Castration-resistant prostate cancer,<br />
Cushing's Syndrome<br />
Retinal Degeneraton Program Lead Series Retinitis pigmentosa, Dry Age-Related Macular Degeneration<br />
Circadian Rhythm Discovery Program Lead Series CNS disorders<br />
SENIOR MANAGEMENT<br />
Scott Thacher, Chief Executive Officer • Judy Blakemore, Business Development<br />
BOARD OF DIRECTORS<br />
Scott Thacher, Orphagen Pharmaceuticals, Inc. • Timothy Scott, Pharmatek Laboratories, Inc. • Robert Shopes, Tera Biotechnology<br />
Corporation • Leonard Post • Marvin Rosenthale, Pharmaceutical Consultants<br />
BIO Business Forum 2011 31 Participating Company <strong>Profiles</strong>
Immeuble "Le Wilson"<br />
92058 Paris<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Michael Spelta<br />
Marco Liguori<br />
Orphan Europe<br />
Clinical Foci: Genetic Disorders • Metabolic Disease • CNS<br />
www.orphan-europe.com<br />
Phone: 33-1-4773 6458<br />
HIGHLIGHTS<br />
Recent<br />
Carbaglu for the treatment of NAGS deficiency approved in the USA<br />
Vedrop, a water -soluble vitamin E formulation, pproved in the EU<br />
CORPORATE MISSION<br />
Incorporated: 1990<br />
Employees: 130<br />
Ownership: Public<br />
Market Cap: $1200.00 million<br />
ITALIAN STOCK EXCHANGE: REC<br />
Orphan Europe is a European-based pharmaceutical company, committed to the search, development and marketing of orphan drugs, i.e.<br />
drugs which are intended for the treatment of rare and life threatening diseases for which no adequate treatment is available, and more<br />
broadly, to niche specialty care pharmaceuticals. Our business strategy consists in licensing in from different private, public or academic<br />
sources compounds actually or potentially falling into the above mentioned segments, completing their development -where necessaryand<br />
commercializing the upcoming pharmaceutical specialty throughout the world. We have fully owned subsidiaries in the key European<br />
countries and we globally export our products from our home country to more than 50 foreign markets. In December 2007 Orphan Europe<br />
was bought by the Italian multinational group, Recordati, of which Orphan Europe is today a fully owned subsidiary.<br />
The drugs we are interested in belong to diverse therapeutic areas, providing that they meet the criterium of hospital-based, specialty care<br />
pharmaceuticals.<br />
We offer extensive expertise and know-how in all aspects covering the business in the area of orphan drugs (development, regulatory,<br />
production, packaging, distribution, information, marketing, etc. ).<br />
Orphan Europe's turnover in 2010 was above 55 million Euros.<br />
Recordati's net sales in 2010 were close to 730 million Euros.<br />
The main interest for attending the meeting is to get in touch with any partner offering orphan drugs or, generally speaking, secondary or<br />
critical care medicines, for either marketing by our affiliates in their respective countries ( if the drug is already fully developed ) or for<br />
acquiring a development and marketing licence ( if the drug is not yet fully developed and the development needs be completed prior to<br />
marketing ).<br />
Co-development arrangements with final sharing of territorial rights with the co-development partner are also possible.<br />
CORPORATE ALLIANCES<br />
Orphan Europe has a number of collaboration agreements with US, European, Asian and other partners :<br />
US: Enzon, Mylan, TEVA, QoL, Rare Disease Therapeutics<br />
Europe: Schering AG and Merckle ( Germany ), Swedish Orphan (Sweden), Nycomed (Denmark)<br />
Asia: Excelsior Biopharma (Taiwan), CMIC (Japan)<br />
Africa : Tema (Pierre Fabre)<br />
BIO Business Forum 2011 32 Participating Company <strong>Profiles</strong>
Carlos Buesa, Ph.D<br />
Chief Executive Officer<br />
Sant Ferran 74<br />
08940 Cornellà de Llobregat (Barcelona)<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Carlos Buesa, CEO<br />
Emili Torrell, Business Development Director<br />
Oryzon Genomics, S.A.<br />
Clinical Foci: Oncology • CNS • Diagnostics<br />
www.oryzon.com<br />
Phone: 34-93-5151313<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Awarded a $300,000 Research Grant to Accelerate Development of<br />
Novel Therapeutics for Alzheimer's Disease (January 2011)<br />
Oryzon Licenses Human Antibody Phage Display Technology for<br />
Discovery of Novel Therapeutics From Dyax Corp (Nov. 2010).<br />
ProteoNic and Oryzon awarded European grant for joint<br />
development of therapeutic antibodies against prostate cancer<br />
(Sep. 2010)<br />
Oryzon is member of MIND Consortium, devoted to the<br />
multidisciplinary approach in the treatment of Alzheimer's disease.<br />
Oryzon is also member of DENDRIA, a Consortium devoted to the<br />
discovery and development of CNS therapeutic compunds.<br />
Incorporated: 2000<br />
Employees: 60<br />
Ownership: Private<br />
Q2/2011: Preclinical candidate of the CNS LSD1i small molecule<br />
program.<br />
Q4/2011: Preclinical candidate of the cancer LSD1i small molecule<br />
program.<br />
4Q/2011: Launching of proprietary gene expression diagnostic test<br />
on endometrial Cancer<br />
2011-12: Strategic Partnership with pharmaceutical companies on<br />
target validation programs<br />
2012: First internal small molecule program entering in clinical<br />
Phase 1<br />
CORPORATE MISSION<br />
Oryzon is the first Spanish biomarker and target discovery company in cancer and neurodegenerative disorders, with HQ and R&D Centre<br />
located in Barcelona.<br />
After a successful B series funding in 2008, the company acquired Crystax Biopharmaceuticals, gaining fragment screening,<br />
crystallography and structural genomic expertise.<br />
Oryzon biomarker programs have successfully resulted not only in the identification of a new molecular signature useful for the early<br />
diagnosis of endometrial cancer (which has been validated in a clinical trial with 500 patients recruited from 14 hospitals) but also in the<br />
characterization of new druggable targets for several oncological and neurological diseases. Oryzon has a fast moving dynamic chemistry<br />
program with +30 chemists and biologists. Oryzon uses a powerful combination of state of the art fragment screening and molecular<br />
modeling technology, along with traditional SAR approaches, to identify new chemical entities having novel mechanisms of action with<br />
the potential to be first in class. Oryzon is developing a rich pipeline of targets that we are progressing through preliminary target<br />
validation before devoting more medicinal chemistry resources to them.<br />
In view of the novel and interesting modes of actions of the compounds progressing through our pipeline, we expect these programs will<br />
be of interest to many pharmaceutical companies.<br />
Key therapeutic projects are a lead optimization dual LSD1 inhibitor & MAO-B program in CNS covering Huntington, Parkinson, Alzheimer<br />
and other dementias and a lead optimization LSD1 inhibitor program in cancer.<br />
In our CNS program, we have several PoC in several animal models. This program has raised significant interest in the field and we have<br />
been recently awarded with a Grant from the Alzheimer Drug Discovery Foundation. We expect to have a PCDC in 2Q2011 and to be in<br />
Phase I in 2012.<br />
PROPRIETARY TECHNOLOGY<br />
The technology assets of Oryzon include the following platforms:<br />
1.Functional Genomics Platform for Biomedical Projects: (i) biomarker/target discovery programs, (ii) Design of specific microarrays, (iii)<br />
Toxicogenomics and pharmacogenetics studies for the pharmaceutical and biotechnology industry<br />
2.Fragment based approach (NMR and X-Ray Crystallography) combined with medicinal chemistry and computational methods for the<br />
identification and optimization of novel chemical series<br />
CORPORATE ALLIANCES<br />
Oryzon has collaborated and/or currently has alliances with companies such as Almirall, Esteve, Palau Pharma, Ferrer, Servier, Reig-Jofré,<br />
Leti, GVK, etc.<br />
We are ready to partner some of our therapeutic preclinical programs with pharma companies. Additionally, we are interested to set up<br />
alliances based on our Technology Platforms. Our Genomic Platform significantly contribute on Biomedical Projects: (i) biomarker/target<br />
discovery programs, (ii) Design of specific microarrays, (iii) Toxicogenomics and pharmacogenetics studies for the pharmaceutical and<br />
biotechnology industry.<br />
Moreover, our Fragment based approach combined with medicinal chemistry and computational methods in house are key drivers for the<br />
identification and optimization of novel chemical series in a very efficient manner.<br />
BIO Business Forum 2011 33 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Oryzon has a significant number of patent applications in different technologies as well as in products under development. Our current<br />
portfolio comprises the ownership or exclusive license of 41 patent families with over 70 patent applications on chemistry, technology and<br />
biomarkers, some of them already granted.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Dual LSD1 inhibitor & MAO-B<br />
program in PD , AD and other<br />
dementias<br />
LSD1 program ( LSD-1 inhibitors )<br />
in cancer<br />
IVD Endometrial cancer test ( In<br />
vitro diagnostics).<br />
Biophysics based drug discovery<br />
platform B2D2<br />
Genomic and proteomic<br />
platform<br />
IVD Prostate cancer test ( In vitro<br />
diagnostics)<br />
EPHRIN B4 prognostic marker in<br />
colorectal cancer<br />
mAb program in prostate and<br />
endometrial cancer<br />
Optimized Lead Huntington, Parkinson,<br />
Alzheimer and other dementias<br />
Potency equivalent to rasagiline and selegiline<br />
plus the added benefit of LSD1 inhibition.<br />
Molecules able to penetrate the BBB in mouse<br />
and to change key genes in the onset and<br />
progression of the disease.<br />
Optimized Lead Neoplasms / cancer / oncology Inhibitory effect in the nM range leading to<br />
activation of the p53 pathway & overexpression<br />
of key genes that regulate the WNT<br />
signaling pathway, down-reg. of several<br />
oncogenes and tumor progression genes and<br />
inhibition of cell cycle transition genes<br />
Diagnostics Gene expression non-invasive<br />
diagnostic of Endometrial<br />
cancer<br />
Other Structural Genomics /<br />
Molecular modeling<br />
Other Target Discovery (proteomic or<br />
genomic based)<br />
Diagnostics Gene expression diagnostic of<br />
Prostate cancer<br />
Other CCR<br />
Lead Series prostate and endometrial<br />
cancer<br />
FINANCING HISTORY<br />
Investors: Founders (33 %) • Najeti Capital SCR S.A. (32 %) • Minority Shareholders (35 %)<br />
SENIOR MANAGEMENT<br />
IVD kit for early detection of endometrial<br />
cancer. Validated in a DB multicentric<br />
prospective clinical trial with +500 patients.<br />
Excellent NPV, sensitivity and specificity.<br />
Launching expected in Spain in Q4/11.Journal<br />
of Cancer 2011 DOI:10.1002/ijc.25901<br />
A fully human mAb with internalizing<br />
properties that is combined with a toxin and<br />
able to kill selectively the cancer cells<br />
Carlos Buesa, Ph.D, Chief Executive Officer • Jordi Petit, MBA, Chief Financial Officer • Tamara Maes, Ph.D, Chief Scientific Officer •<br />
Emili Torrell, MBA, Chief Business Officer • Jonathan Baker, Ph.D, Director<br />
BOARD OF DIRECTORS<br />
Carlos Buesa Arjol, President • Tamara Maes, Member • Najeti Capital, SCR, S.A., Member • Najeti, S.L, Member • Josep Maria<br />
Echarri, Member<br />
SCIENTIFIC ADVISORY BOARD<br />
Terence Rabbitts, PhD, FRS FMedSci, Institute Director Leeds Inst. of Molec. Medicine • Isidro Ferrer, PhD, Cellular Biology and<br />
Anatomical Pathology University of Barcelona. • Simó Schwartz Jr, PhD, Director of Molecular Oncology and Research into Ageing at the<br />
CIBBIM • Jaume Piulats, PhD, Prof. of Inmunology and medical Biotech.Faculty of Medicine of Barcelona • Francisco José López, MD,<br />
Ph.D, Director, Preclinical Pharmacology, Pharmaceutical R&D BAUSCH & LOMB, INC.<br />
BIO Business Forum 2011 34 Participating Company <strong>Profiles</strong>
Tohru Hashimoto, Governor<br />
Other<br />
Osaka Bio Headquarters - Osaka Prefectural Government<br />
Senri Life Science Center Building 20F, 1-4-2<br />
Shinsenri Higashimachi<br />
Toyonaka 560-0082<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Tomoharu Fujisawa, Chief Senior Staff<br />
CORPORATE MISSION<br />
Clinical Foci: Drug Discovery • Drug Development • Medical Device<br />
www.osaka-bio.jp/en/<br />
Phone: 81-6-6115-8100<br />
Incorporated: 1868<br />
Employees: 8700<br />
Ownership: Other<br />
Located in the center of Japan, Osaka is the heart of bio-industry including over 300 pharmaceuticals and biomedical start-ups, as well as<br />
world leading research institutes. Osaka Prefectural Government is strongly promoting bio-related industry such as pharmaceutical and<br />
medical devices. As an administrative agency, Osaka Bio Headquarters offers the one-stop service for further development of your<br />
business with Osaka. In BIO, we are pleased to introduce Osaka’s advantages for your business, and our unique companies from a<br />
collaborative R&D community focused on protein-related research called “Protein Mall Kansai (PMK.)” PMK consists of over 70 members<br />
including pharmaceutical and biomedical companies and research institutes and seeks for international business partners. One of<br />
Osaka’s major bio-promoting bodies called “Senri Life Science Foundation” closely works with us in the operation of PMK, and will jointly<br />
participate in BIO to provide with detailed information you want.<br />
SENIOR MANAGEMENT<br />
Tohru Hashimoto, Governor, Other • Shinsaku Kimura, Vice Governor, Other • Yasushi Sugimoto, Director General, Other •<br />
Masanobu Fukii, Director<br />
BIO Business Forum 2011 35 Participating Company <strong>Profiles</strong>
2-1 Yamadaoka, Suita<br />
Osaka 565-0871<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Kiyoji Hanasaki, Professor, International Relations<br />
Hachiro Senoo, Professor, International Relations<br />
Osaka University<br />
Clinical Foci: Immunology • Infectious Disease • Oncology<br />
www.osaka-u.ac.jp/en/index.html<br />
Phone: 81-6-68794875<br />
Incorporated: 1931<br />
Employees: 8700<br />
Ownership: Other<br />
CORPORATE MISSION<br />
* Established in 1931, Osaka University is one of the top ranked national universities in Japan, encompassing;<br />
• 11 faculties with 11 Corresponding Graduate Schools<br />
• 6 Independent Graduate Schools, including the Graduate School of Frontier Biosciences<br />
• 5 Research Institutes, including the Research Institute for Microbial Diseases, the Institute of Scientific and Industrial Research, and the<br />
Institute for Protein Research<br />
• 2 University Hospitals<br />
• 3 National Joint-Use Facilities, including the Research Center for Nuclear Physics, the Cybermedia Center, and the Institute of Laser<br />
Engineering.<br />
* National Ranking by Thomson Scientific: 3, with R&D strengths in fields of medicine, immunology and engineering.<br />
* Number of Students (as of May, 2010)<br />
- Undergraduate 15,865<br />
- Graduate 7,924<br />
- International 1,608<br />
Total 25,397<br />
* International Academic Exchange Agreements (as of November 2010)<br />
- Inter-University Agreements: 85<br />
- Inter-Faculty Agreements: 349<br />
* Osaka University’s research strengths lie primarily in basic and applied research in the fields of medicine, immunology, and engineering.<br />
* Among those publishing 500 or more papers, Osaka University is ranked at the first among top 30 institutions in Immunology in the<br />
world by Thomson Reuters Essential Science Indicators database, January 1, 2000 - December 31, 2010.<br />
* The University’s ‘Immunology Frontier Research Center (IFReC), directed by Dr Shizuo Akira at the Research Institute for Microbial<br />
Diseases, was selected as one of the five projects under the World Premier International Research Center Initiative Program by the<br />
Government of Japan. The Center was established in October 2007 with the aim to unveil the entire picture of dynamic immune system by<br />
employing a variety of imaging techniques to visualize the immune cells within live animals.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
New Drug Targets for<br />
Treatment of<br />
Autoimmune Diseases;<br />
eg. Multiple Sclerosis<br />
The New Adjuvant<br />
Delivery Systems for<br />
Dendritic Cells<br />
Anti-Ovarian Cancer<br />
Drugs Targeting HB-EGF<br />
Target<br />
Validated<br />
RGMa is expressed in bone marrow–derived<br />
dendritic cells (BMDCs) and CD4+ T cells express<br />
neogenin, a receptor for RGMa.<br />
Preclinical The CpG dinucleotide-containing<br />
oligodeoxynucleotides (CpG ODNs) are excellent<br />
vaccine adjuvants, to enhance the antigenspecific<br />
immune responses by acting as the<br />
ligands for TLRs.<br />
Phase I HB-EGF is a member of the EGF family of growth<br />
factors and binds to and activates EGFR and<br />
ErbB4. It is synthesized as proHB-EGF, a<br />
membrane-anchored precursor protein, and is<br />
cleaved on the cell surface to yield the soluble<br />
growth factor (sHB-EGF).<br />
Binding of RGMa to CD4+ T cells led to<br />
activation of the small GTPase Rap1 and<br />
increased adhesion of T cells to<br />
intracellular adhesion molecule-1<br />
(ICAM-1).<br />
Our researchers' group succeeded in<br />
forming schizophyllans (SPGs)-CpG ODN<br />
complexes specifically recognized by D-<br />
1 receptor on dendritic cells. The<br />
complexes are useful as new DDS of<br />
adjuvant for influenza virus vaccines.<br />
HB-EGF is involved in the growth,<br />
invasion and metastasis of various<br />
cancers. Increasing evidence suggests a<br />
critical role for HB-EGF in ovarian cancer<br />
cell growth and tumor progression.<br />
BIO Business Forum 2011 36 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
New Therapeutic Targets<br />
for Osteoporosis<br />
Novel Target of Anti-<br />
Cancer, Anti-Allergy or<br />
Anti-Atherosclerosis<br />
Drugs<br />
Therapeutics for Allergic<br />
Diseases by New Vaccine<br />
Target<br />
Validated<br />
Target<br />
Validated<br />
Therapeutics targeting sphingosine-1-phosphate<br />
(S1P), a kind of lipid mediator regulating immune<br />
cell trafficking, has been emerging rapidly as a<br />
novel line of regimen for autoimmune diseases,<br />
including rheumatoid arthritis (RA).<br />
Jumonji domain containing-3 (Jmjd3), a histone 3<br />
Lys27 (H3K27) demethylase, has been implicated<br />
in the activation of macrophages.<br />
Research Inventors recently published the article that<br />
shows how hemozoin, as well as synthetic HZ,<br />
activates TLR9-mediated as well as the<br />
inflammasome-mediated innate immune<br />
responses, and acts as a potent vaccine adjuvant.<br />
S1P-targeted therapy is beneficial not<br />
only for limiting inflammation but for<br />
preventing bone-resorptive disorders,<br />
such as osteoporosis.<br />
Jmjd3 is essential for M2 macrophage<br />
polarization in response to helminth<br />
infection and chitin, though Jmjd3 is<br />
dispensable for M1 responses.<br />
Furthermore, Jmjd3 (also known as<br />
Kdm6b) is essential for proper bone<br />
marrow macrophage differentiation.<br />
The advanced research and<br />
development indicated the synthetic<br />
hemozoin, Beta-hematin is an attractive<br />
vaccine adjuvant candidate.<br />
BIO Business Forum 2011 37 Participating Company <strong>Profiles</strong>
James Jungkeun Kim<br />
Chief Executive Officer<br />
2-17 Omok-ri, Seonggeo-eup<br />
Seoul 156-754<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Samuel Kiim, Senior Project Manager<br />
HIGHLIGHTS<br />
Recent<br />
Oscotec Inc.<br />
Clinical Foci: Oncology • Musculoskeletal • Drug Discovery<br />
www.oscotec.com/english<br />
Phone: 82-41-555-7666<br />
Incorporated: 1998<br />
Employees: 65<br />
Ownership: Public<br />
Market Cap: $30.40 million<br />
KOREA STOCK EXCHANGE: 039200<br />
Oscotec recently licensed out BT-301, a preclinical herbal drug candidate, to Yuhan, one of leading pharmaceutical company in Korea.<br />
Phase 2 clinical trial will be commenced in the second half of 2012.<br />
CORPORATE MISSION<br />
Oscotec Inc. started business with vision of becoming a globally competitive biotech company through leadership and excellence in bone<br />
biology, addressing osteoporosis and arthritis as its core therapeutic targets for drug discovery. Oscotec went public by completing IPO<br />
into KOSDAQ stock exchange in 2007. Currently, Oscotec has 13 new drug development pipelines focusing on Osteoporosis, Arthritis, and<br />
Oncology areas.<br />
The leading osteoporosis small molecule drug candidate, OCT-1547 is currently in phase I clinical trial in Europe under IND/CTA approval.<br />
NCEs targeting arthritis and cancer are also being developed in preclinical stages.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
HIF-143 Preclinical Cancer GLP toxicology study started in Feb 2011<br />
SENIOR MANAGEMENT<br />
James Jungkeun Kim, Chief Executive Officer • Steve Sewon Kim, Chief Technology Officer • Shi-Young Yang, Chief Financial Officer<br />
BIO Business Forum 2011 38 Participating Company <strong>Profiles</strong>
Colin Dawson<br />
Chief Executive Officer<br />
PO Box 56, 87 St David St<br />
Dunedin 9015<br />
New Zealand<br />
CONFERENCE PARTICIPANTS<br />
Alexandra Tickle , PHD<br />
HIGHLIGHTS<br />
Recent<br />
Otago Innovation Limited<br />
Clinical Foci: Drug Discovery • Diagnostics • Infectious Disease<br />
www.otagoinnovation.com<br />
Phone: 64-274-392954<br />
Ownership: Other<br />
Medtronic purchased rights to a chitosan-dextran gel technology from Adelaide Research & Innnovation Pty Ltd, Robinson Squidgel Ltd<br />
and Otago Innovation Ltd. Medtronic acquired this technology for potential use in functional endoscopic sinus surgery.<br />
CORPORATE MISSION<br />
Otago Innovation is a University of Otago company to develop and commercialize the University's intellectual property. Therefore, Otago<br />
Innovation is your gateway to the world class research at the University of Otago, one of the leading research institutes in New Zealand.<br />
We screen new technologies for their market potential and develop paths to market. Our investments include patent protection and<br />
further scientific development to conduct the "killer experiment" that gains interest from external investors and partners. Technology<br />
transfer in the form of licensing, company formation, and anything in between is an important part of our business. Our market insights<br />
feed back into the University to stimulate commercially attractive innovations.<br />
We seek alliances with providers of seed funding, venture capital providers, licensing partners, and commercial partners with expertise<br />
and experience in product related industries, such as drug discovery and development, vaccines, diagnostic biomarkers and medical<br />
devices.<br />
PROPRIETARY TECHNOLOGY<br />
- Suite of biomarkers for screening, diagnostic and prognostic applications in cancer, infectious, cardiovascular and neurological diseases.<br />
- Platform technologies for drug discovery screening and directed drug discovery in particular infectious diseases and cancer targets.<br />
- Platform technology for advantageous oral drug or antigen delivery including oral vaccine development.<br />
- New therapeutics for a variety of diseases including alzheimer's, cancer, cardiovascular, candidiasis, chlamydia, HIV, hepatitis C,<br />
inflammatory, impaired bone growth, malaria, and genetic diseases with non-sense/stop-codon mutations.<br />
INTELLECTUAL PROPERTY<br />
Portfolio of patent applications and granted patents for US, EU, and often worldwide<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Liporale-Chlamydia Preclinical Chlamydia vaccine animal proof of concept (chlamydia<br />
challenge in mice)<br />
Super-Azole Preclinical candida infections including azole<br />
resistant candida<br />
MIF Inhibitor Target Validated anti-inflammatory<br />
VEGF wound healing Target Validated slow healing ulcers<br />
Cardiac biomarkers Diagnostics diagnosis and prognosis of acute<br />
coronary syndroms<br />
Prostate biomarkers Diagnostics diagnosis of prostate cancer from<br />
urine and tissue<br />
Bone growth enhancer Pre-Target Validation complicated bone fractures, joint<br />
implants, etc.<br />
Membrane Protein Expression<br />
systems<br />
Other drug discovery screening with drug<br />
target expressing system<br />
human data<br />
human data<br />
SENIOR MANAGEMENT<br />
Colin Dawson, Chief Executive Officer • Dr Alex Tickle, Business Development • Dr Garth Hendry, Attorney<br />
established on (FACS) high<br />
throughput screening<br />
BIO Business Forum 2011 39 Participating Company <strong>Profiles</strong>
Taro Iwamoto, PhD<br />
President<br />
Kitahama TNK Bldg 10F<br />
Osaka 541-0045<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Yasuhisa Kurogi, Associate Director, Licensing<br />
Otsuka Pharmaceutical Co., Ltd.<br />
Clinical Foci: CNS • Oncology • Renal<br />
www.otsuka.com/en/<br />
Phone: 81-6-6231-7197<br />
Incorporated: 1964<br />
Employees: 5826<br />
Ownership: Public<br />
Market Cap: $14501.00 million<br />
TOKYO STOCK EXCHANGE: 4578<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
March 10, 2011 -- Otsuka received an approval for Additional Indication of L-Cartin® tablets<br />
(nonproprietary name: levocarnitine chloride) for carnitine deficiency in Japan.<br />
February 16, 2011 -- The U.S. Food and Drug Administration (FDA) has approved ABILIFY® (aripiprazole)<br />
as an adjunct to the mood stabilizers lithium or valproate for the maintenance treatment of Bipolar I<br />
Disorder.<br />
February 1, 2011 -- The Phase 2 clinical trial of the cancer vaccine OCV-101 for pancreatic cancer was<br />
started in Japan. OCV-101 is an angiogenesis inhibitor, which has been co-developed by OncoTherapy<br />
Science, Inc and Otsuka Pharmaceutical.<br />
March, 2011 -- Otsuka Group<br />
companies donated 390 million<br />
Japanese Yen and 700,000<br />
products to relief efforts in<br />
disaster areas affected by the<br />
major earthquake that struck<br />
off the Pacific coast.<br />
CORPORATE MISSION<br />
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka -- people creating<br />
new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products,<br />
with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health.<br />
Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company<br />
involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the<br />
natural environment.<br />
PRODUCTS<br />
Name Phase Indication<br />
Abilify On Market schizophrenia and manic episodes<br />
Samsca On Market hyponatremia<br />
Busulfex On Market conditioning agent, in combination with cyclophosphamide, prior to allogeneic hematopoietic stem<br />
cell transplantation<br />
Pletaal On Market intermittent claudication<br />
Mucosta On Market gastric mucosal lesions<br />
Meptin On Market dyspnea<br />
Mikelan On Market hypertension<br />
Sprycel On Market CML<br />
Keppra On Market epilepsy<br />
SENIOR MANAGEMENT<br />
Taro Iwamoto, PhD, President<br />
BIO Business Forum 2011 40 Participating Company <strong>Profiles</strong>
Philip Mathuis<br />
Chief Executive Officer<br />
Rue Engelandstraat 555<br />
1180 Brussels<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Philip Mathuis, CEO<br />
Ovizio Imaging Systems<br />
Clinical Foci: Biology • Diagnostics • Medical Device<br />
www.ovizio.com<br />
Phone: 32-2-600 5090<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Launched first products. sold products to global pharma companies<br />
Won prize as best Belgian spin-off<br />
Started second round of funding<br />
CORPORATE MISSION<br />
Setup USA organization<br />
Incorporated: 2009<br />
Employees: 7<br />
Ownership: Private<br />
Ovizio, Spin-off of the "Université Libre de Bruxelles” (ULB,) is a start-up company, founded in December 2009, specializing in imaging<br />
devices based on Digital Holographic Microscopy (DHM).<br />
The technology is developed around a patent portfolio of the Microgravity Research Center of the University that is exclusively licenced to<br />
Ovizio. The spin-off designs and markets its optical instruments and adapted services primarily to the Pharmaceutical, Biotechnology and<br />
clinical analyses markets.<br />
Ovizio’s technology breaks the barriers between 3D microscopy and Flow Cytometry and has the potential to disrupt the flow cytometry<br />
market. Our objective is to develop devices that help our customers to drastically reduce operational cost while increasing their research,<br />
analyses and production quality.<br />
Typical applications are: dyeless cell counting, automated bioreactor monitoring, biotechnology and cell culture observation, high content<br />
screening, hematology applications and laboratory research. In most cases the innovative technology does not require sample<br />
preparation.<br />
PROPRIETARY TECHNOLOGY<br />
Digital Holographic microscopy for online viable cell counting in bioreactors, flask, culture dishes and other supports in R&D and<br />
production<br />
CORPORATE ALLIANCES<br />
Alliances with large pharmaceutical companies<br />
INTELLECTUAL PROPERTY<br />
Patented technology in Europe and USA<br />
PRODUCTS<br />
Name Phase Indication<br />
oLine Cleared for US Marketing 4D Imaging and viable cell counter for lab and R&D<br />
iLine Cleared for US Marketing 4D Imaging and viable cell counter for online monitoring<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 12/17/2009 (US $1.50 million)<br />
Investors: Philip Mathuis (16 %) • Serge Jooris (15 %) • Frank Dubois (6 %) • Catherine Yourassowsky (6 %) •<br />
Theodorus II Fund (41 %) • SRIB Fund (16 %)<br />
SENIOR MANAGEMENT<br />
Philip Mathuis, Chief Executive Officer • Serge Jooris, Chief Technology Officer • Joris De Weert, Chief Financial Officer • Frank<br />
Dubois, Chief Scientific Officer • Catherine Yourassowky, Executive Partner<br />
BOARD OF DIRECTORS<br />
Philip Mathuius, Ovizio • Olivier Belenger, Theodorus II Fund • Barbara Roose, SRIB Fund • Pierre Baucher, Independant<br />
SCIENTIFIC ADVISORY BOARD<br />
Filip Meysman, NIOO-KNAW (Netherlands institute of Ecology) • Olivier Debeir, ULB - Applied Science Faculty<br />
BIO Business Forum 2011 41 Participating Company <strong>Profiles</strong>
Jean-Marc Allaire, MD<br />
President & CEO<br />
1682 rue de la Valsière, CS 27384<br />
34189 Montpellier Cedex 4<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Jean-Marc Allaire, MD<br />
CORPORATE MISSION<br />
Oxeltis<br />
Clinical Foci: Drug Discovery • Infectious Disease • Chemistry<br />
www.oxeltis.com<br />
Phone: 33-06-7605 4056<br />
Incorporated: 2010<br />
Employees: 5<br />
Ownership: Private<br />
Oxeltis is a medicinal chemistry oriented service company for managing and executing projects involving medicinal and fine organic<br />
chemistry in the fields of pharmaceutical, diagnostic and academic research.<br />
Oxeltis has expertise in the fields of organic chemistry represented by nucleosides and nucleotides, heterocycles, macrocycles, phosphorus<br />
and flurorine chemistry.<br />
Oxeltis team expertise and background has been related to antiviral research for the past 10 years.<br />
Oxeltis focuses its knowhow in fields of application of medicinal chemistry in drug discovery, and in diagnostic.<br />
Medicinal chemistry services in drug discovery: bibliographic and IP research, analysis of patent environment, hit to lead work, lead<br />
optimization, small focused library sets (10-50 compounds), early ADMET and PK studies with a preferred external partner, interpretation<br />
of SAR and biological data, ideas and implementation of prodrug approaches, proposition and initiation of back-up strategies.<br />
Fine organic chemistry services for custom synthesis (from small scale to Kg lab): synthesis of building blocks, scaffolds, intermediates,<br />
reference products…, route scouting and design, optimization, development, transfer of alternative synthetic routes, collaboration with a<br />
specific partner for Kg Lab production (GMP or non GMP).<br />
PROPRIETARY TECHNOLOGY<br />
Oxeltis has put in place a routine phosphorylated nucleoside analogues custom synthesis capability for its clients and distributors.<br />
CORPORATE ALLIANCES<br />
R&D program with IBMM « Nucleosides and Phosphorylated Effectors Team » C. Périgaud/S. Peyrottes (CNRS / UM2 / UM1-Montpellier-Fr).<br />
Business & Innovation Centre of Montpellier-Fr; Languedoc-Roussillon Incubation Center-Fr<br />
Nucleotide analogues distributor: Jena Bioscience GmbH - Germany<br />
SENIOR MANAGEMENT<br />
Jean-Marc Allaire, MD, President & CEO • Jean-Christophe Meillon, PhD, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Michel Abiteboul MD, Strategic Committee member, Vice President of Quintiles Corporate Development • Gilles Avenard MD,<br />
Strategic Committee member, Consultant, Chairman of the Board of Hemarina SA and Board member or adviser for several companies •<br />
Michel Kaczoreck PhD, Strategic Committee member, CEO of Holding Incubatrice DM & Santé, Truffle Capital subsidiary<br />
BIO Business Forum 2011 42 Participating Company <strong>Profiles</strong>
Alden Philbrick<br />
Chief Executive Officer<br />
133 North Fairfax Street<br />
Alexandria, VA 22314<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Oxford Finance LLC<br />
www.oxfordfinance.com<br />
Phone: 1-703-519-4900<br />
Justin McDonie, Director, Business Development<br />
Adam Soller, Director, Business Development<br />
Killu Sanborn , PHD, Director, Business Development - Western US<br />
Laurel Wittman<br />
HIGHLIGHTS<br />
Recent<br />
Select Q1 2011 transactions:<br />
$30 million term loan to Anacor Pharmaceuticals;<br />
$20 million term loan to Neovista;<br />
$2 million equipment loan to Synta Pharmaceuticals;<br />
$10 million term loan to Photothera;<br />
$3 million term loan to AirXpanders;<br />
$20 million term loan to Ligand<br />
Select Q4 2010 transactions:<br />
CORPORATE MISSION<br />
Ownership: Private<br />
$22.5 million term loan to PTC Therapeutics;<br />
$20 million term loan to Intuity Medical;<br />
$20 million term loan to Zalicus;<br />
$15 million term loan to BioVex;<br />
$2 million term loan to Wafergen Biosystems;<br />
$13 million term loan to Tranzyme Pharma<br />
Link to select 2010 and Q1'11 transactions:<br />
http://www.oxfordfinance.com/products_portfolio/recent_trans.html<br />
Oxford Finance, headquartered in Alexandria, Virginia, is a specialty financial services firm that provides capital exclusively to life science<br />
and healthcare services companies worldwide. For over two decades, our management team has been delivering loans to some of the<br />
most innovative participants in this industry—such companies as Alnylam Pharmaceuticals, Supernus Pharmaceuticals, MAP<br />
Pharmaceuticals, Ardea Biosciences, Avanti Health Systems and Great Lakes Home Health and Hospice.<br />
Oxford has remained a leader in the lending industry because of our commitment to remain fair, flexible and responsive to the changing<br />
needs of our clients. Furthermore, since opening our doors, we have been a stable and constant source of capital. Over the past few years,<br />
we have originated over $1.5 billion in loans to over 200 companies, with lines of credit ranging from $500 thousand to $40 million.<br />
Oxford is a portfolio company of Sumitomo Corporation ("Sumitomo") and Welsh, Carson, Anderson & Stowe ("Welsh Carson"). With assets<br />
exceeding $70 billion, Sumitomo is one of Japan's leading traders and distributors of commodities, industrial products and consumer<br />
goods. Welsh Carson is one of the largest and most successful private equity investment firms in the United States, focusing heavily on the<br />
healthcare industry. Since its inception, Welsh Carson has organized 15 limited partnerships with total capital of $20 billion.<br />
SENIOR MANAGEMENT<br />
Alden Philbrick, Chief Executive Officer • Tim Lex, Chief Operating Officer • Hans Houser, Executive Vice President • Chris Herr,<br />
Managing Director • Adam Soller, Business Development • Justin McDonie, Business Development • Marc Chabot, Business<br />
Development • Killu Sanborn, Business Development • Debbie Baker, Business Development<br />
BIO Business Forum 2011 43 Participating Company <strong>Profiles</strong>
Mike Evans<br />
Chief Executive Officer<br />
Begbroke Science and Business Park<br />
Oxford<br />
OX5 1PF<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Oxford Gene Technology<br />
Clinical Foci: Diagnostics • Oncology • AutoImmune<br />
www.ogt.co.uk<br />
Phone: 01144-1865-856 800<br />
Michael Bennett Susan Sutton<br />
HIGHLIGHTS<br />
Recent<br />
2009 - OGT acquires Sense Proteomic to develop biomarker discovery business.<br />
2008 - Single cell programme joins EuroSystem consortium WTCCC project - the world's largest CNV study<br />
2007 - CytoSure launch<br />
Incorporated: 1995<br />
Employees: 64<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to<br />
advance molecular medicine. Clinical & Genomic Solutions: OGT’s Genefficiency is a unique combination of world-leading platforms,<br />
people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT<br />
CytoSure cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of<br />
chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics<br />
research. Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the<br />
purchase of Sense Proteomic in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for<br />
cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also<br />
for collaboration with partner companies.<br />
PROPRIETARY TECHNOLOGY<br />
Our key focus areas are: high throughput genomic services and biomarker discovery, cytogenetics, single cell analysis, and licensing.<br />
We are seeking IP supported nucleic acid tests for incorporation into OGT's Clinical Genomic Services Division. Microarray , PCR based or<br />
novel platform considered. Cytogenetic / oncology / infectious disease interest. Also interested in IP protected biomarkers for cancer for<br />
use in diagnosis / patient stratification / companion diagnostics.<br />
CORPORATE ALLIANCES<br />
Agilent, SciGene, Kreatech<br />
INTELLECTUAL PROPERTY<br />
53 Patent Families encompassing a wide range of techniques and technologies including:<br />
DNA Microarray Technology<br />
Chemistry for attaching oligonucleotides to surfaces<br />
Hybridisation and chain extension technologies for sequence determination.<br />
Optical High Resolution Scanning technology<br />
Mass Tag technology<br />
BCCP tag<br />
Biomarker panels including prostate cancer, systemic lupus erythrematosis and nonsmall cell lung carcinoma.<br />
Protein Microarrays<br />
PRODUCTS<br />
Name Phase Indication<br />
CytoSure for array CGH On Market Cytogenetics<br />
Microbial arrays On Market Gene expression, Comparative Genomics Research<br />
GeneEfficiency On Market Genomic Services<br />
Single Cell Analysis Research Gene Expression<br />
SENIOR MANAGEMENT<br />
Mike Evans, Chief Executive Officer • Mike Bennett, Executive Vice President • John Anson, Executive Vice President • James Clough,<br />
Executive Vice President<br />
BOARD OF DIRECTORS<br />
Prof. Sir Edwin Southern, Founder Chairman and CSO • Mike Evans, CEO • Sonia Morgan, Director • David Owen, Non Executive<br />
Director • Tim Cook, Non Executive Director<br />
BIO Business Forum 2011 44 Participating Company <strong>Profiles</strong>
Dr. Amit Oza<br />
Chief Executive Officer<br />
101 College Street, Suite 404<br />
Toronto, ON M6S5A2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Sandra Harb<br />
Pamela Degendorfer<br />
Ozmosis Research Inc.<br />
Clinical Foci: Oncology • Specialty Pharmaceutical • Biopharmaceuticals<br />
www.ozmosisresearch.ca<br />
Phone: 1-416-673-6522<br />
Incorporated: 2005<br />
Ownership: Other<br />
CORPORATE MISSION<br />
Ozmosis Research is the only Canadian independent, entreprenuerial not for profit (social enterprise) clinical trials management company<br />
that specializes in both investigator and pharma Sponsored clinical trials. The profits from our business get reinvested to further clinical<br />
research development. Ozmosis Research is a social enterprise (not for profit) Clinical Trials Management Company and was founded in<br />
2005. We are an experienced Clinical Trials Management Company offering a full spectrum of services. The company started as a spin-off<br />
incorporating principals from the Princess Margaret Hospital (PMH) Drug Development Program (DDP) to fill a niche organizing and<br />
managing oncology clinical trials. The executives have developed expertise in running Phase I, II and III single and multi-centre oncology<br />
clinical trials. We have also performed protocol development and writing for Phase IV trials.<br />
Ozmosis Research Inc. has established a prestigious Board of Directors comprised of the following individuals: Dr Ben Neel (Chair)- Director<br />
of Research for the Ontario Cancer Institute, Dr Amit Oza- CEO Ozmosis, Pamela Degendorfer- COO Ozmosis, Dr Malcolm Moore, Chief of<br />
the Department of Medical Oncology and Hematology, Dr Christopher Paige- VP of Research at UHN, Dr Mary Gospodarowicz- Medical<br />
Director of Cancer Services for PMH, Mr. Paul Alofs- President and CEO of the Princess Margaret Hospital Foundation and Dr Piyush Patelpast<br />
CEO of Allied Clinical Research. This impressive Board will work with the Ozmosis executive and will bring broad leadership and<br />
scientific expertise to our clients.<br />
We offer services provided by traditional contract research organizations and site management organizations, with a distinct advantage –<br />
our oncology and drug development expertise. Ozmosis Research Inc. works with pharmaceutical and biotechnology companies as well as<br />
investigators to design and implement phase I-IV clinical trials.<br />
SENIOR MANAGEMENT<br />
Dr. Amit Oza, Chief Executive Officer • Ms. Pamela Degendorfer, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Dr. Ben Neel, Director of Research for the Ontario Cancer Institute • Dr Amit Oza, CEO, Ozmosis Research Inc. • Ms. Pamela<br />
Degendorfer, COO, Ozmosis Research Inc. • Dr Malcolm Moore, Chief of the Department of Medical Oncology and Hematology • Dr<br />
Christopher Paige, VP of Research at University Health Network • Dr Mary Gospodarowicz, Medical Director of Cancer Services for<br />
Princess Margaret Hospital • Mr. Paul Alofs, President and CEO of the Princess Margaret Hospital Foundation • Dr Piyush Patel, past<br />
CEO of Allied Clinical Research<br />
BIO Business Forum 2011 45 Participating Company <strong>Profiles</strong>
Ronald R. Helm<br />
Chief Executive Officer<br />
220 W. Harrison St.<br />
Seattle, WA 98119<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ronald Helm<br />
HIGHLIGHTS<br />
Recent<br />
Pacific Biomarkers, Inc.<br />
Clinical Foci: Cardiovascular Disease • Musculoskeletal • Metabolic Disease<br />
www.pacbio.com<br />
Phone: 011-206-298-0068<br />
Incorporated: 1989<br />
Employees: 60<br />
Ownership: Public<br />
Market Cap: $8.00 million<br />
OTCBB: PBMC<br />
March 1, 2011<br />
Pacific Biomarkers' Dr. Amar A. Sethi Recognized by R&D Directions as One of Nine "Most Notable People in R&D"<br />
October 27, 2010<br />
Pacific Biomarkers, Inc. Among Deloitte’s 2010 Technology Fast 500<br />
CORPORATE MISSION<br />
Originally named Pacific Biometrics, Inc., PBI was founded in 1989 as a spin-off from the University of Washington Lipid Research Center,<br />
Dept. of Medicine. In 2007, PBI expanded its capabilities into immunogenicity testing, cell based assay services, and novel biomarker<br />
development. In 2009, PBI officially changed its name to Pacific Biomarkers, Inc. to better reflect our business.<br />
PBI provides clinical trial support as the core of its business. Traditionally, PBI’s therapeutic focus has been Cardiovascular Risk,<br />
Musculoskeletal Disease, Diabetes, Obesity and Metabolic Syndrome and Inflammation.<br />
Today, PBI provides biomarker support across a wide range of therapeutic areas. PBI’s expertise in assay development has allowed it to<br />
establish long-term, collaborative relationships with many diagnostic manufacturers. This access to novel biomarkers allows PBI scientists<br />
to be the first to gain experience and the first to offer cutting-edge technology to its clients.<br />
PBI combines academic excellence with the efficiency and productivity that the industry demands. The result is an organization that<br />
delivers client focused biomarker laboratory services.<br />
SENIOR MANAGEMENT<br />
Ronald R. Helm, Chief Executive Officer • Michael Murphy, PhD, Chief Operating Officer • Elizabeth Leary, PhD, Chief Scientific Officer<br />
• Amar Sethi PhD, Vice President • John Jensen, Vice President • Ken Waters, Director • Timothy Carlson, PhD, Director • Sheri<br />
DuMond, Director • Tonya Aggoune, Director<br />
BOARD OF DIRECTORS<br />
Ronald R. Helm • Mario Ehlers • Stanley Schloz • Curt Scheel • Richard Palfreyman • Ken Waters<br />
SCIENTIFIC ADVISORY BOARD<br />
Mario Ehlers • Ronald Helm • Thomas Lohmann • Jack Bloom • Ronald Gingerich<br />
BIO Business Forum 2011 46 Participating Company <strong>Profiles</strong>
Hugh Martin<br />
Chief Executive Officer<br />
1380 Willow Road<br />
Menlo Park, CA 94025<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jonas Korlach<br />
Lloyd M. Kunimoto<br />
Pacific Biosciences<br />
Clinical Foci: Biopharmaceuticals • Biology • Genetic Disorders<br />
www.pacificbiosciences.com<br />
Phone: 1-650-521-8000<br />
Ownership: Public<br />
Market Cap: $600.00 million<br />
NYSE : PACB<br />
CORPORATE MISSION<br />
Pacific Biosciences’ mission is to transform the way humankind acquires, processes and interprets data from living systems. The company<br />
has developed a disruptive technology platform for the real-time detection of biological events at single molecule resolution. Single<br />
Molecule Real Time (SMRT) Biology promises to revolutionize the life sciences by revealing the underlying networks that define living<br />
systems. The first application for the SMRT Biology platform is a paradigm changing approach to DNA sequencing. The SMRT Sequencing<br />
System will ultimately make it possible to sequence individual genomes as part of routine medical care. DNA sequencing is expected to be<br />
the first of many transformative SMRT Biology applications that will benefit society by driving radical advances in fields such as<br />
personalized medicine, agriculture, clean energy, and global health.<br />
PROPRIETARY TECHNOLOGY<br />
We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and proteins. Combining recent advances in<br />
nanofabrication, biochemistry, molecular biology, surface chemistry and optics, we created a powerful platform called Single-Molecule,<br />
Real-Time, or SMRT, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has<br />
the potential to transform scientific understandings by providing a window into biological processes that has not previously been open for<br />
study. We believe that our SMRT platform represents a new paradigm in biological science, which we refer to as SMRT Biology, that has the<br />
potential to significantly impact a number of areas critical to humankind, including the diagnosis and treatment of disease<br />
INTELLECTUAL PROPERTY<br />
We have an extensive IP portfolio that covers all aspects of the single-molecule, real-time technologies and instrumentations.<br />
SENIOR MANAGEMENT<br />
Hugh Martin, Chief Executive Officer • Stephen W. Turner, Chief Technology Officer • Lloyd Kunimoto, Business Development • Jonas<br />
Korlach, Vice President<br />
BIO Business Forum 2011 47 Participating Company <strong>Profiles</strong>
David Darling<br />
Chief Executive Officer<br />
PO Box 56, 87 St. David St.<br />
Dunedin 9016<br />
New Zealand<br />
CONFERENCE PARTICIPANTS<br />
David Darling, CEO<br />
Pacific Edge Ltd<br />
Clinical Foci: Diagnostics • Oncology • Medical Device<br />
www.peblnz.com<br />
Phone: 64-3-4795800<br />
Incorporated: 2001<br />
Ownership: Public<br />
Market Cap: $40.00 million<br />
OTHER: PEB<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Agreement with Healthscope to commercialise Cxbladder in Australia.<br />
Agreement with Oryzon to commercialise Cxbladder in Spain and Portugal.<br />
Leading cancer centre, Pacific Edge Diagnostics lab, opened by New Zealand's Minister of<br />
Health Tony Ryall in May 2011.<br />
CLIA-certified lab for the commercialisation<br />
of Cxbladder in the US.<br />
CORPORATE MISSION<br />
Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic<br />
technology for the early detection and monitoring of cancer.<br />
Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). The<br />
bladder cancer technology Cxbladder® has been released to the market in Australia and New Zealand. CRC is being readied for commercial<br />
release. Pipeline products still in development include gastric and endometrial cancers and melanoma.<br />
Cxbladder® is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine providing<br />
general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides<br />
urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.<br />
The company is commercialising its products from its new diagnostic laboratory in New Zealand and plans further commercialisation in<br />
the US and Europe as a centralised diagnostic service through its own facilities or as a turn-key solution, licensed to selected partners.<br />
Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to<br />
success in new markets.<br />
PROPRIETARY TECHNOLOGY<br />
Established in 2001, Pacific Edge combines state of the art molecular biology, gene expression analysis and signature development and<br />
validation with world-class tissue banks and clinical data. These combined skills and capabilities, along with proprietary analytical<br />
software, have enabled us to identify unique gene and protein signatures for the development of better cancer management tools.<br />
Our commercial objectives are to discover, develop and commercialise new, simple-to-use genomic and proteomic tools for the earlier<br />
detection, improved characterisation and better management of a range of cancers. Commercial products developed by Pacific Edge<br />
consist of genomic and proteomic tests developed for use in clinical and point of care applications.<br />
CORPORATE ALLIANCES<br />
Healthscope, Australia<br />
Healthscope is a leading private health care provider within Australia that uniquely operates in every State and Territory, and in Asia. It is<br />
the second largest private hospital provider in Australia, operating 44 private hospitals and a growing medical centres division with over<br />
45 clinics. The Cxbladder test is available through Healthscope’s extensive network of hospitals and labs.<br />
Oryzon, Spain<br />
Oryzon is a company dedicated to the discovery of biomarkers with a pipeline focused on oncology and neurological disorders based in<br />
Barcelona. It was created in 2000 as a spin-off of CSIC and University of Barcelona and has since been the fastest growing company in the<br />
emerging Spanish biotechnology sector. Cxbladder is available through Oryzon in Spain and Portugal.<br />
INTELLECTUAL PROPERTY<br />
Pacific Edge underpins its products with a strong portfolio of patents in prosecution. The company has two issued patents, in New Zealand<br />
and Singapore, for its bladder cancer detection product Cxbladder®.<br />
In addition, Pacific Edge has filed provisional patents and PCT applications for cancer specific biomarkers and their application as<br />
diagnostic and prognostic tools for each of the cancers of interest to us. Our next product, Cxcolorectal, will be protected by an issued<br />
patent in New Zealand.<br />
The company also has issued patents in NZ, the USA and Australia covering its SIFTware software platform technology. This technology<br />
enables the analysis of complex fields of data and is used in the company’s biomarker and assay development programmes.<br />
BIO Business Forum 2011 48 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
Cxbladder Diagnostics Diagnostic markers for bladder cancer<br />
Cxcolorectal Target Validated Very high accuracy prognostic markers for colorectal cancer<br />
Gastric cancer diagnosis and prognosis Preclinical Monoclonal antibodies developed for initial target antigens<br />
Gastric cancer triage Preclinical 2-biomarker immunoassay for delivery at point of care<br />
Melanoma diagnosis and prognosis Preclinical Prognostic gene signature for the identification of aggressive stage II<br />
melanoma<br />
SENIOR MANAGEMENT<br />
David Darling, Chief Executive Officer • Parry Guilford, Chief Scientific Officer • Tony Lough, Vice President • Mark Dalphin, Vice<br />
President • Simon Harley, Vice President • Anabela Correia, Vice President • Paul O'Sullivan, Vice President<br />
BOARD OF DIRECTORS<br />
Chris Swann • David Band • Colin Dawson, Otago Innovation Ltd • Peter Foster • Anatole Masfen • Anthony Reeve, University of<br />
Otago<br />
SCIENTIFIC ADVISORY BOARD<br />
Anthony Reeve (Chair), University of Otago • Han Seung Yoon, University of Otago • Murray Brennan, Memorial Sloan Kettering<br />
Cancer Centre • Bryan Williams, Monash Institute of Medical Research, Monash University • Osamu Ogawa, Kyoto School of Medicine<br />
• Paul Spence, Sova Pharmaceuticals • Nik Kasabov, Auckland University of Technology • Ian Morison, Dunedin School of Medicine •<br />
Mike Sullivan, University of Otago<br />
BIO Business Forum 2011 49 Participating Company <strong>Profiles</strong>
12 rue du Faubourg Saint Honoré<br />
75008 Paris<br />
France<br />
CONFERENCE PARTICIPANTS<br />
PACT & PARTNERS Executive Search In Life Sciences<br />
Olivier Isaac SAFIR, Senior Partner and VP International<br />
www.pactpartners.com<br />
Phone: 33-1-5343 8300<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Founded in 1987 in Paris.<br />
London and Lausanne offices opened in 1999.<br />
Madrid office opened in 2004.<br />
Copenhagen office and Nordic HQ established in 2009.<br />
Incorporated: 1987<br />
Employees: 30<br />
Ownership: Private<br />
US Office will open in 2012!!!! (given the increasing number of US-based<br />
clients)<br />
CORPORATE MISSION<br />
Pact & Partners International is one of the leading EMEA PHARMA AND BIOTECH EXECUTIVE SEARCH FIRM.<br />
We are presently working in 17 countries.<br />
From mid-management to top management assignments (including board members) we are experts (25 years) of the Life Sciences<br />
industry in all functions (R&D, Manufacturing, Regulatory, Sales/Marketing, Support functions and GMs throughout Western, Central and<br />
Easter Europe).<br />
We work globally and locally with many of Pharma's and Biotech's top 100.<br />
Our client satisfaction surveys are constantly in the top percentile....<br />
Our fees are extremely competitive and our service is truly outstanding (just ask for reference).<br />
BIO Business Forum 2011 50 Participating Company <strong>Profiles</strong>
Dr Wolfgang Söhngen<br />
Chief Executive Officer<br />
Martinstrasse 10-12<br />
52062 Aachen<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
PAION AG<br />
Presenting Company<br />
Clinical Foci: CNS • Cardiovascular Disease • Biopharmaceuticals<br />
www.paion.com<br />
Phone: 49-241-4453152<br />
Richard Middleton, VP Business Development Wolfgang Soehngen, MD<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
PAION completes Phase IIb study with its Anesthetic/Sedative Remimazolam.<br />
PAIONs Cooperation Partner Lundbeck has started two Phase III trials and (in Japan) one Phase<br />
II trial with desmoteplase.<br />
On 6 December 2010 PAION reported positive preclinical results of its substance Solulin in the<br />
indication haemophilia<br />
Incorporated: 2000<br />
Employees: 27<br />
Ownership: Public<br />
Market Cap: $80.00 million<br />
FRANKFURT STOCK EXCHANGE: PA8<br />
PAION intends to close partnering deal<br />
with Remimazolam during 2011.<br />
CORPORATE MISSION<br />
PAION is a biopharmaceutical company headquartered in Aachen, Germany and has a second site in Cambridge, UK. The company is<br />
focusing on the clinical development of drug candidates for diseases or interventions for which there is a substantial unmet medical need.<br />
After proof of concept in humans the strategy is to out-license or co-develop the drug candidates with pharma partners. Thus revenues<br />
can be generated at an early stage, decreasing development costs and risks. The company further profits from the receipt of payments for<br />
reaching clinical and commercial milestones and receiving royalties after market approval of the drugs. Further upside can be generated<br />
from co-commercialisation activities.<br />
PROPRIETARY TECHNOLOGY<br />
Desmoteplase: the most fibrin-specific plasminogen activator known today; Remimazolam: a new ultra-short-acting general anesthetic<br />
and sedative that acts on GABAA receptors; M6G: major metabolite of morphine with favourable pharmacokinetics resulting in a better<br />
safety profile (less nausea/vomiting/sedation); Solulin: improved variant of the human protein thrombomodulin, an important natural<br />
regulator of blood coagulation, target indication: haemophilia/radiation injury.<br />
GGF2 – a class of naturally occurring protein growth factors that have multiple effects on the nervous system and potential therapeutic<br />
applications in neurologic conditions.<br />
CORPORATE ALLIANCES<br />
H. Lundbeck A/S: Out-licensing Desmoteplase (worldwide development & marketing agreement including co-promotion options for<br />
PAION in Germany, Austria and Switzerland);<br />
Schering AG: In-licensing agreement Desmoteplase, purchase agreement Solulin; Ono Pharmaceutical Co., Ltd.: Development rights of<br />
Remimazolam for Japan<br />
Acorda Therapeutics: Out-licensing GGF2<br />
INTELLECTUAL PROPERTY<br />
More than 30 patent families covering the drugs under development.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Desmoteplase (plasminogen<br />
activator)<br />
Solulin ("intelligent"<br />
anticoagulant)<br />
Phase III Acute ischaemic stroke Expected filing by Lundbeck 2012+<br />
Phase I Haemophilia & radiation injury Pre-clinical data in haemophilia<br />
demonstrate promising approach<br />
M6G Phase III Peri-operative pain Restart of clinical development<br />
GGF2 Phase I heart failure Start of Phase in 2010<br />
Remimazolam Phase II, IIa, IIb Anaesthesia/procedural sedation End of Phase IIb study in 2010<br />
SENIOR MANAGEMENT<br />
Dr Wolfgang Söhngen, Chief Executive Officer • Dr Mariola Söhngen, Chief Medical Officer • Mr Bernhard Hofer, Chief Financial<br />
Officer<br />
BIO Business Forum 2011 51 Participating Company <strong>Profiles</strong>
Rajan George<br />
Chief Technology Officer<br />
8223 Roper Road<br />
Edmonton, AB T6E6S4<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Paladin Biosciences<br />
Clinical Foci: Infectious Disease • Immunology • Biodefense<br />
Rajan George, PhD, Executive Vice President & Chief Technology Officer<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Paladin Biosciences sucessfully completed a Grand Challenges<br />
Explorations grant to develop Chimigen® Malaria Vaccine from the<br />
Bill & Melinda Gates Foundation.<br />
Paladin Biosciences recieves National Research Council of Canada<br />
Industrial Research Assistance Program (NRC-IRAP) financial<br />
assistance for Chimigen® Vaccine development for Hepatitis B<br />
(HBV) and Hepatitis C (HCV) infections.<br />
Phone: 1-780-989-6705 Incorporated: 2001<br />
Employees: 7<br />
Ownership: Other<br />
Result from Phase II proposal to Grand Challenges Explorations<br />
grant to develop Chimigen® Malaria Vaccine from the Bill &<br />
Melinda Gates Foundation.<br />
Start of the clinical trial of Chimigen® HBV Therapeutic Vaccine for<br />
treating chronic HBV infections<br />
Completion of Chimigen® HCV Prophylactic/Therapeutic Vaccine<br />
pre-clincial studies<br />
CORPORATE MISSION<br />
Paladin Biosciences develops innovative targeted therapeutics for infectious diseases and cancer. Using its Chimigen® Platform<br />
Technology, Paladin Biosciences has developed a portfolio of biotherapeutic agents to meet major unmet medical needs such as<br />
treatments for chronic hepatitis B and hepatitis C virus infections, influenza, alphavirus infections, Malaria and cancer.<br />
PROPRIETARY TECHNOLOGY<br />
Paladin Biosciences’ proprietary Chimigen® Platform technology is used to develop biotherapeutic agents. Chimigen® Vaccines are<br />
recombinant fusion proteins of antigen(s) and specific regions of a xenotypic antibody. Chimigen® Vaccines are capable of generating<br />
broad immune responses. The chimeric molecule is recognized by the host immune system as “foreign” and is taken up by antigen<br />
presenting cells, particularly dendritic cells, through specific receptors. This unique platform technology is currently used to develop either<br />
therapeutic or prophylactic vaccines and RNAi.<br />
CORPORATE ALLIANCES<br />
Paladin Biosciences is a division of Paladin Labs Inc. is a specialty pharmaceutical company focused on acquiring or in-licensing innovative<br />
pharmaceutical products for the Canadian market. For more information about Paladin, please visit the company's web site at<br />
www.paladinlabs.com.<br />
INTELLECTUAL PROPERTY<br />
Paladin Biosciences has 6 issued patents 42 pending patent applications both in US and worldwide, which cover the Chimigen® Platform<br />
Technology. These patents cover both the platform and a various applications of the technology. Some of these are currently at the<br />
prosecution stage.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Chimigen® HBV Therapeutic Vaccine Preclinical Chronic HBV Infection Phase I<br />
Chimigen® Malaria Vaccine Research Malaria, prophylaxis, therapeutic<br />
Chimigen® HCV Prophylactic/Therapeutic<br />
Vaccine<br />
Chimigen® WEEV Prophylactic Vaccine Preclinical WEEV<br />
Chimigen® H5N1 Therapeutic Vaccine Preclinical Avian Influenza<br />
Chimigen® H1N1 Therapeutic Vaccine Research Swine Influenza<br />
Preclinical HCV prevention, therapy Immune response in animals<br />
Chimigen® Bionanoparticles Research RNAi Various applications<br />
Chimigen® HIV Prophylactic/Therapeutic<br />
Vaccine<br />
SENIOR MANAGEMENT<br />
Rajan George, Chief Technology Officer<br />
Research HIV Prophylaxis, eraly intervention<br />
therapy<br />
BIO Business Forum 2011 52 Participating Company <strong>Profiles</strong>
Igancio Faus<br />
Chief Executive Officer<br />
AVINGUDA CAMÍ REIAL, 51-57<br />
08184 PALAU-SOLITA I PLEGAMANS (BCN)<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Heidi Sisniega<br />
Jordi Vilar<br />
IGNACIO FAUS<br />
PALAU PHARMA, S.A.<br />
Presenting Company<br />
Clinical Foci: AutoImmune • Musculoskeletal • Skin/Dermatological<br />
www.palaupharma.com<br />
Phone: 34-93-8649692<br />
Employees: 28<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Palau Pharma, S.A. (“Palau”) is a product-driven biopharmaceutical company focused on the discovery and development of revolutionary<br />
and differentiated new medicines that are designed to address the unmet needs of patients suffering from inflammatory and<br />
autoimmune diseases.<br />
Palau’s core business model is based on identifying unmet medical needs in order to create novel drugs and develop them through Phase<br />
IIa clinical trials. At that point, decisions are made on a cese-by-case basis whether to keep the development in-house or partner the<br />
compound for further late stage development and commercialization.<br />
Our R&D strategy is focused on developing “best-in-class” drugs that modulate the activity of validated targets with established<br />
preclinical or clinical proof-of-concept. Based on a unique and high-quality cost-effective structure, our final objective is to achieve early<br />
positive differentiation from our competitor’s molecules by addressing their limitations and designing a clear, focused and fast path to<br />
market success.<br />
Our primary focus is on inflammatory and autoimmune diseases, however, we consider other therapeutic fields, such as oncology, where<br />
there are synergies and commercial opportunities with existing development projects.<br />
PROPRIETARY TECHNOLOGY<br />
Our expertise relies on integrating our knowledge of medicinal chemistry, discovery biology and preclinical pharmacology with a<br />
profound understanding of the clinical aspects of inflammatory and autoimmune based diseases. We maintain and implement a<br />
commercial perspective that ensures the fast development of innovative drugs directed to specific unmet medical needs with a large<br />
market potential.<br />
CORPORATE ALLIANCES<br />
We have a broad portfolio of projects at different stages of development from early discovery to the late clinical stage, and have forged<br />
partnerships with leading pharmaceutical companies.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Cimicoxib (n.) Phase II, IIa, IIb Depression and Schizophrenia Partnered with Affectis<br />
Pharmaceuticals (DE)<br />
UR-13870 Phase I Inflammatory and autoimmune<br />
diseases<br />
Available for Out-Licensing<br />
DD-3 (Neogenius Pharma) Research Inflammatory diseases (Osteoarthritis) Consortium with Almirall (ES) and<br />
Esteve (ES)<br />
ACTIVE and IRIST Stents On Market Coronary restenosis Partnered with Iberhospitex (ES)<br />
Cimicoxib (v.) NDA/BLA filed, or<br />
in process<br />
UR-63325 (Histamine H4<br />
receptor)<br />
UR-65318 (Histamine H4<br />
receptor)<br />
UR-67767 (Balanced Jak<br />
selective inhibitor)<br />
Infalmmation and pain in companion<br />
animals<br />
Partnered with Vetoquinol<br />
Phase II, IIa, IIb Asthma & Allergic rhinitis Available for Out-licensing<br />
Other Atopic dermatitis Available for Out-licensing<br />
Preclinical Inflammatory & Autoimmune<br />
diseases<br />
Available for Out-licensing<br />
Dersalazine sodium Phase II, IIa, IIb Ulcerative colitis Phase IIa clinical trials completed.<br />
Available for Out-licensing<br />
Albaconazole Phase III onychomycosis, vaginitis Available for Out-licensing<br />
BIO Business Forum 2011 53 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Investors: Grupo Uriach (0 %) • Caixa Catalunya (0 %) • Caja Duero (0 %) • Andosins Capital (0 %) • Najeti<br />
Capital (0 %) • Senior Management (0 %)<br />
SENIOR MANAGEMENT<br />
Igancio Faus, Chief Executive Officer • Xavi Bartrolí, Chief Technology Officer • Manuel Merlos, Chief Scientific Officer • Heidi<br />
Sisniega, Chief Business Officer • Neus Virgili, Attorney<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Roderick Flower, Deputy Chairman of the William Harvey Research Institute (UK) • Dr. Thomas Luger, Department of Dermatology<br />
University of Munster (DE) • Dr. Desmond Fitzgerald, Materia Medica Manchester (UK) • Dr. Alberto Grignolo, Parexel Consulting (USA)<br />
BIO Business Forum 2011 54 Participating Company <strong>Profiles</strong>
Julio Castro<br />
Chief Executive Officer<br />
Baldiri Reixac 15-21<br />
08028 BARCELONA - CATALUNYA<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Julio Castro-Palomino<br />
CORPORATE MISSION<br />
Palobiofarma<br />
Clinical Foci: CNS • Pulmonary • Ophthalmic<br />
www.palobiofarma.com<br />
Phone: 34-93-4020815<br />
Palobiofarma´s mision is to dicover new drugs based on the modulation of adenosine receptors<br />
PROPRIETARY TECHNOLOGY<br />
Incorporated: 2008<br />
Employees: 5<br />
Ownership: Private<br />
PBF-680 is a potent adenosine A1 antagonist in preclinical development as a first in class asthma treatment<br />
PBF-509 is a potent A2a antagonist in preclinical development as a best in class Parkinson´s Disease treatment<br />
PBF-695 is a potent adenosine A3 antagonist as development candidate for the oral Glaucoma treatment<br />
INTELLECTUAL PROPERTY<br />
Over 12 patent applications claiming novel adenosine receptors modulators<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PBF-680 Preclinical Oral asthma Phase I<br />
PBF-509 Preclinical Parkinson´s Disease Phase I<br />
PBF-695 Optimized Lead Glaucoma Development Candidate<br />
PBf-799 Optimized Lead Schizophrenia Development Candidate<br />
SENIOR MANAGEMENT<br />
Julio Castro, Chief Executive Officer<br />
BIO Business Forum 2011 55 Participating Company <strong>Profiles</strong>
Kenneth H. Huang<br />
Chief Executive Officer<br />
7020 Kit Creek Road; Suite 180<br />
Research Triangle Park, NC 27709<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Pamlico Pharmaceutical, Inc<br />
Clinical Foci: Oncology • Metabolic Disease • Drug Discovery<br />
www.pamlicopharma.com<br />
Phone: 1-919-313-9658<br />
Incorporated: 2<br />
Employees: 11<br />
Ownership: Private<br />
James M. Veal, PhD, Vice President, Research Patrick Fadden Kenneth Huang, Chief Executive Officer<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
The lead compound for our Hedgehog program, PI-722, is now at preclinical<br />
candidate status. Excellent in vivo efficacy is observed for PI-722<br />
and potency exceeds clinical compound GDC-0449. We are currently<br />
preparing for IND enabling studies.<br />
We have identified a novel inhibitor series targeting Nedd8 activating<br />
enzyme. Optimization is currently ongoing and a provisional patent has<br />
been filed.<br />
We have identified novel agonists targeting the bile acid receptor TGR5.<br />
Optimization is currently ongoing and we seek a profile of a potent, orally<br />
dosed agonist t that functions solely in the gut and is non-absorbed.<br />
A range of in vivo PK, efficacy, and toxicology studies are<br />
now being conducted for our Hedgehog pathway inhibitor,<br />
PI-722. We anticipate being at IND status during 2011.<br />
We expect to have an advanced Nedd8 Activating Enzyme<br />
inhibitor that shows in vivo efficacy in cancer xenograft<br />
models in 2011.<br />
We expect to have an advanced, non-absorbed TGR5 agonist<br />
that shows in vivo efficacy in a mouse diabetic model in<br />
2011.<br />
CORPORATE MISSION<br />
Pamlico Pharmaceutical conducts research from target initiation to IND enabling studies. Pamlico’s scientific team consists of researchers<br />
with a wide range of both biotech and large pharma experience. The company was founded in 2009 with the objective of performing high<br />
quality pre-clinical research targeted at cancer and metabolic diseases. We engage in house in medicinal chemistry, analytical chemistry,<br />
computational chemistry, enzymology, library screening, and cellular biology activities. Additionally, we manage in vivo pharmacokinetic,<br />
pharmacodynamic, and efficacy studies through our relationship with Hengrui Pharmaceuticals.<br />
We are not backed by venture capital funds, and therefore do not seek an exit strategy based on a merger and acquisition model. Rather,<br />
we have been initially funded by Jiangsu Hengrui Medicine Company. Pamlico owns proprietary rights to its drug candidates, and seeks to<br />
engage in partnership and out-licensing arrangements with pharmaceutical companies worldwide. Because we are not VC backed, we<br />
believe we can provide highly economical out-licensing opportunities to interested pharma companies, as we do not require a large<br />
multiple return on investment. Rather, we seek growth and the opportunity for joint development with Hengrui Pharmaceuticals.<br />
In summary, Pamlico Pharmaceutical Inc.'s primary objective is to discover novel, high quality, small molecule compounds capable of<br />
favorably impacting disease states. We will progress these compounds through the pre-clinical research process and, in some cases, IND<br />
enabling studies and then seek partnerships or out-licensing arrangements prior to entering clinical trials.<br />
INTELLECTUAL PROPERTY<br />
Patents have been filed for our lead oncology programs.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Hedgehog Pathway Inhibitor Preclinical Oncology Preclinical candidate with in vivo efficacy;<br />
patent filed<br />
Nedd8 Activating Enzyme<br />
Inhibitor<br />
Preclinical Oncology Novel lead series currently being<br />
optimized; patent filed<br />
TGR5 Preclinical Diabetes and metabolic disease Novel agonist lead series currently being<br />
optimized;<br />
GPR120 Preclinical Diabetes and metabolic disease Novel agonist hit series identified<br />
FINANCING HISTORY<br />
Investors: Jiangsu Hengrui Medicine Co., Ltd. (100 %)<br />
SENIOR MANAGEMENT<br />
Kenneth H. Huang, Chief Executive Officer • James Veal, Vice President • Patrick Fadden, Director • Robert Atkinson, Director<br />
BOARD OF DIRECTORS<br />
Sun, Piaoyang, Jiangsu Hengrui Medicine Co., Ltd., Chairman • Kenneth H. Huang, Pamlico Pharmaceutical Inc. • Zhou, Yunshu,<br />
Jiangsu Hengrui Medicine Co., Ltd. • Wang, Jieping, Jiangsu Hengrui Medicine Co., Ltd. • Wang, Weilie, Jiangsu Hengrui Medicine Co.,<br />
Ltd.<br />
BIO Business Forum 2011 56 Participating Company <strong>Profiles</strong>
Marco A. Chacon, PhD<br />
President & CEO<br />
801 West Baltimore Street<br />
Baltimore, MD 21201<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jessica Boehmer, Director, Sales & Business Development<br />
Marco Chacon, PhD, President & CEO<br />
Philip Wills, Corporate-Scientific Liaison<br />
Aaron H. Heifetz, PhD, Stem Cells & Regenerative Medicine<br />
HIGHLIGHTS<br />
Recent<br />
Paragon Bioservices, Inc<br />
Clinical Foci: Biopharmaceuticals • Gene/Cell Therapy • Vaccines<br />
www.paragonbioservices.com<br />
Phone: 1-410-975-4050<br />
Incorporated: 1990<br />
Employees: 61<br />
Ownership: Private<br />
The University of Maryland Baltimore (UMB) and Paragon Bioservices, Inc. Announce the Formation of a Public-Private Stem Cell<br />
Technology Consortium<br />
Paragon Bioservices Launches Second Expansion to Celebrate its 20th Anniversary<br />
Paragon Bioservices Awarded $4.99 Million U.S. Army Contract to Assist with Ebola Vaccine Development<br />
CORPORATE MISSION<br />
Paragon Bioservices is a CMC Center of Excellence delivering research, development and cGMP manufacturing services to pharmaceutical<br />
companies, biotechnology companies and federal agencies. With a focus on vaccines (VLPs), monoclonal antibodies, therapeutic proteins,<br />
and stem cells, our role is to bridge the translational divide and to enable vaccines—as well as proteins and cell-based therapeutics—to<br />
move from the research bench into Phase I/II clinical trials. Paragon is well recognized as The CMO of Choice for Venture Investors and<br />
driven to deliver superior quality, scientific excellence and the best ROI for its clients. As scientists and engineers, it is our recognition of<br />
the need for better public health that gets us motivated about the work that we perform.<br />
SENIOR MANAGEMENT<br />
Marco A. Chacon, PhD, President & CEO • Ronald A.J. Wilson, Chief Financial Officer • Robert Eberwein, Vice President - GMP<br />
Operations, Vice President • Jessica Boehmer, Director - Sales & Business Development, Director<br />
BIO Business Forum 2011 57 Participating Company <strong>Profiles</strong>
Tom Bigger<br />
Chief Executive Officer<br />
75 Kneeland Street<br />
Boston, MA 02111<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Dennis Molnar, MBA<br />
CORPORATE MISSION<br />
Paratek Pharmaceuticals, Inc<br />
Clinical Foci: Infectious Disease • CNS • Gastroenterology<br />
www.paratekpharm.com<br />
Phone: 1-617-275-0040<br />
Incorporated: 1996<br />
Employees: 45<br />
Ownership: Private<br />
Paratek Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company headquartered in Boston, MA, that is engaged in the<br />
discovery and commercialization of new therapeutics that treat life-threatening infectious and other serious diseases. Paratek’s mission<br />
at its founding was to overcome the major worldwide problem of bacterial resistance through the application of its proprietary<br />
technology. More recently, Paratek has also focused on therapies for neurodegenerative dieases MS and SMA, gastrointestinal diseases<br />
IBD and CDAD and rheumatoid arthritis. More than $134 million in equity has been raised to date from private investors and corporate<br />
partners.<br />
PROPRIETARY TECHNOLOGY<br />
• Tet Antibacterials – Paratek is applying its chemistry and anti-infectives expertise to create new antibiotics that overcome multi-drug<br />
resistance. Paratek’s lead antibiotic, PTK796, is in Phase 3 testing for ABSSI and CABP.<br />
• Non-Antibacterial Tetracyclines – Recent discoveries at Paratek and elsewhere have led to new applications for Paratek’s extensive<br />
collection of novel classes derived from the tetracyclines that may be used to treat inflammatory and neurodegenerative conditions.<br />
• MAR Program – Paratek has identified small molecules that inhibit a bacteria-specific proteins called the MAR locus that control bacterial<br />
infectivity and resistance development. Drugs from this new paradigm of treatment will prevent life-threatening infections such as VAP<br />
and cUTI.<br />
CORPORATE ALLIANCES<br />
Novartis - PTK796; for ABSSSI and CABP - worldwide<br />
Warner Chilcott - for acne and rosacea - US<br />
INTELLECTUAL PROPERTY<br />
To date, more than 135 patents have been issued around the world, and over 240 more are pending.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PTK796 Phase III - Oral & IV antiobiotic for the treatment of serious<br />
resistant & susceptible bacterial infections<br />
(ABSSSI, CABP & DFI)<br />
Acne agent Phase I Oral narrow spectrum novel tetracycline analogue<br />
with improved anti-inflammatory activity for<br />
treatment of inflammatory acne & rosacea<br />
MS agent Preclinical Oral novel neuroprotective small molecule for<br />
treatment of multiple sclerosis<br />
Oral Small molecule for IBD Preclinical Novel oral small molecule modulator of T Cell<br />
activation in ulcerative colitis and Crohn's Disease<br />
File IND<br />
Partner<br />
SMA therapeutic Optimized Lead RNA splicing agent to restore SMN protein levels Begin preclinical<br />
development<br />
CDAD therapeutic Optimized Lead Novel oral therapeutic to treat C difficile<br />
associated infections and reduce relapses<br />
Begin preclinical testing<br />
MAR inhibitor Research MAR inhibitor to prevent Pseudomonas & other<br />
nosocomial bacterial infections such as VAP, HAP,<br />
cUTI<br />
SENIOR MANAGEMENT<br />
Tom Bigger, Chief Executive Officer<br />
Identify lead<br />
BIO Business Forum 2011 58 Participating Company <strong>Profiles</strong>
Luigi Tarenzi<br />
Chief Executive Officer<br />
Via Einstein, Loc. Cascina Codazza<br />
26900-Lodi<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Gianluca Carenzo<br />
John Lewis Williams, Chief Scientific Officer<br />
Parco Tecnologico Padano Foundation<br />
Clinical Foci: Food & Ag • Diagnostics • Veterinary<br />
www.tecnoparco.org<br />
Phone: 39-0371-466 2215<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Lodi Science Cluster comprises academic, national and private<br />
institutions active in the area of agrifood research, technology<br />
transfer and commercialisation<br />
PTP incubator, ALIMENTA (www.incubatorealimenta.it) hosts<br />
innovative companies in the field of biotech & agrifood providing<br />
them with all support services they need<br />
The CERSA research centre of PTP participates in international<br />
sequencing projects of 11 genomes, and leads important EU and<br />
nationally funded project with research budget exceeding € 26M<br />
Ownership: Private<br />
In the next 5 years the University of Milan Faculties of Veterinary<br />
Medicine and Agricultural Science will move to Lodi bringing an<br />
additional 3000 students and researchers to the Cluster<br />
The Alimenta Incubator is extending its operations by creating a<br />
new Business Park with 36Ha of offices, laboratories and industrial<br />
units with services and logistic support<br />
The PTP research centre is programming the expansion of its<br />
genomic facility into a genome centre operating at international<br />
level. PTP is the reference centre for agrifood for international EXPO<br />
2015<br />
CORPORATE MISSION<br />
Parco Tecnologico Padano (PTP, www.tecnoparco.org) is a Science and Technology Park based in Lodi (Milan metropolitan area, Italy) and<br />
strongly supported by the regional government and local institutions. The Park, which occupies 280.000 sqm, incorporates departments<br />
from several Universities, public and private research organizations, an enterprise incubator and a business park (under development)<br />
within a single-site Agricultural Science Centre of Excellence.<br />
PROPRIETARY TECHNOLOGY<br />
PTP has its own research institute: CERSA, which has 65 researchers in six research groups working on plant and animal molecular<br />
genetics, molecular biology and bioinformatics. Research is focused on the application of genomic approaches to understand the<br />
molecular basis of phenotypic variation and the application of genome based technologies to genetic improvement of plants and animals.<br />
CORPORATE ALLIANCES<br />
PTP has a long track record of networking, it was the coordinator of an European program (ABC network/IASP) to integrate European<br />
science parks and is leader of the Italian Science Park network (APSTI). PTP has an extensive portfolio of collaborating industry and research<br />
organisations in the food and agribiotech sector and bilateral research and development agreements with the leading Italian food<br />
companies, e.g. milk production chain, meat industry, feed industry, swine and cattle farming, wine industry, pharmaceutical industry,<br />
biotech industry, life sciences industry.<br />
INTELLECTUAL PROPERTY<br />
PTP’s IP portfolio comprises ten patents related to food safety, molecular diagnostics, molecular farming, and veterinary applications of<br />
stem cells.<br />
PTP also holds an extensive portfolio of innovative molecular methods for diagnostics of food contamination, composition, origin<br />
approved by the Italian Ministry of Agriculture.<br />
SENIOR MANAGEMENT<br />
Luigi Tarenzi, Chief Executive Officer • Gianluca Carenzo, Manager • John Lewis Williams, Chief Scientific Officer • Francesco<br />
Salamini, Other • Marco Pancaldi, Business Development<br />
SCIENTIFIC ADVISORY BOARD<br />
Francesco Salamini-President, University of MIlan • Daniel Zamir, Hebrew University of Jerusalem • Michel Georges, University of<br />
Liege • Maurizio Cocucci, University of Milan • Eugenio Scanziani, University of Milan<br />
BIO Business Forum 2011 59 Participating Company <strong>Profiles</strong>
Denis Tersen<br />
Chief Executive Officer<br />
3, rue des Saussaies<br />
75008 Paris<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Francoise MAILLARD<br />
CORPORATE MISSION<br />
Paris Region Economic Development Agency<br />
Clinical Foci: Service<br />
www.paris-region.com<br />
Phone: 33-1-5818 6900<br />
Employees: 60<br />
Ownership: Public<br />
Founded in 2001, the Paris Region Economic Development Agency (PREDA) helps attract new investment to the region to foster<br />
development and generate employment.<br />
PREDA has developed an array of services to assist businesses looking to set up and grow their operations in Paris Region: seeking premises<br />
and recruiting staff, advice on tax and legal matters, identifying commercial partners and R&D, media promotion and practical day-to-day<br />
information.<br />
In 2010, 243 foreign businesses (startups, expansions and takeovers) moved to Paris Region and will provide the local economy with more<br />
than 8,400 jobs over the next three years.<br />
Key figures :<br />
- Around 15 international direct investment projects per year in the life science sector.<br />
- More than 10 sites dedicated to the location and development of companies in the life sciences sector, including 3 Science Parks<br />
- Paris Region is host to more than 30% of foreign companies setting up operations in France every year.<br />
Join the Paris Region "biocluster"! Be part of the leading French industry in terms of R&D spending, be close to prestigious, worldrenowned<br />
institutions and key decision-making authorities!<br />
SENIOR MANAGEMENT<br />
Denis TERSEN, Chief Executive Officer • Frédérique de BAST, Corporate Communications • Laurence CURTI, Business Development •<br />
Françoise MAILLARD, Consultant<br />
BIO Business Forum 2011 60 Participating Company <strong>Profiles</strong>
1 Research<br />
Dartmouth, NS B2Y4M9<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Mark Regular, Director of Business Development<br />
Erica Sosnowski, Market Development Manager<br />
Partner International<br />
Phone: 1-902-431-3171 Ownership: Private<br />
CORPORATE MISSION<br />
Partner International is a leading full service corporate and business development company, with offices globally, focused on accelerating<br />
transactions in the life sciences industry. We are specialized in search and evaluation, in and out licensing, partnering, mergers and<br />
acquisitions, divestitures, raising capital, and due diligence support. With offices in the United States, Europe, Japan, and Canada, and<br />
associates in other regions, we have strategically positioned ourselves to represent our clients globally, through our vast network within<br />
the industry in the most cost effective manner. Over the last 11 years, we have built a significant reputation and track record in the life<br />
sciences sector as a company focused on deliverables for our clients. We have recently handled a divestiture from a big pharma, a product<br />
acquisition project from a specialty European pharma in oncology and urology, a licensing/partnering mandate from a North America<br />
pharma focused on pain and oncology, among numerous others.<br />
Partner International is interested to meet with companies who are seeking representation internationally or who have business<br />
development mandates that could benefit from the our support.<br />
We look forward to meeting with you to review your current corporate and business development objectives and discuss how our<br />
company could add value to your management team.<br />
BIO Business Forum 2011 61 Participating Company <strong>Profiles</strong>
101 Huntington Ave, 4th Floor<br />
Boston, MA 02199-8001<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Partners HealthCare System, Inc<br />
Clinical Foci: Immunology • Infectious Disease • Gene/Cell Therapy<br />
http://rvl.partners.org/<br />
Phone: 1-617-954-9385<br />
Brian McTigue, Director, Business Strategy and Marketing<br />
Mary Auge, Sr. Business Strategy and Marketing Manager<br />
Sylvia Eash, PhD, Licensing Manager, Brigham and Women's Hospital<br />
Wendi Yajnik, PhD, Director, Research and Licensing, Brigham and Women's Hospital<br />
Susu Wong<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Brigham and Women's and Massachusetts General Hospital continue to top the list of independent hospital recipients of NIH funding in<br />
the country. Combined, the two have research expenditures of approx. $1 billion and royalty revenue of $55 million.<br />
Research Ventures & Licensing (RVL) is a division of Partners HealthCare that coordinates all commercialization services across Partners<br />
HealthCare, Massachusetts General Hospital and Brigham and Women’s Hospital.<br />
CORPORATE MISSION<br />
Research Ventures & Licensing (RVL) is a division of Partners HealthCare that coordinates all commercialization services across Partners<br />
HealthCare, Massachusetts General Hospital and Brigham and Women’s Hospital. The intent is for RVL to be a cohesive, coordinated group<br />
to service inventors, thought-leaders, entrepreneurs and industry. The team has backgrounds in technology licensing, patenting, bench<br />
research, finance, funding, business, law and start-ups.<br />
PROPRIETARY TECHNOLOGY<br />
Partners has more than 1400 technologies available for licensing across all areas of medicine and patient care.<br />
BIO Business Forum 2011 62 Participating Company <strong>Profiles</strong>
Dr. Michael A. Yeomans<br />
President<br />
P.O. Box 609<br />
Gladstone, NJ 07934<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Michael A. Yeomans, PhD, President<br />
CORPORATE MISSION<br />
Partners In Pharma LLC<br />
www.partnersinpharma.com<br />
Phone: 1-908-532-0800<br />
Ownership: Private<br />
Partners in Pharma LLC is a private partnership that offers independent business development advice and services to the global<br />
pharmaceutical industry. The company is based in New Jersey, USA, home to many pharmaceutical and biopharmaceutical companies.<br />
What we do<br />
Partners in Pharma LLC advises companies on business development and licensing strategies and specific opportunities, which may<br />
include:<br />
- licenses to or acquisition of a product or technology<br />
- strategic alliances for joint research, development, and/or commercialization of a new product<br />
- joint ventures<br />
- company acquisitions<br />
Partners in Pharma provides advice on the optimal timing and structure of potential partnerships to further the implementation of your<br />
strategy. We leverage our worldwide network to identify potential partners for you and arrange introductions through exploratory<br />
meetings. Where both parties agree to move forward, we assist with structuring, negotiating, closing, and implementing the necessary<br />
contracts to achieve a value-adding partnership.<br />
We are also available to tackle disputes in existing partnerships. After making an objective assessment of the views of both sides, Partners<br />
in Pharma will propose a fair settlement, to avoid potential escalation to expensive and resource-intensive arbitration or litigation.<br />
In cases where litigation has already been initiated, we offer expert witness services on licensing and partnering arrangements in the<br />
pharmaceutical industry.<br />
We have access to a global network of pharmaceutical industry experts who can provide advice on all aspects of the business and potential<br />
transactions. These can include technical, commercial and financial assessments of new and existing products and businesses, optimized<br />
registration and market access strategies, corresponding clinical development programs and securing a dependable and high-quality<br />
manufacturing and supply chain. We can tailor our team to meet your needs.<br />
SENIOR MANAGEMENT<br />
Dr. Michael A. Yeomans, President • Elaine Yeomans, Managing Director<br />
BIO Business Forum 2011 63 Participating Company <strong>Profiles</strong>
Christopher J. Elias, MD, MPH<br />
President & CEO<br />
2201 Westlake Avenue, Suite 200<br />
Seattle, WA 98121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sonia Pelkowski<br />
David Marks<br />
Alexander Golden<br />
PATH<br />
Clinical Foci: Vaccines • Infectious Disease • PGH – Neglected Diseases<br />
www.path.org<br />
Phone: 1-206-285 3500<br />
Incorporated: 1979<br />
Employees: 900<br />
Ownership: Private<br />
CORPORATE MISSION<br />
PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide<br />
to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide<br />
appropriate health technologies and vital strategies that change the way people think and act. PATH improves global health and wellbeing.<br />
PATH currently works in more than 70 countries in the areas of health technologies, maternal and child health, reproductive health,<br />
vaccines and immunization, and emerging epidemic diseases. Staff provide expertise in public health, epidemiology, technology<br />
development and transfer, technology introduction, biotechnology and vaccine development, vaccine distribution, business development,<br />
education and training, communication, advocacy, and procurement. Headquartered in Seattle, Washington, since its inception in 1977,<br />
PATH operates offices in 30 cities in 21 countries. PATH’s annual budget is approximately US$250 million, which is provided by<br />
foundations, the US Government, other governments, multilateral agencies, corporations, and individuals.<br />
PROPRIETARY TECHNOLOGY<br />
PATH develops technologies and products through a combination of in-house research and collaborations with corporate and academic<br />
partners. Current partnering interests include: 1) partnerships to apply technologies to improve vaccine stability (both heat- and freeze)<br />
that have been developed and successfully validated by PATH and its collaborators; 2) research collaborations to develop vaccine delivery<br />
technologies that improve mucosal immunity; and 3) new vaccines against pneumococcal disease, diarrheal diseases (ETEC, Shigella, and<br />
rotavirus), and pandemic influenza.<br />
CORPORATE ALLIANCES<br />
Collaboration with the private sector is a key element in PATH’s approach. To advance health technologies on a global scale, PATH has<br />
worked with a wide variety of commercial partners dedicated to developing and providing health technology solutions that serve those<br />
with the highest unmet need, including large pharmaceutical companies, biotechnology companies, and developing country<br />
manufacturers. We capitalize on the strengths of our corporate partners in research and development, regulatory affairs, commercial<br />
marketing, manufacturing, and distribution to achieve maximum sustainable benefit for health technology consumers and end users.<br />
SENIOR MANAGEMENT<br />
Christopher J. Elias, MD, MPH, President & CEO<br />
BIO Business Forum 2011 64 Participating Company <strong>Profiles</strong>
James C. Mullen<br />
Chief Executive Officer<br />
4721 Emperor Blvd, Suite 200<br />
Durham, NC 27703<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Heather McClellan<br />
Ray Sison<br />
Shelby Brown<br />
Patheon, Inc<br />
www.patheon.com<br />
Phone: 1-919-226-3200<br />
Ownership: Public<br />
Market Cap: $294.50 million<br />
TSX: PTI<br />
CORPORATE MISSION<br />
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation,<br />
analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global<br />
clinical packaging and distribution services and Patheon's Quick to Clinic programs can accelerate early phase development projects to<br />
clinical trials while minimizing the consumption of valuable API. The company's integrated development and manufacturing network of<br />
10 manufacturing facilities, and nine development centers and one clinical trial material packaging facility across North America and<br />
Europe, enables customer products to be launched with confidence anywhere in the world.<br />
SENIOR MANAGEMENT<br />
James C. Mullen, Chief Executive Officer<br />
BIO Business Forum 2011 65 Participating Company <strong>Profiles</strong>
Julie Cherrington<br />
Chief Executive Officer<br />
409 Illinois St.<br />
San Francisco, CA 94158<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sanjay Lakhotia<br />
Julie Cherrington<br />
Pathway Therapeutics, Inc<br />
Clinical Foci: Oncology • Immunology • Drug Development<br />
www.pathwaytx.com<br />
Phone: 1-925-360-2574<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
IND for PWT33597 - PI3K alpha / mTOR inhibitor in 1Q 2011. FPI in PWT33597 Phase 1 data in 2H 2012<br />
June 2011.<br />
PI3K delta DC in 1H 2012<br />
Series A financing in May 2011<br />
Incorporated: 2008<br />
Employees: 10<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Pathway Therapeutics is a privately held pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase<br />
(PI3K) inhibitors for oncology and inflammation. The company’s lead product, PWT33597, is a balanced dual PI3K alpha/mTOR inhibitor<br />
which is entering the clinic in June 2011. Pathway Therapeutics is also developing PI3K delta inhibitors for hematological malignancies<br />
and inflammatory diseases.<br />
Pathway Therapeutics will target its development programs towards specific populations of patients most likely to respond to PI3K<br />
pathway inhibition. This focused and efficient clinical development approach, based on solid scientific principles, is expected to increase<br />
the probability of success in the clinic while reducing development costs and timelines to registration.<br />
Pathway employs a highly capital efficient operating model, with the critical discovery and development activities conducted in-house,<br />
and other activities conducted in collaboration with an established network of contract organizations and consultants. The company’s<br />
approach has been validated with the filing of an IND application for PWT33597, which was selected as a development candidate in less<br />
than 1 year and then advanced to IND in another 9 months.<br />
Pathway is led by an experienced management team with an established track record of advancing important therapeutics from the<br />
bench to the market. The company has raised $17.5 million to date in a Series A financing from GBS Venture Partners, CM Capital<br />
Investments, the Breast Cancer Research Trust, the Trans-Tasman Commercialization Fund, and the New Zealand Venture Investment<br />
Firm. Pathway Therapeutics is located in San Francisco, CA<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PI3K alpha / mTOR Inhibitor Phase I Oncology Phase 1 data in 2H 2012<br />
PI3K delta Inhibitor Optimized Lead Respiratory and Inflammation Development Candidate in 2012<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 05/31/2011 (US $17.50 million)<br />
Investors: GBS Venture Partners (0 %) • CM Capital (0 %) • Breast Cancer Research Trust (0 %) • New Zealand<br />
Venture Investment Fund Limited (0 %) • Trans Tasman Commercialization Fund (0 %)<br />
SENIOR MANAGEMENT<br />
Julie Cherrington, Chief Executive Officer • David Matthews, Vice President • Sanjay Lakhotia, Vice President • Marie O'Farrell,<br />
Director<br />
BOARD OF DIRECTORS<br />
Julie Cherrington • Mark Harvey • Joshua Funder • Hilary Lewis • William Charles<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. William Denny, University of Auckland • Alex Bridges, PhD, IDSC • Len Post, PhD, Biomarin • Ursula Matulonis, MD, Dana<br />
Farber • Jeffrey Engelman, Harvard Medical School<br />
BIO Business Forum 2011 66 Participating Company <strong>Profiles</strong>
Leif Nielsen<br />
Chief Executive Officer<br />
Fredens Torv 3A<br />
8000 Aarhus C<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Peter Elsner, Patent Attorney<br />
Leif Nielsen, CEO, European Patent Attorney<br />
CORPORATE MISSION<br />
PATRADE A/S<br />
Clinical Foci: Diagnostics • Drug Delivery • Biology<br />
www.patrade.com<br />
Phone: 45-70-203770<br />
Incorporated: 1995<br />
Employees: 50<br />
Ownership: Private<br />
COPENHAGEN STOCK EXCHANGE:<br />
Patrade A/S is a well-experienced European IPR agency based in Denmark. We are authorised European and Danish patent attorneys<br />
offering a large variety of IPR services both nationally, regionally and worldwide, including patent consultancy and prosecution.<br />
Patrade’s patent attorneys have strong competencies within the fields of life science, including medico-technology, biotechnology,<br />
pharmaceuticals and innovative food science. Having extensive research backgrounds our life science patent attorneys are able to advice<br />
you and your clients in all aspects of life science patenting.<br />
As we are a medium-sized patent agency, the risk of conflicting interests between our clients is minimal compared to large patent<br />
agencies.<br />
We are seeking contact with overseas patent agencies as well as biotech and medtech companies for cooperation on patent attorney work,<br />
including adaptation of your PCT applications and national applications to EPO standard. We are also interested in work related to<br />
infringement and appeal cases before the European Patent Office and the Danish courts, patent infringement analyses, freedom to<br />
operate analyses, and supplemental protection certificates.<br />
We should very much like to meet with you to discuss cooperation possibilities.<br />
SENIOR MANAGEMENT<br />
Leif Nielsen, Chief Executive Officer<br />
BIO Business Forum 2011 67 Participating Company <strong>Profiles</strong>
Lionel Leventhal<br />
Partner<br />
140 East 45th Street<br />
New York, NY 10017-3144<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
John R. Leone, MBA<br />
Matt Wotiz<br />
Ken Macleod, Partner<br />
Julie Rahman, Senior Associate<br />
Lionel Leventhal<br />
Andrew Rubinstein<br />
www.paulcap.com<br />
Paul Capital<br />
Phone: 1-646-264-1100<br />
Incorporated: 1999<br />
Employees: 14<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Paul Capital Partners established Paul Capital Healthcare in 1999 to meet the financing needs of healthcare companies, institutions and<br />
inventors. Today, the firm manages one of the largest dedicated healthcare funds globally with more than US$1.6 billion in assets under<br />
management. Paul Capital Healthcare has offices in New York, San Francisco, and London.<br />
The Fund focuses on commercial and late stage healthcare products and investment opportunities in North America, Europe and Asia. The<br />
Fund provides capital through novel non-dilutive structures such as royalty interest and revenue interest financings – the provision of<br />
cash in exchange for a percentage of future product revenues – as well as through debt and equity. To date, Paul Capital Healthcare has<br />
closed 41 investments in the pharmaceutical, biotechnology, medical device and diagnostics areas. Public and private companies, research<br />
institutions and universities, and individual inventors have all benefited from the flexibility of Paul Capital Healthcare's investment<br />
approach. This capital has enabled them to transfer product risk, finance clinical and commercial development projects, acquire new<br />
products, fund university programs and capital needs, avoid conflicts of interest, unlock shareholder value and monetize product<br />
royalties.<br />
Paul Capital Healthcare’s investment criteria are as follows:<br />
Focus: Commercial stage healthcare products and investment opportunities.<br />
Investment Size: US$20-$100+ million.<br />
Investment Characteristics: Royalty, revenue interest, debt, equity and hybrid structures.<br />
Term of Investment: 5-10+ years.<br />
More information and examples of transactions can be found on our website on www.paulcapitalhealthcare.com<br />
SENIOR MANAGEMENT<br />
Lionel Leventhal, Partner • Jean-Pierre Naegeli, Partner • John Leone, Partner • Ken Macleod, PhD, Partner • Andrew Rubinstein,<br />
Partner<br />
BIO Business Forum 2011 68 Participating Company <strong>Profiles</strong>
Per Walday<br />
Chief Executive Officer<br />
Strandveien 55<br />
1366 Lysaker<br />
Norway<br />
CONFERENCE PARTICIPANTS<br />
Per Walday, CEO<br />
Anders Hogset, CSO<br />
PCI Biotech<br />
Clinical Foci: Oncology • Drug Delivery • Gene/Cell Therapy<br />
www.pcibiotech.com<br />
Phone: 47-67-115400<br />
Incorporated: 2000<br />
Employees: 8<br />
Ownership: Public<br />
Market Cap: $70.00 million<br />
CORPORATE MISSION<br />
PCI Biotech® has developed a unique and patented photochemical drug delivery technology for use in cancer therapy and other diseases.<br />
PCI (PhotoChemical Internalisation) is a technology for light-directed drug delivery by triggered endosomal release and was developed to<br />
introduce therapeutic molecules in a biologically active form specifically into diseased cells. This proprietary technology can provide local<br />
enhancement of a range of different drugs, including several cytotoxics currently in clinical use. The company is developing combination<br />
products based on the proprietary photosensitiser Amphinex®. The lead product PC-A11 combines Amphinex® with the well established<br />
cytotoxic agent bleomycin.<br />
PCI Biotech® has an ongoing clinical phase I/II study with PC-A11 at University College Hospital in London that has completed patient<br />
inclusion. The study primarily enrolled patients with Head & Neck cancer, a disease with local control issues that the PCI technology could<br />
potentially contribute to solve. Preliminary results are encouraging, with strong tumour response observed in all patients.<br />
The company is working to establish other cancer indications where the PCI technology could potentially meet a need of improved local<br />
cancer control. The company aims to start 1-2 clinical Proof of Concept studies during 2011/2012 with new combination products.<br />
PROPRIETARY TECHNOLOGY<br />
PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried<br />
by antibodies or nanoparticles, and some small molecule drugs.<br />
The basis of the PCI technology is a light-induced rupture of endocytic vesicles, releasing endocytosed molecules into the cell cytosol, from<br />
where they can reach their intracellular target of action, realizing their therapeutic potential.<br />
The PCI effect is achieved by the use of photosensitising compounds specifically localising in the membranes of endocytic vesicles,<br />
destroying these membranes by an oxidative process after illumination.<br />
The PCI technology has potential to improve the effect both of existing drugs and emerging treatments such as gene therapy and other<br />
macromolecules.<br />
CORPORATE ALLIANCES<br />
PCI Biotech® collaborates closely with The Norwegian Radium Hospital in Oslo, Norway and receives substantial funding on several<br />
projects from both the Norwegian Research Council and the EU. The company has an extensive international collaboration network with<br />
recognised drug delivery expert groups.<br />
INTELLECTUAL PROPERTY<br />
The PCI technology is protected by several granted patents and pending patent applications.<br />
PRODUCTS<br />
Name Phase Indication<br />
Amphinex Phase II, IIa, IIb Drug delivery<br />
PC-A11 Phase II, IIa, IIb Recurrent non-metastatic head & neck cancer<br />
PC-A12 Preclinical Oncology<br />
PC-A31 Preclinical Oncology<br />
SENIOR MANAGEMENT<br />
Per Walday, Chief Executive Officer • Anders Hogset, Chief Scientific Officer • Bernt-Olav Rottingsnes, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Erling Overland, MBE • Flemming Ornskov, MD, MBA • Theresa Comiskey Olsen, BA, JD • Prof. Kjetil Taskén, MD, PhD • Else<br />
Kruger Hagen, MD, PhD<br />
BIO Business Forum 2011 69 Participating Company <strong>Profiles</strong><br />
PCIB
Chuck Bramlage<br />
Chief Executive Officer<br />
200 Saginaw Drive<br />
Redwood City, CA 94063<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Lyn Baranowski, Vice President, Business Development<br />
CORPORATE MISSION<br />
Pearl Therapeutics, Inc<br />
Clinical Foci: Pulmonary • Biopharmaceuticals • Drug Development<br />
www.pearltherapeutics.com<br />
Phone: 1-650-305-2600<br />
Ownership: Private<br />
Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases,<br />
including chronic obstructive pulmonary disease (COPD). PT003, Pearl's lead product, is a combination product composed of glycopyrrolate<br />
(LAMA) and formoterol (LABA) given twice daily from an HFA-MDI being studied for COPD. In a recent Phase 2b study, PT003 met its<br />
primary endpoint and demonstrated overwhelming superiority against market leader Spiriva.<br />
PROPRIETARY TECHNOLOGY<br />
Our hydrofluoroalkane (HFA) MDI-based products use proprietary engineered particle technology to achieve unprecedented performance<br />
and reliability from an MDI, and are intended to treat patients at all stages of chronic obstructive pulmonary disease (COPD) and asthma.<br />
Pearl has successfully formulated a majority of the bronchodilators and inhaled steroids commonly used in the respiratory space, along<br />
with their combinations, thereby demonstrating the versatility of its platform. The company is focused on developing high value<br />
combination products for patients across all stages of disease, with our lead product a twice-daily bronchodilator LAMA/LABA<br />
combination for the treatment of COPD.<br />
CORPORATE ALLIANCES<br />
None (unpartnered)<br />
INTELLECTUAL PROPERTY<br />
IP to 2030 on lead programs in Phase 2 development, with large pipeline<br />
PRODUCTS<br />
Name Phase Indication<br />
PT003 (glycopyrrolate / formoterol) Phase II, IIa, IIb Chronic Obstructive Pulmonary Disorder<br />
PT001 (glycopyrrolate) Phase II, IIa, IIb Chronic Obstructive Pulmonary Disorder<br />
PT010 (PT003 + ICS) Preclinical Chronic Obstructive Pulmonary Disorder and Asthma<br />
PT014 (LAMA + ICS) Preclinical Chronic Obstructive Pulmonary Disorder and Asthma<br />
PT005 (formoterol) Phase II, IIa, IIb Chronic Obstructive Pulmonary Disorder<br />
SENIOR MANAGEMENT<br />
Chuck Bramlage, Chief Executive Officer • Lyn Baranowski, Vice President • Colin Reisner, Chief Medical Officer • Michael Golden,<br />
Vice President • Sarvajna Dwivedi, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Jim Young, 5AM Ventures • Nick Simon, Clarus Ventures • Howie Rosen, Independent Board Member • Kathy LaPorte, New Leaf<br />
Venture Partners • Sundar Kodiyalam, Vatera Healthcare Partners • Tom Koestler (Board Observer), Vatera Healthcare Partners<br />
BIO Business Forum 2011 70 Participating Company <strong>Profiles</strong>
1801 E 9th St., Suite 1200<br />
Cleveland, OH 44114<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Paul A Serbinowski, Partner<br />
HIGHLIGHTS<br />
Recent<br />
Pearne & Gordon LLP<br />
Clinical Foci: Biomaterials • Medical Device • Service<br />
www.pearne.com<br />
Phone: 1-216-579-1700<br />
Incorporated: 100<br />
Employees: 100<br />
Ownership: Private<br />
Pearne & Gordon, LLP has been in business in various forms for about 100 years. We have been expanding in size these past several years<br />
and now have about 30 attorneys, making us one of the largest intellectual property law firms in Cleveland, Ohio.<br />
CORPORATE MISSION<br />
We are a boutique patent and trademark law firm located in Cleveland, Ohio. We specialize in patent law for clients in the U.S. and<br />
overseas ranging in size from small companies and individuals to Fortune 500 companies. Relevant areas of technology in which we have<br />
handled patent work include organic and inorganic chemistry, biochemistry, pharmaceuticals, medical devices and biotechnology. We are<br />
looking for new clients who need assistance in patenting biotech products and methods. Another interest is to develop relationships with<br />
patent law firms in foreign countries. We have implemented a discounted schedule for filing foreign based patent applications in the U.S.<br />
due to the substantial number of patent applications we file for Asian clients. We can also assist in trademarking product names. In this<br />
regard, we maintain extensive trademark portfolios for various clients. We also have experience in negotiating and drafting patent<br />
licensing agreements. We also have experience handling patent work for universities through their technology transfer or licensing<br />
offices.<br />
Our representative of the firm who is attending the conference is partner and attorney, Paul Serbinowski. He has been a patent attorney<br />
for 17 years for various law firms including a large firm in the Washington D.C. area and small and midsized law firms in the Philadelphia,<br />
Pennsylvania area and in Cleveland, Ohio. He has extensive experience preparing and prosecuting patent applications in the areas of<br />
biotech inventions, medical devices and chemistry. He also has a graduate degree from Case Western University in biochemistry and an<br />
undergraduate degree in the area of materials science. He can be reached at the conference on his cell phone at (330) 603-4873.<br />
BIO Business Forum 2011 71 Participating Company <strong>Profiles</strong>
Hans Nicasy<br />
Managing Director<br />
Ketelaarstraat 8<br />
2340 Beerse<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Hans Nicasy<br />
CORPORATE MISSION<br />
Peira<br />
Clinical Foci: CNS • Drug Discovery • Oncology<br />
www.peira.be<br />
Phone: 32-14-600 800<br />
Ownership: Private<br />
Peira is a technology provider/integrator and ‘applied science’ partner for life science groups who want to build new, innovative research<br />
or proof of principle set ups. The company has industrial experience in developing tools for pharmaceutical development activities, in<br />
vivo/ex vivo and in vitro experimental set ups and imaging automation for researchers in several therapeutic areas, such as neuroscience<br />
and oncology. Peira designs, builds and maintains customized research platforms.<br />
PROPRIETARY TECHNOLOGY<br />
Peira TM900: Cancer tumor measurement stereo-vision system: This invention concerns a measuring system for the calculation of<br />
dimensions, including surface and volume, of objects in various shapes. It is also the objective of the current invention of a measurement<br />
system to ensure that said handheld device also ha a processor module, a user interface, power supply and a data communication<br />
interface, and exchangeable measuring chambers to give the device the necessary flexibility and autonomy to speed up the measurement<br />
procedure, and to significantly improve the reproducibility of the measurement.<br />
CORPORATE ALLIANCES<br />
Peira ArguScope: The ArguScope is a flexible and fully automated imaging system for macroscopic image recording. In combination with<br />
the imaging analysis solutions of DCILABS, this powerful instrument enhances the throughput and accuracy of a variety of "macroscopic<br />
imaging assays" in diverse application domains such as drug discovery R&D and material sciences. Whereas an automated microscope is<br />
an instrument used for imaging of very small objects, the Arguscope is intended for imaging of larger samples. The typical magnifications<br />
used by microscopes lie in the range of 4x to 100x, the magnifications used by the Arguscope are 0.75x up to 4x, thus within the range of<br />
macroscopic imaging.<br />
INTELLECTUAL PROPERTY<br />
2 patent applications pending<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Peira TM900 Research Cancer tumor measurement device Launch December 2011<br />
Peira SliceTilter On Market Neuro science research platform Version 2.0 available<br />
Peira ArguScope On Market Macro imaging research platform Fluorescence module available<br />
Peira FlyWorld On Market Drosophila tracking platform Behavioural assays under<br />
development<br />
Peira FlyCrawler On Market Drosophila tracking platform Behavioural assays under<br />
development<br />
Peira SCOD22 On Market Skeleton colouring device Beta testing<br />
Peira Opacitometer On Market Improvement of the bovine corneal opacity<br />
permeability (BCOP) assay<br />
Launch August 2011<br />
Peira HumanShaker On Market Suspension redispersibility measurement GLP approval pending<br />
Peira RollerMill On Market Micronisation of API's (active pharmaceutical<br />
ingredients)<br />
GLP approved<br />
Peira HTSScratcher On Market Scratch assay preparation tool New assays under development<br />
SENIOR MANAGEMENT<br />
Hans Nicasy, Managing Director • Manu sneyders, Chief Technology Officer<br />
BIO Business Forum 2011 72 Participating Company <strong>Profiles</strong>
Wim Mol, PhD<br />
Chief Executive Officer<br />
Zuidersluisweg 2<br />
NL-8243RC Lelystad<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Wim E.M. Mol, PhD, Chief Executive Officer<br />
Michiel Lodder , PHD, Chief Business Officer<br />
Pepscan Therapeutics NV<br />
Clinical Foci: Biopharmaceuticals • Drug Discovery • Drug Development<br />
www.pepscan.com<br />
Phone: 31-320-225300<br />
Employees: 35<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Signed five new collaboration agreements in the last nine months, confirming the value of the CLIPS technology in therapeutic peptide<br />
development.<br />
CORPORATE MISSION<br />
Pepscan has developed a well established and unique protein mimicry technology platform that is being applied to the discovery and<br />
development of novel monoclonal antibodies and therapeutic peptides.<br />
The technology platform covers efficient synthesis and fast screening of conformationally constrained peptides that lead to improved<br />
activity and improved proteolytic stability in peptide drugs. Applying Pepscan’s protein mimicry capabilities to the design and synthesis of<br />
complex immunogens has also led to a truly innovative way to unlock the full potential of antibodies against cell membrane integrated<br />
receptor targets which are characterized by extracellular loops such as GPCRs and ion channels.<br />
In addition to a growing proprietary pipeline of therapeutic peptides and anti-GPCR monoclonal antibodies, Pepscan has various ongoing<br />
collaborations with leading pharmaceutical companies to develop novel therapeutics based on its proprietary CLIPS technology.<br />
PROPRIETARY TECHNOLOGY<br />
Pepscan has developed a novel and broadly applicable technology called CLIPS (Chemical LInkage of Peptides onto Scaffolds) which<br />
increases the activity and stability of peptides by enabling structural fixation. The majority of peptides derived from intact proteins lack a<br />
well-defined structure in solution. The CLIPS technology provides scaffolded peptides that adopt the same spatial structure as the<br />
corresponding sequence in the intact protein. The CLIPS technology is used to fix linear peptides into cyclic structures (‘single-loop’), and to<br />
bring together different parts of a protein binding site (‘double-loop’, ‘triple-loop’, etc.). The CLIPS technology is highly versatile, unique for<br />
the ease of application, and compatible with highly sensitive biological systems like bacterial phages.<br />
CORPORATE ALLIANCES<br />
Tibotec,<br />
Crucell,<br />
Zealand Pharma,<br />
Phylogica,<br />
Mercator Therapeutics, and<br />
Bicycle Therapeutics<br />
PRODUCTS E<br />
Name Phase Indication<br />
anti-GPCR antibody Preclinical Cancer<br />
anti-GPCR antibody Preclinical Cancer<br />
anti-GPCR antibody Preclinical Cancer, Immunology<br />
SENIOR MANAGEMENT<br />
Wim Mol, PhD, Chief Executive Officer • Michiel Lodder, PhD, Chief Business Officer • Peter Timmerman, PhD, Chief Technology Officer<br />
• Klaus Schwamborn, PhD, Chief Technology Officer • Henk van der Meer, Chief Financial Officer<br />
BIO Business Forum 2011 73 Participating Company <strong>Profiles</strong>
ue de Ransbeek, 310<br />
B - 1120 Brussels<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Marc Fouassier<br />
CORPORATE MISSION<br />
Peptisyntha SA<br />
Clinical Foci: Chemistry • Biomaterials • Generics<br />
www.peptisyntha.com<br />
Phone: 32-2-2642245<br />
Incorporated: 1987<br />
Employees: 100<br />
Ownership: Private<br />
Peptisyntha is a globally recognized cGMP manufacturer of clinical and commercial PEPTIDE APIs.<br />
With peptide-dedicated labs, kilo-labs, pilot scale and commercial scale manufacturing units (for peptide synthesis, HPLC purification and<br />
freeze drying), Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs,<br />
therefore supporting its pharma and biotech clients throughout the entire life cycle of their peptide based products.<br />
Peptisyntha's activities are conducted at development and production sites located in Belgium and the USA, the combination of the two<br />
offering the choice of solid phase peptide technology (SPPS), solution phase peptide technology (LPPS) and solid-solution hybrid<br />
technology.<br />
Cost efficiency and continuous improvement are key components of the Peptisyntha's business model.<br />
In addition to the peptide production capabilities of its FDA and EMEA inspected site, Peptisyntha also conducts for its clients a full range<br />
of CMC support services : including synthesis of impurities, preparation of reference standards, development and validation of analytical<br />
methods, stability studies, preparation and filing of DMFs, etc.<br />
With a dedicated offering in peptide APIs and a history of 25 years in GMP peptides production, Peptisyntha is a manufacturing partner of<br />
choice for companies with activity in the field of therapeutic peptides<br />
PROPRIETARY TECHNOLOGY<br />
As a technology-driven company, Peptisyntha has developed a portfolio of innovative technologies and know-hows : these offer benefits<br />
such as shortening synthetic processes and/or reducing the number of manufacturing steps, controlling the risk of racemization,<br />
simplifying (or even eliminating) HPLC purification steps, etc.<br />
Besides its long-standing experience in the development and production of 'classical' peptides, Peptisyntha also is recognized as an expert<br />
in :<br />
- PEG-ylated peptides<br />
- cyclic peptides<br />
- peptides with multiple (up to 4) disulfide bridges<br />
- arginine-rich peptides<br />
- conjugated peptides (with fatty acids, carbohydrates, proteins, etc)<br />
PRODUCTS<br />
Name Phase Indication<br />
Leuprolide Other Oncology<br />
Goserelin Other Oncology<br />
Triptorelin Other Oncology<br />
Eptifibatide Other Cardiovascular<br />
Bivalirudin Other Cardiovascular<br />
Exenatide Other Diabetes<br />
Pramlintide Other Diabetes<br />
Octreotide Other Acromegaly<br />
BIO Business Forum 2011 74 Participating Company <strong>Profiles</strong>
Steven W. King<br />
Chief Executive Officer<br />
14272 Franklin Ave<br />
Tustin, CA 92780-7062<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Chris Eso<br />
Mary J. Boyd, PhD, Head, Business Development<br />
Peregrine Pharmaceuticals, Inc<br />
Clinical Foci: Oncology • Infectious Disease • Biopharmaceuticals<br />
www.peregrineinc.com<br />
Phone: 1-714-508-6000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Two randomized bavituximab PIIb trials, in refractory and frontline<br />
NSCLC well underway. Third randomised PhII trial in<br />
pancreatic cancer initiated in January 2011.<br />
Randomised PhII trial in HCV patients with bavituximab and<br />
ribavirin versus standard of care, initiated in January 2011.<br />
PhI data in HCV/HIV co-infected patients reported at EASL 2011.<br />
Incorporated: 1996<br />
Employees: 146<br />
Ownership: Public<br />
Market Cap: $80.00 million<br />
NASDAQ: PPHM<br />
Advancing trials with data expected for bavituximab, PIIb front-line<br />
NSCLC and PIIb refractory NSCLC, as well as additional company<br />
and investigator-sponsored trials.<br />
Report data from Phase II glioblastoma multiforme (GBM) trial for<br />
Cotara mid 2011.<br />
Complete enrollment in randomised Phase II HCV trial for<br />
bavituximab.<br />
CORPORATE MISSION<br />
We are developing first-in-class monoclonal antibodies with broad-spectrum potential in cancer and viral infections. Last year we<br />
reported positive results from three Phase II trials, which led to two new randomized Phase IIb trials in non-small cell lung cancer (NSCLC).<br />
Additionally, our management team includes executives with track records in developing some of the most important monoclonal<br />
antibodies on the market today, including Avastin, Herceptin, and Raptiva.<br />
Our pipeline of novel investigational monoclonal antibodies includes bavituximab and Cotara. Bavituximab is a first-in-class<br />
phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer and has demonstrated broadspectrum<br />
potential in multiple solid tumors. Based on encouraging Phase II results, we initiated a randomized, placebo-controlled,<br />
double-blinded Phase IIb trial evaluating bavituximab in combination with standard chemotherapy in refractory NSCLC, which represents<br />
a significant unmet medical need and potential fastest path to market. We initiated a second randomized Phase IIb trial evaluating<br />
bavituximab in combination with chemotherapy in front-line NSCLC, a second potential regulatory path for bavituximab. We are<br />
planning additional trials to evaluate bavituximab’s potential in other oncology and viral infection indications.<br />
Our novel brain cancer therapy Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the<br />
tumor, destroying the tumor from the inside out, with minimal exposure to healthy tissue. In Phase II development, Cotara has been<br />
granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme (GBM) and anaplastic astrocytoma<br />
by the U.S. FDA.<br />
We also have a biomanufacturing subsidiary Avid Bioservices, Inc., which provides integrated cGMP commercial and clinical<br />
manufacturing services for Peregrine and third-party clients.<br />
PROPRIETARY TECHNOLOGY<br />
We have two proprietary technology platforms, phosphatidylserine (PS)-targeting monoclonal antibodies and Tumor Necrosis Therapy<br />
(TNT)-based products.<br />
Our lead PS-targeting antibody is bavituximab, a first-in-class monoclonal antibody in Phase II clinical development for cancer and Phase<br />
Ib development for HCV/HIV coinfection. Bavituximab targets the cellular membrane phospholipid PS and represents an entirely new<br />
approach to treating cancer and viral infections. PS is a highly immunosuppressive molecule usually located inside the membrane of<br />
healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, virus-infected cells, and enveloped<br />
virus particles creating a specific target for anti-cancer and antiviral treatments.<br />
CORPORATE ALLIANCES<br />
We have been actively seeking regional strategic partners for our preclinical and clinical programs that either are not currently in<br />
development or for territories where we do not plan to pursue development. Agreements to date include:<br />
• Stason - Licensed development and commercialization rights to TNT products in certain APEC countries.<br />
• Merck KgaA – Licensed Tumor Necrosis Therapy (TNT) for delivery of cytokines.<br />
• Affitech AS - Licensed exclusive worldwide rights to develop and commercialize products under Peregrine's selective anti-VEGF<br />
intellectual property portfolio including the fully human antibody r84.<br />
BIO Business Forum 2011 75 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Our extensive patent portfolio covers a number of technologies, including our drug product candidates and preclinical platforms.<br />
Peregrine holds or has an exclusive license to over 200 issued patents and published patent applications worldwide. These include patents<br />
directed to treating cancer using antibodies and immunoconjugates that target phosphatidylserine (PS) and phosphatidylethanolamine<br />
(PE) exposed on tumor blood vessels. Our lead PS targeting antibody bavituximab is protected by several composition and method patents,<br />
including those directly supporting our clinical programs of treating cancer and viral infections using bavituximab in combination<br />
therapies. Peregrine also holds composition and method patents for our novel cancer therapy Cotara®.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Bavituximab Phase II, IIa, IIb Non-Small Cell Lung Cancer Complete enrollment in two Phase IIb<br />
trials by mid-year 2011<br />
Cotara Phase II, IIa, IIb Glioblastoma Multiforme Report data from Phase II trial mid<br />
2011.<br />
Bavituximab Phase II, IIa, IIb Oncology (Advanced Breast<br />
Cancer/NSCLC)<br />
Report final data from three Phase IIa<br />
trials once mature.<br />
Bavituximab Phase II, IIa, IIb HCV .Phase I reported at EASL 2011,<br />
Initiated Jan 2011, randomised Phase<br />
II combination with ribavirin<br />
Bavituximab Phase II, IIa, IIb Pancreatic Cancer Complete enrollment by end 2011<br />
Bavituximab Preclinical Anti-viral<br />
SENIOR MANAGEMENT<br />
Steven W. King, Chief Executive Officer • Paul J. Lytle, Chief Financial Officer • Joseph S. Shan, M.P.H., Vice President • Shelley P. M.<br />
Fussey, PhD, Vice President • Robert L. Garnick, PhD, Vice President • Mary J. Boyd, PhD, Business Development • Christopher E. Eso,<br />
Vice President<br />
BOARD OF DIRECTORS<br />
Steven W. King, Peregrine Pharmaceuticals • David H. Pohl, Herold & Sager • Eric S. Swartz, Roswell Capital Partners LLC • Carlton M.<br />
Johnson, Roswell Capital Partners, LLC<br />
SCIENTIFIC ADVISORY BOARD<br />
Harold F. Dvorak, MD, Harvard Medical School • Christopher C. W. Hughes, PhD, University California Irvine • Preston A. Marx, PhD,<br />
Tulane University Health Sciences Center • Donald M. McDonald, MD, PhD, University of California San Francisco • Clarence J. Peters,<br />
MD, University of Texas Medical Branch • Wolfram Ruf, MD, The Scripps Research Institute • Alan J. Schroit, PhD, MD Anderson Cancer<br />
Center • Donald R. Senger, Ph.D, Harvard Medical School • Philip E. Thorpe, PhD, University of Texas Southwestern Medical Center<br />
BIO Business Forum 2011 76 Participating Company <strong>Profiles</strong>
Jonas Ekblom<br />
Chief Executive Officer<br />
Fogdevreten 2a<br />
171 65 Solna<br />
Sweden<br />
CONFERENCE PARTICIPANTS<br />
Jorgen Thorball<br />
Pergamum AB<br />
Clinical Foci: Biopharmaceuticals • Skin/Dermatological • Infectious Disease<br />
www.pergamum.com<br />
Phone: 46-8-52489100<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
One of Pergamum’s major owners, Karolinska Development, has collected around<br />
USD 97m (SEK 608m) in a successful IPO on the exchange in Stockholm in April of<br />
this year, giving Karolinska Development a market cap of some USD 310m.<br />
Extended clinical-stage pipeline by introducing additional indication, external<br />
otitis, drawing from already established Phase I data for DPK-060 (peptide API) to<br />
initiate a Phase II study in 2011.<br />
Extended Phase IIb clinical trial for PXL01 (peptide API) in prevention of postsurgical<br />
adhesions to clinical centers in Germany, following already actively<br />
involved centers in Sweden and Denmark.<br />
Incorporated: 2009<br />
Employees: 17<br />
Ownership: Private<br />
Submit filing for Phase I study for LL-37 (peptide API)<br />
in leg ulcer patients in Q2 of 2011.<br />
Commence Phase II study for DPK-060 (peptide API)<br />
in external otitis in 2011.<br />
Complete patient enrollment in Phase IIb study for<br />
PXL01 (peptide API) in prevention of post-surgical<br />
adhesions at the end of 2011.<br />
CORPORATE MISSION<br />
Pergamum is a clinical-stage biopharmaceutical company developing state-of-the-art products for local application in dermatology,<br />
wound healing and anti-infection – based on therapeutic peptides derived from human motifs.<br />
Four programs are currently in clinical phase in prevention of surgical adhesions and in treatment of dermal infections. Another program<br />
in healing of chronic wounds is planned to enter clinical trials this year. Pergamum is planning to deliver full Phase IIb data in four<br />
programs until 2013.<br />
In 2010, Pergamum consolidated three innovative biotech start-ups (PharmaSurgics, DermaGen and Lipopeptide) into one operational<br />
company. This unique business model enables Pergamum to pursue multiple exit and partnering opportunities, and to improve return on<br />
investment.<br />
INTELLECTUAL PROPERTY<br />
Pergamum holds 14 patent families, and patent applications are routinely filed in international key territories (e.g. US, EP, India, China,<br />
and Japan). A number of patents have been granted and others have progressed well through the examination phase. The patentability of<br />
additional substances, applications, combinations, methods, formulations and delivery systems is continuously evaluated in an effort to<br />
further strengthen the products and technologies.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PXL01 (short peptide API) Phase II, IIa, IIb Prevention of post-surgical adhesions Complete patient enrollment in Phase<br />
IIb study end of 2011<br />
DPK-060 (short peptide API) Phase II, IIa, IIb Skin infections (atopic dermatitis and<br />
external otitis)<br />
SENIOR MANAGEMENT<br />
Jonas Ekblom, Chief Executive Officer<br />
Commence Phase II study in external<br />
otitis in 2011<br />
BOARD OF DIRECTORS<br />
Jorgen Thorball, XOventure Life Science Experts • Conny Bogentoft, Karolinska Development • Goran Linder, Midroc • Jan Bohme,<br />
The Baltic Fund (Ostersjostiftelsen) • Bertil Rydevik<br />
BIO Business Forum 2011 77 Participating Company <strong>Profiles</strong>
Frederic Chereau<br />
Chief Executive Officer<br />
One Kendall Square STE B6101<br />
Cambridge, MA 02139<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Frederic Chereau, MBA<br />
HIGHLIGHTS<br />
Recent<br />
Pervasis Therapeutics<br />
Presenting Company<br />
Clinical Foci: Biopharmaceuticals • Gene/Cell Therapy • Regenerative Medicine<br />
www.pervasistx.com<br />
Phone: 1-617-621-3407<br />
Incorporated: 2004<br />
Employees: 10<br />
Ownership: Private<br />
Received FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis.<br />
Received Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis<br />
Received SPA and Orphan Drug Status for Hemodialysis Access.<br />
CORPORATE MISSION<br />
Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep<br />
understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with<br />
disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions,<br />
such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious<br />
complications and a significant increase in medical costs. The company’s most advanced program, Vascugel®, has demonstrated proof of<br />
concept and safety in two Phase 2 trials in patients undergoing vascular access for hemodialysis. In addition, Pervasis is pursuing a cellbased<br />
oncology program focused on targeting and regulating cell stroma in order to prevent key processes that play a role in advancing<br />
solid tumor growth and survival. Pervasis is also applying its platform technology to develop products in other key therapeutic areas<br />
including inflammatory disease and orthopedic injury.<br />
PROPRIETARY TECHNOLOGY<br />
Vascugel (matrix-embedded allogenic endothelial cells). PVS 10-200 (injectable formulation).<br />
INTELLECTUAL PROPERTY<br />
14 issued patents from 5 families; 58 patent applications pending<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Vascugel Phase III Hemodialysis access Received SPA, Start Phase III, FDA Fast Track Status,<br />
Orphan Drug approval - Europe<br />
PVS-10200 Phase II, IIa, IIb Peripheral Artery Disease Complete Phase I/II<br />
PVS-30200 Preclinical Oncology Complete preclinical plans<br />
PVS-50200 Preclinical Orthopedics Complete preclinical plans<br />
SENIOR MANAGEMENT<br />
Frederic Chereau, Chief Executive Officer • Helen Marie Nugent, PhD, Vice President • Jack Harvey, Director • Margaret E. O'Toole,<br />
Director • Matthias Jaffe, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Earl M. Collier, CEO, Arsenal Medical • Elazer Edelman, MD, PhD, Professor, Massachusetts Institute of Technology • Robert F. Higgins,<br />
Managing General Partner, Highland Capital Partners • Peter Baron Hutt, Senior Partner, Covington and Burling • Edwin M. Kania,<br />
Managing Partner & Chairman, Flagship Ventures • Robert S. Langer, Sc.D, Professor, Massachusetts Institute of Technology • Frank<br />
Litvack, MD, Professor, David Geffen School of Medicine, University of California • Amir H. Nashat, PhD, Principal, Polaris Venture<br />
Partners • Yoram Richter, PhD, Vice President, R&D, BIOrest Ltd. • Frederic Chereau, President & CEO, Pervasis Therapeutics<br />
SCIENTIFIC ADVISORY BOARD<br />
Michael S. Conte, MD, Professor and Chief, Division of Vascular Surgery, University of California San Francisco Medical Center • Bradley<br />
S. Dixon MD, Associate Professor of Medicine, Roy and Lucille Carver School of Medicine, University of Iowa • Elazer Edelman, MD, PhD,<br />
Professor, Massachusetts Institute of Technology • Marc Glickman, MD, Managing Director, Vascular and Transplant Specialists •<br />
Jeffrey H. Lawson, MD, PhD, Vascular Surgeon, Associate Professor of Surgery, Assistant Professor of Pathology, Duke University Medical<br />
Center • Prabir Roy-Chaudhury, MD, PhD, Associate Professor of Medicine, Section Chief of Transplantation, Division of Nephrology,<br />
University of Cincinnati • Mohamed H. Sayegh, M.D, Director of the Transplantation Research Center, Brigham and Women’s Hospital,<br />
Boston • A. Frederick Schild, MD, F.A.C.S., Professor of Surgery, Vascular Access Surgery, The DeWitt Daughtry Family Dept.of Surgery,<br />
Leonard M. Miller School • Joseph P. Vacanti, MD, Chief of Pediatric Surgery, Massachusetts General Hospital<br />
BIO Business Forum 2011 78 Participating Company <strong>Profiles</strong>
Mikael Dolsten<br />
President<br />
235 East 42nd Street<br />
New York, NY 10017-5755<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Pfizer Inc<br />
BIO Board Member, Sponsor,Presenting Company<br />
www.pfizer.com<br />
Phone: 1-212-573-2323<br />
Pamela Weakland<br />
Elizabeth Bachert , PHD<br />
Robert Bagdorf, MD<br />
Deborah Baron, Vice President, Worldwide Business Development<br />
& Innovation, Primary Care<br />
Ann Barry<br />
Douglas Giordano<br />
Cynthia D. Green, PhD, MBA, Director, WBD&I<br />
Richard Griffiths, Senior Director Worldwide Business Development<br />
and Innovation<br />
Thomas Heffner<br />
Elaine Jones<br />
Michael J. Kennedy<br />
Erik Kuja<br />
Jonathan Lanfear<br />
Debra Mangone<br />
Philip McGurk, Senior Director, Worldwide Business Development<br />
& Innovation<br />
John Watson<br />
Laura Winka<br />
Albert B. Bianchi, Senior Director, Worldwide Business Development<br />
& Innovation<br />
Paul Buckley<br />
CORPORATE MISSION<br />
Employees: 116500<br />
Ownership: Public<br />
Market Cap: $138649.00 million<br />
NYSE : PFE<br />
Beverly Miller<br />
Jan Reid, Senior Director, Worldwide Business Development &<br />
Innovation<br />
Monika Vnuk, Senior Director, Worldwide Business Development &<br />
Innovation<br />
Bob Smith<br />
Ashish Dugar, External Opportunities & Alliance Management,<br />
Commericial Development<br />
Dana Hughes, Senior Director, Worldwide Strategy<br />
Francine Salamone<br />
Jamsheed Banaji<br />
Karim Dabbagh<br />
Barbara Sosnowski, PhD, Executive Director, External R&D<br />
Innovation<br />
Uwe Schoenbeck, Chief Scientific Officer, External R&D Innovation<br />
Sophie Opdyke, VP - Biosimilars, Emerging Markets/Established<br />
Products<br />
Tiffanee Mackey, Primary Care, Commercial Assessment - External<br />
Opportunities<br />
Denis R. Patrick, Sr. Director, Head External R&D Innovation<br />
Oncology RU<br />
Joel Hayflick, Head External R&D, Rinat Labs<br />
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard<br />
for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global<br />
health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and<br />
many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to<br />
advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our<br />
responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local<br />
communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has<br />
worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.<br />
SENIOR MANAGEMENT<br />
Mikael Dolsten, President • Ian Read, Chief Executive Officer • Frank D'Amelio, Chief Financial Officer • Freda C. Lewis-Hall, Chief<br />
Medical Officer • Cavan Redmond, Senior Vice President • Mark Swindell, President • Geno Germano, President<br />
BIO Business Forum 2011 79 Participating Company <strong>Profiles</strong>
Ellen Morgan<br />
Chief Executive Officer<br />
555 N El Camino Real, Suite A263<br />
San Clemente, CA 92672<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ellen Morgan<br />
HIGHLIGHTS<br />
Recent<br />
PHACT<br />
Clinical Foci: Drug Development • Infectious Disease • Vaccines<br />
www.phactcro.org<br />
Phone: 1-760-533-1884<br />
Employees: 90<br />
Ownership: Private<br />
PHACT currently has offices in California and Germany, and soon will be opening offices in Africa and Bangladesh.<br />
CORPORATE MISSION<br />
Public Health Alliance for Clinical Trials (PHACT) is the very first non-profit Clinical Research Organization dedicated to conducting clinical<br />
trials for products to treat diseases that affect the poorest people in developing countries. The company’s goal is to provide high quality,<br />
yet very cost-effective services to non-profit organizations and for-profit companies who are developing health products that target<br />
diseases disproportionately affecting these people. The goal is to do this at 50% of what other CROs typically charge, thus enabling clinical<br />
trials to be done which otherwise would be cost prohibitive. This would be accomplished by 1) use of technology to reduce manual labor, 2)<br />
training and utilizing local employees in developing countries, and 3) effective management to keep overhead costs to a minimum.<br />
PHACT uses electronic source document collection on tablet computers, which increases accuracy while decreasing the manual labor<br />
involved in the clinical data collection process. The founders of PHACT previously founded and led two successful international for-profit<br />
CROs, one based in the US and one in Europe with combined annual revenues of approximatley $75M.<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 05/12/2011 (US $0.25 million)<br />
SENIOR MANAGEMENT<br />
Ellen Morgan, Chief Executive Officer • Christian Sacher, Chief Business Officer<br />
BIO Business Forum 2011 80 Participating Company <strong>Profiles</strong>
Syed Abidi, PhD<br />
Chief Executive Officer<br />
10819 Gilroy Road<br />
Hunt Valley, MD 21030<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Elizabeth Hickman, Marketing Manager<br />
CORPORATE MISSION<br />
Pharmaceutics International, Inc<br />
Clinical Foci: Service • Drug Development • Drug Delivery<br />
www.pharm-int.com<br />
Phone: 1-410-584-0001<br />
Incorporated: 1994<br />
Employees: 400<br />
Ownership: Private<br />
Pii (Pharmaceutics International, Inc) is a science driven contract development and manufacturing company providing dosage form<br />
development and GMP manufacturing services to the global pharmaceutical industry. Pii’s vision is to become the benchmark in<br />
pharmaceutical product development and commercial manufacturing outsourcing.<br />
Pii’s comprehensive offerings include drug substance optimization, preformulation testing, dosage form development, CTM<br />
manufacturing and commercial manufacturing, with full analytical, regulatory and project management support. Pii develops and<br />
manufactures a wide range of dosage forms covering solid, semi-solid, sterile and inhalation.<br />
With more than 400 development programs under our belt, Pii’s highly trained scientific team has extensive experience working with a<br />
variety of drug substances having a range of physiochemical characteristics. Additionally, Pii’s development capabilities include modified<br />
and extended release formulations. For poorly soluble compounds, Pii offers a variety of bioavailablity enhancement technologies,<br />
including solid dispersion development and lipid based or micro/nano emulsions.<br />
Today, Pii has over 300,000 square feet of pharmaceutical development and manufacturing space in both the U.S. and Europe. Facilities<br />
are cGMP qualified and include dedicated formulation development centers for solid oral, liquid, inhalation and sterile products, 6<br />
analytical laboratories and 59 manufacturing suites, all of which have been inspected by the FDA, EMEA and other international<br />
regulatory bodies. Manufacturing facilities includes 22 containment suites for potent compounds and dedicated suites for softgel<br />
manufacturing.<br />
Founded in 1994, Pii has grown to more than 400 scientists and support staff. By providing a high level of customer service, Pii continues<br />
to grow. This has resulted in a balanced client base of major multinational and virtual pharmaceutical companies located across the globe.<br />
PROPRIETARY TECHNOLOGY<br />
Pii puts its exciting portfolio of drug delivery technologies to work to assist clients with their product development needs, be they earlystage<br />
drug candidate optimization through to the revitalization of a marketed compound. Services can be tailored to the needs of the<br />
client and typically start with a feasibility study or technology transfer, operating on a fee-for-service basis.<br />
SENIOR MANAGEMENT<br />
Syed Abidi, PhD, Chief Executive Officer • Steve King, Senior Vice President • Prasad Gullapalli, PhD, Vice President • Hem Pandya,<br />
Vice President • Alan Saidel, Vice President • Tony Horton, Vice President • Donald Johnson, PhD, Vice President<br />
BIO Business Forum 2011 81 Participating Company <strong>Profiles</strong>
Thomas Marten<br />
President<br />
46701 Commerce Center Drive<br />
Plymouth, MI 48170<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas Marten<br />
HIGHLIGHTS<br />
Recent<br />
Pharmacision LLC<br />
Clinical Foci: Biopharmaceuticals • Specialty Pharmaceutical • Diagnostics<br />
www.pharmacision.com<br />
Phone: 734-895-3670<br />
Incorporated: 2007<br />
Ownership: Private<br />
May, 2011.<br />
MichBio has teamed up with Preferred Provider, Pharmacision, to provide biopartnering support at the BIO Business Forum during the<br />
upcoming 2011 BIO International Convention in Washington, DC.<br />
CORPORATE MISSION<br />
Pharmacision provides strategic consulting, market research, licensing, and business development support to help innovative biotech,<br />
pharma, medical device and diagnostics companies develop and grow their businesses. Founded in 2007 and managed by seasoned<br />
industry veterans with both big pharma and start-up experience, we provide commercialization consulting support from bench top to<br />
bargaining table. Pharmacision will also be available at Bio to provide onsite assistance with making partnering connections, and<br />
providing pitch deck reviews and refinements. For more information, visit our website at www.pharmacision.com or contact us at<br />
info@pharmacision.com.<br />
We integrate the full spectrum of pharma and life science commercialization support, ranging from conducting opportunity assessments,<br />
to new product commercial planning, to developing successful licensing and business development strategies.<br />
Why Pharmacision:<br />
- Market focus on commercializing life science opportunities.<br />
- All work managed by seasoned pharma, biopharma and life science industry veterans with over 80 years of combined strategic<br />
planning, new product commercialization, brand marketing and business development experience.<br />
-Strong customer focus on supporting specialty pharma, biotech, and emerging life science companies.<br />
-Breadth of knowledge and extensive pharma and life science industry contacts.<br />
-Seamless integration of business intelligence and market research into new product commercial planning processes, forecasting, and<br />
financial valuations.<br />
-Licensing and M&A experience from both licensor and licensee perspectives.<br />
-Alliances with regulatory experts, IP attorneys, market research firms, and medical communications providers.<br />
-Access to wide range of business intelligence and market tracking resources, including MedTRACK.<br />
PROPRIETARY TECHNOLOGY<br />
Rapid Insights<br />
When evaluating new product development and business opportunities, Rapid Insights combines the latest in health care market trends<br />
along with an understanding of future customer insights to help you develop and implement profitable business plans and partnering<br />
strategies. For more informatino, visit www.rapid-insights.com.<br />
CORPORATE ALLIANCES<br />
Pharmacision is a preferred provider with MichBio and will be exhibiting in the<br />
Michigan Economic Development Corporation Bio 2011 Pavilion.<br />
To expand our abilities to evaluate opportunities and network on a global basis, we have partnering arrangements to collaborate on<br />
projects with Morpace International and Ducker Worldwide. Morpace is a full service market research provider who, in addition to<br />
providing a global market research scope, have developed regulatory panels to evaluate clinical strategy and regulatory risks. Ducker<br />
Worldwide provides global strategic consulting, market research and financial advisory services with a strong presence in Asian markets.<br />
SENIOR MANAGEMENT<br />
Thomas Marten, President • Don Zinn, Partner • Frank DeLucia, Partner • Robert Morlock, Partner • R.W. (Charlie) Turner, Partner<br />
BIO Business Forum 2011 82 Participating Company <strong>Profiles</strong>
Wesley D. Sterman, MD<br />
Chief Executive Officer<br />
75 Shoreway Road<br />
San Carlos, CA 94070<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Greg Sturmer<br />
PharmacoFore, Inc<br />
Presenting Company<br />
Clinical Foci: CNS • Drug Discovery<br />
www.pharmacofore.com<br />
Phone: 1-650-331-4010<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
PF329 hydromorphone: Achieved human proof-of-concept<br />
demonstrating our hydromorphone Bio-MD system is working as<br />
designed; also supports application of our technology to codones<br />
and amphetamines.<br />
PF06 oxycodone prodrug: Advanced our lead product candidate<br />
into development. Human proof-of-concept of the underlying<br />
technology demonstrated in PF329 clinical study.<br />
PF06 oxycodone MPAR: Advanced our lead multi-pill abuseresistant<br />
(oral overdose resistant) product candidate into<br />
development.<br />
Incorporated: 2004<br />
Employees: 25<br />
Ownership: Private<br />
Advance up to two additional product candidates leveraging our<br />
Bio-MD and MPAR technologies into development.<br />
Enter partnership with leading pharmaceutical companies to<br />
accelerate the development and commercialization of our 1)<br />
PF0713 IV sedative-hypnotic and antiemetic; and 2) our opioid Bio-<br />
MD and MPAR programs.<br />
Advance our lead peripheral opioid antagonist for relief of opioidinduced<br />
side effects into development.<br />
CORPORATE MISSION<br />
PharmacoFore is a privately-held biopharmaceutical company focused on creating novel medicines to improve upon the therapeutic<br />
utility of existing drugs, enhance patient care, and prevent the misuse, abuse, and overdose of prescription medications.<br />
We pursue carefully chosen programs in which: 1) the targets of our compounds have known mechanisms-of-action; and 2) human proofof-concept<br />
(hPOC) can be achieved early in the development process. Consequently, commercial launch can be achieved more rapidly. Our<br />
initial focus is on medicines that target the CNS and address unmet medical needs in areas such as sedation, pain management, and<br />
attention deficit hyperactivity disorder.<br />
As an innovator in the discovery of next-generation proprietary medicines, PharmacoFore applies insights and experience in medicinal<br />
chemistry, applied biology, clinical pharmacology, and early stage development to create and advance a pipeline of lower-risk<br />
development candidates. Our strategy is to leverage our expertise in these areas to generate data that demonstrate human clinical proofof-concept<br />
and support partnerships with leading pharmaceutical companies that have the capabilities to successfully develop and<br />
commercialize our products.<br />
We have achieved hPOC in our sedative-hypnotic program, demonstrating safety, efficacy and, importantly, competitive advantages which<br />
support our target product profile. The development and regulatory path for this program could lead to a commercial launch in the 2014-<br />
15 time-frame. This program has multiple product opportunities as an IV sedative-hypnotic and antiemetic, with a combined worldwide<br />
market of ~US$3.6 billion.<br />
In addition, we have demonstrated hPOC of our molecular-level delivery technology. Our technology is broadly applicable to known drugs<br />
of abuse. Because our technology results in the release of known drugs systemically, the development risk and time to market are reduced,<br />
with a launch potentially as early as 2015.<br />
PROPRIETARY TECHNOLOGY<br />
PharmacoFore has created a novel Bio-Activated Molecular Delivery technology designed to effectively deter prescription drug abuse at a<br />
molecular level. This technology does not involve (1) the reformulation of existing opioid drugs in physical matrices that are easily<br />
circumvented by simple extraction methods; or (2) adding aversive agents or opioid antagonists which may expose patients to additional<br />
risks. The company’s opioid Bio-MD systems are designed to release clinically effective opioid drugs only when exposed to the correct<br />
physiologic conditions when orally ingested. PharmacoFore's complementary MPAR technology provides multi-pill abuse resistance –<br />
taking away the incentive to abuse with multiple pills, including self-escalating the dose, and protecting from oral overdose.<br />
BIO Business Forum 2011 83 Participating Company <strong>Profiles</strong>
CORPORATE ALLIANCES<br />
In an effort to further develop our lead compounds, we aim to collaborate with global companies to accelerate the development and<br />
commercialization of our products.<br />
We are currently seeking partners for multiple programs.<br />
PF0713 Sedative-Hypnotic (human proof-of-concept – hPOC – achieved)<br />
Moderate-to-Severe Pain<br />
Bio-Activated Molecular Delivery Systems and MPAR Technology for Abuse-Resistant Opioids<br />
PF03<br />
Hydromorphone (hPOC achieved for hydromorphone Bio-MD system)<br />
Oxymorphone<br />
Morphine<br />
PF06<br />
Oxycodone (advanced into development)<br />
Hydrocodone<br />
PF16: Tapentadol<br />
PF05 Reduced Opioid-Associated Side Effects (including OIC)<br />
PF0713 Antiemetic<br />
PF08 Attention Deficit Hyperactivity Disorder (ADHD)<br />
Bio-MD Systems and MPAR Technology for Abuse-Resistant Amphetamine<br />
INTELLECTUAL PROPERTY<br />
PharmacoFore internally created all of its lead compounds and product candidates and works diligently to protect intellectual property<br />
assets. Our extensive patent portfolio covers compositions-of-matter, methods-of-use, pharmaceutical formulations, and manufacturing<br />
processes.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PF0713 Phase II, IIa, IIb IV sedative-hypnotic Human proof-of-concept - safety, efficacy, and<br />
competitive advantages - achieved.<br />
PF0713 Phase I Antiemetic Demonstrated highly potent antiemetic in<br />
animal studies.<br />
PF03 Tamper- and abuseresistant<br />
hydromorphone<br />
PF06 Tamper- and abuseresistant<br />
oxycodone<br />
PF06 Multi-pill abuse-resistant<br />
oxycodone<br />
PF05 Peripheral opioid<br />
antagonist<br />
PF08 tamper- and abuseresistant<br />
amphetamine<br />
Phase I Pain Human proof-of-concept of our prodrug's<br />
mechanism-of-activation achieved.<br />
Preclinical Pain Product candidate advanced into development.<br />
Preclinical Pain Product candidate advanced into development.<br />
Lead Series Opioid-induced constipation Expect to advance product candidate into<br />
development in 2H11.<br />
Optimized Lead ADHD Expect to advance product candidate into<br />
development in 2H11.<br />
PF14 Peripheral opioid agonist Research Inflammatory pain<br />
SENIOR MANAGEMENT<br />
Wesley D. Sterman, MD, Chief Executive Officer • A. Gregory Sturmer, Chief Financial Officer • Thomas E. Jenkins, PhD, Chief Scientific<br />
Officer • Judy A. Magruder, Vice President • Narinder Banait, PhD, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
David Alpers, MD, Washington School of Medicine • Douglas Gourlay, MD, Wasser Pain Management Centre, Mt. Sinai Hospital •<br />
Cynthia McCormick, MD, Former FDA Division of Anesthetic, Critical Care and Addiction Drug Products Director • Steven Passik, PhD,<br />
Memorial Sloan Kettering Cancer Center • Steven L. Shafer, MD, Columbia University and Editor-in-Chief, Anesthesia & Analgesia •<br />
Lynn Webster, MD, Lifetree Pain Clinic<br />
BIO Business Forum 2011 84 Participating Company <strong>Profiles</strong>
Richard Soltero, PhD<br />
President & CEO<br />
5001 Weston Parkway<br />
Cary, NC 27513<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Rick Soltero, PhD<br />
PharmaDirections, Inc.<br />
Clinical Foci: Drug Development • Biopharmaceuticals • Drug Delivery<br />
www.pharmadirections.com<br />
Phone: 1-919-657-0701<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Drs. Soltero and Rehlaender are the co-inventors of “A COMPOSITION AND METHOD FOR THE<br />
TREATMENT OF A GASTROINTESTINAL DISORDER.” PharmaDirections, under contract to Alte<br />
Biosciences, developed these innovative molecules to treat IBD.<br />
Drs. Soltero and Rehlaender are co-inventors of “A METHOD FOR STABILIZING ACIDIC AND<br />
ALKALINE LABILE PHARMACEUTICAL PRODUCTS” which describes devices and methods of<br />
supplying acid or base stabilization for drug products that are pH unstable.<br />
PharmaDirections developed manufacturing systems called Instant GMP. These web based<br />
electronic records, SOPs and quality systems are specifically tailored to increase quality,<br />
decrease time and reduce costs in CTM manufacturing.<br />
Incorporated: 2003<br />
Employees: 6<br />
Ownership: Private<br />
This summer PharmaDirections will<br />
launch version 2.0 of InstantGMP, their<br />
newest web-based, interactive<br />
manufacturing system. After three<br />
years of development and validation,<br />
this will replace version 1.0 which was<br />
in use for 6 years.<br />
CORPORATE MISSION<br />
We are a drug development company who designs and manages preclinical development, CMC programs and regulatory submissions. Our<br />
experts and project managers run outsourced programs using “best of breed” CROs at very competitive prices.<br />
PharmaDirections focuses on preclinical and CMC management with a staff of highly educated and experienced pharmaceutical project<br />
managers and development experts. Our common purpose is to assure that your drug product is ready when you need it and that IND<br />
enabling studies are well executed and that CMC stays off your clinical critical path. Our experience is not theoretical. We have a wellpracticed<br />
track record of helping firms increase their investment value while controlling their costs for outsourced manufacturing<br />
activities.<br />
One of our specialties is designing oral formulations that overcome clinical issues such as poor bioavailability or excessive side effects. We<br />
use computer absorption models that mimic the entire gastro-intestinal tract when designing oral formulations or interpreting clinical PK<br />
results. These models utilize all available data, including physicochemical characterization of the API, in vitro results, and animal PK data<br />
to generate detailed and surprisingly accurate simulations of human absorption. Once we have a good understanding of how the drug<br />
interacts with the body, we can apply that information to the rational design of formulations or to develop an understanding of unusual<br />
clinical results.<br />
The drug development services that we offer include:<br />
Strategic Planning<br />
Preclinical Development<br />
IND Enabling CMC<br />
Formulation development<br />
API and Drug Product Manufacturing<br />
PROPRIETARY TECHNOLOGY<br />
Clinical Pharmacology and Pharmacokinetics<br />
Regulatory<br />
Quality Assurance<br />
Project Management<br />
PharmaDirections has an internal process for developing intellectual property to protect new products or indications that are not<br />
protected by composition of matter or treatment patents. Our approach is to use clinical data, PK modeling, gastro-intestinal tract<br />
simulations and other tools to seek unexpected outcomes that can be translated into inventions.<br />
PharmaDirections evaluates literature and data on the drug and its clinical uses, and then develops a GastroPlus pharmacokinetic model<br />
for post-oral uptake of the drug. Initial data from this program provide an understanding of the complexities of in-vivo dissolution,<br />
absorption and metabolism of various simulated formulations. This information is critical in predicting drug dispositions and in finding<br />
novel, unexpected outcomes.<br />
INTELLECTUAL PROPERTY<br />
PharmaDirections' internal IP development process has lead to 19 issued and published patents for our clients. PharmaDirections’ staff<br />
are “inventor’s for hire” and thus do not expect royalty payments on the IP generated for their clients.<br />
SENIOR MANAGEMENT<br />
Richard Soltero, PhD, President & CEO<br />
BIO Business Forum 2011 85 Participating Company <strong>Profiles</strong>
Peter Ferdinandy, MD, PhD, MBA<br />
Chief Executive Officer<br />
Hajnoczy u 6<br />
Szeged 6722<br />
Hungary<br />
CONFERENCE PARTICIPANTS<br />
Zsolt Murlasits, Business Development Manager US<br />
PharmaHungary<br />
Clinical Foci: Cardiovascular Disease • Metabolic Disease • Service<br />
www.pharmahungary.com<br />
Phone: 36-30-9251498<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
A cost-effective, reliable preclinical & clinical CRO is most valuable in the time of<br />
financial difficulties. Unique risk-sharing opportunities are available.<br />
Pharmahungary plans to out-license or find a strategic partner for the development<br />
of a new patented technology: enhancement of biglycan<br />
activity for protecting the ischemic heart and to provide anti-atherosclerotic action<br />
(www.biglycan.com).<br />
Pharmahungary is seeking for representatives for US and Asian markets.<br />
Incorporated: 2003<br />
Employees: 15<br />
Ownership: Private<br />
Strengthening presence of Pharmahungary in the<br />
US market.<br />
To build co-development alliances for our<br />
patented technologies such as selective matrix<br />
metalloproteinase-2 (MMP2) inhibitor molecules<br />
and biglycan therapy. For further details see:<br />
www.mmpharma.com, and www.biglycan.com<br />
CORPORATE MISSION<br />
1. Pharmahungary is a global provider of innovative preclinical and clinical pharmacology R&D services for pharmaceutical, biotech and<br />
food supplement companies, focusing on cardiovascular and metabolic diseases (myocardial infaction, stroke, heart failure, arrhythmias,<br />
diabetes, insulin resistance, hyperlipidemia, atherosclerosis, obesity), and aging. Custom-designed combined disease models are available,<br />
including large animal models. Our services are cost-effective, fast, and reliable with top scientific support. Ask for unique risk-sharing<br />
opportunities!<br />
2. Pharmahungary manages internal R&D projects to develop new technologies for the diagnosis and therapy of cardiovascular and<br />
metabolic diseases.These technologies, such as the world-wide patented biglycan therapy (see www.biglycan.com) as well as the small<br />
molecule project MMP inhibitors (www.mmpharma.com), are open for co-development or outlicensing.<br />
PROPRIETARY TECHNOLOGY<br />
Cardiovascular Platform:<br />
- acute and chronic infarction studies due to special technology<br />
- in vivo heart failure and cardioprotection (pigs, dogs as well)<br />
- systemic inflammatory response syndrome models<br />
- in vivo cardiac gene and stem cell therapy<br />
- proof-of-concept studies<br />
- in vitro cardiac myocyte assays<br />
- ex vivo isolated heart perfusion systems, myocardial infarction, ischemia/reperfusion<br />
-stroke<br />
Metabolic (diabetes, hyperlipidemia/atherosclerosis, obesity) Platform:<br />
- in vivo diabetes models (STZ, Goto-Kakizaki rats)<br />
- in vivo metabolic disease models (diet and genetic models, e.g. Zucker Fatty, ZDF, db/db mice)<br />
- in vivo hyperlipidemia/atherosclerosis models (hyperlipidemic diet, genetic models)<br />
- in vivo diet-induced and genetic obesity models<br />
- aging models<br />
CORPORATE ALLIANCES<br />
Some of our major present and past clients: Affymax, Amgen, AMRI, Medestea, Roche, Pfizer, Sanofi-Aventis, etc. Pharmahungary has<br />
recently signed collaboration agreement with Cellmid, Australia, for the development of Midkine therapy against ishcemic heart diseases.<br />
Pharmahungary was the leading company of a consortium of 4 companies and 2 academic research groups focusing on the development<br />
of selective matrix metalloproteinase inhibitor development (for further details, see www.mmpharma.com). Pharmahungary was<br />
involved in a consortium developing stem-cell based cardiovascular assays.<br />
BIO Business Forum 2011 86 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
1. Biglycan project: development of biglycan activators for atherosclerosis and ischemic heart disease, see www.biglycan.com (IP<br />
protection currently in national phases world-wide, primary filing date Jan 2007).<br />
2. MMPharma project: development of selective inhibitors (small molecules) of matrix metalloproteinases (www.mmpharma.com).<br />
Primary patent filing date Dec 2010.<br />
3. Nitroscience project: development of peroxynitrite inactivators for acute<br />
ischemic heart disease (see www.nitroscience.com).<br />
PRODUCTS<br />
Name Phase Indication<br />
biglycan Preclinical atherosclerosis, myocardial infarction, cytoprotection<br />
MMP2 inhibitor Preclinical acute infarction, other MMP-realted diseases<br />
FINANCING HISTORY<br />
Investors: Peter Ferdinandy (95 %) • others (5 %)<br />
SENIOR MANAGEMENT<br />
Peter Ferdinandy, MD, PhD, MBA, Chief Executive Officer • Tamas Csont, MD, PhD, Chief Scientific Officer • Csaba Csonka, MD, PhD,<br />
Chief Technology Officer • Eszter Fodor, MD, Chief Medical Officer • Aniko Gorbe, MD, PhD, Manager • Peter Bencsik, MD, PhD,<br />
Manager<br />
SCIENTIFIC ADVISORY BOARD<br />
Mehrdad Shamloo, MD, PhD, Stanford University, CA, USA • Jacques van Rooyen, PhD, Cape Peninsula Univerity, South Africa<br />
BIO Business Forum 2011 87 Participating Company <strong>Profiles</strong>
Avda de los Reyes, 1<br />
28770 Colmenar Viejo (Madrid)<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
PharmaMar<br />
Clinical Foci: Oncology • Ophthalmic • Other<br />
www.pharmamar.com<br />
Phone: 34-91-846 6000<br />
Aranzazu Garces, Manager, Business Development & Licensing<br />
Jörg Landwehr, Director, Business Development & Licensing<br />
Roberto Weinmann<br />
HIGHLIGHTS<br />
Recent<br />
New compound, PM060184, initiated Phase I trial in solid tumors.<br />
Initiation of PM01183 Phase II trial in pancreatic cancer.<br />
Incorporated: 1986<br />
Employees: 297<br />
Ownership: Public<br />
Market Cap: $1300.00 million<br />
MADRID STOCK EXCHANGE: ZEL<br />
CORPORATE MISSION<br />
PharmaMar (a member of the Zeltia Group) is a biopharmaceutical company devoted to advance cancer care through the discovery,<br />
development and commercialization of innovative marine-derived medicines.<br />
Our lead compound, Yondelis®, received in September 2007 the marketing authorization from the European Commission for the<br />
treatment of advanced or metastatic soft-tissue sarcoma.<br />
In September 2009, Yondelis® in combination with Caelix® received the marketing authorization from the European Commission for to<br />
the treatment of patients with relapsed platinum-sensitive ovarian cancer.<br />
Phase II clinical trials are ongoing in breast cancer. Other products in phase II include Aplidin, Zalypsis and Irvalec.<br />
In addition, PharmaMar has 4 different compounds in Phase I and II in clinical development for cancer. PharmaMar has also an important<br />
preclinical pipeline derived from its own drug discovery program, and a marine library of more than 72.000 samples.<br />
A partnership exists for Yondelis®, with Taiho Pharmaceutical in Japan and OrthoBiotech (Johnson & Johnson) covering territories outside<br />
of Europe and Japan.<br />
PharmaMar is currently seeking development and commercialization partners in the US and Japan for several of its anticancer pipeline<br />
compounds.<br />
PharmaMar is offering access to its unique and wordwide largest library of extracts from marine organisms (>100'000 samples) for<br />
screening in a wide range of therapeutic areas.<br />
Over the last years, PharmaMar has identified a number of compounds with high cytotoxic potenticy in the nanomolar and picomolar<br />
range, which may be suitable for an Antibody Drug Conjugate (ADC) approach. PharmaMar is seeking a collaboration partner interested in<br />
having access to such compounds.<br />
Having established its own European Oncology sales force, PharmaMar is open to evaluate late-stage or on-the-market in-licensing<br />
opportunities in the Oncology/Hematology area (incl. supportive care) for commercialization in Europe.<br />
PROPRIETARY TECHNOLOGY<br />
Synthetic, marine-derived anticancer compounds.<br />
World's largest library of marine extracts (Samples from >100'000 different marine organisms)<br />
Topical siRNAs.<br />
CORPORATE ALLIANCES<br />
Licensing agreement with OrthoBiotech (Johnson & Johnson), for Yondelis®, covering territories outside of Europe and Japan. (2001)---<br />
Licensing agreement with Taiho Pharmaceuticals for development and commercialization of Yondelis in Japan. (March 2009) ---<br />
Licensing agreement with Marinomed Biotechnology for analogs of Kahalalide F, for all indications outside of Oncology and Neurology.<br />
(March 2009) ---<br />
Licensing agreement with Medimetriks Pharmaceuticals for Kahalalide F and two of its analogs, for all indications outside of oncology and<br />
neurology, targeting dermatological diseases such as psoriasis. (June 2009)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Yondelis On Market Soft Tissue Sarcoma<br />
Yondelis On Market Ovarian Cancer Complete market authorisations ex-EU<br />
Aplidin Phase III Relapsed/refractory Multiple Myeloma<br />
and T-Cell lymphoma.<br />
Interim Analysis in pivotal Phase III trial<br />
in Multiple Myeloma<br />
BIO Business Forum 2011 88 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Irvalec Phase II, IIa, IIb Esophageal & Gastric Complete recruitment in Phase II trial in<br />
Esophageal & Gastric Cancer<br />
Zalypsis Phase II, IIa, IIb Multiple Myeloma, Ewing Sarcoma &<br />
Urothelial Carcinoma<br />
Complete recruitment<br />
PM01183 Phase II, IIa, IIb Pancreatic Cancer & Solid tumors Complete recruitment<br />
Sylentis 40012 Phase I Glaucoma Phase Ib Top Line Results in 3Q 2011<br />
Sylentis 1001 Phase I Dry eye , pain Complete recruitment<br />
PM060184 Phase I Solid Tumors Complete recruitment<br />
Library of marine-derived<br />
extracts<br />
Research All indications<br />
BIO Business Forum 2011 89 Participating Company <strong>Profiles</strong>
504 Carnegie Center<br />
Princeton, NJ 08540<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Susan Calandra<br />
PharmaNet Inc<br />
Clinical Foci: Drug Development • Biopharmaceuticals<br />
www.pharmanet.com<br />
Phone: 1-609-951-6113<br />
Ownership: Private<br />
BIO Business Forum 2011 90 Participating Company <strong>Profiles</strong>
David Goodman<br />
Chief Executive Officer<br />
6111 Avenue Royalmount<br />
Montreal, QC H4P 2T0<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Frank Puglisi, Director Business Development<br />
CORPORATE MISSION<br />
Pharmascience<br />
Clinical Foci: Specialty Pharmaceutical • Oncology • Urological<br />
Phone: 1-514-340-9800 Incorporated: 1983<br />
Employees: 1300<br />
Ownership: Private<br />
Pharmascience is a pharmaceutical company headquartered in Montreal, Canada. Pharmascience is a vertically integrated pharmaceutical<br />
company with over 1300 employees and a wide range of capabilities: from manufacturing to commercialization. Pharmascience has a well<br />
established generic business as well as a brand prescription division. Pharmascience's growth strategy includes in-licensing and<br />
acquisitions of late stage specialty pharmaceutical brand products; more specifically hospital prescription products. Co-development may<br />
be a consideration for a strategically aligned opportunities.<br />
FINANCING HISTORY<br />
Investors: Goodman Family (100 %)<br />
SENIOR MANAGEMENT<br />
David Goodman, Chief Executive Officer • Elise Vezina, Vice President • Frank Puglisi, Director<br />
BIO Business Forum 2011 91 Participating Company <strong>Profiles</strong>
Jeffrey A. Bibbs, PhD<br />
Chief Executive Officer<br />
7330 Carroll Road, Suite 200<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Brent Moody, Technical Sales Representative<br />
HIGHLIGHTS<br />
Recent<br />
Pharmatek Laboratories, Inc.<br />
Clinical Foci: Drug Development • Biopharmaceuticals • Oncology<br />
www.pharmatek.com<br />
Phone: 1-858-805-6383<br />
Incorporated: 1997<br />
Employees: 75<br />
Ownership: Private<br />
Pharmatek has purchased a Buchi B-290 spray dryer for feasibility studies and small-scale clinical manufacture. This technology can be<br />
used for both oral and parenteral dosage forms, and enhances our formulation capabilities for insoluble compounds.<br />
Pharmatek has been approved by the US DEA for the analysis of Schedules I through V controlled substances, complementing its existing<br />
license to develop and manufacture drug products containing Schedules IV and V controlled substances.<br />
Pharmatek has expanded GMP manufacturing capabilities by adding roller compaction, large-scale blending (36 kg per batch), and faster<br />
encapsulation and tablet production to our Phase I/II drug development and manufacturing services.<br />
CORPORATE MISSION<br />
Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development organization supporting the pharmaceutical and<br />
biotechnology industries. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include<br />
compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, ICH stability<br />
storage and testing, and high-potent & cytotoxic development and manufacturing.<br />
PROPRIETARY TECHNOLOGY<br />
Hot Rod Chemistry® (HRC): Every year hundreds of drug candidates are abandoned due to poor solubility. Formulation technology<br />
becomes a key enabler for ensuring continued development. Pharmatek Laboratories' Hot Rod Chemistry® is a formulation screening kit<br />
designed to solubilize drug candidate compounds and prepare them for testing in animal models.<br />
CORPORATE ALLIANCES<br />
Major biotech & pharmaceutical companies including virtual and speciality companies.<br />
SENIOR MANAGEMENT<br />
Jeffrey A. Bibbs, PhD, Chief Executive Officer • Timothy Scott, President • Mark G. Foletta, CPA, Director, Chief Financial Officer<br />
BIO Business Forum 2011 92 Participating Company <strong>Profiles</strong>
Dr Fintan Walton<br />
Chief Executive Officer<br />
Florey House<br />
Oxford Science Park<br />
Oxford<br />
OX4 4GP<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Adrian Dawkes<br />
PharmaVentures, Ltd<br />
www.pharmaventures.com<br />
Phone: 44-1865-332 725<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
TRANSACTION: PharmaVentures acts as exclusive advisor to sanofi-aventis in landmark<br />
divestment deal with Covance<br />
http://www.pharmaventures.com/aboutus/press/news/1637<br />
PharmaDeals®, the publishing division of PharmaVentures, are launching a new interactive<br />
publishing platform that significantly enhances the utility of its highly acclaimed reports for its<br />
clients http://www.pharmaventures.com/pharmadeals/reports<br />
TRANSACTION: PharmaVentures facilitates manufacturing divestment for UCB to Aesica<br />
Pharmaceuticals<br />
http://www.pharmaventures.com/aboutus/press/news/1647<br />
Incorporated: 1997<br />
Employees: 30<br />
Ownership: Private<br />
PharmaVentures is seeking to acquire<br />
in market or close to market products<br />
for the East European region on behalf<br />
of a global pharmaceutical company.<br />
CORPORATE MISSION<br />
In the increasingly, and rapidly, changing business of healthcare it is imperative you have the most insightful, expert and up-to-date<br />
information and support to allow you to make the best choices.<br />
PharmaVentures® is uniquely placed to help you make the decision you need to make. Over the last 20 years our experts have provided<br />
assistance to clients ranging from start-ups to global pharmaceutical corporations, their advisors, investment companies and<br />
governments.<br />
To drive growth in this current market, having the right people to provide you support, when & where you need it is critical. As the home<br />
to some of the thought leaders in Healthcare Corporate Advisory Services, particularly in the fields of; strategic transactions, asset<br />
valuation, asset divestment, M&A support and deal structuring, PharmaVentures® (http://www.pharmaventures.com) has been able to<br />
support our clients maximise their return on investment.<br />
With our PharmaDeals® range of intelligence products including analysis tools and industry leading reports, you can be confident of<br />
having the best insights into the worlds of; Mergers & Acquisitions, strategic alliances, licensing and large transactions available at your<br />
finger tips.<br />
The fast pace of the healthcare business world demands you have access to the most up-to-date information and analysis.<br />
PharmaTelevision® (PTV) (http://www.pharmatelevision.com) is the world's first dedicated online television channel for the BioPharma<br />
industry, providing daily television news, analysis and feature interviews with industry leaders.<br />
Produced by news & television experts, at our own dedicated studios in the UK, PTV has been providing insight to healthcare leaders for<br />
four years. With a worldwide audience of ~12,000 dedicated viewers and now, through a syndication relationship with Reuters, having<br />
access to approximately 500,000 financial specialist’s desktops globally, PTV is becoming the must-go-to place for Healthcare & Financial<br />
executives.<br />
PROPRIETARY TECHNOLOGY<br />
With our PharmaDeals® range of intelligence products including analysis tools and industry leading reports, you can be confident of<br />
having the best insights into the worlds of; Mergers & Acquisitions, strategic alliances, licensing and large transactions available at your<br />
finger tips.<br />
The fast pace of the healthcare business world demands you have access to the most up-to-date information and analysis.<br />
PharmaTelevision® (PTV) (http://www.pharmatelevision.com) is the world's first dedicated online television channel for the BioPharma<br />
industry, providing daily television news, analysis and feature interviews with industry leaders.<br />
SENIOR MANAGEMENT<br />
Dr Fintan Walton, Chief Executive Officer • Mr Geoff Brooker, Chief Financial Officer • Adrian Dawkes, Director • Mr Kevin Bottomley,<br />
Other • Mrs Anne Vindenes Allen, Managing Director<br />
BIO Business Forum 2011 93 Participating Company <strong>Profiles</strong>
Jean-Chretien Norreel<br />
President & CEO<br />
Parc Scientifique de Luminy - IBDML<br />
13288 MARSEILLE<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Jean-Chretien Norreel, CEO<br />
François Thomas<br />
Pharmaxon<br />
Clinical Foci: Neurology • Drug Development<br />
www.pharmaxon.com<br />
Phone: 33-4-86948510<br />
Incorporated: 2004<br />
Employees: 10<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Pharmaxon has validated the efficacy of PR21 on various nervous injury models of spinal cord injuries, both in vitro and in vivo.<br />
PR21 has been shown to fulfill several criteria for an in vivo use as it is neither toxic, nor immunogenic in preliminary toxicology studies<br />
and displays good stability in biological fluids.<br />
CORPORATE MISSION<br />
Pharmaxon is a biotechnology company aiming at developing new drugs for treating central nervous system traumas by manipulating<br />
cell mobility.<br />
The company is based on the seminal work of Pr Geneviève Rougon - head of the Marseille-Luminy Developmental Biology Institute - on<br />
the modulation of adhesion molecules. Cell surface adhesion molecules play vital roles in numerous cellular processes, including cell<br />
growth, differentiation, embryogenesis, immune response, cancer metastasis and neuroplasticity. Neuroplasticity refers to the ability of<br />
the brain to modify its neuronal circuitry in response to new experiences but also to adapt following traumas in general and spinal cord<br />
injuries (SCI) in particular .<br />
The company acquired in 2005 exclusive rights on a compound - short 12 amino-acid long peptide named PR21 - with a therapeutic<br />
potential in central nervous system (CNS) traumas.<br />
Pharmaxon aims at completing the preclinical regulatory package as well as conducting a phase I clinical trial of PR-21 in the next 30<br />
months.<br />
PROPRIETARY TECHNOLOGY<br />
The cyclic peptide PR21 mimics the Polysialic Acic (PSA) specifically carried by the adhesion molecule NCAM (PSA-NCAM). PSA-NCAM has<br />
emerged as an excellent candidate for promoting plasticity and brain repair. Pharmaxon has validated the efficacy of PR21 on various<br />
nervous injury models, both in vitro and in vivo. PR21 has been shown to fulfill several criteria for an in vivo use as it is neither toxic, nor<br />
immunogenic in preliminary toxicology studies and displays good stability in biological fluids. Intrathecal administration of PR21 after<br />
spinal cord hemisection in mice or contusion in rats significantly improved motor recovery in several sets of experiments.<br />
INTELLECTUAL PROPERTY<br />
In 2005, Pharmaxon has been granted an exclusive license with the right to sublicense on PR21 by the CNRS, the Hamburg university,<br />
Schaffer N' Corp and the Mediterranean university of Marseille on one hand and Sanofi-Aventis on the other hand.<br />
PR21 patent has been granted in the US (10531701) and in Europe (EP2295568) and is currently under review in Japan and Canada.<br />
Germany, Belgium, Spain, France, Danemark, Italy, Netherlands, Portugal, United Kingdom, Sweden and Switzerland have been chosen for<br />
national filling in Europe.<br />
The initial application has been filed in October 2003. Thus, PR21 is currently protected up to 2023.<br />
The patent covers the use of PR21 for the preparation of a drug for the prevention and/or treatment of neurodegenerative diseases, brain<br />
and spine lesions, age-rel<br />
PRODUCTS<br />
Name Phase Indication<br />
PR21 Preclinical Spinal Cord Injury<br />
GGTI Preclinical Spinal Cord Injury<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Seed Round: 09/01/2006 (US $0.50 million)<br />
Round A: 09/01/2009 (US $2.00 million)<br />
Investors: SHAM (29 %) • Jean-Chretien Norreel (22 %) • Pascal Deschaseaux (15 %) • Primaveris (12 %) •<br />
Esperante (11 %) • Inserm-Transfert (5 %)<br />
BIO Business Forum 2011 94 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Jean-Chretien Norreel, President & CEO • Isabelle Boquet, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Jean-Chretien Norreel, Pharmaxon • Thierry Abribat, Alizee Pharma • Stephane Boissel, Transgene • Stephane Debono, Ipsogen •<br />
Pascal Deschaseaux, Gelarc<br />
SCIENTIFIC ADVISORY BOARD<br />
Genevieve Rougon, CNRS • Melitta Schachner, UKE • John Steeves, Icord<br />
BIO Business Forum 2011 95 Participating Company <strong>Profiles</strong>
Sijmen de Vries<br />
Chief Executive Officer<br />
P.O. Box 451<br />
2300 AL Leiden<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Karl Keegan, PhD, CFO<br />
Sijmen De Vries<br />
Christine De Los Reyes , PHARMD<br />
Pharming Group N.V.<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Specialty Pharmaceutical<br />
www.pharming.com<br />
Phone: 31-71-5247181<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Commercialisation deal for Ruconest agreed with SOBI for Europe<br />
and with Santarus for North America<br />
European approval and launch of Ruconest. First sales recorded in<br />
late 2010.<br />
Capital structure improved with debt settled and equity added<br />
Incorporated: 1988<br />
Employees: 75<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
AMSTERDAM STOCK EXCHANGE: PHARM<br />
Successful completion of our ongoing Phase IIIb study of Rhucin in<br />
HAE, filing with FDA<br />
Expansion of/ additional commercialisation partnerships for<br />
Rhucin<br />
Initiation of development of new recombinant human proteins on<br />
the Pharming transgenic platform<br />
CORPORATE MISSION<br />
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest (Rhucin® in non-European<br />
territories) is a recombinant human C1 inhibitor approved and marketed for the treatment of angioedema attacks in patients with HAE in<br />
all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development for follow-on indications, i.e. antibodymediated<br />
rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the company<br />
include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of<br />
these products. Additional information is available on the Pharming website, www.pharming.com.<br />
PROPRIETARY TECHNOLOGY<br />
Transgenic animals provide the possibility to produce bulk amounts of recombinant proteins, at low cost. Production is simple to scale-up<br />
and required capital investments are substantially lower than for cell culture systems, flexibility enhanced by early bulk intermediate<br />
holding option (frozen milk) . Most recombinant human proteins, have expression level in cell culture of < 1 g/L, expression levels in<br />
transgenic animals are typically in the 5-15 g/L range. The transgenic system is also capable to express complex proteins that cannot be<br />
produced otherwise. The capacity of upstream production is virtually unlimited and very robust. Regulatory acceptance through the<br />
approvals of rhAT III (GTC Biotherapeutics) and rhC1 Inhibitor (Pharming Group) from goat and rabbit milk, respectively.<br />
CORPORATE ALLIANCES<br />
2004, Laboratorios del Dr Esteve, SA in Spain for the development and sales of Rhucin® in Spain, Portugal, Greece and Andorra<br />
2008 signed a similar agreement with Eczacibasi Ilaç Pazarlama AS , covering Turkey.<br />
April 2010, an exclusive distribution partnership with Swedish Orphan Biovitrum (SOBI) for Iceland, Norway, Switzerland and all the<br />
remaining territories of the European was signed. SOBI will also have the option to participate in the development of subsequent<br />
indications, which will provide them with commercialization rights following regulatory approval of such indications.<br />
In September 2010, Pharming entered into an exclusive commercialization partnership for Rhucin with Santarus. This partnership covers<br />
Canada, Mexico and the USA.<br />
INTELLECTUAL PROPERTY<br />
Pharming has an extensive IP portfolio covering relevant aspects of the transgenic technology and its product portfolio<br />
PRODUCTS<br />
Name Phase Indication<br />
Ruconest On Market Hereditary Angioedema<br />
Rhucin Phase III Hereditary Angioedema<br />
SENIOR MANAGEMENT<br />
Sijmen de Vries, Chief Executive Officer • Karl Keegan, Chief Financial Officer<br />
BIO Business Forum 2011 96 Participating Company <strong>Profiles</strong>
Christopher Prior, PhD<br />
Chief Executive Officer<br />
One Great Valley Parkway<br />
Malvern, PA 19355<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Kathryn Gregory<br />
Phasebio Pharmaceuticals Inc.<br />
Clinical Foci: Biopharmaceuticals • Metabolic Disease • Cardiovascular Disease<br />
www.phasebio.com<br />
Phone: 1-610-981-6500<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
November 2010 - First human dosing with Glymera and ELP<br />
technology platform for hyperglycemia in Type 2 diabetes<br />
November 2010 - Received second tranche of Series B financing<br />
totaling $25 million<br />
October 2010 - Research collaboration with major pharmaceutical<br />
company (undisclosed)<br />
Employees: 17<br />
Ownership: Private<br />
2011 - Completion of PI/IIa trial of Glymera<br />
2011 - File 2nd IND for Vasomera for treatment of resistant<br />
hypertension<br />
2011 - Advance third preclinical candidate<br />
CORPORATE MISSION<br />
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs with an initial focus on<br />
endocrine, metabolic and cardiovascular disease. The company uses a proprietary class of recombinant biopolymers called elastin-like<br />
polymers (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides that have been shown<br />
to be clinically active with the goal of achieving greater drug potency, fewer side effects and better patient compliance.<br />
PhaseBio has two lead programs. Our first lead candidate Glymera, is currently being evaluated in humans for the treatment of<br />
hyperglycemia associated with Type 2 diabetes with potential for future use in obesity. Our second candidate Vasomera, with an<br />
expected IND filing in 2011 will be tested as a treatment for resistant hypertension with potential for future use in Pulmonary Arterial<br />
Hypertension (PAH) and heart failure.<br />
Advantages of ELP Biopolymers:<br />
In vitro receptor binding studies have shown that ELP-fused peptides and proteins retain high activity similar to their non-fused<br />
counterparts. This translates into increased drug potency and bioavailability, which in turn permits delivery of a lower dose of drug with<br />
less frequent administration. Further, ELPs demonstrate a slow absorption profile and significant half-life extension, a unique<br />
combination that results in a prolonged steady-state drug level following subcutaneous administration. This increase in bioavailability<br />
allows for less frequent administration, resulting in greater efficacy with the potential for fewer side effects. In the case of Glymera, the<br />
side-effect profile typically associated with delivery of the free GLP-1 peptide (nausea and GI effects) is greatly reduced or non-existent.<br />
PROPRIETARY TECHNOLOGY<br />
PhaseBio’s proprietary technology is based on recombinant biopolymers, called ELPs, to which peptides and proteins can be genetically<br />
fused (ELP fusion proteins) and small molecule drugs can be chemically conjugated (ELP-drug conjugates). The individual subunit or<br />
building blocks of ELPs are derived from a five amino acid motif found in nature present in the ubiquitous elastin protein. Fusion to ELPs<br />
improves significantly the solubility and bioavailability of peptides and proteins, and the fusion protein retains almost identical activity to<br />
the native peptide or protein. Modifying the sequence of the individual subunits of the ELP and its length is used to optimize the physical<br />
and chemical properties of each ELP-fusion protein or biopolymer-drug conjugate.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Glymera Phase II, IIa, IIb Type 2 Diabetes and Obesity Phase I/IIa completion 2011<br />
Vasomera Preclinical Resistant Hypertension and Related<br />
Cardiovascular Diseases<br />
Oxymera Preclinical Obesity<br />
SENIOR MANAGEMENT<br />
IND filing 2011<br />
Christopher Prior, PhD, Chief Executive Officer • Craig Rosen, PhD, Chairman • Lynne Georgopoulos, RN, BS, RAC, Senior Vice President<br />
• Susan Arnold, Vice President • Joel F. Sussman, Chief Financial Officer • Kathryn J. Gregory, MBA, Vice President<br />
BOARD OF DIRECTORS<br />
Craig Rosen, PhD, PhaseBio Executive Chairman and Chief Scientific Officer • James Barrett, PhD, New Enterprise Associates (NEA) •<br />
Ashutosh Chilkoti, PhD, Duke University • Guy Fish, MD, Fletcher Spaght Ventures • Bob Ingram, Hatteras Venture Partners • Justin<br />
Klein, MD, J.D., New Enterprise Associates (NEA) • Clay Thorp, Hatteras Venture Partners • Asish Xavier, PhD, Johnson & Johnson<br />
Development Corporation • Christopher Prior, PhD, PhaseBio Chief Executive Officer<br />
BIO Business Forum 2011 97 Participating Company <strong>Profiles</strong>
Robert W. Overell, PhD<br />
President & CEO<br />
410 W. Harrison Street, Suite 300<br />
Seattle, WA 98119<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Robert W. Overell, PhD, President and CEO<br />
Richard Rieger, Vice President, Business Development<br />
CORPORATE MISSION<br />
PhaseRx, Inc.<br />
Clinical Foci: Drug Delivery • Oncology • Biopharmaceuticals<br />
www.phaserx.com<br />
Phone: 1-206-805-6334<br />
Incorporated: 2006<br />
Ownership: Private<br />
PhaseRx is an RNAi delivery technology company developing a breakthrough polymer-based system that enables the systemic, targeted<br />
delivery of RNAi-based drugs and potentially other macromolecules as therapeutic products. Development of RNAi therapeutics, a new<br />
class of pharmaceuticals with significant market potential, has been hindered to date by the lack of effective delivery technology. PhaseRx<br />
was founded in 2006 to solve a critical challenge in RNAi delivery: the need for a versatile, developable system that delivers RNAi drugs into<br />
the cytoplasm where they can reach and inhibit drug targets. PhaseRx is deploying an integrated delivery system based on novel synthetic<br />
polymers that delivers RNAi drugs into the cytoplasm by effecting their escape from intracellular vesicles called endosomes, where these<br />
drugs are often trapped and sequestered. The synthetic polymers exploit natural cellular processes and pH changes to effect endosome<br />
escape, delivering RNAi drugs into the cytoplasm where they can reach and inhibit the desired target of interest. This proprietary delivery<br />
system represents a turnkey approach to developing RNAi-based drugs. It is designed to provide pharmaceutical and biotechnology<br />
partners with a robust, developable, and versatile RNAi delivery system that will enable them to take their novel molecules forward into<br />
clinical development. The PhaseRx system offers significant advantages: effective RNAi delivery, broad applicability and consistency with<br />
pharmaceutical development standards. With a comprehensive intellectual property portfolio, an experienced management team, toptier<br />
investor syndicate and a breakthrough RNAi delivery system, PhaseRx is well positioned to establish a portfolio of licensing<br />
transactions to ensure a diverse and sustainable revenue stream to sustain the company’s business model.<br />
PROPRIETARY TECHNOLOGY<br />
RNAi therapeutics generally cannot penetrate the cell membrane and access the cytoplasm where they can reach drug targets. The<br />
PhaseRx polymer system overcomes the central stumbling block in the field of RNAi therapeutics by delivering RNAi molecules into the<br />
cytoplasm where they can reach and inhibit the desired target of interest. PhaseRx’ polymers work by responding to the lower pH<br />
environment of the endosome and use a novel mechanism to effect passage of siRNA across the endosomal membrane and into the<br />
cytoplasm. The system uses natural cellular functions to enable endosome escape, can be targeted to specific cells and is versatile, robust,<br />
reproducible and scalable. The PhaseRx RNAi delivery system can deliver RNAi therapeutics predictably to selected tissues in vivo.<br />
INTELLECTUAL PROPERTY<br />
PhaseRx has a comprehensive, substantial portfolio of intellectual property, including patent families filed in major pharma markets.<br />
SENIOR MANAGEMENT<br />
Robert W. Overell, PhD, President & CEO • Andew J. Leon, PhD, JD, Vice President • Paul H. Johnson, PhD, Chief Scientific Officer •<br />
Richard P. Rieger, MBA, Vice President • Samuel Zalipsky, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Steven Gillis, PhD, Managing Director, ARCH Venture Partners • John D. Diekman, PhD, Founder and Managing Partner, 5AM Ventures<br />
• Brian Atwood, Managing Director, Versant Ventures • John A. Schmidt, Jr., MD, Private Physician and Former CSO, Alnylam<br />
Pharmaceuticals • Robert W. Overell, PhD, President and CEO, PhaseRx • Paul H. Johnson, PhD, Chief Scientific Officer, PhaseRx<br />
BIO Business Forum 2011 98 Participating Company <strong>Profiles</strong>
Katell Morvan<br />
Chief Executive Officer<br />
1 rue Laurent Fries<br />
67400 ILLKIRCH<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Tania Sorg<br />
CORPORATE MISSION<br />
Phenopro Sas<br />
Clinical Foci: CNS • Metabolic Disease • Cardiovascular Disease<br />
www.phenopro.com<br />
Phone: 33-3-88655657<br />
Ownership: Private<br />
PhenoPro is an early preclinical CRO -before registration process- dedicated to mouse phenotyping protocols including:<br />
- Characterization and validation of genetically modified mouse models<br />
- Target validation / identification<br />
- In vivo preclinical drug screening<br />
- Efficacy / risks evaluation<br />
SENIOR MANAGEMENT<br />
Katell Morvan, Chief Executive Officer • Tania Sorg, Chief Operating Officer<br />
BIO Business Forum 2011 99 Participating Company <strong>Profiles</strong>
Dr. Carlton D. Donald<br />
President & CEO<br />
191 Peachtree Street Suite 3200<br />
Atlanta, GA 30318<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Carlton D. Donald, President/CEO<br />
CORPORATE MISSION<br />
Phigenix, Inc.<br />
Clinical Foci: Oncology • Diagnostics • Oncology<br />
www.phigenix.com<br />
Phone: 1-404-946-1811<br />
Incorporated: 2007<br />
Ownership: Private<br />
Phigenix, Inc. is a discovery-stage biotechnology company currently developing novel diagnostic and therapeutic technology for prostate<br />
and breast cancers. The PAX2 oncogene is aberrantly up-regulated in prostate and breast cancers. Recent publications and press releases<br />
have demonstrated the significant role the PAX2 oncogene plays in cancer as well as its potential importance as a cancer biomarker and<br />
therapeutic target. Furthermore, PAX2 expression was shown to predict clinical outcome in both breast and prostate cancer patients and<br />
it has been suggested that a PAX2 diagnostic test would have significant clinical utility. Phigenix has in its development pipeline a<br />
proprietary diagnostic kit for breast and prostate cancers which measures expression and activity of PAX2 and not only predicts disease<br />
stage, but also the most efficacious treatment modality. These diagnostic kits are expected to be of great benefit to both the patient and<br />
clinician regarding prostate and breast cancer disease management.<br />
In summary, Phigenix, Inc. is offering access to this novel and first-in-class set of preclinical compounds and diagnostic kits through<br />
strategic partnership. Unlike other therapeutic approaches which involve targeting cell signaling such as Kinase pathways (e.g. MEK<br />
inhibitors) or other cellular regulatory systems (e.g. Hsp90 inhibitors), PAX2 plays a direct role in cancer initiation, progression,<br />
proliferation and survival. Therefore, anti-PAX2 therapies may offer more of a cancer-specific therapeutic approach to treating<br />
malignancies such as prostate and breast cancer, and our PAX2 diagnostic kits may serve as a valuable addition to cancer detection and<br />
disease management.<br />
PROPRIETARY TECHNOLOGY<br />
The PAX2 oncogene is aberrantly up-regulated in both prostate and breast cancer. Phigenix is developing diagnostic tests that detect<br />
prostate and breast tissue abnormalities at the pre-malignant state years before the onset of cancer. Phigenix also is developing<br />
proprietary inhibitors of the PAX2 oncogene and the subsequent PAX2- mediated cancer cell survival and proliferation pathways. In<br />
addition, Phigenix is developing peptides that increase the expression of the tumor suppressor Human Beta Defensin-1 (DEFB1), a critical<br />
component of the innate immune system and regulator of the anti-tumor response. Phigenix’s therapeutics in development involves<br />
blocking the expression of PAX2 and the subsequent re-expression of DEFB1 to fight cancer.<br />
INTELLECTUAL PROPERTY<br />
Phigenix possesses an impressive patent portfolio that covers its inventions in the U.S. and internationally. Phigenix’s U.S. patent portfolio<br />
includes both issued and pending applications on diagnosis and treatment of prostate and breast cancer. Corresponding international<br />
patent applications are currently under examination in Europe, Canada, Mexico, Australia, New Zealand, Japan, China, India, Brazil, the<br />
African regional Authority, South Africa and the World Intellectual Property Organization.<br />
PRODUCTS<br />
Name Phase Indication<br />
Prostate Cancer Diagnostic Kit Diagnostics Functional Diagnostic for Early Detection and Monitoring<br />
Breast Cancer Diagnostic Kit Diagnostics Cancer Detection and Determining Course of Treatment<br />
Prostate Cancer Therapeutic Drugs Preclinical PAX2 Inhibitor<br />
Prostate Cancer Therapeutic Vaccine Preclinical PAX2 Antibody<br />
Prostate Cancer Therapeutic Vaccine Preclinical DEFB1 Peptide<br />
Breast Cancer Therapeutic Drugs Preclinical PAX2 Modulators<br />
FINANCING HISTORY<br />
Investors: Dr. Carlton D. Donald (80 %) • MUSC Foundation for Researcd Development (10 %) • Investors &<br />
Directors (10 %)<br />
SENIOR MANAGEMENT<br />
Dr. Carlton D. Donald, President & CEO • Mrs. Wennifer H. Donald, Chief Operating Officer • Dr. Kenneth Robinson, Director • Dr.<br />
Richard Roy, Director • Dr. Eddie Long, Director • Dr. James P. Brown, Business Development<br />
BIO Business Forum 2011 100 Participating Company <strong>Profiles</strong>
Duccio Neri<br />
Chief Executive Officer<br />
Via Bellaria 35, Sovicille<br />
53018-Siena<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Jane Wilton, Director of Business Development<br />
Manuela Kaspar, Head of Protein Engineering<br />
Philogen S.p.A.<br />
Clinical Foci: Biopharmaceuticals • Oncology • Drug Discovery<br />
www.philogen.com<br />
Phone: 39-0577-1781 614<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Recruitment progressing in Phase IIb melanoma trials of Darluekin.<br />
Recent discussions with the European Medicines Agency on<br />
pathway to approval<br />
Recruitment has reached 50% for the trial of Radretumab for brain<br />
metastases, and some striking positive responses have been<br />
observed.<br />
Deals with Merck-Serono and Pfizer Inc on Antibody generation<br />
and Oncology Target Discovery respectively.<br />
Ownership: Private<br />
Dekavil (F8-IL10) will commence the Phase I trial in humans - study<br />
site is opened and enrollment is expected to start imminently.<br />
Teleukin (F16-IL2) is entering Phase II development for metastatic<br />
breast cancer.<br />
Philogen and its clinical investigators will be presenting 3 posters<br />
at ASCO, and have recently submitted other manuscripts, for<br />
example one on Darleukin to Journal of Clinical Oncology.<br />
CORPORATE MISSION<br />
Philogen is a fully integrated biotechnology company engaged in the discovery and development of biopharmaceutical products for the<br />
treatment certain diseases that are characterized by angiogenesis, the proliferation of newly formed blood vessels.<br />
Philogen’s strategy is to deliver bioactive agents (for example cytokines or radioactivity) to the site of disease using antibodies that<br />
specifically and efficiently target the new blood vessels. Philogen helped pioneer this strategy, having participated in more than 200<br />
publications in leading scientific journals since 1997 in relation to this therapeutic approach. This technology has generated a strong<br />
proprietary pipeline of seven bio-pharmaceutical products that are undergoing Phase I/II clinical trials in cancer and chronic inflammation<br />
indications.<br />
Philogen is based in Siena, Italy and in Zurich, Switzerland and has R&D facilities and a EMA-certified GMP production facility that<br />
accelerates transition of its ‘armed antibodies’ to the clinic.<br />
We are at BIO seeking to out-license our clinical stage armed antibodies and our technologies.<br />
PROPRIETARY TECHNOLOGY<br />
Philogen has established discovery technologies, including human antibody technology, chemical proteomics for the discovery of vascular<br />
markers of disease and DNA-encoded libraries for the isolation of chemical entities.<br />
CORPORATE ALLIANCES<br />
Merck-Serono, Pfizer Inc.<br />
INTELLECTUAL PROPERTY<br />
Extensive portfolio of international patents protecting out portfolio and technologies<br />
PRODUCTS<br />
Name Phase Indication<br />
Darleukin (L19-IL2) Phase II, IIa, IIb Oncology<br />
Teleukin (F16-IL2) Phase II, IIa, IIb Oncology<br />
Fibromun (L19-TNF) Phase II, IIa, IIb Oncology<br />
Dodecal Preclinical Oncology<br />
Radretumab (L19-131I) Phase II, IIa, IIb Oncology<br />
Tenarad (F16-131I) Phase II, IIa, IIb Oncology<br />
Tenapet (F16-I124) Phase II, IIa, IIb Oncology<br />
Dekavil (F8-Il10) Phase I Chronic Inflammation<br />
Vangiolux (L19-PDT) Preclinical Opthalmology<br />
Albufluor Preclinical Opthalmology<br />
SENIOR MANAGEMENT<br />
Duccio Neri, Chief Executive Officer • Dario Neri, Chief Scientific Officer • Hans Menssen, Chief Medical Officer<br />
BIO Business Forum 2011 101 Participating Company <strong>Profiles</strong>
John Lawson, PhD<br />
Chief Executive Officer<br />
525 West 465 North<br />
Providence, UT 84332<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Phoenix Pharmalabs, Inc<br />
Clinical Foci: CNS • Drug Development • Neurology<br />
www.phoenixpharmalabs.com<br />
Phone: 1-435-213-9361<br />
William W. Crossman, President and Chief Development Officer<br />
Tim Chou<br />
Incorporated: 2003<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
December, 2010: Phoenix Pharmalabs, Inc. announced that a Composition of Matter Patent Application was filed for a long-duration<br />
analog of its novel family of ligands with high binding affinity and balanced activity at all three opioid receptors.<br />
December, 2010: Phoenix Pharmalabs, Inc. announced that a Composition of Matter Patent Application was filed for a new, advanced<br />
analog with higher binding affinity and more balanced activity at all three opioid receptors.<br />
Phoenix Pharmalabs, Inc. announced a license agreement for China with Aoxing Pharma (NYSE: AXN). Aoxing, in collaboration with China<br />
NIDA (Beijing Univ.), will conduct clinical trials in China and provide FDA-acceptable data for approval in the US.<br />
CORPORATE MISSION<br />
Phoenix PharmaLabs, Inc. (PPL) is a preclinical drug discovery company focused on the development and commercialization of new nonaddictive<br />
treatments for pain and new therapies for treatment of opiate addiction. PPL has designed a novel family of ligands with high<br />
binding affinity at all three opiate receptors: mu, kappa and delta, having more balanced partial agonist /antagonist receptor activity<br />
than morphine and other opioids. This profile results in first-ever opiate analgesics that appear to be non-addicting and free of all<br />
dangerous side effects.<br />
Studies of the drugs conducted by the NIH and SRI demonstrated analgesic potency 4x - 20x stronger than morphine; no respiratory<br />
depression - even at 100x dosage (and hence no risk of death from overdose); no physical dependence; very little or no abuse potential; no<br />
dysphoria and no GI tract side-effects. The drugs are orally active and inexpensive to produce using PPL's patented manufacturing<br />
methods. They do not precipitate withdrawal and hence offer promising use for addiction therapy as well as for pain.<br />
The cost and risk of achieving a New Drug Approval (NDA) from the FDA is substantially lower than other NCEs with equivalent market<br />
potential. Few drug classes have more longitudinal test data than opioids as a predictor of success in trials. Therefore, the risk of<br />
pharmaceutical product development is significantly reduced compared to the risk of developing less understood and potentially<br />
problematic drug classes (such as COX-2 inhibitors, etc.).<br />
Furthermore, a vast amount of opioid testing data is available concerning the transition of effects of pure opioid compounds from<br />
animals to humans. Consequently, our experts and advisors predict that the risk of problems in toxicology and safety pharmacology is<br />
close to zero. The prediction correlation from animals to humans is very high, and thus there is a high level of confidence that the<br />
compounds will be safe, effective and beneficial for humans.<br />
PROPRIETARY TECHNOLOGY<br />
PPL has designed a novel family of ligands with high binding affinity at all three opiate receptors. These unique ligands have more<br />
balanced receptor activity than morphine and other opioids, with partial agonist / antagonist activity at mu, relatively higher, but not full,<br />
kappa agonist activity, and moderate delta activity. This profile results in first-ever opiate analgesics that appear to be non-addicting and<br />
free of all dangerous side effects.<br />
Studies by the NIH and SRI demonstrated analgesic potency 4x - 20x stronger than morphine; no respiratory depression - even at 100x<br />
dosage; no physical dependence; very little or no abuse potential; no dysphoria and no GI tract side-effects. The drugs are orally active and<br />
inexpensive to produce using PPL's patented methods.<br />
CORPORATE ALLIANCES<br />
PPL has entered into a license agreement for China (the PRC, Hong Kong and Macau) with Aoxing Pharmaceutical Company (NYSE: AXN).<br />
Aoxing will conduct clinical trials in China using GLP (Good Laboratory Practices) protocols, and United States FDA-acceptable data will be<br />
provided to the FDA for approval in the US, as well as to the SFDA (the Chinese equivalent of the U.S. FDA) for approval in China. This work<br />
is being done in collaboration with the China NIDA (Beijing University). The Aoxing agreement applies to PPL's lead drug only, but may be<br />
extended to include other analogs as well. PPL retains all rights to the drugs outside of China.<br />
INTELLECTUAL PROPERTY<br />
Lead Drug: Use Patent issued 2009; Methods Patent filed 2008.<br />
Long Duration Analog: Composition Patent filed 2010.<br />
Advanced Analog: Composition and Methods Patent filed 2010.<br />
BIO Business Forum 2011 102 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
PPL-101 Preclinical Pain and / or Addiction IND<br />
PPL-102 Preclinical Pain and / or Addiction IND<br />
PPL-103 Preclinical Pain and / or Addiction IND<br />
PPL-104 Research Pain and / or Addiction Target Validated<br />
SENIOR MANAGEMENT<br />
John Lawson, PhD, Chief Executive Officer • William Crossman, President • Timmy Chou, Chief Financial Officer • Chris Tew, Vice<br />
President • Lawrence Toll, PhD, Director • Theodore Stanley, MD, Director • Bruce W. Jenett, J.D., General Counsel<br />
BOARD OF DIRECTORS<br />
John Lawson, PhD, CEO and Chief Scientist • William Crossman, President and Chief Development Officer • Timmy Chou, CFO •<br />
Lawrence Toll, PhD, Pharmacology Consultant • Chris Tew, Vice President • Theodore Stanley, MD, Medical Consultant<br />
SCIENTIFIC ADVISORY BOARD<br />
Louis Harris, PhD, Scientific Consultant - Animal Model Evaluation • Anthony Fox, MD, PhD, Clinical Trial Design Consultant • Alan<br />
Mueller, PhD, CRO Consultant • Scott Lukeman, PhD, Scientific Consultant • Leah Reimer, PhD, Lead Patent Attorney • L. Anne<br />
Maxwell, PhD, Patent Counsel • Pen Yang, PhD, Biomedical Consultant - China • Jiang Ping, PhD, Medical Consultant - China<br />
BIO Business Forum 2011 103 Participating Company <strong>Profiles</strong>
Thomas A. Collet<br />
Chief Executive Officer<br />
300 North Fifth Avenue<br />
Ann Arbor, MI 48104<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas A. Collet, President & CEO<br />
Phrixus Pharmaceuticals, Inc<br />
Presenting Company<br />
Clinical Foci: Musculoskeletal • Cardiovascular Disease • Genetic Disorders<br />
www.phrixuspharmaceuticals.com<br />
Phone: 1-734-926-0966<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Opened Phase 2 IND, ready for Proof-of-Concept trials in ADHF and<br />
DMD<br />
First patents issued<br />
$890,000 in funding from NIH for further pre-clinical studies in<br />
DMD and ADHF. Orphan drug status granted for DMD product<br />
candidate<br />
Incorporated: 2006<br />
Employees: 6<br />
Ownership: Private<br />
Complete manufacturing of clinical supplies for DMD and ADHF<br />
product candidates<br />
Initiate both Phase 2 Proof-of-Concept trials<br />
Expect $1.2 million orphan drug grant from FDA for DMD product<br />
candidate<br />
CORPORATE MISSION<br />
Phrixus Pharmaceuticals, Inc. is a clinical development-stage specialty pharmaceutical company developing Carmeseal (poloxamer 188<br />
or P-188) to treat cardiac dysfunction in patients with Duchenne muscular dystrophy (DMD) and to treat acute decompensated heart<br />
failure (ADHF). The original work with P-188 was done at the University of Michigan in a muscular dystrophy model of heart failure.<br />
Phrixus extended these findings to ischemic heart failure models so that the compound is now active in four different in vivo models<br />
predictive of human efficacy. Phrixus selected Carmeseal for development not only because of its in vivo efficacy in heart failure models<br />
but also because of the extensive investment made by others, including Burroughs-Wellcome in its development in unrelated indications.<br />
This includes safety in >2,500 subjects at 10-100x the doses planned for Phrixus’s development plan. Furthermore, Phrixus is<br />
repositioning P-188 for DMD and ADHF – both very large medical needs – that we expect will elicit favorable treatment from FDA during<br />
development, including orphan drug status and associated marketing exclusivity of seven and ten years in the US and Europe,<br />
respectively. Unlike CHF, approval for DMD and ADHF can be achieved without long term outcome trials – approval is expected based in<br />
SENIOR MANAGEMENT<br />
Thomas A. Collet, Chief Executive Officer • Bruce Markham, Chief Scientific Officer • James Symons, Vice President • Jack Luderer,<br />
Chief Medical Officer • David Williams, Vice President<br />
BOARD OF DIRECTORS<br />
Leslie Browne, President & CEO, Senesco Technologies, Inc. • Thomas A. Collet, President & CEO, Phrixus Pharmaceuticals, Inc. • Gerald<br />
Brennan, Fmr. CFO Aastrom Biosciences, Inc. • Bruce Markham, VP Research and CSO, Phrixus Pharmaceuticals, Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
Linda Cripe, MD, Pediatric Cardiologist, Children’s Hospital Medical Center, Cincinnati, OH • Steven Goldman, MD, Chief of Cardiology,<br />
VA, Tucson, AZ, & Professor of Medicine/Cardiology, University of Arizona • Daniel Kelly, MD, Scientific Director, Burnham Institute,<br />
Orlando, FL. Former Chief of Cardiology, CVRC Director, Washington University, S • Elizabeth McNally, MD, PhD, Director, Institute for CV<br />
Research, University of Chicago, Chicago, IL • Joseph Metzger, PhD, Inventor, Professor and Chair, Department of Biology and Integrative<br />
Physiology, University of Minnesota, Minneapolis, MN • Hani N. Sabbah, PhD, Professor of Medicine and Director of Cardiovascular<br />
Research, Henry Ford Health Center, Detroit, MI • R. Sanders Williams, MD, President, The J. David Gladstone Institute, UCSF, Board of<br />
Directors Bristol-Myers Squibb<br />
BIO Business Forum 2011 105 Participating Company <strong>Profiles</strong>
Dr Paul M Watt<br />
Chief Executive Officer<br />
105 Hay Street<br />
Subiaco, WA 6008<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Paul Watt, BSc, DPhil, CEO<br />
Nick Woolf, CFO and VP Corporate Developoment<br />
Phylogica Ltd<br />
Clinical Foci: Drug Discovery • AutoImmune • Infectious Disease<br />
www.phylogica.com<br />
Phone: 61-8-93828888<br />
Incorporated: 2001<br />
Employees: 21<br />
Ownership: Public<br />
Market Cap: $27.00 million<br />
ASX: PYC<br />
HIGHLIGHTS<br />
Recent<br />
December 2009 closed a deal with Roche around discovery of Cell Penetrating Peptides, now extended to discovery of peptides for delivery<br />
across the blood brain barrier. Terms not disclosed.<br />
August 2010 closed a deal with Medimmune around discovery of antimicrobial peptides for the treatment of Pseudomonas aeruginosa.<br />
Approximately $100 million total deal size<br />
December 2010 closed a deal with Pfizer vaccines around a therapeutic vaccine target. Approximately $135 million total deal size<br />
CORPORATE MISSION<br />
Phylogica is a company based in Perth, Australia and Oxford, UK which is commercializing a new class of proprietary peptide therapeutics<br />
called Phylomers for the Pharmaceutical industry. In the last year Phylogica has done deals with Roche, Medimmune and Pfizer in<br />
exchange for license fees, milestone payments and royalties. Phylomer libraries contain the most structurally diverse source of biologics<br />
available, with billions of distinct peptide compounds from thousands of structural families [Watt, PM., Nature Biotech 24:177-83(2006)].<br />
This diversity results in the highest functional hit-rates in peptide discovery as well as the best quality of hits (including biologically active<br />
picomolar primary hits, prior to any optimisation). Phylomers also have potential to provide alternative specificities when fused to<br />
proteins such as antibodies.<br />
This new source of bioactive peptide leads is validated by demonstration of efficacy in multiple animal models for Phylomers directed<br />
against intracellular or extracellular targets. Since adopting a discovery focussed business model, Phylogica is out-licensing its preclinical<br />
programs in inflammation, neuroprotection and potent antimicrobials against multi-resistant hospital acquired pathogens.<br />
PROPRIETARY TECHNOLOGY<br />
Phylomer peptide libraries are the most structurally diverse libraries available, comprising billions of peptides from thousands of<br />
structural families. Phylomers are derived from parts of biodiverse microbial proteins.Phylomer libraries yield a superior quality and<br />
quantity of peptide hits to conventional random peptide libraries. Primary hits from phylomer libraries can have exquisite target<br />
specificity and can bind targets with picomolar affinities, even prior to any sequence optimization. Phylomer peptides have been<br />
validated in multiple animal models, including Phylomers against intracellular as well as extracellular targets of multiple structural<br />
classes. Phylomers have also been identified with intrinsic cell penetration activity and the ability to deliver cargos into cells.<br />
CORPORATE ALLIANCES<br />
Roche<br />
Medimmune<br />
Pfizer<br />
INTELLECTUAL PROPERTY<br />
Patents cover methods of making and screening Phylomer libraries and composition-of-matter on peptides and the libraries themselves<br />
17 patent families, 26 granted/ allowed patents and 28 patent applications covering the markets of US, Europe, Japan and Australia<br />
SENIOR MANAGEMENT<br />
Dr Paul M Watt, Chief Executive Officer • Mr Nick Woolf, Chief Financial Officer • Dr Richard Hopkins, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Dr Douglas Wilson, Former Senior VP Medicine (global), Boehringer Ingelheim • Mr Bruce McHarrie, Non-executive • Mr Nick Woolf,<br />
Executive • Dr Paul Watt, Executive<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Greg Weiss, UC Irvine • Professor Jonathan Licht, University of Chicago • Professor Patrick Holt, Telethon Institute for Child<br />
Health Research • Professor Wayne Thomas, Telethon Institute for Child Health Research • Dr Erica Golemis, Fox Chase Cancer Centre<br />
• Professor Marie Bogoyevitch, Melbourne University • Dr Roland Dunbrack, Fox Chase Cancer Centre • Dr Trevor Payne, University<br />
of Western Australia (ex Novartis) • Professor Rob Alberse, University of Amsterdam<br />
BIO Business Forum 2011 106 Participating Company <strong>Profiles</strong>
Mark Chadwick<br />
Chief Executive Officer<br />
THE MAGDALEN CENTRE, THE OXFORD<br />
SCIENCE PARK<br />
OXFORD<br />
OX44GA<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Mark Chadwick<br />
HIGHLIGHTS<br />
Recent<br />
PHYSIOMICS PLC<br />
Clinical Foci: Oncology • Informatics • Systems Biology<br />
www.physiomics-plc.com<br />
Phone: 44-1865-784 985<br />
Incorporated: 2001<br />
Employees: 5<br />
Ownership: Public<br />
Market Cap: $11.00 million<br />
OTHER: PYC<br />
New study with Oncodesign showed that we can increase the efficacy of a combination, purely through schedule changes predicted by the<br />
Virtual Tumour<br />
CORPORATE MISSION<br />
Physiomics’ Virtual Tumour technology helps companies in the oncology field to determine optimal doses, schedules and combinations for<br />
pre-clinical animal studies. These optimised regimens can then be used as part of the planning process for clinical trials. An optimised<br />
regimen can make the difference between success and failure of an NCE or NBE.<br />
During 10 years of operations in Oxford, UK, our computational modelling approach has been validated with a number of big pharma and<br />
biotech customers.<br />
Virtual Tumour provides the following key benefits:<br />
1. Improve success rates for oncology candidates entering clinical studies, by increasing efficacy.<br />
2. Reduce the time taken to do proof-of-principle studies.<br />
3. Reduce the cost of xenograft study programmes (fewer experiments needed).<br />
4. Provide regulatory agencies with a rationale for the design of a clinical study programme.<br />
In addition, our techniques can be used to:<br />
(a) Unlock the potential of ‘sleeper drugs’ which have failed in clinical trials due to sub-optimal dosing or inappropriate schedules or<br />
combinations.<br />
(b) Assess data packages for potential oncology in-licensing candidates.<br />
Virtual Tumour can be accessed through:<br />
• Fee-for service.<br />
• Reduced up-front fees with downstream milestones/success payments.<br />
• Full risk-sharing for selected projects.<br />
PROPRIETARY TECHNOLOGY<br />
Virtual Tumour provides the following key benefits:<br />
1. Improve success rates for oncology candidates entering clinical studies, by increasing efficacy.<br />
2. Reduce the time taken to do proof-of-principle studies.<br />
3. Reduce the cost of xenograft study programmes (fewer experiments needed).<br />
4. Provide regulatory agencies with a rationale for the design of a clinical study programme.<br />
In addition, our techniques can be used to:<br />
(a) Unlock the potential of ‘sleeper drugs’ which have failed in clinical trials due to sub-optimal dosing or inappropriate schedules or<br />
combinations.<br />
(b) Assess data packages for potential oncology in-licensing candidates.<br />
CORPORATE ALLIANCES<br />
Jubilant and<br />
Pharmacometrics<br />
SENIOR MANAGEMENT<br />
Mark Chadwick, Chief Executive Officer<br />
BIO Business Forum 2011 107 Participating Company <strong>Profiles</strong>
Stephen Yoder<br />
Chief Executive Officer<br />
Lise-Meitner-Str. 30<br />
85354 Freising<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Birgit Zech<br />
Stephen S. Yoder<br />
Pieris AG<br />
Clinical Foci: Biopharmaceuticals • Oncology • AutoImmune<br />
www.pieris-ag.com<br />
Phone: 49-8161-1411400<br />
Incorporated: 2001<br />
Employees: 45<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create safer, more<br />
efficacious and more convenient protein therapeutics. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical<br />
needs and expand the therapeutic potential of current targeted approaches. Pieris’ pipeline ranges from its Phase I compound, PRS-050<br />
(anti-VEGF, oncology), to multiple Anticalins in preclinical development. The company has four ongoing discovery and development<br />
collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier<br />
biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures.<br />
PROPRIETARY TECHNOLOGY<br />
The essence of Pieris’ technology is simplicity: Anticalins are engineered lipocalins, endogenous human proteins found in blood plasma<br />
that naturally bind, store and transport a wide spectrum of molecules. Based on their pliable binding pocket, yet rigidly conserved betabarrel<br />
backbone, Anticalins combine high affinity and specificity with durability, creating greater flexibility of formulation and delivery.<br />
Moreover, Anticalins tightly bind a target as a monovalent molecule, overcoming the complications of multivalent binding molecule<br />
approaches. The company maintains significant protein engineering know-how and multiple robust libraries, which it uses to rapidly<br />
generate Anticalins for its pipeline and for its partners. Pieris is the exclusive owner of a large patent estate covering.<br />
CORPORATE ALLIANCES<br />
Daiichi Sankyo (2011)<br />
Takeda San Francisco (2011)<br />
Sanofi Aventis and Sanofi Pasteur (2010)<br />
Allergan (2009)<br />
INTELLECTUAL PROPERTY<br />
Pieris exclusively owns the Anticalin patent estate, which offers complete freedom to<br />
operate outside the patent boundaries defined by conventional antibody products.<br />
Key patents have already been granted both in the US, Asia and in Europe.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PRS-050 VEGF Phase I Cancer Completion of phase I in Q2 2011<br />
PRS-110 cMet Preclinical Cancer<br />
PRS-060 IL4Ra Optimized Lead Asthma<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round B: 03/01/2008 (US $38.00 million)<br />
SENIOR MANAGEMENT<br />
Stephen Yoder, Chief Executive Officer • Claus Schalper, Chief Financial Officer • Laurent Audoly, Chief Scientific Officer • Birgit Zech,<br />
Business Development<br />
BOARD OF DIRECTORS<br />
Hans Kuepper, Global Life Science Ventures<br />
BIO Business Forum 2011 108 Participating Company <strong>Profiles</strong>
16, rue J. Rostand<br />
81603 GAILLAC CEDEX<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Hubert Lochard, Project Manager<br />
Bernard Freiss<br />
PIERRE FABRE MEDICAMENT<br />
www.supercritical-solutions.com<br />
Phone: 33-5-63812400<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
2008 CPhI Silver Innovation Award for FORMULPLEX. "The Silver award went to Pierre Fabre Medicament for the development of new tools<br />
for "green" formulation of active ingredients using supercritical fluids".<br />
2009 Pierre Potier Prize for FORMULPLEX. "Pierre Fabre Laboratories receive the 2009 Pierre Potier Prize Innovation in Chemistry in favour<br />
of Sustainable Development.<br />
CORPORATE MISSION<br />
The Pierre Fabre Supercritical Fluids Department has developed an extensive expertise in SuperCritical Fluids, focused on the development<br />
of innovative A.P.I. formulations: taste-masking, bioavailability, solubility of poorly soluble drugs. Our main patented technologies are<br />
performed in a multi-purpose platform in compliance with cGMP. FORMULCOAT, FORMULPLEX and FORMULDISP processes are used to<br />
improve bioavailability, solubility or for taste-masking and particle design. FORMULCOAT is an innovative patented coating process using<br />
lipidic agent and leading to a uniform and homogeneous layer without agglomeration. FORMULCOAT key advantages : it permits to coat<br />
very small particles without any use of organic solvent during the coating process and at room temperature, with a high productivity.<br />
FORMULPLEX is a novel patented formulation process in a supercritical medium : complexation with cyclodextrin in a solid form. It permits<br />
enhancement of the apparent solubility of a poorly soluble drug. FORMULPLEX key advantages : It is considered as a first step of<br />
formulation process by Health Authorities and consequently permits new formulations of API's already marketed, generating Intellectual<br />
Property (Life Cycle Management). FORMULDISP is an innovative stable solid dispersion patented process using ScCO2 as a medium to load<br />
an API in an excipient matrix. FORMULDISP key advantages : it is a suitable formulation process for oral administration using GRAS<br />
(Generally Recognized As Safe) polymers. RECOGNIZED QUALITY ENGAGEMENT : a multi-purpose platform in compliance with cGMP.<br />
Recognized as Pharmaceutical Establishment by French Health Authorities. Meets FDA requirement. ISO 14001 certified site since 1998 and<br />
awarded by the French Ministry of Environment for its efforts within environment protection. 2008 CPhI Silver Innovation Award for<br />
FORMULPLEX technology and 2009 Pierre Potier Prize (Green Chemistry Award).<br />
PROPRIETARY TECHNOLOGY<br />
FORMULCOAT : innovative coating process for sensitive API and small particles. Excellent results in term of taste-masking.<br />
FORMULPLEX : complexation with cyclodextrins in supercritical medium. Improved solubility, bioavailability enhancement and reduction<br />
of variability.<br />
FORMULDISP : stable solid dispersion. Improved excipient functionality.<br />
CORPORATE ALLIANCES<br />
Collaboration with pharmaceutical, cosmetic, nutraceutical and veterinary companies.<br />
INTELLECTUAL PROPERTY<br />
FORMULCOAT, FORMULPLEX and FORMULDISP are patented processes.<br />
BIO Business Forum 2011 109 Participating Company <strong>Profiles</strong>
Klaus Kristensen<br />
Chief Executive Officer<br />
Roevedvej 1, Spoerring<br />
8380 Trige<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Klaus Kristensen, CEO<br />
HIGHLIGHTS<br />
Recent<br />
Validated model for skin inflammation<br />
Validated model for haemostasis<br />
Validated model for gonadotopin potency<br />
Pipeline Biotech A/s<br />
Clinical Foci: Oncology • Immunology • Skin/Dermatological<br />
www.pipeline-biotech.dk<br />
Phone: 45-0-8748 9770<br />
Incorporated: 1999<br />
Employees: 18<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Pipeline Biotech was established in 1999 as an independent pre-clinical CRO. Our main activities are research pharmacology mainly within<br />
cancer, inflammation and metabolic diseases. In 2003 the company became GLP-compliant and in 2005 GMP-compliant (QC activities).<br />
Our laboratories are designed and approved to experimental animal research and cell biology. Laboratory animals of the species mouse,<br />
rat, guinea pig, rabbit and mini-pig are housed at different levels of barrier protection including GMO Class I and Class II and Biohazard<br />
Class III. All studies and experiments are performed in accordance with EU-regulations are approved by the National Animal Experiments<br />
Inspectorate. We are a dedicated and active partner in drug discovery and preclinical development. We are chosen by our sponsors<br />
because we are reliable, experienced and flexible.<br />
PROPRIETARY TECHNOLOGY<br />
Pre-clinical contract research is carried out covering the following indications:<br />
• Cancer/Oncogenesis<br />
• Inflammation Diseases<br />
• Appetite Regulation and Obesity<br />
• Hormonal Dysfunctions<br />
Additionally we perform DMPK studies and Early Toxicology studies.<br />
PRODUCTS<br />
Name Phase Indication<br />
Xenograft studies On Market Oncology<br />
Anti-inflammatory studies On Market Arthritis, colitis, MS, skin inflammation, pro-inflammation<br />
Pharmacokinetic studies On Market Any<br />
Proof of Concept preclinical studies On Market Oncology / Inflammation / Metabolic diseases<br />
Custom Tailored pre-clinical studies On Market Oncology / Inflammation / Metabolic diseases<br />
FINANCING HISTORY<br />
Investors: Klaus Kristensen (100 %)<br />
SENIOR MANAGEMENT<br />
Klaus Kristensen, Chief Executive Officer<br />
BIO Business Forum 2011 110 Participating Company <strong>Profiles</strong>
Don Stewart<br />
Chief Executive Officer<br />
1920 Yonge Street, Suite 200<br />
Toronto, ON M4S 3E2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Donald Stewart, CEO<br />
PLANTFORM<br />
Clinical Foci: Generics • Biopharmaceuticals • Oncology<br />
www.plantformcorp.com<br />
Phone: 1-416-452-7242<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successfully implemented scaled manufacturing process for<br />
biosimilar trastuzumab with CMO (Kentucky Bioprocessing, USA)<br />
Initiated animal studies with biosimilar trastuzumab.<br />
Initiated ongoing Series A financing with Medwell Capital<br />
Incorporated: 2008<br />
Employees: 10<br />
Ownership: Private<br />
Completion of animal studies for biosimilar trastuzumab H2, 2011<br />
Initiate GLP and GMP manufacturing of biosimilar trastuzumab for<br />
Safety and Toxicology studies and Phase I clinical trials.<br />
Complete characterization of biosimilar trastuzumab.<br />
CORPORATE MISSION<br />
PlantForm Corporation is a Canadian biotechnology company focused on developing low cost therapeutic drugs. Founded in 2008,<br />
PlantForm has licensed the rights to a powerful technology for the manufacture of biological drugs in plants and will establish the<br />
commercial applications of the platform for biosimilar (generic) antibodies. The initial focus is on a biosimilar version of Herceptin, the $6<br />
billion breast cancer drug. PlantForm has shown the drug can be manufactured at low cost using tobacco plants, and has found the<br />
properties of the plant-derived and name brand versions are directly comparable. PlantForm is seeking financing and a development,<br />
sales and marketing partnership for its biosimilar drugs including biosimilar Herceptin.<br />
PROPRIETARY TECHNOLOGY<br />
The novel technology platform was developed at the University of Guelph to produce a broad range of antibody drugs and vaccines in<br />
greenhouse-grown tobacco plants. It will be used to produce fully active biosimilar drugs at ultra low cost in plant-based bioreactors.<br />
These drugs are formatted to minimize potential adverse effects in humans. The key aspect of the technology is that it produces<br />
therapeutic drugs at 10% of the cost of current traditional manufacturing methods. The company will be able to translate this capability<br />
into very a competitive market position for its products.<br />
CORPORATE ALLIANCES<br />
PlantForm is seeking financing and a development, sales and marketing partnership for its biosimilar drugs including biosimilar<br />
Herceptin.<br />
INTELLECTUAL PROPERTY<br />
The company has filed three families of patents:<br />
a. Core platform technology<br />
“Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments”<br />
US Provisional Application No. 61/111,915 (November, 2008)<br />
PCT Application No. PCT/CA2009/001606 (November, 2009)<br />
Advanced to National Phase in May 2011 in Australia, Canada, Europe, India, US.<br />
b. Innovative drug candidate.<br />
“Anti-Cobra Toxin Antibody Fragments”<br />
US Provisional No. 61/120,208 (December, 2008)<br />
PCT Application No. PCT/CA2009/001760 (November, 2009)<br />
To be advanced to National Phase June, 2011, in Canada and US.<br />
c. Herceptin production process patent<br />
“Production of HER Receptor Antibodies in Plant”<br />
US Provisional Application No. 61/355,300 (June 2011).<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Biosimilar trastuzumab<br />
(Herceptin)<br />
Preclinical Breast Cancer Animal efficacy study<br />
Undisclosed biosimilar antibody Preclinical Oncology Proof of concept<br />
Undisclosed biosimilar antibody Preclinical Inflammatory disease Proof of concept<br />
BIO Business Forum 2011 111 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Investors: York Medtech Partners (9 %) • Directors and Officers (39 %) • Officers not Directors (12 %) •<br />
Employees (15 %) • Outsiders (25 %)<br />
SENIOR MANAGEMENT<br />
Don Stewart, Chief Executive Officer • Chris Hall, Chief Scientific Officer • Ron Hosking, Chief Financial Officer • Doug Cossar,<br />
Manager • Mike McLean, Manager<br />
BOARD OF DIRECTORS<br />
Mark Goldberg, MTE Consulting and Founder • Chris Hall, PlantForm CSO and Founder • Jim Rae, Remedis • Don Stewart, PlantForm<br />
CEO and Founder • Warren Whitehead, Formally Arius Research<br />
SCIENTIFIC ADVISORY BOARD<br />
Chris Hall, PhD, CSO PlantForm Corporation • Doug Cossar, PhD, PlantForm and Structural Genomics Consortium • Malcolm Devine,<br />
PhD, bioQED Strategic Consultants • John Hassel, PhD, McMaster University • Ken Hughes, PhD, Rx&D • Steve Narod, MD, Women’s<br />
College Hospital • Steve Rothestein, PhD, Elastin Specialties<br />
BIO Business Forum 2011 112 Participating Company <strong>Profiles</strong>
Dennis Saw<br />
Chief Executive Officer<br />
2, Royal College Street<br />
London<br />
NW1 0NH<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Lilian Hook, Research Director<br />
HIGHLIGHTS<br />
Recent<br />
Plasticell Limited<br />
Clinical Foci: Regenerative Medicine • Biology<br />
www.plasticell.co.uk<br />
Phone: 44-7811-168177<br />
Ownership: Private<br />
Spin off of regenerative drug discovery company - Progenitor Labs<br />
Recent fundraising round of £3.5m<br />
Collaborations with Sigma Aldrich to generate reporter cell lines for use with Combicult, providing a turn-key solution for stem cell<br />
research and with UCB for discovery of small molecule directed differentiation protocols<br />
CORPORATE MISSION<br />
Plasticell is a pioneering biotechnology company specialising in high throughput stem cell technologies. Our proprietary, award-winning<br />
platform, Combinatorial Cell Culture (CombiCult ), allows us to test cell culture variables in tens of thousands of combinations to<br />
rapidly and cost effectively discover optimal protocols for the differentiation of adult or pluripotent stem cells.<br />
Plasticell provides services to, and forms strategic alliances with, industry partners to produce high value differentiated cells and culture<br />
media for drug discovery and cell therapy applications.<br />
PROPRIETARY TECHNOLOGY<br />
CombiCult - a high throughput platform for discovery of stem cell differentiation protocols. The platform has been validated on a number<br />
of starting cell types (mES, hES, MSC etc) and differentiated lineages (hepatic, cardiac, neural, osteogenic, chondrogenic etc.). Applications<br />
include elimination of serum , small molecule only differentiation, gaining of freedom to operate through new IP discovery and reducing<br />
the cost of cell production. Bespoke bioinformatics software (Ariadne) has been developed to allow rapid and simple analysis of results.<br />
INTELLECTUAL PROPERTY<br />
Issued patents in Europe and Singapore and application pending in US covering core technology. Several other applications pending<br />
covering other aspects of the technology.<br />
PRODUCTS<br />
Name Phase Indication<br />
Combicult 10,000 plex kit Other Regenerative medicine<br />
SENIOR MANAGEMENT<br />
Dennis Saw, Chief Executive Officer • Dr Yen Choo, Chairman • Dr Lilian Hook, Other<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Aaron Klug • Professor Martin Evans, University of Cardiff, UK • Dr Tony Cass, Imperial College of Science and Technology,<br />
London, UK • Dr Nick Allen, University of Cardiff, UK<br />
BIO Business Forum 2011 113 Participating Company <strong>Profiles</strong>
Zami Aberman<br />
President & CEO<br />
MATAM Advanced Technology Park, Bldg. #20<br />
31905 Haifa<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Zami Aberman, Chairman & CEO<br />
William R Prather<br />
Pluristem Therapeutics, Inc<br />
Clinical Foci: Biopharmaceuticals • Gene/Cell Therapy • Immunology<br />
www.pluristem.com<br />
Phone: 972-74-7107171<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Phase I/IIa dose-escalating studies using PLX-PAD in critical limb<br />
ischemia (CLI) in the USA and German have been completed. Safety<br />
and potentially efficacy demonstrated.<br />
Completed a parallel scientific advisory process with FDA and EMA<br />
that will allow us to pursue our comprehensive approach towards<br />
the treatment of PAD, intermittent claudication (IC) and critical<br />
limb ischemia (CLI).<br />
Pluristem raised $38M in a public offering in January, 2011. The<br />
company now has cash of $44 million without debt.<br />
Incorporated: 2003<br />
Employees: 60<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
NASDAQ: PSTI<br />
Following successful animal trials in muscle injury, Pluristem will<br />
initiated a Phase II trial in Germany in patients post hip<br />
replacement and a Phase II trial in the USA in muscle sports injury.<br />
Results from ongoing or completed animal trials in inflammatory<br />
bowel disease, neuropathy and radiation exposure.<br />
Preclinical work with PLX cells for other inflammatory and ischemic<br />
indications.<br />
CORPORATE MISSION<br />
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented<br />
PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic<br />
inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an<br />
off-the-shelf product that requires no tissue matching prior to administration. Data from two phase I studies indicate that Pluristem’s first<br />
PLX product candidate, PLX-PAD, is safe and potentially effective for the treatment of end stage peripheral artery disease.<br />
Pluristem’s pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage, when<br />
administered locally, and in inflammatory bowel disease, MS and stroke, when administered systemically. Pluristem has a strong patent<br />
portfolio, GMP certified manufacturing and research facilities as well as strategic relationships with major research institutions.<br />
PROPRIETARY TECHNOLOGY<br />
Pluristem’s PLX cells are mesenchymal-like adherent stromal cells (ASCs) derived from full term human placenta. The cells are expanded in<br />
the company's proprietary bioreactor system, which provides a three-dimensional (3D) microenvironment that enables full control over<br />
the manufacturing process. The use of 3D bioreactors, as applied to PLX-PAD production, allows for on-line controlled large-scale growth,<br />
optimisation, standardisation, scale-up, and a “hands-off” operation, making the end-product predictable, assuring batch to batch<br />
consistency, with minimal risk of contaminants, therefore suitable for cell based regenerative therapy.<br />
CORPORATE ALLIANCES<br />
Clinical Sites and Product Development Partners:<br />
Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig,<br />
Duke University School of Medicine, Durham, NC, USA.<br />
Germany.<br />
Center for Therapeutic Angiogenesis, Birmingham, AL, USA.<br />
Hadassah Medical Center, Jerusalem, Israel.<br />
Standford University, School of Medicine, Stanford, CA, USA.<br />
Rambam Health Care Campus, Haifa, Israel.<br />
New York University, Medical Center, New York, NY, USA.<br />
Sheba Medical Center, Tel Hashomer, Israel.<br />
Franziskus Hospital Berlin, Berlin, Germany.<br />
Technion - Israel Institute of Technology, Haifa, Israel.<br />
Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Tel Aviv University, Tel Aviv, Israel.<br />
Germany.<br />
INTELLECTUAL PROPERTY<br />
Pluristem owns the patent rights to its 3D cell expansion technology, which is protected by a series of granted patents in several<br />
jurisdictions including the US and Europe. In addition, Pluristem has related patent applications pending worldwide.<br />
Pluristem's technology was initially developed at the Weizmann Institute of Science and the Technion-Israel Institute of Technology, two<br />
global leaders in the field of innovative biological product development.<br />
BIO Business Forum 2011 114 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
PLX-PAD Phase III Critical Limb Ischemia (CLI) the end-stage<br />
of peripheral artery disease (PAD)<br />
PLX-PAD Phase II, IIa, IIb Preventive treatment for intermittent<br />
claudication (IC)<br />
All treated patients to date demonstrate<br />
that PLX-PAD is safe<br />
PLX-DFU Preclinical Diabetic Foot Ulcers Collaboration with the New York<br />
University Medical Center (NYUMC)<br />
PLX-MI Preclinical Muscle Injury PLX cell administration resulted in a<br />
significant improvement in the recovery<br />
of function of the involved muscles.<br />
PLX- NP Preclinical Neuropathic Pain PLX cell therapy may be an effective<br />
treatment for both neuropathic and<br />
inflammatory nerve pain.<br />
PLX-IS Preclinical Ischemic Stroke Results were published in the journal<br />
Brain Research (Brain Research, Feb. 22,<br />
Vol. 1315)<br />
PLX-RS Preclinical Radiation Sickness Collaboration with Hadassah University<br />
Medical Center<br />
PLX-IBD Preclinical Inflammatory Bowel Disease<br />
PLX-MS Research Multiple Sclerosis<br />
SENIOR MANAGEMENT<br />
Zami Aberman, President & CEO • Yaky Yanay, Chief Financial Officer • William R. Prather RPh, MD, Senior Vice President • Frida<br />
Grynspan PhD, Vice President • Chaya Mazouz, Vice President • Daya Lettvin, Investor Relations<br />
BOARD OF DIRECTORS<br />
Zami Aberman, Pluristem's Chairman & CEO • Mark Germain, Banker serving primarily the biotech and life sciences industries • Doron<br />
Shorrer, Shorrer international ltd. • Hava Klemperer Meretzki, Law firm of Ben-Noun Meretzki • Israel Ben Yoram, Accounting firm of<br />
Mor, Ben-Yoram and Partners • Nachum Rosman, An expert in finance, management and organization • Shai Pines, Hamburger Evron<br />
& Co. • Isaac Braun, Co-founder and board member of several hi-tech start-ups<br />
SCIENTIFIC ADVISORY BOARD<br />
Edwin M Horwitz, MD, PhD, Children’s Hospital of Philadelphia • Aristidis Veves, MD, Joslin-Beth Israel & Harvard Medical School •<br />
Arnon Nagler, MD, Tel Aviv University Sackler School of Medicine • Jacob Michael Rowe, MD, Rambam Medical Center, Haifa, Israel •<br />
Ron Gonen, MD, Bnai-Zion Medical Center, Haifa, Israel • Avinoam Kadouri, PhD, A leading scientist in biotechnology<br />
BIO Business Forum 2011 115 Participating Company <strong>Profiles</strong>
Ken-ichi MARUYAMA, PhD, MBA<br />
Chief Executive Officer<br />
Kita-21, Nishi-11 Kita-ku<br />
Sapporo 001-0021<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Ken-Ichi MARUYAMA, CEO<br />
HIGHLIGHTS<br />
Recent<br />
Polaris Technology Inc.<br />
Clinical Foci: Diagnostics • Industrial Biotech • Biosensing<br />
www.polaris-t.com/<br />
Phone: 81-11-706 7321<br />
Synthesis of Solvatochromic dye for fluorescent probe by using Suzuki-Miyaura cross coupling method<br />
CORPORATE MISSION<br />
Employees: 4<br />
Ownership: Private<br />
Polaris technology provides novel fluorescent probe for bio imaging, diagnostics and bio assay. Our fluorescent probe is sovatochromic<br />
dye, called POLARIC. For example, our POLARIC probe indicates the shift of fluorescent wavelength by local environmental changes like a<br />
organ in live cell not usual fluorescent probe with change in fluorescent intensity. This fluorescent reaction system also apply the new<br />
technology to label with DNA, RNA, peptide, molecularly-targeted drug and antibody for immunoassay.<br />
PROPRIETARY TECHNOLOGY<br />
Products:POLARIC Fluorescent probe (Solvatochromic Dye)<br />
Service of Intelligent Fluorescent Probes for biotechnology<br />
Intelligent fluorescent probe, whose fluorescent wavelength is shifted by microenvironmental changes, has been desired for biological<br />
applications.<br />
Fluorescent solvatochromic dyes are potential probes for biological applications.<br />
·Many biological reactions accompany polatiry change.<br />
(Ex. Antigen-antibody reactions, denaturation and renaturaion of DNA, membrane dynamics)<br />
·Absorption wavelength is scarcely shifted by polarity change.<br />
(Multicolor signals can be generated by single wavelength laser)<br />
·Very small probe size<br />
(Avoiding interference with biological reactions)<br />
INTELLECTUAL PROPERTY<br />
Available for out-licensing<br />
PRODUCTS<br />
Name Phase Indication<br />
POLARIC On Market fluorescent dye for cell imaging<br />
POLARIC Diagnostics fluorescent dye for labeling<br />
SENIOR MANAGEMENT<br />
Ken-ichi MARUYAMA, PhD, MBA, Chief Executive Officer • Koji YAMADA, PhD, Chief Technology Officer<br />
SCIENTIFIC ADVISORY BOARD<br />
Toshio TAIRA, Primary Cell, Inc. • Takehiro TAKOSHIMA, PhD, Polaris technology, Inc.<br />
BIO Business Forum 2011 116 Participating Company <strong>Profiles</strong>
Tracy Thompson<br />
Chief Executive Officer<br />
PO 1210<br />
Palmerston North 4452<br />
New Zealand<br />
CONFERENCE PARTICIPANTS<br />
Tracy Thompson<br />
HIGHLIGHTS<br />
Recent<br />
Polybatics<br />
Clinical Foci: Biomaterials • Vaccines • Diagnostics<br />
WWW.polybatics.com<br />
Phone: 64-06-352 0200<br />
Ownership: Private<br />
Demonstrated potential of PolyBind series as single use replacement for agarose immobilized Protein A. Also demonstrated potential as<br />
custom ligand platform for non antibody targets.<br />
PolyVax-TB demonstrated clinical protection in mice of the TB antigen displaying particles equivalent to the current standard of care, BCG<br />
vaccine.<br />
Increased stability in immobilized enzymes and cascade enzymatic activity on multi-enzyme displaying beads.<br />
CORPORATE MISSION<br />
PolyBatics is a development stage biotechnology company engaged in the design, development, manufacturing and marketing of<br />
functional bionanoparticles. This platform technology has demonstrated potential across a number of applications from vaccines to<br />
diagnostics to bioprocessing and beyond. The company is engaged in developing its own line of products and is also seeking partied who<br />
can benefit from the technology's potential.<br />
PROPRIETARY TECHNOLOGY<br />
The primary technology is the display of proteins on the surface of biopolyester particles. These multi-functional particles are produced in<br />
vivo using standard fermentation processes. Functions can be combined on a single particle to impart unique properties to the particles.<br />
CORPORATE ALLIANCES<br />
PolyBatics is collaborating with a number of companies and universities on specific targets and application areas. Our goal is to make the<br />
platform available to as many organizations as possible through our licensing and collaboration projects.<br />
INTELLECTUAL PROPERTY<br />
Two patents covering the basic technology have been granted and we have seven additional patent families under prosecution covering<br />
specific uses, methods of production and unique constructs.<br />
SENIOR MANAGEMENT<br />
Tracy Thompson, Chief Executive Officer • Bernd Rehm, Chief Scientific Officer • Andy Herbert, Vice President • Rick Gain, Chief<br />
Financial Officer<br />
BOARD OF DIRECTORS<br />
Brad Duft, CoDa Therapeutics • James Mervis, CoDa Therapeutics • Richard Garland, NZ Pharmaceuticals<br />
SCIENTIFIC ADVISORY BOARD<br />
Uwe Gottschalk, Sartorius Stedium • Wiltrud Treffenfeldt, Dow AgriSciences • Robert Hancock, U of British Columbia<br />
BIO Business Forum 2011 117 Participating Company <strong>Profiles</strong>
Nicholas Landekic<br />
President & CEO<br />
170 North Radnor Chester Road, Suite 300<br />
Radnor, PA 19087<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Steffen Helmling, Vice President Business Development<br />
Nicholas Landekic, President & CEO<br />
PolyMedix, Inc<br />
Presenting Company<br />
Clinical Foci: Infectious Disease • Cardiovascular Disease • Other<br />
www.polymedix.com<br />
Phone: 1-484-598-2400<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Conducted financing with $20 million gross proceeds from<br />
fundamental intitutional investors.<br />
Initiated Phase 2 clinical trials for both lead products - antibiotic<br />
PMX-30063 and heptagonist PMX-60056.<br />
Established three clinical advisory boards to focus on the antibiotic<br />
program, heptagonist program and research. Each board is<br />
comprised of world-renowned scientists and clinicians with<br />
expertise in the respective area.<br />
Incorporated: 2002<br />
Employees: 24<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
OTC BB: PYMX<br />
Anticipate interim analysis results after 80 patients are enrolled in<br />
the on-going Phase 2 clinical trial assessing the safety and efficacy<br />
of PMX-30063 as treatment for ABSSSI infections caused by Staph.<br />
Anticipate completion of a Phase 2 clinical trial in 2011 using PMX-<br />
60056 to reverse heparin in patients undergoing percutaneous<br />
coronary intervention procedures.<br />
Anticipate completion of the on-going Phase 2 clinical trial with<br />
PMX-30063 in ABSSSI patients in 2011.<br />
CORPORATE MISSION<br />
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious<br />
diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug<br />
candidates. PolyMedix’s lead antibiotic compound, PMX-30063, is currently in a Phase 2 clinical trial for treatment of Acute Bacterial Skin<br />
and Skin Structure Infections (ABSSSI) caused by Staph, including MRSA. PMX-30063 is a small-molecule that mimics the mechanism of<br />
action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make<br />
bacterial resistance unlikely to develop. PolyMedix’s lead heptagonist compound, PMX-60056, is in a Phase 2 clinical trial in patients<br />
undergoing PCI procedures. PMX-60056 is designed to reverse the anticoagulant activity of both heparin and low molecular weight<br />
heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with<br />
broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics,<br />
PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides®. PolyCides are intended for use in<br />
antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.<br />
PROPRIETARY TECHNOLOGY<br />
PolyMedix created its entire product pipeline using the proprietary computational technology platform licensed from the University of<br />
Pennsylvania. PolyMedix’s compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic<br />
the activity of proteins. PMX-30063 is a small molecule mimetic of human host-defense proteins, one of the oldest and most effective<br />
antimicrobial defense systems found in virtually all living creatures. PMX-60056 is a synthetic, small molecule that reverses the<br />
anticoagulant activity of both heparin and Low Molecular Weight Heparins (LMWHs). PolyMedix is also developing polymeric formulations<br />
as antimicrobial biomaterials, which can be used as additives to create self-sterlizing materials and surfaces.<br />
CORPORATE ALLIANCES<br />
PolyMedix seeks partners throughout the world for a number of its products. The preferred partnering strategy may vary depending on<br />
the compound, target indication(s), stage of development and geographic markets.<br />
INTELLECTUAL PROPERTY<br />
PolyMedix owns a total of 19 patents and patent applications, including an exclusive license to make and sell products utilizing seven<br />
issued or pending patents from the University of Pennsylvania. The patents cover the composition of matter on antimicrobial compounds,<br />
including small molecules, oligomers and polymers. In addition PolyMedix has a five-year sponsored research agreement with the<br />
University of Massachusetts that provides an exclusive option to license any intellectual property generated under the agreement.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PMX-30063 Phase II, IIa, IIb ABSSSI caused by Staph Anticipate completion of study in 2011<br />
PMX-60056 Phase II, IIa, IIb Reversal of heparin and LMWH Completed 4 Phase 1 clinical studies that<br />
met safety & efficacy endpoints. Anticipate<br />
initiation of Phase 2 in early 2011.<br />
BIO Business Forum 2011 118 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Antimicrobial polymers Preclinical Antimicrobial surfaces including paints,<br />
plastics, extrusions, coatings, fabrics, etc.<br />
defensin antibiotics Preclinical Tuberculosis<br />
defensin antibiotics Preclinical Malaria<br />
SENIOR MANAGEMENT<br />
Nicholas Landekic, President & CEO • Edward F. Smith, Chief Financial Officer • Richard Scott, PhD, Vice President • Bozena Korczak,<br />
PhD, Senior Vice President • Steffen Helmling, Vice President • Lisa Caperelli, Investor Relations<br />
BOARD OF DIRECTORS<br />
Brian Anderson, Healthcare advisor; Formerly of Alkermes, MediciNova, Cognetix • Richard W. Bank, MD, President, BioVest Advisors,<br />
LLC • Michael E. Lewis, PhD, President, BioDiligence Partners, Inc. • Stefan D. Loren, PhD, Principal, Westwicke Partners, LLC • Shaun F.<br />
O'Malley, Chairman Emeritus, Price Waterhouse LLP • Douglas J. Swirsky, Sr. Vice President & CFO, GenVec, Inc. • Nicholas Landekic,<br />
President & CEO, PolyMedix, Inc. • Frank Slattery, Jr., Former President & CEO, LFC Financial Corp.<br />
SCIENTIFIC ADVISORY BOARD<br />
William DeGrado, Professor, Dept. of Biochemistry and Biophysics, University of Pennsylvania • Gregory Tew, PhD, Professor, Dept. of<br />
Polymer Science and Engineering, University of Massachusetts • Michael Klein, PhD, BSc, Professor and Director, Temple Institute for<br />
Computational Molecular Science, Temple University<br />
BIO Business Forum 2011 119 Participating Company <strong>Profiles</strong>
Jane Salik, PhD<br />
Chief Executive Officer<br />
365 Maple Ave<br />
Torrance, CA 90503<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Clifford Young<br />
Edouard Weill<br />
Trishul Shah<br />
Robert Hagopian, Director, Business Development<br />
PolyPeptide Group<br />
www.polypeptide.com<br />
Phone: 1-310-782-3569<br />
Incorporated: 1996<br />
Employees: 450<br />
Ownership: Private<br />
CORPORATE MISSION<br />
The PolyPeptide Group employs about 450 staff at six locations, including sites in Denmark, France, India, and Sweden, as well as two<br />
facilities in the USA (San Diego and Torrance). The Group manufactures over one third of all approved peptide drug substances and<br />
accounts for over 25% of the sales of outsourced peptide therapeutics worldwide, with each site having a record of at least one commercial<br />
product related FDA inspection.<br />
The PolyPeptide Group offers the most complete peptide manufacturing service including the following:<br />
- Custom research grade products (peptides, peptidomimetics, small molecules, special amino acids and building blocks)<br />
- Isotopically, including radio labeled peptides<br />
- Lead compound optimization and innovative solutions in support of peptide development<br />
-Development of Analytical methods<br />
- cGMP manufacturing of peptides and small molecules from gram up to tens of kilograms<br />
- Process research and development<br />
- Flexibility of solid and liquid phase chemistry<br />
- Full support with regulatory filings<br />
- Partnership approach focused on customer satisfaction<br />
PROPRIETARY TECHNOLOGY<br />
Peptide manufacturing, including small scale for basic research, radiolabeled peptides for pharmacokinetics or distribution studies, non-<br />
GMP pilot scale for pre-clinical studies, GMP grade for clinical trials, commercial production for product launch, -<br />
In addition, we offer modified peptides and related molecules through multi step organic synthesis<br />
SENIOR MANAGEMENT<br />
Jane Salik, PhD, Chief Executive Officer • Clifford Young, Chief Operating Officer • Rodney Lax, PhD, Director • Robert Hagopian,<br />
Director<br />
BIO Business Forum 2011 120 Participating Company <strong>Profiles</strong>
Jean-Pierre Obrecht<br />
Chief Executive Officer<br />
Hegenheimermattweg 125<br />
CH-4123 Allschwil<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Polyphor Ltd<br />
Clinical Foci: Hematology • Oncology • Infectious Disease<br />
www.polyphor.com<br />
Phone: 41-61-5671600<br />
Michael Altorfer, Head Corporate Development and deputy CEO<br />
HIGHLIGHTS<br />
Recent<br />
Incorporated: 1996<br />
Employees: 90<br />
Ownership: Private<br />
Polyphor discovers a new class of antibiotics with a novel mode of action.<br />
New weapon in the fight against multi-drug resistant bacteria published in “Science”. (Science, 2010, VOL 327, ISSUE 5968).<br />
Polyphor and Novartis announce PEMfinder® collaboration.<br />
Polyphor establishes second drug discovery technology platform MacroFinder that yields fully synthetic, orally available macrocyclic<br />
compounds addressing complex intra-cellular targets (e.g. PPIs).<br />
CORPORATE MISSION<br />
Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high therapeutic benefit to the patient<br />
and providing high quality support to its industry partners engaged in drug discovery.<br />
Polyphor has established two complementary innovative, proprietary technology platforms, delivering fully synthetic macrocyclic<br />
molecules. They cover an alternative molecular diversity space with respect to traditional small molecules and biologics. Polyphor’s<br />
MacroFinder® and PEMfinder® drug discovery technology platforms were specifically developed for discovering potent and selective<br />
modulators of Protein-Protein Interactions (PPIs) and other challenging targets.<br />
MacroFinder® and PEMfinder® generate molecules with complementary properties; PEMfinder® addresses mainly extracellular large<br />
surface PPI-targets, whereas MacroFinder® molecules are designed to penetrate into the cells and hit intracellular PPIs with the potential<br />
for oral delivery.<br />
Compared to biological drugs, MacroFinder® and PEMfinder® technologies yield compounds that are synthetically accessible and<br />
amenable to a rapid and efficient optimization process.<br />
Compared to small molecules, MacroFinder® and PEMfinder® technologies have a higher potential to provide innovative drug candidates<br />
for complex target classes.<br />
The PEMfinder® Platform has supported Polyphor in building a broad clinical candidate pipeline and diverse internal research programs.<br />
PROPRIETARY TECHNOLOGY<br />
PEMfinder® Platform<br />
Protein Epitope Mimetics (PEM) are fully synthetic, cyclic peptide-like molecules able to mimic all relevant secondary structure motifs<br />
involved in Protein-Protein Interactions (PPIs), in particular the ß-hairpin and the a-helix.<br />
MacroFinder® Platform<br />
MacroFinder® molecules are fully synthetic, macrocyclic compounds consisting of several subunits, which can be efficiently assembled in a<br />
modular fashion by high yielding organic chemistry transformations.<br />
MacroFinder® molecules are ideally suited to tackle difficult intracellular targets and depending on the TPP, MacroFinder® compounds can<br />
be readily optimized to achieve oral bioavailability.<br />
Polyphor Library a proprietary small molecule screening library available for drug discovery collaborations or to purchase<br />
CORPORATE ALLIANCES<br />
Allergan Inc.<br />
Axxam S.p.A.<br />
Acino Holding Ltd<br />
Novartis Pharma AG<br />
INTELLECTUAL PROPERTY<br />
> 20 Patent applications and granted patents on PEM Technology, MacroFinder® Technology, patents on PEMdrugs (antibiotics, CXCR4<br />
antagonists, antibiotics, protease inhibitors, chemokine inhibitors, etc.)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
POL6326 Phase II, IIa, IIb Hematopoietic stem cell<br />
transplantation (HSCT), tissue repair,<br />
chemosensitization<br />
Ongoing Phase IIa clinical studies<br />
(stem cell transplant)<br />
BIO Business Forum 2011 121 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
POL7080 Phase I Nosocomial Pseudomonas infections Ongoing Phase I clinical studies<br />
POL6014 Preclinical COPD In vivo efficacy and safety & inhaled<br />
formulation feasibility shown<br />
PEMfinder Drug Discovery<br />
Collaboration<br />
MacroFinder Drug Discovery<br />
Collaboration<br />
Research Drug discovery with difficult targets:<br />
GPCRs and protein-protein<br />
interactions (PPIs)<br />
Research Drug discovery with difficult targets:<br />
GPCRs and protein-protein<br />
interactions (PPIs)<br />
SENIOR MANAGEMENT<br />
Jean-Pierre Obrecht, Chief Executive Officer • Michael Altorfer, Other<br />
Partnering from hit identification to<br />
clinical candidate selection<br />
Partnering from hit identification to<br />
clinical candidate selection<br />
BIO Business Forum 2011 122 Participating Company <strong>Profiles</strong>
Mark Bloomfield<br />
Chief Executive Officer<br />
Bd Sebastien Brandt<br />
67401 Illkirch<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Pascale Belguise, Business Development Manager<br />
Mark Bloomfield, Chief Executive Officer<br />
Gabriel Festoc, Chairman<br />
Polyplus Transfection<br />
Clinical Foci: Oncology • Gene/Cell Therapy<br />
www.polyplus-transfection.com<br />
Phone: 33-3-9040 6180<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Significant improvement in mouse survival rates and duration in<br />
siRNA cancer therapeutics models<br />
Incremental licensing revenues from the Polyplus IP portfolio<br />
New funding round in Dec 2010 (Euros 2.5 M)<br />
Incorporated: 2001<br />
Employees: 34<br />
Ownership: Private<br />
Upscale R&D resources to accelerate the development of Polyplus’<br />
innovative delivery technologies for therapeutic RNA interference<br />
Complete data sets from preclinical studies using STICKY SIRNA<br />
proprietary technology<br />
Generate incremental revenues from IP portfolio through outlicensing<br />
agreements<br />
CORPORATE MISSION<br />
Polyplus-transfection SA is a biotechnology company that develops, markets and sells innovative solutions for the in vivo, in vitro and ex<br />
vivo delivery of nucleic acids in research, bio-production and therapeutics. Located close to Strasbourg (France), Polyplus-transfection<br />
supplies its proprietary range of catalogue reagents for the transfection of genes, oligonucleotides and siRNA in vitro and in vivo through<br />
a worldwide distributor network. In addition, Polyplus-transfection cGMP transfection reagents are involved into a growing number of<br />
clinical trials worldwide. The company holds a broad portfolio of patents and licenses in the fields of nucleic acid delivery and modified<br />
oligonucleotides. Polyplus-transfection is the worldwide exclusive licensee of PEI and derivates for stable and transient transfection of<br />
eucaryotic cells. Polyplus-transfection is Private Equity owned company and completed a new funding round in December 2010. The<br />
company plans to use the new capital to upscale its research & development resources, specifically in the area of new compound<br />
development for siRNA delivery. Polyplus has developed a novel design of siRNA which significantly improves siRNA delivery in vivo, STICKY<br />
SIRNA. By adding longer overhangs, STICKY SIRNAs are able to form concatemers in the presence of in vivo-jetPEI (Polyplus’ proprietary<br />
reagent for in vivo gene delivery), mimicking the structure of DNA and so significantly increasing siRNA delivery. Polyplus R &D team has<br />
obtained significant results from preclinical studies in lung and prostate cancer mouse models for STICKY SIRNA. In addition, Polyplustransfection<br />
is developing a “new generation” of modified synthetic oligonucleotides (“cationic” siRNA) capable of silencing a targeted<br />
gene by RNA interference without the use of a delivery reagent. Polyplus is actively seeking additional scientific and commercial<br />
partnerships for the further clinical development of its siRNA therapeutics.<br />
PROPRIETARY TECHNOLOGY<br />
Technologies:<br />
- Transfection reagents for in vitro DNA delivery: jetPRIME (versatile transfection reagent for routine applications) and jetPEI (in vitro<br />
DNA transfection for HTS applications and for bioproduction)<br />
- Transfection reagent for in vitro siRNA delivery: INTERFERin<br />
- Technologies for the delivery of nucleic acids as therapeutics: in vivo-jetPEI (DNA & siRNA in vivo delivery reagent) and STICKY SIRNA<br />
- More recently, Polyplus designed and patented new generation of modified oligonucleotides, ZNA. ZNA offers increased affinity for<br />
nucleic acids and significantly improved performance in molecular hybridization techniques.<br />
CORPORATE ALLIANCES<br />
SHIP_In project (Generation of Induced Pluripotent Stem (iPS) cells, French Competitive Clusters)<br />
INTELLECTUAL PROPERTY<br />
3 exclusive licences and 8 patents pending including:<br />
- exclusive worldwide license for transfection of nucleic acids using polyethylenimine (PEI) and its derivatives<br />
- Exclusive rights worldwide over ZNA (modified oligonucleotides for molecular biology) - Patent pending over STICKY SIRNA (in vivo<br />
delivery of siRNA)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
in vivo-jetPEI Phase II, IIa, IIb Cancer therapy End of phase II in 2012<br />
STICKY SIRNA Pre-Target Validation Cancer therapy Preclinical data in 2011<br />
Cationic siRNA Pre-Target Validation Cancer research Preclinical data early 2012<br />
BIO Business Forum 2011 123 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Mark Bloomfield, Chief Executive Officer • Anne-Lise Monjanel, Marketing • Patrick Erbacher, Chief Scientific Officer • Bernard<br />
Gromb, Corporate Finance • Frederic Perraud, Chief Operating Officer • Pascale Belguise, Business Development • Alain Cuzange,<br />
Vice President • Dwight Navis, Vice President<br />
BOARD OF DIRECTORS<br />
Gabriel Festoc, Chairman • Karine Lignel, Directeur de Participations CM-CIC Capital Innovation • Gilles Alberici, President-Directeur<br />
General OCTALFA SAS • Michel Ronc, Director Airfi Conseil SARL • Jean-Paul Behr, Founder • Anne-Lise Monjanel, Founder<br />
SCIENTIFIC ADVISORY BOARD<br />
Jean-Paul Behr, Founder<br />
BIO Business Forum 2011 124 Participating Company <strong>Profiles</strong>
John Burt<br />
Chief Executive Officer<br />
London Bioscience Innovation Centre<br />
London<br />
NW1 0TU<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Keith A. Powell<br />
Ajay Mistry<br />
John Burt, Chief Executive Officer<br />
POLYTHERICS LIMITED<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Drug Delivery<br />
www.polytherics.co.uk<br />
Phone: 44-207-6914927<br />
Incorporated: 2002<br />
Employees: 30<br />
Ownership: Private<br />
CORPORATE MISSION<br />
PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. These two classes of<br />
drugs are administrated to patients by injection and are generally cleared from the body very quickly. This rapid clearance can reduce the<br />
efficacy of the drug and increase the frequency that injections have to be administrated to patient. Our precision chemistry technologies<br />
can extend the duration of action of these classes of drugs so patients require fewer injections, and can create more efficacious products.<br />
This reduces the cost of treatment and improves patient compliance.<br />
PolyTherics has three proprietary precision chemistry technologies for attaching one or more molecules of the polymer poly (ethylene<br />
glycol) (PEG) to any therapeutic peptide or protein to slow its elimination from the body. PEGylation is an established method for<br />
improving medicines and nine PEGylated products are already approved for use in either the US and/or EU. PolyTherics’ methods of<br />
PEGylation add PEG to a specific site on proteins and peptides producing a more homogeneous product than traditional PEGylation<br />
technologies.<br />
PROPRIETARY TECHNOLOGY<br />
PolyTherics has three proprietary precision chemistry technologies for attaching one or more molecules of the polymer poly (ethylene<br />
glycol) (PEG) to any therapeutic peptide or protein to slow its elimination from the body:<br />
• TheraPEG - PEGylation across one or more disulfide bonds naturally present in a protein<br />
• HiPEG - PEGylation at a histidine tag that is expressed at one or both ends of a protein or peptide<br />
• CyPEG - PEGylation at the thiol group of free cysteine within a protein or peptide<br />
CORPORATE ALLIANCES<br />
PolyTherics has a number of commercial agreements enabling our partners to develop and commercialize pegylated products, including a<br />
multi-product deal with Celtic Pharma Celtic Pharma for the development and commercialization of a therapeutic protein PEGylated<br />
using TheraPEG<br />
INTELLECTUAL PROPERTY<br />
PolyTherics has granted patents for TheraPEG in the EU (July 2009), US (September 2009), India (November 09) and China (February 10)<br />
and patents pending for HiPEG and CyPEG. In addition PolyTherics has filed further patent applications for specific PEGylation reagents<br />
and PEGylated products and for the use of specific polymer formulations for the solubilisation of insoluble molecules.<br />
SENIOR MANAGEMENT<br />
John Burt, Chief Executive Officer • Ajay Mistry, Business Development • Sally Waterman, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Ken Cunningham • Robert Bahns, Imperial Innovations • Tony Brampton • Mike Hayes • Steve Brocchini, London School of<br />
Pharmacy<br />
BIO Business Forum 2011 125 Participating Company <strong>Profiles</strong>
Mel Kronick, PhD<br />
Chief Executive Officer<br />
Babraham Research Campus<br />
Cambridge<br />
CB22 3AT<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Jason Mundin, Director of Collaborations<br />
Andrew Slatter, Scientific Officer<br />
Population Genetics Technologies<br />
Clinical Foci: Pharmacogenetics • Diagnostics • Genetic Disorders<br />
www.popgentech.com<br />
Phone: 44-01223-497 360<br />
Incorporated: 2005<br />
Employees: 14<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Quintiles and Population Genetics Technologies partner to deliver cost-effective, large scale genomic testing to biopharma - 16th May<br />
2011<br />
Population Genetics Technologies Receives £800,000 Award for Population Study on Alzheimer’s Disease Predisposition - October 2010<br />
PGT Awarded NHS Grant to Fund Pharmacogenetic Study on Patient Response to Breast Cancer Chemotherapy - March 2010<br />
CORPORATE MISSION<br />
Population Genetics Technologies has developed a novel approach for the rapid identification of rare genetic variants. This approach<br />
represents a significant advancement in the identification and utilisation of genetic biomarkers, which are fundamental to the<br />
development of personalised medicine.<br />
The goal of personalised medicine depends on knowing which drugs will work for which people. To find this out clinicians and<br />
pharmaceutical companies need a system for rapid discovery of clinical biomarkers, genetic variants that are associated with drug efficacy<br />
or toxicity. Unfortunately faster genome sequencing doesn’t mean researchers will discover the biomarkers that they hope exist.<br />
Such biomarkers, genetic signposts that point to our likely individual drug responsiveness or disease predisposition, are hidden among<br />
millions of insignificant gene variants. Simplistic predictions of a new age of personalised medicine driven by faster sequencing<br />
technology underestimate the scope of the problem<br />
Our unique proprietary technology, based on the work of one of our founders, Nobel Laureate Sydney Brenner, enables large-scale<br />
population genetics studies to be conducted, through the simultaneous analysis of regions of interest in thousands of individual<br />
genomes. This allows the identification of clinically and/or scientifically important genetic variations that cause predisposition to major<br />
diseases and varying responses to drug therapy.<br />
Using our technology and expertise, which together have widespread applications in both the commercial and academic setting,<br />
Population Genetics will partner with you to harness the power of population genetics analysis to enable targeted genetic research to<br />
become a reality.<br />
PROPRIETARY TECHNOLOGY<br />
Population Genetics has developed and protected a process which allows the simultaneous preparation, sequencing and analysis of<br />
thousands of genomes to identify causal variations while retaining the ability to identify which original genome carried the variant. This<br />
method produces order-of-magnitude reductions in the cost and time required for large-scale population studies. The company has begun<br />
to build a network of clinical and academic collaborators who will provide high quality, clinically defined DNA samples for studies key<br />
disease areas. PopGenTech will provide access to its capability to source, validate and analyze DNA from clinically relevant samples and<br />
provide information on genetic biomarkers predictive of disease or of drug response.<br />
CORPORATE ALLIANCES<br />
The company is already engaged in several projects spanning breast cancer, renal cancer, Alzheimer’s disease and leukaemia. Our method<br />
gives researchers and clinicians order-of-magnitude reductions in the cost and time required for large-scale population studies.<br />
Collaborations and commercial agreements are in place with two major pharmaceutical companies, a leading Clinical Research<br />
Organisation (CRO) and highly respected academic institutions including Cancer Research UK and the Wellcome Trust.<br />
As well as clinical and academic collaborators there is considerable potential for strategic commercial alliances since Population Genetics<br />
offers the solution to a problem faced by every major pharmaceutical company and most CROs.<br />
INTELLECTUAL PROPERTY<br />
PopGenTech has developed a strong IP portfolio of 9 issued, 4 pending and 6 filed patents protecting its methods. In addition we are<br />
working on two proprietary, disruptive technologies, Whole Population Amplification and Reflex Technology, that will maintain our<br />
competitive advantage in the medium and long term.<br />
SENIOR MANAGEMENT<br />
Mel Kronick, PhD, Chief Executive Officer • Frank Massam, PhD, Chief Business Officer • Conrad Lichtenstein, PhD, Chief Scientific<br />
Officer<br />
BIO Business Forum 2011 126 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Sam Eletr, PhD, Executive Chairman of PGT; also Chairman of the Board of SpinX Technologies and of Domain Therapeutics • Mel<br />
Kronick, PhD, CEO of PGT, former R&D Manager and Chief Scientist for Genomics at Agilent Technologies, R&D Manager at ABI • Mark<br />
Treherne, PhD, Representative of the Wellcome Trust, Chief Executive of Senexis and former Chief Executive of Cambridge Drug Discovery<br />
• Bernard Daugeras, PhD, Managing Partner, Auriga Partners • Stephane Mery, DVM, Investment Director, Beringea Ltd<br />
SCIENTIFIC ADVISORY BOARD<br />
Sydney Brenner, MD, DPhil, Professor, Kings College, Cambridge University, Salk Institute; Nobel Prize in Physiology or Medicine in 2002 •<br />
Philip Goelet, PhD, Venture Capitalist with Red Abbey LLC (which he co-founded); founder and CEO of Molecular Tool<br />
BIO Business Forum 2011 127 Participating Company <strong>Profiles</strong>
Mark Duxon, PhD<br />
Chief Executive Officer<br />
9 bis, rue Henri Martin<br />
92100 Boulogne Billancourt<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Toni Wolinsky<br />
Mark DUXON<br />
Porsolt<br />
Clinical Foci: CNS • Cardiovascular Disease • Metabolic Disease<br />
www.porsolt.com<br />
Phone: 33-1-4610 9990<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Porsolt has expanded its European laboratory operations with a custom builit 5500 sqm facility in Laval (France). The new facility offers<br />
increased capacity for Porsolt’s expanding cross-therapeutic area models and GLP safety pharmcology.<br />
Porsolt USA Inc, a wholly-owned subsidiary of the Porsolt parent in France, was recently established in San Antonio, Texas. This non-human<br />
primate laboratory will perform abuse liability, safety pharmacology, and pharmacokinetic studies.<br />
CORPORATE MISSION<br />
Porsolt has been delivering the highest quality research to the pharmaceutical and biotech industries for over 25 years. Throughout our<br />
history, our primary focus and core expertise has been in vivo disease models. The scientific experience of our dedicated team, many with<br />
backgrounds in drug discovery, enables us to be both proactive and reactive to the needs of our clients; new model development is very<br />
much client-driven. Personalized contact with designated project managers for each client ensures continuity and consistency within each<br />
project, facilitating scientific discussions and interaction. We provide a wide range of preclinical in vivo pathophysiological models across<br />
a variety of disease areas including CNS, cardiovascular, and metabolic disorders, pain and inflammation. Our safety pharmacology<br />
programs, which can performed to GLP, cover all in vivo and in vitro components of the safety battery, as well as assessment of drug<br />
dependence and abuse liability in both rodents and non-human primates. We also provide PK services, including dog and non-human<br />
primate CSF sampling.<br />
SENIOR MANAGEMENT<br />
Mark Duxon, PhD, Chief Executive Officer • Roger Porsolt, PhD., President • Martine Lemaire, PhD, Director • Guillaume Froget, PhD,<br />
Director • David Pushett, PhD, Business Development<br />
BIO Business Forum 2011 128 Participating Company <strong>Profiles</strong>
Commissioner Mark Phillips<br />
Other<br />
1st National Bank Bldg., 332 Minnesota<br />
Street<br />
Saint Paul, MN 55101<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sarah Walbert, Manager - Bioscience/Medical Device Sector<br />
Positively Minnesota<br />
Clinical Foci: Metabolic Disease • Regenerative Medicine • Medical Device<br />
www.positivelyminnesota.com<br />
Phone: 1-651-259-7442<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
* Mayo Clinic - University of Minnesota announce Decade of Discovery to conquer diabetes<br />
* Mayo Clinic ranked #1 in diabetes and endocrinology<br />
* University of Minnesota pioneer in pancreas & islet cell transplantation<br />
* Swine Models for Diabetes and Cardiovascular Research<br />
* 80 active clinical trials on Diabetes Melitus in Minnesota<br />
* Institute for Therapeutics Discovery and Development - Selected for leading role in<br />
National Cancer Institute’s newly formed drug discovery Consortium<br />
Incorporated: 1858<br />
Employees: 800<br />
Ownership: Other<br />
Minnesota- based Medtronic and Ford<br />
Motor announce prototype car dashboard<br />
to monitor glucose for diabetic drivers<br />
Diabetes Industry Board to be launched by<br />
4th quarter 2011<br />
CORPORATE MISSION<br />
There’s a reason why the highest number of FORTUNE 500 companies per capita reside in the State of Minnesota, joined by 600 FDA<br />
approved manufacturers. Just ask 3M, MEDTRONIC, CARGILL, UPSHER-SMITH and MAYO CLINIC.<br />
Are you seeking research or licensing partners? Or looking to establish an R&D facility or a sales office in the US? Minnesota's STABILITY,<br />
QUALITY, and CENTRAL location may be your ideal solution.<br />
WHO IS MINNESOTA?<br />
(A) Diabetes & regenerative medicine initatives augment Minnesota's stature in cardiology, orthopedics and oncology.<br />
(B) US leader in biomedical research including drug discovery and drug delivery, specifically in the areas of small molecules, biologics and<br />
cell therapies<br />
(C) World leading innovator in coating technologies and combination products<br />
(D) World’s first stem cell institute was established at the University of Minnesota and first marrow transplants done here.<br />
(E) Bioinformatics powerhouse in academia as well as industry<br />
Minnesota’s Office of Business Development is here to help you make connections and offer you a “smooth landing” as you seek<br />
collaborators.<br />
Note: STAFF SPEAKS JAPANESE.<br />
PROPRIETARY TECHNOLOGY<br />
Minnesota launched the "Decade of Discovery." The goal -- to prevent, optimally treat and ultimately cure diabetes. Conquering a disease<br />
is not something we can do alone. We need your help. Mayo Clinic, the University of Minnesota and hundreds of companies are seeking<br />
collaborators.<br />
CORPORATE ALLIANCES<br />
* Mayo Clinic and University of Minnesota Partnership "Decade of Discovery" to conquer DIABETES<br />
* BioBusiness Alliance of Minnesota Memorandum of Understanding with Osaka Chamber of Commerce and Industry (JAPAN);<br />
* Life Science Alley (600+ industry members)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Institute for Therapeutics<br />
Discovery and Development -<br />
University<br />
Research Contract services in Chemical<br />
Process Development, High<br />
Throughput Screening and Lead<br />
and Probe Discovery Cores<br />
DCI/DCI Biolafitte Cleared for US Marketing Bioreactors, fermentors,<br />
automation<br />
Exsulin Phase II, IIa, IIb Islet regeneration for Type I, Type II<br />
diabetes<br />
Single use bioreactor and 250 liter<br />
until available for process trial<br />
Clinical trials at Mayo Clinic and<br />
McGill University<br />
BIO Business Forum 2011 129 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Commissioner Mark Phillips, Other • Mark Lofthus, Director • Sarah Walbert, Manager<br />
SCIENTIFIC ADVISORY BOARD<br />
Betsy Seaquest, University of Minnesota • Victor Montori, Mayo Clinic • Larry Pease, PhD, Mayo Clinic • Stephen Russell, D. PhD,<br />
Mayo Clinic • Eric Wieben, PhD, Mayo Clinic<br />
BIO Business Forum 2011 130 Participating Company <strong>Profiles</strong>
Thomas Kuhn<br />
Chief Executive Officer<br />
200 avenue Jean Jaurès<br />
69007 LYON<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Thomas KUHN<br />
Pascale MALGOUYRES<br />
POXEL<br />
Clinical Foci: Metabolic Disease • Drug Development<br />
www.poxel.com<br />
Phone: 33-4-37372010<br />
HIGHLIGHTS<br />
Recent<br />
Poxel raised €16 million in a Series A financing from a syndicate of 3 private investors<br />
CORPORATE MISSION<br />
Incorporated: 2009<br />
Employees: 9<br />
Ownership: Private<br />
Poxel is a biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes. The company<br />
develops drug candidates to clinical proof of concept before partnering with pharmaceutical companies. Poxel operates independently as<br />
a lean organization with strong in-house drug development expertise.<br />
Its pipeline consists in innovative projects with new mechanisms of action, with an activity on glucose metabolism, other cardiovascular<br />
risk factors and with an improved safety profile compared to currently available therapies.<br />
INTELLECTUAL PROPERTY<br />
Poxel owns all rights on its programs<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Imeglimin Phase II, IIa, IIb Type 2 Diabetes Confirmatory program<br />
Direct AMPK activators Optimized Lead Type 2 Diabetes Closed to preclinical<br />
development candidates<br />
Oral GLP-1 agonists Lead Series Type 2 diabetes<br />
FXR agonists Lead Series Type 2 Diabetes<br />
11 beta HSD inhibitors Research Type 2 diabetes Lead Series<br />
GK activators Research Type 2 diabetes Lead Series<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 07/08/2010 (US $20.00 million)<br />
SENIOR MANAGEMENT<br />
Thomas KUHN, Chief Executive Officer • Pascale MALGOUYRES, Business Development • Eric MASSOU, Chief Financial Officer •<br />
Pascale FOUQUERAY, Chief Medical Officer • Sophie BOZEC, Chief Scientific Officer • Sebastien BOLZE, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Thierry HERCEND, Edmond de Rotschild Investment Partners • Raphael WISNIEWSKI, Edmond de Rotschild Investment Partners •<br />
Olivier MARTINEZ, CDC Entreprises Innobio Funds • Bruno MONTANARI, Credit Agricole Private Equity • Thomas KUHN, Poxel<br />
SCIENTIFIC ADVISORY BOARD<br />
Harold LEBOVITZ, Staten Island, NY 10310, USA • Silvio INZUCCHI, Yale School of Medicine, Fitkin 106, 333 Cedar Street, New Haven, CT<br />
06510, USA • Clifford J. BAILEY, Pharmaceutical Science Biology Section, Aston University, Aston Triangle, Birmingham B4 7ET, UK •<br />
Guntram SCHERNTHANER, Department of Medicine I, Rudolfstiftung Hospital, Juchgasse 25, A 1030 Vienna, AUSTRIA • Michaela<br />
DIAMANT, Chair of Diabetology, Director Diabetes Center VUMC, PO Box 7057; 1007 MB Amsterdam, NL<br />
BIO Business Forum 2011 131 Participating Company <strong>Profiles</strong>
Marius Prins<br />
Managing Director<br />
Meander 601<br />
8602EE Arnhem<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Pieter Rhemrev<br />
CORPORATE MISSION<br />
www.ppmoost.nl<br />
PPM Oost NV<br />
Clinical Foci: Other<br />
Phone: 31-26-28876084<br />
Incorporated: 1970<br />
Employees: 19<br />
Ownership: Private<br />
State funded private equity fund (development fund). Total fund approximately € 115 mln. Approximately 115 companies in portfolio of<br />
which app. 15 in the life sciences sector. Focus: finance early stage till series A and or B and find partner, second round financer etc.<br />
PROPRIETARY TECHNOLOGY<br />
Portfolio Companies active in oncology (inteRNA BV), ADC (Syntarga BV), peptides/antibodies (Pepscan Holding BV),<br />
INTELLECTUAL PROPERTY<br />
All protfolio companies have their IP portfolio.<br />
SENIOR MANAGEMENT<br />
Marius Prins, Managing Director • Pieter Rhemrev, Other<br />
BIO Business Forum 2011 132 Participating Company <strong>Profiles</strong>
Ginette Serrero<br />
Chief Executive Officer<br />
9130 Red Branch Road<br />
Columbia, MD 21045<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jun Hayashi<br />
CORPORATE MISSION<br />
Precision Antibody<br />
Clinical Foci: Immunology • Diagnostics • Drug Development<br />
www.precisionantibody.com<br />
Phone: 011-410-884-4100<br />
Incorporated: 2000<br />
Ownership: Private<br />
Precision Antibody has been providing comprehensive service for high quality rapid antibody development to pharmaceutical, biotech,<br />
diagnostic, academic and federal laboratory customers for over 10 years. Our antibody team strives to deliver successful projects to our<br />
customers in 40 to 60 days for standard monoclonal antibody projects. We are known for our personal service, cutting edge technology,<br />
speed, confidentiality, and delivering antibodies that work in our client’s intended assay.<br />
Our team of immunologists have extensive experience with the most challenging projects. Whether it is making a single amino-acid<br />
mutation site-specific monoclonal antibody for a neurology project, a gold standard proteomic antibody for the National Cancer Institute<br />
(NCI)’s Clinical Proteomic Technologies for Cancer (CPTC), a multi-strain malaria antibody for NIAID's Malaria Vaccine Initiative, or an antiidiotypic<br />
antibody for a drug PK study, Precision Antibody succeeds where other antibody developers fail. Successful development of<br />
antibody reagent that meets your application is our goal and we measure our success attaining that goal.<br />
We can also help you pick the right antibody. Precision Antibody’s Biacore Analysis Service using GE Healthcare’s Biacore 3000 Surface<br />
Plasmon Resonance (SPR) technology helps you choose the right antibodies for your assays and provides essential information for your<br />
antibody characterization. Our custom Biacore Analysis Service can help you:<br />
* Rank your monoclonal antibodies based on association/disassociation rates and binding affinity (Scouting analysis).<br />
* Obtain detailed binding kinetic data (Full kinetic analysis).<br />
* Identify monoclonal antibodies binding to different epitopes of the antigen.<br />
Precision Antibody has broad experience in pilot scale, small scale, and large scale mammalian cell culture of hybridomas for production of<br />
monoclonal antibodies.<br />
PROPRIETARY TECHNOLOGY<br />
Rapid Custom Antibody Development.<br />
Our team of immunologists have extensive experience with the most challenging projects:<br />
* Anti-idiotypic Antibodies<br />
* Biomarker Discovery Antibodies<br />
* Anti-neoepitope Antibodies<br />
* Anti-receptor Antibodies<br />
* Infectious Disease Antibodies<br />
* Proteomic Antibodies<br />
* Small Molecule Antibodies<br />
CORPORATE ALLIANCES<br />
We are proud to be the preferred antibody developer for three federal reagent repositories- NCI’s Proteomics, NIAID’s Malaria, and CDC’s<br />
Influenza as well as many companies worldwide<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Custom Antibody Development On Market CRO 40 to 60 days<br />
Contract Antibody Production On Market CRO Pilot to Large Scale<br />
Antibody Characterization Services On Market CRO Biacore Analysis Service<br />
Antibody Humanization Services On Market CRO Stable Cell Line Development & Humanization<br />
SENIOR MANAGEMENT<br />
Ginette Serrero, Chief Executive Officer • Michael Keefe, Chief Operating Officer • Jun Hayashi, Senior Vice President • David Hicks,<br />
Business Development • Bing Miller, Director • Joe Corvera, Director<br />
BIO Business Forum 2011 133 Participating Company <strong>Profiles</strong>
Matthew Kane<br />
Chief Executive Officer<br />
302 E. Pettigrew St., Dibrell Warehouse A-100<br />
Durham, NC 27701<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Matthew Kane, CEO<br />
Derek Jantz, VP, Scientific Development<br />
CORPORATE MISSION<br />
Precision Biosciences<br />
www.precisionbiosciences.com<br />
Phone: 1-919-314-5512<br />
Incorporated: 2006<br />
Employees: 16<br />
Ownership: Private<br />
Precision BioSciences, Inc. is a biotechnology company focused on developing and commercializing therapeutics and services based upon<br />
its ability to enable site-specific genome modifications within a living organism. This technology, called the Directed Nuclease Editor<br />
(DNE), is a fully rational, proprietary methodology that allows for the insertion, removal, or modification of DNA at nearly any gene in<br />
nearly any organism.<br />
Precision is harnessing its DNE technology to enable the development of treatments for genetic and viral diseases, the creation of greatly<br />
needed new crops and fuel sources, and the construction of new tools for biomanufacturing and diagnostic applications.<br />
Precision was founded in 2006 and is headquartered at the Venable Center in downtown Durham, North Carolina. The company has<br />
formed significant partnerships with several of the world's leading biotechnology companies, including DuPont, Bayer, and BASF, and has<br />
built a highly dedicated and motivated team of scientists and business experts that are continuing to propel its growth.<br />
PROPRIETARY TECHNOLOGY<br />
Precision BioSciences' Directed Nuclease Editor (DNE) is a robust platform for genome engineering. The technology is based on the<br />
production of custom-made DNA-cutting enzymes called "DNE meganucleases". Using state-of-the-art protein engineering techniques,<br />
Precision BioSciences alters the genetic sequence of a natural genome-editing meganuclease to create a custom meganuclease with<br />
unique DNA-recognition and cleavage properties. The result is a DNE enzyme with the ability to precisely modify a specific, user-defined<br />
target within a genome. The targeted manipulation of genomic DNA has a broad range of applications including the correction of genetic<br />
disorders, the treatment of viral infections, the improvement of crops, and the engineering of cell lines for research or biomanufacturing.<br />
CORPORATE ALLIANCES<br />
DuPont/Pioneer, Bayer, BASF<br />
INTELLECTUAL PROPERTY<br />
Precision BioSciences' intellectual property portfolio covers methods for designing and utilizing engineered homing endonucleases or<br />
meganucleases.<br />
SENIOR MANAGEMENT<br />
Matthew Kane, Chief Executive Officer • Derek Jantz, Senior Vice President • Jeff Smith, Chief Scientific Officer • Todd Melby, Chief<br />
Financial Officer<br />
BIO Business Forum 2011 134 Participating Company <strong>Profiles</strong>
Dr. Bettina Ernst<br />
Chief Executive Officer<br />
Route de la Corniche 9A<br />
1066 Epalinges-Lausanne<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Bettina Ernst<br />
CORPORATE MISSION<br />
Preclin Biosystems AG<br />
Clinical Foci: Infectious Disease • Pulmonary • AutoImmune<br />
www.preclinbiosystems.com<br />
Phone: 41-44-5860776<br />
Ownership: Private<br />
Preclin Biosystems AG offers an extensive range of infectious and chronic inflammatory disease models for testing the efficacy of lead<br />
candidate therapeutics and vaccines. -<br />
The range of disease models offered by Preclin Biosystems is unparalleled in the industry and gives customers the unique opportunity to<br />
assess their drug candidates simultaneously in multiple disease models. Such a strategy can highlight the market potential and possible<br />
side effects of a drug candidate in addition to revealing its effectiveness. -<br />
The scientific team behind Preclin Biosystems has well over 40 years of experience modeling infectious and inflammatory diseases in mice<br />
and identifying the cellular and molecular mechanisms that drive the disease. They are committed to offering customers a flexible and<br />
personalized service to ensure their goals are reached in the timeliest manner.<br />
PROPRIETARY TECHNOLOGY<br />
Preclin Biosystems AG offers a comprehensive in vivo preclinical testing platform for the identification and validation of lead candidate<br />
therapeutics. Their range of over 20 chronic inflammatory and infectious disease models are run routinely in our core facility providing a<br />
‘one stop shop’ for preclinical drug efficacy testing.<br />
CORPORATE ALLIANCES<br />
Preclin Biosystems AG serves biotech and pharmaceutical companies around the world.<br />
SENIOR MANAGEMENT<br />
Dr. Bettina Ernst, Chief Executive Officer • Prof. Benjamin Marsland, Chief Scientific Officer<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Nicola Harris, Advisory Board Member • Dr. Georges Haas, Advisory Board Member<br />
BIO Business Forum 2011 135 Participating Company <strong>Profiles</strong>
Jan Borg<br />
Chief Executive Officer<br />
Uppsala Science Park<br />
SE-751 83 Uppsala<br />
Sweden<br />
CONFERENCE PARTICIPANTS<br />
Daniel Walker, Business Development<br />
Jacob Testor, Board Member<br />
Premacure AB<br />
Clinical Foci: Biopharmaceuticals • Metabolic Disease<br />
www.premacure.com<br />
Phone: 46-7611-74243<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Premacure has completed and reported a Phase I clinical trial utilizing Premiplex<br />
for prevention of complications from preterm birth.<br />
Premacure has completed the initial part (Section A) of a Phase II, multi-center,<br />
clinical trial utilizing Premiplex for prevention of complications from preterm<br />
birth.<br />
Incorporated: 2002<br />
Ownership: Private<br />
Premacure anticipates completing the current Phase<br />
II clinical trial in Q2, 2012.<br />
CORPORATE MISSION<br />
Complications of Preterm Birth – Unmet Medical Needs.<br />
Premacure AB, located in Uppsala, Sweden owns exclusive worldwide rights to develop and commercialize Insulin-Like Growth Factor 1<br />
(IGF-I) together with or without its natural binding protein, IGFBP-3, as a product for the “prevention of complications of preterm birth”.<br />
Deprivation of IGF-I to the human infant, as a consequence of preterm birth causes several lifelong complications involving visual<br />
impairment (improper retinal vascular growth termed Retinopathy Of Prematurity (ROP)), bronchopulmonary dysplasia (BPD), necrotizing<br />
enterocolitis (NEC), impaired brain growth and mental retardation etc. Chronic complications following premature birth are present in up<br />
to 70% of the neonates. There is a strong correlation between the gestational age at birth and the severity and complexity of<br />
complications, with 40% of all infants being born prior to the 32nd week of gestation developing severe complications. Administration of<br />
IGF-I to premature infants, as a substitute for the maternal source, allows for the establishment of physiological (equivalent to in utero)<br />
level of the hormone. Such a treatment is believed to provide for normal development and thereby prevent the development of these<br />
syndromes. Currently there is no efficacious treatment available. In the EU and the US, there are approximately 54,000 and 87,000<br />
premature infants (born before the 32nd gestational week) delivered annually. All of these children are at risk to develop serious<br />
complications due to low concentrations of IGF-I.<br />
PROPRIETARY TECHNOLOGY<br />
Premacure owns the intellectual property for the prevention of complications associated with the deprevation of IGF-I to the human infant<br />
as a consequence of preterm birth. A Phase I clinical trial was conducted and results demonstrate that the levels of IGF-I were increased to<br />
within physiological levels and that administration of IGF-I/IGFBP-3 (Premiplex®) to preterm infants is safe and well tolerated. A Phase II,<br />
safety and efficacy multi-center clinical trial has started in Sweden and is currently recruiting patients.<br />
CORPORATE ALLIANCES<br />
Premacure has initiated the process to partner with pharmaceutical companies for the continuation of the development of Premiplex®<br />
into Phase III clinical trials and ultimately commercialization.<br />
INTELLECTUAL PROPERTY<br />
Premacure owns the intellectual property for the prevention of complications associated with the deprevation of IGF-I to the human infant<br />
as a consequence of preterm birth.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Premiplex Phase II, IIa, IIb Complications from Preterm Birth Finalize Phase II trial in Q2, 2012<br />
FINANCING HISTORY<br />
Investors: Private Investor (not VC) (17 %) • Private Investor (not VC) (14 %) • Private Investor (not VC) (14 %) •<br />
Private Investor (not VC) (10 %) • Private Investor (not VC) (10 %) • Private Investor (not VC) (10 %) •<br />
Private Investor (not VC) (4 %) • Private Investor (not VC) (4 %) • Remainder (not VC) (17 %)<br />
SENIOR MANAGEMENT<br />
Jan Borg, Chief Executive Officer • Daniel Walker, Business Development<br />
BOARD OF DIRECTORS<br />
Curt Nilsson, PhD, Gruvstigaren AB • Jan Borg, Premacure AB • Daniel Walker, PhD, Premacure AB • Jacob Testor, Hang Time AB •<br />
Thomas Pollare, MD, PhD • William Gunnarsson<br />
BIO Business Forum 2011 136 Participating Company <strong>Profiles</strong>
Thierry Langer<br />
Chief Executive Officer<br />
Boulevard Gonthier d'Andernach<br />
67400 Strasbourg- Illkirch<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Prestwick Chemical<br />
Clinical Foci: Drug Discovery • CNS • Oncology<br />
www.prestwickchemical.com<br />
Phone: 33-3-6920 1600<br />
Paul Bikard, COO/CFO Eric Jamois, VP of US Operations<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Contract research collaboration:<br />
Outstanding track record with 100% success for projects lasting 18-<br />
24 months. Currently: 1 client product in Phase III, 2 in Phase II, 3 in<br />
Phase I, and 6 compounds in earlier development.<br />
Licensing out of DT1687, an optimized lead for the treatment of<br />
Parkinson disease<br />
2 new optimization projects with an Austrian biotech firm<br />
1 new optimization project with a Swiss animal health company<br />
Incorporated: 1999<br />
Employees: 45<br />
Ownership: Private<br />
Significant expansion of capacity and know-how, with the<br />
integration of screening capabilities (project based: primary and<br />
secondary screening, DMPK), large scale parallel synthesis all in a<br />
new European site<br />
Initiation of several new collaborations with small or medium<br />
biotechs and/or pharma groups<br />
In late 2011, Initiation of a dyskinesia project (not Parkinson<br />
related) for outlicensing in 2013<br />
CORPORATE MISSION<br />
Prestwick Chemical a premium provider of drug discovery services was founded in 1999 by Prof. C. G. Wermuth, a world-known expert in<br />
medicinal chemistry, along with top scientists from Strasbourg University.<br />
Prestwick Chemical, located in the Strasbourg innovation park, offers a broad range integrated drug discovery services, with a<br />
focus/expertise in all areas of medicinal chemistry, ranging from custom synthesis including patent exemplification, to research projects<br />
aimed at hit validation, ligand profiling, and lead optimization.<br />
Prestwick’s experienced team of intuitive medicinal chemists develops innovative synthetic strategies tailored to the client’s needs. They<br />
are supported by state of the art computer-aided molecular design, large-scale virtual screening and expertise to address ADME/TOX and<br />
selectivity issues. In addition to research services, Prestwick Chemical provides the pharmaceutical industry and academic research<br />
laboratories with a supply of smart and original drug-like screening libraries.<br />
PROPRIETARY TECHNOLOGY<br />
Contract research services in Medicinal Chemistry :<br />
- Hit validation<br />
- Lead Optimization<br />
- Ligand profiling<br />
Prestwick Chemical's team of well trained medicinal chemists and pharmacists develops innovative medicinal chemistry strategies<br />
tailored to client's needs. They are supported by state-of-the -art computational ligand design, inluding large scale virtual screening and<br />
take into account ADME/Tox and selectivity issues from the project's start.<br />
CORPORATE ALLIANCES<br />
Strategic alliance with Inte:Ligand GmbH, Vienna (Austria), a leading modelling sofware and contract research provider for in silico drug<br />
discovery.<br />
Strategic Alliance with Caliper Life Sciences (CDAS), a leading drug discovery CRO for in vitro and in vivo screening.<br />
Strategic Alliance with Domain Therapeutics, a specialist in GPCR drug discovery.<br />
Corporate alliances for lead optimization services include Sanofi-Aventis (F), Glaxo (US), Merck (Germany) , Johnson and Johnson (US-B),<br />
Nycomed (D), Servier (F) and mid-size pharma as well as biotech companies from several countries.<br />
INTELLECTUAL PROPERTY<br />
IP always belong to our clients. Alternative business models available.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
DT 1687 Optimized Lead Parkinson Licensed out in late 2010<br />
Oncology Lead Series Oncology Optimized lead<br />
CNS Lead Series CNS Optimized lead<br />
Metabolic Research Metabolic Optimized lead<br />
SENIOR MANAGEMENT<br />
Thierry Langer, Chief Executive Officer • Paul Bikard, Chief Financial Officer • Bruno Giethlen, Chief Scientific Officer • Eric Jamois,<br />
Vice President • Marie-Louise Jung, Vice President<br />
BIO Business Forum 2011 137 Participating Company <strong>Profiles</strong>
Mark Larkin<br />
Partner<br />
Centaur House, Ancells Road<br />
Fleet<br />
GU51 2UJ<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Mark Larkin, Partner<br />
HIGHLIGHTS<br />
Recent<br />
PRMA Consulting<br />
Clinical Foci: Biopharmaceuticals • Oncology • Immunology<br />
www.prmaconsulting.com<br />
Phone: 44-1272-786 284<br />
Incorporated: 2006<br />
Employees: 35<br />
Ownership: Private<br />
Publication of 6 PRMA Insights (www.prmainsights.com) global (US, EU5 + Japan) pricing and reimbursement and market access reports -<br />
NSCLC, metastatic breast cancer, type 2 diabetes, renal cell carcinoma, renal cell carcinoma and COPD.<br />
CORPORATE MISSION<br />
Founded in 2006, PRMA Consulting is a specialist global market access consultancy headquartered in the UK, with a team of more than<br />
35 across the EU, US, and Asia.<br />
We provide best in class strategic, commercial and technical based pricing, reimbursement and market access advisory services to<br />
companies to overcome their global and local market access hurdles across the pharmaceutical and healthcare industries.<br />
PRODUCTS<br />
Name Phase Indication<br />
PRMA Insights Report Other Non Small Cell Lung Cancer<br />
PRMA Insights Report Other Psoriasis<br />
PRMA Insights Report Other Metastatic Breast Cancer<br />
PRMA Insights Report Other Type II Diabetes<br />
PRMA Insights Report Other Renal Cell Carcinoma<br />
PRMA Insights Report Other COPD<br />
SENIOR MANAGEMENT<br />
Mark Larkin, Partner • Sotiria Papanicolaou, Partner • David Sykes, Partner<br />
BIO Business Forum 2011 138 Participating Company <strong>Profiles</strong>
Dr. Wieland Wolf<br />
Chief Executive Officer<br />
Goethestrasse 54<br />
13086 Berlin<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Gabriele Schneider, Vice President Business Development<br />
Oliver Schub, Business Development Manager<br />
ProBioGen AG<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Immunology<br />
www.probiogen.de<br />
Phone: 49-30-9240 060<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
ProBioGen invented its GlymaxX® technology as an innovative,<br />
simple, robust & potent technology to enhance ADCC of<br />
monoclonal antibodies through Fc-Fucose depletion, even<br />
applicable to novel and existing mAb producer cell lines.<br />
ProBioGen & Life Technologies launch the new Freedom CHO-S<br />
Kit. The Kit, co-developed with Life Technologies enables end users<br />
to create royalty-free cGMP compliant CHO cell lines even for<br />
commercial use.<br />
Developed robust, flexible & rapid industrial bioreactor<br />
manufacturing process for highly attenuated viral vaccine<br />
manufacturing, with AGE1®.CR duck cell line & chemically defined<br />
media platform. Raw titers above 1x10E9 pfu/ml for MVA's<br />
achieved.<br />
CORPORATE MISSION<br />
Incorporated: 1994<br />
Employees: 70<br />
Ownership: Private<br />
GlymaxX® technology implemented in antibody platforms of<br />
several leading biopharmaceutical companies.<br />
Additional proof as leading technology provider and development<br />
partner in the field of animal cell-derived biopharmaceuticals.<br />
Further expanded manufacturing capacity, based on disposable<br />
bioreactor technologies to extend our proven CMO services track<br />
record, from cell line development up to GMP manufacturing of<br />
mAbs, Interferons, enzymes, Biosimilars, FSH, Factor VIII, etc<br />
Broader use of our Human neuronal AGE1.HN cell line which shows<br />
superior product quality and titers over CHO when producing<br />
difficult-to express, complex human glycoproteins, such as clotting<br />
Factor VIII, alpha 1-Antitrypsin, growth factors etc.<br />
ProBioGen AG is an international Contract Development and Manufacturing Organization (CDMO) and technology provider with focus on<br />
cell line and process engineering, up to GMP manufacturing of biopharmaceuticals.<br />
With almost 20 years of experience in mammalian cell culture and our innovative scientific excellence and strong intellectual property<br />
base, we cover the entire drug development value chain, including regulatory support for IND-filing.<br />
This makes ProBioGen, together with our outstanding service quality, variable project and deal structures, responsiveness and flexibility,<br />
the partner of choice for biopharmaceutical companies seeking high quality cell line development and manufacturing capabilities.<br />
All our services and technologies are embedded in a total quality management system to assure compliance with international ISO and<br />
GMP standards (EMA/FDA).<br />
ProBioGen’s reputation is based on a highly dedicated specialist team, striving for excellence in quality and speed in every project, which is<br />
led by a seasoned management team with more than 60 years of biopharmaceutical industry experience.<br />
Beyond offering state-of-the-art, fee-for-service-based services from cell line development up to GMP manufacturing, we also developed<br />
various innovative technologies for optimized biopharmaceutical manufacturing and analysis.<br />
Our State-of-the-Art Services include :<br />
- Production Cell Line Engineering (Royalty-free, Fee-for-Service-based) including Media Optimization<br />
- Glycoengineering, Metabolic Engineering<br />
- Upstream and Downstream Process Development<br />
- GMP and non-GMP Manufacturing<br />
- Analytical Services, including sophisticated Cell-Based Bioassays<br />
PROPRIETARY TECHNOLOGY<br />
1 – Proprietary starter CHO cell lines (DG44 and K1), promoter and vector design for developing fee-for-service-based, royalty-free highproducer<br />
cell lines<br />
2 – Proprietary chemically defined media platform<br />
3 - GlymaxX® Technology (Glyco engineering via pathway deflection) as a novel, simple, robust and potent technology to enhance the<br />
ADCC activity of monoclonal antibodies through minimizing Fc-Fucose content; applicable to novel and existing cell lines<br />
4 – Avian AGE1®.CR (duck) cell lines for industrial viral vaccine manufacturing<br />
5 – Human neuronal AGE1®.HN cell line for high-yield production of glycoproteins and vaccines<br />
6 – Human Artificial Lymph Node (HuALN) technology for predicting drug-related effects on the human immune system in vitro<br />
BIO Business Forum 2011 139 Participating Company <strong>Profiles</strong>
CORPORATE ALLIANCES<br />
Boehringer Ingelheim, Merck Serono SA, Novartis Vaccines & Diagnostics, Sanofi Pasteur, NovImmune SA, Functional Genetics Inc., PAION<br />
AG, Vakzine Projekt Management GmbH (VPM), IDT Biologika GmbH (Impfstoffwerk Dessau-Tornau), Affitech, Unilever, etc.<br />
SENIOR MANAGEMENT<br />
Dr. Wieland Wolf, Chief Executive Officer • Dr. Volker Sandig, Chief Scientific Officer • Dr. Rene Brecht, Executive Vice President • Dr.<br />
Gabriele Scheider, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Dr. Wafik Bardissi, Minapharm<br />
BIO Business Forum 2011 140 Participating Company <strong>Profiles</strong>
Alon Natanson<br />
Chief Executive Officer<br />
3 Habosem st.<br />
77610 Ashdod<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Ilana Belzer<br />
Alon Natanson<br />
Procognia<br />
Clinical Foci: Diagnostics • Drug Discovery • Biopharmaceuticals<br />
www.procognia.com<br />
Phone: 972-54-4836954<br />
Incorporated: 2000<br />
Ownership: Public<br />
Market Cap: $10.00 million<br />
HIGHLIGHTS<br />
Recent<br />
15/05/2011<br />
Procognia signs a cooperation agreement with the Weizmann Institute for the implementation of the company's unique glycoanalysis<br />
technologies as a tool for the identification and optimal development of stem cells<br />
29/03/2011<br />
Procognia has been Granted an Additional Patent in Japan -<br />
Joining 21 additional patents granted in the USA, EU, Australia, Japan, and other countries, these patents broadly protect the company's<br />
technology and its various applications<br />
22/12/2010<br />
Binding Memo of Understanding with Euro-Diagnostica -<br />
Procognia agreed to grant ED an exclusive service license to provide diagnostic services for gastric (stomach) cancer on the basis of the<br />
technological capabilities she developed.<br />
CORPORATE MISSION<br />
Procognia is an innovative expert biotechnology company, specializing in glycobiology and lectin array based glycoanalysis. A leader in<br />
ground-breaking glycomics applications, the company developed GlycoScope , a quantitative high throughput lectin array based<br />
glycoanalysis platform technology featuring automatic data analysis software.<br />
Procognia is positioned at the frontier of glycomics research, with the development of lectin array based diagnostics platforms for a range<br />
of cancers, and new cancer management strategies based on screening and selection of MAbs for cancer specific glycan epitopes.<br />
Procognia is working intensively in R&D, combining ingenuity, innovation and state-of-the-art biotechnologies in solutions meeting the<br />
pharmaceutical and diagnostic challenges of tomorrow.<br />
Procognia's four innovative platforms express a huge and promising potential in the pharmaceutical and diagnostic arenas based on the<br />
emerging understanding in Glycomics and its fundamental role in biological drugs, diagnostics and therapeutic value.<br />
The GlycoScope is a marketed product for biopharmaceutical glycoanalysis supports efficiently and reliably development and<br />
manufacturing of glycoprotein drugs.<br />
The Glycodiagnostic platform is an accurate non-invasive diagnostic application for serum samples, based on the company HTP<br />
glycoanalysis technology. The validated Proof of concept demonstrates the potential of the technology to become a reliable platform for a<br />
wide range of cancer diagnostic applications<br />
The Pharma platform based on specific and selective MAbs directed to glycan epitopes specific for cancer Adencarcinoma are a new path<br />
in cancer therapy & diagnostics and is expected to become a breakthrough in cancer management.<br />
The Stem cells glycoprofiling study aiming to identify membranes glycosylation profiles that can predict differentiation and tumorigenic<br />
potential, monitor cells efficient survival and maintenance and to improve in vivo homing and engraftment.<br />
PROPRIETARY TECHNOLOGY<br />
The proprietary lectin array platform is based on dozens of well characterized lectins in an array format. Interaction with the glycoproteins<br />
applied on the array creates a fluorescent image that is de-convoluted into a fingerprint and a quantitative result with patented<br />
automatic data analysis software. The platform offers a HTP, quantitative glycoanalysis enabling accurate analysis of dozens of samples in<br />
parallel, in a simple and rapid test.<br />
This platform is used to monitor biopharmaceuticals glycosylation, glycoprofiling of stem cells and serum samples for diagnosis of a<br />
variety of cancerous diseases.<br />
Procognia developed a screening technology for selection of MAbs for cancer specific glycan epitopes for the detection & treatment of<br />
cancerous cells<br />
BIO Business Forum 2011 141 Participating Company <strong>Profiles</strong><br />
PRCG
CORPORATE ALLIANCES<br />
Procognia has scientific and clinical collaboration with several academic and medical institutes, among them are:<br />
Tel-Aviv University<br />
Weizmann Institute<br />
Sheba medical center<br />
In addition Procognia is working with several leading biopharmaceutical companies.<br />
INTELLECTUAL PROPERTY<br />
The company’s IP portfolio includes 13 patent families, which have already generated 22 patents and many more patents pending,<br />
covering the lectin arrays, the set of computational algorithms, novel antibodies and their various applications.<br />
Among the company's patents granted in USA, Canada, Europe, Japan and other Asian countries are listed:<br />
Method and composition for analyzing a carbohydrate polymer<br />
System and method for analyzing saccharide fingerprint data<br />
Method and assay for glycosylation pattern detection related to cell state and stem cells<br />
Methods For Screening For Therapeutic Molecules And Use Of The Molecules Therefrom<br />
Lectin-Displacing Antibodies And Methods Of Use For The Treatment And Diagnosis Of Cancer.<br />
Diagnosis of cancer through glycome analysis.<br />
PRODUCTS<br />
Name Phase Indication<br />
GlycoScope Other Glycoanalysis of Biopharmaceuticals<br />
SENIOR MANAGEMENT<br />
Alon Natanson, Chief Executive Officer • Dr. Yeshayahu Yakir, Executive Vice President • Dr. Ilana Belzer, Vice President • Einav<br />
Netzer, Chief Financial Officer • Larisa Amir, Director<br />
BOARD OF DIRECTORS<br />
Ron Long • Prof. Ruth Arnon • Dr. Yeshayahu Yakir • Prof. Raphael Catane (MD) • Mrs. Daphna Peleg • Prof. Shmuel Penchas •<br />
Ofer Lavie<br />
BIO Business Forum 2011 142 Participating Company <strong>Profiles</strong>
Largo Donegani 4/A<br />
I-28100-Novara<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Emanuela Tosi, Licensing Manager<br />
Giancarla Dondi, Managing Director<br />
PROGE FARM S.r.L.<br />
Clinical Foci: Gastroenterology • Reproductive • Other<br />
www.progefarm.it<br />
Phone: 39-0321-693 011<br />
Incorporated: 1992<br />
Employees: 14<br />
Ownership: Private<br />
CORPORATE MISSION<br />
PROGE FARM is an Italian pharmaceutical company founded in 1992 with the aim of developing, registering, commercialising medicinal<br />
products, medical devices and food supplements.<br />
Since 2000 PROGE FARM pharmaceutical expertise was engaged in a specialized field to develop and register medicinal products, medical<br />
devices and food supplements containing lactobacillus strains with probiotic features.<br />
In fact, in PROGE FARM’s GLP laboratory, probiotic strains are selected from human habitat, genetically identified and then deposited at<br />
International Culture Collections such as Institute Pasteur (in France) and LMG (in Belgium).<br />
These particular strains are covered by International and European patents (one of this is an U.S. patent already granted).<br />
The strains and the products were tested and studied either in vitro and in vivo and there are different published articles of them.<br />
The main products containing probiotics are for gynaecological use and for gastrointestinal use.<br />
The PROGE FARM probiotic strains are produced in own manufacturing plant.<br />
In Italy PROGE FARM commercialises all these products directly or by licensees and since from 2006 it started to out-license and supply<br />
these products all over the world. In fact PROGE FARM has already signed some license and supply agreements with local or multinational<br />
pharmaceutical companies in different countries in Europe and in South-America.<br />
PROGE FARM is looking for new partners to license and supply products containing probiotic strains all over the world.<br />
CORPORATE ALLIANCES<br />
PROGE FARM has already signed license and supply agreements with different Companies all over the world. The main Companies are:<br />
SIGMA-TAU, RATIOPHARM, ISDIN and SCHARPER.<br />
INTELLECTUAL PROPERTY<br />
PROGE FARM S.r.l. owns different International and European patens, most of them already granted.<br />
PRODUCTS<br />
Name Phase Indication<br />
ECOCILLIN On Market Vaginal capsules (hard and softgel) containing a particular probiotic lactobacillus able to adhere to<br />
the vaginal cells and to restore the normal microflora after a bacterial and/or mycotic infection.<br />
ENETROBACILLI On Market Food supplement, in sachets, capsules and oil, containing particular Lactobacilli and vitamins able<br />
to rebalance and restore the bacterial flora in the gastrointestinal tract.<br />
BIO Business Forum 2011 143 Participating Company <strong>Profiles</strong>
Fabrizio Giannotta<br />
Chief Executive Officer<br />
Boulevrad du Rectorat 27b, B22<br />
B4000 LIEGE<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Fabrizio Giannotta<br />
CORPORATE MISSION<br />
ProGenosis<br />
Clinical Foci: CNS • Drug Discovery • PGH – Neglected Diseases<br />
Phone: 32-4-361 3329 Ownership: Private<br />
ProGenosis is a Belgian based company possessing two bacterial protein scaffold technologies allowing the providing of R&D customized<br />
services in four essential application areas:<br />
- Protein engineering and production<br />
- Antigenes & Antibodies development<br />
- Antibodies characterization<br />
- Protein-protein domain interaction<br />
The technology approaches have been extensively and successfully concept-proved by numerous world-wide biotech and blue-chip<br />
pharma companies.<br />
One of these technology platforms, called Bifunctional Hybrid Protein (BHP), allows access to protein domains known to be insoluble,<br />
difficult to express or even both.<br />
The BHP platform is particularly dedicated to perform efficient and straightforward epitope mapping experiments.<br />
The second technology, called Alpha-hemolysin Hybrid Protein (AHP), is dedicated to reshape GPCR and ion-channel. The recreated hybrid<br />
protein can be use for NCE screening, NBE discovery & development or receptor deorphanisation.<br />
PROPRIETARY TECHNOLOGY<br />
undisclosed<br />
CORPORATE ALLIANCES<br />
undisclosed<br />
INTELLECTUAL PROPERTY<br />
granted<br />
SENIOR MANAGEMENT<br />
Fabrizio Giannotta, Chief Executive Officer • Patrice Filée, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Bernard Dauby, Freelance • Guy Heynen, Medical doctor ex-pfizer • Gustave Moonen, Neurologist - Director of the Center of Neurology<br />
in Liège<br />
BIO Business Forum 2011 144 Participating Company <strong>Profiles</strong>
Tauseef R Butt Ph.D<br />
President & CEO<br />
277 Great Valley Parkway<br />
Malvern, PA 19355<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Tauseef R. Butt, PhD<br />
Marc Hixson, Sr. Director, Business Development<br />
Progenra, Inc<br />
Clinical Foci: Oncology • AutoImmune • Musculoskeletal<br />
www.progenra.com<br />
Phone: 1-610-644-6974<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Funding secured for pre-clinical programs until 2012.<br />
Several new chemical entities identified. Patent applications filed<br />
in 2010 to protect several new chemical entities for oncology<br />
applications. Other NCE applications will be filed in mid 2011.<br />
Novel Drug Targets for anti-cancer approach validated in cellular<br />
proof of concept studies and different animal models. The oncology<br />
target is first in its class of novel enzymes of the ubiquitin<br />
proteasome pathway.<br />
Incorporated: 2002<br />
Employees: 21<br />
Ownership: Private<br />
Corporate partnership to develop several clinical candidates will be<br />
announced..<br />
Release of efficacy data on P-5091 and other leads in this series for<br />
in vivo models of multiple myeloma and other human tumor<br />
models.<br />
Demonstration of cellular proof of concept and in vivo efficacy for<br />
optimized E3 ligase inhibitor HTS hit associated with muscle<br />
wasting.<br />
CORPORATE MISSION<br />
Through our leadership in ubiquitin pathway, Progenra is discovering new medicines, first in class for the treatment of unmet medical<br />
needs.Ubiquitin-based drug discovery is at the exciting initial stage - much like that of kinases and phosphatases fifteen years ago.<br />
Enzymes such as deubiquitylating enzymes (DUBs) and ubiquitin ligases, like phosphatases and kinases, play key roles in the control of<br />
cellular signal transduction pathways. Progenra is committed to discovering and developing high value novel therapeutic medicines based<br />
on ubiquitin and ubiquitin-like protein pathways and has established an early stage product portfolio that addresses major unmet<br />
medical needs in cancer, inflammation, metabolic diseases, pathogen infection, muscle wasting, and neurodegenerative disease.<br />
Progenra's world-class technology, a unique target and drug discovery platform, is being utilized internally and with our partners to<br />
exploit the role of ubiquitin in pathologies with the goal of developing drugs targeting the ubiquitin-proteasome pathway. Progenra has<br />
established collaborations with a number of academic laboratories that are leaders in the ubiquitin field giving us access to the latest<br />
thinking on the ubiquitin-proteasome pathway.<br />
PROPRIETARY TECHNOLOGY<br />
Progenra’s world-class technology, unique targets and drug discovery platform is being utilized to exploit the role of ubquitin ligases and<br />
de-ubiquitylases in pathologies with the goal of developing novel medicines. Our drug discovery platform is complemented by internal<br />
biochemical, biological target validation programs and medicinal chemistry/lead optimization. Please see more at<br />
http://www.progenra.com<br />
CORPORATE ALLIANCES<br />
Progenra has established alliances with the following companies:<br />
Jubilant Chemsys Ltd,<br />
LifeSensors Inc.<br />
Progenra has on-going drug discovery collaborations with pharma and biotech companies, and other corporate collaborations are<br />
underway. . We continue to seek partnerships due to the broad nature of our program. The following institutions use Progenra<br />
compounds to uncover physiological roles of the ubiquitin pathway using cell based or animal model systems:<br />
NIH/NCGC,<br />
Emory University,<br />
Harvard University/Dana Farber Cancer Center,<br />
University of the Sciences in Philadelphia,<br />
University of Pennsylvania, Philadelphia PA,<br />
University of Toronto,<br />
Fox Chase Cancer Center,<br />
Yale University,<br />
University of Oxford, U.K,<br />
UCLA<br />
BIO Business Forum 2011 145 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Progenra has licensed protein production technologies from LifeSensors Inc for its HTS platforms.<br />
World-wide patent rights have been granted to Progenra for its de-ubiquitylase HTS platform. Number of patent applications for ubiquitin<br />
ligase HTS platform as well as de-ubiquitylase are under review or PCT filing.<br />
A PCT application has been filed that describe new classes of chemical entities targeting ubiquitin pathway enzymes for various<br />
therapeutic areas, principally cancer.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
P-5091 Optimized Lead Oncology Leads optimized, animal model<br />
efficacy demonstrated, pre-IND work<br />
ongoing<br />
P-18215 Lead Series Musculoskeletal disease<br />
P-22995 Lead Series Oncology<br />
De-ubiquitylase Drug Discovery<br />
Technology platform<br />
Ubiquitin ligase Drug Discovery<br />
Technology Platform<br />
FINANCING HISTORY<br />
Most Recent Round: C Round<br />
Seed Round: 04/10/2003 (US $0.55 million)<br />
Round A: 11/10/2004 (US $2.75 million)<br />
Investors: Principals (100 %)<br />
SENIOR MANAGEMENT<br />
Target Validated Variety of novel drug targets are being<br />
persued<br />
Target Validated Number of ubiquitin ligases screens<br />
have indentified lead compounds<br />
A number of organizations are using<br />
the platform for drug discovery<br />
A number of organizations are using<br />
the platform for drug discovery<br />
Round B: 10/11/2006 (US $4.56 million)<br />
Round C: 11/12/2008 (US $12.53 million)<br />
Tauseef R Butt Ph.D, President & CEO • Michael R Mattern Ph.D, Chief Operating Officer • Mark Dorfman CPA, Chief Financial Officer •<br />
Marc A Hixson MBA, Business Development • David Counts Ph.D, Business Development • Thomas Argentieri Ph.D, Business<br />
Development • Joseph A Weinstock Ph.D, Director • William Kingsbury Ph.D, Director • Randy Murphy Ph.D, Vice President •<br />
Benjamin Nicholson Ph.D, Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Joseph Weinstock Ph.D, Former Senior Director Med Chem, GSK • William D. Kingsbury Ph.D, Former Director Med Chem, GSK • Wafik<br />
S. El-Deiry MD. Ph.D, Prof of Medicine, Hershey Medical School, Hershey PA • Keith D. Wilkinson Ph.D, Professor of Biochemistry/Asst<br />
Dean, Emory University Medical School, Atlanta GA • Arthur L. Haas Ph.D, Professor and Chair, Biochemistry, LSU Medical School, New<br />
Orleans • Mark Hochstrasser, Prof Molecular Biophysics & Biochemistry, Yale University<br />
BIO Business Forum 2011 146 Participating Company <strong>Profiles</strong>
Dr. Nikolai Schwabe<br />
Chief Executive Officer<br />
4281 Express Lane, Suite L2378<br />
Sarasota, FL 34238<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
ProImmune Limited<br />
Presenting Company<br />
Clinical Foci: Immunology • Biopharmaceuticals • Infectious Disease<br />
www.proimmune.com<br />
Phone: 1-888-505-7765<br />
Incorporated: 1999<br />
Employees: 50<br />
Ownership: Private<br />
Nikolai Schwabe Jeremy Fry Tynetta Fletcher<br />
HIGHLIGHTS<br />
Recent<br />
The REVEAL Immunogenicity System is a comprehensive suite of services that help in the design and selection of biological drug leads at<br />
the preclinical stage, thereby minimizing the risk of adverse drug reactions related to unwanted immunogenicity.<br />
The REVEAL B Cell Epitope Discovery System accelerates the development of biological therapies and our understanding of diseases. It<br />
consists of comprehensive consensus epitope prediction and rapid high throughput linear epitope mapping in vitro.<br />
ProImmune has been formally accepted into the UK GLP compliance monitoring program by the MHRA enabling pharmaceutical and<br />
biotech companies to seamlessly incorporate ProImmune’s GLP compliant services into their pre-clinical and clinical programmes.<br />
CORPORATE MISSION<br />
ProImmune is a leading provider of immunology products and services serving a broad range of customers in industry and academia. We<br />
are committed to helping our customers take their studies to success through innovation, responsive service and focused application<br />
support.<br />
Drawing on over 10 years of expertise in adaptive immunity, our portfolio includes assays for antigen characterization, immunogenicity<br />
risk assessment, and immune monitoring.<br />
For antigen characterization and biomarker discovery, our proprietary technologies enable investigators to accelerate the discovery and<br />
development of new biopharmaceutical drugs in all areas of major unmet medical need, such as cancer, infectious diseases, and<br />
autoimmunity. Used to identify disease state epitopes, ProImmune REVEAL assays can save years of validation work for researchers<br />
seeking useful biomarkers or immunotherapy targets. For lead optimization of vaccine candidates, ProImmune’s integrated epitope<br />
discovery platform and follow-on immune-monitoring assays (all of which can be tailored to customer specifications) are invaluable.<br />
Unwanted immunogenicity to biological components of drugs, consumer products and food ingredients can cause significant<br />
complications including reduced efficacy or allergies. In response to this, ProImmune have developed a suite of assays to enable our<br />
customers to understand the likely immune effects of an agent at an early stage in its development. We offer ultra-sensitive CFSE T cell<br />
proliferation assays, and these can be used in conjunction with our cell-free HLA-peptide binding assays to yield maximum information in<br />
a very short time.<br />
We offer unique immune monitoring solutions for clinical trials and immunology research, including tracking antigen-specific immune<br />
responses with state of the art ELISpot and flow cytometric analysis techniques. We are part of the UK GLP compliance monitoring<br />
program, offering these assays to GLP and GCP conditions.<br />
PROPRIETARY TECHNOLOGY<br />
ProImmune REVEAL Immunogenicity System for identification of CD4+ T cell epitopes: Antigenicity profiling; HLA-peptide binding assays<br />
for 56 class II HLA alleles, including rate assays to characterize epitopes<br />
Highly sensitive CFSE-based T cell proliferation assays for epitope characterization; DC- T cell proliferation assays for whole protein<br />
antigenicity assessment.<br />
ProImmune REVEAL & ProVE® Rapid Epitope Discovery System for identification of CD8+ T cell epitopes.<br />
Linear and Conformational B cell Epitope Discovery: ProArray analysis.<br />
Pro5® Class I MHC Pentamers: For detection of antigen specific CD8+ T cells with high accuracy and avidity – the largest range of<br />
commercial available MHC multimer reagents plus the option to custom-order new peptide/allele combinations.<br />
CORPORATE ALLIANCES<br />
ProImmune has forged business relationships with numerous companies, including many of the world’s top 10 pharma companies,<br />
leading biotech companies and also with world-leading research institutes.<br />
Recently, Merck KGaA used the ProImmune REVEAL & ProVE® Rapid Epitope Discovery System in their immunotherapy programme.<br />
Oxford BioMedica have used ProVE® Pentamers to detect new T cell epitopes following vaccination with the TroVax® cancer vaccine.<br />
Defence Science and Technology Laboratory (DSTL), at Porton Down, UK, used ProImmune’s highly sensitive naïve T cell proliferation assays<br />
as part of their antibody research programme.<br />
SENIOR MANAGEMENT<br />
Dr. Nikolai Schwabe, Chief Executive Officer • Dr. Linda Tan, Chief Operating Officer • Dr. Jeremy Fry, Business Development • Dr.<br />
Marc Wiles, Senior Vice President<br />
BIO Business Forum 2011 147 Participating Company <strong>Profiles</strong>
Abraham (Avri) Havron<br />
Chief Executive Officer<br />
3 Sapir Street<br />
74140 Nes Ziona<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Avri Havron<br />
PROLOR Biotech, Inc<br />
Clinical Foci: Biopharmaceuticals • Hormone Therapy • Hematology<br />
www.prolor-biotech.com<br />
Phone: 972-89-300051<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Interim data of Phase II of hGH-CTP (MOD-4023) in growth<br />
hormone deficient adults indicate potential of single weekly<br />
injection in the 2 tested doses. T1/2 is x10 that of hGH. Interin data<br />
also indicate high safety profile.<br />
PK and clotting efficacy of factor IX-CTP was found to be superior to<br />
commercial FIX in KO mice model.<br />
Excluisive license agreement signed with Yeda the Weizmann<br />
Institute of Science TTO for the reversible pegylation technology.<br />
CORPORATE MISSION<br />
Incorporated: 2005<br />
Employees: 25<br />
Ownership: Public<br />
Market Cap: $280.00 million<br />
NYSE : PBTH<br />
Completion of Phase II in hGH-CTP in growth hormone deficient<br />
adults and regulatory submission in US and EU for approval of<br />
Phase II in growth hormone deficienft children and Phase III in<br />
growth hormone deficient adults<br />
Data from obese mice animal model re efficacy of RevPeg-<br />
Oxyntomodulin and beginning of lpre-clinical studies.<br />
Initiation of Phase II with hGH-CTP (MOD-4023) in growth hormone<br />
deficient children and Phase III in growth hormone deficient adults.<br />
PROLOR Biotech Inc. (NYSE: PBTH) is a clinical stage company developing next-generation, bio-better long acting versions of therapeutic<br />
proteins, peptides and small molecule drugs utilizing two technologies named CTP and Reversible PEGylation. The CTP technology was<br />
exclusively licensed from Washington University. PROLOR’s second longevity enhancing technology named Reversible-PEGylation was<br />
exclusively licensed from the Weizmann Institute of Science in Israel.<br />
CTP is a naturally occurring peptide that extends the durability of a certain hormone in the body. Merck & Co., who licensed the technology<br />
from Washington University just for 4 fertility hormones, received already marketing authorization in Europe for FSH-CTP (ELONVA®). One<br />
weekly injection of Elonva®) replaces 7 daily FSH injections. Prolor's lead product hGH-CTP is currently in Phase II trial. CTP based pipeline<br />
products include long acting blood coagulation factors VIIa and IX and interferon beta-1a. To date the CTP technology was shown to be<br />
effective in prolonging the half-life and maintaining the biological activity of proteins belonging to differnet families such as hormones,<br />
cytokines and enzymes.<br />
Reversible-PEGylation is a chemistry based half-life enhancing technology which enables to develop long-acting versions of small<br />
molecules and peptides. It utilizes a synthetic labile linker between a drug and a longevity enhancing polymer like PEG. After being<br />
injected into the body the drug detaches itself gradually from the polymer in its authentic active form. Proloris uses RevPeg to develop<br />
long acting Oxyntomodulin to treat obesity.<br />
PROLOR’s leadership team includes CEO Abraham Havron, who has extensive experience developing protein therapeutics, including Merck<br />
Serono’s MS drug Rebif, and Chairman and major investor Dr. Phillip Frost, a biopharma entrepreneur and currently Chairman of Teva<br />
PROPRIETARY TECHNOLOGY<br />
CTP is a human peptide that was created by nature during evolution to provide the hormone hCG with the longevity required to sustain<br />
pregnancy. The CTP “cassette” which carries 4 O-glycans can be attached in one or more copies to the ends of the therapeutic protein chain<br />
by means of rDNA techniques. The CTP technology is based on standard industrial biotechnology - mammalian cell culture and protein<br />
purification.<br />
RevPeg is based on a synthetic chemistry and involves a bifunctional hydrolysable linker which bridges between a peptide or small<br />
molecule drug and a PEG chain. Once administered into the body the liker hydrolyses in a controlled manned releasing the intact active<br />
drug and the PEG chain. The pK is controlled by linker’s nature and size of PEG chain.<br />
INTELLECTUAL PROPERTY<br />
PROLOR is the exclusive licensee from Washington University in St. Louis to a series of CTP patents that have been issued by the U.S. Patent<br />
and Trademark Office, including US #5,712,122, US #5,759,818 and US #6,225,449. In addition, PROLOR has been issued its own patents: US<br />
#7,553,940 and US #7,553,941–both composition-of-matter patents of new forms of CTP-modified proteins. Seven pending patent<br />
applications cover additional CTP innovations, including configurations, compositions and methods. Prolor is the exclusive license to a<br />
series of Reversible PEGylation patents issued by the USPTO covering the basic platform<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
MOD-4023 Phase II, IIa, IIb Growth hormone deficiency All end points met following single weekly injection<br />
MOD-5013 Preclinical Hemophilia A & B- Long lasting<br />
FVIIa<br />
Animal model pK supporting 1/w injection in humans<br />
BIO Business Forum 2011 148 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
MOD-3013 Preclinical Hemophilia B-Long lasting FIX Animal model pK supporting 1/w injection in humans<br />
MOD-600 Preclinical Obesity-long lasting OXM Animal model pK supporting 1/w injection in humans<br />
MOD-9012 Preclinical MS- long lasting IFN- Beta Primate data completed supporting 1/w injection<br />
SENIOR MANAGEMENT<br />
Abraham (Avri) Havron, Chief Executive Officer • Shai Novik, President • Eyal Fima, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Philip Frost, The Frost Group • Jane Hsiao, The Frost Group • Steven Rubin, The Frost Group • Marian Gorecki, none • Fuad Fares,<br />
Prolor-Biotech • Shai Novik, Prolor-Biotech • Abrahan (Avri) Havron, Prolor-Biotech<br />
SCIENTIFIC ADVISORY BOARD<br />
Fuad Fares, Haia University • Dan Shochat, Kalobios Inc. • Marian Gorecki, Valin Bio Ltd. • Ron Rosenfeld, Stanford Univ. (Emeritus) •<br />
Christian Strasburger, Humbold Univ. Berlin (Charite)<br />
BIO Business Forum 2011 149 Participating Company <strong>Profiles</strong>
John F. Manzello<br />
President & CEO<br />
369 Lexington Avenue<br />
New York, NY 10017<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
John F. Manzello<br />
HIGHLIGHTS<br />
Recent<br />
Promosome, LLC<br />
Clinical Foci: Biopharmaceuticals • Biology • Other<br />
www.promosome.com<br />
Phone: 1-508-845-2255<br />
Incorporated: 2004<br />
Ownership: Private<br />
December 31, 2010 - Promosome had closed a $4.1 Million Series C Financing Round.<br />
March 31, 2011 - Promosome Licenses the Site Specific Chromosomal Integration (Landing Pad) Technology through their TSRI based<br />
research relationship.<br />
April 1, 2010 - Promosome signs a Technology License and Equity position deal with Recopharma AB of Stockholm.<br />
CORPORATE MISSION<br />
Promosome is a New York City based biotechnology company founded by William J. Gedale and John R. Costantino, to commercialize the<br />
translation initiation based discoveries of Nobel Laureate Dr. Gerald M. Edelman and his colleague Dr. Vincent P. Mauro of The Scripps<br />
Research Institute (TSRI) in La Jolla, California.<br />
Promosome has made considerable commercial in-roads through its current bioproduction applications after launching two significant<br />
translation initiation based technologies. (1.) Translational Enhancing Elements (TEEs) and (2.) Re-Engineering of the mRNA Primary<br />
Sequence (RESCUE) technologies, (3.)Site Specific Chromosomal Integration / Landing Pad technology, All three technologies are available<br />
for license through Promosome in the biopharmaceutical realm, the industrial bioproduction realm and for use in conjunction with the<br />
development of DNA vaccines.<br />
Through the use of its unparalleled understanding of mRNA translation Promosome will follow on these successes with a pipeline of other<br />
significant bioproduction based solutions in 2011.<br />
Promosome has established a Research Funding and Option Agreement (RFO) with TSRI and the laboratories of Dr.'s Edelman and Mauro<br />
that will continue to fill Promosome's commercial application pipeline. Promosome has already taken a world-wide exclusive license for<br />
the TEEs and RESCUE and Landing Pad.<br />
PROPRIETARY TECHNOLOGY<br />
Translation Enhancing Elements (TEEs), in for mammalian manufacturing platforms.<br />
Re-Engineering of the mRNA Primary Sequence (RESCUE) for all prokaryotic and eukaryotic manufacturing platforms.<br />
Site Specific Chromosomal Integration / Landing Pad for mammalian cell lines.<br />
CORPORATE ALLIANCES<br />
Lonza, Recopharma AB, BioProcess Technology Consultants<br />
INTELLECTUAL PROPERTY<br />
All proprietary technologies and associated IP reside with The Scripps Research Institute of La Jolla, CA. Promosome has exclusive<br />
Worldwide rights with the rights to sublicense.<br />
FINANCING HISTORY<br />
Most Recent Round: C Round<br />
Round A: 04/01/2004 (US $1.90 million)<br />
Round B: 10/01/2008 (US $9.60 million)<br />
Round C: 12/01/2010 (US $4.10 million)<br />
SENIOR MANAGEMENT<br />
John F. Manzello, President & CEO • William J. Gedale, Chairman<br />
BOARD OF DIRECTORS<br />
William J. Gedale, Promosome LLC • John R. Costantino, NGN Capital, NY NY • Susan Borden, Bumper Development, Calgary Alberta<br />
Canada • James T. Jahnke, Palisade Captital Management, Ft. Lee NJ • John F. Manzello, Promosome LLC<br />
BIO Business Forum 2011 150 Participating Company <strong>Profiles</strong>
10 The Courtyard, East Park,<br />
Crawley<br />
RH10 6AG<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Peter Cozens, Managing Partner<br />
HIGHLIGHTS<br />
Recent<br />
ProPharma Partners Ltd<br />
www.propharmapartners.biz<br />
Phone: 44-1293-425 300<br />
Incorporated: 2000<br />
Employees: 10<br />
Ownership: Private<br />
Recent deals: Alfresa Pharmaceuticals and Biovail (Valeant): Esperance Pharmaceuticals and Teva: Biodelivery Sciences with Kunwha and<br />
TTY Biopharm: Besins Healthcare and Bayer<br />
CORPORATE MISSION<br />
ProPharma Partners, with offices in London, San Francisco and Tokyo provide extensive business development and strategic advisory<br />
expertise at the local, regional and/or global level in the major pharmaceutical markets of Japan & Asia, Europe and North America.<br />
ProPharma Partners have an extensive record of successfully providing a range of services which include: · Product and technology<br />
inlicensing/ outlicensing and acquisitions · Strategic business and product development consulting · Business and product due diligence<br />
and valuation modeling · A team of individuals with expertise in preclinical, pharmacokinetics, CMC, clinical and regulatory affairs to<br />
assist in defining and implementing drug development plans.<br />
PROPRIETARY TECHNOLOGY<br />
ProPharma Partners provides biotechnology and pharmaceutical clients with a range of business and product development services<br />
including: global product and patent licensing; strategic planning; corporate partnering; patent strategy and management; pre-clinical<br />
planning and implementation; clinical development; regulatory strategy; due diligence and technology assessment.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Nocturel Phase I Panic disorders, depression Partnering out<br />
Colostrinin (Cognisure) On Market Nutraceutical for cognitive deficit Partnering out<br />
SurgeDose Preclinical Quick onset formulation Partnering out<br />
Prothyx Preclinical Stable, latent, targeted delivery system Partnering out<br />
Once weekly aripiprazole Phase II, IIa, IIb Schizophrenia and related disorders Partnering out<br />
TRK560 Phase II, IIa, IIb Multiple sclerosis Partnering out<br />
Antibacterial and antiinflammatory<br />
products<br />
Preclinical antibacterial and anti-inflammatory with<br />
novel MOA<br />
Partnering in<br />
Autism biodiagnostic Diagnostics Autism Partnering out<br />
BIO Business Forum 2011 151 Participating Company <strong>Profiles</strong>
Peter Traber, MD<br />
Chief Executive Officer<br />
7 Wells Avenue<br />
Newton, MA 02459<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Theodore D. Zucconi, PhD<br />
Pro-Pharmaceuticals, Inc<br />
Clinical Foci: Oncology • Drug Development • Vaccines<br />
www.galectintherapeutics.com<br />
Phone: 1-617-559-0033<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
March 31, 2011, the company had $6.9 million of unrestricted cash and<br />
cash equivalents available to fund future operations. Subsequently the<br />
company received $600k for the exercise of common stock warrants.<br />
Dr. Scott Friedman at the Mount Sinai School of Medicine is conducting<br />
advanced pre-clinical trials on our galectin therapeutic compounds to<br />
treat liver fibrosis. Our compounds have reversed liver fibrosis and<br />
cirrhosis in pre-clinical studies.<br />
Pro-Pharmaceuticals changes name to Galectin Therapeutics to better<br />
reflect the company technology and direction.<br />
Incorporated: 2002<br />
Employees: 8<br />
Ownership: Public<br />
Market Cap: $94.00 million<br />
OTC BB: PRWP<br />
The Ludwig Institute for Cancer Research in Brussels will<br />
initiate a Phase I/II trial using our galectin targeting<br />
compounds in administration with their cancer vaccines in<br />
QIII, 2011.<br />
Potential approval to market GM-CT-01 in Colombia in QI,<br />
2012.<br />
Potential submission of IND for human trials for liver<br />
fibrosis/cirrhosis in Q1, 2011.<br />
CORPORATE MISSION<br />
Galectin Therapeutics, OTC: PRWP, the leader in the field of galectin blocker therapeutics, is developing promising carbohydrate-based<br />
therapies for fibrotic liver disease and cancer based on the company’s unique understanding of galectin proteins, key mediators of<br />
biologic functions. We are leveraging extensive scientific and development expertise, as well as, established relationships with external<br />
sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and<br />
commercialization for our lead compounds in liver fibrosis and cancer. We have an advanced program to gain approval in Colombia and<br />
Latin America for our lead oncology drug. Additional information is available at www.GalectinTherapeutics.com<br />
PROPRIETARY TECHNOLOGY<br />
Galectins are indicated in many inflamatory diseases. We have the only galectin blockers in human trials. Our drugs are based on<br />
carbohydrate technology so they have little potential toxicity.<br />
CORPORATE ALLIANCES<br />
Ludwig Institute for Oncology in Brussels Belgium for galcetin blockers to enhance cancer vaccines.<br />
Procaps SA, for distribution of oncology products in Latin America.<br />
Center for Liver Disease at Mt. Sinai in New York City for fibrosis and cirrhosis therapies.<br />
INTELLECTUAL PROPERTY<br />
We have U.S. and international patents for composition of matter, oncology use, and fibrosis use. Drugs for other indications are in the<br />
pipeline.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
GM-CT-01 (DAVANAT®) Phase III CRC FDA approved Phase III<br />
development program<br />
GM-CT-01 (DAVANAT®) Phase I Cancer vaccines, metastatic<br />
melanoma<br />
GM-CT-01 (DAVANAT®) NDA/BLA filed, or in process Oncology for CRC in Colombia<br />
and Latin America<br />
initiate Phase I/II in Europe in<br />
Q3 2011<br />
Approval in Colombia QI 2012<br />
GR-MD-01 Preclinical fibrosis/cirrhosis submit IND QI, 2012<br />
SENIOR MANAGEMENT<br />
Peter Traber, MD, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Jim Czirr<br />
SCIENTIFIC ADVISORY BOARD<br />
Gil Omenn, University of Mich • Scott Friedman, Mt Siani, New York<br />
BIO Business Forum 2011 152 Participating Company <strong>Profiles</strong>
Hans Schikan<br />
Chief Executive Officer<br />
J.H. Oortweg 21<br />
2333 CH Leiden<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Isabel Ferreira, Business Development Manager<br />
Prosensa Therapeutics<br />
Clinical Foci: Genetic Disorders • CNS • PGH – Neglected Diseases<br />
www.prosensa.com<br />
Phone: 31-71-3322103<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
PRO051/GSK2402968 entered pivotal Phase III study in 18<br />
countries, recruiting 180 patients in up to 35 centres.<br />
Landmark publication of Phase I/II systemic study with<br />
PRO051/GSK2402968 in NEJM.<br />
Stronlgy encouraging 48 weeks efficacy data from open-label<br />
extension with PRO051/GSK2402968 presented at AAN.<br />
Incorporated: 2002<br />
Employees: 80<br />
Ownership: Private<br />
Results from Phase I/II study PRO044, Prosensa's secound DMD<br />
compound in clincal development targeting a different<br />
subpopulation of patients.<br />
Two additional DMD compounds directed at two more DMD<br />
subpopulations to enter clinical studies in 2012.<br />
72-weeks data from open-label extension study<br />
PRO051/GSK2402968 to be presented.<br />
CORPORATE MISSION<br />
Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA<br />
modulating therapeutics correcting gene expression. The company targets genetic disorders with a large unmet medical need, with a<br />
primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy<br />
(DM1) and Huntington's Disease (HD). Prosensa focuses on rare diseases and is committed to make a difference for patients and families.<br />
The company has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. The company’s primary focus is on<br />
developing a treatment for Duchenne Muscular Dystrophy. In 2009 Prosensa entered into a strategic alliance for part of its DMD exon<br />
skipping program with GSK. Prosensa’s lead compound (GSK2402968/PRO051), being developed by GSK, aims at restoring dystrophin<br />
expression and improving muscle condition and function in a relatively large subpopulation of Duchenne patients and entered phase III<br />
clinical trials in January 2011.<br />
Prosensa was founded in 2002 and is located in Leiden, The Netherlands. The company works closely together with Leiden University<br />
Medical Center (LUMC) and is supported by a consortium of leading biotech investors, including Abingworth, Life Sciences Partners, GIMV,<br />
AGF and MedSciences Capital. In October 2009, Prosensa entered into a strategic alliance with GlaxoSmithKline (GSK) to accelerate and<br />
broaden the development of its DMD product candidates.<br />
PROPRIETARY TECHNOLOGY<br />
RNA-modulating therapeutics provide a powerful tool for targeted modulation of gene expression. Prosensa’s unique proprietary<br />
technology platform employs single-stranded RNA-based antisense oligonucleotides (AONs) to correct mutated mRNA causing life<br />
threatening disorders.<br />
Prosensa's technological approach applies some of the most advanced techniques known in modern genetics and molecular biology: RNA<br />
modulation through exon-skipping, exon inclusion, mutant RNA removal or other prorietary applications.<br />
CORPORATE ALLIANCES<br />
GSK: Prosensa and GSK entered in an exclusive worldwide collaboration for the development and commercialization of RNA based<br />
therapeutics for Duchenne Muscular Dystorphy. The scope of the alliance includes four RNA-based products intended to treat specific, but<br />
different, subpopulations of patients suffering from DMD. The financial terms include a GBP 16 million (USD 25 million) upfront payment<br />
and up to GBP 412 million (USD 655 million) in milestones payments as well as double-digit royalties on product sales. Prosensa will retain<br />
commercial participatory rights, and has an option to expand its commercial rights, in certain European countries on products resulting<br />
from the collaboration.<br />
INTELLECTUAL PROPERTY<br />
Prosensa has an active IP strategy, whereby it carefully protects its interests. The company has ensured a good level of IP protection for its<br />
lead products in DMD in both Europe and the US with both issued claims in Europe (DMD exon claims) and the US (composition of matter<br />
PRO051/GSK2402968) and pending claims in both Europe and the US.<br />
In addition, Prosensa has developed or licensed a broad set of patent families covering pipeline products and discovery projects. This<br />
position will further be strengthened by an active in-licensing strategy through its strong academic network.<br />
SENIOR MANAGEMENT<br />
Hans Schikan, Chief Executive Officer • Luc Dochez, Chief Business Officer • Berndt Modig, Chief Financial Officer • Giles Campion,<br />
Chief Medical Officer<br />
BIO Business Forum 2011 153 Participating Company <strong>Profiles</strong>
Peter Allen<br />
Chief Executive Officer<br />
Galabank Business Park<br />
Galashiels Selkirkshire<br />
TD1 1QH<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Wayne Bowler<br />
Thomas Stratford, PhD<br />
ProStrakan Group plc<br />
Clinical Foci: Oncology • Specialty Pharmaceutical • Hematology<br />
www.prostrakan.com<br />
Phone: 44-1896-664 000<br />
Employees: 342<br />
Ownership: Public<br />
Market Cap: $472.00 million<br />
HIGHLIGHTS<br />
Recent<br />
ProStrakan has recently become a wholly-owned subsidiary of Kyowa Hakko Kirin Co. Ltd a Tokyo-headquartered specialty pharmaceutical<br />
business whose shares are traded on the Tokyo Stock Exchange (TSE: 4151).<br />
CORPORATE MISSION<br />
ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of<br />
prescription medicines for the treatment of unmet therapeutic needs in major markets.<br />
ProStrakan is a wholly-owned subsidiary of Kyowa Hakko Kirin Co. Ltd a Tokyo-headquartered specialty pharmaceutical business whose<br />
shares are traded on the Tokyo Stock Exchange (TSE: 4151).<br />
ProStrakan's head office is located in Galashiels in Scotland. The company’s development capabilities are centered in Galashiels and<br />
Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK,<br />
US, France, Germany, Spain, Italy and other EU countries.<br />
CORPORATE ALLIANCES<br />
ProStrakan operates many alliances with both Licensors (including Orexo, Strathmann, IFC Cantabria & Helm) and Licensees (including<br />
Endo Pharmaceuticals, Paladin Labs Inc, Gedeon Richter, Er Kim, Pharmaswiss, LG Life & Solasia)<br />
PRODUCTS<br />
Name Phase Indication<br />
Abstral On Market Breakthrough cancer pain<br />
Sancuso On Market Chemotherapy-induced nausea & vomiting<br />
Fortesta On Market Testosterone replacement therapy<br />
Cellegesic NDA/BLA filed, or in process Pain associated with chronic anal fissures<br />
SENIOR MANAGEMENT<br />
Peter Allen, Chief Executive Officer • Dr Tom Stratford, Business Development • Allan Watson, Chief Financial Officer<br />
BIO Business Forum 2011 154 Participating Company <strong>Profiles</strong>
Dr Jason Slingsby MBA<br />
Chief Executive Officer<br />
Impulszentrum Graz-West<br />
A-8020 Graz<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Jason Slingsby, CEO<br />
Martin Nicholson , PHD, Director, Business Development<br />
Protaffin Biotechnologie Ag<br />
Clinical Foci: Pulmonary • AutoImmune • Oncology<br />
www.protaffin.com<br />
Phone: 43-316-382541<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Initiation of manufacturing of lead compound PA401 for clinical<br />
development<br />
ProtAffin AG granted patent in EU for CellJammer® discovery<br />
technology<br />
ProtAffin AG announces compelling preclinical data in COPD for<br />
lead product PA401<br />
Incorporated: 2005<br />
Employees: 25<br />
Ownership: Private<br />
Start of registrational tox studies for PA401 in Q3 2011<br />
Appointment of new members to Supervisory Board and<br />
Management Board<br />
Initiation of first clinical trial for lead compound, PA401 in COPD, in<br />
Q2 2012<br />
CORPORATE MISSION<br />
ProtAffin is developing a novel class of next generation biologics which target glycans driving disease processes in inflammation and<br />
oncology. Using our CellJammer® discovery technology, we have developed a pipeline of anti-inflammatory decoy proteins which work by<br />
inhibiting infiltration of white blood cells in chronic and acute inflammatory diseases. PA401 is our lead product and is a modified form of<br />
human IL-8. PA401 is in pre-clinical development for COPD. Composition of Matter patents for PA401 have been granted in the USA and<br />
EU. PA401 was granted Orphan Drug designation for an acute inflammatory indication in the US and EU in 2008. ProtAffin is well funded<br />
by a strong syndicate of leading US and European VC's: Aescap, Atlas Venture, Entrepreneur's Fund, SR One (GSK's venture fund) and Z-<br />
Cube.<br />
PROPRIETARY TECHNOLOGY<br />
Using our CellJammer® discovery technology, we have developed a pipeline of anti-inflammatory decoy proteins which work by inhibiting<br />
infiltration of white blood cells in acute and chronic inflammatory diseases. PA401 is our lead product and is a modified form of human IL-<br />
8. PA401 is in pre-clinical development for neutrophilic chronic lung inflammation in COPD. ProtAffin's second product is PA508, a<br />
mutant form of chemokine MCP-1, and is in preclinical research for MS and cardiovascular/metabolic indications.<br />
PRODUCTS<br />
Name Phase Indication<br />
PA401 Preclinical Chronic Obstructive Pulmonary Disease<br />
PA508 (MCP-1 decoy) Preclinical Multiple Sclerosis, CVM indications, Diabetes<br />
SDF1alpha decoy program Preclinical Oncology, autoimmune disorders<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round A: 12/11/2007 (US $6.00 million)<br />
Round B: 04/27/2009 (US $20.00 million)<br />
SENIOR MANAGEMENT<br />
Dr Jason Slingsby MBA, Chief Executive Officer • Prof Andreas Kungl, Chief Scientific Officer • Dr Martin Nicholson, Business<br />
Development<br />
BOARD OF DIRECTORS<br />
Kreske Nickelsen, Aescap Venture Management • Dr Bruce Booth, Atlas Venture • Dr Maciek Drozdz, The Entrepreneurs Fund • Dr<br />
Deborah Harland, SR One • Dr Simon Moroney, CEO, Morphosys AG (Independent Director)<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof John Gallagher, University of Manchester • Prof Robert Huber FRS, ex-Head Max Planck Institute of Biochemistry • Dr Barrett<br />
Rollins, CSO Dana-Faber Cancer Institute, Boston • Dr Antal Rot, Group Leader, Novartis Institute of Biomedical Research • Dr Robert<br />
Linhardt, Rensselaer Institute, Albany • Dr Tim Wells, ex SVP R&D Serono • Prof Tim Williams, Imperial College, London<br />
BIO Business Forum 2011 155 Participating Company <strong>Profiles</strong>
Dr. Stefan Müllner<br />
Chief Executive Officer<br />
Otto-Hahn-Str 15<br />
44227 Dortmund<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Stefan Muellner<br />
Protagen AG<br />
Clinical Foci: Diagnostics • Biopharmaceuticals • Informatics<br />
www.protagen.de<br />
Phone: 49-231-97426300<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Q3/2010 Protagen closed a financing round with a new investor and a total<br />
volume of € 10 mio<br />
Q1-2/2011 Protagen AG has entered into two multi-centre studies to validate<br />
their lead development programs in Multiple Sclerosis and Prostate Cancer with<br />
renowned clinical institutions (up to 1000 patients/disease indication).<br />
Q1/2011 Protagen AG successfully closed cooperation agreement with Biogen<br />
Idec Inc. to identify predictive and response biomarkers associated with multiple<br />
sclerosis (MS) therapy using the UNIarray® Platform.<br />
Incorporated: 1997<br />
Employees: 47<br />
Ownership: Private<br />
Closing of strategic cooperations with biotech and big<br />
pharma in autoimmune and oncology indicactions<br />
for the development of autoantibody signature based<br />
patient stratification tools.<br />
Expand the protein services business, e.g. GMP<br />
compliant comparability studies on biosimilars, in<br />
Asia and the pacific rim.<br />
Transfer of autoantigen marker panels on market<br />
suitable multiplex platforms.<br />
CORPORATE MISSION<br />
Protagen AG is a leading provider of solutions in protein science. With a highly experienced and motivated team Protagen AG provides<br />
products and GMP compliant services of outstanding quality.<br />
Protagen AG has developed the patent protected UNIarray® technology platform for the development of novel diagnostics based on<br />
indication specific autoantibody patterns in patient sera. These indication specific autoantibody patterns were already proven to be<br />
present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals.<br />
Therefore, the systematic and indication-specific determination of autoantibody patterns will serve as a unique basis to address hitherto<br />
unmet diagnostic needs.<br />
In addition, UNIarray® allows the targeted development of product specific companion diagnostics and patient stratification for clinical<br />
studies.<br />
Protagen in-house R&D programs are presently focused on Prostate-, Colon-, Breast-, Ovarian-, Pancreas Cancer, Multiple Sclerosis,<br />
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, SLE, Morbus Parkinson, and Alzheimer’s.<br />
PROPRIETARY TECHNOLOGY<br />
The patented platform of protein expression libraries UNIclone® is one of the technology innovations of Protagen AG. This highly efficient<br />
technology platform allows Protagen AG the development of a new class of diagnostics based on autoantibody signatures in blood.<br />
CORPORATE ALLIANCES<br />
Commercial Partners:<br />
•Bayer Schering Pharma AG<br />
•Biogen Idec Inc.<br />
•Biogenes GmbH<br />
•Mikrogen GmbH<br />
•Zelle Biotechnology<br />
•TS DYNE Co.<br />
Clinical Research Network:<br />
•10 centres in Germany (Univ. of Mainz, Univ of Bochum, Clinique Lüdenscheid, Univ. of Düsseldorf, Univ. of Duisburg-Essen, Univ of<br />
Applied Sciences in Gelsenkirchen and Bonn-Rhein-Sieg St. Augustin, TU Munich, European Tumor Sample Institute GmbH,<br />
Blutspendedienst des Bayrischen Roten Kreuzes GmbH)<br />
•2 centres in USA (Johns Hopkins Medical School and Accelerated Cure Project for Multiple Sclerosis)<br />
•3 centres in Austria (Medical University of Innsbruck, Medical University of Graz, Medical University of Vienna)<br />
•1 centre in Netherlands (VU University Medical Center)<br />
•1 centre in Sweden (Karolinska H<br />
INTELLECTUAL PROPERTY<br />
Granted patents on UNIclone® technology; patents filed for diagnostic markers in Prostate-, Colon-, Breast-, Ovarian-, Pancreas Cancer,<br />
Multiple Sclerosis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, SLE, Morbus Parkinson, and Alzheimer’s;patents filed for protein<br />
microarray technology.<br />
BIO Business Forum 2011 156 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
UNIarray Diagnostics Prostate Cancer Biopsy Survaillance Dx<br />
UNIarray Diagnostics Multiple Sclerosis Disease Verification Dx<br />
UNIarray On Market Patient Stratification by Autoantibody<br />
Signatures in Serum<br />
UNIarray On Market Indication independent biomarker discovery<br />
UNIchip On Market Antibody Specificity Analysis and PK prediction<br />
UNIarray On Market Platform for Vaccine Developments<br />
Protein Services On Market GMP compliant protein characterization,<br />
comparability of Biosimilars<br />
Protein Services On Market Proteome studies for biomarker discovery<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Seed Round: 10/01/2004 (US $1.50 million)<br />
Round A: 03/01/2006 (US $3.00 million)<br />
Round B: 12/31/2008 (US $7.00 million)<br />
Round C: 08/01/2009 (US $)<br />
Investors: MIG Fonds (50 %) • S-Venture Capital GmbH (5 %) • S-Capital Dortmund GmbH (5 %) • KfW (10 %) •<br />
NRW Bank (10 %)<br />
SENIOR MANAGEMENT<br />
Dr. Stefan Müllner, Chief Executive Officer • Dr. Peter Schulz-Knappe, Executive Vice President • Martin Blüggel, Executive Vice<br />
President<br />
BOARD OF DIRECTORS<br />
Prof. Dr. Axel Kleemann • Dr. Thomas Schweins, Qiagen AG • Prof. Dr. Theo Dingermann, Johann Wolfgang Goethe University<br />
Frankfurt/M. • Gerhard Steinkamp, Stadtsparkasse Dortmund • Dr. Aristotelis Nastos, NRW Bank • Michael Motschman, MIG AG<br />
BIO Business Forum 2011 157 Participating Company <strong>Profiles</strong>
Dinesh V. Patel<br />
President & CEO<br />
1300 Seaport Blvd<br />
Redwood City, CA 94063<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Mark Smythe, PhD, Founder & Head of Research Alliances<br />
Dinesh V. Patel, PhD, President & CEO<br />
Protagonist Therapeutics, Inc<br />
Clinical Foci: Drug Discovery • Drug Development<br />
www.protagonist-inc.com<br />
Phone: 1-317-489-0289<br />
Incorporated: 2006<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Technology validating collaboration Additional strategic partnership on ion channel and GPCR platform<br />
Additional funding to support broader applications of DRP platform and to fund<br />
activities aimed at discovering & developing well differentiated NCEs against targets<br />
and diseases that are not adequately served by small molecules or biologics.<br />
CORPORATE MISSION<br />
Protagonist Therapeutics is a peptide & peptidomimetic therapeutics company pursuing the discovery and development of DISULFIDE<br />
RICH PEPTIDES (DRPs) as new chemical entities (NCEs) against those Targets for which;<br />
1) Small molecules (SMs) or antibodies (Abs) do not offer a good product and<br />
2) well differentiated and superior ‘alternatives to antibodies’.<br />
The company is currently applying its technology platform against a family of ION CHANNEL and GPCR targets.<br />
Protagonist has successfully applied its DRP technology platform to the discovery and preclinical development of injectable and orally<br />
stable cytokine peptide antagonists. Novel de novo hits (50 uM) were identified and converted into viable leads (10 nM) over a period of 9<br />
months, and IND candidate selection is expected in the next 12 months. These NCEs will be well differentiated from and have significant<br />
advantages (delivery, tissue distribution, lack of immunogenicity, daily clearance, lower COGS, novel IP etc.) over conventional antibody<br />
based products.<br />
Protagonist is headquartered in Redwood City, CA, USA and has discovery research operations in Brisbane, AU and R&D operations in USA.<br />
Over the next 3-5 years, the company intends to excel as a peptide therapeutics company with; 1) a validated DRPs technology platform<br />
against multiple target classes (eg ion channels, GPCRs and cytokines), 2) lucrative collaborations with good earn outs and 3) Well<br />
differentiated NCEs in different stages of IND/Ph2POC development.<br />
PROPRIETARY TECHNOLOGY<br />
Disulfide Rich Peptides (DRPs) have evolved characteristics (stability, affinity and specificity) to overcome limitations that have plagued the<br />
development of peptide-based drugs. DRPs can be engineered to combine the beneficial features of biologics and small molecule drugs<br />
into the one entity. They are a validated class of drugs (oral and injectables) and have large target scope (GPCRs, ion channels and<br />
cytokines). Protagonist’s technology involves a deep understanding of selection and manipulation of DRPs. DRP scaffolds for the target of<br />
interest are selected from thousands of DRPs. By integrating drug design and diversity oriented tools, phage display and medicinal<br />
chemistry, the company identifies hits against targets of interest and turns them into development worthy NCEs.<br />
CORPORATE ALLIANCES<br />
In early 2011, Protagonist established a technology validating collaboration with Ironwood Pharmaceuticals to discover novel peptides<br />
against clinically validated targets in therapeutic areas with significant unmet medical needs. In late 2011, the company will seek new<br />
collaboration and funding as it expands the scope of the DRP platform to develop better and well differentiated NCEs.<br />
INTELLECTUAL PROPERTY<br />
Protagonist has broad patent coverage for its proprietary technology platform. The company files patents covering novel disulfide rich<br />
peptides for targets of interest.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Ion channel platform Research pain Improve in vivo efficacy, yet maintain exquisite<br />
specificity and affinity<br />
GPCR platform Research metabolic Hit discovery<br />
Protein-protein interaction<br />
(cytokine) platform<br />
Preclinical inflammation and cancer IND candidate selection<br />
BIO Business Forum 2011 158 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 01/20/2009 (US $9.00 million)<br />
Investors: Lilly Ventures, USA (30 %) • Startfish Ventures, Australia (30 %) • QBF, Australia (30 %)<br />
SENIOR MANAGEMENT<br />
Dinesh V. Patel, President & CEO • Mark Smythe, Chief Business Officer • Craig Murphy, Chief Scientific Officer • Ashok Bhandari, Vice<br />
President • Gregory Bourne, Vice President • Tran Trung Tran, Vice President • Rick Fallahee, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Dinesh V. Patel, President & CEO, Protagonist • Kathy Nielsen, Investment Manager, Queensland BioCapital Fund • Nicholas Peace,<br />
Investment Director, Starfish Ventures • Armen Shanafelt, Venture Partner, Lilly Ventures • Harold E. "Barry" Selick, CEO, Threshold<br />
Pharmaceuticals<br />
SCIENTIFIC ADVISORY BOARD<br />
Charles Craik, Professor, UCSF • Edward Roberts, Professor, Scripps Research Institute • Mike Gresser, Formerly VP of Inflammation,<br />
Amgen • Scott Plevy, Assoc, Professor of Medicine, Uni of North Carolina • Heather Webb, Director of Drug Safety, Calistoga<br />
Pharmaceuticals • Mark Gallop, Formerly of Xenoport and Affymax<br />
BIO Business Forum 2011 159 Participating Company <strong>Profiles</strong>
Dr. David Aviezer PhD, MBA<br />
President & CEO<br />
2 Snunit St. Science Park,POB: 455<br />
20100 Carmiel<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Sandra Lauterbach<br />
Elisha Nathan, Business Development Leader<br />
Protalix Biotherapeutics Inc.<br />
Clinical Foci: Biopharmaceuticals • Genetic Disorders • Generics<br />
www.protalix.com<br />
Phone: 972-523-561265<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Protalix reported positive Phase III results from the company's trial<br />
of taliglucerase alfa for the treatment of Gaucher disease. The trial<br />
met its primary endpoint, demonstrating a 38% spleen reduction<br />
for the 60U/kg dose at 9 months (p
INTELLECTUAL PROPERTY<br />
9 patent families, including -<br />
---Cell & tissue culturing device<br />
---System and method<br />
---Large scale bioreactor system<br />
---Expression of lysosomal enzymes in plant cells<br />
---Delivery of proteins through oral administration<br />
---Expression of antibodies in plant cells<br />
--- Expression of FSH variant protein in plant cells.<br />
The Protalix patent estate consists of over 100 patents and patent applications. These patents aim to cover wide aspects of technology,<br />
products and platform improvements and enables the development and potential commercialization of therapeutically equivalent or<br />
superior recombinant proteins.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Taligluserase alfa NDA/BLA filed, or in process Gaucher's disease partnered with pfizer, awaiting FDA<br />
approal<br />
PRX-105 is a plant cell expressed<br />
recombinant human<br />
Acetylcholinestrase (AChE)<br />
PRX-102 is a plant cell expressed<br />
recombinant alphagalactosidase<br />
enzyme<br />
PRX-106 is a plant cell expressed<br />
recombinant form of anti-TNF<br />
Fusion protein<br />
PRX-112 - Oral delivery of<br />
Glucocerebrosidase<br />
Phase I Bio-Defense Additional Phase I and preclinical safety<br />
studies<br />
Preclinical Fabry Disease Expected to begin Phase 1/2 during<br />
2011<br />
Preclinical Rheumatoid Arthritis,<br />
other autoimmume<br />
disease<br />
Hold pre-IND meeting with FDA<br />
Preclinical Gaucher's disease Phase I planned to initiate in the near<br />
future<br />
SENIOR MANAGEMENT<br />
Dr. David Aviezer PhD, MBA, President & CEO • Dr. Yoseph Shaaltiel, PhD, Research and Development, Executive Vice President • Dr.<br />
Einat Brill Almon, PhD - Product Development, Senior Vice President • Yossi Maimon CPA, Chief Financial Officer • Sandra Lauterbach<br />
- Sales and Commercial Operations, Vice President • Tzvi Palash, M.Sc., B.Sc., Chief Operating Officer • Yaron Naos, B.Sc., MBA -<br />
Production, Vice President • Moshe Chechik, B.Sc., MBA -Engineering, Vice President • Michal Kahana, DVM - Quality Affairs, Vice<br />
President • Dafna Shelly, M.Sc., MBA -HR, Vice President<br />
BOARD OF DIRECTORS<br />
Zeev Bronfeld, Interim Chairman, CEO Biocell Ltd. • David Aviezer, PhD, MBA., CEO and President, Protalix Biotherapeutics • Yoseph<br />
Shaaltiel, PhD, EVP, R&D, Protalix Biotherapeutics • Afred Akirov, CEO and Chairman of the Board, Alrov Group • Eyal Sheratzky, CEO,<br />
Ituran Location & Control • Roger D. Kornberg, Ph.D (nobel Prize laureate), Winzer Professor of Medicine in the Department of<br />
Structural Biology at Stanford University, • Amos Bar Shalev, Director, Technorov Portfolio<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Aharon Ciechanover, Laureate, Nobel Prize in Chemistry; DIstinguished Research Professor at Rappaport Research Institute, •<br />
Professor Gad Galili, Head of the Department of Plant Sciences at the Weizmann Institute of Science in Rehovot, Israel • Professor Ari<br />
Zimran, Associate Professor of Medicine, Hebrew University; Director of Gaucher Clinic, Shaare Zedek Medical Center<br />
BIO Business Forum 2011 161 Participating Company <strong>Profiles</strong>
Ram Sesha<br />
Chief Executive Officer<br />
116, Village Boulevard Suite 200<br />
Princeton, NJ 8540<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ram Sesha, Chief Executive Officer<br />
CORPORATE MISSION<br />
Protect Pharmaceutical Corporation<br />
Presenting Company<br />
Clinical Foci: CNS • Drug Discovery • Drug Delivery<br />
Phone: 1-609-945-1198 Ownership: Public<br />
Market Cap: $45.00 million<br />
OTC BB: PRTT<br />
Protect Pharmaceutical Corporation (OTCBB: PRTT, www.protectpharm.com) is a Princeton, NJ based drug discovery and early stage<br />
development company that focuses on using an innovative bioprecursor platform for discovering novel drugs for unmet needs.<br />
The company’s business model is to identify and advance novel drug candidates till Phase II clinical program, and then seek a licensing<br />
partner. The company’s core capabilities are in identifying opportunities, designing newer drug candidates, outsourcing development<br />
affordably, accumulating safety/ preliminary efficacy data and building valuable intellectual properties.<br />
PROPRIETARY TECHNOLOGY<br />
The Bioactive platform is an unique in-silico assaying platform used for identifying lead candidates from thousands of new chemical<br />
designs. The platform uses an algorithm developed by feeding bioactivity and functional group relationship from thousands of known<br />
compounds. The platform then uses a pre-selected level of biological response (For Example- Receptor Binding) to screen a large number of<br />
NCEs. The biological response of the investigative compound can be compared with a reference (approved) drug to determine the key<br />
pharmacological characteristics (release pharmacokinetics and quantification of target properties) that correlate with therapeutic efficacy<br />
or safety<br />
CORPORATE ALLIANCES<br />
The company recently licensed/sold two of its patents to Grunenthal GmBH, Aachen Germany. The patents were related novel drugs for<br />
neuropathic pain and fibromyalgia.<br />
INTELLECTUAL PROPERTY<br />
The company has filed a number of patent applications to protect these portfolios of NCEs. All the drug candidates are novel and are<br />
eligible for 20 years patent protection. In addition, upon approval, the drug candidates are eligible for 5 years and 10 years of new<br />
molecular/data exclusivity from FDA and EMEA.<br />
PRODUCTS<br />
Name Phase Indication<br />
PRTT-200 Preclinical Neuropathic Pain<br />
PRTT-300 Preclinical Severe to Moderate pain<br />
PRTT-100 Preclinical Acute and Chronic pain<br />
PRTT-400 Preclinical Acute and Chronic pain<br />
PRTT-500 Preclinical Depression<br />
PRTT-600 Preclinical Depression<br />
SENIOR MANAGEMENT<br />
Ram Sesha, Chief Executive Officer • Keith Elison, Chief Financial Officer • Senthil Sundaram, Other<br />
BOARD OF DIRECTORS<br />
Ram Sesha, Chairman & Chief Executive Officer • Dr Robert Royds, Founder & Chairman of Theradex In (www.theradex.com)<br />
BIO Business Forum 2011 162 Participating Company <strong>Profiles</strong>
Josh Levine<br />
Chief Executive Officer<br />
2 Holzman st.<br />
76124 Rehovot<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Josh M. Levine<br />
Avishai Levy<br />
Proteologics LTD.<br />
Clinical Foci: Drug Discovery • Oncology • Metabolic Disease<br />
www.proteologics.com<br />
Phone: 972-8-9475666<br />
Ownership: Public<br />
Market Cap: $15.00 million<br />
CORPORATE MISSION<br />
Proteologics Ltd. (TASE “PRTL”) is an Ubiquitin Translation company – transforming world-class knowledge of the ubiquitin system into the<br />
development of novel therapeutics. Dr. Avram Hershko and Dr. Aaron Ciechanover – 2004 Nobel Prize laureates for the discovery of the<br />
ubiquitin system – lead the company’s scientific advisory board. Proteologics’ scientific excellence is supported by a unique target and<br />
drug discovery platform, which implements state of the art technologies for the generation of a sustainable pipeline of small molecules.<br />
In March 2010, Proteologics became a public company upon completing a successful IPO on Tel Aviv Stock Exchange (TASE). Investors<br />
include GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Aurum Ventures MKI, Giza Venture Fund, The Challenge Fund, and<br />
Concord Ventures.<br />
PROPRIETARY TECHNOLOGY<br />
Proteologics unites a team of passionate scientists, Nobel laureates and business leaders bringing together their collective experiences in<br />
UPS-based drug discovery. Proteologics' technology platform integrates powerful capabilities in Target Validation, Lead Discovery and<br />
Lead Optimization. During the target identification stage, Proteologics utilizes its unique in depth knowledge and vast accumulated<br />
experience in researching the UPS, using sophisticated bioinformatics and “wet lab” tools. Validated targets then proceed to the Lead<br />
Discovery stage, where a battery of cell-free ubiquitination assays and robotic platform are used to conduct high throughput screening of<br />
potent small molecules.<br />
CORPORATE ALLIANCES<br />
Glaxo Smith Kline (GSK) - six drug discovery programs, and<br />
Teva Pharmaceutical industries - three drug discovery programs<br />
INTELLECTUAL PROPERTY<br />
Leading know-how in drug discovery in the ubiquitin system<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
cancer lead Lead Series Oncology Lead generation<br />
Novel drug discovery from<br />
research to Candidate<br />
Novel drug discovery from<br />
research to Candidate<br />
Novel drug discovery from<br />
research to Candidate<br />
anti inflammatory and anti<br />
metastatic compound<br />
SENIOR MANAGEMENT<br />
Research metabolic disorders<br />
Research Neurodegenerative disorders<br />
Research Oncology<br />
Optimized Lead inflammation and metastatic<br />
cancers<br />
Josh Levine, Chief Executive Officer • Avishai Levy, Business Development<br />
SCIENTIFIC ADVISORY BOARD<br />
Aaron Ciechanover, Nobel Laureate 2004, Technion • Avram Hershko, Nobel Laureate 2004, Technion • Jonathan Schapiro, Stanford<br />
BIO Business Forum 2011 163 Participating Company <strong>Profiles</strong><br />
PRTL
P. Victor Schut<br />
Chief Business Officer<br />
Niels Bohrweg 11-13<br />
2333CA Leiden<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
P. Victor Schut<br />
Raymond MD Verhaert, PhD<br />
HIGHLIGHTS<br />
Recent<br />
Frost & Sullivan 2010 Technology Innovation Award<br />
ProteoNic BV<br />
Clinical Foci: Biopharmaceuticals • Generics • Industrial Biotech<br />
www.proteonic.nl<br />
Phone: 31-71-5231951<br />
Incorporated: 2004<br />
Employees: 20<br />
Ownership: Private<br />
CORPORATE MISSION<br />
ProteoNic, the 2010 Frost & Sullivan Technology Innovation Award winner, offers specialized products and services for improving<br />
recombinant protein expression. Its proprietary UNic technology is used to enhance the translation of messenger RNA (mRNA) resulting<br />
in more protein per mRNA. This leads to significantly higher yields and greater manufacturing flexibility with lower production costs. The<br />
company has successfully developed its own platform-specific Translation Enhancement Elements UNic-MTee and UNic-YTee,<br />
specifically for recombinant protein production in mammalian and yeast host systems. We use these elements in commercial expression<br />
vectors without changing strain generation processes. The result: yield enhancement factors up to 10-fold and significant cost savings.<br />
ProteoNic licenses its UNic technology and offers services that include construct design, cloning, cell line and strain generation as well as<br />
scale up process development.<br />
PROPRIETARY TECHNOLOGY<br />
The UNic expression technology toolbox offers molecular biology services for production strain engineering and includes production<br />
platform specific Translation Enhancement Elements (TEEs). Implementation of these TEEs lead to a more efficient use of mRNA and<br />
consequently more protein per mRNA. The technology is complementary to other yield enhancing approaches.<br />
CORPORATE ALLIANCES<br />
Clients and partners. Including, but not limited to:<br />
Novozymes-<br />
Oryzon Genomics-<br />
Genencor-<br />
Oxford Expression Technologies-<br />
Wageningen UR -<br />
TNO-<br />
Fraunhofer IME -<br />
Maastricht University-<br />
INTELLECTUAL PROPERTY<br />
IP portfolio of granted patents and several applications covering expression enhancement in all industry relevant production hosts<br />
PRODUCTS<br />
Name Phase Indication<br />
UNic-MTee On Market Mammalian host systems<br />
UNic-YTee On Market Yeast host systems<br />
UNic-FTee On Market Fungal host systems<br />
UNic-PTee On Market Plant host systems<br />
SENIOR MANAGEMENT<br />
P. Victor Schut, Chief Business Officer • Dr. Raymond Verhaert, Chief Scientific Officer<br />
BIO Business Forum 2011 164 Participating Company <strong>Profiles</strong>
Les Docks 10.5 - 10, place de la Joliette<br />
13002 Marseille<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Matthieu Vis, Business Development Manager<br />
CORPORATE MISSION<br />
Provence Promotion<br />
Clinical Foci: Medical Device • Infectious Disease • Immunology<br />
www.investinprovence.com<br />
Phone: 33-4-96116025<br />
Ownership: Other<br />
Provence Promotion is the Official Inward Investment agency of Marseille-Provence area, south of France.<br />
Created by the Marseille-Provence Chamber of Commerce & Industry and the County Council, we assist free of charge companies relocate<br />
and/or develop their activities in our Mediterranean region, which has become a strategic destination for biotech and medtech<br />
companies.<br />
Provence hosts worldwide known laboratories like the Luminy Immunology centre CIML, the University Hospital Institute (IHU) in<br />
infectious diseases, or the Oncology Research Institute of Paoli-Calmettes Hospital.<br />
Our region comprises one of the most concentrated networks of hospital with important drug development activities, the largest<br />
university in France and leading firms such as Innate Pharma, Ipsogen, Supersonic Imagine, Beckman Coulter, Provepharm, Trophos…<br />
Eurobiomed, the Mediterranean biocluster, where world class research and leading innovation are conducted in infectious and emerging<br />
pathologies, immunology, rare and orphan diseases, medical devices, and neurological diseases, is also headquartered in Marseille-<br />
Provence.<br />
Provence Promotion will accompany you throughout your project:<br />
• Help with relocating: general economic information, current legislation…<br />
• Financial engineering: assistance in applying for grants and financing, financial round-tables,<br />
• Refer you to commercial, industrial or scientific partners,<br />
• HR engineering: assistance in recruiting personnel,<br />
• Real Estate engineering: assistance in finding real estate solutions,<br />
• Mobility: assistance to newly transferred employees.<br />
The Provence Partnership is your unique partner for building and growing a business in Provence while making the most of everything the<br />
region has to offer.<br />
We are ISO 9001:2000 certified.<br />
CORPORATE ALLIANCES<br />
International collaborations in California - USA, New Jersey - USA, Hyderabad - India, Haifa - Israel, Singapore...<br />
BIO Business Forum 2011 165 Participating Company <strong>Profiles</strong>
Gary L. Olson, PhD<br />
President & CEO<br />
9 Deer Park Drive<br />
Monmouth Junction, NJ 08852<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gary L. Olson, PhD, President & CEO<br />
Provid Pharmaceuticals, Inc<br />
Clinical Foci: Drug Discovery • AutoImmune • Drug Development<br />
www.providpharma.com<br />
Phone: 1-732-565-1101<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Provid's has delivered novel leads and drug candidates for biotech,<br />
academic, and pharma customers, evidenced by multiple patent<br />
applications assigned to clients. Since 2005, 8 drug candidates<br />
have been discovered and transitioned into development.<br />
PV-267, Provid's drug candidate for MS has shown promising<br />
activity in human cells from a DR2+ MS patient as an antagonist.<br />
The compound is also active in vivo in EAE models in DR2<br />
transgenic mice in prevention and treatment modes.<br />
Provid has expanded its team to bring together a uniquely skilled<br />
team of experts with outstanding success in transforming<br />
promising molecules into drugs. Newly appointed are Drs.<br />
Wolfgang Oster and Martin Stogniew.<br />
Incorporated: 2001<br />
Employees: 15<br />
Ownership: Private<br />
Completion of IND-enabling studies of PV-267 and define clinical<br />
plan for phase I biomarker study of DR2 inhibition.<br />
Grants funding a peptide mimetics program in cardiovascular<br />
disease and a small molecule infectious disease program are<br />
expected to generate new leads in these therapeutic areas. Both<br />
are collaborations with academic groups.<br />
Expansion of Provid services in drug discovery and extending scope<br />
into drug development.<br />
CORPORATE MISSION<br />
Provid Pharmaceuticals Inc. provides expert drug discovery capabilities for clients in the life sciences, coupled with internal R&D in<br />
autoimmune diseases and oncology, including PV-267, Provid's novel DR2 inhibitor for MS. Provid delivers comprehensive drug discovery<br />
and development support to clients with a unique focus on invention and value creation.<br />
Our team also has high level expertise in program management, due diligence and aspects of drug development. In drug discovery<br />
programs, Provid combines intellectual investigation with hypothesis-driven drug discovery, including in-house expert medicinal<br />
chemistry and the creation of novel intellectual property. The Provid team collaborates with clients to integrate and synergize aspects of<br />
drug discovery and development, saving time and ensuring a smooth transition through each stage, from target…to hit…to lead…to drug.<br />
We have collaborated and supported programs with the full spectrum of research organizations, from groups still within academia, to<br />
disease foundations, biotech start-ups, small-, and mid-sized pharma, all the way to top 10 Pharma companies and government<br />
laboratories. In each case, we recognize that every organization brings unique capabilities and must work within different sets of<br />
regulatory, financial, and practical constraints to deliver against its mission.<br />
PROPRIETARY TECHNOLOGY<br />
Provid has outstanding capabilities and core competencies in medicinal chemistry, organic synthesis, structure-based drug design, hit-tolead<br />
translation and lead optimization. Provid is a known as a world leader in peptide chemistry and peptide mimetics technology, an<br />
approach pioneered by Provid’s founders to create novel, proprietary drug compounds starting from information derived from peptides.<br />
Several client collaborations have been based on this expertise, including lead discovery programs in inflammation, Huntington’s disease,<br />
infectious disease, brain trauma, ophthalmology and cardiovascular disease. Provid's internal pipeline in autoimmune disease<br />
therapeutics is based on peptide mimetics technology.<br />
INTELLECTUAL PROPERTY<br />
Issued US patents for autoimmune disease therapeutic compounds. Compounds for other proprietary targets in oncology and for third<br />
party discoveries are protected by worldwide patent filings.<br />
PRODUCTS<br />
Name Phase Indication<br />
PV-267 Preclinical Multiple Sclerosis<br />
PV-1019 series of CHK2 kinase inhibitors Optimized Lead Oncology<br />
Other Autoimmune targets Research Celiac and Type 1 Diabetes<br />
Rheumatoid Arthritis Research DR1 and DR4-mediated RA<br />
SENIOR MANAGEMENT<br />
Gary L. Olson, PhD, President & CEO • Edwin J. Thomas, Chief Financial Officer • Christopher R. Self, Vice President • Richard H.<br />
Christie, Vice President<br />
BIO Business Forum 2011 166 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
A. Wayne Tamarelli, PhD, AWT Private Investments • Bryan Wood, Alta Berkeley • Gary L. Olson, PhD, Provid Pharmaceuticals • Edwin<br />
J. Thomas, Provid Pharmaceuticals • Martin Stogniew, PhD • Wolfgang Oster, MD PhD, PolyTechnos Venture-Partners • Christopher<br />
R. Self, PhD, Provid Pharmaceuticals<br />
SCIENTIFIC ADVISORY BOARD<br />
Lawrence Steinman, MD, Stanford University • Amos B. Smith, III PhD (chair), University of Pennsylvania • Warren Strittmatter, MD,<br />
Duke University School of Medicine • Jeffery Kelly, PhD, Scripps Research Institute • Thomas Forsthuber, MD PhD (immunology<br />
collaborator), University of Texas San Antonio • Suhayl Dhib-Jalbut, MD (clinical consultant), UMDNJ • Ann F. Welton, PhD (drug<br />
development consultant)<br />
BIO Business Forum 2011 167 Participating Company <strong>Profiles</strong>
Dr John Beadle<br />
Chief Executive Officer<br />
PO Box 10972<br />
Essex<br />
CM12 2BS<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
John Beadle, Chief Executive Officer<br />
Psioxus Therapeutics, Ltd.<br />
Clinical Foci: Oncology • Musculoskeletal • Vaccines<br />
www.psioxus.com<br />
Phone: 44-1277-829 859<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Merger of Myotec Therapeutics and Hybrid Biosystems to form<br />
Psioxus in December 2010<br />
Initiation of Phase II clinical study with MT-102 in cancer cachexia<br />
in March 2011.<br />
CORPORATE MISSION<br />
Incorporated: 2006<br />
Employees: 12<br />
Ownership: Private<br />
Phase II data from MT-102 cachexia program in 2012<br />
Initiation of Phase I/II program with ColoAd1 in 2012<br />
Psioxus Therpaeutics Ltd., is a private Oxford, UK development stage biotechnology company developing novel therapeutics in the field of<br />
Cancer. Our lead program, MT-102, is a Catabolic Anabolic Transforming Agent (ACTA) in phase II clinical development for cancer cachexia.<br />
Our second development program, ColoAd1, is a systemically delivered oncolytic virus. ColoAd1 will enter phase I/II clinical development in<br />
2012. PolyMAP and PolySTAR are our two research stage vaccine platforms.<br />
PROPRIETARY TECHNOLOGY<br />
MT-102:<br />
Phase II for Cachexia and Sarcopenia. Anabolic Catabolic Transforming Agent (ACTA). Multicenter international double blind placebo<br />
controlled randomised phase II data available in 2012. Aim to partner in 2012.<br />
ColoAd1:<br />
Phase I/II systemically available oncolytic virus with high levels of potency and selectivity. Suitable for a wide range of cancers with lead<br />
programs in metastatic colorectal and hepatocellular carcinoma.<br />
PolySTAR:<br />
A polymer coated stealthed viral vaccine vector system. Available for partnership on a field by field basis.<br />
PolyMAP:<br />
A potent polymerised TLR vaccine adjuvant platform. Available for partnership on a field by field basis.<br />
CORPORATE ALLIANCES<br />
Seeking alliances and partnerships at this meeting<br />
INTELLECTUAL PROPERTY<br />
MT-102 : Granted and pending patents internationally<br />
ColoAd1 : Granted and pending patents internationally<br />
PolySTAR : Granted and pending patents internationally<br />
PolyMAP : Pending patents internationally<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
MT-102 Phase II, IIa, IIb Cachexia and Sarcopenia Data in 2012<br />
ColoAd1 Phase I Oncolytic virus for metastatic colorectal<br />
and hepatocellular carcinom<br />
PolySTAR Research A stealthed viral vaccine vector platform<br />
PolyMAP Optimized Lead A potent polymerised TLR vaccine adjuvant<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 12/13/2010 (US $10.50 million)<br />
Investors: Imperial Innovations (40 %) • Invesco Perpetual (28 %) • Mercia Seed Fund (10 %)<br />
Phase I initiation in 2012<br />
BIO Business Forum 2011 168 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Dr John Beadle, Chief Executive Officer • Theo Harold, Chief Financial Officer • Kerry Fisher, Chief Scientific Officer • Priya Mande,<br />
Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Michael Moore, Chairman • Maina Bahman, Imperial Innovations • Mark Payton, Mercia Seed Fund • Phil L'Huillier, Cancer Research<br />
UK • Charles Swingland, Independant NED<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Stefan Anker, Charite Medical School, Berlin, Germany • Professor Len Seymour, University of Oxford, UK • Professor<br />
Andrew Coats, University of East Anglia, UK • Dr Kerry Fisher, University of Oxford, UK<br />
BIO Business Forum 2011 169 Participating Company <strong>Profiles</strong>
Richard E. Chipkin, PhD<br />
President & CEO<br />
20451 Seneca Meadows Parkway<br />
Germantown, MD 20876<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Richard E. Chipkin, PhD<br />
Psyadon Pharmaceuticals, Inc<br />
Clinical Foci: CNS • Neurology • Drug Development<br />
www.psyadonrx.com<br />
Phone: 1-301-919-2020<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion of Phase 1 safety and tolerability study in adult,<br />
adolescent and pediatric Lesch-Nyhan patients, and receipt of<br />
orphan drug status<br />
Initiation of Phase 2 trial in Tourette Syndrome, and receipt of<br />
orphan drug status<br />
Initiation of Phase 2 trial in Compulsive Gambling<br />
Incorporated: 2008<br />
Employees: 15<br />
Ownership: Private<br />
Initiation of Phase 3 trial in Lesch-Nyhan Disease<br />
Completion of Phase 2 trial in Tourette Syndrome<br />
Completion of Phase 2 trial in Compulsive Gambling<br />
CORPORATE MISSION<br />
Psyadon Pharmaceuticals, Inc. is a privately-held pharmaceutical company that develops drugs for the treatment of diseases afflicting the<br />
central nervous system. Our strategy is to license mechanism-specific drugs whose primary indication has not been identified, and to do<br />
targeted development programs to bring them to market. In particular, we focus on rare and orphan diseases.<br />
Psyadon Pharmaceuticals was founded in 2008 and is based in Germantown, Maryland. It receives financial support from New Enterprise<br />
Associates (Chevy Chase, MD) whose partner Dr. James Barrett acts as the Chairman of Psyadon’s Board of Directors. For more information<br />
visit our website at www.psyadonrx.com.<br />
PROPRIETARY TECHNOLOGY<br />
Our first licensed compound is ecopipam. This is a novel drug that selectively antagonizes the one of the receptors for dopamine in the<br />
brain (the D1-receptor). Ecopiam has a very large clinical safety database and a complete NDA-ready pre-clinical package.<br />
CORPORATE ALLIANCES<br />
We currently have an alliance with the Tourette Syndrome Association who is collaborating with us on the development of ecopipam for<br />
the treatment of Tourette Syndrome.<br />
INTELLECTUAL PROPERTY<br />
Psyadon Pharmaceuticals has exclusive worldwide rightst to ecopipam.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Ecopipam Phase III Treatment of Self-Injurious Behaviors in<br />
Lesch-Nyhan Patients<br />
Initiation of Phase III in 2011<br />
Ecopipam Phase II, IIa, IIb Tourette Syndrome Completion of Phase 2 in 2011<br />
Ecopipam Phase II, IIa, IIb Compulsive Gambling Completion of Phase 2 in 2011<br />
Ecopipam Phase I Novel Formulation Completion of Phase 1 in 2011<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 10/01/2008 (US $8,000,000.00 million)<br />
Investors: New Enterprise Associates (100 %)<br />
SENIOR MANAGEMENT<br />
Richard E. Chipkin, PhD, President & CEO • Rudolf Kwan, MD, Other • David Christ, PhD, Other • Richard Solero, Other<br />
BOARD OF DIRECTORS<br />
James Barrett, PhD, New Enterprise Associates • Jeff Rothstein, MD, Johns Hopkins Medical School<br />
BIO Business Forum 2011 170 Participating Company <strong>Profiles</strong>
Emer Leahy, PhD, MBA<br />
Chief Executive Officer<br />
765 Old Saw Mill River Road<br />
Tarrytown, NY 10591-6715<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Bavani Shankar<br />
CORPORATE MISSION<br />
PsychoGenics, Inc<br />
Clinical Foci: CNS • Neurology<br />
www.psychogenics.com<br />
Phone: 1-914-593-0640<br />
Incorporated: 1999<br />
Employees: 140<br />
Ownership: Private<br />
PsychoGenics Inc. (PGI) has pioneered the translation of rodent behavioral activity into robust, high content drug discovery platforms that<br />
have led to partnerships with major pharma companies. Using its platforms PGI screens tens of thousands of compounds for in vivo CNS<br />
activity. PGI’s technologies are being applied to discover treatments for psychiatric, cognitive, movement and neurodegenerative<br />
disorders, and pain. PGI is creating a broad pipeline of novel compounds from its internal programs. Of note in the pipeline are the<br />
following:<br />
PGI’s most advanced compound Eltoprazine recently completed a phase 2 clinical trial of adult ADHD where it showed clinically and<br />
statistically significant improvement in the overall ADHD rating score and on the subscales of inattention and hyperactivity/impulsivity.<br />
The company expects to initiate a clinical trial of Eltoprazine in L-Dopa induced dyskinesia in Parkinson’s patients in 3Q10 supported by<br />
the MJFF based on preclinical rodent and primate data and a Cognition Impairment Associated with Schizophrenia trial in 2011 supported<br />
by the NIH. This compound is wholly-owned by PGI with partnering discussions ongoing.<br />
PGI’s proprietary drug discovery technologies have identified novel nicotinic compounds with antidepressant (incl. effects in treatmentresistant<br />
depression models), anxiolytic, analgesic and antipsychotic profiles. These compounds have different pharmacological profiles to<br />
existing nicotinic ligands. Patents have been filed and compounds from these series are undergoing IND-enabling studies. In a third<br />
program, through use of its in vivo screening technologies, PGI has identified highly potent Adenosine A1/A2 receptor antagonists with<br />
activity in a model of Parknison’s Disease for which patents have been filed. All three programs are available for licensing.<br />
PGI has established a profitable service business and relationships with more than 100 companies worldwide which supports PGI’s<br />
ongoing operations.<br />
PROPRIETARY TECHNOLOGY<br />
PsychoGenics’ proprietary discovery platforms combine behavioral neurobiology insight integrated with high-tech robotics, computer<br />
vision (video capture and analysis) and the power of bioinformatics to process and analyze massive temporal datasets using probability<br />
causal inference algorithms. PsychoGenics competitive advantage in this area is sustainable through a combination of well crafted<br />
patents and carefully guarded trade secrets.<br />
The technologies offer numerous distinct advantages over current behavioral assessment:<br />
High throughput - can screen tens of thousands of compounds for CNS activity;<br />
High content – thousands of features are collected;<br />
Unbiased – eliminate human involvement.<br />
CORPORATE ALLIANCES<br />
PsychoGenics partners include AstraZeneca, Speracor/Sunovion, Dainippon Sumitomo Pharma, Eli Lilly, Roche and with others in<br />
discussion.<br />
INTELLECTUAL PROPERTY<br />
Eltoprazine – patents issued for ADHD; pending for Parkinson’s disease and specifically for L-dopa induced dyskinesia, pending for<br />
cognitive impairment associated with neurological and psychiatric disorders.<br />
Nicotinics ligands – composition of matter patent filed<br />
Adenosine ligands – composition of matter filed<br />
PRODUCTS<br />
Name Phase Indication<br />
Eltoprazine Phase II, IIa, IIb ADHD<br />
Eltoprazine Phase II, IIa, IIb L-dopa induced dyskinesia associated with Parkinson's<br />
Eltoprazine Phase II, IIa, IIb CIAS<br />
nicotinic ligand Optimized Lead Depression/pain<br />
Adenosine A1/A2 ligand Optimized Lead Parkinson's and depression<br />
SENIOR MANAGEMENT<br />
Emer Leahy, PhD, MBA, Chief Executive Officer • David Lowe, PhD, Chief Scientific Officer • Bill Fasnacht, Chief Financial Officer •<br />
Bavani Shankar, Vice President<br />
BOARD OF DIRECTORS<br />
Henry Jarecki, MD, Chairman<br />
BIO Business Forum 2011 171 Participating Company <strong>Profiles</strong>
Leo Linbeck<br />
President<br />
3900 Essex Lane, Suite #250<br />
Houston, TX 77027<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Brenton Scott, Chief Operating Officer<br />
Pulmotect, Inc.<br />
Presenting Company<br />
Clinical Foci: Infectious Disease • Pulmonary • Biodefense<br />
www.pulmotect.com<br />
Phone: 1-713-579-9226<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Significant peer-reviewed grant funding to date (SBIR, UO1, etc)<br />
Completion of lead product (PUL-042) optimization and<br />
formulation<br />
Commenced PUL-042 tox studies for IND<br />
Ownership: Private<br />
Commence PUL-042 Phase I in 2012<br />
Rapid follow-on of PUL-042 Phase II in leukemia patients<br />
Follow-on indications further pursued<br />
CORPORATE MISSION<br />
Pulmotect has developed a proprietary inhaled agent, PUL-042, that stimulates the lungs’ innate immune system upon contact and<br />
provides immediate protection against a broad range of viral, bacterial, and fungal pathogens, ranging from influenza to anthrax. With<br />
more than five years in development by leading researchers at M. D. Anderson and Texas A&M, PUL-042 will dramatically benefit millions<br />
of individuals annually who are exposed to, and suffer from, airborne contracted viruses and bacterial infections. Importantly,<br />
Pulmotect's innovative inhaled product represents a radical departure from competing technologies by providing a safer and more<br />
practical approach to address this market opportunity.<br />
Pulmotect has identified a substantial market opportunity for its product, which includes three market segments: 1) prevention of<br />
pneumonia in leukemia patients, a leading cause of their death worldwide and a multibillion dollar market segment; 2) prevention and<br />
early treatment of influenza, including pandemic risks, such as the recent H1N1 scare, a $1+ billion market segment; and 3) protection<br />
against a range of bioterror agents, such as anthrax, also a $1+ billion market opportunity. Pulmotect’s initial point of entry will be the<br />
high risk leukemia market ($500 million), offering a solution that will prevent respiratory infections for those receiving chemotherapy,<br />
where today 30-40% contract pneumonia, and nearly half of those die. This market opportunity is significant, as evidenced by Amgen’s<br />
blockbuster Neupogen, which generates $4+ billion annually, and only partially addresses the problem. Pulmotect's solution provides<br />
nearly complete protection.<br />
PROPRIETARY TECHNOLOGY<br />
PUL-042 is composed of synthetic TLR ligands. It is administered locally to the lungs, avoiding the need to generate a systemic host<br />
response. It has been developed as a joint effort between leading researchers at M. D. Anderson and Texas A&M. More than $5 million in<br />
seed funding and grant awards have funded the development of the initial product and the execution of initial studies to validate the<br />
safety and efficacy against multiple pathogens in in vitro and in vivo models. The company is currently executing IND-enabling studies<br />
that have been presented to the FDA in Pre-IND discussions.<br />
CORPORATE ALLIANCES<br />
M. D. Anderson Cancer Center;<br />
Texas A&M;<br />
Baylor College of Medicine;<br />
U. T. Medical Branch, Galveston;<br />
AlphaDev, LLC;<br />
Sage Group, Inc<br />
INTELLECTUAL PROPERTY<br />
Provisional application filed. Extensive Freedom-to-Operate and patentability analysis<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PUL-042 Preclinical Prevent pneumonia in<br />
immunocompromised leukemia patients<br />
Favorably pre-IND meeting completed -<br />
Phase I 2012<br />
PUL-042 Preclinical Influenza (e.g. Pandemic) Follow-on indication; animal data in<br />
hand<br />
PUL-042 Preclinical Biodefense (e.g. Anthrax) Follow-on indication; US<br />
contracts/grants applied for; animal<br />
data in hand<br />
BIO Business Forum 2011 172 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
PUL-042 Preclinical Asthma Follow-on indication, animal data in<br />
hand<br />
SENIOR MANAGEMENT<br />
Leo Linbeck, President • Brenton Scott, PhD, Chief Operating Officer • Gordon Ramseier, Business Development<br />
BOARD OF DIRECTORS<br />
Leo Linbeck, Aquinas Corp/AlphaDev, LLC • Magnus Hook, PhD, Texas A&M • Mark Worscheh, Aquinas Corp/AlphaDev, LLC<br />
SCIENTIFIC ADVISORY BOARD<br />
Burton Dickey, MD, M. D. Anderson Cancer Center • Magnus Hook, PhD, Texas A&M • Scott Evans, MD, M. D. Anderson Cancer Center<br />
• Michael Tuvim, PhD, M. D. Anderson Cancer Center<br />
BIO Business Forum 2011 173 Participating Company <strong>Profiles</strong>
One Stamford Forum<br />
Stamford, CT 06901-3431<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Purdue Pharma, LP<br />
Clinical Foci: CNS • Specialty Pharmaceutical • Gastroenterology<br />
www.purduepharma.com<br />
Phone: 1-203-588-8000<br />
James J. Dolan<br />
Ann Kraft<br />
Allen Downs, Sr. Exec. Director, Licensing & Business Development<br />
Danny Chen, Director, Business Development (Canada)<br />
Graham Clarke, Manager, Business Development (Canada)<br />
Christian M Darland, Manager, Licensing & Business Development<br />
CORPORATE MISSION<br />
Incorporated: 1952<br />
Employees: 1600<br />
Ownership: Private<br />
Purdue Pharma L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on<br />
meeting the needs of healthcare providers and the patients in their care.<br />
Together with its independent associated companies, Purdue has long been known for its pioneering research on persistent pain, a<br />
principal cause of human suffering. Purdue has led the battle against inadequate treatment of pain by developing sustained-release<br />
medications to manage pain and provide meaningful benefits for patients. Purdue continues to seek and develop innovative products in<br />
pain management and related gastrointestinal disease areas, and the treatment of sleep disorders.<br />
Purdue also has a growing line of non-prescription products including laxatives and nutraceuticals. The company is dedicated to serving<br />
the evolving needs of healthcare providers, patients, and caregivers with innovative prescription and non-prescription medicines. A<br />
commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to<br />
demonstrating their medical value.<br />
BIO Business Forum 2011 174 Participating Company <strong>Profiles</strong>
Tristan Rousselle<br />
President & CEO<br />
7 Parvis Louis Néel - MINATEC BHT/52B<br />
38000 Grenoble<br />
France<br />
CONFERENCE PARTICIPANTS<br />
CLAIRE UNTEREINER, Chief Business Officer<br />
Laurent SACCUCCI, Project Manager - PX' Cell Therapy<br />
Px'Therapeutics<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Gene/Cell Therapy<br />
www.px-therapeutics.com<br />
Phone: 33-0-438 023 650<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
2011: From human to human: acquisition of technologies enabling us to develop fully<br />
human antibodies and to produce them in human cells.<br />
2010: launching of Promise Advanced Proteomics, subsidiary of PX'Therapeutics offering<br />
a innovative patented technology for the quantification of proteins in biological samples<br />
using mass spectrometry (PSAQ).<br />
2010. Set up of an additional manufacturing unit dedicated to biotherapeutics<br />
production in mammalian cells. The GMP plant allows cell banking as well as<br />
biomanufacturing (up to 200L) for clinical phases as well as for niche markets.<br />
Incorporated: 2000<br />
Employees: 65<br />
Ownership: Private<br />
2011. Set up of a new immunotherapy<br />
division, named PX'Cell Therapy, providing<br />
clients with a range of innovative<br />
pharmaceutical-grade & custom-made<br />
products and services related to cell therapy<br />
including an MHC class I multimers.<br />
CORPORATE MISSION<br />
Located in Grenoble and Lyon (France), PX’Therapeutics provides integrated biotherapeutics and recombinant vaccines development and<br />
manufacturing contract services. Organized around four integrated service platforms (recombinant protein R&D, monoclonal antibody<br />
development, cGMP manufacturing, protein and mAbs analytics), PX’Therapeutics offers custom programmes which may include<br />
depending on clients specifications, murine antibody generation, humanization strategies, fully human antibody development, protein<br />
engineering, process development and/or small scale cGMP manufacturing services. PX’Therapeutics has been extensively involved into<br />
the discovery, development and manufacturing of drug targets and therapeutic proteins with over 800 projects performed over the past<br />
10 years. The company has thus gained substantial experience in the production of challenging proteins and developed trusted<br />
relationships with now more than 160 pharmaceutical, biotech and academic partners (European, Japanese & American). Our specific<br />
organization and the mix of R&D and manufacturing competences of our team ensure added value to customers. Our strengths rely on<br />
1/a scientific expertise associated to the regulatory understanding of biotherapeutic products development; 2/the capability to<br />
accompany our clients from very early stage research and engineering up to clinical batches manufacturing and 3/ the optimization of<br />
timelines for the development of therapeutic candidates due to the synergy between the research and cGMP manufacturing platforms.<br />
PROPRIETARY TECHNOLOGY<br />
Our services are mainly based on extensive know how in terms of recombinant protein/monoclonal antibodies development. We have<br />
recently acquired proprietary technologies to help our customers to get access to human cell lines with high productivity and for the<br />
development of fully human mAbs.<br />
We also make available to our customers some products/technologies developed in-house with applications in cell therapy (cell-sorting<br />
reagents).<br />
SENIOR MANAGEMENT<br />
Tristan Rousselle, President & CEO • Nicolas Mouz, Chief Scientific Officer • Claire Untereiner, Chief Business Officer • David Siegrist,<br />
Chief Financial Officer • Lucile Marron Brignone, Managing Director • Walter Low, Chief Technology Officer • Marie-Gaëlle Roger,<br />
Managing Director<br />
BIO Business Forum 2011 175 Participating Company <strong>Profiles</strong>
Maurice A. Gaubatz<br />
Chief Executive Officer<br />
4720 Forge Road, Suite 108<br />
Colorado Springs, CO 80907<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Maurice A. Gaubatz, President and CEO<br />
HIGHLIGHTS<br />
Recent<br />
Pyxant Labs, Inc<br />
Clinical Foci: Service • Drug Development • Biopharmaceuticals<br />
www.pyxant.com<br />
Phone: 1-719-593-1165<br />
Incorporated: 2000<br />
Employees: 26<br />
Ownership: Private<br />
John Begley joined Pyxant Labs as Operations Director in January 2011. John joins Pyxant Labs following leadership roles at Gilead<br />
Sciences and Triangle Pharmaceuticals.<br />
Added fifth LC/MSMS, API 5000, in April 2011 to support growing business demands.<br />
Dave Robaugh, PhD, presenting at the AAPS National Biotechnology Conference in San Francisco, Tissue Bioanalytical for 20-mer Antisense<br />
Oligonucleotide.<br />
CORPORATE MISSION<br />
Pyxant Labs is a contract research organization specializing in bioanalytical development support.<br />
Service areas include: GLP regulatory bioanalytical for non-clinical and clinical development programs, turnkey (including in-life phase)<br />
non-GLP exploratory PK support, bioanalytical method development and validation, tissue bioanalytical, and biomarkers. Expertise spans<br />
small-molecule, peptides, and large-molecule bioanalytical including for RNA therapeutics.<br />
We are the leading CRO providing bioanalytical services as our sole business. We have provided successful bioanalytical support for more<br />
than 200 FDA studies. Our mission is "Quality Data. On Time."<br />
Our strengths center on developing, tuning, and performing bioanalytical methods at very low limits of quantitation (LOQ) and on<br />
demanding scenarios, such as tissue bioanalytical for RNA therapeutics. We are bioanalytical specialists, with the strongest mass<br />
spectrometry personnel in the industry.<br />
We offer extensive experience and capabilities within the following project areas:<br />
• Picogram-level bioanalytical method development, including • Metabolism and toxicology bioanalytical support<br />
validation and optimization<br />
• Tissue bioanalytical, and other challenging biological matrices<br />
• Bioanalytical for ADME studies<br />
• Bioequivalence support<br />
• Bioanalytical for PK/PD studies<br />
PROPRIETARY TECHNOLOGY<br />
Pyxant Labs specialties include the following technologies:<br />
• Proprietary low-LLOQ bioanalytical methods, including budesonide, scopolamine, capsaicin, methotrexate<br />
• Specialized low-LLOQ bioanalytical methods for endocrine disruptors, including testosterone and estradiols<br />
• Bioanalytical expertise for intracellular assays, including on PBMC<br />
• Tissue bioanalytical, including rare tissues such as monkey fetal development studies<br />
• Concurrent ELISA-hybridization-LC/MSMS techniques, as applicable to early-stage tox investigations for RNA therapeutics<br />
• Specialized iron assays, including drug-bound and physiologic moeities<br />
CORPORATE ALLIANCES<br />
Clinical affiliations with Comprehensive Clinical Development and West Coast Clinical Trials.<br />
Non-clinical affiliations with Southwest Biolabs and Plato Biopharma.<br />
INTELLECTUAL PROPERTY<br />
Seeking to identify and develop biomarker assays in collaboration with drug development companies.<br />
FINANCING HISTORY<br />
Investors: Individual investors (100 %)<br />
SENIOR MANAGEMENT<br />
Maurice A. Gaubatz, Chief Executive Officer • David Robaugh, Vice President • John Begley, Director • Audrey Knobloch, Manager •<br />
Jerrod Langley, Corporate Finance • Brian Graham, Manager • Kimberly Carpenter, Business Development • Shane Karnik, Manager<br />
BOARD OF DIRECTORS<br />
Dean Stull, PhD, CEO NuMe, founding CEO Hauser Laboratories • Mike Carruthers, CFO, Array Biopharma • Ed Wetherbee, Managing<br />
Director, CVM Equity Funds • John Gloriod, President, Gloriod & Associates<br />
BIO Business Forum 2011 176 Participating Company <strong>Profiles</strong>
Ken Powell<br />
Chairman<br />
Oddfellows House<br />
Cardiff Wales<br />
CF24 0AA<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Q-Chip Ltd<br />
Clinical Foci: Oncology • Biopharmaceuticals • Drug Delivery<br />
www.q-chip.com<br />
Phone: 44-29204-0180<br />
Employees: 24<br />
Ownership: Private<br />
Tony Mills, Chief Business Officer Ken Powell, PhD, Chairman Cora Griffin, Business Development Manager<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
On February 23rd 2011, Q Chip announced it has successfully completed<br />
preclinical studies with sustained release formulations of two leading therapeutic<br />
cancer peptides, Q-Leuprolide and Q-Octreotide for prostate cancer and<br />
acromegaly respectively.<br />
On 13 September 2010 , Q Chip announced it has reached the first close £2 million<br />
of a planned £3 million funding round.<br />
Second closing of £1 million of planned £3 million<br />
funding round expected Q2 2011<br />
CORPORATE MISSION<br />
Q Chip is using a novel approach to encapsulate therapeutics in bioresorbable polymer microspheres for injection and sustained drug<br />
release (SR). We avoid the use of harsh solvents, high temperatures and shearing forces and achieve high API loading and microsphere<br />
monodispersity - two of the most desirable features of any encapsulation approach, minimising production cost and enhancing<br />
controllable burst release. We have recently demonstrated successful sustained release over one month of octreotide in a preclinical<br />
model. A small initial burst release was seen, followed by sustained and essentially zero order octreotide release over at least 35 days.<br />
Interestingly, there was no lag phase of octreotide release which might otherwise mandate additional daily injections to achieve<br />
therapeutic dosing.<br />
We have had similar success with one and three month SR formulations of leuprolide and intend to go next to POC in man. Our octreotide<br />
and leuprolide SR formulations are available for licensing.<br />
We use a similar benign approach to therapeutic protein encapsulation and are collaborating with Artes GmbH on the encapsulation of<br />
interferon alpha 2a for SR - targeting an improvement on the weekly shots of pegylated interferon currently taken by hep C sufferers.<br />
PROPRIETARY TECHNOLOGY<br />
Q Chip is developing generic versions of the sustained release (SR) peptide drugs leuprolide and octreotide. Its technology platform Q-<br />
Sphera is based on the use of benign encapsulation and desolvation conditions to create highly monodisperse microspheres of<br />
bioresorbable polymer containing drug. The technology lends itself to the rapid development of novel SR formulations and is adaptable to<br />
the encapsulation of conventional NCEs as well as larger recombinant proteins, including therapeutic antibodies and cells.<br />
CORPORATE ALLIANCES<br />
Q Chip is developing its own pipeline but is willing to partner with companies seeking sustained release formulations. A collaboration<br />
with Artes GmbH on the encapsuation of alpha interferon 2a for the treatment of hepatitis C was recently announced.<br />
INTELLECTUAL PROPERTY<br />
Q Chip is developing a portfolio of patents around its technology platform and novel drug formulations.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Q-Sphera Other A benign drug encapsulation process Transition to dedicated cGMP<br />
facility H2 2011<br />
Q-Leuprolide Preclinical Prostate cancer Initiation of POC in man Q2<br />
2012<br />
Q-Octreotide Preclinical Acromegaly Initiation of Phase I studies<br />
2012<br />
Interferon alpha 2a Preclinical Hepatitis C<br />
SENIOR MANAGEMENT<br />
Ken Powell, Chairman • Ian Smith, Chief Financial Officer • Jo MacPherson, Chief Technology Officer • Tony Mills, Chief Business<br />
Officer • Daniel Palmer, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Ken Powell<br />
BIO Business Forum 2011 177 Participating Company <strong>Profiles</strong>
Susan McGoldrick<br />
Managing Director<br />
Unit 19 Scion House<br />
Stirling<br />
FK9 4NF<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Susan McGoldrick, CEO<br />
Zak Dutton<br />
QCTR Ltd<br />
Clinical Foci: CNS • Neurology • Other<br />
www.qctr.co.uk<br />
Phone: 44-1786-270 403<br />
rship: Private<br />
CORPORATE MISSION<br />
QCTR is a niche CRO specialising in neurology and psychiatry and orphan diseases. We are recognised internationally as experts in<br />
conducting proof of concept, phase II and phase III trials.<br />
The company was established in 2006 to fill the need of providing high quality, clinical research capabilities to companies operating the in<br />
the areas of neurology and psychiatry and orphan diseases. QCTR provides its clients with transparent budgeting, accurate and timely<br />
project information, access to key project personnel, and a practical knowledge of best practice in clinical study design in CNS and orphan<br />
disease areas.<br />
We recently completed the fastest recruiting clinical trial in Huntington’s disease. This was a large, phase III study which enrolled over<br />
430 patients in 12 month at 32 sites in 11 countries across the EU. The study had a completion rate of 92% with 82% in full compliance of<br />
the protocol.<br />
SENIOR MANAGEMENT<br />
Susan McGoldrick, Managing Director • Fiona Duffy, Director • Dr. Crispin Bennett, Director • Zachary Dutton, Vice President • Mark<br />
Sanderson, Director<br />
BIO Business Forum 2011 178 Participating Company <strong>Profiles</strong>
Robert Butchofsky<br />
Chief Executive Officer<br />
887 Great Northern Way<br />
Vancouver, BC V5T 4T5<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Alexander Lussow, PhD, Sr VP Bus Devel & Comm Ops<br />
CORPORATE MISSION<br />
QLT, Inc<br />
Clinical Foci: Ophthalmic<br />
www.qltinc.com<br />
Phone: 1-604-707-7000<br />
Ownership: Public<br />
Market Cap: $300.00 million<br />
NASDAQ: QLTI<br />
QLT is a biotechnology company dedicated to the development and commercialization of innovative therapies for the eye. We are<br />
currently focused on our commercial product, Visudyne®, for the treatment of wet age related macular degeneration (“wet AMD”), and<br />
developing our ophthalmic product candidates.<br />
We have one commercial product, Visudyne, which utilizes light-activated photodynamic therapy (“PDT”) to treat the eye disease known<br />
as wet AMD, the leading cause of blindness in people over the age of 50 in North America and Europe.Visudyne was co-developed by QLT<br />
and Novartis Pharma AG of Switzerland (“Novartis”) and is marketed and sold in over 80 countries worldwide. Total revenue from the sale<br />
of Visudyne for each of the fiscal years ended December 31, 2010, 2009 and 2008 was $44.7 million, $42.1 million and $48.3 million,<br />
respectively.<br />
The majority of our research and development spending for the past three years has been directed towards our proprietary punctal plug<br />
technology, which is a minimally invasive drug delivery system that we are developing with the goal of delivering a variety of drugs<br />
topically to the eye through controlled sustained release to the tear film. We are targeting the treatment of glaucoma and ocular<br />
hypertension and are presently conducting a Phase II study in the latanoprost punctal plug drug delivery program (“L-PPDS”).<br />
We are currently conducting a Phase Ib clinical proof-of-concept study of QLT091001, a synthetic retinoid replacement therapy for 11-cisretinal,<br />
a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (“LCA”) and Retinitis<br />
Pigmentosa (“RP”).<br />
SENIOR MANAGEMENT<br />
Robert Butchofsky, Chief Executive Officer • Cameron Nelson, Chief Financial Officer • Linda Lupini, Senior Vice President • Alexander<br />
R. Lussow, PhD, Senior Vice President<br />
BIO Business Forum 2011 179 Participating Company <strong>Profiles</strong>
Mr Terry Hurst<br />
Chief Executive Officer<br />
PO Box 78<br />
Brisbane, QLD 4029<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Terence Hurst<br />
Nathan Martinez<br />
Q-Pharm Pty Limited<br />
Clinical Foci: Drug Development • Biopharmaceuticals • Vaccines<br />
www.qpharm.com.au<br />
Phone: 61-7-3845 3636<br />
Ownership: Private<br />
CORPORATE MISSION<br />
OVERVIEW:<br />
Q-Pharm is a premier clinical trials provider. We conduct contract clinical research, specialising in phase I and II trials and BE, BA and<br />
Vaccine studies for the international pharmaceutical and biotechnology industries.<br />
THE BENEFITS OF WORKING WITH US:<br />
Save TIME, Save MONEY, and COMFORT in working with and established provider. Here's how:<br />
Save TIME<br />
- Fast clinical trial start-up (only 4-6 weeks from regulatory/ethics submission to commencement of the clinical trial)<br />
- Frequent dates for regulatory/ethics submission (40 meetings per year total - local & commercial committee options,)<br />
- Local IRB: Fixed timelines; In round/live review; Expedited approvals possible; ~10 meetings/yr<br />
- Commercial IRB: 3 submission dates / month (~30 meetings per year); Very rapid turn-around.<br />
Save COSTS<br />
- Time is money – your clinical trials are completed on time and within budget<br />
- Low average cost (very cost competitive compared to U.S. and Western Europe)<br />
COMFORT in working with an established provider<br />
- Excellent working relationship with local HREC (submitted, managed and conducted > 300 studies) and commercial HREC (multiple<br />
submissions approved in single round of review)<br />
- USA (FDA), Europe (AFSSAPS and AEMPS), and South America (ANVISA) inspected<br />
- Data accepted worldwide by regulators<br />
- Safe location (high level of IP protection, low-risk stable destination)<br />
CORPORATE ALLIANCES<br />
TETRAQ: A centre for Integrated Preclinical Drug Development and an accredited provider of comprehensive bioanalytical services.<br />
CLINICAL NETWORK SERVICES: An Australian CRO focused on providing full clinical trial services particularly during early phase<br />
development.<br />
NOVOTECH: A CRO offering a full range of ICH compliant clinical services from first in human through to Phase III trials.<br />
QUEENSLAND CLINICAL TRIALS NETWORK: A primary point of contact for domestic and international organisations seeking to undertake<br />
preclinical and clinical research in Australia.<br />
QUEENSLAND INSTITUTE OF MEDICAL RESEARCH: one of the largest medical research institutes in the southern hemisphere, and recognised<br />
worldwide for the quality of its research into infectious diseases, cancers and other disorders<br />
SENIOR MANAGEMENT<br />
Mr Terry Hurst, Chief Executive Officer • Dr Nathan Martinez, Business Development • Dr Joanna Marjason, Chief Medical Officer • Dr<br />
Suzanne Elliott, Chief Operating Officer • Mr Rob Box, Chief Financial Officer • Dr Wayne Hooper, Consultant<br />
BIO Business Forum 2011 180 Participating Company <strong>Profiles</strong>
Hal Gunn, MD<br />
Chief Executive Officer<br />
887 Great Northern Way, Suite 150<br />
Vancouver, BC V5T 4T5<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Hal Gunn, MD, CEO<br />
Brett A. Premack, PhD, Vice President, Drug Development<br />
Qu Biologics Inc.<br />
Clinical Foci: Oncology • Immunology • Biopharmaceuticals<br />
www.qubiologics.com<br />
Phone: 1-604-734-1450<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Qu Biologics' SSI therapy is associated with an 18-month survival<br />
advantage in late stage colon cancer and a 6-month survival<br />
advantage in late-stage lung cancer. No significant side effects<br />
reported in 950 cancer patients treated to-date.<br />
Animal studies demonstrate novel mechanism of action, with shift<br />
in tumour associated macrophages (TAMs) from pro-cancer M2<br />
macrophage dominance to anti-cancer M1 dominance in targeted<br />
organ. Safety and efficacy confirmed in all tumor models tested.<br />
Broad patent for Site Specific Immunotherapy to be issued in EU.<br />
Broad patent issued in Australia<br />
Incorporated: 2007<br />
Employees: 6<br />
Ownership: Private<br />
Six Phase 2 trials to begin within the next 10 months (lung cancer,<br />
colon cancer, and pancreatic cancer). 3 RCTs (stage 3B/4 lung<br />
cancer, stage 4 colon cancer and pancreatic cancer) with survival<br />
end-point, and 3 MOA studies to assess M2 to M1 shift.<br />
Collaboration underway with Dr. Franco Marincola (NIH), funded<br />
by NCI, to assess the therapeutic effect of SSI therapy on the<br />
tumour microenvironment in both animal studies and human<br />
trials (lung cancer and melanoma), using RNA gene array analysis.<br />
First US patent anticipated Q4 2011, with additional US patents to<br />
follow. Robust international patent protection anticipated.<br />
CORPORATE MISSION<br />
Qu Biologics is a clinical stage biopharmaceutical company pioneering a safe, revolutionary approach to cancer immunotherapy, Site<br />
Specific Immunotherapy (SSI), that engages the body’s innate immune response to cancer. This novel class of cancer immunotherapies<br />
targets immune cells within the specific tissue or organ in which the cancer is growing, reversing the immune suppression that underlies<br />
cancer development and stimulating an anti-cancer immune response.<br />
Unlike most new drugs, Qu Biologics’ proprietary technology was developed in clinical practice, with demonstration of 18-month survival<br />
advantage in late-stage colon cancer (stage 4) and 6-month survival advantage in late-stage lung cancer (stage 3B). Animal studies<br />
confirmed the marked targeted immune stimulation and therapeutic efficacy in all cancer models tested to-date (lung, colon and skin).<br />
SSI therapy shifts tumour associated macrophage (TAM) function from M2 (pro-cancer) macrophage dominance to M1 (anti-cancer)<br />
dominance, relieving immunosuppression and stimulating a broader anti-cancer immune response including NK cells, dendritic cells and<br />
CD8 and CD4 T cells. Over 950 cancer patients have been treated to-date, with no significant side effects reported. Animal studies have<br />
confirmed the inherent safety and efficacy of this approach.<br />
SSI therapy is fully compatible with standard cancer treatments and potentially synergistic with other immunotherapies. With the broad<br />
European patent to be granted and a robust international patent portfolio anticipated, Qu Biologics is poised to become a leader in the<br />
cancer immunotherapy arena. Broadly applicable to a wide range of cancer types and sites, Qu Biologics’ SSIs hold the promise of a future<br />
of cancer treatment and prevention, based not on attacking the tumour, but on correcting the chronic immune suppression that underlies<br />
cancer growth and stimulating the body’s own immune response.<br />
PROPRIETARY TECHNOLOGY<br />
Qu Biologics’ Site Specific Immunotherapies (SSIs), a novel class of cancer immunotherapies, shift tumour associated macrophages (TAMs)<br />
from pro-cancer M2 macrophage dominance to anti-cancer M1 dominance, relieving immunosuppression within the tumour<br />
microenvironment and stimulating an anti-cancer immune response. SSIs recruit M1 macrophages to the organ/tissue in which the<br />
cancer is growing, shifting macrophage dominance to the anti-cancer M1 role, inducing a broader marked targeted anti-cancer immune<br />
response, including NK cells, dendritic cells and CD4 and CD8 Tcells. As TAM function is highly correlated with prognosis (M2 correlated<br />
with poor prognosis, M1 correlated with good prognosis), SSIs provide a safe proprietary approach to this leading edge anti-cancer MOA.<br />
CORPORATE ALLIANCES<br />
NCI funded retrospective studies and current collaboration with Dr. Franco Marincola (NIH) to assess the effects of SSI therapy on the<br />
tumour microenvironment (specifically M2 macrophage dominance to M1 macrophage dominance) using RNA gene array analysis, in<br />
animal studies (lung tumour model) and in clinical studies (lung tumour model and skin tumour model). Clinical trial collaboration with<br />
Dr. Janessa Laskin and Dr. Stephen Lam, British Columbia Cancer Agency, and Dr. Ralf Kleef, Dr. Otto Pecher and Dr. Sebastian Reischle,<br />
Austria. Collaboration with Dr. Bob Hancock, Prof. Microbiology, University of British Columbia, to assess the effects of SSI therapy on anticancer<br />
innate immune response using RNA gene array analysis.<br />
INTELLECTUAL PROPERTY<br />
Broad patent for Site Specific Immunotherapy to be issued in EU. Broad patent issued in Australia. First US patent anticipated Q4 2011.<br />
Robust international patent protection anticipated.<br />
BIO Business Forum 2011 181 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
QBKPN Phase II, IIa, IIb Early and late stage lung cancer<br />
QBECO Phase II, IIa, IIb Pancreatic, colon, colorectal cancer<br />
QBSAU Phase II, IIa, IIb Melanoma<br />
SENIOR MANAGEMENT<br />
Hal Gunn, MD, Chief Executive Officer • Brett A. Premack, PhD, Vice President • Jerry Calver, PhD, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Simon Sutcliffe, MD, FRCP, FRCPC, FRCR, Chair of the Canadian Partnership Against Cancer, Chair of the International Cancer Control<br />
Congress • Dr. Robert Hancock, PhD, OC, OBC, FRSC, Professor of Microbiology & Immunology at UBC • Dr. Julia Levy, PhD, Past CSO &<br />
President and CEO of QLT Inc. • Dr. Mohammad Azab, MD, MSc, MBA, Chief Medical Officer of SuperGen Inc • Dr. David G. Barnes, MD,<br />
Past Head, Biotechnology Products Surveillance Unit, Marketed Health Products Directorate, Health Canada • Dr. Kent R. Van Kampen,<br />
D.V.M., PhD, COO of Vaxin Inc. • Dr. Ralf Kleef, MD, CEO of the Institute for Hyperthermia and Immunotherapy (IWIT) • Dr. Michael<br />
Noble, MD, FRCPC, Past Division Head, Medical Microbiology, UBC Hospital and Infection Control Officer for UBC Hospital<br />
BIO Business Forum 2011 182 Participating Company <strong>Profiles</strong>
Philippe Draux<br />
Chief Executive Officer<br />
Technoparc de Thudinie 1<br />
B6536 Donstiennes<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Kevin Goosse, Business Development<br />
CORPORATE MISSION<br />
Quality Assistance SA<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Vaccines<br />
www.quality-assistance.be<br />
Phone: 32-71-890142<br />
Incorporated: 1982<br />
Employees: 108<br />
Ownership: Private<br />
As a leading European Contract Research Organisation, Quality Assistance provides (bio)pharmaceutical companies with comprehensive<br />
analytical services.<br />
Quality Assistance holds a unique position on the market thanks to our 29 years’ experience and our 6 laboratories on one site covering all<br />
the analytical technologies needed to support your drug development: Molecular Biology, Cell Culture, Physico-chemistry, Mass<br />
Spectrometry, Bioanalysis and Microbiology.<br />
Our core competences are the development and validation of analytical methods, stability studies, DS characterisation, EU batch release<br />
and bioanalysis to support PK and TK studies.<br />
Our multi-disciplinary team, combined with the highest quality standards required by FDA (last inspection February 2010) EMA and PMDA,<br />
ensures the best management of your projects, including troubleshooting and respect of timelines. It makes sense - and it is cost effective<br />
- to concentrate all analytical expertise on one site.<br />
Finally, our position, independent of CMOs and pre-clinical and clinical administration sites, is also an important asset to be taken into<br />
consideration when establishing your sub-contracting strategy.<br />
SENIOR MANAGEMENT<br />
Philippe Draux, Chief Executive Officer<br />
BIO Business Forum 2011 183 Participating Company <strong>Profiles</strong>
Lionel Segard<br />
Chief Executive Officer<br />
2-12, chemin des femmes<br />
91300 MASSY<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Lionel Segard, President & Chief Executive Officer<br />
QUANTUM GENOMICS<br />
Clinical Foci: Cardiovascular Disease • Metabolic Disease<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Oral efficacy demonstrated in relevant animal models (SHR and<br />
DOCA-salt rats).<br />
No risk of chemical instability highlighted.<br />
Properties compatible with an oral solid dosage form.<br />
Efficient and robust synthetic route available.<br />
No issue of toxicity observed in vitro and in vivo.<br />
Strong IP.<br />
Safety completed in rats and dogs. Good bioavailability in dogs.<br />
Phone: 33-1-6013 7686 Employees: 7<br />
Ownership: Public<br />
Market Cap: $82.00 million<br />
CORPORATE MISSION<br />
Quantum Genomics<br />
is a specialty biopharmaceutical company<br />
that is developing first in class treatments addressing high blood pressure and associated disorders<br />
OTHER: MLQGC<br />
2011 – Filing of the first IMPD / IND application.<br />
2011/12 – Completion of the Phase I (single and multiple dose<br />
escalation study).<br />
2012-2013 – Completion of the first phase IIa study in hypertensive<br />
patients with low plasma renin and high vasopressin levels (LRHV<br />
profile).<br />
Signing a partnership agreement with an industrial partner.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
QGC001 Preclinical Hypertension targeting LRHV patients IMPD / IND Filing<br />
QGC006 Preclinical Hypertension targeting LRHV patients Lead optimization<br />
SENIOR MANAGEMENT<br />
Lionel Segard, Chief Executive Officer • Fabrice Balavoine, Chief Scientific Officer • Michel Lepers, Chief Business Officer<br />
BOARD OF DIRECTORS<br />
Lionel SEGARD • Christian BECHON, President LFB • Maurice SALAMA, President Multifinances International<br />
BIO Business Forum 2011 184 Participating Company <strong>Profiles</strong>
Samuel Ogunsalu<br />
Other<br />
Queen Mary, University of London, Mile End<br />
Road<br />
London<br />
E1 4NS<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
QUEEN MARY INNOVATION LTD<br />
www.qminnovation.co.uk<br />
Phone: 44-207-882 3119<br />
Samuel Ogunsalu<br />
Barny Cox, Technology Transfer Manager Healthcare and Life Sciences<br />
GEORGIOS TRICHAS, Business Development Manager<br />
Christopher Pugmire<br />
Michele Hill-Perkins<br />
Incorporated: 1973<br />
Employees: 20<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Queen Mary Innovation Ltd generate income and capital value by developing collaborations and partnerships with industry to bring<br />
College generated research and expertise to the marketplace.<br />
Queen Mary, University of London is one of London and the UK's leading research-focused higher education institutions, with an annual<br />
research income exceeding £40m. Over 80% of our research staff is judged to be producing work of national or international excellence<br />
demonstarted by Queen Marys ranking of 13th in the UK in the 2008 Research Assessment Exercise (RAE). The College is home to the world<br />
famous Barts & The London School of Medicine and Dentistry, a major centre for life sciences research and innovation.<br />
Life sciences research at Queen Mary benefits from the extensive clinical expertise and facilities of its associated hospitals, St Barts and The<br />
Royal London. This combination offers exciting benefits for healthcare research, a fact that was recognised by Cancer Research UK in its<br />
decision to site its first CRUK Clinical Centre here. The Medical School also has a number of specialist research units including the Wolfson<br />
Institute of Preventive Medicine and the William Harvey Research Institute.<br />
Key areas of research include cancer, cardiovascular, cutaneous, diabetes and obesity, gastroenterology, haematology, infectious disease,<br />
inflammation, neurodegenerative disease, oral health and respiratory disease.<br />
PROPRIETARY TECHNOLOGY<br />
We anticipate bringing several exciting out-licensing and collaborative opportunities with us to BIO this year and would be happy to meet<br />
with anyone interested in learning more about these prospective technologies.<br />
PRODUCTS<br />
Name Phase Indication<br />
Pancreatic Cancer / Chronic Pancreatitis Biomarkers / Diagnostic Diagnostics Pancreatic Cancer/Chronic Pancreatitis<br />
Alzheimer's Disease/Therapeutic Preclinical CNS Disease<br />
Potent HDAC inhibitors/Therapeutic Preclinical Cancer<br />
Apoptosis inducing anti cancer drug/therapeutic Preclinical Cancer<br />
Antibody delivery platform for arthritic conditions Preclinical Arthritic Conditions<br />
Early Rheumatoid Arthritis Cohort Preclinical Rheumatoid Arthritis/<br />
Autoimmune/Inflammation<br />
Cancer Biomarkers / Diagnostic Diagnostics Squamous Cell Carcinoma<br />
SENIOR MANAGEMENT<br />
Samuel Ogunsalu, Other • Caroline Quest, Chief Executive Officer • Graeme Brown, Director<br />
BIO Business Forum 2011 185 Participating Company <strong>Profiles</strong>
Prof Robert Henry<br />
Director<br />
Queensland Alliance for Agriculture & Food Innovation (QAAFI)<br />
The University of Queensland<br />
Brisbane, QLD 4072<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Paul F. Greenfield<br />
Robert J Henry<br />
www.qaafi.uq.edu.au<br />
Phone: 61-7-334 60551<br />
Employees: 50<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
New biofuel crops are being identifed by screening potential Australian species.<br />
Our scientist are leading an international food security research collaboration that aims to increase crop production by 30 per cent and<br />
reduce crop failures for 500,000 African farmers to reduce poverty and improve food security.<br />
QAAFI scientists have shown that a nanoformulation based on a form of the protein from BVDV can successfully be administered to<br />
animals as nanoparticles, making a new nanovaccine a real possibility for the Australian cattle industry.<br />
CORPORATE MISSION<br />
Launched on October 21 2010 the Queensland Alliance for Agriculture and Food Innovation (QAAFI) is an Institute of the University of<br />
Queensland (UQ) and was formed through an alliance between UQ and the Queensland Government.<br />
QAAFI brings together UQ and the Queensland Government’s Department of Employment, Economic Development and Innovation (DEEDI)<br />
research scientists from across the areas of plant, animal and food sciences.<br />
The QAAFI mission is to significantly improve the productivity, competitiveness and sustainability of tropical and subtropical food, fibre<br />
and agri-business industries. QAAFI will be an internationally recognised agriculture and food research institute providing excellence in<br />
research and development.<br />
QAAFI incorporates three centres – The Centre for Plant Science, The Centre for Animal Science and the Centre for Nutrition and Food<br />
Sciences. Each of these Centres operates as independent entities and as part of the bigger coordinated effort known as QAAFI.<br />
For more information go to: www.qaafi.uq.edu.au<br />
CORPORATE ALLIANCES<br />
The University of Queensland (UQ),<br />
Queensland’s Department of Employment, Economic Development and Innovation (DEEDI)<br />
SENIOR MANAGEMENT<br />
Prof Robert Henry, Director • Prof Mike Gidley, Centre for Nutrition and Food Sciences, Director • Prof Graeme Hammer, Centre for<br />
Plant Science, Director • Dr Stu McLennan, Centre for Animal Sciences, Director<br />
BIO Business Forum 2011 186 Participating Company <strong>Profiles</strong>
Alexandre Templier<br />
Chief Executive Officer<br />
11, rue Galvani<br />
75017 Paris<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Alexandre Templier, Managing Partner<br />
CORPORATE MISSION<br />
Quinten<br />
Clinical Foci: Service • Informatics • Drug Development<br />
www.quinten-healthcare.com<br />
Phone: 33-6-0843 8281<br />
Incorporated: 2008<br />
Employees: 12<br />
Ownership: Private<br />
Quinten is a Strategic & Operational Consulting firm that uses a powerful proprietary bioinformatics technology to improve the success<br />
rate of your clinical trials, anticipate and prevent drug safety issues & shorten your drug development programs.<br />
Enabled by its extremely powerful bioinformatics technology, Quinten detects profiles that are undetected with other sophisticated<br />
analytical approaches (including advanced data mining techniques), and within a few weeks delivers concrete and strategic insights &<br />
recommendations that have been proven to save time, enhance product performance, and mitigate risks in drug development programs.<br />
Quinten, having already signed more than 30 contracts with top players in the Pharmaceutical industry (Sanofi-Aventis, Roche, Ipsen, etc),<br />
and with preeminent biotechnology companies (Transgène, etc) can help you for instance to:<br />
• Accelerate your Lead to Candidate programs (up to 4 times faster),<br />
• Increase the success rates of your late stage clinical trials,<br />
• Revive products from failed clinical trials,<br />
• Anticipate and mitigate safety risks through early detection of patients’ profiles,<br />
• And much more …<br />
In a wide range of applications, Quinten delivers superior value by unraveling your data’s hidden potential.<br />
Need to improve your results and exceed key performance indicators?<br />
Contact us and request an audit to evaluate the potential of your data.<br />
Quinten’s 3-step engagement process has been designed to guarantee your satisfaction.<br />
Not satisfied? Not invoiced.<br />
PROPRIETARY TECHNOLOGY<br />
Quinten’s® proprietary "Q-Finder" artificial intelligence technology allows for exhaustively exploring the most complex databases, from a<br />
hundred to several thousands observations, whatever the number of variables, without the need for selecting or pre processing these<br />
variables. We allow for instance for identifying and describing precisely all subgroups of patients showing a significantly higher<br />
therapeutic response or adverse events than in average in order to better design and improve the success rate of upcoming clinical<br />
studies, and develop personalized medicine strategies.<br />
CORPORATE ALLIANCES<br />
Sanofi-Aventis<br />
Ipsen<br />
Novagali Pharma<br />
Roche<br />
INTELLECTUAL PROPERTY<br />
Transgène<br />
Inserm Transfert<br />
Quinten's original technology and methodology have been entirely developed and are fully owned by Quinten.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Phase III protocol<br />
design optimization<br />
Phase III Increase chances for<br />
approval<br />
Drug Safety Other Anticipate and prevent<br />
safety issues<br />
Medicinal chemistry Optimized Lead Productivity &<br />
performance services<br />
SENIOR MANAGEMENT<br />
We help our clients’ increase their products’ chances to pass<br />
phase III by identifying & targeting the patients profiles that<br />
show the best benefice/risk ratios in Phase II<br />
We identify, within our clients’ clinical data, in very short time<br />
frames, the profiles of patients likely to develop one or several<br />
side effects following the drug’s intake<br />
We help our clients develop better drug candidates (more<br />
active and more « drugable ») 2 to 4 times faster than before.<br />
Alexandre Templier, Chief Executive Officer • Guillaume Bourdon, Chief Executive Officer • Mariem Alaoui, Chief Operating Officer •<br />
Bassel El Cheikh, Manager<br />
SCIENTIFIC ADVISORY BOARD<br />
Christophe Geissler, Ecole Normale Supérieure - Ulm - Paris<br />
BIO Business Forum 2011 187 Participating Company <strong>Profiles</strong>
Ulf Nehrbass<br />
Chief Executive Officer<br />
696 Sampyeong-dong, Bundang-gu<br />
Seongnam 463-400<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Kiyean Nam<br />
June Kim<br />
Joongsik Hwang<br />
Quro Science<br />
Clinical Foci: Infectious Disease • Immunology • PGH – Neglected Diseases<br />
www.quroscience.com<br />
Phone: 82-31-8018-8350<br />
Incorporated: 2008<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Quro Science Inc. is a spin-off biotechnology company from Institut Pasteur Korea (IPK) dedicated to develop novel therapeutics against<br />
diseases such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), tuberculosis (TB) infection and inflammatory disorders.<br />
Quro has exclusive rights to use discovery research products (drug candidates) and resources at IPK including the PhenomicScreen and<br />
PhenomicID platform technologies for above the mentioned disease indications.<br />
Quro has an operations scheme similar to virtual company in order to maximize the efficiency. Quro collaborates with IPK to conduct the<br />
discovery phase of its portfolio programs and works with CROs for the preclinical and clinical research. Quro does not intend to<br />
commercialize the products on its own, rather it intends to partner with larger pharmaceutical/biotech companies which have clinical<br />
development, sales and marketing capabilities.<br />
Quro;s portfolio includes followings;<br />
Antibiotics against MDR/XDR Tuberculosis<br />
Selective redox inhibitors against 5-LO for asthma/COPD treatment<br />
Anti-HIV agents against unknown novel targets<br />
Novel anti-HCV agents against non-protease/polymerase targets<br />
PROPRIETARY TECHNOLOGY<br />
PhenomicScreen<br />
Visual, target free high contents screening (HCS) system set up in the biosafety level 3 lab that uses customized proprietary image mining<br />
software.<br />
PhenomicID<br />
High contents target identification platform using RNAi reverse transfection<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 11/24/2009 (US $5.00 million)<br />
SENIOR MANAGEMENT<br />
Ulf Nehrbass, Chief Executive Officer • Kiyean Nam, Chief Operating Officer • Joongsik Hwang, Business Development<br />
BIO Business Forum 2011 188 Participating Company <strong>Profiles</strong>
7 Harewood Avenue<br />
London<br />
40745<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Tom Frost<br />
Harin Mahadeva<br />
R&D Focus Drug News<br />
Phone: 44-203-755161 Ownership: Private<br />
CORPORATE MISSION<br />
IMS LifeCycle R&D Focus is one of three modules in the IMS LifeCycle suite of databases. R&D Focus covers global pharmaceutical and<br />
biotechnology product development. The database is used by pharmaceutical companies and market analysts worldwide.<br />
The R&D Focus editorial team also produces a weekly newsletter, Drug News. Drug News covers developments in pharmaceutical and<br />
biotechnology R&D, including product launches, approvals, filings and clinical trial information, as well as licensing agreements and<br />
partnering opportunities.<br />
Information from IMS LifeCycle R&D Focus is also featured in IMS Knowledge Link, an online platform combining extensive global sales<br />
information with comprehensive qualitative insights.<br />
The IMS LifeCycle suite of products also includes IMS LifeCycle Patent Focus and IMS LifeCycle New Product Focus. IMS LifeCycle Patent<br />
Focus enables you to identify patent expiry and priority dates and extensions using molecule, chemical, trade name or CAS number<br />
searches. IMS LifeCycle New Product Focus enables the monitoring of product launches worldwide and analysis of the history of product<br />
launches.<br />
IMS Health is a business information company providing market intelligence to the healthcare sector globally, integrating healthcare<br />
information (including unparalleled sales data), analytics, consulting and services to meet the needs of any client. IMS LifeCycle R&D Focus<br />
is one of many editorial publications the company offers.<br />
BIO Business Forum 2011 189 Participating Company <strong>Profiles</strong>
Kohkan Shamsi<br />
Partner<br />
712 Hyde Park<br />
Doylestown, PA 18902<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Richard Patt<br />
Doug Stefanelli<br />
RadMD, LLC<br />
Clinical Foci: Diagnostics • Drug Development • Oncology<br />
www.rad-md.net<br />
Phone: 1-215-348 5644<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
First Accredited Course on Imaging in Cancer Clinical Trials Hosted by Blinded Reader and Investigator Training Institute (BRITI) April 16,<br />
2011. Imaging in Cancer Clinical Trials: The 1 Day Course was attended by over 70 industry personnel.<br />
CORPORATE MISSION<br />
RadMD provides Imaging expertise to help define, develop and implement imaging strategies in clinical trial programs for Pharmaceutical<br />
and BioTech companies. We also support Contract Research Organizations (CRO's) and Imaging Core labs (ICRO's). Our expertise lies in<br />
our ability to construct and implement unique and customized medical imaging solutions. We offer consulting services in protocol<br />
development, to optimize imaging endpoints, and the development of Imaging Charters. We provide standardized and customized<br />
training for imaging in clinical trials for both sponsors and physicians involved in clinical trials. We can perform site selection and<br />
qualification as well as post-approval data mining and marketing support. In addition to commercial support we have extensive<br />
knowledge and experience in regulatory affairs to provide assistance for all regulatory meetings and submissions. We have a database of<br />
over 600 pre-qualified, vetted specialists, including radiologists, cardiologists, oncologists, pathologists, neurologists and others to<br />
perform blinded read analyses. Readers are available for safety, efficacy, inclusion evaluations and confirmation of disease progression.<br />
We also offer consulting services to prepare and review study reports, publications and expert reports.<br />
PROPRIETARY TECHNOLOGY<br />
BRITI - Blinded Reader and Investigator Training Institute. Only BRITI provides targeted training on imaging in clinical trials and offers<br />
category I CME certification courses, improving training compliance, reducing site data variability, resulting in overall robust site data.<br />
SENIOR MANAGEMENT<br />
Kohkan Shamsi, Partner • Rick Patt, Partner • Doug Stefanelli, Chief Operating Officer<br />
BIO Business Forum 2011 190 Participating Company <strong>Profiles</strong>
Yaron Zakhyem<br />
Chief Executive Officer<br />
5 Slomo Halevi Street<br />
91003 Jerusalem<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Amita Sankar<br />
Betina Brymer<br />
Rafa Laboratories<br />
Clinical Foci: Oncology • Gastroenterology • Neurology<br />
www.rafa.co.il<br />
Phone: 972-2-589 3966<br />
Incorporated: 1937<br />
Employees: 210<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Rafa is a leading Israeli pharmaceutical company operating mainly in the local Israeli market. Since 1973, Rafa is one of the Purdue/<br />
Mundipharma/Napp independent associated companies.<br />
We are seeking for in-licensing opportunities of registered and late-stage developing products for marketing in Israel. Rafa is active<br />
mainly in the therapeutic areas of pain, palliative care (Oncology), CNS, GI, respiratory, dermatology and OTC.<br />
SENIOR MANAGEMENT<br />
Yaron Zakhyem, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Amir Levin<br />
BIO Business Forum 2011 191 Participating Company <strong>Profiles</strong>
Dr Peter Fitzgerald<br />
Managing Director<br />
55 Diamond Road<br />
Crumlin<br />
BT29 4QY<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Chris Moriarty, Global Manager<br />
CORPORATE MISSION<br />
Randox Pharma Services<br />
Clinical Foci: Diagnostics • Oncology • Metabolic Disease<br />
www.randoxpharmaservices.com<br />
Phone: 44-2894-422413<br />
Incorporated: 1982<br />
Employees: 800<br />
Ownership: Private<br />
Randox Laboratories supplies diagnostic reagents and Biomarker solutions to Pharmaceutical companies, CRO's, central labs and academic<br />
research centers globally.<br />
While our off-the-shelf product range is unrivalled, custom biomarker assay development (including custom quality control sera) is<br />
available to provide a tailor-made solution right through to companion diagnostic assay development and full regulatory approval. This is<br />
supported by our extensive Life Science division, offering a range of polyclonal and monoclonal antibodies, conjugates and human<br />
recombinant proteins to allow flexibility and speed in your novel assay development programmes.<br />
Randox was founded on its clinical chemistry expertise and offers over 130 enzymatic, substrate and Immunoturbidimetric assays, utilized<br />
at every phase from pre-clinical through clinical trials on 3rd party or its own-brand RX clinical chemistry analysers.<br />
Randox's Biochip Array Technology enables multiple biomarker results from a single sample and offers a vast range of arrays including;<br />
cytokines, adhesion molecules, cardiac, cerebral, drugs of abuse, fertility, tumour and thyroid. In addition new DNA/RNA multiplex arrays<br />
are now available which include infectious disease screening and oncology arrays for CRC, Breast and Ovarian cancer under development.<br />
Kras mutation arrays are also available with application for anti-EGFR therapy.<br />
Quality is at the core of Randox’s product offering and our Quality control sera covers over 170 parameters and is known to be of the most<br />
accurate, stable and consistent control material available. QC products include blood gas, cardiac, clinical chemistry, coagulation,<br />
diabetes, drugs of abuse, immunoassay, lipids, speciality controls, therapeutic drugs and urine. Fully customised QC (analytes & levels) is<br />
also available which is a key benefit for specific clinical trials.<br />
PROPRIETARY TECHNOLOGY<br />
Biochip Array Technology<br />
CORPORATE ALLIANCES<br />
Strategic relationships with top 10 ranked pharmaceutical companies, CRO's, central laboratories and academic research centers globally.<br />
INTELLECTUAL PROPERTY<br />
Broad range of patents relating to diagnostic testing, biomarkers and multiplex testing platforms.<br />
SENIOR MANAGEMENT<br />
Dr Peter Fitzgerald, Managing Director • Mr John Lamont, Chief Scientific Officer<br />
BIO Business Forum 2011 192 Participating Company <strong>Profiles</strong>
304 N. Segoe Rd. #102<br />
Madison, WI 53705<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ben Moga, Vice President<br />
CORPORATE MISSION<br />
Ratio, Inc.<br />
Presenting Company<br />
Clinical Foci: Drug Delivery<br />
Phone: 1-608-225-3669 Ownership: Private<br />
Ratio, Inc. is dedicated to developing elegant drug delivery products for enhancing the life cycle and effectiveness of approved<br />
pharmaceuticals. Our strategy, products and decisions are patient driven with a focus on the bottom line.<br />
PROPRIETARY TECHNOLOGY<br />
Ratio has developed a proprietary hydrogel pump for a wearable drug delivery device that administers injections.<br />
CORPORATE ALLIANCES<br />
Currently seeking alliances with fill/finish CMOs and pharmaceutical companies that have commercialized or are commercializing an<br />
injectable product.<br />
INTELLECTUAL PROPERTY<br />
The company has filed 10 utility and 2 design patents to protect the NuPrivo® product line, all pending and at different stages of<br />
prosecution.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
NuPrivo-SC Preclinical TBD Design and process validation<br />
NuPrivo-ID Research Vaccines Proof-of-concept<br />
NuPrivo-CI Research TBD Research and Development<br />
BIO Business Forum 2011 193 Participating Company <strong>Profiles</strong>
Two Embarcadero Center, Suite 1200<br />
San Francisco, CA 94111<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Nate J. Chang, Sr. Vice President<br />
CORPORATE MISSION<br />
RBC Capital Markets<br />
Clinical Foci: Biopharmaceuticals • Diagnostics • Medical Device<br />
www.rbccm.com<br />
Phone: 415-633-8500<br />
Incorporated: 1864<br />
Employees: 80000<br />
Ownership: Public<br />
Market Cap: $86000.00 million<br />
TORONTO STOCK EXCHANGE: RY<br />
RBC Capital Markets' Healthcare Group is focused on Biotechnology, Specialty Pharmaceuticals, Medical Technology and Healthcare<br />
Services companies in the U.S., Canada, Europe and Asia. We provide our clients with the full range of financing and advisory services to<br />
assist them throughout the business lifecycle. Our services include private placements, public offerings, mergers and acquisitions,<br />
syndicated & leveraged finance, high-yield debt, corporate banking and financial advisory services.<br />
Our team of investment banking professionals is led by senior-level bankers who possess significant healthcare and capital markets<br />
experience. Our commitment to superior industry knowledge combined with outstanding client service and execution has resulted in<br />
numerous transactions with our clients as they migrate through every stage of growth.<br />
BIO Business Forum 2011 194 Participating Company <strong>Profiles</strong>
105 Magnolia Dr.<br />
Chester Springs, PA 19425<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Rami Daoud, President<br />
CORPORATE MISSION<br />
RD Consulting<br />
Phone: 1-484-252-1527 Incorporated: 2011<br />
Employees: 1<br />
Ownership: Private<br />
RD Consulting is a transaction advisory firm that provides strategic, corporate and business development support for pharmaceutical,<br />
biotech and medical device companies.<br />
The firm is hired mainly to develop and execute partnering processes (“sell-side” and “buy-side” engagements) on behalf of our clients,<br />
support ongoing partnering projects at our clients’ firms, provide actionable strategic advice derived from rigorous research and analyses<br />
or temporarily fill in when resource gaps / needs arise within our clients’ business development organizations.<br />
Our services include, but are not limited to, the following: 1) sourcing product or company partnership opportunities from an extensive<br />
global network of BD contacts, 2) in-depth opportunity assessment, 3) conducting market research and estimating commercial potential,<br />
4) managing or conducting multi-functional due diligence assessment, 5) utilizing robust financial modeling and analyses to value<br />
projects and terms , 6) identifying potential partners and developing appropriate positioning and communication strategy, 7) preparing<br />
business development documents, 8) assisting with deal construction and negotiations, 9) developing corporate, product or therapeutic<br />
area strategies, 10) assisting early stage companies in business plan preparation, business development projects and fund raising<br />
activities.<br />
RD Consulting is based in the Philadelphia, PA area and consults for clients on a global basis. The company represents a great business<br />
development resource for Ex-US companies interested in securing products or partners for their projects in the US market.<br />
BIO Business Forum 2011 195 Participating Company <strong>Profiles</strong>
Peter Coleman<br />
Chief Executive Officer<br />
Stephenson Building<br />
Keele Staffordshire<br />
ST5 5SP<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
RecipharmCobra Biologics<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Generics<br />
www.recipharmcobrabio.com<br />
Phone: 44-178-287 7221<br />
John Terlingo, Director, Business Development, North America<br />
Magnus Gustafsson, Business Manager<br />
Philip Ridley-Smith, Business Development and Marketing Manager<br />
Jason Rahal<br />
Incorporated: 1992<br />
Employees: 80<br />
Ownership: Private<br />
CORPORATE MISSION<br />
RecipharmCobra Biologics (“RecipharmCobra”) is a CDMO providing a comprehensive range of services from early stage development to<br />
the supply of cGMP material for Phase I, II and III clinical trials.<br />
RecipharmCobra's services include; cell line development, analytical and process development and cGMP production of recombinant<br />
proteins, antibodies, DNA, viruses and cell products.<br />
This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop for their biologics outsourcing<br />
needs.<br />
RecipharmCobra also offers stand-alone analytical services including; assay development, qualification and validation, cell based potency<br />
assays, product characterization, product release testing and stability testing to ICH guidelines.<br />
RecipharmCobra is also pleased to offer the maxXpress service, which combines the power of the UCOE technology with the experience<br />
and expertise of RecipharmCobra’s cell line development team.<br />
The group has a proven track record of successful manufacturing and has developed proprietary technologies for the benefit of customers’<br />
projects including ORT, a method of producing plasmid DNA without antibiotics, antibiotic resistance genes or any other selectable<br />
marker genes.<br />
The specialist biologics division of Recipharm AB, RecipharmCobra, operates two GMP facilities located in Keele, UK and Södertälje,<br />
Sweden.<br />
The Recipharm AB group consists of 11 facilities employing over 1800 people across Sweden, Germany, France, Spain and the United<br />
Kingdom, of which over 120 are employed by RecipharmCobra Biologics. Recipharm’s vision is to be acknowledged as the best in class<br />
provider of contract development and manufacturing services to the pharmaceutical industry by customers, employees and other<br />
stakeholders.<br />
PROPRIETARY TECHNOLOGY<br />
maxXpress service: Rapid and high-yielding production of protein using UCOE technology. Harness the power of UCOE technology with the<br />
experience and expertise of RecipharmCobra’s cell line development team including the Cello robotic system. Enables rapid production of<br />
gram quantities of antibody and recombinant proteins.<br />
ORT (Operator-Repressor Titration): A method of producing plasmid DNA without antibiotics, antibiotic resistance genes or any other<br />
selectable marker genes in Escherichia coli.<br />
ORT-VAC System: A gene-based oral attenuated bacterial vaccine delivery technology.<br />
Xer-cise: A method of inserting genes into or deleting genes from bacterial<br />
chromosomes without permanently inserting antibiotic resistance genes.<br />
CORPORATE ALLIANCES<br />
Collaborations with major universities: Oxford, UK; University College London, UK; Newcastle-upon-Tyne, UK; Cambridge, UK; Royal<br />
Holloway University of London, UK; Universita' degil Studi di Padova, Italy; Universita' Cattolica del Sacro Cuore, Italy; Bernard Nocht<br />
Institute of Tropical Medicine, Germany<br />
FINANCING HISTORY<br />
Investors: Recipharm AB (100 %)<br />
SENIOR MANAGEMENT<br />
Peter Coleman, Chief Executive Officer • Tracey Pughe, Other • Lorraine Borland, Other • Ulrika Ljungvist, Other<br />
BOARD OF DIRECTORS<br />
Carl-Johan Spak • Peter Coleman<br />
BIO Business Forum 2011 196 Participating Company <strong>Profiles</strong>
Giovanni Recordati<br />
Chief Executive Officer<br />
Via Matteo Civitali 1<br />
20148-Milano<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Duccio Favara<br />
HIGHLIGHTS<br />
Recent<br />
Recordati<br />
Clinical Foci: Urological • Cardiovascular Disease • Metabolic Disease<br />
www.recordati.com<br />
Phone: 39-02-4878 7614<br />
Incorporated: 1926<br />
Employees: 3000<br />
Ownership: Public<br />
Market Cap: $1.70 million<br />
ITALIAN STOCK EXCHANGE: REC.MI<br />
Silodosin approved by EMEA on January 29, 2010 via the centralized procedure, launched in France, Germany, Spain and other EU<br />
countries.<br />
Pitavastatin approved in Europe through a Decentralized Procedure (July 2010). First launch in Spain together with Esteve in May 2011.<br />
LIcensing Agreement signed with Nymox for the latter NX-1207 an innovative treatment of BPH, currently completing phase III clinical<br />
trials.<br />
CORPORATE MISSION<br />
Recordati is an European pharmaceutical group, mainly dedicated to the research, development, manufacturing and marketing of<br />
pharmaceuticals.<br />
Headquartered in Milan, Italy, it has commercial operations in most of Western & Eastern European countries including Italy, France,<br />
Germany, Portugal, Greece, Ireland, Russia, CIS, Turkey, Czech Republic, Slovakia, Romania.<br />
Recordati offers a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas such as<br />
cardiology, gastroenterology, central nervous system, anti-infective and pain relief.<br />
The company's leading product is Lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension discovered<br />
and entirely developed by Recordati.<br />
Pharmaceutical production is based in Italy , France and Turkey. Besides Italy, a plant for the production of proprietary active ingredients is<br />
situated in Ireland.<br />
Strengths:<br />
Proven and successful expertise to develop and register drugs in Europe.<br />
Successful development and commercialization partnerships with global and regional pharmaceutical companies.<br />
Coverage of the EU market with more than 1400 reps and continuous expansion throughout geographical Europe.<br />
Key consolidated data:<br />
Consolidated revenue for 2010 was € 728.1 million. Pharmaceutical sales were € 702.3. Operating income was € 154.8 million, and Net<br />
income was € 108.6 million.<br />
PROPRIETARY TECHNOLOGY<br />
Recordati's drug discovery efforts are directed towards Cardiovascular and Micturition disorders.<br />
CORPORATE ALLIANCES<br />
Almirall, Nycomed, Alza (now J&J), Dexcel, Kissei, Kowa, Lundbeck, Mylan, Ono, Pfizer, Roche, Rotta, Schering Plough, Watson, Nymox,<br />
Menarini, Merck-Serono, Esteve are only part of the current partners of Recordati. Partnerships are the backbone of Recordati's business.<br />
The company is seeking European licensing In opportunities preferably after proof of concept in man.<br />
SENIOR MANAGEMENT<br />
Giovanni Recordati, Chief Executive Officer<br />
BIO Business Forum 2011 197 Participating Company <strong>Profiles</strong>
Neil Murray<br />
Chief Executive Officer<br />
MerseyBio<br />
Liverpool Merseyside<br />
L69 7ZB<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Neil Murray, Chief Executive Officer<br />
Pete Jackson, Chairman<br />
Norman Molyneux, Chief Financial Officer<br />
HIGHLIGHTS<br />
Recent<br />
Closed a USD 4m Series A round in Feb 2011<br />
Redx Pharma Ltd<br />
Clinical Foci: Cardiovascular Disease • Infectious Disease • Oncology<br />
www.redxpharma.com<br />
Phone: 44-151-795 4200<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Redx Pharma is a UK-based company developing new drug candidates using the broad-based potential of its innovative Redox Switch<br />
platform.<br />
The Redox Switch platform has allowed Redx Pharma to secure novel intellectual property around existing therapeutics through<br />
preparation of structurally similar new compounds. This novel medicinal chemistry approach has provided us with fast and efficient<br />
access to an extensive pipeline of new drug candidates across multiple high value therapeutic applications. The structural similarity of<br />
these compounds to parent drugs that are well-characterised and understood reduces the overall risk profile for Redx Pharma's programs<br />
and cuts development times.<br />
Redx Pharma is currently progressing four programs through development in cardiovascular, influenza, antibacterials and neuropathic<br />
pain.<br />
In each case, Redx Pharma has secured novel IP around new compounds which have the potential to produce significant improvements in<br />
efficacy, safety and usability resulting in better treatments for patients.<br />
Redx is also progressing an extensive pipeline of oncology compounds through the discovery phase.<br />
SENIOR MANAGEMENT<br />
Neil Murray, Chief Executive Officer • Pete Jackson, Chairman • Norman Molyneux, Chief Financial Officer<br />
BIO Business Forum 2011 198 Participating Company <strong>Profiles</strong>
Kenneth T Mills<br />
President & CEO<br />
750 17th Street, NW<br />
Washington, DC 20006<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Vit Vasista, MBA, MSME, CFO<br />
Kenneth T. Mills<br />
Katherine Maynard<br />
ReGenX Biosciences, LLC<br />
Clinical Foci: Gene/Cell Therapy • Metabolic Disease • Ophthalmic<br />
www.regenxbio.com<br />
Phone: 1-202-785 7438<br />
Incorporated: 2008<br />
Employees: 6<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
ReGenX Biosciences announced an exclusive license agreement with ARIAD Pharmaceuticals, Inc. for its ARGENT gene expression<br />
regulation technology for use with human therapeutics and vaccines based on in vivo gene delivery using viral vectors.<br />
ReGenX Biosciences received a $2.8 million grant from National Eye Institute (NEI), to support the advancement of REGENX’s novel<br />
program using its NAV technology for the treatment of X-Linked Retinitis Pigmentosa.<br />
ReGenX Biosciences received a grant from the National Institutes of Health (NIH), to support the development of scalable manufacturing<br />
process for AAV vectors.<br />
CORPORATE MISSION<br />
ReGenX BioSciences is leading the effort to translate promising gene delivery applications into a pipeline of next generation personalized<br />
therapies for a range of severe diseases with serious unmet needs. ReGenX’s NAV gene delivery technology includes recombinant adenoassociated<br />
viral (rAAV) vectors that offer a platform for safer, highly efficient and specific expression of biologics with therapeutic effect.<br />
The company's core technology is based on work out of the University of Pennsylvania. ReGenX is focused on translating the over $50<br />
million spent to date on the development of the rAAV vectors into commercially available therapeutics for a range of diseases. ReGenX is<br />
focused on developing therapeutics in a few key areas (hematologic and metabolic disorders, ocular diseases and neurodegenerative<br />
disorders) and is interested in establishing collaborations to advance the development of these programs. Collaborations could come in<br />
the form of Sponsored Research Agreements or licenses to ReGenX’s developed therapeutics. In addition, ReGenX is open to licensing its<br />
technology to outside organizations committed to developing and commercializing therapeutics based on rAAV vectors for indications<br />
and fields that are not part of its core areas of interest. ReGenX is currently in the process of submitting its first IND based on an NAV<br />
vector rAAV8 treatment for Familial Hypercholesterolemia (FH). Worldwide, there have been 81 clinical trials using AAV vectors which<br />
have spanned a wide range of therapeutic areas, including inherited diseases, CNS disorders, heart failure, and vaccines. The trials which<br />
have demonstrated at least some efficacy include therapies for lipoprotein lipase deficiency, Parkinson’s disease, heart failure, Leber<br />
congenital amaurosis, and hemophilia B.<br />
PROPRIETARY TECHNOLOGY<br />
ReGenX AAV Vector Technology is protected by an intellectual property estate that includes over a 100 patents and patent applications.<br />
We believe that no other company possesses a portfolio of such broad and exclusive rights to the patents required for the development of<br />
AAV vector based therapeutics, making us the leader in the field. Our intellectual property includes a wide range of important biology,<br />
genetic material delivery, and therapeutic target patents, the most fundamental of which provides us with exclusive rights to vectors<br />
derived from novel serotypes of rAAV, including rAAV8, rAAV9 and rAAVrh10. ReGenX believes its intellectual property is important in<br />
providing competitive advantage and product exclusivity for its mission to develop novel AAV vector based therapeutics.<br />
INTELLECTUAL PROPERTY<br />
ReGenX AAV Vector Technology is protected by an intellectual property estate that includes over a 100 patents and patent applications.<br />
We believe that no other company possesses a portfolio of such broad and exclusive rights to the patents required for the development of<br />
AAV vector based therapeutics, making us the leader in the field. Our intellectual property includes a wide range of important biology,<br />
genetic material delivery, and therapeutic target patents, the most fundamental of which provides us with exclusive rights to vectors<br />
derived from novel serotypes of rAAV, including rAAV8, rAAV9 and rAAVrh10. ReGenX believes its intellectual property is important in<br />
providing competitive advantage and product exclusivity for its mission to develop novel AAV vector based therapeutics.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
RGNX 001 Preclinical Homozygous Familial Hypercholesterolemia IND filing by the end of 2011<br />
RGNX 002 Preclinical MPS 1 IND filing by 2014<br />
RGNX 003 Preclinical MPS 6 IND filing by 2013<br />
RGNX 004 Pre-Target Validation Wet AMD<br />
BIO Business Forum 2011 199 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Kenneth T Mills, President & CEO • James Brown, Chief Operating Officer • Vit Vasista, Chief Financial Officer • Karen Kozarsky, Vice<br />
President • Maritza McIntyre, Vice President<br />
BOARD OF DIRECTORS<br />
Allan M. Fox, Partner, FOXKISER • John Daniel Kiser, Partner, FOXKISER • Kenneth T. Mills, President & Chief Executive Officer, ReGenX<br />
Biosciences • Amber Salzman, PhD, President & Chief Executive Officer, Cardiokine, Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
James M. Wilson, MD, Ph.D, Scientific Founder and Director of the Gene Therapy Program at the University of Pennslyvania • Judith L.<br />
Swain, MD, Executive Director of the Singapore Institute for Clinical Sciences within A*STAR • Inder M. Verma, PhD, Professor of<br />
Molecular Biology, Salk Institute, La Jolla<br />
BIO Business Forum 2011 200 Participating Company <strong>Profiles</strong>
Haru MORITA<br />
President & CEO<br />
1-7-8 Kaigan<br />
Tokyo 105-0022<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Haru Morita, President and CEO<br />
REGiMMUNE Corporation<br />
Clinical Foci: AutoImmune • Transplant • Immunology<br />
www.regimmune.com<br />
Phone: 81-3-6809-2199<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
IND of the lead program, RGI-2001, was accepted by US FDA and initiating clinical<br />
trial in major clinical sites in US. It is to confirm clinical efficacy in GvHD<br />
CORPORATE MISSION<br />
Incorporated: 2006<br />
Ownership: Private<br />
Series C finance in a few month<br />
REGiMMUNE Corporation is a biotechnology company focused on the discovery, development, and potential commercialization of<br />
immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders, including allergies, autoimmune and<br />
inflammatory disease. REGiMMUNE applies its reVax (reverse vaccination) technology and product development and clinical experience to<br />
generate, support and potentially commercialize a broad range of products for itself and its partners.<br />
Our business strategy is to develop novel and proprietary products focused on therapeutic areas that can be addressed with immuneregulating<br />
technology. We expedite programs by actively using outside resources and partnering with biotechnology and pharmaceutical<br />
companies to leverage technology assets. Our growth is driven by our flexible and precision management based on clear-sighted vision.<br />
PROPRIETARY TECHNOLOGY<br />
REGiMMUNE has a proprietary technology platform, reVax (reverse vaccination).<br />
This is the only technology that can lead immuno-tolerance against specific antigen through induction of regulatory T cell (Treg) and is<br />
proven to be efficacious in various animals.<br />
In some disorders like allergies and in autoimmune diseases such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), the immune<br />
system responds excessively or abnormally and may ultimately result in tissue destruction.<br />
The reVax technology "re-educate" the immune system by inducing immune regulatory cells. In contrast to immunosuppressant which<br />
broadly downregulate immune system or typical vaccine therapy which enhance immunoprotective ability against an antigen by<br />
immunizing it with a specific adjuvant, this technology suppre<br />
CORPORATE ALLIANCES<br />
Kyowa-Hakko KIRIN, Astellas<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
RGI-1001 Phase I GvHD associated with hematopoietic stem cell transplantation Clinical PoC is expected in 2012<br />
RGI-3100 Optimized Lead Type I diabetes<br />
RGI-1001 Lead Series Cedar polinosis<br />
RGI-4000 Research Vaccine Adujvant Technology for intra nasal and SQ<br />
FINANCING HISTORY<br />
Investors: Daiwa (0 %) • SMBC Capital (0 %) • Japan Asia Investment (0 %) • Yasuda (0 %) • Mitsubishi UFJ<br />
Capital (0 %)<br />
SENIOR MANAGEMENT<br />
Haru MORITA, President & CEO<br />
BOARD OF DIRECTORS<br />
Haru MORITA, REGiMMUNE • Hiroki Narita, Daiwa Enterprise • Shirley Clayton • Yasuyuki Ishii<br />
BIO Business Forum 2011 201 Participating Company <strong>Profiles</strong>
Anita Falezza<br />
Managing Director<br />
C.so Italia, 108<br />
56125-Pisa<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Anita Falezza, Managing Director<br />
Lucia Piampiani, Senior consultant<br />
Regulatory Pharma Net S.R.L.<br />
Clinical Foci: Service • Specialty Pharmaceutical • Drug Development<br />
HIGHLIGHTS<br />
Recent<br />
Management of successful registration procedures<br />
Successful orphan drug applications<br />
Management of price and reimbursement applications and market access in EU<br />
CORPORATE MISSION<br />
Phone: 39-050-503 954 Incorporated: 1999<br />
Employees: 10<br />
Ownership: Private<br />
Regulatory Pharma Net is a regulatory affairs consulting company providing support through development, registration, launch and life<br />
cycle management.<br />
RPN, founded in Italy in 1999, has become the regulatory affairs partner of many pharmaceutical companies.<br />
The highly qualified RPN team includes regulatory affairs specialists with competences and expertise in different fields: medicinal<br />
products including advanced therapies and orphan drugs, medical devices, cosmetics, biocides, food supplements.<br />
RPN work with the clients, complementing their skill-sets and resources to help them overcome obstacles in the management of<br />
regulatory affairs activities.<br />
MAIN SERVICES<br />
General Activities<br />
EVALUATION OF THE ADHERENCE TO REGULATIONS AND APPLICABLE GUIDELINES FOR REGULATORY DOSSIERS; ADVICE ON REGISTRATION<br />
STRATEGY AND HEALTH AUTHORITY REQUIREMENTS; REGULATORY DUE-DILIGENCES; LIAISON WITH THE REGULATORY AUTHORITIES;<br />
PROJECT MANAGEMENT; FACILITATION OF LOCAL CONCERNS VIA A NETWORK OF PARTNERS IN EU COUNTRIES AND IN USA<br />
Development Phase<br />
REGULATORY REVISION OF DEVELOPMENT PLANS; SCIENTIFIC ADVICE REQUESTS; ORPHAN DRUG DESIGNATION APPLICATIONS; PAEDIATRIC<br />
INVESTIGATION PLAN (PIP) APPLICATIONS; CLINICAL TRIAL APPLICATIONS<br />
Dossier preparation and registration procedures<br />
PREPARATION OF REGISTRATION DOSSIERS for Marketing Authorisation and variation applications in CTD AND eCTD FORMAT; REVISION OF<br />
SPC, PIL AND LABELLING; READABILITY TESTING OF PIL; MANAGEMENT OF REGULATORY PROCEDURES (MAA, VARIATIONS, MA RENEWAL &<br />
TRANSFER)<br />
Price and reimbursement<br />
PREPARATION OF NATIONAL PRICE & REIMBURSEMENT APPLICATIONS; SUPPORT DURING THE NEGOTIATION PROCESS WITH THE<br />
AUTHORITIES; COORDINATION OF THE PRICE & REIMBURSEMENT APPLICATIONS IN EU COUNTRIES<br />
National Support for Market Access<br />
ADVICE & ASSISTANCE FOR COMPLIANCE WITH THE LOCAL REQUIREMENTS; LOCAL PHARMACOVIGILANCE SUPPORT; REVISION OF<br />
PROMOTIONAL MATERIAL; ASSISTANCE IN COMPASSIONATE USE PROGRAMS<br />
PROPRIETARY TECHNOLOGY<br />
Highly qualified services.<br />
Regulatory affairs support during all development phases, registration and maintenance.<br />
RA support and advices for the business establishment in EU.<br />
SENIOR MANAGEMENT<br />
Anita Falezza, Managing Director • Lucia Piampiani, Manager<br />
BOARD OF DIRECTORS<br />
Anita Falezza<br />
BIO Business Forum 2011 202 Participating Company <strong>Profiles</strong>
Dr David Mauléon<br />
Chief Executive Officer<br />
Vía Augusta, 59; of. 113<br />
08006 BARCELONA<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Lidia Canovas, General Manager, Operations<br />
Michael Schaub, Business Development Director<br />
Regulatory Pharma Net, S.L.<br />
Clinical Foci: Service<br />
www.rpn.es<br />
Phone: 34-93-2385945<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
International team of 25 professional consultants; 107<br />
International clients and 126 Spanish clients; around 200 ongoing<br />
active projects; over 1600 accumulated projects; experience in over<br />
50 countries<br />
eCTD system implemented in 2008; over 600 eCTD submissions;<br />
first Spanish Consultancy submitting eCTD in European and FDA<br />
Procedures<br />
eCTD registration dossier submission in DCP/MRP procedures with<br />
up to 20 countries; all types of eSubmissions<br />
Regulatory Pharma Net started working in Centralised Procedures<br />
already in the year 2000. In more than 10 years, we have gained<br />
experience in all aspects of this most comprehensive of all<br />
European Registration Procedures.<br />
Incorporated: 2000<br />
Employees: 30<br />
Ownership: Private<br />
World-wide regulatory support (currently existing experience in<br />
over 50 countries):<br />
- Consolidation of growing network of local partners and contacts<br />
in all regions of the world during the fourth quarter of 2011.<br />
Establishment of medical device expert group in borderline<br />
classification and respective clinical evaluation by the end of 2011.<br />
Capacity of world-wide, beyond Europe, Advanced Therapies<br />
development and registration business model support by<br />
beginning of 2012. Currently we have excellent knowledge of EU<br />
Advanced Therapies regulatory processes, such as ODD, IMPDs, SA,<br />
PA, CPs.<br />
CORPORATE MISSION<br />
Regulatory Pharma Net, S.L. (RPN) is an International Drug Development and Regulatory Affairs Consultancy based in Barcelona.<br />
Founded in 2000, RPN has consistently grown for over 10 years and now consists of over 25 professional consultants with backgrounds in<br />
Pharmacy, Chemistry, Biology and Biotechnology.<br />
RPN is structured into working groups for International Registration Procedures, Clinical and Medical Writing, Electronic Submission of<br />
Regulatory Data, CMC/Quality and Pharmacovigilance.<br />
RPN offers comprehensive services, including:<br />
- Assessment of Project Feasibility and International Regulatory Strategy<br />
- Strategic Planning and Design of Non-Clinical and Clinical Development Plans<br />
- Preparation and Submission of Regulatory Documentation (CTA, IND, IMPD, IB, MAA, NDA, eCTD, etc.)<br />
- Contacts and negotiations with Regulatory Authorities worldwide<br />
SENIOR MANAGEMENT<br />
Dr David Mauléon, Chief Executive Officer • Lidia Cánovas, Managing Director • Núria Romero, Managing Director • Consol Bozzo,<br />
Director • Carmen Ulla, Director • Núria Coderch, Director • Mercè Blanchart, Director • Michael Schaub, Business Development<br />
BIO Business Forum 2011 203 Participating Company <strong>Profiles</strong>
Dr. Nikolaus F. Rentschler<br />
President & CEO<br />
Erwin-Rentschler-Str. 21<br />
88471 Laupheim<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Alexander Goetz, Sales Director North America<br />
Klaus B. Schoepe, SVP Client Relations<br />
Rentschler Biotechnologie GmbH<br />
Presenting Company<br />
Clinical Foci: Service • Biopharmaceuticals • Drug Development<br />
www.rentschler.de/92l<br />
Phone: 49-7392-701555<br />
Incorporated: 1974<br />
Employees: 600<br />
Ownership: Private<br />
Isa M. Stehle, Sales Director International<br />
Stephan Brockmann, Sales Director Europe<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
2010 Commissioning of the first 1,000 L single-use bioreactor production unit<br />
2009 Inauguration of the new logistics and administration buildings<br />
2008 Commissioning of the 2,500 L GMP production line<br />
July 2011 Inauguration of the new part of the<br />
laboratory building<br />
Further expansion in production capacities<br />
CORPORATE MISSION<br />
Rentschler Biotechnologie is an international full-service contract manufacturer with more than 35 years of experience in the<br />
development, production and approval of biopharmaceuticals in compliance with international standards in good manufacturing<br />
practice (GMP). Dedicated to deliver high-quality biopharmaceuticals produced in mammalian cell culture, Rentschler has nine standalone<br />
GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 litres, allowing the production of material for clinical trials (phase I to<br />
III) and for market supply. Rentschler also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes<br />
and injection vials. As a pioneer in the development and production of biopharmaceuticals, Rentschler was the first company in the world<br />
to gain market authorization for an interferon-containing drug.<br />
Rentschler provides customized, integrated biopharmaceutical services, from cell line to the development and production of the active<br />
ingredient and from marketing authorization to fill and finish. The long-term experience of Rentschler Biotechnologie combined with the<br />
range of comprehensive services ensures the success of any project - rapidly and reliably.<br />
Rentschler is flexible when it comes to services, capacity and products - for process development or production of materials for clinical<br />
trials and the market, whether low-dose cytokines or high-dose antibodies and biosimilars.<br />
At present, there are 9 ultra modern, state-of-the-art suites for GMP production and three GMP filling lines operated by currently approx.<br />
600 well-trained employees. This makes Rentschler Biotechnologie one of the market leaders in the industry worldwide. Rentschler<br />
Biotechnologie will continue expanding its capacities in the future in order to be able to take on new and challenging tasks.<br />
PROPRIETARY TECHNOLOGY<br />
GMP certified services provided by Rentschler Biotechnologie:<br />
> Cell Line and Process Development<br />
> Fill and Finish<br />
> Production of Active Pharmaceutical Ingredients<br />
o Aseptic filling in vials:<br />
o Stainless steel bioreactors:<br />
- with/without Lyophilization<br />
- 30 L to 2,500 L<br />
- Volumes up to 30 mL<br />
o Single-use bioreactors:<br />
- Batch size: 100 to 70,000 vials<br />
- 250 L to 1,000 L<br />
o Aseptic filling of pre-filled syringes:<br />
o Cultivation methods:<br />
- Volumes up to 20 ml<br />
- Batch, repeated batch, fed batch<br />
- Batch size: 100 to 15,000 syringes<br />
- Continuous methods (e.g. perfusion)<br />
> Analytics and Quality Control<br />
> Marketing Authorization Application and Consulting<br />
> Quality Assurance<br />
> Corporate Project Management<br />
CORPORATE ALLIANCES<br />
Preferred partnership agreement with Boehringer Ingelheim for a seamless project transfer to large-scale manufacturing of up to 15,000 L.<br />
Cooperation agreement with CELLCA GmbH aimed at the development, application and marketing of a high-level expression system for<br />
mammalian cells.<br />
SENIOR MANAGEMENT<br />
Dr. Nikolaus F. Rentschler, President & CEO • Mr. Reiner Winkelbauer, Executive VP • Dr. Klaus B. Schoepe, Senior VP • Prof. Roland<br />
Wagner, Senior VP • Mr. Thomas Siklosi, Senior VP • Mr. Horst Schröter, Senior VP<br />
BIO Business Forum 2011 204 Participating Company <strong>Profiles</strong>
Walter C. Herlihy, Ph.D<br />
President & CEO<br />
41 Seyon Street<br />
Waltham, MA 02453-8346<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Howard Benjamin, Vice President, Business Development<br />
Christopher McNulty, Director, Business Development<br />
Walter Herlihy<br />
RepliGen Corporation<br />
Clinical Foci: CNS • Neurology • Diagnostics<br />
www.repligen.com<br />
Phone: 1-781-250-0111<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Repligen announces successful Phase III trial with RG1068 in<br />
pancreatic imaging.<br />
Repligen prepares for clinical trials with RG2833 in Friedreich's<br />
Ataxia and RG3039 in Spinal Muscular Atrophy.<br />
Incorporated: 1981<br />
Employees: 75<br />
Ownership: Public<br />
Market Cap: $120.00 million<br />
NASDAQ: RGEN<br />
File NDA for RG1068; enter into partnership for ex-US<br />
commercialization.<br />
Initiate clinical trials with RG2833 and RG3039; enter into<br />
partnership(s) for one or both programs.<br />
Grow the bioprocessing business through development and<br />
acquisition of new products.<br />
CORPORATE MISSION<br />
Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of<br />
patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development<br />
programs: (1) RG1068, synthetic human secretin to improve magnetic resonance imaging of the pancreas, preparing for NDA filing; (2)<br />
RG2833, Class 1 HDAC inhibitor for Friedreich's Ataxia, IND filed; (3) RG3039, increases SMN levels for treatment of Spinal Muscular<br />
Atrophy, late preclinical development. For over 20 years, the company has also made a difference in patients' lives through its<br />
commitment to quality in its bioprocessing business. Through the sale of its Protein A products, Repligen provides the biopharmaceutical<br />
industry with tools used in the manufacturing of therapeutic and diagnostic monoclonal antibodies. Sales of recombinant Protein A<br />
products have resulted in a steady revenue stream, allowing Repligen to continue to invest in its bioprocessing product line in order to<br />
capture this growing market, while at the same time funding development of its therapeutic pipeline.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Protein A On Market Antibody Purification<br />
RG1068 NDA/BLA filed, or in process Pancreatic Imaging File NDA<br />
RG2833 IND Filed Friedreich's Ataxia Initiate clinical trial in 2011<br />
RG3039 IND Filed Spinal Muscular Atrophy Initiate clinical trial in 2011<br />
SENIOR MANAGEMENT<br />
Walter C. Herlihy, Ph.D, President & CEO • Michael Hall, MD, Chief Medical Officer • William J. Kelly, Chief Financial Officer • James R.<br />
Rusche, PhD, Senior Vice President • Howard Benjamin, PhD, Vice President • Stephen Tingley, Vice President • Laura Whitehouse,<br />
Vice President • Daniel P. Witt, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Alexander Rich, MD, Massachusetts Institute of Technology • Glenn L. Cooper, MD, Retired • Karen A. Dawes, Knowledgeable<br />
Decisions, LLC • Alfred L. Goldberg, PhD, Harvard Medical School • Earl Webb Henry, MD, inVentiv Clinical Solutions • Walter C.<br />
Herlihy, PhD, Repligen Corporation • Thomas F. Ryan, Jr., Retired/Private Investor<br />
BIO Business Forum 2011 205 Participating Company <strong>Profiles</strong>
Ryoko Yoshioka<br />
Director<br />
Mitsui-Life Bldg. 2F, 1-7-23 Morino, Machida-<br />
City<br />
Tokyo 194-0022<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Junko Kashiwa<br />
Kiyu Suzuki<br />
ReqMed Company, Ltd<br />
Clinical Foci: CNS • Neurology • Musculoskeletal<br />
www.reqmed.co.jp<br />
Phone: 81-42-732-2207<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Asahi Kasei Pharma, our partner for Sodium Pentosan Polysulfate<br />
(NaPPS) for the treatment of Osteoarthritis (OA), has initiated PIIa<br />
study in April, 2010 in Japan.<br />
POC studies of Eltoprazine for Cognitive Impairment Associated<br />
with Schizophrenia and Dyskinesia in Parkinson's disease are<br />
progressed with grant of TURNS program by NIH and with fund of<br />
Michael J. Fox Foundation.<br />
One of our clients, MEDRx, a Japanese biopharmaceutical company,<br />
has successfully concluded a licensing agreement with KOWA,<br />
granting KOWA the exclusive sales right of Etodolac Patch for the<br />
treatment of acute pain in US.<br />
CORPORATE MISSION<br />
Incorporated: 1998<br />
Employees: 15<br />
Ownership: Private<br />
PIIa study of NaPPS for OA will be completed in the middle of 2011.<br />
ReqMed expects to find the Asian partners for the development<br />
and marketing of Eltoprazine for the treatment of ADHD and other<br />
potential CNS indications.<br />
ReqMed will expand our pipeline of drug development through inlicensing,<br />
co-development and government grants projects.<br />
ReqMed was established in May, 1998 and the company name was derived from our motto "Required Medicine for all who request it". That<br />
motto drives our corporate goal: To help people worldwide obtain medicine and good health. We provide extensive services, such as drug<br />
development and business consulting, as BioBiz Navigator.<br />
PROPRIETARY TECHNOLOGY<br />
We offer partnering opportunities through our worldwide network, and support in building R&D strategies and licensing activities. To<br />
minimize the risk and to maximize the project value, we would involve its development process as "Drug Discovery Coordinator", which we<br />
have created as the business model.<br />
CORPORATE ALLIANCES<br />
Partners: PsychoGenics (www.psychogenics.com): Joint Development of CNS drugs based on its expertise in behavioral neurobiology.<br />
bene-pharmaChem(www.bene-gmbh.de): Joint Development of NaPPS as OA drug. Asahi Kasei Pharma: partner in Japan to conduct<br />
further development and marketing of NaPPS as OA drug. Clients of business consulting: ReqMed provides its services to many<br />
pharmaceutical companies and venture companies in US, EU and Japan.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Sodium Pentosan Polysulfate<br />
(NaPPS)<br />
Phase II, IIa, IIb Osteoarthritis (OA) Completing PIIa study in<br />
1H2011<br />
Eltoprazine Phase II, IIa, IIb ADHD and other CNS<br />
indications<br />
Finding development and<br />
marketing partner in Asia<br />
SENIOR MANAGEMENT<br />
Ryoko Yoshioka, Director • Takehiko Kaseda, Director • Junko Kashiwa, Business Development • Tadashi Matsumoto, PhD, MBA,<br />
President & CEO<br />
BOARD OF DIRECTORS<br />
Tadashi Matsumoto, PhD, MBA, ReqMed Company, Ltd. • Ryoko Yoshioka, ReqMed Company, Ltd. • Takehiko Kaseda, ReqMed<br />
Company, Ltd. • Masayuki Ushida, ReqMed Company, Ltd. • Jack Lief, Arena Pharmaceuticals, Inc.<br />
BIO Business Forum 2011 206 Participating Company <strong>Profiles</strong>
Robert Webber, PhD<br />
President & CEO<br />
2645 West Cheyenne Avenue<br />
Las Vegas, NV 89032<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Robert J. Webber, PhD, President and CEO<br />
Research & Diagnostic Antibodies<br />
Clinical Foci: Diagnostics • Biopharmaceuticals • Infectious Disease<br />
www.rdabs.com<br />
Phone: 1-702-638-7800<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
We received a $2.6 million NIH grant to conduct a pivotal clinical<br />
study to obtain FDA market clearance for the first accurate and<br />
reliable IVD test that detects the onset of the sepsis pathology 24 –<br />
72 hours prior to appearance of symptoms.<br />
Our discovery of a new pathophysiologic pathway for the sepsis<br />
pathology and our new therapeutic target for treating sepsis have<br />
been confirmed and validated by at least three independent<br />
groups of investigators.<br />
Our aSeptiMab® candidate therapeutic mAb treatment for sepsis<br />
has been shown to be effective by rescuing up to 80% of the<br />
challenged animals from death by sepsis in three different animal<br />
models of sepsis.<br />
Incorporated: 1984<br />
Ownership: Private<br />
A pivotal clinical study to obtain FDA market clearance is being<br />
conducted in the US on our plasma iNOS IVD (PliNOSa® test) to<br />
detect early the onset of the sepsis pathology. We anticipate<br />
market launch will be no later than first quarter of 2013.<br />
Initiation of production of our candidate therapeutic mAb<br />
aSeptiMab® to support both Phase I and IIa clinical trials is<br />
anticipated to start in early 2012. A Phase I safety trial on<br />
aSeptiMab® is anticipated to be completed by early 2014.<br />
A Phase IIa efficacy clinical study on our candidate therapeutic mAb<br />
for sepsis, aSeptiMab®, is anticipated to be completed by early<br />
2015. The patients will be pre-screened and stratified prior to<br />
enrollment using our IVD PliNOSa® test.<br />
CORPORATE MISSION<br />
Research & Diagnostic Antibodies (R&D Abs) was founded in 1984, and since its inception has been successfully producing and selling its<br />
proprietary products to researchers worldwide. Our main expertise is developing antibodies to the individual members of multi-protein<br />
families. In addition to being the primary producer of all antibodies and research use only (RUO) kits in its catalogue, R&D Abs has also<br />
developed hundreds of monoclonal and polyclonal antibodies on contract. These custom antibodies have been used to develop<br />
immunoassays in numerous assay formats.<br />
One of R&D Ab’s goals is to capture a large fraction of an $850 million per year clinical IVD testing market for the onset of sepsis based<br />
upon new enabling technologies that have been discovered and patented. This market will be captured by commercializing new clinical<br />
products that are emerging from our patented technologies, for example autoanalyzer tests and point-of-care (POC) devices that can<br />
prognosticate the onset of sepsis as-well-as diagnose and monitor the course of the pathology. All of these new products will meet existing<br />
market needs to diagnose the medically underserved hyperinflammatory pathology known as sepsis. We are seeking a licensee/codevelopment<br />
partner to commercialize our IVD tests.<br />
The second goal of R&D Ab is to capture a large fraction of a multi-billion dollar market for treating sepsis. We have developed and tested<br />
in pre-clinical experiments a candidate monoclonal antibody (mAb) therapeutic that neutralizes in vivo the deleterious effects of a<br />
recently validated new therapeutic target for sepsis. In three different animal models of sepsis, intervention with our patented mAb<br />
rescues up to 80% of the challenged animals from death by sepsis. We are seeking a licensee/co-development partner to assist with the<br />
clinical trials on, and worldwide commercialization of, our candidate therapeutic mAb treatment for sepsis.<br />
PROPRIETARY TECHNOLOGY<br />
Our IP includes patented monoclonal antibodies and immunoassays for inducible nitric oxide synthase including clinical assay kits and<br />
apparatuses. We also have issued patents and additional pending patent applications on a new therapeutic target to treat sepsis. Our<br />
discoveries describe a new pathophysiologic pathway for the sepsis pathology and how to detect, diagnose, monitor and treat this<br />
hyperinflammatory condition in its very early stages, i.e. prior to organ damage and dysfunction.<br />
INTELLECTUAL PROPERTY<br />
Patents issued in the USA, Germany, France, UK, Ireland, Switzerland, Italy, Japan, and Australia.<br />
Additional patent applications pending worldwide to protect more recent discoveries.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PliNOSa test Diagnostics early sepsis diagnosis NIH $2.6 million award to conduct pivotal clinical study<br />
aSeptiMab Target Validated early sepsis Rescues up to 80% of the septic animals in 3 different models<br />
of sepsis<br />
SENIOR MANAGEMENT<br />
Robert Webber, PhD, President & CEO • Thelma Dunnebacke-Dixon, PhD, Vice President • Douglas Webber, PhD, Vice President<br />
BIO Business Forum 2011 207 Participating Company <strong>Profiles</strong>
Shaun A. Kirkpatrick<br />
President & CEO<br />
5210 East Williams Circle, Ste 240<br />
Tucson, AZ 85711-4410<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Shaun A. Kirkpatrick<br />
Chad W. Souvignier, PhD, MBA<br />
Kurt R. Gehlsen, PhD<br />
Research Corporation Technologies, Inc<br />
Clinical Foci: Biopharmaceuticals • Drug Discovery • Medical Device<br />
www.rctech.com<br />
Phone: 1-520-748-4400<br />
Incorporated: 1987<br />
Employees: 20<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Research Corporation Technologies is a technology investment and management company that provides early-stage funding and<br />
development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from<br />
universities and research institutions worldwide. Founded in 1987, the company carries on a vision chartered in 1912 by Frederick Gardner<br />
Cottrell, a university professor and inventor who championed the transfer of academic innovation to commercial use. RCT has assets of<br />
more than $300 million to advance technology development through venture investment, partnerships and special licensing programs.<br />
RCT employs investment professionals with expertise in the life sciences, development of medical devices and therapeutics, and financial<br />
management. Other RCT professionals support all technology development activities, including managing and coordinating new company<br />
formation, filing patent applications and infringement protection, negotiating licenses and other agreements, patents and literature<br />
searches and marketing support. RCT's unparalleled experience and expertise, and its financial resources and partnerships are a powerful<br />
combination that gives important new companies and technologies their best chance for commercial success.<br />
PRODUCTS<br />
Name Phase Indication<br />
Pichia Yeast Expression System Other For License<br />
CH2 Domain Scaffold Other Seeking Partnerships<br />
FreE.coli Endotoxin-free E.coli System Other For License and Partnership<br />
FINANCING HISTORY<br />
Investors: Research Corporation Technologies (100 %)<br />
SENIOR MANAGEMENT<br />
Shaun A. Kirkpatrick, President & CEO • Christopher P. Martin, Chief Financial Officer • Kurt R. Gehlsen, PhD, Chief Scientific Officer •<br />
David Bramhill, PhD, Business Development • Paul Grand, Managing Director • Chad Souvignier, Managing Director<br />
BOARD OF DIRECTORS<br />
Gary M. Munsinger, PhD, Research Corporation Technologies, Inc. • J. Lyle Bootman, PhD, University of Arizona • James A. Mack,<br />
Cambrex Corporation • John P. Schaefer, PhD, University of Arizona • Shaun A. Kirkpatrick, Research Corporation Technologies, Inc. •<br />
Christopher P. Martin, Research Corporation Technologies, Inc. • Theodore M. Welp, E & T Investment Co. • John W. McIntyre, Villa<br />
Tecolote Consulting<br />
BIO Business Forum 2011 208 Participating Company <strong>Profiles</strong>
Donald McCaffrey<br />
President & CEO<br />
202 - 279 Midpark Way SE<br />
Calgary, AB T2X 1M2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Donald J. McCaffrey<br />
ResVerlogix Corporation<br />
Presenting Company<br />
Clinical Foci: Cardiovascular Disease • Drug Development • Biopharmaceuticals<br />
www.resverlogix.com<br />
Phone: 1-403-254-9252<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completed Phase 2a clinical trials with the Cleveland Clinic (Aug. 2010).<br />
Secured 30 Million Canadian equity financing (Dec. 2009).<br />
CORPORATE MISSION<br />
Incorporated: 2001<br />
Employees: 32<br />
Ownership: Public<br />
Market Cap: $110.00 million<br />
TORONTO STOCK EXCHANGE: RVX<br />
IVUS Phase 2b Clinical Trial with Cleveland Clinic 2Q11.<br />
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical<br />
markets with significant unmet medical needs. The NexVas Plaque Regression program is the company’s primary focus which is to<br />
develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important<br />
diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer’s disease, Peripheral Artery Disease and other vascular disorders.<br />
Lead Drug, RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most<br />
promising emerging drugs in the treatment of atherosclerosis. To the company’s knowledge RVX-208 is the only novel small molecule that<br />
is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse<br />
cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for<br />
excretion, thus preventing atherosclerosis. Resverlogix is currently conducting a Phase 2 clinical trial with the Cleveland Clinic with RVX-<br />
208.<br />
PROPRIETARY TECHNOLOGY<br />
The company’s primary CVD program is NexVas Plaque Regression which targets ApoA-I enhancement via novel small molecules for<br />
plaque stabilization and regression. The company’s second CVD program, NexVas Vascular Inflammation is a research stage technology<br />
focused on molecular targets of vascular inflammation. The company’s third cardiovascular program ReVas is dedicated to the R&D of<br />
therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD. NexVas<br />
Alzheimer’s disease is a<br />
discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.<br />
INTELLECTUAL PROPERTY<br />
As of December 15, 2009, Resverlogix owns and/or has rights to six patent families comprised of one issued US patent application and<br />
numerous pending applications. This includes non-provisional US and Patent Cooperation Treaty applications. The pending patent<br />
applications are interrelated and assert rights to substantially similar inventions in different jurisdictions.<br />
PRODUCTS<br />
Name Phase Indication<br />
NexVas Plaque Regression Phase II, IIa, IIb CVD<br />
NexVas Vascular Inflammation Phase I Vascular Inflammation<br />
NexVas Alzheimer's Disease Phase I Alzheimer's Disease<br />
ReVas Preclinical Restenosis<br />
NexVas Auto Immune Preclinical RA, MS, Asthma<br />
SENIOR MANAGEMENT<br />
Donald McCaffrey, President & CEO • Brad A. Cann, CA, Chief Financial Officer • Kenneth Lebioda, Senior Vice President • Jan<br />
Johansson, MD, PhD, Senior Vice President • Norman Wong, MD, FRCP, Chief Scientific Officer • Gregory Wagner, PhD, DABT, Senior<br />
Vice President • Allan Gordon, MD, PhD, Senior Vice President<br />
BOARD OF DIRECTORS<br />
Peter Johann, PhD, Managing General Partner, NGN Capital • Kenneth Zuerblis, Former Chief Financial Officer & Senior VP, ImClone<br />
Systems • Arthur Higgins, Blackstone Group • Eldon Smith, OC, MD, FRCPC, FCAHS, FAHA, FIACS, Editor-in-Chief of the Canadian<br />
Journal of Cardiology; Former Dean of the Faculty of Medicine, University of Calga • Donald McCaffrey, Co-Founder, President, & CEO,<br />
Resverlogix Corp. • Kelly McNeill, BComm (Hons), MAcc, CA, Exec. Vice President of Finance and Administration & CFO, IMRIS<br />
BIO Business Forum 2011 209 Participating Company <strong>Profiles</strong>
SCIENTIFIC ADVISORY BOARD<br />
Bo Angelin, MD, PhD, Karolinska Institutet • Philip Barter, MBBS, PhD, MRACP, FRACP, The Heart Research Institute, Sydney, Australia •<br />
Steven Nissen, MD, Cleveland Clinic • Daniel J. Rader, MD, Professor of Medicine and Pathology, University of Pennsylvania School of<br />
Medicine • Prediman K. (P.K.) Shah, MD, Director, Division of Cardiology and the Atherosclerosis Research Center, Cedars-Sinai Medical<br />
Center • Stephen J. Nicholls, MBBS, PhD, Cleveland Clinic • Christie M. Ballantyne, MD, Professor of Medicine & Chief, Section of<br />
Atherosclerosis and Vascular Medicine, Baylor College of Medicine • John J.P. Kastelein, MD, PhD, Professor of Medicine & Chairman of<br />
the Dept. of Vascular Medicine, Academic Medical Centre, University of Amsterdam • Allen Taylor, MD, Washington Hospital Center<br />
BIO Business Forum 2011 210 Participating Company <strong>Profiles</strong>
Dr. Chang Ahn<br />
Chief Executive Officer<br />
15245 Shady Grove Road<br />
Rockville, MD 20850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Vikas Sharma, Director, Business Development<br />
Rick Soni, MBA, President and COO<br />
Rexahn Pharmaceuticals, Inc<br />
Clinical Foci: CNS • Oncology • Reproductive<br />
www.rexahn.com<br />
Phone: 1-240-268-5300<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Initiation of 300 patient Phase IIb study for Serdaxin® for the<br />
treatment of Major Depressive Disorder.<br />
RX-5902 pre-clinical data presentation at the 2011 AACR meeting.<br />
Equity investment by Teva Pharmaceutical - Teva now own 6.29%<br />
of the outstanding shares of Rexahn.<br />
Incorporated: 2001<br />
Employees: 15<br />
Ownership: Public<br />
Market Cap: $105.00 million<br />
AMEX: RNN<br />
Phase IIb data for Serdaxin® in Major Depressive Disorder.<br />
IND submission for RX-5902 (oral, first-in-class small molecule with<br />
novel mechanism of action) for treatment of solid tumors.<br />
Initiation of Phase IIb trials for Zoraxel® for treatment of Erectile<br />
Dysfunction.<br />
CORPORATE MISSION<br />
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development, and<br />
commercialization of innovative treatments for cancer, central nervous system (CNS) disorders and sexual dysfunction. Rexahn is<br />
developing innovative products with unique differentiated profiles that address unmet medical needs and improve quality of life for<br />
patients. Our clinical stage pipeline includes 3 drugs, Archexin, Serdaxin, and Zoraxel in Phase II trials. In addition to the clinical programs,<br />
Rexahn has a robust pipeline of oncology molecules in preclinical development with one or more IND filings planned in 2011. Our<br />
oncology programs leverage internal expertise, R&D capabilities, proprietary nanomedicine and drug discovery technologies.<br />
PROPRIETARY TECHNOLOGY<br />
1) TIMES (The Inhibitors of Multi-Expression Signals) - a unique ligand discovery platform targeting multi-expression signals.<br />
2) 3-D GOLD (3-D Gateway of Ligand Discovery) - a drug discovery platform that integrates 3-D natures of molecular modeling, databases<br />
of chemicals and proteins, and ligand filtering and generation.<br />
3) Nano-medicine Drug Delivery - unique proprietary drug delivery nano-systems that may increase the availability of a drug at the<br />
disease site, minimize adverse reactions, and/or provide longer duration of action.<br />
CORPORATE ALLIANCES<br />
1) Development and Commercialization Agreement with Teva Pharmaceuticals for Novel Anti-cancer Compound RX-3117.<br />
2) Licensing Partnership with Korea Research Institute of Chemical Technology for the development of a synthetic process for Quinoxalines<br />
compounds.<br />
3) Myltiple sponsored research agreements with Academic institutions.<br />
4) Future Alliances: Rexahn is seeking partners for its clinical and pre-clinical stage programs in cancer, CNS (anxiety/depression), and<br />
Sexual Dysfunction (SD).<br />
PRODUCTS<br />
Name Phase Indication<br />
Serdaxin Phase II, IIa, IIb Depression<br />
Archexin Phase II, IIa, IIb Pancreatic cancer, RCC, ovarian<br />
Zoraxel Phase II, IIa, IIb Sexual Dysfunction<br />
Serdaxin Phase II, IIa, IIb Parkinson's disease<br />
RX-5902 Preclinical Solid tumors<br />
RX-3117 Preclinical Cancer<br />
RX-0201-N Preclinical Cancer<br />
RX-0047-N Preclinical Cancer<br />
RX-8243 Preclinical Cancer<br />
RX-1792 Preclinical Cancer<br />
BIO Business Forum 2011 211 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Dr. Chang Ahn, Chief Executive Officer • Rick Soni, Chief Operating Officer • Ted Jeong, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Dr. Chang Ahn, CEO & Chairman, Rexahn Pharmaceuticals, Inc. • Ted Jeong, Board Secretary; CFO, Rexahn Pharmaceuticals, Inc. •<br />
Charles Beever, Partner & VP, Booz Allen & Hamilton, Inc. • David McIntosh, Partner, Mayer, Brown, Rowe & Maw LLP • Kwang Soo<br />
Cheong, Assoc. Professor, Dept. of Finance, Johns Hopkins • Peter Brandt, Past President of US operation at Pfizer • Richard Kivel,<br />
Chairman of Rhapsody Biologics<br />
SCIENTIFIC ADVISORY BOARD<br />
Michael Thase, MD, Chairperson, University of Pennsylvania • Maurizio Fava, MD, Massachusetts General Hospital, Harvard •<br />
Madhukar Trivedi, MD, UT Southwestern University • Stephen Stahl, MD, University of California San Diego • Susan Kornstein,<br />
Virginia Commonwealth University • Margaret Tempero, MD, Chairperson, UCSF Helen Diller Family Comprehensive Cancer Center •<br />
Gauri Varadhachary, MD, MD Anderson Cancer Center • Barbara Burtness, MD, Fox Chase Cancer Center • David I. Quinn, MD,<br />
USC/Kenneth J. Norris Comprehensive Cancer Center<br />
BIO Business Forum 2011 212 Participating Company <strong>Profiles</strong>
Dr. Serge Bischoff<br />
President & CEO<br />
20C rue de Chemnitz<br />
68200 Mulhouse<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Serge Bischoff, President & CE0<br />
Rhenovia Pharma<br />
Clinical Foci: CNS • Systems Biology • Service<br />
www.rhenovia.com<br />
Phone: 33-389-321180<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Rhenovia has expanded its fields of application to the prevention of<br />
neurodegenerative diseases. We signed a partnership with the<br />
world leader in nutrition Sodiaal Candia for the use of the<br />
biosimulation to maximize milk and derivative products.<br />
Rhenovia has succeeded in expanding its technology to a multiscale,<br />
multi-dimensional biosimulation platform modeling the<br />
cellular and molecular events of the excitatory/inhibitory<br />
transmission, the neuronal firing and networks in brain systems.<br />
Rhenovia has expanded the use of its biosimulation platform to the<br />
risk assessments of neurotoxic chemicals and agents by signing<br />
two contracts with Departments of Defense and clusters of<br />
chemicals and agriculture industry.<br />
Incorporated: 2007<br />
Employees: 12<br />
Ownership: Private<br />
Rhenovia is anticipating strategic alliances with major pharma and<br />
biotech companies or foundations for the implementation of the<br />
biosimulation technology to optimize their DD&D and enrich their<br />
drug pipeline, or boost their research programs.<br />
Rhenovia is starting its international deployment with plans of<br />
creating entities in Switzerland, Germany and USA for the<br />
development of specific business units involving technologies, the<br />
transdermal delivery system and the DD&D program.<br />
Rhenovia is launching a 2nd call for private investment of $2.5 Mio<br />
for the expansion of our biosimulation platforms, the start of our<br />
own DD&D program and the development to an out-licensing<br />
stage of the transdermal prototype for drug combinations.<br />
CORPORATE MISSION<br />
Rhenovia is a biotech company managed by professionals of the top pharma industry and world-known neuroscientists. The mission is to<br />
speed up the time-to-market of new and/or more effective and safer drugs to treat Alzheimer’s and other diseases of the central and<br />
peripheral Nervous System (NS) by developing new technologies that exploit the complexity and multifactorial features of NS diseases.<br />
Rhenovia possesses the most elaborate biosimulation platform directly applicable to Drug Discovery & Development (DD&D). RHENOMS<br />
models the excitatory and inhibitory synaptic transmission with the pre-, intra- and postsynaptic electrical and biochemical events<br />
involving the major signalling cascades downstream to GPCR, ligand- and voltage-gated ion channels. The first proprietary platform<br />
simulates cognitive deficit and other pathologies in the brain, eye, spinal cord and muscular junction associated with the GLU/GABA<br />
homeostasis and Ca2+ deregulation. Further development of this platform expands the application fields to most neurological,<br />
neurodegenerative and psychiatric diseases.<br />
Rhenovia provides several high value added service – partnership programs to the pharma and biotech industry for optimization of their<br />
DD&D at any stage of drug development, from the very early research and discovery stage up to strengthening the life cycle of marketed<br />
drugs having reached patent expiration. One offer is to leverage on the existing drugs of the partners by searching for synergistic<br />
combinations that address the multifactorial feature of diseases by improving efficacy vs side effects and creating differentiation from<br />
competitors.<br />
Rhenovia has elaborated unique computational tools to perform target discovery and validation, drug selection and pharmacological<br />
profiling, and to optimize the type and design of experiments and identify safety issues and toxicity alerts at very early stage with the goal<br />
to increase the success rate of licensing activities.<br />
PROPRIETARY TECHNOLOGY<br />
Rhenovia owns several technologies that provide new solutions and tools to the pharma and biotech companies aiming at maximizing<br />
their in-out-licensing activity and optimizing their DD&D process:<br />
- Biosimulation platform that models the cellular and molecular events and cascades of the excitatory-inhibitory neuronal transmission<br />
and mimics neurological and psychiatric diseases;<br />
- Platform of predictive safety/neurotoxicity for any drugs and toxic agents applicable in Biodefense, Bioterrorism, environmental,<br />
industrial and agricultural toxicity<br />
- In silico flowcharts and virtual compound profiling to accelerate DD&D process and create differentiation<br />
- Transdermal delivery device that allow controlled release in time and doses of single as well combinations of drugs.<br />
CORPORATE ALLIANCES<br />
1. Pilot project with Sanofi-Aventis, providing successful proof of concept of the 1st biosimulation platform on the pharmaceutical<br />
company’s molecules in Phase I-II for cognitive deficits; 2. Two-years R&D program with the French Association against Myopathies for the<br />
development of a dual Glu/GABA synapse platform with future applications in neglected diseases, spinal cord diseases and myopathies; 3.<br />
Three-years R&D program with the SME SynapCell and the Universities of Montpellier and Grenoble for the development of an epilepsy<br />
platform; 5. Collaborative Eurostars project for the development of a unique transdermal delivery system together with Portmann<br />
Instrument AG (Switzerland). 6. Establishment of a partnership with the nutritional leading company Sodiaal Candia.<br />
BIO Business Forum 2011 213 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Worldwide exclusive license on the core of the first biosimulation from the University of Southern California, Los Angeles, USA; Worldwide<br />
exclusive license on some basic principles of the transdermal drug delivery technology from the Fraunhofer Institute, Germany;<br />
Ownership of a multi-scale neuronal network and circuitry biosimulation platform; Trade secret deposited on the first biosimulation<br />
platform, RHENOMS SYNAPSE; Trade secret deposited on the second biosimulation platform, RHENOMS MULTISYNAPSE; Trade secret on<br />
the rate controlled transdermal device for drug combinations; Trade secret on the technology of isoelectric protein purification for<br />
detection of biomarkers for drug efficacy and side effects.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
RHENOMS PFG-1 Monosynapse<br />
Simulation Platform<br />
Other Central and peripheral nervous system Offered for partnership<br />
RHENOMS PFG-2 Dual Synapse<br />
Simulation Platform<br />
Other Central and peripheral nervous system Offered for partnership<br />
SAFETY/TOX platform Other Any central and peripheral indication Offered for partnership<br />
NEUROTOX platform Other Applied to Defense nerve agents,<br />
Chemical and Agricultural toxic agents<br />
RHEDAR drug canditate Phase II, IIa, IIb CNS - orphan repositioning and<br />
expansion<br />
RHENACOLINE, synergistic drug<br />
combination series<br />
ALTHERAS rate controlled<br />
multiple drug patch<br />
Offered for partnership<br />
Identify licensing partner<br />
On Market CNS Identify co-development or lincensing<br />
partner<br />
Research Any indication Search for early partnership for codevelopment<br />
or licensing<br />
VIRTUAL COMPOUND PROFILING Other Central and peripheral nervous system Offered for partnership to maximize<br />
licensing activities<br />
IN SILICO FLOWCHART Other Central and peripheral nervous system Offered for partnership for drug<br />
selection and qualification<br />
ISOELECTRIC PROTEIN<br />
PURIFICATION & SEPARATION<br />
Technology<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 02/28/2010 (US $2.50 million)<br />
Round A: 06/11/2009 (US $0.50 million)<br />
Research Biopharmaceuticals, vaccines,<br />
antibiotics<br />
Identify licensing partner<br />
Investors: Founders and Team Members (82 %) • University of Southern California (3 %) • Alsace Business Angel,<br />
Sodiv, Friend Angels (15 %)<br />
SENIOR MANAGEMENT<br />
Dr. Serge Bischoff, President & CEO • Dr. Michel Baudry, Chief Scientific Officer • Dr. Jan Kremers, Vice President • Michel Faupel, Vice<br />
President • Dr. Florian George, Chief Financial Officer • Dr. Jean-Marie Bouteiller, Director<br />
BOARD OF DIRECTORS<br />
Dr Serge Bischoff, President & CEO, Rhenovia Pharma • Peter Stark, CEO Portmann Instrument AG Switzerland • Jacques Baudry,<br />
General Director, co-founder Rhenovia Pharma • Michel Faupel, Vice President, co-founder Rhenovia • Marc Loizeau, Alsace Business<br />
Angels • Alain Aouizerats, Alsace Business Angels • Dr. Robert Zimmer, CEO Immupharma<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Theodore Berger (Chairman), Prof. at University of Southern California, California, USA • Dr. Jan Kremers (Co-Chairman), Prof. at<br />
University of Erlangen, Germany • Dr. Georges Haas, Former Global Head of Research, Ciba-Geigy, Switzerland • Dr. Serge Braun,<br />
Scientific Director, AFM, Paris, France • Prof. Pierre Braunstein, Director CNRS, Strasbourg, France, Member of the French Academy of<br />
Sciences • Dr. Bernard Scatton, Former Head of Preclinical Research, Sanofi-Aventis, Paris, France • Dr. James Koenig, Prof. at University<br />
of Baltimore, Maryland, USA • Dr. Hans Allgeier, Former Program Head at Novartis, Germany<br />
BIO Business Forum 2011 214 Participating Company <strong>Profiles</strong>
Tony Eisenhut<br />
President<br />
22 Thornwood Drive<br />
Ithaca, NY 14850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
RHEONIX, INC<br />
Clinical Foci: Diagnostics • Pharmacogenetics • Infectious Disease<br />
www.rheonix.com<br />
Phone: 1-607-257-1242<br />
Richard Montagna , PHD, Senior VP, Corp Bus Dev & Scientific Affairs<br />
Tony Eisenhut<br />
Incorporated: 2008<br />
Employees: 25<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Established joint venture with Bohui Innovative Technology Co., Ltd. (Beijing, China) which provides Rheonix with not only access to the<br />
expanding diagnostic markets in China, but also state-of-the-art medical device manufacturing facilities.<br />
Successful progress report for multi-year POC Partnership grant awarded by NIH has resulted in the continuation of funding commitment<br />
for the development of a next-generation, fully automated CARD® to detect multiple STIs and UTIs.<br />
Received additional $500K of funding from NSF to complete the development of a CARD® system for monitoring recreational water for the<br />
presence of microbial contamination. The system will also establish the viability status of the detected microbes.<br />
CORPORATE MISSION<br />
Rheonix® has created a powerful microfluidic platform for the evolving molecular diagnostics industry. This system incorporates low cost<br />
disposable Rheonix CARD® technology to analyze single or multiple clinical raw samples. The Rheonix CARD® system provides multiplexed<br />
endpoint analysis and can be rapidly customized for a wide breadth of diagnostic applications.<br />
Rheonix began its microfluidic efforts approximately seven years ago as the microfluidic division of KIONIX, Inc., (Ithaca, NY) a global<br />
leader in the design and fabrication of high-performance, silicon-micromachined MEMS inertial sensors. After spinning out of KIONIX in<br />
December 2008 and acquiring Innovative Biotechnologies International, Inc., Rheonix has focused on the development of its fully<br />
integrated CARD® platform for molecular diagnostics. Once a “raw” clinical specimen is introduced to the CARD® all sample preparation,<br />
analysis and readout functions are automatically performed without any requirement for user intervention. Molecular assays (PCR, RT-<br />
PCR, NASBA, etc.) or immunoassays can be easily configured on the CARD® allowing either uniplex or multiplex assays to be performed.<br />
Numerous CARD® devices have been developed for use in both human in vitro diagnostics markets, as well as the drinking and<br />
recreational water testing markets. In general, an existing “bench top” assay can be migrated and prototyped on a CARD® device within 6-<br />
12 weeks. Having recently raised equity capital, the company has adequate financial resources to complete the necessary development<br />
and regulatory approval processes to validate its revolutionary products. In addition to its own development efforts, the company also is<br />
the recipient of grants from the EPA, NIH, NSF and NYSERDA.<br />
PROPRIETARY TECHNOLOGY<br />
A fully integrated molecular diagnostic device known as a CARD® (Chemistry And Reagent Device) that is capable of performing all sample<br />
preparation, analysis and readout functions without any user intervention. Once a "raw" clinical specimen is introduced to the CARD®,<br />
required steps are automatically performed under the control of our software. The CARD® platform is available in both a "point-of-care"<br />
and central laboratory format, which includes a XYZ liquid handler.<br />
CORPORATE ALLIANCES<br />
A joint venture with Beijing Bohui Innovative Technology Co., Ltd provides Rheonix with access to the expanding diagnostic markets in<br />
China. The first product to be introduced will be the multi HPV CARD®, capable of simultaneously detecting 20 clinically relevant HPV<br />
subtypes. The company is also under contract to the U.S. EPA to develop a rapid molecular sensor for the detection and determination of<br />
the viability status of Cryptosporidium parvum in drinking water. As a recipient of a multi-year NIH/NIAID "point-of-care partnership"<br />
award through the NIH/NIAID, Rheonix is also developing a fully integrated molecular biosensor for the detection of sexually transmitted<br />
infections (STIs) and urinary tract infections (UTIs) and under an NSF grant is developing a molecular sensor to evaluate<br />
INTELLECTUAL PROPERTY<br />
The company owns or has licensing rights to over 300 US and Foreign patents, covering its various technologies, including its microfluidic<br />
CARD® platform and lamination processes, electrochemical detection methods and use, and an isothermic gene amplification method and<br />
use.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Multi-HPV CARD® Diagnostics Cervical Screening Capable of automatically and simultaneously detecting 20<br />
clinically relevant HPV subtypes, directly from clinical<br />
specimens. .<br />
Warfarin Sensitivity<br />
CARD®<br />
Diagnostics Warfarin sensitivity<br />
genotyping<br />
Starting with whole blood or a raw buccal swab, capable of<br />
automatically detecting SNPs related to CYP2C9*2 and *3 and<br />
VKORC1 to predict sensitivity to warfarin.<br />
BIO Business Forum 2011 215 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Multi STI CARD® Diagnostics Sexually transmitted<br />
infections<br />
Capable of automatically processing a sample and<br />
simultaneously detecting multiple STIs in a multiplex PCR<br />
format.<br />
Multi UTI CARD® Diagnostics Urinary tract infections Capable of automatically processing a sample and<br />
simultaneously detecting multiple UTIs in a multiplex PCR<br />
format.<br />
Sepsis CARD® Diagnostics Stat detection of sepsis Capable of processing ml volumes of blood to simultaneously<br />
detect diverse microbes responsible for sepsis using a multiplex<br />
PCR assay.<br />
Crypto CARD® Diagnostics Drinking water testing Capable of automatically processing raw drinking water<br />
samples for the presence and viability status of<br />
Cryptosporidium parvum. Can detect a single oocyst.<br />
Recreational Water<br />
CARD®<br />
Research Beach water testing Under development to automatically and simultaneously detect<br />
E. coli and four enterococci in recreational waters and<br />
determine their viability status.<br />
KRAS CARD® Research Tumor markers Developing methods to process raw clinical specimens for<br />
automatic detection of tumor markers.<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Seed Round: 01/01/2004 (US $5.50 million)<br />
Round A: 04/21/2010 (US $13.50 million)<br />
SENIOR MANAGEMENT<br />
Tony Eisenhut, President • Peng Zhou, PhD, Chief Scientific Officer • Richard Montagna, PhD, Senior Vice President • John Brenner,<br />
Vice President • Greg Mouchka, Other • Greg Galvin, PhD, Chairman • Christopher Smith, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Greg Galvin, PhD, KIONIX, Inc. • Tony Eisenhut, Rheonix, Inc. • Phil Proujanski, Cayuga Venture Fund<br />
BIO Business Forum 2011 216 Participating Company <strong>Profiles</strong>
Mark Leuchtenberger<br />
President & CEO<br />
300 George Street, Suite 301<br />
New Haven, CT 06511<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jarrod Longocr<br />
CORPORATE MISSION<br />
Rib-X Pharmaceuticals, Inc<br />
Clinical Foci: Infectious Disease<br />
www.rib-x.com<br />
Phone: 1-203-848-6260<br />
Incorporated: 2000<br />
Ownership: Private<br />
Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards<br />
of care for patients with serious infections. The company’s Nobel Prize winning platform enables a unique understanding of how<br />
antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Delafloxacin Phase II, IIa, IIb community acquired pneumonia (CAP) and<br />
uncomplicated skin and soft tissue infections<br />
(uSSTI)<br />
Radezolid Phase II, IIa, IIb community acquired pneumonia (CAP) and<br />
uncomplicated skin and soft tissue infections<br />
(uSSTI)<br />
Conduct Phase 2B study to define new objective<br />
endpoints for Phase 3 (1Q11-4Q11).<br />
Complete long-term preclinical study to<br />
provide key safety differentiation (4Q11).<br />
RX-04 Preclinical cUTI and HapVap Complete partnership and initiate<br />
collaboration (1Q11).<br />
SENIOR MANAGEMENT<br />
Mark Leuchtenberger, President & CEO • Robert Conerly, Chief Financial Officer • Erin Duffy, PhD, Vice President • Eric Burak, PhD,<br />
Vice President • Scott Hopkins, MD, Chief Medical Officer • Jarrod Longcor, Director • Anthony Sabatelli, PhD, JD, Attorney<br />
BIO Business Forum 2011 217 Participating Company <strong>Profiles</strong>
Nordkanalstrasse 28<br />
20097 Hamburg<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Federico Pollano<br />
Philipp Goepel<br />
Boy Ehlers<br />
Richter-Helm Biotec Gmbh & Co. KG<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Vaccines<br />
www.richter-helm.eu<br />
Phone: 49-40-23750<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Improved process yields:<br />
FDA approval 2012<br />
Downstream Processing at Richter-Helm with 2nd Generation Expanded Bed Adsorption Chromatography<br />
resulted in 56% efficiancy increase;<br />
Fermentation process optimisation resulted in >20g/L recombinant protein yield<br />
Richter-Helm completed the modernisation of its GMP facilities:<br />
Fully modernized pilot scale train (300L) available for manufacturing since September 2009;<br />
Support tank volume of up to 4000L is available for the large scale 1500L manufacturing line;<br />
Process development for highly efficient low COG mnufacturing processes for first two biosimilar projects<br />
finalized; Technology Transfer to GMP manufacturing faciliies initiated<br />
CORPORATE MISSION<br />
Richter-Helm BioTec is a dynamic and expanding biotechnology company located in Hamburg, Germany. Being one of the first<br />
biopharmaceutical enterprises in Europe Richter-Helm has more than 20 years of experience in the development and GMP-compliant<br />
production of recombinant proteins, plasmid DNA and microbial vaccines. With more than 120 employees Richter-Helm is offering<br />
customized state of the art solutions for all steps in biopharmaceutical projects via contract development and manufacturing services in<br />
GMP facilities for microbial production (fermentation scale up to 1500L). Beside our strong expertise in E.coli Richter-Helm successfully<br />
produces proteins in yeast (e.g. Pichia). Thus Richter-Helm is the ideal partner for biopharmaceuticals development by offering material<br />
from pre-clinical and clinical trials to market supply at a large scale.<br />
In addition Richter-Helm is the platform of Gedeon-Richter and Helm AG for worldwide licensing options as well as partnerships for codevelopment<br />
and marketing of microbial derived biopharmaceutical development projects (innovative and biosimilars).<br />
PRODUCTS<br />
Name Phase Indication<br />
Interferon alpha 2a API ready for marketing Other Hepatitis infection<br />
PEG Interferon alpha 2a Preclinical Hepatitis infection<br />
Teriparatide Preclinical Osteoporosis<br />
BIO Business Forum 2011 218 Participating Company <strong>Profiles</strong>
James M. Gower<br />
Chief Executive Officer<br />
1180 Veterans Boulevard<br />
South San Francisco, CA 94080-1985<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Dolly A. Vance, General Counsel<br />
Raul Rodriguez, President & COO<br />
Rigel Pharmaceuticals, Inc<br />
Clinical Foci: Drug Discovery • AutoImmune • Metabolic Disease<br />
www.rigel.com<br />
Phone: 1-650-624-1100<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Rigel assumes development of R343, its inhaled syk inhibitor for allergic asthma<br />
that recently completed several Phase 1 clinical trials. Rigel expects to design a<br />
Phase 2 clinical trial with R343 later this year. (May 2011)<br />
Rigel received the Licensing Deal of the Year award at the Sixth Annual Scrip<br />
Awards. The Award, presented jointly to Rigel and AstraZeneca, recognizes the<br />
significance of the collaboration forged by the companies to develop<br />
fostamatinib. (Dec 2010)<br />
Rigel earned US$25 million from AZ for the fulfillment of two major milestones<br />
relating to the clinical development of fostamatinib (R788). (Sept. 2010)<br />
CORPORATE MISSION<br />
Incorporated: 1996<br />
Ownership: Public<br />
Market Cap: $399.00 million<br />
NASDAQ: RIGL<br />
JAK3 inhibitor oral - Rigel expects to initiate a Ph1<br />
clinical trial for transplant rejection and other systemic<br />
immune diseases in 2011.<br />
JAK3 inhibitor topical - Rigel expects to initiate a Ph1<br />
clinical trial for discoid lupus in 2011.<br />
R343 - inhaled syk inhibitor Rigel expects to initiate P2<br />
clinical trials for asthma/COPD in 2012.<br />
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of<br />
inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling<br />
pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with<br />
large pharmaceutical partners to develop and market its product candidates. Current product development programs include<br />
fostamatinib (R788), an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis (w/AstraZeneca), and<br />
R343, an inhaled syk inhibitor that has completed Phase 1 clinical trials for asthma.<br />
PROPRIETARY TECHNOLOGY<br />
Our drug discovery technologies are designed to identify protein targets for compound screening and validate the role of those targets in<br />
the disease process. Unlike genomics-based approaches, which begin by identifying genes and then searching for their functions, our<br />
approach identifies proteins that are demonstrated to have an important role in a specific disease pathway. By understanding the disease<br />
pathway, we attempt to avoid studying genes that will not make good drug targets and focus only on the subset of expressed proteins of<br />
genes that we believe are specifically implicated in the disease process.<br />
CORPORATE ALLIANCES<br />
Rigel has signed partnerships with leading pharmaceutical companies including, AstraZeneca, Pfizer, Merck, Johnson & Johnson, Novartis<br />
and Daiichi Sankyo. During our collaborations with many of these organizations, they added new programs or extended their relationship<br />
with Rigel beyond the scope of the initial agreements. To date Rigel has received over US$292 million from collaborations. These<br />
partnerships are in addition to Rigel's own proprietary research and product development programs.<br />
INTELLECTUAL PROPERTY<br />
Rigel has a strong IP position, which includes over 100 pending patent applications and around 180 issued patents in the United States, as<br />
well as pending corresponding foreign patent applications and issued foreign patents.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Fostamatinib (R788) - Oral syk<br />
Inhibitor (AstraZeneca)<br />
Phase III Rheumatoid Arthritis AZ initiated a Ph3 clinical trial program in Sept 2010<br />
R343 - Inhaled Syk Inhibitor Phase I Asthma/COPD Rigel plans to initiate ph2 clinical trials in 2012<br />
Jak3 Inhibitor Oral Preclinical Transplant rejection /<br />
systemic immune<br />
Rigel plans to initiate a Ph1 clinical trial in 2011<br />
Jak3 Inhibitor Topical Preclinical Discoid lupus Rigel plans to initiate a Ph1 clinical trial in 2011<br />
PKC Inhibitor Preclinical Multiple Sclerosis Rigel plans to initiate a Ph1 clinical trial in 2012<br />
ACVR2B Preclinical Muscle Atrophy Rigel plans to initiate a Ph1 clinical trial in<br />
2012/2013<br />
BIO Business Forum 2011 219 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
AMPK Activator Preclinical Muscle Metabolism Rigel plans to initiate a Ph1 clinical trial in<br />
2012/2013<br />
SENIOR MANAGEMENT<br />
James M. Gower, Chief Executive Officer • Raul R. Rodriguez, President • Donald G. Payan, MD, Chief Scientific Officer • Elliott B.<br />
Grossbard, MD, Chief Medical Officer • Dolly Vance, General Counsel • Ryan D. Maynard, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
James M. Gower, Rigel Pharmaceuticals, Inc. • Bradford S. Goodwin, Keren Pharmaceuticals • Gary A. Lyons, Neurocrine Biosciences,<br />
Inc. • Walter H. Moos, PhD, SRI International • Donald G. Payan, MD, Rigel Pharmaceuticals, Inc. • Hollings C. Renton, Affymax, Inc. •<br />
Peter S. Ringrose, PhD, Biotechnology and Biological Sciences Research Council (UK) • Stephen A. Sherwin, MD, Ceregene, Inc.<br />
BIO Business Forum 2011 220 Participating Company <strong>Profiles</strong>
Ryoji Noyori<br />
President<br />
2-1, Hirosawa<br />
Wako 351-0198<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Motomichi Kono, coordinator<br />
Riken<br />
Clinical Foci: Biology • Drug Discovery • Immunology<br />
www.riken.jp<br />
Phone: 81-48-4679762<br />
Incorporated: 1917<br />
Employees: 3000<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Stem cells make 'retina in a dish':<br />
Mouse cells have been coaxed into forming a retina, the most complex tissue yet engineered (in 2011)<br />
Clones from dead frozen mice:<br />
Implications for species conservation and the possibility of “resurrecting” extinct species (in 2008)<br />
Development of a hybrid enzyme that incorporates a non-natural amino acid into proteins:<br />
Possibility of development of novel protein applied to medicne<br />
Above highlight one will<br />
be possibly applied to<br />
human organ soon.<br />
CORPORATE MISSION<br />
RIKEN, Japan’s flagship research organization, conducts basic and applied experimental research in a wide range of science and<br />
technology fields including physics, chemistry, medical science, biology and engineering. Initially established as a private research<br />
foundation in Tokyo in 1917, RIKEN became an independent administrative institution in 2003.<br />
PROPRIETARY TECHNOLOGY<br />
With respect to Bioscience, the Yokohama Institute south of Tokyo is home to the RIKEN Plant Science Center, the RIKEN Research Center for<br />
Allergy and Immunology, the RIKEN Center for Genomic Medicine, the RIKEN center of the Research Network for Infectious Diseases, the<br />
RIKEN Omics Science Center, the RIKEN Systems and Structural Biology Center, and the RIKEN Bioinformatics And Systems Engineering<br />
division. The Kobe Institute, located on an artificial island of reclaimed land in Kobe Bay, hosts the RIKEN Center for Developmental Biology<br />
and the RIKEN Center for Molecular Imaging Science. The Wako Institute near Tokyo, is home to the RIKEN Advanced Science Institute and<br />
the RIKEN Brain Science Institute.<br />
CORPORATE ALLIANCES<br />
RIKEN has many good alliances with significant public institutes, universities and private companies worldwide.<br />
INTELLECTUAL PROPERTY<br />
RIKEN registered a total of 1,100 patents in fiscal 2010-2011. About 54 % of these patents were registered outside Japan. In addition, 276<br />
patent applications -evenly split between foreign and domestic filings- were made in the same year period.<br />
SENIOR MANAGEMENT<br />
Ryoji Noyori, President • Akihiro Fujita, Other • Teruo Furuya, Other • Maki Kawai, Other • Masaaki Tanaka, Other • Kenji Oeda,<br />
Other<br />
BOARD OF DIRECTORS<br />
Ryoji Noyori, president • Kohei Tamao, Advanced Science Institute • Susumu Tonegawa, Brain Science Institute • Yuichi Obata,<br />
Tsukuba Institute BioResource Center • Toshio Goto, Program for Drug Discovery and Medical Technology Platforms • Kazuo Shinozaki,<br />
Plant Science Center • Naoyuki Kamatani, Center for Genomic Medicine • Masaru Taniguchi, Research Center for Allergy and<br />
Immunology • Masatoshi Takeichi, Center for Developmental Biology • Yasuyoshi Watanabe, Center for Molecular Imaging Science<br />
SCIENTIFIC ADVISORY BOARD<br />
Rita R. Colwell, University of Maryland • Zach W. Hall, University of California, San Francisco • Tsung-Dao Lee, Columbia University •<br />
Yuan Tseh Lee, Academia Sinica • Howard Alper, University of Ottawa • Colin Blakemore, University of Oxford • Hiroo Imura,<br />
Foundation for Biomedical Research and Innovation • Yuichiro Anzai, Keio University • Teruhiko Beppu, Nihon University<br />
BIO Business Forum 2011 221 Participating Company <strong>Profiles</strong>
Severin Schwann<br />
Chief Executive Officer<br />
1 DNA<br />
South San Francisco, CA 94080<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Roche<br />
BIO Board Member, Sponsor, Presenting Company<br />
www.roche.com<br />
Phone: 1-650-225-4225<br />
Theadora J. Calabrese, Licensing Director<br />
Andrew Sleight<br />
Michael Motz<br />
Bardia Akbari<br />
Patrick Schleck<br />
Joe McCracken<br />
Ketan Mehta, Global Business Director, Virology and Infectious<br />
Diseases<br />
Kevin Anderson<br />
Sarah Katharine Holland<br />
Iqbal Mufti<br />
Gerardo Aizencang<br />
Incorporated: 1895<br />
Employees: 80000<br />
Ownership: Public<br />
Market Cap: $120000.00 million<br />
OTHER: RO.S<br />
Mohamed Ragab, Global Head of Partnering, Oncology<br />
Joyce Pei<br />
Shafique Virani, Global Head CNS Business Development &<br />
Licensing<br />
Robert Narquizian<br />
Sharon Valdettaro<br />
Robert Silverman<br />
Peter M. Paciorek, PhD, Licensing Director<br />
Mark T. Noguchi, Global Head, Alliance Management<br />
Barbara Lueckel<br />
Amanda Gett<br />
Patricia Kartelias<br />
CORPORATE MISSION<br />
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and<br />
diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation,<br />
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes<br />
management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible<br />
improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested<br />
almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned<br />
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.<br />
PROPRIETARY TECHNOLOGY<br />
Small molecule medicines, Large Molecule medicines, including monoclonal antibodies, Diagnostics products<br />
CORPORATE ALLIANCES<br />
Over 200 different alliances<br />
PRODUCTS<br />
Name Phase Indication<br />
mabthera On Market non-hodgkins lymphoma, chronic lymphocytic leukemia, rhematoid arthritis<br />
Avastin On Market Colorectal cancer, breast cancer, non-small cell lung cancer, kidney cancer<br />
Herception On Market HER2-postive breast cancer<br />
Cellcept On Market transplantation<br />
NeoRecormon On Market anemia<br />
Pegasys On Market hepatitis B and C<br />
Tarceva On Market lung and pancreatic cancer<br />
Xeloda On Market colorectal cancer, breast cancer<br />
Bonviva On Market osteoporosis<br />
Lucentis On Market macular degeneration<br />
SENIOR MANAGEMENT<br />
Severin Schwann, Chief Executive Officer • Alan Hippe, Chief Financial Officer • Pascal Soriot, Chief Operating Officer • Dan<br />
Zabrowski Global Head of Partnering, Executive Vice President • Jean Jacques Garaud (Roche Research and Early Development),<br />
Executive Vice President • Richard Scheller (Genentech Research and Early Development), Executive Vice President • Osamu<br />
Nagayama (Chugai) Chairman of the Board of Directors and CEO, Chief Executive Officer • Daniel O Day (Diagnostics), Chief<br />
Operating Officer • Silvia Ayoubi (Human Resources), Director<br />
BIO Business Forum 2011 222 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Franz Humer (Chairman) • William M Burns • Andre Hoffman • John Irving Bell • Christoph Franz • DeAnne Julius • Peter<br />
Voseri • Art Levinson • Beatrice Weder di Mauro • Paul Bulcke<br />
BIO Business Forum 2011 223 Participating Company <strong>Profiles</strong>
9115 Hague Road<br />
Indianapolis, IN 46250<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Elizabeth Strum , MSC, Key Account Manager<br />
CORPORATE MISSION<br />
Roche Applied Science/Custom Biotech<br />
Sponsor<br />
Clinical Foci: Industrial Biotech • Biomaterials • Biology<br />
www.roche-applied-science.com<br />
Phone: 1-317-521-2000<br />
Ownership: Other<br />
Roche offers customized biotech solutions for the Pharmaceutical, Diagnostics and Biotech industry: With the experience and strong<br />
customer orientation, Roche Custom Biotech supplies diagnostic reagents, products and services, customized to the quality and regulatory<br />
needs of the customer.<br />
We have enhanced our portfolio to meet the demanding needs of the pharmaceutical manufacturers. Our expanding pharma product<br />
portfolio, including Recombinant Trypsin and Recombinant Dispase, are manufactured under GMP regulations, to meet the exacting<br />
demands of the pharmaceutical manufacturers. With a portfolio of over one thousands products, we also custom manufacture to your<br />
needs.<br />
The Roche product portfolio is the just the start. We can specifically modify existing products and provide consultancy on the development<br />
of completely new items. We offer customization and contract development and manufacturing in nearly all fields of our portfolio,<br />
including but not limited to custom antibody and custom enzyme productions. Whether you require raw materials, labeled antibodies, or<br />
finished kits, our contract manufacturing service will deliver according to your specifications.<br />
Our product portfolio includes a wide range of products used in in-process quality control testing as well as Pharma Biotech enzymes for<br />
dissociating cells from primary tissues, downstream proteases, and biocatalysts.<br />
Roche is in a unique position to fulfill your manufacturing needs using the state-of-the-art innovative and proprietary technologies. The<br />
Roche Custom Biotech team is your window to the wide range of Roche products and services. Each company is assigned a Key Account<br />
Manager who is the key interface between your company and Roche. A logistics Specialist will maintain and monitor your secure supply.<br />
And finally there is a technical specialist assigned to each account to provide product technical support. This unique committed group<br />
assures your needs are met.<br />
PRODUCTS<br />
Name Phase Indication<br />
MycoTool Test On Market In-process control and quality assurance<br />
Liberase Enzymes GMP grade On Market Tissue dissociation<br />
Trypsin recombinant GMP grade On Market Used in insulin production<br />
Catalase On Market For use in personal health applications<br />
Cofactors, gluten-free and animal-free On Market Biocatalytic synthesis<br />
Streptavidin R-Phycoerythrin LumiGrade<br />
Reagents<br />
On Market Laboratory Reagents<br />
Cedex HiRes On Market Image-Based High Resolution Cell Analysis<br />
Cedex Bio Bioprocess Analyzer On Market Metabolite screening, substrate analysis, in-line monitoring<br />
fermentation analysis<br />
BIO Business Forum 2011 224 Participating Company <strong>Profiles</strong>
220 South Broadway, Suite 100<br />
Rochester, MN 55904<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gary Smith<br />
CORPORATE MISSION<br />
Rochester Area Economic Development Inc<br />
Clinical Foci: Regenerative Medicine • Gene/Cell Therapy • Informatics<br />
www.raedi.com<br />
Phone: 1-507-288-0208<br />
Incorporated: 1986<br />
Employees: 6<br />
Ownership: Private<br />
If you are searching for a strategic productive business location RAEDI will help you gather the data and information needed to assess the<br />
Rochester Minnesota area as possible location for your business expansion. Rochester is the fastest growing city in Minnesota and is at the<br />
center of the state's burgeoning Bioscience sector. Home to Mayo Clinic, other notable businesses and institutions located in the area<br />
include IBM, Hormel Institute, and University of Minnesota Rochester. We are looking to assist business that want to investigate the<br />
strategic benefit of a Rochester area location. Let's meet while at Bio and discover whether or not there might be mutual benefit in<br />
working together.<br />
PROPRIETARY TECHNOLOGY<br />
We can connect you with Mayo Clinic, University of Minnesota, IBM and area businesses that have proprietary technology and help make<br />
Rochester, Minnesota, one of the top 10 places in America for Intellectual Property on a per capita basis.<br />
CORPORATE ALLIANCES<br />
Rochester Area Economic Development, Inc., supports a number of partnerships, educational and research institutions in the bioscience<br />
and life science fields located in the heart of southeastern Minnesota. These world-class resources and world changing programs and<br />
partnerships include: Minnesota Partnership for biotechnology and Medical Genomics, Mayo Clinic, University of Minnesota Rochester,<br />
Minnesota BioBusiness Center, The Hormel Institute, Biomedical Informatics and Computational Biology Program, and Mayo Clinic's<br />
Center for Translational Science and Medical Imaging Informatics Innovation Center.<br />
INTELLECTUAL PROPERTY<br />
Companies in our area have hundreds of patents and are seeking out licensing opportunities for some of them.<br />
BIO Business Forum 2011 225 Participating Company <strong>Profiles</strong>
Wilhelm Stahl, PhD<br />
Partner<br />
100 Intrepid Lane<br />
Syracuse, NY 13205<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Wilhelm Stahl, Managing Partner<br />
Joel R. Lirot<br />
Rondaxe Pharma, LLC<br />
www.rondaxe.com<br />
Phone: 1-315-638-4493<br />
Incorporated: 2003<br />
Employees: 10<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Rondaxe is offering consulting and drug development services to small and large companies in the pharmaceutical industry. Recognizing<br />
the challenges and complexities of drug development in the disciplines covered by “Chemistry, Manufacturing and Controls”, we offer<br />
critical expertise, service and software solutions to our customers.<br />
Our goal is to effectively help emerging pharmaceutical and biotechnology companies navigate through all phases of the drug<br />
development and commercialization process. Customers can choose from our full suite of services and products, or select a specific<br />
offering at any point along the drug development timeline.<br />
PROPRIETARY TECHNOLOGY<br />
Rondaxe proprietary systems in knowledge management for cost-of-goods and CMC drug development keep our client's timelines on<br />
track allowing our clients complete control of their projects, from big picture overviews to the smallest of details.<br />
SENIOR MANAGEMENT<br />
Wilhelm Stahl, PhD, Partner • Ann P. Kich, Partner • Kenton Shultis, Chief Executive Officer<br />
BIO Business Forum 2011 226 Participating Company <strong>Profiles</strong>
3200 Whitehaven Street, N.W.<br />
Washington, DC 20008<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Joakim Steen Mikkelsen, Lifesciences & Healthcare Attache<br />
Royal Danish Embassy<br />
Clinical Foci: Drug Development • Diagnostics • Biodefense<br />
Phone: 1-202-234 4300 Ownership: Other<br />
CORPORATE MISSION<br />
Trade Council of Denmark offers export promotion, innovation services and inward investment, he provides regulatory, policy and market<br />
guidance for the life science industry.<br />
BIO Business Forum 2011 227 Participating Company <strong>Profiles</strong>
Nick Stephens<br />
Chief Executive Officer<br />
Stuttgarter Str. 25-29<br />
D-60329 Frankfurt am Main<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Robert L. Bates<br />
CORPORATE MISSION<br />
RSA<br />
Clinical Foci: Service<br />
www.thersagroup.com<br />
Phone: 49-69-2197760<br />
Incorporated: 2004<br />
Employees: 10<br />
Ownership: Private<br />
RSA is a global leader in the provision of Executive Search and Interim Management to the life sciences industries. With offices in the UK -<br />
our head office in Hertfordshire and premises in London - plus China, Germany in Frankfurt and Munich, Singapore, Switzerland and the<br />
USA, RSA consultants talk to hundreds of industry leaders every day, and our network reaches every corner of the worldwide<br />
pharmaceutical, biotechnology and allied industries.<br />
SENIOR MANAGEMENT<br />
Nick Stephens, Chief Executive Officer • Keith Hobson, Chief Operating Officer • Shawn O'Conner, President • Robert Bates, Managing<br />
Director<br />
BOARD OF DIRECTORS<br />
Roger (Steve) Stephens, Owner<br />
BIO Business Forum 2011 228 Participating Company <strong>Profiles</strong>
Yukihiko Mashita, MD<br />
Chief Executive Officer<br />
NBF Hibiya Bldg., 10F, 1-1-7 Uchisaiwaicho,<br />
Chiyoda-ku<br />
Tokyo 100-0011<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Richard Lowenthal, BD representative<br />
R-Tech Ueno, Ltd.<br />
Clinical Foci: Ophthalmic • Skin/Dermatological • Neurology<br />
www.rtechueno.com/en/index.html<br />
Phone: 81-33596-8011<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion Phase 2a clinical study of RK-023 to treat androgenetic alopecia<br />
Initiated Phase I Clinical Study of RK-023 for the Treatment of Hypotrichosis of the Eyelashes<br />
R-tech's partner, Sucampo, initiated Phase 3 Clinical Trial of Lubiprostone<br />
Incorporated: 1989<br />
Employees: 79<br />
Ownership: Public<br />
Market Cap: $105.00 million<br />
TOKYO STOCK EXCHANGE: 4573<br />
Completes Phase I linical Study of RK-023<br />
for the Treatment of Hypotrichosis of the<br />
Eyelashes<br />
CORPORATE MISSION<br />
A global pharmaceutical company specializing in ophthalmology, dermatology and neurology drug products. R-tech Ueno has multiple<br />
products marketed and in development. We are seeking a partner to develop RK-023 for alopecia and hypotrichosis of the eyelashes with<br />
worldwide market rights external to Japan.<br />
PROPRIETARY TECHNOLOGY<br />
R-tech Ueno has multiple products in ophthalmology, dermatology and neuropathy area including a marketed product in the US and<br />
Japan. RK-023 is a proprietary product with full patent protection that has completed Phase 1 and 2 studies in dermatology indications.<br />
RK-023 has a pharmacological and safety profile similar or superior to bimatoprost.<br />
CORPORATE ALLIANCES<br />
- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP): License Agreement to develop, manufacture, and commercialize Unoprostone<br />
(Rescula®)<br />
- Astellas Pharma: Licensed RTU-007 for Diabetic cataract, Diabetic retinopathy and Age-related macula degeneration<br />
INTELLECTUAL PROPERTY<br />
Robust intellectual property for products in development granted.<br />
PRODUCTS<br />
Name Phase Indication<br />
Rescula® (US) Cleared for US Marketing Glaucoma·Ocular hypertension<br />
Rescula® (Japan) On Market Glaucoma·Ocular hypertension<br />
Unoprostone Phase II, IIa, IIb Retinitis pigmentosa<br />
Unoprostone Phase I Dry type Age-related macula degeneration<br />
RTU-007 Preclinical Diabetic cataract, Diabetic retinopathy, Age-related macula<br />
degeneration<br />
RU-101 Preclinical Dry eye<br />
RK-023 Phase II, IIa, IIb Alopecia<br />
RK-023 Phase I hypotrichosis of the eyelashes<br />
RTU-1096 (VAP-1 inhibitor) Preclinical Atopic dermatitis, Contact Dermatitis, Psoriasis vulgaris<br />
RTU-1096 (VAP-1 inhibitor) Preclinical Diabetic neuropathy<br />
SENIOR MANAGEMENT<br />
Yukihiko Mashita, MD, Chief Executive Officer • Tadashi Hayashi, Managing Director<br />
BOARD OF DIRECTORS<br />
Yukihiko Mashima, MD, President and CEO, R-tech Ueno Ltd. • Tadashi Hayashi, Managing Director, R-tech Ueno Ltd. • Sachiko Kuno,<br />
PhD, Sucampo Pharmaceuticals, Inc. • Shinya Homma, Law offices of Nasu & Homma<br />
BIO Business Forum 2011 229 Participating Company <strong>Profiles</strong>
Teleshev Alexey<br />
Director<br />
1, bld. 75B, Leninsky Gory<br />
119992 Moscow<br />
Russian Federation<br />
CONFERENCE PARTICIPANTS<br />
Teleshev Alexey<br />
CORPORATE MISSION<br />
Russian Venture Company Seed Fund, Ltd<br />
www.rvcseed.ru<br />
Phone: 8-495-2879600<br />
Incorporated: 2009<br />
Ownership: Private<br />
The Seed Fund is focused on investing into Russian innovative companies with high growth potential on Russian and foreign technology<br />
markets.<br />
The Seed Fund goals are: 1) Promote seed capital in Russia;<br />
2) Encourage development of the System of Seed Fund Venture Partners in order to engage professional managers, experts and business<br />
angels to launch new companies;<br />
3) Enable conditions to generate a deal flow to venture capital funds, including RVC backed funds;<br />
4) Significantly more and better small technology businesses, which will subsequently apply for early and later stage venture capital.<br />
Capital under management — 67 million dollars, the Fund co-invests together with private investors and covers no more than 75% of an<br />
innovative company’s investment demand in cash providing about 1 million dollars at the first investment round.<br />
Any legal and financial transaction terms permitted by the Russian Federation law are allowed.<br />
The Seed Fund activities are assisted by Venture Partners and Initiators, who have access to scientific, material, technical and financial<br />
resources which are essential for Venture Partners’ activities.<br />
At Round 1, the Fund invests a maximum of 75% of capital demanded by an innovative company, about 1 million dollars.<br />
Key assessment criteria used by the Fund to select innovative companies are as follows: potential for significant growth of an innovative<br />
company, Innovative company complies with the Investment Memorandum of the Fund, qualified team, transparent ownership<br />
structure of the innovative company.<br />
PROPRIETARY TECHNOLOGY<br />
For the purposes of the investment process of the Fund, its assets can only be invested into innovative companies whose activities lie<br />
within one of the priority areas of development of Russian science, technology and engineering and (or) whose products are on the list of<br />
critical technologies of Russia<br />
PRODUCTS<br />
Name Phase Indication<br />
OFC Cardio Lead Series project: immunochromatographic test strips for the determination of myocardial<br />
infarction on the basis of fatty-acid-binding proteins, FABP.<br />
OnkoMaks Preclinical project: innovative targeted drug to treat kidney cancer<br />
Sintegal Phase III project: development, registration and follow-up to market innovative products of<br />
treatment neurological diseases<br />
Remegal Phase II, IIa, IIb project: new treatment of refractory epilepsy with the possibility of extension treatment<br />
of neuropathic pain, manic-depressive psychosis and Parkinson's disease.<br />
AVR-0560 Preclinical project: drug for hepatitis C treatment.<br />
Emdeya Lead Series project: medical device for diagnostic cardiovascular disease<br />
Fotonics Lead Series project: medical devices for surgery soft and hard tissue on the basis of innovative laser<br />
technologies<br />
Plazan Lead Series nanotransdermal systems for production professional anti-aging cosmetics<br />
FINANCING HISTORY<br />
Investors: Russian Venture Company (99 %) • Foundation for Assistance to Small Innovative Enterprises (1 %)<br />
SENIOR MANAGEMENT<br />
Teleshev Alexey, Director<br />
BIO Business Forum 2011 230 Participating Company <strong>Profiles</strong>
Office of Research Alliances, 96<br />
Frelinghuysen Road<br />
Piscataway, NJ 08854<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas Richardson<br />
Shrijay Vijayan<br />
Rutgers, The State University of New Jersey<br />
Clinical Foci: Oncology • Infectious Disease • Drug Delivery<br />
www.ora.rutgers.edu<br />
Phone: 1-732-445-0320<br />
Employees: 9000<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
The Office of Research Alliances was recently formed to partner faculty and centers with industry and to enable cost-effective, outsourced<br />
R&D. Currently, we generate almost $20mm annually in industry research contracts<br />
We recently partnered with Akribio America to build on campus a robotics-based, chemical discovery platform to enable real-time data<br />
chain management and streamlined workflow management for pharma and chemical companies<br />
CORPORATE MISSION<br />
Rutgers, The State University of New Jersey, is one of the premier research institutions in the United States,receiving over $433 million in<br />
external research funding in FY2010. Located on three campuses, Rutgers has over 200+ research institutes/centers, 50,000 students, and<br />
9,000 faculty and staff. Our world class faculty and staff (including thirty-two faculty members in the national academies) bring cutting<br />
edge research and technology to the marketplace.<br />
PROPRIETARY TECHNOLOGY<br />
Drugs (oncology, antibiotics);<br />
Gene silencing drug discovery platform;<br />
Vaccines;<br />
Targets (cancer, CNS);<br />
Drug delivery (polymers, dendrimers, nanolipids, biomaterials);<br />
Devices (microfluidics);<br />
Stem cells (methods to create, analyze)<br />
CORPORATE ALLIANCES<br />
Rutgers has partnerships, alliances and collaborations with companies in Big Pharma, Biotech, start-ups.<br />
We are currently seeking licensees, VC's, partners and/or collaborators, as appropriate for the various technologies Rutgers has available<br />
for partnering<br />
INTELLECTUAL PROPERTY<br />
As of June 30, 2009, Rutgers owned over 500 U.S. Patents, 300 of which have issued in the last decade. The Office of Technology<br />
Commercialization's consistent patent activity showcases the diversity and innovative research taking place at the university and is a<br />
tribute to the quality of our researchers.<br />
BIO Business Forum 2011 231 Participating Company <strong>Profiles</strong>
Egor V. Beketov<br />
Chief Executive Officer<br />
1 Leninskie Gory, bld. 75B<br />
119992 Moscow<br />
Russian Federation<br />
CONFERENCE PARTICIPANTS<br />
Evgeniya A. Selezneva<br />
Egor V. Beketov<br />
HIGHLIGHTS<br />
Recent<br />
Authorized capital USD 50 mln<br />
RVC Biofund, Ltd<br />
Clinical Foci: Biopharmaceuticals • Service<br />
www.rvcbio.ru<br />
Phone: 7-495-9308504<br />
Incorporated: 2011<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The cornerstone of the BioFund Investment Strategy is to invest capital of the Fund into stakes in Russian infrastructure service provides or<br />
innovative companies of Russian biopharmaceutical sector.<br />
Industry Focus of BioFund:<br />
• Service providers (SPs specialized in providing technology, research and development, consulting and/or information and analytical<br />
services to biopharmaceutical, pharmaceutical or medical companies that employ experts of respective qualifications;<br />
• Innovative biopharmaceutical companies (IBCs) whose profiles covers one or more priority areas of development of Russian science,<br />
technology and engineering, specialized in respective biopharmaceutical, pharmaceutical or medical areas, and (or) whose products<br />
are mentioned in biotechnology, pharmaceutics or medicine items of the Critical Technologies Schedule of the Russian Federation;<br />
• Intellectual property rights (subsequently to be contributed to charter capitals of SPs and/or IBCs).<br />
Private co-investment terms:<br />
1) BioFund shall cover up to 50% of investment demand of an IBC during Round One to an amount not exceeding USD 3.3 mln.<br />
Contribution may be made in form of cash, property or patents and/or licenses appraised by an independent appraiser.<br />
A private investor shall cover at least 50% of the investment demand of an IBC during Round One. Such contribution shall be made in form<br />
of cash only.<br />
2) BioFund shall cover up to 75% of aggregate investment demand of a SP to an amount not exceeding USD 3.3 mln. Such contribution<br />
may be made in form of cash, property (including rights to intangible assets appraised by an independent appraiser).<br />
A private investor shall cover at least 25% of aggregate investment demand of a SP. Such contribution shall be made in form of cash only.<br />
SENIOR MANAGEMENT<br />
Egor V. Beketov, Chief Executive Officer • Evgeniya A. Selezneva, Analyst/Equity Research • Irina V. Ovchinnikova, Analyst/Equity<br />
Research • Vadim S. Pokrovsky, Analyst/Equity Research<br />
BIO Business Forum 2011 232 Participating Company <strong>Profiles</strong>
Mark J. Ahn, PhD<br />
President & CEO<br />
60 Prescott Street<br />
Worcester, MA 01605<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
RXi Pharmaceuticals Corporation<br />
Presenting Company<br />
Clinical Foci: Oncology • Skin/Dermatological • Ophthalmic<br />
www.rxipharma.com<br />
Phone: 1-508-767-3861<br />
Mark J. Ahn, PhD, President & CEO<br />
Mark W. Schwartz, PhD, Executive Vice President & Chief Operating Officer<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
RXi Pharmaceuticals and the University of Massachusetts Medical<br />
School Announce Massachusetts Life Sciences Center Cooperative<br />
Research Grant for RNAi Therapeutics for ALS<br />
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical<br />
Development with the Agreement to Acquire Apthera, Inc.<br />
RXi Pharmaceuticals Presents New Preclinical RNAi Data at the<br />
Keystone Mechanism and Biology of Silencing Conference<br />
Incorporated: 2006<br />
Employees: 15<br />
Ownership: Public<br />
Market Cap: $21.78 million<br />
NASDAQ: RXII<br />
NeuVax is slated to commence Phase III clinical trials under a<br />
Special Protocol Agreement in 1H 2012 in low-to-intermediate<br />
HER2+ breast cancer patients, not eligible for Herceptin®.<br />
RXi’s first self-delivering RNAi product candidate, RXI-109 which<br />
targets CTGF (connective tissue growth factor), scheduled to<br />
commence human clinical trials for anti-scarring in planned<br />
surgeries in early 2012.<br />
CORPORATE MISSION<br />
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering, developing and commercializing<br />
innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies.<br />
PROPRIETARY TECHNOLOGY<br />
RXi is developing NeuVax for the treatment of HER2 1+ & 2+ breast cancer patients in the adjuvant setting. The company anticipates<br />
initiating phase III trials under an approved SPA in first half 2012. NeuVax consists of the E75 peptide derived from HER2 combined with<br />
the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T<br />
cells in a highly specific manner to target cells expressing any level of HER2.<br />
RXi has initiated development of clinical candidate RXI-109, a self-delivering RNAi compound (sd-rxRNA) for the reduction of dermal<br />
scarring in planned surgeries.<br />
SENIOR MANAGEMENT<br />
Mark J. Ahn, PhD, President & CEO • Mark W. Schwartz, PhD, Chief Operating Officer • Anastasia Khvorova, PhD, Chief Scientific<br />
Officer • Pamela Pavco, PhD, Vice President • Robert E. Kennedy, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Sanford J. Hillsberg • Richard Chin, MD • Stephen S. Galliker • Steven A. Kriegsman • Rudolph Nisi, MD • Mark J. Ahn, PhD<br />
SCIENTIFIC ADVISORY BOARD<br />
Craig C. Mello, PhD, Founder and Scientific Advisory Board Chairman • Tod Woolf, PhD, Founder and Scientific Advisory Board Member<br />
• George Peoples, MD, Chief Medical Advisor<br />
BIO Business Forum 2011 233 Participating Company <strong>Profiles</strong>
Rakesh Sachdev<br />
Chief Executive Officer<br />
6211 El Camino Real<br />
Carlsbad, CA 92009<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
David Backer<br />
CORPORATE MISSION<br />
SAFC Pharma<br />
Clinical Foci: Biopharmaceuticals • Oncology • Gene/Cell Therapy<br />
www.safcglobal.com<br />
Phone: 1-760-710-6202<br />
Ownership: Public<br />
Market Cap: $8400.00 million<br />
NASDAQ: SIAL<br />
About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. We are recognized as a top 10<br />
global fine molecule supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology<br />
industries. Utilizing global “Centers of Excellence” and dedicated manufacturing facilities, SAFC can resolve development and<br />
manufacturing challenges and accelerate the production of custom materials. Our rich portfolio includes high-purity inorganic materials<br />
for high technology applications, cell culture products, services for biopharmaceutical manufacturing and biochemical production, and<br />
complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com.<br />
PROPRIETARY TECHNOLOGY<br />
Specific CMO capabilities and facilities to support viral gene therapy and vaccines, ADCs, HPAPIs. Custom cell lines using ZFN<br />
SENIOR MANAGEMENT<br />
Rakesh Sachdev, Chief Executive Officer<br />
BIO Business Forum 2011 234 Participating Company <strong>Profiles</strong>
Gordon Ramseier<br />
Partner<br />
1802 Route 31 North, Suite 381<br />
Clinton, NJ 08809<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gordon Ramseier<br />
HIGHLIGHTS<br />
Recent<br />
Sage Group<br />
www.sagehealthcare.com<br />
Phone: 1-908-231-9644<br />
Incorporated: 1994<br />
Employees: 10<br />
Ownership: Private<br />
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and<br />
dynamic health care industry and its investors.<br />
The Sage Group's principals have been Founders, Chairmen, Presidents, CEO's and COO's of a number of emerging health care companies.<br />
These principals have also held senior level management positions in large multi-national organizations.<br />
The Sage Group is located in the USA, Europe, Japan, Israel and Australia.<br />
CORPORATE MISSION<br />
The Sage Group is a leader in the provision of strategic and transactional advice to healthcare companies in the diagnostics, medical<br />
device, pharmaceutical, biotechnology, life science and analytical instrument fields. We have extensive experience in M&A transactions,<br />
licensing, strategic partnering, strategy development and implementation, valuations and due diligence and new venture development<br />
and funding. Sage has, for 15 years, provided authoritative, knowledge-driven and value-creating services to the healthcare industry in<br />
more than 300 client engagements. We have led numerous transactions ranging from strategic planning to partnering, licensing and<br />
mergers, to acquisitions and divestments of value from $ 5-100 million and above. The services we provide include:<br />
- Mergers, Acquisitions, MBI and MBO, Divestments<br />
- Licensing for Products and Technologies<br />
- Strategy Development & Implementation<br />
- Business Development and Corporate Partnering<br />
- Commercial Due Diligence and Technical Assessment<br />
- Valuations and Value-Enhancement Planning<br />
- Opportunity, Forecasting and Risk Assessment<br />
- Interim Management<br />
- New Ventures<br />
- Technology Oriented Positioning Strategy<br />
SENIOR MANAGEMENT<br />
Gordon Ramseier, Partner • Chuck Casamento, Partner • Wayne W. Pambianchi, Partner • R. Douglas Hulse, Partner • William T.<br />
Mason, PhD, Partner • Daniel Tripodi, PhD, Partner<br />
BIO Business Forum 2011 235 Participating Company <strong>Profiles</strong>
Walter P. Havenstein<br />
Chief Executive Officer<br />
5202 PRESIDENTS COURT<br />
Frederick, MD 21703<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
SAIC<br />
Clinical Foci: Biopharmaceuticals • Biodefense • Drug Development<br />
www.saic.com<br />
Phone: 011-240-529-0414<br />
Michael Salgaller, PhD, Business Development Manager, Health Solutions Business Unit<br />
CORPORATE MISSION<br />
Employees: 42000<br />
Ownership: Public<br />
Market Cap: $6200.00 million<br />
NYSE : SAI<br />
SAIC is a FORTUNE 500® scientific, engineering, and technology applications company that uses its deep domain knowledge to solve<br />
problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and<br />
health. We do this with the constant and deliberate commitment to ethical performance and integrity that has marked SAIC since its<br />
founding.<br />
We contribute to projects of national importance, drawing upon our extensive knowledge of the health industry. We approach each<br />
project from a solid grounding in the health domain, allowing for significant insight and a disciplined approach to tackling our customers'<br />
most difficult problems. We feature health, scientific, engineering and technical personnel who are experienced professionals in the areas<br />
of Health Information Technology, Public Health, Life Sciences, and Health Services. We strive to provide best value solutions, without<br />
sacrificing functionality, performance, or quality. Our core skill sets in Healthcare include: Health IT - Systems integration, Software<br />
lifecycle management, Health data management, Security and privacy; Life Sciences - Virtual Pharma, Research Management Support,<br />
Product Development Support Services, Operations, Regulatory Affairs, and Compliance; Public Health - Disease/medical surveillance,<br />
Epidemiology and Biostatistics support, Bioinformatics, Emergency preparedness and response, Health Services, Healthcare Services, Cost<br />
Containment , Supply Chain Management, and Behavioral Health and Outreach Support.<br />
CORPORATE ALLIANCES<br />
Numerous government agencies, including: Health and Human Services (National Institutes of Health, Food and Drug Administration,<br />
Center for Disease Control, National Science Foundation, etc.), Department of Defense (Army, Navy, Air Force), Department of Homeland<br />
Security, and Department of Veterans Affairs.<br />
SENIOR MANAGEMENT<br />
Walter P. Havenstein, Chief Executive Officer • Joseph W. Craver, III, President<br />
BIO Business Forum 2011 236 Participating Company <strong>Profiles</strong>
Fernando de Mora<br />
Partner<br />
Eureka building. Universitat Autònoma de<br />
Barcelona<br />
08193 Bellaterra Barcelona<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Ana Aldea, Business Development Director<br />
CORPORATE MISSION<br />
Salupharma Biosimilars SA<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Service<br />
www.salupharma.com<br />
Phone: 34-65-9284808<br />
Incorporated: 2008<br />
Employees: 2<br />
Ownership: Private<br />
Salupharma Biosimilars SA is a recently established biotechnology start-up company founded by promoters who boast vast experience<br />
within the national and international pharmaceutical markets.<br />
We are fundamentally devoted to the development and marketing of biosimilars, or similar biological medicines, i.e. biotechnologyderived<br />
medicines that have been shown to be similar in quality, safety and efficacy to an EU approved reference biopharmaceutical<br />
product under the European Medicines Agency (EMA) regulations. Salupharma Biosimilars' project arises primarily from the need to fulfill<br />
a social demand and we are firmly committed to generating competitive biosimilars for the global biopharmaceutical marketplace.<br />
In addition to its core activity, we offer consulting and research services to those companies wishing to market and/or develop biosimilar<br />
medicines.<br />
Our expert knowledge of the biosimilars market and of EMA regulatory guidelines, a solid strategic partnership with the UAB, and our<br />
experienced Board of Directors provide the company with a significant added value and competitive advantage in the worldwide<br />
biopharmaceutical arena.<br />
PROPRIETARY TECHNOLOGY<br />
Salupharma Biosimilars aims to develop and market highly competitive (guaranteed and cost-efficient) biosimilar products betting on<br />
innovative and highly cost-efficient expression platforms for the development and production of biosimilars.<br />
We are interested to hear from service companies owning experimental platforms or development expertise on R+D+i of biotech<br />
therapeutic medicines (i.e., cell-line developers, CMOs, formulation developers, preclinical and clinical CROs).<br />
CORPORATE ALLIANCES<br />
Salupharma Biosimilars SA is a start-up company based at the Universidad Autónoma de Barcelona (UAB), a leading Spanish university in<br />
the area of biomedical research. It is internationally recognised for its excellent health care and clinical research activity (>900 highly<br />
ranked publications in 2009 alone). In addition, the UAB is affiliated with several highly ranked academic hospitals and health care<br />
institutions.<br />
The technological and strategic alliance between Salupharma Biosimilars and the UAB ensures the smooth transfer of knowledge,<br />
innovation and technology from the university to Salupharma Biosimilars, and provides our entrepreneurial endeavor with competitive<br />
advantages in the field of biosimilars development, as well as in strategic pre-marketing and sales approaches.<br />
SENIOR MANAGEMENT<br />
Fernando de Mora, Partner • Fernando de Mora, Consultant • Ana Aldea, Business Development<br />
BOARD OF DIRECTORS<br />
Juan Uriach Torello, Snagell SL<br />
SCIENTIFIC ADVISORY BOARD<br />
Fernando de Mora, Universidad Autónoma de Barcelona<br />
BIO Business Forum 2011 237 Participating Company <strong>Profiles</strong>
990-1 Bangbae-Dong, Seocho-Gu<br />
Seoul 137-061<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Jin-Sook Kim, Managing Director<br />
Choi Chung, Team Manager of Business Development<br />
SAMIL PHARM CO, LTD<br />
Clinical Foci: Gastroenterology • Musculoskeletal • CNS<br />
www.samil-pharm.com<br />
Phone: 82-2-520 0381<br />
HIGHLIGHTS<br />
Recent<br />
Signed exclusive distribution agreement for Mirapex (anti-Parkinson's disease) and launched by Samil<br />
Signed exclusive distribution agreement for Zenpep with Eurand (now Aptalis)<br />
Set up representative office in Vietnam<br />
Incorporated: 1947<br />
Ownership: Public<br />
Market Cap: $30.00 million<br />
KOREA STOCK EXCHANGE: 000520<br />
CORPORATE MISSION<br />
Samil Pharm. Co., Ltd. was established in 1947, based on the philosophy of maintaining the human health with excellent medicines and<br />
consistent research and development. Samil Pharm, headquartered in Seoul, Korea, is a fully integrated pharmaceutical company with<br />
R&D, manufacturing, marketing and sales. The company has commercialized proprietary prescriptions as well as OTCs.<br />
Samil Pharm has focused and showed successful performances in several therapeutic areas such as Gastro-intestinal, Liver, Anti-allergy,<br />
Musculoskeletal, Dentistry and Ophthalmology. Recently, Samil Pharm entered into new therapeutic fields such as Neurological and<br />
Cardiovascular field for the continuous growth.<br />
We are seeking the new products opportunities to expand our product portfolio in our main therapeutic areas.<br />
CORPORATE ALLIANCES<br />
Allergan, Boehringer Ingelheim, GSK, Ajinomoto, Abbott, Eurand (Aptalis), Pfizer, Laboratoires Thea, Theramex, Aspen, Laphal, Gentium,<br />
DiscusDental<br />
BIO Business Forum 2011 238 Participating Company <strong>Profiles</strong>
Mr. Yoon Kim<br />
Chairman<br />
263 Yeonji-dong, Jongno-gu<br />
Seoul 110-725<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Chulwoong Sohn, Vice President<br />
Gun Seomoon, Senior Manager<br />
Alex Chang, Director of Business Development<br />
Samyang Corporation<br />
Clinical Foci: Drug Delivery • Oncology • Generics<br />
www.samyang.com/eng<br />
Phone: 82-2-7407280<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
In 2007, Samyang launched a Cremophor-free, high-dosage<br />
paclitaxel formulation (Genexol-PM) to the Korean market.<br />
Genexol-PM was approved as a first-line therapy for Non-Small Cell<br />
Lung Cancer (NSCLC) and Metastatic Breast Cancer.<br />
Samyang launched Genexol-PM to various Asian countries. In 2010,<br />
Genexol-PM was launched in India, and additional Asian countries<br />
for the treatment of NSCLC and breast cancer. In 2010, Samyang<br />
received EU-GMP manufacturing certification.<br />
Samyang received promising results after completing a US Phase<br />
IIa study using Genexol-PM as a monotherapy, and a US Phase I<br />
combination therapy using Genexol-PM and Gemcitabine against<br />
advanced pancreatic cancer.<br />
Incorporated: 1924<br />
Employees: 3000<br />
Ownership: Public<br />
Market Cap: $600.00 million<br />
KOREA STOCK EXCHANGE: 00070<br />
In 2011, Samyang anticipates completion of a Phase I study of<br />
Doctaxel-PNP, which is a polymeric nanoparticle (PNP) I.V.<br />
formulation of docetaxel using slow release technology.<br />
In 2011, Samyang anticipates completion of a BEQ study of<br />
Doctaxel-PM, which is polymeric micelle(PM) formulation of<br />
docetaxel.<br />
Samyang is seeking to out-license Genexol-PM, Docetaxel-PM and<br />
Docetaxel-PNP for the global market.<br />
CORPORATE MISSION<br />
Established in 1924, the Samyang Group is engaged in diversified research and development activities, manufacturing and global<br />
marketing activities through its R & D and manufacturing base in Korea, overseas branches and alliances all over the world. As its core<br />
unit for future growth, Samyang's Pharmaceuticals Business Unit is engaged in the development and manufacturing of novel oral,<br />
parenteral and transdermal drug delivery systems, and of medical devices for wound healing. Samyang owns a Korean Good<br />
Manufacturing Practice (KGMP) approved, modern manufacturing plant for the production of transdermal patches and a diverse array of<br />
medical devices. Samyang Genex, another division of Samyang Group, recently received EU-GMP manufacturing certification for oncology<br />
finished products and API. Adherence to GMP's and excellence in product quality control have been the strengths of Samyang Group, as it<br />
has been inspected and GMP-certified by several EU members. Samyang has established a unique position in the pharmaceutical industry<br />
as a company specialized in the drug delivery systems; oral drug delivery, parenteral drug delivery and transdermal drug delivery; and the<br />
Samyang Group of companies are developing advanced drug delivery systems and medical devices using its in-depth experiences in<br />
polymer chemistry and collaborative relationships with academic institutions and companies in Korea and the US. As Samyang's<br />
Pharmaceutical Business Unit incorporates new drug delivery technologies enabling effective delivery of various types of drugs to specific<br />
target sites, the most recent application involves a set of proprietary polymers that enable the sustained delivery of bio-pharmaceuticals.<br />
PROPRIETARY TECHNOLOGY<br />
Samyang is engaged in the development and manufacture of novel drugs using its patented and innovative drug delivery systems in oral<br />
drug delivery, parenteral drug delivery, and transdermal drug delivery, which include a polymer based solubilizing reagent and delivery<br />
system, a polymer based fast dissolving tablet, a polysaccharide colon specific delivery system, and a hydrogel patch.<br />
CORPORATE ALLIANCES<br />
Samyang Corporation has numerous academic and corporate alliances. The most recently announced collaboration was with Takeda<br />
Pharmaceutical Company Limited for the discovery of a novel DDS platform technology for RNAi therapeutics.<br />
INTELLECTUAL PROPERTY<br />
Samyang has proprietary rights for all of its technologies and products. For the polymeric micelle system and Genexol-PM, patents are<br />
issued in Korea, USA, Japan, EP, Australia, Canada, China, and Mexico. For Samyang’s Fast Dissolving Tablet (FDT) technology, classified as<br />
an orally disintegrating tablet (ODT) technology; and Colon Specific Delivery System (CSDS), patents have been issued or are pending in<br />
Korea, Australia, USA, Europe, and other countries.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Genexol-PM, polymeric micelle<br />
formulation of paclitaxel<br />
On Market Metastatic breast cancer, NSCLC Launched in Korea (2007), India and<br />
various Asian countries<br />
BIO Business Forum 2011 239 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Genexol-PM, polymeric micelle<br />
formulation of paclitaxel<br />
Docetaxel-PM, polymeric<br />
micelle formulation of<br />
docetaxel<br />
Docetaxel-PNP, polymeric nanoparticle<br />
formulation of<br />
docetaxel<br />
Phase II, IIa, IIb Advanced pancreatic cancer Completed Phase II (US)<br />
Phase I Breast cancer, NSCLC, ovarian cancer,<br />
stomach cancer, prostate cancer,<br />
head/neck cancer<br />
BEQ study will be completed in 2011<br />
(Korea)<br />
Phase I Resistant cancer Phase I will be completed by Nov/2011<br />
(Korea)<br />
Capsaicin topical patch Phase III Neuropathic pain Phase II study completed in May/2011<br />
(Korea)<br />
Fast dissolving tablet<br />
technology products<br />
Bioavailability (BA) enhancing<br />
technology<br />
Exenatide-PMP, polymeric<br />
micro particle formulation of<br />
exenatide<br />
SENIOR MANAGEMENT<br />
On Market Cetrizine, Loratadine, Donepezil,<br />
Risperidone, Tramadol etc.<br />
Phase I Applied to API with poor solubility<br />
and/or poor stability<br />
Preclinical Type II diabetes<br />
Mr. Yoon Kim, Chairman • Mr. Cheolho Kwak, Chief Operating Officer • Dr. Chulwoong Sohn, Vice President<br />
Cetrizine-FDT launched in 2008 (Korea)<br />
Two ongoing phase I studies (Korea)<br />
BIO Business Forum 2011 240 Participating Company <strong>Profiles</strong>
Via Olgettina 58<br />
20132-Milan<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Paola Pozzi, IP Business Development, Senior Associate<br />
CORPORATE MISSION<br />
San Raffaele Scientific Institute<br />
Clinical Foci: Gene/Cell Therapy • Oncology • Immunology<br />
www.fondazionesanraffaele.it/EN_home/ind<br />
ex.html<br />
Phone: 39-02-2643 4882<br />
Ownership: Private<br />
The San Raffaele Scientific Institute - Fondazione Centro San Raffaele del Monte Tabor hosts around 729 basic research scientists and 673<br />
physicians scientist working at translational programs. In 2009, the Institute published 774 papers with an average impact factor of 4154.<br />
The Institute is located within one of the largest private biomedical science park in Europe including the San Raffaele Hospital (1400 beds,<br />
around 250 clinical trials/year), the University Vita-Salute San Raffaele (established in 1996, hosts faculties of medicine, psychology and<br />
philosophy and provides specialized post-graduate courses, resident programs in various medical specialties and international PhD<br />
programs in Cellular/Molecular Biology and Molecular Medicine), and three fully integrated Research Institutes funded by external<br />
entities:<br />
- The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), which is a joint venture with the Telethon Foundation, is pioneering<br />
cell and gene therapy strategies in genetic diseases.<br />
- The Institute for Experimental Neurology (INSPE), supported by a research contract with Merck-Serono, investigates the biological and<br />
molecular mechanisms underlying diseases of the nervous system and their clinical translation, with a strong focus on multiple sclerosis.<br />
- The recently established Diabetes Research Institute (HSR-DRI), which is part of the international Diabetes Research Institutes Federation.<br />
The main areas of translational research are Oncology; Diabetes; Cell and Gene Therapy; Immunology and Immunotherapy;<br />
Cardiovascular; Neuroscience and Stem Cell Research.<br />
The San Raffaele Scientific Institute is seeking industrial partners to further develop and exploit its technologies and research results.<br />
PROPRIETARY TECHNOLOGY<br />
microRNA-regulated lentiviral vector platform for therapeutic use<br />
CORPORATE ALLIANCES<br />
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases, see press release:<br />
http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10113.htm<br />
Merck Serono and San Raffaele Scientific Institute to Collaborate on<br />
Research in Neurodegenerative Diseases, see press release:<br />
http://www.merckserono.com/corp.merckserono_2011/en/images/20101212_en_tcm1494_61604.pdf?Version=<br />
INTELLECTUAL PROPERTY<br />
The patent portfolio includes 46 patent families (267 applications/patents of which 101 patents granted) alive in 2011. Patented<br />
technologies include products (peptides, new combination of existing drugs with synergistic effect, therapeutic target), methods (in vivo<br />
and ex vivo) for therapeutic and diagnostic use, protocols, medical device (safety administration of volatile agents during<br />
cardiopulmonary bypass), drug delivery (targeted liposomes), research tools, new cellular models for drug screeening (aggressive<br />
glioblastoma multiforme). Patented technologies are useful in the following diseases: oncology, immune diseases, HIV, regenerative<br />
medicine of muscular dystrophies or neurological diseases.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Clinical use of Rapamycinexpanded<br />
regulatory T cells<br />
Preclinical immune diseases GMP protocol defined in diabetic pts. Ready for Phase1<br />
Ex vivo generation of anergic T<br />
regulatory (Tr1) cells and<br />
therapeutic uses<br />
Neuroprotective role of neural<br />
stem cells in inflammatory CNS<br />
disorders<br />
Periangioblasts, skeletal muscle<br />
progenitors<br />
Therapeutic applications of<br />
microRNA-regulated lentiviral<br />
Vectors<br />
Phase I immune diseases Phase 1 ended with success on 10 pts (safety acheived<br />
in bone marrow transplanted pts affected by leukemia)<br />
Preclinical CNS disorders GMP protocol defined; ready to start phase 1<br />
Preclinical muscular dystrophies Phase 1 started in kids with Duchenne muscular<br />
dystrophy<br />
Preclinical gene therapy of genetic<br />
disorders and other<br />
diseases<br />
safety and efficacy evaluation acheived in dogs<br />
BIO Business Forum 2011 241 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Drug delivery with NGR-coated<br />
liposome<br />
eIF6 antagonist impairs tumor<br />
growth and progression in vivo<br />
Ras-ERK inhibitory permeable<br />
peptides for the treatment of<br />
neurological disorder<br />
Pre-operative predictive<br />
markers of Acute Kidney Injury<br />
in patients undergoing c<br />
Novel cancer combination<br />
treatments<br />
Preclinical cancer In vivo evidences show significant growth inhibition,<br />
improved efficacy and more pronounced antitumor<br />
effects of Doxorubicin NGR-coated liposome compared<br />
to free Doxorubicin alone, in a doxorubin-resistant<br />
colon-cancer model HCT-116<br />
Preclinical cancer We recently showed that eIF6 is rate-limiting in<br />
tumorigenesis and tumor growth in vivo. eIF6 mutant<br />
impairs tumor growth and progression in vivo both in<br />
heterozygous setting, but most importantly and<br />
unexpectedly in a wild-type setting, in vivo.<br />
Preclinical L-DOPA induced dyskinesia<br />
(LID), addiction to drugs of<br />
abuse, mental retardation<br />
(Ras-MAPK sindromes) and<br />
brain tumors.<br />
Diagnostics renal failure following<br />
cardiac surgery<br />
in vivo data in a mouse and in a non-human primate<br />
(NHP) model of LID are available (Fasano et al., PNAS<br />
2010). Importantly, does not show additional<br />
movement deficit and does not reduce the therapeutic<br />
effect of L-DOPA for the treatment of PD patients.<br />
biomarkers validated on 425 patients undergoing<br />
cardiac surgery have been examined at the San<br />
Raffaele Hospital.<br />
Preclinical cancer, angiogenesis ready for clinical study. In vivo data are available:<br />
combination treatment for restoring antitumor<br />
immune response and for preventing tumor<br />
angiogenesis.<br />
BIO Business Forum 2011 242 Participating Company <strong>Profiles</strong>
Keita Mori<br />
Chief Executive Officer<br />
231 S. Whisman Rd.<br />
Mountain View, CA 94041<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Casey Case, PhD<br />
Keita Mori, Co-CEO<br />
Toru Kawanishi<br />
SanBio, Inc<br />
Presenting Company<br />
Clinical Foci: Regenerative Medicine • Neurology • CNS<br />
www.san-bio.com<br />
Phone: 1-650-625-8965<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Initiated a Phase 1/2a clinical trial for the lead product SB623 for<br />
stroke recovery.<br />
Closed two partnering deals, Teijin Pharmaceuticals and Dainippon<br />
Sumitomo Pharmaceuticals.<br />
Initiated multiple animal pharmacology studies to explore<br />
indications beyond stroke.<br />
Incorporated: 2001<br />
Employees: 12<br />
Ownership: Private<br />
Obtain human clinical safety and evidence of efficacy for SB623 in<br />
stable stroke.<br />
Complete GMP scaled up manufacturing for SB623 later stage<br />
clinical trials and commercialization<br />
Establish efficacy for SB623 in several additional indications,<br />
initiate safety studies and file INDs.<br />
CORPORATE MISSION<br />
SanBio is a clinical-stage biopharmaceutical company developing proprietary stem cell products for stroke recovery and neuroregeneration.<br />
SanBio's products are derived from adult stem cells. Our cell therapy products are used allogeneically, meaning lots from<br />
individual donors can be used to treat thousands of patients.Neither donor matching nor immunosuppressive co-therapy is required.<br />
A Phase 1/2a clinical trial is underway testing SanBio's lead product, SB623, in patients with stable stroke disability.<br />
PROPRIETARY TECHNOLOGY<br />
SanBio's lead product, SB623, is an improved mesenchymal stromal cell derived from adult bone marrow. SB623 has proven particularly<br />
effective in reversing the stable deficits following ischemic stroke.<br />
SB623 is not cell replacement therapy. SB623 works by bolstering the host's regenerative capacity by producing beneficial factors and<br />
reducing inflammation. The SB623 cells themselves are eliminated from the host after a few months, but the benefit persists long term.<br />
SB623 has shown efficacy is models of Parkinson's disease, spinal cord injury and retinal degeneration. It is currently being tested in a<br />
model of spinal cord injury.<br />
SanBio has several additional regenerative cell types in development.<br />
CORPORATE ALLIANCES<br />
SanBio is conducting a Phae 1/2a clinical trial on stable stroke patients in partnership with Stanford University and the University of<br />
Pittsburgh Medical Center. We have strategic partnerships with Teijin Pharmaceuticals and Dainippon Sumitomo Pharmaceuticals.<br />
INTELLECTUAL PROPERTY<br />
Out intellectual property is protected by a multi-layer overlapping patenting strategy. We have licensed the core intellectual property<br />
from several major Japanese universities. We have added to this core by our own applications. Many of these patents have issued, others<br />
are pending.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SB623 Phase I Stable stroke Safety. Efficacy.<br />
SB618 Research Demyelinating diseases, spinal cord injury Extending proof of concept<br />
SB623 Preclinical Spinal Cord Injury Efficacy in a model system<br />
SB623 Preclinical Parkinson's Disease Efficacy in a model system<br />
SB623 Preclinical Retinal Degeneration Efficacy in a model system<br />
SB623 Preclinical Traumatic Brain Injury Efficacy in a model system<br />
SENIOR MANAGEMENT<br />
Keita Mori, Chief Executive Officer • Toru Kawanishi, Chief Executive Officer • Casey Case, Vice President • Ernest Yankee, Vice<br />
President • Michael McGrogan, Vice President<br />
BIO Business Forum 2011 243 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Keita Mori, SanBio • Mario Rosati, Wilson Sonsini Goodrich & Rosati • Toru Kawanishi, SanBio • Brian Frenzel, AnVent Group<br />
SCIENTIFIC ADVISORY BOARD<br />
Hideyuki Okano, PhD, Keio University • Martha Bohn, PhD, Northwestern University • Krys Bankiewicz, MD, Ph.D, UCSF • Arnold<br />
Caplan, Ph.D, Case Western • Douglas Kondziolka, MD, University of Pittsburgh • George R. Martin, Ph.D, Fibrogen. NIH • Yoichi<br />
Nabeshima, MD, Ph.D, Kyoto University<br />
BIO Business Forum 2011 244 Participating Company <strong>Profiles</strong>
Jeff George<br />
Chief Executive Officer<br />
Biochemiestrasse 10<br />
A-6250 Kundl<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Friedrich Nachtmann , PhD<br />
Simon Bateman<br />
Sandoz Austria<br />
Clinical Foci: Biopharmaceuticals • Industrial Biotech • Service<br />
www.sandoz.com<br />
Phone: 43-5338-200680<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Sandoz opened a new, fully integrated 2x13,000 L cGMP facility for<br />
manufacture of mammalian cell culture derived proteins and<br />
antibodies.<br />
In 2009 Sandoz opened a new state of the art 1,300 L fermentation<br />
and purification line for the cGMP manufacture of recombinant<br />
proteins and peptides by microbial systems.<br />
Incorporated: 1946<br />
Employees: 23000<br />
Ownership: Private<br />
With the expansion of manufacturing capacity in the field of<br />
mammalian cell culture, Sandoz is now in the position to support<br />
further manufacturing requests for US, European and Japanese<br />
partners.<br />
With the recent expansion of manufacturing capacity in the field<br />
of microbials, Sandoz is now in the position to support further<br />
manufacturing requests for US, European and Japanese partners<br />
also addressing earlier stage and lower demand products..<br />
With its proprietary expression systems and increased lab capacity<br />
Sandoz offers now also services for process development at all<br />
stages.<br />
CORPORATE MISSION<br />
With more than 60 years experience in biotechnological manufacturing and with more than 25 years experience in Biopharmaceuticals,<br />
Sandoz uses its leading technology for own products and for partnerships with third parties.<br />
Sandoz offers various resources as a fully integrated partner in development and cGMP manufacture of recombinant products (peptides,<br />
proteins and monoclonal antibodies) as well as manufacture of fermentation-derived small molecules.<br />
With regard to Biopharmaceuticals, Sandoz offers cGMP manufacture of recombinant peptides, proteins and antibodies by microbial<br />
systems at 1,300L, 3,000L, 13,000L and 40,000L scale and mammalian cell culture at 3,000L, 13,000L and 2x13,000L scale in its facilities in<br />
Austria. Each upstream unit is equipped with a corresponding downstream line including state-of-the-art isolation, recovery and<br />
purification techniques. Up today Sandoz has manufactured more than 25 different biopharmaceuticals for clinical as well as commercial<br />
use.<br />
In addition to Biopharmaceuticals, Sandoz offers "classical" fermentation services ranging from 3,000 L up to 250,000 L for small molecules<br />
and enzymes.<br />
Sandoz provides aligned laboratories and pilot plant facilities operated by a customer-oriented team with extensive know how in<br />
technology transfer and scale-up of processes.<br />
Today, Sandoz is a partner for numerous pharmaceutical and biotech companies.<br />
Sandoz, a division of Novartis, is a global company dedicated to the development, manufacture and marketing of pharmaceuticals,<br />
biopharmaceuticals and biotechnological active ingredients. Worldwide, Sandoz presently employs about 23,000 people and generated<br />
sales of USD 7.5 billion in 2009.<br />
PROPRIETARY TECHNOLOGY<br />
Sandoz Biopharmaceuticals provides a set of proprietary technology, e.g. a cost effective new expression technology for peptides and<br />
proteins enabling autocatalytic cleavage during isolation process.<br />
Sandoz offers extensive know how on scale up technology and inclusion body technology.<br />
CORPORATE ALLIANCES<br />
Sandoz manufactures more than 20 different recombinant products for well known (bio)pharmaceutical and biotech companies located<br />
in the US, Europe and Japan.<br />
Sandoz´s manufacturing facilities are approved by EMA, FDA and accredited for biological products by PMDA.<br />
INTELLECTUAL PROPERTY<br />
NAFT (NPRO AUTOPROTEASE FUSION TECHNOLOGY) a new proprietary platform technology for the expression of recombinant peptides<br />
and proteins is covered by several patents held by Sandoz.<br />
The technology is available for manufacturing partners and licensees of Sandoz.<br />
BIO Business Forum 2011 245 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Manufacture of recombinant proteins and peptides<br />
at 1.3K, 3K, 13K and 40K liter<br />
Manufacture of antibodies and proteins at 3K, 13K<br />
and 2x13K Liter scale CC<br />
Autoprotease Fusion Technology for the expression of<br />
rec.peptides<br />
FINANCING HISTORY<br />
Investors: Novartis (100 %)<br />
SENIOR MANAGEMENT<br />
Cleared for US Marketing NA FDA/EMEA/PMDA approved<br />
facilities<br />
Phase III NA<br />
Other NA<br />
Jeff George, Chief Executive Officer • Ameet Mallik, Chief Business Officer • Friedrich Nachtmann, Senior Vice President<br />
BIO Business Forum 2011 246 Participating Company <strong>Profiles</strong>
145 Jules-Léger<br />
Boucherville, QC J4B 7K8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Sandoz Canada<br />
Clinical Foci: Generics • Specialty Pharmaceutical • Ophthalmic<br />
www.sandoz.ca/site/en/index.shtml<br />
Phone: 1-450-641-4903<br />
Laurent Masaro, Portfolio Manager, Strategy & Business Development<br />
CORPORATE MISSION<br />
Ownership: Private<br />
Sandoz Canada is an affiliate of Sandoz International GmbH, the second-largest generic company worldwide, and a subsidiary of the Swiss<br />
multinational company Novartis Group. A leader in its field, Sandoz Canada develops, manufactures, markets and distributes a broad<br />
range of generic products in numerous forms for both the retail pharmaceutical sector and the hospital sector.<br />
With more than 225 molecules, Sandoz has one of the largest product ranges in Canada. The company continues to demonstrate its<br />
leadership each year by expanding its range of products with the development of innovative new oral and injectable generics and complex<br />
medications such as controlled-release drugs and subsequent entry biologics.<br />
Sandoz Canada is also a worldwide centre of excellence for the development of injectable products within the Sandoz Group. Dynamic and<br />
creative, the company has one of the highest growth rates among the largest manufacturers of generic pharmaceutical products in the<br />
country.<br />
CORPORATE ALLIANCES<br />
Sandoz Canada has built many partnerships and strategic alliances over the years with both local and international partners.<br />
Sandoz Canada is looking to acquire or in-license specialty pharmaceutical products for the Canadian market. More precisely, Sandoz is<br />
looking for injectable products to strengthen its leading position in the hospital market (Sandoz ranks 1st among generic companies with<br />
over 50% market share, and 4th combining pharmaceutical and generic companies) as well as non-generic products for its retail division<br />
(Sandoz ranks 4th in the retail generic market and is one of the fastest growing company).<br />
FINANCING HISTORY<br />
Investors: Novartis (100 %)<br />
BIO Business Forum 2011 247 Participating Company <strong>Profiles</strong>
Edward Lanphier<br />
President & CEO<br />
501 Canal Boulevard<br />
Richmond, CA 94804<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Curt A Herberts, Director, Corporate Development<br />
David G. Ichikawa<br />
Sangamo BioSciences, Inc<br />
Clinical Foci: Gene/Cell Therapy • Hematology • Genetic Disorders<br />
www.sangamo.com<br />
Phone: 1-510-970-6000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion of Enrollment of Sangamo's Phase 2b Clinical Trial in Diabetic Neuropathy. In<br />
January 2011, the company announced that enrollment of its Phase 2b double-blind,<br />
placebo-controlled clinical trial (SB-509-901).<br />
Presentation of Positive Clinical Data from Sangamo's Novel ZFN Therapeutic® Approach<br />
for the Treatment of HIV/AIDs at the Conference for Retroviral and Opportunistic<br />
Infections (CROI).<br />
Collaboration with the CHDI Foundation, Inc. (CHDI) to Develop a Novel ZFP Therapeutic<br />
for Huntington's Disease (HD).<br />
Incorporated: 1995<br />
Employees: 80<br />
Ownership: Public<br />
Market Cap: $340.00 million<br />
NASDAQ: SGMO<br />
Presentation of data from Phase 2b study of<br />
SB-509 in moderately severe DN in 4Q11.<br />
Presentation of further data from Phase 1<br />
clinical trials of SB-728-T in HIV/AIDS in<br />
2H11.<br />
CORPORATE MISSION<br />
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and<br />
modification. The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety<br />
and clinical effect in patients with diabetic neuropathy and a has recently completed a Phase 2 trial in ALS. Sangamo also has a Phase 1/2<br />
and two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety<br />
and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on<br />
hemophilia, beta-thalassemia, sickle cell, neuropathic pain, nerve regeneration, Parkinson’s disease and monogenic diseases. Sangamo’s<br />
core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By<br />
engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene<br />
expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.<br />
Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow<br />
AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company’s web site at www.sangamo.com.<br />
PROPRIETARY TECHNOLOGY<br />
Zinc Finger DNA-binding Protein (ZFP) Technology, ZFP transcription factors (ZFP TFs) and ZFP nucleases (ZFNs).<br />
CORPORATE ALLIANCES<br />
Sigma-Aldrich Corporation is the exclusive distributor of ZFP technology for research, cell line engineering and transgenic animal<br />
production. Sigma markets ZFP products under the trademark CompoZr.<br />
Dow AgroSciences is the exclusive distributor of ZFP technology in plant agriculture applications. Dow AgroSciences markets ZFP<br />
technology as ExZact Precision Technology.<br />
INTELLECTUAL PROPERTY<br />
Preeminant intellectual property in the area of zinc finger DNA-binding proteins and their applications.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SB-509 Phase II, IIa, IIb Moderately severe diabetic<br />
neuropathy<br />
Phase IIb trial enrollment completed<br />
December 2010, data 4Q11.<br />
SB-728-T Phase I HIV/AIDS Preliminary Phase I/II data in 2H'2011<br />
SB-313 Phase I Glioblastoma multiforme Investigator sponsored trial ongoing<br />
at City of Hope<br />
ZFP TF activator of GDNF Preclinical Parkinson's disease MJFF funding to move into nonhuman<br />
primate models.<br />
SB-509 Phase II, IIa, IIb Neurodegenerative conditions ALS,<br />
Stroke, TBI and SCI<br />
ALS Phase 2 trial complete, others in<br />
preclinical studies.<br />
BIO Business Forum 2011 248 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
ZFNs for gene correction of<br />
Factor 9<br />
ZFP TF repressors of Trk-A and<br />
PN3<br />
Preclinical Hemophila B Publication of data<br />
Preclinical Neuropathic Pain Publication of data.<br />
ZFNs for gene correction Preclinical Mongenic diseases (various) Publication of data.<br />
ZFNs for modification of stem<br />
cells for therapeutic use<br />
SENIOR MANAGEMENT<br />
Research Various Publication of data.<br />
Edward Lanphier, President & CEO • H. Ward Wolff, Chief Financial Officer • Dale Ando, MD, Chief Medical Officer • Philip Gregory,<br />
DPhil, Chief Scientific Officer • David Ichikawa, Senior Vice President<br />
BOARD OF DIRECTORS<br />
William Ringo, Sr. Vice President, Business Dev., Strategy and Innovation, Pfizer Inc. • Paul Cleveland, EVP Corporate Development and<br />
CFO Affymax • Stephen Dilly, MBBS, PhD, President & CEO, APT Pharmaceuticals • William Gerber, MD, Partner, Bay City Capital •<br />
John Larson, Former Partner, Morgan, Lewis and Bockius (Retired) • Steven Mento, PhD, President & CEO, Conatus • Thomas Wiggans,<br />
Former Chairman & CEO, Peplin, Inc. • Edward Lanphier, President & CEO, Sangamo BioSciences, Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
Sir Aaron Klug, OM, FRS, MRC Laboratory of Molecular Biology, Cambridge, UK; Nobel Laureate, Chemistry • Judith Campisi, PhD,<br />
Berkeley National Laboratory • Barrie Carter, PhD • Michael Gilman, PhD, President & CEO, Stromedix, Inc. • Gabor Rubanyi, MD,<br />
PhD, CSO Cardium Therapeutics • Kevin Struhl, PhD, Harvard Medical School<br />
BIO Business Forum 2011 249 Participating Company <strong>Profiles</strong>
174 Avenue de France<br />
75013 Paris<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Carole Badorc<br />
Laurence D'Agay<br />
Eric Sol<br />
Jean Bernard Proust<br />
Bernard Job<br />
Hemant Pachnanda<br />
Carole Wilmot<br />
Sanjay Gupta<br />
Angela Columbano<br />
Philippe Goupit<br />
John Orsato<br />
Frédéric Bouvier<br />
Aude Le-Roux<br />
Tanja Weber<br />
Juergen Mueller-Lehar<br />
Frank Zocher<br />
Hubert Haag<br />
Corinne Venot<br />
Christopher Berry, Partnering & Innovation<br />
Isabelle Thizon De Gaulle<br />
Harald Pacl<br />
Patrick Tricoli<br />
Shiv Krishnan<br />
Sylvaine Cases, PhD<br />
Sanofi<br />
Sponsor<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Veterinary<br />
www.sanofi-aventis.com<br />
Phone: 33-1-54774108<br />
Incorporated: 2004<br />
Employees: 100000<br />
Ownership: Public<br />
Market Cap: $96000000.00 million<br />
EURONEXT: SAN<br />
Wayne Rowe, PhD<br />
Sathapana Kongsamut<br />
Frederic Galli<br />
Renee Horak , PHD<br />
Jean-Christophe Giuge<br />
Mark Gardella<br />
Jeanne Kehren<br />
Bernard Davitian<br />
Alison O'Neill<br />
Sridar Natesan<br />
Irena Melnikova, PhD<br />
Georges T. De Sanctis, PhD, FCCP<br />
Mel Hollis<br />
Christine Korbmacher<br />
Carole Fages<br />
Jean-Pascal Herault<br />
Kathleen Odonnell<br />
Eric Moussaud-Fergeau<br />
Cyrille Leperlier, VP Medical Assessment Corp Strat & BD<br />
Jaderson Lima<br />
Ammad Shorbaji<br />
Kathy Megyery<br />
Sylvain Clermont<br />
CORPORATE MISSION<br />
Sanofi’ ambition is to be a diversified global healthcare leader, focused on patients’ needs.<br />
Sanofi has core strengths in the field of healthcare with seven growth platforms: emerging markets, human vaccines, consumer<br />
healthcare, diabetes treatment, rare diseases, innovative products and animal health.<br />
Sanofi strategy is based on three key principles in order to deliver long-term sustainable growth: increasing innovation in Research &<br />
Development, seizing external growth opportunities, adapting Group structures for future challenges<br />
Sanofi:<br />
- approximately 100,000 employees in 100 countries<br />
- 2010 net sales: €30.4 billion<br />
For more information: www.sanofi.com<br />
BIO Business Forum 2011 250 Participating Company <strong>Profiles</strong>
Olivier Charmeil<br />
President & CEO<br />
Discovery Drive<br />
Swiftwater, PA 18370<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Andrew Murdin, Consultant<br />
Inca Kusters , PHD<br />
Chris Scirrotto, Deputy Director Alliance Management<br />
Timothy Howe<br />
Peter Ellis<br />
Luc Aujame<br />
Marie-Joelle Frachette<br />
Delphine Jullien<br />
Laura Millet, Alliance manager<br />
Jean-Marc Renard<br />
Helène Santacruz<br />
Ken Guito<br />
Sanofi Pasteur<br />
BIO Board Member, Sponsor, Presenting Company<br />
Clinical Foci: Vaccines • Infectious Disease • Biopharmaceuticals<br />
www.sanofipasteur.com<br />
Phone: 1-570-957-7187<br />
Incorporated: 1977<br />
Employees: 12000<br />
Ownership: Public<br />
Market Cap: $100000.00 million<br />
NYSE : SNY<br />
Donna Martin, Vice President, Corporate Development<br />
Jeffrey Almond<br />
Emanuelle Trannoy, PHD<br />
Roman M. Chicz, Head of External Research & Development - North<br />
America<br />
Farshad Guirakhoo, Senior Director external RD NA<br />
Alexander Rumyantsev<br />
John Grano, Vice President, Sales Optimization, Americas<br />
Stuart Feldman<br />
Mark Lievonen<br />
Jason Locklin , BA<br />
Truong Ta<br />
Matthew Wilcox, Director, Strategic and Business Projects<br />
HIGHLIGHTS<br />
Recent<br />
Feb 2011 - Sanofi Pasteur is partnering with the International Vaccine Institute to support the recently launched Dengue Vaccine<br />
Initiative. Sanofi Pasteur’s candidate dengue vaccine—which targets all four virus serotypes— is in Phase III.<br />
Sept 2010 - Sanofi Pasteur has acquired the Modular IMmune In-vitro Construct technology to capture genetic and environmental<br />
diversity in a surrogate human immune system, providing earlier selection of the optimal vaccine candidates.<br />
June 2010 - Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against several Infectious Diseases<br />
and will obtain worldwide exclusive development and commercialization rights for the discovered antibodies.<br />
CORPORATE MISSION<br />
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provides more than 1 billion doses of vaccine each year, making it possible to<br />
immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range<br />
of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a<br />
century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in<br />
research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us<br />
PROPRIETARY TECHNOLOGY<br />
Sanofi Pasteur is the vaccines division of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes<br />
therapeutic (and prophylactic) solutions to improve the lives around the world. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in<br />
New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com<br />
CORPORATE ALLIANCES<br />
Sanofi Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes,<br />
government bodies, biotechnology companies, and contract research organizations. Our collaborations cover virtually all aspects of<br />
vaccine and monoclonal antibody development for the prevention and treatment of infectious disease, including early-stage research.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Sanofi Pasteur manufactures<br />
multiple paediatric and adult<br />
vaccines<br />
Sanofi Pasteur has an extensive<br />
R&D portfolio<br />
On Market Multiple products that protect against<br />
20 bacterial and viral diseases<br />
Multiple products marketed<br />
worldwide<br />
Target Validated Infectious Diseases Multiple projects at all stages of<br />
development<br />
BIO Business Forum 2011 251 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Sanofi Pasteur offers Vaccine<br />
Production<br />
Sanofi Pasteur can<br />
Commercialize your product<br />
Sanofi Pasteur is a leader in<br />
Alliance Management<br />
On Market vaccines production facilities all over the world<br />
On Market vaccines commercial presence in 150 countries<br />
around the world<br />
Research partnerships over 70 alliances at any given time<br />
SENIOR MANAGEMENT<br />
Olivier Charmeil, President & CEO • Michel DeWilde, Senior Vice President • Jean-Marc Renard, Vice President • Jeffrey Almond, Vice<br />
President<br />
BIO Business Forum 2011 252 Participating Company <strong>Profiles</strong>
Soren Tulstrup<br />
President & CEO<br />
Kogle Alle 6<br />
DK-2970 Horsholm<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Soren Andersen, Chief Business Officer<br />
Soren Tulstrup, President & CEO<br />
Santaris Pharma, AS<br />
Clinical Foci: Specialty Pharmaceutical • Genetic Disorders • Biopharmaceuticals<br />
www.santaris.com<br />
Phone: 45-4517-9800<br />
Incorporated: 2003<br />
Employees: 65<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
11 May 2011 Santaris Pharma A/S advances a second drug from its cardiometabolic program, SPC4955, inhibiting apoB, into Phase 1<br />
clinical trials for the treatment of high cholesterol<br />
4 May 2011 Santaris Pharma A/S advances new cholesterol-lowering drug, SPC5001 inhibiting exciting new target PCSK9, into Phase 1<br />
clinical trials for the treatment of high cholesterol<br />
23 Sep 2010 Santaris Pharma A/S advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat<br />
patients infected with Hepatitis C virus<br />
CORPORATE MISSION<br />
Santaris Pharma A/S, a privately held clinical-stage biopharmaceutical<br />
company focused on the discovery and development of microRNA and<br />
mRNA-targeted therapies, is delivering on the promise of RNA-targeted medicines today.<br />
PROPRIETARY TECHNOLOGY<br />
The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s<br />
proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded<br />
LNA-based drug candidates across a multitude of disease states. Santaris Pharma A/S internal research and development activities<br />
currently focus on infectious diseases and cardiometabolic disorders while partnerships with major pharmaceutical companies cover a<br />
range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders.<br />
CORPORATE ALLIANCES<br />
Enzon Pharmaceuticals, GSK, Pfizer, Shire and miRagen.<br />
PRODUCTS<br />
Name Phase Indication<br />
SPC3649 - Miravirsen - miR-122 Phase II, IIa, IIb Hepatitis C<br />
HIF-1a Phase I Cancer<br />
Survivin Phase I Cancer<br />
Androgen Receptor Phase I Cancer<br />
SPC5001 - PCSK9 Phase I High Cholesterol<br />
SPC4955 - Apolipoprotein B Phase I High Cholesterol<br />
Beta-catenin Optimized Lead Cancer<br />
PI3KCA Optimized Lead Cancer<br />
Her-3 Phase I Cancer<br />
Gli2 Optimized Lead Cancer<br />
FINANCING HISTORY<br />
Most Recent Round: C Round<br />
Round A: 06/29/2005 (US $6.00 million)<br />
Round B: 03/15/2006 (US $60.00 million)<br />
Round C: 12/31/2007 (US $37.00 million)<br />
Investors: Forbion (12 %) • LD (11 %) • Novo (10 %) • Sunstone Capital (8 %) • Gilde (8 %) • Sunstone (6 %)<br />
SENIOR MANAGEMENT<br />
Soren Tulstrup, President & CEO • Soren Andersen, Chief Business Officer • Henrik Oerum, Chief Scientific Officer • Henrik Stage,<br />
Chief Financial Officer • Art Levin, President • Michael Hodges, Chief Medical Officer • Bolette Wildt, General Counsel • Troels Koch,<br />
Chief Technology Officer<br />
BIO Business Forum 2011 253 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Flemming Ørnskov, Bayer Healthcare • Walter Wenninger, Noxxon Pharma AG • Claus Braestrup, University of Copenhagen • Soren<br />
Carlsen, Novo • Edwin de Graaf, Gilde • Martien van Osch, Forbion • Hans A Kuepper, Global Life Science Ventures • Claus A.<br />
Andersson, Sunstone Capital<br />
BIO Business Forum 2011 254 Participating Company <strong>Profiles</strong>
3-9-19, Shimoshinjo, Higashiyodogawa-ku<br />
Osaka 533-0021<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Tatsuyuki Yamane<br />
Komei Okabe, Business Development<br />
Craig Skenes, Sr. Director, Business Development<br />
Hidehito Matsuoka, Manager, R & D Division<br />
Takashi Ota, External research<br />
Santen Pharmaceutical Co., Ltd.<br />
HIGHLIGHTS<br />
Recent<br />
Licensing-in Adenosine A2A agonsit for Glaucoma from PGxHealth<br />
Licensing-out tafluprost to Merck & Co., for the U.S. and some Euroeapn countries<br />
Licensing-in sirolimus for Ocular Diseases and Conditions from MacuSight<br />
CORPORATE MISSION<br />
Phone: 81-66321-7294 Ownership: Public<br />
Market Cap: $65.00 million<br />
Santen Pharmaceutical Co., Ltd. specializes in ophthalmic and anti-rheumatic pharmaceuticals to protect and improve people's eyesight<br />
and health.<br />
Since its foundation in 1890, the company now becomes leading ophthalmic pharmaceutical company in Japan and worldwide. Santen is<br />
in the No.1 position in the Japanese prescription ophthalmic pharmaceuticals market with a 37% share. Santen is also No.1 in the<br />
Japanese market for disease-modifying anti-rheumatic drugs, with a 44% share. In fiscal 2009, Santen recorded net sales of 110 billion<br />
yen. Total employee is 2,760. This time at BIO, we are actively seeking in-licensing opportunities in ophthalmic field (Retinal diseases,<br />
glaucoma, dry eye, etc.) and also systemic compounds which might be applied for ophthalmic usage. Further, we are interested in the<br />
drug delivery technologies applicable to the sustained release formulation for glaucoma and retinal diseases.<br />
CORPORATE ALLIANCES<br />
Asahi Glass, Inspire, Daiichi-Sankyo, Oakwood, Ube Industries, Merck & Co, MacuSight, etc.<br />
PRODUCTS<br />
Name Phase Indication<br />
tafluprost On Market Glaucoma<br />
Diquafosol sodium On Market Dry eye<br />
Sirolimus Phase I wet AMD, DME<br />
DE-098 Phase II, IIa, IIb Rheumatoid Arthritis<br />
BIO Business Forum 2011 255 Participating Company <strong>Profiles</strong>
Kazuo Yamamoto<br />
President & CEO<br />
35 Higashisotobori-cho, Higashi-ku<br />
Nagoya 461-8631<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Sanwa Kagaku Kenkyusho Co., Ltd.<br />
Clinical Foci: Metabolic Disease • Renal • Ophthalmic<br />
www.skk-net.com<br />
Phone: 81-52-951-8130<br />
Hiroyuki Ohwaki, General Manager, Licensing and Business Development<br />
Toshiyuki Saito, Manager<br />
Yoshihito Kanai<br />
Incorporated: 1953<br />
Employees: 1362<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) is a Japan-based pharmaceutical company that has been engaged in R&D, production and<br />
marketing of ethical pharmaceuticals, diagnostics, medical nutritionals and other health care products, and contract manufacturing of<br />
pharmaceuticals. The targeted therapeutic areas are metabolic disorders, renal diseases and ophthalmic diseases. We are actively seeking<br />
products for in-licensing not only in these areas but also in other related areas.<br />
PROPRIETARY TECHNOLOGY<br />
SKK has established a new formulation technology, One-Step Dry-Coating (OSDrC), with a partner in Japan. The OSDrC rotary tableting<br />
machine, with its variable double-punch configuration, supports single-step manufacturing of pharmaceutical products. This accurate<br />
and flexible control technology allows placement of any number of cores of any shape into one tablet, and enables high value-added drug<br />
formulation development, such as divided tablets with two cores, pulsatile tablets with three cores, and combination products. The<br />
technology also allows incorporation of core ingredients with poor compressibility, thus OSDrC tablets can replace conventional capsules.<br />
Oral rapid disintegration tablets are also possible with the technology.<br />
CORPORATE ALLIANCES<br />
In-license: Bayer AG (Miglitol); Allergan (Posurdex); Fujiyakuhin (FYX-051)<br />
Out-license: Choongwae (Argamate jelly); Kolon (Carnaculin); Kowa (SK-0403); Choongwae (SK-0403); Elmed Eisai (Menilet jelly); Mylan<br />
(Adelavin).<br />
PRODUCTS<br />
Name Phase Indication<br />
Seibule (Miglitol) On Market Type-2 diabetes<br />
Argamate jelly On Market Hyperpotassemia<br />
SK-0403 Phase III Type-2 diabetes<br />
SK-0910 (FYX-051) Phase III Gout, Hyperuricemia<br />
SK-0503 (Ozurdex) Phase III Macular edema<br />
Fidarestat Phase II, IIa, IIb Ophthalmic diseases, Inner ear disorder, Acute kidney injury<br />
SENIOR MANAGEMENT<br />
Kazuo Yamamoto, President & CEO<br />
BIO Business Forum 2011 256 Participating Company <strong>Profiles</strong>
Dr Tim Mitchell<br />
Chief Executive Officer<br />
2a Langford Arch<br />
Cambridge<br />
CB22 3FX<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
John Reader<br />
CORPORATE MISSION<br />
Sareum Ltd.<br />
Clinical Foci: Oncology • AutoImmune • Drug Discovery<br />
www.sareum.co.uk<br />
Phone: 44-1223-497 704<br />
Incorporated: 2003<br />
Ownership: Public<br />
Market Cap: $50.00 million<br />
LONDON STOCK EXCHANGE: SAR<br />
Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics<br />
to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical<br />
and biotechnology companies at the pre-clinical or early clinical trials stage.<br />
Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer<br />
Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of<br />
current cancer therapeutics in in-vivo cancer models.<br />
Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further<br />
information, please visit www.sareum.co.uk<br />
PROPRIETARY TECHNOLOGY<br />
SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the company’s Aurora,<br />
VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research<br />
programmes against other kinase targets.<br />
CORPORATE ALLIANCES<br />
The Institute of Cancer Research (ICR) and Cancer Research Technology Ltd (CRT): To develop small molecule inhibitors of Checkpoint 1<br />
(Chk1) kinase<br />
PRODUCTS<br />
Name Phase Indication<br />
Checkpoint kinase 1 (Chk1) programme Optimized Lead Cancer / oncology<br />
Aurora / FLT3 kinase programme Optimized Lead Cancer / oncology<br />
VEGFR-3 (FLT4) kinase programme Lead Series Cancer / oncology<br />
FLT3 kinase programme Lead Series Autoimmune / MS Multiple Sclerosis/ RA Rheumatoid Arthritis<br />
Aurora / ALK kinase prgramme Lead Series Cancer / Oncology<br />
TYK2 kinase programme Lead Series Autoimmune / MS Multiple Sclerosis / RA Pheumatoid Arthritis /<br />
Psoriasis<br />
SENIOR MANAGEMENT<br />
Dr Tim Mitchell, Chief Executive Officer • Dr John Reader, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Dr Paul Harper<br />
BIO Business Forum 2011 257 Participating Company <strong>Profiles</strong>
Randy H. Weiss, PhD, MBA<br />
President & CEO<br />
4041 Forest Park Avenue<br />
Saint Louis, MO 63108<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Randy Weiss<br />
Sarmont, LLC<br />
Clinical Foci: Drug Discovery • Chemistry • None<br />
www.sarmont.com<br />
Phone: 1-314-604-2850<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
SARmont was founded in 2010 to fill a void in medicinal chemistry<br />
design and lead optimization to help pharmaceutical companies,<br />
venture capital firms, and research institutions bring promising<br />
new drugs to the market..<br />
Ownership: Private<br />
A national press release on May 25, 2011 will be issued announcing<br />
that Dr. John Talley, inventor of Celbrex and seven other drugs that<br />
have entered the market, will serve as chief scientific officer for St.<br />
Louis-based SARmont.<br />
CORPORATE MISSION<br />
SARmont, a trusted provider of medicinal chemistry design and lead optimization services, helps pharmaceutical companies, venture<br />
capital firms, and research institutions bring promising new drugs to market. Dr. John Talley, the inventor of Celebrex and seven other<br />
drugs that successfully reached the market, leads SARmont' medicinal chemistry design team and works in partnership with its clients to<br />
identify high-quality and proprietary investigational new drug (IND) candidates.<br />
Contracting medicinal chemistry design with SARmont means that there's no need to build or hire an internal chemistry department.<br />
SARmont give clients access to the best minds in the business, precisely when they are needed.<br />
SARmont helps streamline and accelerate the drug design process for its client companies and it can advise, guide or manage the design<br />
process.<br />
SARmont is a trusted strategic partner that leads the drug design process and uses Asian contract research organizations for efficiency<br />
and cost savings.<br />
PROPRIETARY TECHNOLOGY<br />
SARmont identifies high-quality drug candidates for its clients. Dr. John Talley, one of the world's most accomplished medicinal chemists,<br />
uses a combination of rational drug design, insightful activity trend analysis, informed interpretation of medical need, and careful<br />
synthetic planning.<br />
CORPORATE ALLIANCES<br />
SARmont partners with pharmaceutical companies, venture capital firms and research institutions to increase their probabiliy of success<br />
in drug discovery. Efficiency and cost savings are achieved through SARmon'ts high quality outsourcing partners, in including Escientia<br />
Life Sciences. Escientia is a high quality Indian CRO partner and provide cost savings and efficiency in chemical synthesis. SARmont<br />
provides project management of all chemical synthesis activities.<br />
INTELLECTUAL PROPERTY<br />
SARmont guarantees confidentiality in an increasingly competitive market. Client companies own all intellectual property that's<br />
generated to help its client companies institutionalize that knowledge. SARmont protects its clients' investment and provides guidance on<br />
its clients' intellectual property strategy. Dr. John Talley has more than 200 issued patents.<br />
SENIOR MANAGEMENT<br />
Randy H. Weiss, PhD, MBA, President & CEO • Rick L. Ryan, PhD, MBA, Business Development • John J. Talley, PhD, Chief Scientific<br />
Officer • Eduardo J. Martinez, PhD, Director • Robert W. Karr, MD, Other • Robert W. Calcaterra, D.Sc., Other<br />
BIO Business Forum 2011 258 Participating Company <strong>Profiles</strong>
Bayerstr. 83<br />
80335 Munich<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Bojan Savic<br />
CORPORATE MISSION<br />
Intellectual propety law firm<br />
FINANCING HISTORY<br />
Savic Patentanwälte<br />
www.savicpatent.eu<br />
Phone: 49-089-5155 5450<br />
Investors: Dr. Bojan Savic (50 %) • Dr. Sven Rihm (50 %)<br />
Incorporated: 2009<br />
Ownership: Private<br />
BIO Business Forum 2011 259 Participating Company <strong>Profiles</strong>
Oliver Szolar<br />
Chief Executive Officer<br />
Veterinärplatz 1<br />
1210 Vienna<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Oliver Szolar, CEO<br />
Otto Doblhoff-Dier<br />
Savira Pharmaceuticals Gmbh<br />
Clinical Foci: Infectious Disease<br />
www.savira.at<br />
Phone: 43-664-845 9742<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Savira focuses on the development of novel therapeutics for the treatment of influenza. The lead program aims at the development of<br />
polymerase inhibitors targeting the unique influenza cap-snatching mechanism.<br />
SENIOR MANAGEMENT<br />
Oliver Szolar, Chief Executive Officer • Helmut Buschmann, Chief Scientific Officer<br />
BIO Business Forum 2011 260 Participating Company <strong>Profiles</strong>
Juha Saharinen<br />
Chief Executive Officer<br />
Mikonkatu 8<br />
FI-00100 Helsinki<br />
Finland<br />
CONFERENCE PARTICIPANTS<br />
Juho Evasoja, Sales Director<br />
CORPORATE MISSION<br />
SBW Corp Ltd<br />
Clinical Foci: Drug Discovery • CNS • Metabolic Disease<br />
www.sbw.fi<br />
Phone: 358-10-439 9440<br />
Ownership: Private<br />
SBW is a Finnish consolidated CRO offering comprehensive services and platforms ranging from target identification to pre-clinical testing<br />
and clinical data management and biostatistics. SBW is headquartered in Finland and has operations also in India, Sweden, Canada and<br />
Switzerland, operating as SBW/Biodix, SBW/Infodix, SBW/Toxis, SBW/novamass and SBW/4Pharma.<br />
SBW's discovery platform combines the European and Indian high-tech knowledge, skills and cost efficiency with state of the art facilities,<br />
instrumentation and expertise. Our services have more than 150 customers in over 20 countries in Europe, Asia and US. We have<br />
experience form over 600 customer project engagements, ranging from virtual biotechs to global big-pharma companies. We offer<br />
services on a fee for service –basis as well as contracting early discovery projects on milestone reward basis.<br />
Our services and platforms include:<br />
* In Silico services, Bioinformatics, Chemoinformatics, Rational Drug Design<br />
* Discovery Biology, Genomics, Proteomics, Molecular Biology<br />
* Biomarker Discovery and Validation<br />
* Dozens of In Vivo Disease Models in CNS, CVD, Diabetes etc.<br />
* Metabolism and Drug Interaction Studies, Bioanalytics and ADME<br />
* PK (rodents and dogs for small and large molecules)<br />
* In Silico, In Vitro and In Vivo Toxicology and Safety Pharmacology<br />
* Clinical Data Management and Biostatistics<br />
We put significant part of our revenues to develop new methods and models for drug discovery. We are participating in a number of<br />
national and international consortia for R&D projects with academic and industrial partners.<br />
You are welcome to visit www.sbw.fi for further information about us and our services and platforms.<br />
PROPRIETARY TECHNOLOGY<br />
Omics technology for biomarker discovery with experimental technologies (genomics and proteomics) coupled with computational<br />
systems biology approach (biological pathways, protein interaction networks).<br />
Patented Ontomine computational platform for predicting bioactivities, adverse effects and toxicities for small molecules, based on<br />
curated proprietary knowledgebase of over 100.000 small molecules experimental results formed into hierarchical models and data<br />
mining.<br />
CORPORATE ALLIANCES<br />
We have been working with over 150 companies globally in more than 600 engagements. These companies range from virtual biotechs to<br />
many global big pharmas.<br />
In addition we are participating in numerous R&D projects with academic and industrial partners with external funding, like the EU FPs<br />
and various technology development agencies.<br />
We alos work directly with many academic groups for new methods in drug discovery.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
InSilico services Pre-Target Validation All Ontomine Software Suite<br />
Invivo Services Lead Series Diabetes,<br />
Cardiovascular, CNS<br />
DIsease models, Safety, Tow, PK, GLP<br />
Drug Metabolism Lead Series All CYP, Pampa, Hepatocytes, ADME, DMPK<br />
Bio Statistics and Data<br />
Management<br />
Phase III Opthalmology,<br />
Parkinson, Cancer<br />
FDA, Submissions, eCTD, EDC<br />
Proteomics, Biomarker research Research All Biologics, Analytics, DIGE, Maldi-TOF, Gel<br />
FINANCING HISTORY<br />
Investors: Tooltech Ltd (50 %) • University of Helsinki Funds (50 %)<br />
BIO Business Forum 2011 261 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Juha Saharinen, Chief Executive Officer • Kristoffer Öström, Chief Financial Officer • Juho Eväsoja, Business Development • Atul<br />
Khanna, Chairman<br />
BOARD OF DIRECTORS<br />
Mr Atul Khanna, Chairman • Mr Ilkka Hyvärinen • Jonathan Knowles • Juha Tuominen<br />
SCIENTIFIC ADVISORY BOARD<br />
Mart Saarma, Professor, University of Helsinki<br />
BIO Business Forum 2011 262 Participating Company <strong>Profiles</strong>
Prof Lindy Durrant<br />
Chief Executive Officer<br />
Dept Clinical Oncology, City Hospital,<br />
Hucknall Rd<br />
Nottingham<br />
NG5 1PB<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Richard Goodfellow<br />
Scancell<br />
Clinical Foci: Oncology • Immunology • Vaccines<br />
www.scancell.co.uk<br />
Phone: 44-115-823 1863<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Listed on London AIM Stock Exchange<br />
Commenced clinical trials with SCIB1 in patients with metastatic<br />
melanoma and secured approval of safety committee to proceed to<br />
second dose level.<br />
Collaboration agreements signed with ImmuneRegen and<br />
immatics for the development of new ImmunoBody vaccines<br />
Incorporated: 1999<br />
Employees: 6<br />
Ownership: Public<br />
Market Cap: $19.00 million<br />
LONDON STOCK EXCHANGE: SCLP<br />
Approval of safety committee to commence dosing at highest dose<br />
level in Phase 1 study<br />
Update on pipeline progress<br />
Further agreements on IP to enhance the potential and utility of<br />
the ImmunoBody platform<br />
CORPORATE MISSION<br />
Scancell is an AIM listed clinical stage UK based biotechnology company focussed on the development of novel ImmunoBody DNA vaccines<br />
for the treatment of cancer and infectious disease.<br />
ImmunoBody vaccines kill tumour cells by generating T cells of unprecedented avidity.<br />
The company's lead vaccine, SCIB1, which is being developed for the treatment of melanoma, has shown outstanding results in animals.<br />
Phase 1 clinical trials with SCIB1 commenced in the UK in April 2010 and are expected to be completed early in 2012.<br />
PROPRIETARY TECHNOLOGY<br />
ImmunoBody® vaccines use a human monoclonal antibody as a vector to target key cells that are essential in stimulating immune<br />
responses against cancer<br />
ImmunoBody® vaccines deliver unprecedented high avidity T cell responses that lyse tumour cells, inhibit the growth of solid tumours<br />
and prevent the spread of metastatic disease<br />
ImmunoBody® technology can be used to develop therapeutic DNA vaccines for both cancer and infectious diseases<br />
Technology USP:<br />
100 fold increase in avidity compared to peptide vaccination<br />
1,000 fold increase in avidity compared to DNA whole antigen<br />
equivalent to the best conventional dendritic cellular vaccine but targets dendritic cells in vivo<br />
CORPORATE ALLIANCES<br />
NIH<br />
ImmuneRegen<br />
Merck Serono<br />
immatics<br />
INTELLECTUAL PROPERTY<br />
Patents have been filed to protect the ImmunoBody technology worldwide. The European patent has now been granted<br />
PRODUCTS<br />
Name Phase Indication<br />
SCIB1 Phase I melanoma<br />
SCIB2 Lead Series lung cancer<br />
SCIB3 Research colorectal cancer<br />
SENIOR MANAGEMENT<br />
Prof Lindy Durrant, Chief Executive Officer • Dr Richard Goodfellow, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
David Evans • Mike Rippon • Matthew Frohn, Oxford Technology VCT • Nigel Evans • Richard Goodfellow • Lindy Durrant<br />
BIO Business Forum 2011 263 Participating Company <strong>Profiles</strong>
Frederick R. Blattner<br />
President & CEO<br />
1202 Ann Street<br />
Madison, WI 53713<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Robert Novy, Chief Scientific Officer<br />
Tony A. Pharo, Director of Business Development<br />
Scarab Genomics<br />
Clinical Foci: Vaccines • Biopharmaceuticals • Industrial Biotech<br />
www.scarabgenomics.com<br />
Phone: 1-608-237-2727<br />
Incorporated: 2002<br />
Employees: 16<br />
Ownership: Private<br />
BIO Business Forum 2011 264 Participating Company <strong>Profiles</strong><br />
AMEX:<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Wisconsin Institute for Sustainable Technology at UW-Stevens Point to use Scarab<br />
Genomics’ Clean Genome E. coli to produce isoprene.<br />
2007 paper demonstrates difficult to clone expression vectors in Scarab’s Clean Genome E.<br />
coli.<br />
Chakiath, C.S. and Esposito, D., 2007. Improved recombinational stability of lentiviral<br />
expression vectors using reduced-genome E. coli. BioTech. 43:466.<br />
Licensing by animal therapeutic company to use MDS42 for the commercial production of<br />
an animal vaccine. Ongoing collaboration with animal therapeutic company for additional<br />
novel vaccine development.<br />
Market release of animal vaccine<br />
produced in Clean Genome E. coli in fall of<br />
2011.<br />
FDA approval of biotherapeutic produced<br />
in Clean Genome E. coli.<br />
Market release of a new Medical Product<br />
produced with Clean Genome E. coli in<br />
2012<br />
CORPORATE MISSION<br />
Scarab Genomics specializes in developing and licensing E. coli bacteria that have been extensively modified to be safe and efficient hosts<br />
for the production of DNA, protein and antibodies. By removing harmful and unnecessary genes, our patented Clean Genome® E. coli are<br />
efficient, safe and generate higher yields of DNA and protein compared with other production platforms. The ability of our strains to grow<br />
robustly in inexpensive, defined media makes them a clear alternative to conventional E. coli production strains.<br />
PROPRIETARY TECHNOLOGY<br />
The Clean Genome® E. coli strains have been engineered to remove over 15% of the E. coli K-12 genome. Using synthetic biology methods, a<br />
series of deletions were made to eliminate non-essential genes, mobile DNA, and virulent genes including cryptic prophages. Since mobile<br />
DNA (insertion sequences or IS elements) is a cause for contamination in plasmid DNA production, our strains, which are IS free, generate<br />
pure, high yield plasmid DNA. Further, the elimination of cryptic prophage within Clean Genome® strains completely eliminates the<br />
problem of batch lysis observed in non-Clean Genome®, large scale E. coli fermentations. Clean Genome® E. coli are the strains of choice for<br />
a wide spectrum of applications ranging from routine cloning to large scale production of biopharmaceuticals.<br />
CORPORATE ALLIANCES<br />
WARF (Wisconsin Alumni Research Foundation)<br />
University of Wisconsin – Madison<br />
Dr, Nian Shi, University of Wisconsin Medical School<br />
Dr. Sarah W. Harcum, Clemson University<br />
INTELLECTUAL PROPERTY<br />
Reduced Genome E. coli<br />
PCT/US2006/03525 and WO 2007/024756<br />
A Method for Producing Plasmid DNA Preparation with Reduced Endotoxin"<br />
PCT/US07/069685 which has subsequently gone in US 12/294,159<br />
EP 07784120.3<br />
JP serial number is pending.<br />
PRODUCTS<br />
Name Phase Indication<br />
MDS42 Electrocompetent Cells On Market Molecular Biology Reagents<br />
MDS42 Chemically Competent Cells On Market Molecular Biology Reagents<br />
ScarabXpress T7lac Chemically Competent Cells On Market Molecular Biology Reagents<br />
MDS42recA trfA Competent Cells On Market Molecular Biology Reagents<br />
MDS42recA trfA Blue Competent Cells On Market Molecular Biology Reagents
PRODUCTS<br />
Name Phase Indication<br />
MDS42recA Competent Cells On Market Molecular Biology Reagents<br />
MDS42recA Blue Competent Cells On Market Molecular Biology Reagents<br />
White Glove IS Detection Kit On Market Molecular Biology Reagents<br />
Scarab Strain Identification Kit On Market Molecular Biology Reagents<br />
10X Modified Korz Medium Kit On Market Molecular Biology Reagents<br />
SENIOR MANAGEMENT<br />
Frederick R. Blattner, President & CEO • Tony A. Pharo, Business Development • Bob Novy, Chief Scientific Officer<br />
BIO Business Forum 2011 265 Participating Company <strong>Profiles</strong>
Friedhelm Blobel, PhD<br />
President & CEO<br />
950 Tower Lane, Suite 900<br />
Suite 900<br />
Foster City, CA 94404<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
SciClone Pharmaceuticals, Inc<br />
Clinical Foci: Oncology • Infectious Disease • CNS<br />
www.sciclone.com<br />
Reinhard Oesterle, Senior Director, Business Development<br />
Jeff Lange, Vice President, Business Development<br />
Phone: 1-650-358-3456<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
April 2011: SciClone acquires NovaMed Pharmaceutical, a China-based specialty<br />
pharmaceutical company for up to $105 Million in cash and SCLN stock<br />
2011 Guidance provided in May 2011: 2011 full year revenue US$133-138 million;<br />
US$0.52-$0.57 EPS; >US$45 million cash and equivalents on 12/31/11<br />
January 2011: Phase 2b trial initiated to evaluate the efficacy and safety of SCV-07 in<br />
attenuating oral mucositis in patients with head and neck cancer<br />
Incorporated: 1990<br />
Employees: 700<br />
Ownership: Public<br />
Market Cap: $270.00 million<br />
NASDAQ: SCLN<br />
Achieve regulatory approval for DC Bead in<br />
China in 2011<br />
Achieve regulatory approval for Tramadol in<br />
China in 2011<br />
File IDLs (Import Drug Licenses) for<br />
Thioctacid (oral), Formoterol, Budesonide<br />
and Loramyc in China in 2011<br />
CORPORATE MISSION<br />
SciClone is a revenue-generating, China-centric specialty pharmaceutical company with a product portfolio of novel therapies for cancer,<br />
infectious diseases, and cardiovascular, urology, central nervous system and respiratory disorders. SciClone’s ZADAXIN® (thymalfasin) is<br />
approved in over 30 countries for the treatment of hepatitis B, hepatitis C and cancer, and as a vaccine adjuvant. SciClone markets nearly<br />
20 other products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China, Tritace, an ACE<br />
inhibitor for the treatment of hypertension, Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as<br />
Ambien® in the US), and Aggrastat®, a recently-launched intervention cardiology product. On the development side, SciClone is evaluating<br />
SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the<br />
registration of several other therapeutic products in China.<br />
CORPORATE ALLIANCES<br />
SciClone has partnerships with many leading pharma and biotech companies, including Sanofi-Aventis, Pfizer, Baxter, Sigma-Tau, BTG,<br />
Iroko, Ethypharm, EUSA, APR Applied Pharma Research, BioAlliance, Meda and Orexo. Our focus for BIO will be to find a global or regional<br />
development and commercialization partner for SCV-07 in oral mucositis (Ph. II), HCV (Ph. II) and oncology (pre-clinical) as well as<br />
evalauating the in-license of late stage products for our China business.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SCV-07 Phase II, IIa, IIb Oral Mucositis 01/11: Phase 2b initiated<br />
enrollment<br />
Zadaxin Phase II, IIa, IIb Melanoma. liver cancer, acute infections, hepatitis B, hepatitis C,<br />
vaccine adjuvant<br />
SENIOR MANAGEMENT<br />
Friedhelm Blobel, PhD, President & CEO • Gary Titus, Chief Financial Officer • Mark Lotter, Other • Israel Rios, MD, Chief Medical<br />
Officer • Cynthia Tuthill, PhD, Chief Scientific Officer • Jeffery Lange, Vice President<br />
BOARD OF DIRECTORS<br />
Jon Saxe, Former President, PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.); Former VP, F. Hoffmann-LaRoche, Inc. • Friedhelm<br />
Blobel, PhD, President & CEO, SciClone Pharmaceuticals, Inc. • Roberto Camerini, MD, Head of Clinical Research II - Worldwide Drug<br />
Development, Sigma-Tau Industrie Farmaceutiche Riunite SpA • Richard Hawkins, Chairman, President & CEO, id2, Inc. • Trevor Jones<br />
PhD, Group R&D Director, Sigma-Tau • Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc. • Ira Lawrence, MD, CMO & Sr. VP, R&D,<br />
Medicis Pharmaceutical Corporation • Dean Woodman, Founding partner, Robertson Stephens; Former Managing Director, ING Barings<br />
• Mark Lotter, Chief Executive Officer of SciClone’s China operations • Peter Barrett, Ph.D, Partner, Atlas Venture<br />
BIO Business Forum 2011 266 Participating Company <strong>Profiles</strong>
Dipl.-Kfm. Christian Nafe<br />
Chief Executive Officer<br />
Fraunhoferstrasse 15<br />
82152 Martinsried<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Iris Margraf<br />
HIGHLIGHTS<br />
Recent<br />
Scil Technology<br />
Clinical Foci: Biopharmaceuticals • Regenerative Medicine • Drug Development<br />
www.sciltechnology.com<br />
Phone: 49-089-8565 1800<br />
Incorporated: 1999<br />
Employees: 40<br />
Ownership: Private<br />
Osteoarthritis and cartilage repair: Proof of efficacy in large animals achieved and signs of pain relief observed<br />
Scil Techology successfully brought two of its development projects through clinical phase II.<br />
Scil Technology created an independent business unit called "formycon" to offer formulation development and GMP or non-GMP<br />
analytical services for third parties.<br />
CORPORATE MISSION<br />
Scil Technology GmbH (Scil Technology) is a privately held German biopharmaceutical company focused on developing innovative<br />
regenerative biopharmaceuticals through bridging growth factors and biomaterials. Its particular strengths excel in recombinant protein<br />
know-how, and specific formulation technologies.<br />
Two independent business units ensure a risk balanced business concept:<br />
Internal project development and fee for service business.<br />
Product Development. Scil Technology’s orthopaedic lead project aims to provide a completely novel therapeutic approach to<br />
osteoarthritis by interrupting the cartilage destruction process and inducing cartilage regeneration. Efficacy has been achieved in large<br />
animal models and in addition signs of pain reduction have been observed.<br />
Furthermore Scil Technology is expanding its pipeline with further indications requiring innovative regenerative therapies based on<br />
biopharmaceuticals like rheumatoid arthritis.<br />
Partnered Projects. Besides current development, Scil Technology already out-licensed projects in the field of dental tissue regeneration.<br />
Two of these projects had successfully been developed by Scil Technology through clinical phase II and a third one was out-licensed at the<br />
preclinical stage.<br />
Service. With its business unit “formycon”, Scil Technology adds substantial value to collaborations with biotech and pharma companies<br />
by offering formulation development and GMP as well as non-GMP analytics (www.formycon.com).<br />
PROPRIETARY TECHNOLOGY<br />
Scil Technology’s product candidates are based on proprietary technologies that combine biodegradable biomaterials with proprietary<br />
recombinant human growth factors which are released in a controlled manner over time. Resulting products are activated ceramics,<br />
organic or inorganic polymers, as well as coated metals. Scil Technology is also developing liposomal, liquid and systemic formulations.<br />
The development of biomaterials and implants by Scil Technology involves a unique interdisciplinary approach combining protein science,<br />
material science and pharmaceutical development.<br />
CORPORATE ALLIANCES<br />
Medtronic Inc.<br />
Universities<br />
INTELLECTUAL PROPERTY<br />
Scil Technology has protected its projects on a global basis with a comprehensive portfolio of patents and patent applications owned by<br />
Scil Technology or licensed from third parties. The IP basis covers not only the product candidates and growth factors but also production<br />
and process technologies.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ST04 Preclinical Osteoarthritis PoP and PoC in large animal<br />
ST03 Preclinical Cartilage Defects PoP and PoC in large animal<br />
ST01 Preclinical Spinal Fusion animal studies<br />
ST05 Research Disc Regeneration<br />
ST06 Research Tissue Regeneration<br />
MD06 Preclinical Implantology<br />
SENIOR MANAGEMENT<br />
Dipl.-Kfm. Christian Nafe, Chief Executive Officer<br />
BIO Business Forum 2011 267 Participating Company <strong>Profiles</strong>
Stephen Hammond<br />
Chief Executive Officer<br />
Todd Campus<br />
Glasgow Scotland<br />
G620 OXA<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Lisa Murphy, Business Development Manager<br />
CORPORATE MISSION<br />
Scottish Biomedical<br />
Clinical Foci: Biology • Drug Discovery • Service<br />
www.scottish-biomedical.com<br />
Phone: 44-0141-587 6100<br />
Employees: 25<br />
Ownership: Private<br />
Scottish Biomedical is a leading Contract Research Organization based in Glasgow supplying efficient, cost-effective integrated drug<br />
discovery and biological services to the pharmaceutical and biotech industries. Established in 1994 SB has a proven international track<br />
record successfully completing a wide range of projects for clients across the UK, Europe, North America, the Far East and Australia. With a<br />
team of experienced, highly skilled life-science researchers and state of the art laboratories SB offers a comprehensive portfolio of services<br />
including molecular biology, assay development, cell line and recombinant protein production, high-throughput screening and<br />
pharmacology, with new services continuously being added. Selected areas of expertise include cell signalling (PDEs, phosphatases,<br />
GPCRs, kinases), epigenetics (HDACs, sirtuins, MTs), ion channels and electrophysiology, protein-protein interactions and antibacterials.<br />
Target therapeutic areas include CNS disorders, inflammation, pain, oncology and metabolic diseases. SB employs a flexible approach,<br />
designing and adapting each project to meet clients needs with a dedicated project manager to ensure milestones are achieved.<br />
PROPRIETARY TECHNOLOGY<br />
SBXpress - technology allowing multiparallel optimisation of cloning strategies.<br />
Recombinant protein capacity to 200L E.coli and 50L insect and mammalian culture. Human Nav 1.1-1.8 ion channels. Comprehensive<br />
services for studying protein-protein interactions from SILAC for identification of novel interactions through to development of cell-based<br />
assays for screening blocking compounds.<br />
PRODUCTS<br />
Name Phase Indication<br />
Phosphodiesterase enzymes Research CNS, inflammation<br />
Phosphodiesterase antibodies Research CNS, inflammation<br />
HDAC enzymes Research Epigenetics, oncology<br />
Ion channel cell lines Research CNS, pain<br />
Recombinant proteins Research all indications<br />
Custom cell lines Research all indications<br />
SENIOR MANAGEMENT<br />
Stephen Hammond, Chief Executive Officer • Eric Smith, Chief Financial Officer • Ian McPhee, Chief Scientific Officer • Lisa Murphy,<br />
Business Development • David Dalrymple, Business Development<br />
BIO Business Forum 2011 268 Participating Company <strong>Profiles</strong>
150 Broomielaw<br />
Glasgow<br />
G2 8LU<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Scottish Development International<br />
Clinical Foci: Drug Discovery • Regenerative Medicine • Informatics<br />
www.sdi.co.uk<br />
Phone: 44-141-228 2223<br />
Mr. Neil Guthrie, International Business Advisor - Life Sciences<br />
Ian Leslie, Senior Manager - Life Sciences<br />
Paul McDermed, Vice President<br />
Nathan Elia<br />
Larry Reynolds<br />
Employees: 40<br />
Ownership: Other<br />
CORPORATE MISSION<br />
Scottish Development International is a government funded organisation with a dedicated life sciences team which provides access to key<br />
Scottish product and service companies, together with research and clinical expertise from Scottish Universities and Research Institutes<br />
working in a number of areas including: - Basic and Clinical Research in therapeutic areas including Cardiovascular Disease & Metabolism,<br />
Neuroscience, Inflammation, Oncology and Womens Health - Bioinformatics - Contract Research [CRO's] - Drug Discovery & Development -<br />
Medical Technologies including Diagnostics & Wound Healing - Regenerative Medicine & Stem Cells - Translational Medicine<br />
PROPRIETARY TECHNOLOGY<br />
Scottish Development International (SDI) can work with you to facilitate access to Scottish researchers and companies with leading<br />
proprietary technologies in areas such as drug discovery and development, regenerative medicine and medical technologies. SDI is leading<br />
the development of Edinburgh BioQuarter – Europe’s leading location for biomedical R&D, comprising a science park co-located with a<br />
major teaching hospital, the UK’s highest-rated University for clinical research (Edinburgh), state-of-the-art clinical trials and imaging<br />
facilities, the Scottish Centre for Regenerative Medicine.<br />
CORPORATE ALLIANCES<br />
Scotland has a strong track record of collaborative approaches (http://www.lifesciencesscotland.com/lss/lss-solutions/lss-collaborativepartnerships.htm).<br />
Examples of collaborative approaches within Scotland include: Scottish Stem Cell Network - www.sscn.co.uk, NHS<br />
Scotland Clinical Research Co-ordination Centre (www.nhsgrampian.org/nrscc)<br />
INTELLECTUAL PROPERTY<br />
Scotland’s powerful research and technology base includes 640 organisations and over 32,000 employees. We house over 15% of the<br />
United Kingdom’s biotech companies. With international partnerships, robust capital investments from the government and funding<br />
from private VC firms, we will continue to secure our standing as a world leader in biotechnology.<br />
BIO Business Forum 2011 269 Participating Company <strong>Profiles</strong>
Clay B. Siegall, PhD<br />
Chief Executive Officer<br />
21823 30th Drive SE<br />
Bothell, WA 98021-3907<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Shannon Thomas, Associate Director Business Development<br />
Natasha Hernday, VP of Corporate Development<br />
Seattle Genetics, Inc<br />
Clinical Foci: Oncology • AutoImmune • Drug Development<br />
www.seattlegenetics.com<br />
Phone: 1-425-527-4000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
FDA accepted for filing two BLAs for brentuximab vedotin, granting<br />
a six-month priority review of both applications and establishing a<br />
PDUFA date of August 30, 2011.<br />
Expanded our ADC collaboration with Genmab for an additional<br />
target for which Seattle Genetics received an undisclosed upfront<br />
payment and will have an end of phase I option for 50:50 codevelopment<br />
and co-commercialization<br />
Entered into an ADC collaboration with Abbott for a single target<br />
deal for which Seattle Genetics received an $8M upfront and<br />
potentially $200M in milestones plus royalties<br />
Ownership: Public<br />
Market Cap: $2000.00 million<br />
NASDAQ: SGEN<br />
August 30, 2011 PDUFA for brentuximab vedotin BLA filings for<br />
Hodgkin lymphoma and anaplastic large cell lymphoma<br />
In the second quarter of 2011, planning a regulatory submission<br />
for approval in Europe in partnership with Millennium Takeda<br />
Plan to initiate new clinical trials during 2011, including a trial in<br />
other CD30-positive hematologic malignancies and a trial in CD30positive<br />
non-lymphoma indications<br />
CORPORATE MISSION<br />
Seattle Genetics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal<br />
antibody-based therapies for the treatment of cancer and autoimmune disease. The FDA has accepted for filing two BLAs for the<br />
company's lead product conadidate brentuximab vedotin (SGN-35) and has granted a six month priority review for both applications<br />
resulting in an August 30, 2011 PDUFA date. Brentuximab vedotin is being developed in collaboration with Millennium: The Takeda<br />
Oncology Company. Under the collaboration, Seattle Genetics retains full commercialization rights to brentuximab vedotin in the U.S. and<br />
Canada, while Millennium has exclusive rights to commercialize brentuximab vedotin in the rest of the world.<br />
Brentuximab vedotin is one of 14 antibody-drug conjugates in clinical development using Seattle Genetics' proprietary antibody-drug<br />
conjugate (ADC) technology, including two additional internal programs, SGN-75 and ASG-5ME, and 11 collaborator programs. These<br />
collaborations are with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics,<br />
Daiichi Sankyo, Genentech, GlaxoSmith-Kline, Millennium, Pfizer and Progenics as well as ADC co-development collaborations with<br />
Agensys, an affiliate of Astellas, and Genmab.<br />
Current business initiatives include partnering on clinical programs or marketed products in oncology or hematologic diseases. Antibodies<br />
and targeted small molecule opportunities will be prioritized. Preclinical antibody oncology projects are also of interest.<br />
PROPRIETARY TECHNOLOGY<br />
Seattle Genetics has developed next generation antibody-drug conjugates (ADCs) that link the proven selectivity and activities of<br />
monoclonal antibodies with highly potent cytotoxic agents. With more than a decade of experience and knowledge in ADC innovation,<br />
Seattle Genetics' proprietary technology employs synthetic, potent tumor cell-killing agents called auristatins and stable linker systems<br />
that attach the auristatin to the antibody. Our linkers are designed to be stable in the bloodstream and release the potent cell-killing agent<br />
once inside the targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of<br />
traditional chemotherapy, while potentially enhancing antitumor activity.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
brentuximab vedotin (SGN-35) Phase II, IIa, IIb Hodgkin lymphoma and systemic anaplastic<br />
large cell lymphoma<br />
SGN-75 (anti-CD70 antibody<br />
drug conjugate)<br />
pivotal top line data expected in<br />
the second half of 2010<br />
Phase I renal cell carcinoma and NHL 2011 ASCO presentation on<br />
interim Phase I data<br />
AGS-5ME Phase I Pancreatic and prostate cancer<br />
SGN-40 Phase I NHL and MM<br />
SGN-70 Phase I Autoimmune disease<br />
SGN-19A Preclinical NHL<br />
BIO Business Forum 2011 270 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Clay B. Siegall, PhD, Chief Executive Officer • Eric L. Dobmeier, Chief Business Officer • Thomas C. Reynolds, MD, Ph.D, Chief Medical<br />
Officer • Todd E. Simpson, Chief Financial Officer • Vaughn B. Himes, PhD, Executive Vice President • Morris Z. Rosenberg, D.Sc,<br />
Executive Vice President • Bruce J. Seeley, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Clay B. Siegall, PhD, Seattle Genetics • Srinivas Akkaraju, MD, PhD, New Leaf Venture Partners • Felix J. Baker, PhD, Baker Brothers<br />
Investments • Franklin M. Berger, CFA, Independent Research Analyst • David W. Gryska, Independent Consultant • Marc E.<br />
Lippman, MD, University of Miami • John P. McLaughlin, PDL Biopharma, Inc. • Daniel G. Welch, Intermune, Inc.<br />
BIO Business Forum 2011 271 Participating Company <strong>Profiles</strong>
Ron Gutterman<br />
Chief Executive Officer<br />
1 Haarava St<br />
70100 Airport City<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Esti Grunbaum, VP BD & marketing<br />
CORPORATE MISSION<br />
SE-CURE PHARMACEUTICALS<br />
Presenting Company<br />
Clinical Foci: Drug Development • Drug Development<br />
www.femarelle.com<br />
Phone: 972-3-9731111<br />
Incorporated: 1997<br />
Ownership: Private<br />
Se-cure Pharmaceuticals has developed a unique technology platform for the development of botanical drugs, characterized by a complex<br />
compound that enables to treat target tissues in different manners, thus enabling to develop drugs acting as multiple agents in the body<br />
with agonistic or antagonistic properties depending on the target tissue. Through the implementation of our unique R&D and production<br />
methodology, the company’s first product, Femarelle, a SERM for the treatment of menopause, is currently entering into Phase III (USFDA)<br />
following a marketing pilot, and a second product is in its final stages of being prepared for pilot testing in several markets.<br />
PROPRIETARY TECHNOLOGY<br />
Se-cure has developed a model for the development of botanical based complexes creating a unique platform for the development of<br />
Botanical Drugs. The API compound provides Multiple Agents with agonistic & antagonistic properties, depending on the tissue.<br />
Controlled industrial processes are used to create proven standardized API’s with validated biochemical and biological fingerprints to<br />
analyze the consistency of the API.<br />
CORPORATE ALLIANCES<br />
Se-cure's strategic goal is to turn Femarelle, a SERM for the treatment of menopause and bone health, into the leading product for the<br />
management of menopause favored by the medical community as well as the consumer. In order to achieve this feat we are looking to<br />
partner with leading pharmaceutical companies based on territorial strength.<br />
INTELLECTUAL PROPERTY<br />
Patents are based on differentiation between technologies, platforms, processes, and applications/products. 4 patent families –<br />
technologies, methods, compounds and proprietary bioassays. 3 patent applications in process, 11 patent applications in drafting.<br />
Creation of a protectable Botanical Drug from technology through application.<br />
PRODUCTS<br />
Name Phase Indication<br />
Femarelle Phase III menopausal symptoms<br />
Brizo (SC012) Phase I BPH<br />
SC106 Preclinical prevention of stasis in severe burns<br />
SC661 Preclinical Guided bone regeneration for a dental implants<br />
SENIOR MANAGEMENT<br />
Ron Gutterman, Chief Executive Officer • Esti Grunbaum, Business Development • Ilan Vadai, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Lila Nachtigall MD, PhD, NYU School of Medicine, NY, USA • Richard Nachtigall, MD PhD, NYU School of Medicine, NY, USA • Andrea<br />
Genazzani, MD, PhD, University of Pisa, Pisa, Italy • Rafael Sanchez Borego, MD, President of the "Spanish Association for the Study of<br />
Menopause" (AEEM) • Nick Panay, MD, Queen Charlotte's & Chelsea Hospital, London, UK<br />
BIO Business Forum 2011 272 Participating Company <strong>Profiles</strong>
Simon Saxby<br />
Chief Executive Officer<br />
Fyfield Business and Research Park<br />
Essex<br />
CM5 0GS<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Simon Bury, Business Development Director - Discovery<br />
Simon Saxby, CEO<br />
Selcia Limited<br />
Clinical Foci: Drug Discovery • Chemistry • Biology<br />
www.selcia.com<br />
Phone: 44-01277-367 000<br />
Employees: 77<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
February 28, 2011<br />
Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA (Paris, France), using<br />
Selcia’s fragment screening technology.<br />
December 07, 2010<br />
Selcia Limited is pleased to announce that its radiochemistry facility has been granted a Good Manufacturing Practice (GMP) certificate for<br />
the preparation of C-14 labeled Active Pharmaceutical Ingredients (APIs)<br />
November 29, 2010<br />
Building on an established partnership following significant progress made to date, Selcia’s chemists and biologists will continue to<br />
provide integrated drug discovery services to support Gilead’s liver disease research programmes.<br />
CORPORATE MISSION<br />
A leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP accredited 14-C custom radiolabelling services,<br />
Selcia is a self-funded, profitable, private company with around 80 employees operating from state-of-the-art laboratories close to<br />
London, UK and Boston, USA.<br />
The company has 2 operating divisions, Selcia Discovery and Selcia Radiolabelling.<br />
Selcia Discovery has established a number of integrated drug discovery collaborations with pharmaceutical/biotechnology companies,<br />
academic research institutions and non-profit organisations/charities around the world. Selcia Discovery specialises in fragment based<br />
drug discovery and provides screening biology, medicinal chemistry with eADME support and in vivo DMPK services. Selcia Discovery's<br />
proven expertise in lead optimisation enables our medicinal chemists and biologists to rapidly progress fragment hits to novel pre-clinical<br />
and clinical candidates.<br />
In addition, Selcia Discovery has a number of internal research programs which are available for partnering.<br />
Selcia Radiolabelling is the partner of choice for carbon-14 radiosynthesis, offering a level of service and dedication equivalent to an<br />
internal isotope laboratory.<br />
Both divisions are supported by Selcia's GLP MHRA accredited laboratory where our analysts, experienced in structural biology, structural<br />
elucidation and impurity profiling operate with exceptional infrastructure including three high-field NMR spectrometers to ensure the<br />
quality of our services.<br />
MedChemPlus Projects<br />
Selcia has a few selected projects available for partnerships. In this type of project we offer a package consisting of non-optimised<br />
proprietary compounds plus biological activity and intellectual property.<br />
MedChemPlus projects are offered as a collaborative project. In return for research funding during the lead optimisation phase the<br />
customer gets exclusive and comprehensive worldwide rights to manufacture and sell the resulting products.<br />
PROPRIETARY TECHNOLOGY<br />
Selcia's CEfrag screen offers an innovative, proprietary methodology to identify mM to pM binding interactions between low molecular<br />
weight compounds and a therapeutic target, under physiological conditions.<br />
Selcia Discovery's capabilities include screening biology, medicinal chemistry with eADME support and in vivo DMPK, ensuring that we are<br />
able to deliver drug candidates for our partners.<br />
With our wide-ranging capabilities in assay development & screening we can help our customers to initiate drug discovery programs. Our<br />
expertise in capillary electrophoresis and fragment based screening offers customers a unique approach for primary or orthogonal target<br />
screening and our highly experienced medicinal chemists are able to rapidly expand hits into promising lead series and generate optim<br />
CORPORATE ALLIANCES<br />
Selcia Discovery's projects are focused on delivering robust development candidates. Creativity in medicinal chemistry is coupled with<br />
rapid evaluation of physico-chemical and pharmacological properties including vivo DMPK .<br />
We help our customers to generate and advance hits, optimise leads and deliver optimised pre-clinical and clinical candidates.<br />
BIO Business Forum 2011 273 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Capillary Electrophoresis (CE) was pioneered in the 1990s for high throughput screening (HTS). Many HTS campaigns for major<br />
pharmaceutical companies have been carried out using this technology and multiple lead compounds have been discovered.<br />
Selcia has acquired the intellectual property for this technique and adapted it for fragment screening, creating the CEfrag screen.<br />
Selcia's CEfrag screen offers an innovative, proprietary methodology to identify mM to pM binding interactions between low molecular<br />
weight compounds and a therapeutic target, under physiological conditions.<br />
CEfrag is a powerful tool for identifying hits on particularly challenging biological targets including protein-protein interactions.<br />
All of the IP generated by Selcia is owned by our customers.<br />
SENIOR MANAGEMENT<br />
Simon Saxby, Chief Executive Officer • Hans Fliri, Chairman • Simon Bury, Business Development • Clive Cornell, Vice President<br />
BOARD OF DIRECTORS<br />
Hans Fliri • Andreas Rummelt<br />
BIO Business Forum 2011 274 Participating Company <strong>Profiles</strong>
Igor Fisch, PhD<br />
Chief Executive Officer<br />
18, chemin des Aulx<br />
1228 Plan-les-ouates<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Igor Fisch, PhD, President and Chief Executive Officer<br />
Andrew Sandford<br />
Denise Huber, Director, Business Development<br />
Armelle Gaussin, Chief Technology Officer<br />
Selexis SA<br />
Clinical Foci: Service • Drug Development • Drug Discovery<br />
www.selexis.com<br />
Phone: 41-22-3089360<br />
Incorporated: 2001<br />
Employees: 20<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
3/23/2011 Selexis Completes Sequencing of the Selexis SURE CHO- JUNE 2011: Establishment of Scientific Advisory Board<br />
M Genome - Major Milestone Will Speed Regulatory Filings for JUNE 2011: Annotation of CHO-M Genome<br />
Recombinant Protein Therapeutics and Monoclonal Antibodies<br />
Developed with the Proprietary Selexis SURE CHO-M Cell Line<br />
JUNE 2011: Two commercial license agreements<br />
3/8/2011 Selexis Launches the SUREvarient Screening Service -<br />
New Service Will Speed Library Screening Campaigns<br />
2/9/2011 Selexis Doubles Cell Line Development Laboratory Space<br />
in Geneva, Switzerland - Major Expansion Includes Protein<br />
Purification Unit<br />
CORPORATE MISSION<br />
Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative<br />
technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing highperformance<br />
mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The company's SURE Cell Line<br />
Development Technology Platform is based on Selexis Genetic Elements -- novel DNA-based elements that control the dynamic<br />
organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The<br />
technology platform also includes Selexis SUREtech Vectors, Selexis SUREfection Transfection Methods, Selexis VS Variant Screening<br />
and the proprietary Selexis SURECHO-M Cell Line.<br />
PROPRIETARY TECHNOLOGY<br />
Selexis SURE Cell Line Development Technology Platform<br />
Selexis World-Class Services<br />
(SUREtech)<br />
- Selexis SURE Cell Line Development<br />
- Selexis Genetic Elements(SGE)<br />
o Selexis SUREminipools<br />
- Selexis SUREtech Vectors<br />
o Selexis SUREclones<br />
- Selexis SURE CHO-M Cell Line<br />
- Selexis SUREvariant Screening<br />
- Selexis SURE CHO-M Genome<br />
o Selexis SUREnatant,<br />
- Selexis SUREfeed Strategy<br />
o Selexis SUREpools<br />
- Selexis SUREmedia<br />
- Selexis SUREfection Procedures<br />
CORPORATE ALLIANCES<br />
For over 10 years, Selexis has built interactive collaborations, partnerships and commercial deals with leading biotechnology and<br />
pharmaceutical companies worldwide. Our innovative technologies and world-class expert services significantly reduce the time, effort,<br />
and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth<br />
factors, enzymes). From discovery to Phase II clinical trials, Selexis’ technology has been and is currently being used by more than 50<br />
companies worldwide. Furthermore, the recent launch of the Selexis SUREvariant Screening platform enables our customers to improve<br />
clinical success by identifying high quality lead candidates.<br />
INTELLECTUAL PROPERTY<br />
Selexis’ technology is fully protected by 23 granted patents and 33 pending patents covering both its unique Intellectual Property and<br />
some of its know-how.<br />
PRODUCTS<br />
Name Phase Indication<br />
Selexis Genetic Elements (SGE) Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
BIO Business Forum 2011 275 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
Selexis SUREtech Vectors Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SUREfection Procedures Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis CHO-M Cell Line Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SURE CHO-M Genome Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SURE Cell Line Development Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SUREvariant Screening Research antibodies<br />
Selexis Genetic Elements (SGE) Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SUREtech Vectors Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
Selexis SUREfection Procedures Phase II, IIa, IIb therapeutic recombinant proteins and monoclonal antibodies<br />
SENIOR MANAGEMENT<br />
Igor Fisch, PhD, Chief Executive Officer • Pierre-Alain Girod, PhD, Chief Scientific Officer • Regine Brokamp, Chief Operating Officer •<br />
Armelle Gaussin, PhD, Chief Technology Officer • Andrew Sandford, Vice President • Denise Huber, PhD, Business Development<br />
BOARD OF DIRECTORS<br />
Igor Fisch, Selexis SA • Nicolas Mermod, University of Lausanne • Peter Pfister, PhD • Gian-Luigi Berini<br />
BIO Business Forum 2011 276 Participating Company <strong>Profiles</strong>
Pawel Przewiezlikowski<br />
Chief Executive Officer<br />
ul. Bobrzynskiego 14<br />
30-348 Krakow<br />
Poland<br />
CONFERENCE PARTICIPANTS<br />
Pawel Przewiezlikowski, CEO<br />
Piotr Prelich, VP Sales and Marketing<br />
Selvita S.A.<br />
Clinical Foci: Oncology • Drug Discovery • Service<br />
www.selvita.com<br />
Phone: 48-12-297 4700<br />
Incorporated: 2007<br />
Employees: 113<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion of a $ 5.5 Million Private Placement by Selvita Group. Selvita Group shares to be listed on stock exchange in June 2011<br />
GLP certification of Selvita Group molecular biology laboratory SEL24 clinical candidate to be ready in 2012<br />
CORPORATE MISSION<br />
Selvita is a Polish, privately-owned, biotechnology company engaged in the discovery and development of breakthrough medicines to treat<br />
CNS, oncology and autoimmune disorders as well as provision of non-clinical research services. The company was established in 2007 and<br />
currently employs 115 people including 40 PhDs.<br />
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with<br />
partners from the pharmaceutical industry. Selvita has currently several projects at early or late discovery stage and is expected to move<br />
its first candidates to the clinic in 2012.<br />
The service part of the company delivers a comprehensive panel of products and solutions targeted at lowering the cost of, and<br />
accelerating, the introduction of new drugs to the market.<br />
Since 2010, Selvita is also the owner of BioCentrum, which provides range of in vitro preclinical ADMET services, biochemistry services with<br />
special focus on protein engineering and recombinant protein production.<br />
Selvita Group has experience in several areas of life sciences, and offers the following types of projects:<br />
- Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and<br />
preclinical development.<br />
- Chemistry services, including contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as<br />
computational chemistry services.<br />
- Biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence<br />
anisotrophy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification<br />
- Advanced protein modeling solutions, based on our proprietary protein modeling platform, as well as services in computational<br />
chemistry.<br />
Selvita Group's laboratories were granted the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice<br />
certification.<br />
PROPRIETARY TECHNOLOGY<br />
Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and<br />
preclinical development.<br />
Chemistry services, including contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as<br />
computational chemistry services.<br />
Biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence<br />
anisotrophy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification<br />
Advanced protein modeling solutions, based on our proprietary protein modeling platform, services in computational chemistry.<br />
CORPORATE ALLIANCES<br />
Selvita Group - Orion Corporation - development of SEL103 project (Alzheimer's disease)<br />
INTELLECTUAL PROPERTY<br />
Proprietary IP<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SEL24 Lead Series Leukemia and solid tumours Clinical development to be<br />
initiated in 2012<br />
SEL103 Preclinical Alzheimer's disease, cognitive disorders<br />
SEL113 Research Oncology and autoimmune diseases<br />
BIO Business Forum 2011 277 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
SEL24 Lead Series Leukemia and solid tumours Clinical development to be<br />
initiated in 2012<br />
SEL103 Preclinical Alzheimer's disease, cognitive disorders<br />
SEL113 Research Oncology and autoimmune diseases<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Seed Round: 07/05/2007 (US $0.50 million)<br />
Round A: 12/01/2009 (US $3.00 million)<br />
Round B: 05/05/2011 (US $5.50 million)<br />
Investors: Pawel Przewiezlikowski (63 %) • Boguslaw Sieczkowski (12 %) • Other shareholders (25 %)<br />
SENIOR MANAGEMENT<br />
Pawel Przewiezlikowski, Chief Executive Officer • Boguslaw Sieczkowski, Chief Operating Officer • Dr Nicolas Beuzen, Chief Scientific<br />
Officer • Piotr Romanowski, Chairman<br />
BOARD OF DIRECTORS<br />
Dr Piotr Romanowski, Partner at PriceWaterhouseCoopers • Dr Tadeusz Wesolowski, Founder and owner of PROSPER • Rafal Chwast,<br />
Nowy Styl Group • Adam Przewiezlikowski • Adam Dubin, Jagiellonian University<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Adam Dubin, Vice-dean at the Faculty of Biochemistry, Biophysics and Biotechnology at the Jagiellonian University • Professor<br />
Jakub Golab, Medical University of Warsaw, Israel Deaconess Medical Center (Harvard Institutes of Medicine) • Professor Andrzej<br />
Kolinski, Laboratory of Theory of Biopolymers research group at University of Warsaw • Professor Jan Lubinski, International Hereditary<br />
Cancer Center in Szczecin • Professor Ryszard Ostaszewski, Institute of Organic Chemistry, Polish Academy of Sciences • Professor<br />
Andrzej Pilc, Deputy Director for Scientific Research of the Institute of Pharmacology, Polish Academy of Sciences • Professor Jaroslaw<br />
Polanski, Professor of Chemistry at the Institute of Chemistry, University of Silesia, Katowice, Poland<br />
BIO Business Forum 2011 278 Participating Company <strong>Profiles</strong>
Dr. Krathish Bopanna DSc PhD<br />
President & CEO<br />
75A, 15th Cross, 1st Phase, J.P.Nagar<br />
Bangalore 560078<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Jayanti Gupta, Vice President, Clinical Development<br />
Semler Research Center Pvt. Ltd.<br />
Clinical Foci: Ophthalmic • Oncology • Skin/Dermatological<br />
www.semlerresearch.com<br />
Phone: 91-80-42627225<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
India’s first, independent organization to fully integrate drug development, clinical<br />
development and manufacturing services.<br />
Several decades of exposure to various regulatory bodies across the globe for both<br />
generic and patented products.<br />
Innovative capital solutions to emerging pharma, biotech and virtual companies.<br />
State-of-the-art equipment and infrastructure across locations (over 60,000sft.) to<br />
facilitate smooth and quality services.<br />
24 International Audits cleared as of April 2011.<br />
DCGI, Drug controller, Karnataka and Karnataka State Pollution Control Board<br />
approved clinical facilities.<br />
Inspected by WHO with 'No' major non-conformance.<br />
Incorporated: 2006<br />
Employees: 180<br />
Ownership: Private<br />
ISO 9001 for managerial requirements.<br />
ISO 27001 for information security<br />
management systems.<br />
ANVISA & Turkey certifications.<br />
USFDA & EU inspections.<br />
CORPORATE MISSION<br />
Semler Research Center (SRC) is part of US based Arnold A. Semler Inc, in business since 1946. SRC, founded in 2006, is a privately owned<br />
pharmaceutical services company with its business offices in Los Angeles, CA and Bangalore, India. SRC has some of industry's top<br />
management and scientific talent, along with state-of-the-art R & D facilities in Bangalore and Salem in India. We provide a wide range of<br />
services, primarily in the areas of pharmaceutical development, bioavailability/bioequivalence studies, early & late phase clinical<br />
development, GxP business consulting, regulatory services including medical & scientific writing. Our range of services helps global<br />
pharmaceutical, biotech and device companies significantly enhance their R & D success from quality, cost and timeline perspectives.<br />
SENIOR MANAGEMENT<br />
Dr. Krathish Bopanna DSc PhD, President & CEO • Gurudatta GG, Chief Operating Officer • Dr Suresh Venkataram PhD, Chief<br />
Scientific Officer • Umesh BA, Vice President • Dr. Jayanti Gupta PhD, Vice President • Anil Kumar BH, Director • Parijat Nandy,<br />
Director • Bill O'Brien, Vice President<br />
BOARD OF DIRECTORS<br />
Ronald Semler, Chairman • Dr. Krathish Bopanna, Director • Ravi Achar, Director • Gurudatta GG, Director • Dr. Guru Betageri,<br />
Director<br />
BIO Business Forum 2011 279 Participating Company <strong>Profiles</strong>
Eiji Katayama<br />
President & CEO<br />
27100 Oxnard Street<br />
Woodland Hills, CA 91367<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Senju USA, Inc.<br />
Clinical Foci: Ophthalmic • Drug Delivery • CNS<br />
www.senju-usa.com<br />
Elji Katayama<br />
Jun Inoue , PHD, VP, Product formulation and development<br />
Takemasa Sugioka, Director, Business Affairs<br />
HIGHLIGHTS<br />
Recent<br />
5 our licensed prodcut are on the market in the U.S.<br />
Phone: 1-818-719-7190<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Research-based Japanese pharmaceutical company that develops, manufactures and commercializes a variety of innovative products as<br />
focusing on the field of ophthalmology. Senju improves the health and quality of life for people worldwide through our products in the<br />
field of ophthalmic.<br />
The characters that comprise Senju's company name in the Japanese language are "Sen" and "Ju“, which literally mean "thousand" and<br />
"bringing happiness", respectively. Senju, bringing much (a thousand) happiness, has an objective that we bring a "happiness" to the<br />
people associated with Senju through the development of original pharmaceutical products for the care of the five senses (eye, ear, nose,<br />
throat and skin), that improve the joy of living.<br />
PROPRIETARY TECHNOLOGY<br />
Ophthalmic Research and Development, and Formulation<br />
CORPORATE ALLIANCES<br />
Major ophtalmic and systemic companies in the US, EU and Asia<br />
INTELLECTUAL PROPERTY<br />
all related to ophthalmic application<br />
PRODUCTS<br />
Name Phase Indication<br />
Calpain inhibitor Preclinical Neuroprotective (Retinopathy/Glaucoma)<br />
Ecabet Sodium Phase II, IIa, IIb Dry eye<br />
Bepotastine Besilate On Market Allergy<br />
Difluprednate On Market Inflammation<br />
SENIOR MANAGEMENT<br />
Eiji Katayama, President & CEO • Takahiro Ogawa, Vice President • Jun Inoue, Chief Technology Officer • Hidnori Ikemura, Director •<br />
Akiharu Isowaki, Director • Takemasa Sugioka, Business Development<br />
BIO Business Forum 2011 280 Participating Company <strong>Profiles</strong>
Tadamitsu Kishimoto, MD<br />
Chairman<br />
1-4-2 Shin-Senri-Higashimachi<br />
Toyonaka 560-0082<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
TAMIO SUGAWARA, Coordinator<br />
CORPORATE MISSION<br />
Senri Life Science Foundation<br />
Clinical Foci: Other<br />
Phone: 81-6-6873 2006 Incorporated: 1970<br />
Employees: 20<br />
Ownership: Private<br />
Senri Life Science Foundation founded in 1990 is conducting various projects such as human resources development programs, research<br />
grant for young researchers and supporting programs to commercialize the research outcomes, aiming to contribute to the society by<br />
promoting the R&D and activation of industries through strengthening the relationship among industries, universities, research<br />
institutes, and administrative organizations in the life science fields.<br />
Protein Mall Kansai, launched in May 2009 is a collaborative R&D community focused on protein-related research including small<br />
molecular chemical entities.<br />
The community actively promotes joint projects among its members through close industry-academia-government partnership. A total of<br />
75 companies and associations participate in and cooperate closely in various ways with Protein Mall Kansai.<br />
Participation in the “protein” community will bring many alliance opportunities. The community enhances corporate cooperation among<br />
members in RDPM platform, and with external communities.<br />
We are working closely with Osaka Bio Headquarters and offer comprehensive support to promote alliance opportunities.<br />
SENIOR MANAGEMENT<br />
Tadamitsu Kishimoto, MD., Chairman<br />
BIO Business Forum 2011 281 Participating Company <strong>Profiles</strong>
Bob Boyle<br />
Chief Executive Officer<br />
23 Cambridge Science Park<br />
CAMBRIDGE<br />
CB40EY<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Bob Boyle<br />
SENTINEL ONCOLOGY LIMITED<br />
Clinical Foci: Oncology • Drug Discovery<br />
www.sentineloncology.com<br />
Phone: 44-1223-437 123<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Sentinel Oncology is a privately owned drug discovery company developing novel drugs for the treatment of cancer. We are committed to<br />
the advancement of new approaches focusing on areas of unmet medical need.<br />
The company’s portfolio comprises programmes focused on the PI3K pathway (P70S6Kinase), DNA repair (Checkpoint kinase 1) and cell<br />
signalling (FLT-3). Furthermore, Sentinel has established a novel an innovative strategy for cancer treatment, “Targeted Synergy” that was<br />
developed with funding received from the Wellcome Trust’s Seeding Drug Discovery initiative.<br />
Our business model is to seek out-licensing or collaborative opportunities at the pre-clinical candidate drug selection phase.<br />
SENIOR MANAGEMENT<br />
Bob Boyle, Chief Executive Officer • Stuart Travers, Chief Operating Officer • John Dixon, Consultant • Ashok Venkitaraman,<br />
Consultant<br />
BIO Business Forum 2011 282 Participating Company <strong>Profiles</strong>
Tim J. Mitchell<br />
President<br />
4605 Decatur Boulevard<br />
Indianapolis, IN 46241<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jennifer Marcum, Chief Executive Officer<br />
Tim J Mitchell, President<br />
Sentry Biopharma Services<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Biodefense<br />
www.sentrybps.com<br />
Phone: 1-317-856-5889<br />
Incorporated: 2005<br />
Employees: 25<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Sentry safeguards the integrity of temperature-sensitive biopharmaceutical products throughout the supply chain utilizing our cGMP<br />
processes and facility. Validated lT systems, infrastructure and processes accommodate ICH recommended storage ranges while allowing<br />
virtually any customized storage environment for the unique and stringent requirements of biopharmaceutical products. We maintain<br />
control over product classifications and locations, with segregation capabilities to support returns, quarantine material, controlled<br />
substances and enhanced security for high-risk products. Our expertise, quality program and validated processes present an opportunity<br />
to meet any cGMP storage and distribution need.<br />
Sentry is committed to helping clients meet development deadlines while minimizing risk. With our FDA labeler code, Sentry performs<br />
labeling, packaging, and kitting operations to support Phase l-lll clinical studies and small scale commercial products in the USA and<br />
globally. Sentry excels in minimizing time out of temperature (TOT) and satisfying tight deadlines through exemplary communications,<br />
expertise, and project management. Optimization is achieved by providing scalable labeling operations, kitting capabilities and<br />
distribution services. Our unified, cohesive approach integrates manufacturers, researchers, distributors, software systems, consultants<br />
and channel supply partners to meet client expectations. Sentry's systems can be accessed via web portal or integrated with client systems<br />
to streamline order fulfillment. As with all programs, Sentry maintains regulatory compliance and transparency in fulfilling orders placed<br />
by clinics, hospitals, distributors and other licensed recipients.<br />
Sentry anticipates, understands and addresses regulatory expectations and best practices, ensuring product integrity at every phase<br />
under our control. With 24/7 online data access, clients can monitor their inventory and track information in real time for total<br />
transparency.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Lifescience Cold Chain<br />
Management<br />
Other Investigate, Design, Implement Solutions to<br />
protect product integrity throughout supply chain<br />
GMP Storage Other Validated systems and environments coupled<br />
with robust quality program provides unequaled<br />
risk mitigation. Includes ambient, +5C, -20C and -<br />
80C storage environments<br />
Seasonal/Pandemic Solutions Cleared for<br />
US Marketing<br />
Clinical Trial Support (U.S.<br />
Depot)<br />
Vaccine and biodefense product storage and<br />
rotation combined with executable plans for<br />
epidemic or pandemic surge distribution support<br />
Other Receive, Store, Label, Pick and Ship products in<br />
support of clinical trials<br />
Labeling & Packaging Other FDA labeler code and in-house expertise provide<br />
flexible and quick-turn execution of labeling and<br />
kitting needs<br />
Import Optimization Other Carrier relationships and customs bond provide<br />
risk mitigation for high value products moving<br />
into U.S.<br />
Controlled Substance Program Other DEA Licensed to handle controlled substance<br />
storage and distribution<br />
Pre-Clinical through<br />
Commercial<br />
Pre-Clinical through<br />
Commercial<br />
Commercial<br />
Phase I - IV<br />
Clinical and Small-scale<br />
Commercial<br />
Pre-Clinical through<br />
Commercial<br />
Pre-Clinical through<br />
Commercial<br />
SENIOR MANAGEMENT<br />
Tim J. Mitchell, President • Jennifer A. Marcum, PMP, Chief Executive Officer • Randy L. Lloyd, General Counsel • W. Dwayne Marcum,<br />
Chief Operating Officer • Don K. Kouns, Director • April L. Lentz, Business Development • Bryan S. Hudson, Other<br />
BIO Business Forum 2011 283 Participating Company <strong>Profiles</strong>
Carol Nacy<br />
Chief Executive Officer<br />
9610 Medical Center Drive<br />
Rockville, MD 20850-3347<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Alan Klein, EVP Corporate Development<br />
Sequella, Inc<br />
Clinical Foci: Infectious Disease • Gastroenterology • Diagnostics<br />
www.sequella.com<br />
Phone: 1-301-762-7776<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
April 2011<br />
Sequella Licenses Rights to Develop and Commercialize SQ109 for<br />
Tuberculosis in Russia and Commonwealth of Independent States<br />
April 2011<br />
Sequella Awarded $4.6 million in New NIH Grants to Expand Anti-<br />
Infectives Pipeline for Clostridium Difficile Infections<br />
November 2010<br />
FDA allows IND for SQ109 in Helicobacter pylori-related infections<br />
CORPORATE MISSION<br />
Incorporated: 1997<br />
Employees: 16<br />
Ownership: Private<br />
SQ109 licensing in additional worldwide territories for<br />
Tuberculosis<br />
SQ109 licensing in worldwide territories for Helicobacter pylori<br />
infections<br />
Licensure/Partnering of BSMART Infectious Disease Diagnostic<br />
Sequella is a private, clinical-stage pharmaceutical company that discovers, develops, and intends to commercialize novel first-in-class<br />
antibiotics for treatment of serious life-threatening infectious diseases. We initially created a<br />
65,000 small molecule compound library from which we identified a novel antibiotic now in clinical development for treatment of<br />
tuberculosis (TB), SQ109. Following initiation of SQ109 human clinical trials in 2006, we expanded our small molecule library to >150,000<br />
compounds and broadened<br />
our therapeutic focus to include other bacteria and fungi based on biologic activity of our proprietary library. In addition to new<br />
pathogen-specific antibiotics, we also have a vigorous research program to discover novel broad spectrum antibiotics that target the<br />
enzyme translocase-1,<br />
an essential enzyme in all bacteria.<br />
Our product portfolio addresses global health threats with<br />
significant market opportunity in disease areas of known<br />
or suspected infectious etiology:<br />
TB (Mycobacterium tuberculosis);<br />
Duodenal ulcers & Gastric carcinomas (H. pylori);<br />
Systemic fungal infections (Candida glabrata);<br />
Crohn’s Disease (M. avium paratuberculosis);<br />
Pneumonias (M. avium avium);<br />
Clostridium difficile infections<br />
PROPRIETARY TECHNOLOGY<br />
Sequella has created a > 150,000 small molecule compound library from which it has identified a novel antibiotic now in clinical<br />
development for treatment of tuberculosis (TB), SQ109. We continue to investigate our small molecule library for molecules with<br />
additional therapeutic focus to include other pathogenic bacteria and fungi for infections caused by Helicobacter pylori, Clostridium<br />
difficile, and Candida glabrata.<br />
Diagnostics<br />
Event Marker System A system to measure events (such as medication ingestion) via transdermal detection of a marker. A prototype<br />
assessed in a 'proof-of-principle' clinical study at Wills Eye Institute in Philadelphia, PA. demonstrated that the non-invasive, transdermal<br />
system readily detected a fluorescent marker in peripheral blood.<br />
CORPORATE ALLIANCES<br />
National Institutes of Health (NIH)<br />
Maxwell Biotech<br />
Johnson & Johnson / Tibotec<br />
Sanofi<br />
Pfizer<br />
Daiichi-Sankyo Co. Ltd.<br />
University of Maryland<br />
Chembio Diagnostics<br />
Japan BCG Laboratories<br />
BIO Business Forum 2011 284 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
Sequella's intellectual property portfolio consists of 179 issued and pending patents covering the U.S., E.U., Japan, and selected countries<br />
of the ROW<br />
Sequella has 20 or more issued patents and additional patent filings for SQ109, including a U.S. patent for compositions of matter and<br />
uses of diamine anti-infectives. These patents provide broad coverage for compositions, methods and use claims for treatment of<br />
tuberculosis, H. pylori<br />
-related ulcers, systemic fungal agents and other infectious pathogens.<br />
Sequella currently has issued and pending patents in the U.S., EU,<br />
Japan, South Africa, India, Brazil, China, Eurasia, Canada, Austrailia, Korea and other key international markets.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SQ109 Phase II, IIa, IIb Tuberculosis Phase IIa to complete enrollment by August<br />
2011<br />
SQ109 Phase II, IIa, IIb Helicobacter Pylori Infections IND allowed by FDA; Phase IIa to begin 2H<br />
2011<br />
SQ609 Preclinical Tuberculosis IND enabling pre-clinical toxicology studies<br />
ready to begin<br />
SQ641 Preclinical Tuberculosis, M. Avium<br />
infections, Crohn's disease, non-<br />
TB pneumonias<br />
Lead optimization underway<br />
BSMART Diagnostics AST and ART Testing Proof of Principle complete<br />
Event Marker System Diagnostics Drug Compliance Clinical Proof of Prinicple complete<br />
SENIOR MANAGEMENT<br />
Carol Nacy, Chief Executive Officer • Leo Einck, Chief Scientific Officer • Marty Zug, Chief Financial Officer • Gary Horwith, Chief<br />
Medical Officer • Alan Klein, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Carol Nacy, CEO, Sequella • Leo Einck, CSO, Sequella • Brad Rotter, Director • John Friedman, Easton Capital Investment Group •<br />
Ronald Meltzer, Wilmer Hale • Lawrence Miller, Secretary<br />
SCIENTIFIC ADVISORY BOARD<br />
Michael Cynamon, SUNY Syracuse & VA Medical Center • Micheal Doyle, University of Maryland • Micheal Dudley, MPEX<br />
Pharmaceuticals • John Lonsdale, Director<br />
BIO Business Forum 2011 285 Participating Company <strong>Profiles</strong>
22 Rue Garnier<br />
92200 NEUILLY SUR SEINE<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Joseph O'Sullivan<br />
Pascal Touchon, Director of Business Development<br />
Servier<br />
Clinical Foci: Drug Discovery • Drug Development<br />
www.servier.com/<br />
Phone: 33-1-55727052<br />
Employees: 20000<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Servier is a privately-held pharmaceutical company with a mission to satisfy the needs of the physicians and the patients, contribute<br />
through our research to the progress of medicine, and to fulfill our employees needs through and by their work. Servier has considerable<br />
expertise in the discovery, development and commercialisation of therapeutics for diverse fields of medicine including cardiovascular,<br />
metabolic disease, oncology, CNS and rheumatology. Servier has an annual turnover of €3.6 billion, 25% of which is invested in R&D. We<br />
are established in 140 countries.<br />
CORPORATE ALLIANCES<br />
Servier is active in partnering with both commercial and academic institutions. We have a range of collaborations with biotechnology<br />
companies based on our business strategy and expertise. We are looking for innovative medicines, whatever their stage of development,<br />
in our 5 fields of activity: cardiovascular, metabolism, oncology, CNS and rhumatology.<br />
BIO Business Forum 2011 286 Participating Company <strong>Profiles</strong>
Chunlin Chen<br />
Chief Executive Officer<br />
585 Chuanda Road<br />
201200 Shanghai<br />
China<br />
CONFERENCE PARTICIPANTS<br />
Mingzhu Zhang Zhang<br />
HIGHLIGHTS<br />
Recent<br />
Shanghai Medicilon Inc.<br />
Clinical Foci: Oncology • Metabolic Disease • Chemistry<br />
www.medicilon.com.cn<br />
Phone: 86-215-859 1500<br />
Medicilon got AAALAC full accreditation in 2009 and is providing GLP-Tox services.<br />
Providing strucutre biology services (Gene to protein to structure) to big pharma and biotech, biopharma.<br />
All VPs and directors are from US and Europe.<br />
CORPORATE MISSION<br />
Incorporated: 7<br />
Employees: 350<br />
Ownership: Private<br />
Shanghai Medicilon, founded in 2004, is the pioneer in integrated drug R & D service in China that offers chemistry, biology and structure<br />
biology, DMPK/PD, toxicology services to pharmaceutical and biotech companies. With near 350 employees, Medicilon occupies over<br />
218,000 square feet of R&D facilities equipped with state-of the-art instruments in Shanghai, and is managed by a team with 10 to 20<br />
years of working experience in US-based pharmaceutical companies.<br />
Medicilon owns 105,000 square feet of animal facility (mice, rats, dogs and monkeys in house) which allows us to provide high quality<br />
preclinical ADMET, tox and efficacy services to many companies around the world since 2005. With MPI's help and Guidance, Medicilon got<br />
has AAALAC full accreditation in 2009 and is providing GLP-Tox services. Medicilon’s chemistry department provides medicinal chemistry<br />
services as well as custom synthesis. Medicilon’s structure biology is one of our specialty and we have ongoing collaboration with big<br />
pharma.<br />
PROPRIETARY TECHNOLOGY<br />
Structure biology, biology, DMPK, tox, efficacy (oncology, CNS, metabolic disease, inflammation disease, etc.) and Chemistry.<br />
CORPORATE ALLIANCES<br />
Near 100 clients worldwide.<br />
SENIOR MANAGEMENT<br />
Chunlin Chen, Chief Executive Officer • Peter Rehse, Vice President • Jun Wang, Vice President • Wen-Cherng Lee, Vice President •<br />
Xingchu Gu, Manager • Mingzhu Zhang, Vice President<br />
BIO Business Forum 2011 287 Participating Company <strong>Profiles</strong>
Jun REN<br />
President & CEO<br />
No.7, Lane 67, Li Bing Road, Shanghai<br />
Zhangjiang Hi-tech Park<br />
201203 Shanghai<br />
China<br />
CONFERENCE PARTICIPANTS<br />
Ke Shao, Managing Director<br />
CORPORATE MISSION<br />
Shanghai Newsummit Biopharma R&D Co., Ltd<br />
www.newsummitbio.com/<br />
Phone: 86-21-5079 8788<br />
Ownership: Other<br />
Shanghai Newsummit Biopharma R&D Co.Ltd is located in Zhangjiang Hi-tech park, Shanghai. As a Chinese pharmaceutical accelerator<br />
public service and investment organization, our main business focus on new drug back-end R & D technology service and program<br />
investment operation. Through the platform of chain R & D, PCRD, together with national high-tech parks and development zones, we<br />
provide one-stop solution for our clients: investment and financial service for international new drug R & D, regulations and policy service,<br />
SFDA/FDA/EMEA application, program implantation, pre-clinical/clinical CRO service, License in/License out service, pilot-industrialization<br />
development, advanced technology platform implantation and expertise talents training and exchange.<br />
PROPRIETARY TECHNOLOGY<br />
Pharmacy service: Recombinant protein high expression Process Optimization and scale up Final bulk production for IND Quality<br />
standards establishment and analysis Pre-clinical research service: Public service platform for pharmacodynamic research Research service<br />
platform for drug safety study ADME-TOX research platform IND&NDA pilot production service: Pilot study with IND standards, pilot<br />
production with the standards of clinical certificates GMP/cGMP production with the standards of NDA Manufacturing certificates, GMP<br />
verification service Portfolio: Feasibility Analysis, Engineering, Construction, GMP / cGMP training and certification services<br />
CORPORATE ALLIANCES<br />
State Biomedical Science and Technology Industrial Base, Shanghai Taizhou National Medical High-tech Industrial Park (China Medical<br />
City) Wuhan National Hi-tech Development Zone and national Bio-Industrial Base (Biolake)<br />
Dalian Economic and Technological Development Zone and Bio-Industrial Base The Hamner institutes for health sciences Shenyang<br />
Medical Device Industry Base (Sishui Science and Technology Park) Tianjin Economic and Technological Development Zone and Bio-<br />
Industrial Base Tianjin Tasly Biotechnology Venture Capital Management Co., Ltd. (TBD) Medical Research Council Technology<br />
(MRCT),CompanDX, Huya Bioscience International,Cleveland BIO Fund<br />
SENIOR MANAGEMENT<br />
Jun REN, President & CEO • Jun YIN, Chief Technology Officer • Weiguo HUANG, Chief Business Officer • Caidy, Chief Financial Officer •<br />
Lillian CAO, Managing Director • Yangbing HUANG, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Jun REN (Chairman)<br />
BIO Business Forum 2011 288 Participating Company <strong>Profiles</strong>
Tel Hashomer<br />
52621 Ramat Gan<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Sylvie Luria<br />
CORPORATE MISSION<br />
Sheba Medical Center<br />
Clinical Foci: Biopharmaceuticals • Medical Device • Diagnostics<br />
www.sheba.health.gov.il<br />
Phone: 972-3-5305998<br />
Incorporated: 2004<br />
Employees: 9000<br />
Ownership: Other<br />
THM – the Technology Transfer of Sheba Medical Center (SMC), Israel<br />
THM, the technology transfer arm of SMC, has been established as a "company for the benefit the public" to promote the transfer of SMC<br />
technologies, innovation and professional know-how for society's use and benefit, and for the development of the medical and health care<br />
delivery fields.<br />
SMC facilities, experience, human resources and regulations enable the development of a novel idea from its basic science to its product<br />
development and prototype, thus rapidly generating value to its IP for commercialization.<br />
THM Intellectual property's portfolio spans over therapeutics, diagnostics, medical devise and medical tools in the fields of<br />
Pharmaceuticals, BioMarkers, Medical devices, Imaging tools, regenerative medicine spanning vast medical applications as Onco-<br />
Genetics, Hemato-Oncology, Epidemiology of Malignant Diseases and Trauma, Lipids, Diabetes, Hypertension, Onco-Surgery , including<br />
research in Breast and Colon Cancer, Regenerative medicine, Immunology, Neuro-Immunology, Alzheimer's Disease, Multiple Sclerosis and<br />
Psychiatry.<br />
PROPRIETARY TECHNOLOGY<br />
IP portfolio in the bio-medical fields : Bio-Pharmaceuticals, BioMarkers, Medical devices, Imaging tools, regenerative medicine spanning<br />
vast medical applications<br />
CORPORATE ALLIANCES<br />
Many of them - including HUTCHISON WHAMPOA LIMITED , NIKKEN SOHONSHA Corporation , SIGMA-ALDRICH , PONTIFAX and F.<br />
HOFFMANN-LA ROCHE Ltd, VENTOR-MEDTRONIC, Schering-Plough,I. P. U Industrial, Israel, InSightec , Brainsway, Bioline, Rosetta Genomics,<br />
Wolfson Clore Mayer VC and more.<br />
INTELLECTUAL PROPERTY<br />
we currently have 95 patent families in different stages.<br />
PRODUCTS<br />
Name Phase Indication<br />
GI Guidewire for pan endoscopy Preclinical GI<br />
Miteral Valve Research cardiology<br />
somatostatin analog - for diagnostic and<br />
treatment<br />
Pre-Target Validation cancer<br />
Klotho hormon Pre-Target Validation pancreatic cancer<br />
regenerative medicine Pre-Target Validation ocular AMD, renal failure, cardiac<br />
application and diabetes<br />
Molecular markers Pre-Target Validation Bone diseases, non-invasive prenatal<br />
diagnosis, Multiple Sclerosis<br />
Molecular markers Pre-Target Validation Brain-metastasis<br />
Spectral Scanning of Intestinal Wall by<br />
Ingestible Capsule<br />
Target Validated GI<br />
BIO Business Forum 2011 289 Participating Company <strong>Profiles</strong>
Shiguang Duan<br />
Chief Executive Officer<br />
31 Songhuahu Street<br />
110141 Shenyang<br />
China<br />
CONFERENCE PARTICIPANTS<br />
Yingtong Duan<br />
Shenyang Everbright Pharma<br />
Clinical Foci: Hormone Therapy • Gastroenterology • Metabolic Disease<br />
www.sygdzy.com<br />
Phone: 86-24-25360065<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Reliable scientific style and expericnces<br />
The determination of China's medical reform<br />
Mature software and hardware resources for products operation<br />
Incorporated: 1989<br />
Employees: 100<br />
Ownership: Private<br />
Government's health reform prospects<br />
The new pattern of drug Chinese pharmaceutical market<br />
More mature Everbright Pharma<br />
CORPORATE MISSION<br />
Over 20 years tens of kinds of injection manufacturing and marketing experience, focusing on Frozen Powder and Small Volume Injection<br />
production processes.<br />
PROPRIETARY TECHNOLOGY<br />
Crystal formation and redissolve.<br />
PRODUCTS<br />
Name Phase Indication<br />
Adenosine Injection On Market Conversion to sinus rhythm of paroxysmal supraventricular<br />
tachycardia (PSVT), including that associated with accessory bypass<br />
tracts (Wolff-Parkinson-White Syndrome).<br />
Dexamethasone Sodium Phosphate for<br />
Injection<br />
On Market Increased stability, less impurity.<br />
Pantoprazole Sodium for Injection On Market For gastrointestinal bleeding prevention during surgical operation.<br />
Water-soluble vitamin for Injection On Market Parenteral nutrition Injection for adults and children, meet the daily<br />
physiological needs of water-soluble vitamins.<br />
Immunoglobulin Ribonucleic Acid of Anti-<br />
Cancer for Injection<br />
On Market Specific immune stimulant for anti-oncology<br />
SENIOR MANAGEMENT<br />
Shiguang Duan, Chief Executive Officer • Shidi Zhang, Chief Financial Officer • Zhimei Xie, Chief Operating Officer<br />
BIO Business Forum 2011 290 Participating Company <strong>Profiles</strong>
Nancy Shepherd, PhD MBA<br />
Chief Executive Officer<br />
105 Beech Slope Way<br />
Cary, NC 27518<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Nancy S. Shepherd, CEO<br />
CORPORATE MISSION<br />
SHEPHERD RESEARCH LLC<br />
Clinical Foci: Drug Discovery • Diagnostics • Biopharmaceuticals<br />
www.shepherdresearch.com<br />
Phone: 1-919-208-3946<br />
Ownership: Private<br />
Shepherd Research provides customer-driven business development solutions to pharmaceutical, biotechnology, research, IT and medical<br />
device organizations. Founded in 2008, the firm’s growing base of satisfied customers is a direct result of the company’s commitment to<br />
deliver quality consulting services to enable the optimal use of business opportunities and resources. Whether the need is to build strong<br />
relationships in support of new research or business opportunities, to develop a business or R&D strategy for products or services, or the<br />
negotiation of in/out IP licensing opportunity deals, Shepherd Research has the experience you seek. Each project is managed by a<br />
seasoned professional with PhD-level scientific expertise and decades of relevant industry experience.<br />
Shepherd Research is headquartered in the greater Research Triangle Park area of North Carolina. This enables access to a wide range of<br />
cutting-edge technology and easy communication with product or service based firms, both in the USA and internationally. Contact us at<br />
info@shepherdresearch.com, or visit our website at http://www.ShepherdResearch.co<br />
PROPRIETARY TECHNOLOGY<br />
Shepherd Research's strength is in facilitating technology transfer of your proprietary technology.<br />
CORPORATE ALLIANCES<br />
North Carolina Biotechnology Center's BIO2011 pavilion<br />
SENIOR MANAGEMENT<br />
Nancy Shepherd, PhD MBA, Chief Executive Officer<br />
BIO Business Forum 2011 291 Participating Company <strong>Profiles</strong>
Borys Chabursky<br />
President<br />
162 Cumberland Street<br />
Toronto, ON M5R 3N5<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Borys Chabursky<br />
John McGraw<br />
SHI Consulting<br />
www.shiconsulting.com<br />
Phone: 1-416-236-1054<br />
Ownership: Private<br />
CORPORATE MISSION<br />
SHI Consulting Inc. (SHI) is a global, strategy-through-implementation consultancy specializing in the life sciences. We offer our clients in<br />
government, academia, industry and the not-for-profit sector implementation-focused solutions that couple scientific expertise with a<br />
keen understanding of the international life sciences marketplace.<br />
SENIOR MANAGEMENT<br />
Borys Chabursky, President • John McGraw, Associate<br />
BIO Business Forum 2011 292 Participating Company <strong>Profiles</strong>
Carl Sterritt<br />
Chief Executive Officer<br />
Sihleggstrasse 23<br />
8832 Wollerau Schwyz<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Carl Sterritt, Chief Executive Officer<br />
Richard CM Jones, ACA, Chief Financial Officer<br />
Shield Therapeutics<br />
Clinical Foci: Hematology • Specialty Pharmaceutical • Drug Development<br />
www.shieldtherapeutics.com<br />
Phone: 44-7866-381800<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
H2 2010: Strategic commercialisation agreement signed with AOP<br />
Orphan Pharmaceuticals AG for commercialisation rights to ST10-<br />
021 in Central Eastern Europe and the Middle-East. AOP made a<br />
EUR3m strategic investment in Shield Holdings.<br />
Incorporated: 2008<br />
Ownership: Private<br />
Initiation of two placebo-controlled Phase III trials (AEGIS I & II, 240<br />
patients in total) for ST10-021 in H2 2011.<br />
CORPORATE MISSION<br />
Shield Therapeutics is an independent specialty pharmaceutical company founded in 2008, with a focus on developing clinical stage<br />
pharmaceuticals to treat unmet medical needs. Shield is led by Carl Sterritt, Chief Executive Officer, and Christian Schweiger, Chief<br />
Medical Officer, two experienced senior pharmaceutical executives with 30 years of combined experience of successfully developing and<br />
commercialising pharmaceutical products.<br />
PROPRIETARY TECHNOLOGY<br />
Shield Therapeutics’ lead asset is a novel oral iron-based therapy with a strong and extended intellectual property rights portfolio. ST10-<br />
021 is initially being developed for the treatment of iron deficiency anaemia, a key symptom of both ulcerative colitis and Crohn’s disease.<br />
ST10-021 has the potential to offer patients a simple oral therapy that is well tolerated, efficacious and can be administered to treat and<br />
prevent relapse of IDA. In the second half of 2011 Shield Therapeutics will commence international Phase III trials of ST10-021 (AEGIS I & II)<br />
in patients with these indications.<br />
CORPORATE ALLIANCES<br />
In September 2010, Shield Therapeutics signed an agreement with AOP Orphan Pharmaceuticals AG whereby AOP has commercialisation<br />
rights to ST10-021 in Central Eastern Europe and the Middle-East, Shield Therapeutics retains commercialisation rights to ST10-021 in all<br />
other territories.<br />
INTELLECTUAL PROPERTY<br />
ST10-021 is protected by a robust intellectual property rights portfolio.<br />
PRODUCTS<br />
Name Phase Indication<br />
ST10-021 Phase III Iron Deficiency Anaemia<br />
SENIOR MANAGEMENT<br />
Carl Sterritt, Chief Executive Officer • Richard Jones, Chief Financial Officer • Christian Schweiger, Chief Medical Officer • Laura<br />
Emery, Director • Michael Stockham, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Carl Sterritt, Shield Therapeutics • Christian Schweiger, Shield Therapeutics • Natalie Douglas, IDIS Pharmaceuticals • Richard Jones,<br />
Shield Therapeutics<br />
BIO Business Forum 2011 293 Participating Company <strong>Profiles</strong>
Motozo Shiono<br />
Chairman<br />
1-8, Doshomachi 3-chome, chuo-ku<br />
Osaka 541-0045<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Shionogi & Co., Ltd.<br />
Clinical Foci: Metabolic Disease • Infectious Disease • CNS<br />
www.shionogi.co.jp/index_e.html<br />
Phone: 81-6-62096763<br />
Toshiaki Nagafuji, Deputy General Manager, Business Development<br />
Fumito Aranami, Business Development<br />
Ryuichi Kiyama<br />
Makoto Asakawa, PhD<br />
Incorporated: 1919<br />
Employees: 4162<br />
Ownership: Public<br />
Market Cap: $5200.00 million<br />
TOKYO STOCK EXCHANGE: 4507<br />
Takeo Oshima<br />
Hiroyuki Shimizu, Manager, Business Development<br />
Soichi Shiono, Manager, Business Development<br />
Anjan Aralihalli<br />
HIGHLIGHTS<br />
Recent<br />
Shionogi has signed an agreement on 4/1/2011 with Denmark on the formation of an international network for industry-academic<br />
collaboration in research and development.<br />
Collaboration with GSK focusing on research, development and commercialization of novel cephem antibiotics targeting Gram-negative<br />
bacteria was signed 10/28/2010.<br />
Shionogi-ViiV (jointly owned venture company with GSK) started PhIII clinical study for HIV integrase inhibitor S-349572 monotherapy.<br />
Also started PhIII clinical study for fixed-dose combination therapy with Trii.<br />
CORPORATE MISSION<br />
Shionogi & Co., Ltd. (www.shionogi.co.jp) is headquartered in Osaka, Japan and is a major research-driven pharmaceutical company. For<br />
the fiscal year ending March 31, 2011, Shionogi employed more than 5,000 staff worldwide, reported consolidated revenues of<br />
approximately $3.0 billion, and invested approximately $550 million in R&D. Shionogi Inc. is the US subsidiary of Shionogi, containing<br />
clinical development groups and sales force. Shionogi is dedicated to placing the highest value on patients and strives to provide medicine<br />
of the best possible kind, essential for the protection and health of people. The company has provided such innovative medicines as<br />
Crestor, Irbetan, Finibax, and Cymbalta. Our mission is to deliver pharmaceuticals that offer the greatest possible level of satisfaction to<br />
patients, their families, and healthcare providers. The company’s Research and Development currently targets three therapeutic areas:<br />
Infectious Diseases, Pain, and Metabolic Syndrome, especially obesity/diabetes, viral infection, and chronic pain. In addition, Shionogi is<br />
engaged in new therapeutic areas such as allergy and cancer. In the United States, Shionogi Inc. focuses on Pediatric conditions, and<br />
Women’s health. The company’s Women’s Health products are designed to improve the health and well-being of women and mothers and<br />
their babies; and its Pediatrics products treat allergies, asthma, head lice, attention deficit/hyperactivity disorder (ADHD), and chronic<br />
drooling. For more details, please visit www.shionogi.co.jp. and www.shionogi-inc.com<br />
CORPORATE ALLIANCES<br />
AEterna-Zentaris, Anthera, AstraZeneca, Bayer, BioCryst, Eli Lilly, Enanta, Galderma, GSK, J&J, Kissei, MARNAC,Inc., Mundipharma, Nissan<br />
Chemical, Onco Therapy Science, Purdue, Sanofi-Aventis, Schering-Plough, Stallergenes<br />
PRODUCTS<br />
Name Phase Indication<br />
S-349572 Phase III HIV infection<br />
S-474474 Phase III Hypertension<br />
S-811717 NDA/BLA filed, or in process Cancer pain<br />
S-222611 Phase I Malignant tumor<br />
S-0373 Phase II, IIa, IIb Spinocerebellar ataxia<br />
S-288310 Phase I Bladder cancer<br />
SENIOR MANAGEMENT<br />
Motozo Shiono, Chairman • Isao Teshirogi, PhD, President & CEO • Yasuhiro Mino, Vice President<br />
BOARD OF DIRECTORS<br />
Motozo Shiono, Chairman of the Board and Representative Director • Isao Teshirogi, PhD, Chief Executive Officer and Representative<br />
Director • Sachio Tokaji, Director • Yasuhiro Mino, Director<br />
BIO Business Forum 2011 294 Participating Company <strong>Profiles</strong>
Angus Russell<br />
Chief Executive Officer<br />
725 Chesterbrook Blvd.<br />
Wayne, PA 19087<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Martin Steiner , PHD, Sr. Director, Scientific Licensing<br />
Jenn King<br />
Gregory Robinson<br />
Jonathan Rubin<br />
Armand Girard<br />
Alicia Gomez-Yafal<br />
Cherise Kent<br />
Shire Pharmaceuticals, Inc<br />
Presenting Company<br />
Clinical Foci: Genetic Disorders • Specialty Pharmaceutical • Biopharmaceuticals<br />
www.shire.com<br />
Phone: 1-484-595-8800<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Acquired MOVETIS, a specialty gastrointestinal (GI) company,<br />
enhancing our GI presence in Europe with the addition RESOLOR®,<br />
approved in the EU for the symptomatic treatment of chronic<br />
constipation in women in whom laxatives fail to provide relief.<br />
Approval and launch of VPRIV for the treatment of type 1 Gaucher<br />
disease in the US, EU and other countries.<br />
Shire reports 2010 total revenue of $3.5 billion (USD) with total<br />
product sales topping $3 billion for the first time in company<br />
history.<br />
CORPORATE MISSION<br />
Ownership: Public<br />
Market Cap: $17000.00 million<br />
LONDON STOCK EXCHANGE: SHP.L<br />
Launch of EQUASYM® for the treatment of ADHD in certain<br />
European countries.<br />
Regulatory decision in the US for FIRAZYR® for the symptomatic<br />
treatment of acute attacks of HAE.<br />
Regulatory decision in the US for a label change to LIALDA® to<br />
include the maintenance of remission of ulcerative colitis in the US<br />
(LIALDA is currently approved for the remission of ulcerative colitis).<br />
Shire plc has two divisions: Specialty Pharmaceuticals is actively pursuing opportunities that are targeted to specialist physicians, and the<br />
Human Genetic Therapies (HGT) division is pursuing opportunities in “orphan” and/or genetic diseases. In general, Shire focuses on new<br />
opportunities that have demonstrated proof of concept, but will review earlier opportunities for investment.<br />
A global specialty biopharmaceuticals company with operations in 28 countries and several medicines available in more than 45<br />
countries, Shire focuses its business currently on the areas of Attention Deficient Hyperactivity Disorder, Gastrointestinal disease, and<br />
Genetic disorders. With more than 4,300 employees, Shire is focused on its strategic goal of becoming the leading specialty<br />
biopharmaceutical company serving the needs of specialist physicians. Over the last 15 years, Shire has successfully accomplished more<br />
than a dozen acquisitions and in-licensing agreements, growing revenues from $7 million in 1997 to over $3.5 billion in 2010. Shire’s<br />
acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire’s<br />
carefully selected and balanced portfolio of products is supported by its strategically aligned and relatively small-scale sales forces that<br />
consistently deliver strong results. For further information on Shire, please visit the company’s website: www.shire.com.<br />
PRODUCTS<br />
Name Phase Indication<br />
VPRIV On Market Gaucher Disease<br />
REPLAGAL On Market Fabry Disease<br />
ELAPRASE On Market Hunter Syndrome<br />
FIRAZYR On Market Hereditary Angiodema<br />
INTUNIV On Market ADHD<br />
VYVANSE On Market ADHD<br />
LIALDA / MEZAVANT On Market Ulcerative Colitis<br />
RESOLOR On Market Chronic constipation in women in whom laxatives fail<br />
PENTASA On Market Ulcerative Colitis<br />
EQUASYM On Market ADHD<br />
BIO Business Forum 2011 295 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Angus Russell, Chief Executive Officer • Graham Hetherington, Chief Financial Officer • Mike Cola, President • Sylvie Grégoire,<br />
President • Barbara Deptula, Executive Vice President • Tatjana May, General Counsel<br />
BOARD OF DIRECTORS<br />
Matthew Emmens, Chairman and Non-Executive Director • Angus Russell, Chief Executive Officer • Graham Hetherington, Chief<br />
Financial Officer and Executive Vice President of Global Finance • David Kappler, Senior Non-Executive Director • Patrick Langlois, Non-<br />
Executive Director • Anne Minto, Non-Executive Director • Jeffrey Leiden, Vice Chairman and Non-Executive Director • David Stout,<br />
Non-Executive Director • William Burns, Non-Executive Director • Dr David Ginsburg, Non-Executive Director<br />
BIO Business Forum 2011 296 Participating Company <strong>Profiles</strong>
61 Broadway, 32nd Floor<br />
Manhattan, NY 10006<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jeffrey Fessler, Managing Partner<br />
Sichenzia Ross Friedman Ference LLP<br />
www.srff.com<br />
Phone: 1-212-398-4627<br />
Incorporated: 1998<br />
Employees: 55<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Sichenzia Ross Friedman Ference LLP is a leading securities law firm specializing in corporate and securities law. Our attorneys have<br />
extensive experience with all securities matters including public offerings, PIPE transactions, Alternative Public Offerings, corporate<br />
finance and M&A. We are a recognized leader in PIPE transactions, having completed over 300 transactions since 2001, totaling<br />
approximately $2 billion. We have developed an expertise in providing legal services to healthcare companies including biotechnology,<br />
medical device and diagnostic companies. Many of our clients leverage off of our strong relationships with investment banks and other<br />
funding sources in order to raise capital. Our clients also enjoy our flat fee billing structure as opposed to traditional hourly billing<br />
preferred by many law firms.<br />
BIO Business Forum 2011 297 Participating Company <strong>Profiles</strong>
Rakesh Sachdev<br />
Chief Executive Officer<br />
3050 Spruce Street<br />
St. Louis, MO 63103<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Kevin Gutshall, Sr. Manager Business Development<br />
Eric Rhodes, Director, Business Development<br />
Stephanie Seiler, Business Development Manager<br />
Sigma-Aldrich Corporation<br />
Clinical Foci: Biology • Chemistry • Biomaterials<br />
www.sigmaaldrich.com<br />
Phone: 1-800-521-8956<br />
Employees: 7700<br />
Ownership: Public<br />
Market Cap: $8400.00 million<br />
NASDAQ: SIAL<br />
CORPORATE MISSION<br />
Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in<br />
scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and<br />
as key components in pharmaceutical, diagnostic and other high technology manufacturing.<br />
SENIOR MANAGEMENT<br />
Rakesh Sachdev, Chief Executive Officer • Frank Wicks, Senior Vice President • Gilles Cottier, Vice President • David Smoller, Chief<br />
Scientific Officer<br />
BIO Business Forum 2011 298 Participating Company <strong>Profiles</strong>
Dr. Phil Haworth<br />
Chief Executive Officer<br />
Robert- Roessle-Str. 10<br />
13125 Berlin<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Thomas Christély<br />
Silence Therapeutics PLC<br />
Presenting Company<br />
Clinical Foci: Drug Development • Oncology • Other<br />
www.silence-therapeutics.com<br />
Phone: 49-30-94892800<br />
Incorporated: 1998<br />
Employees: 40<br />
Ownership: Public<br />
Market Cap: $20.00 million<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Phase I Atu027 clinical interims data accepted for presentation at the American Society of Clinical<br />
Oncology 2011 annual meeting in June<br />
New U.S. patent issued in February covering fundamental RNA Interference technology currently in<br />
several clinical trials<br />
Novartis takes an option from Quark Pharma to obtain an exclusive worldwide license to develop<br />
and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates<br />
Silence’s AtuRNAi technology ($80m milestone paym.f. Silence)<br />
LONDON STOCK EXCHANGE: SLN (AIM<br />
Completion of Silence's Atu027<br />
phase I clinical study a liposomal<br />
small interfering RNA<br />
formulation, targeting protein<br />
kinase N3 (PKN3) in patients with<br />
advanced solid tumors<br />
CORPORATE MISSION<br />
SILENCE offers one of the most comprehensive RNAi therapeutic platform available today, comprised of proprietary delivery technologies,<br />
potent short interfering RNA (siRNA) sequences and innovative siRNA structural features. The company has developed a novel, proprietary<br />
siRNA technology (AtuRNAi) and proprietary systemic delivery systems for siRNA (AtuPLEX, DACC and DBTC).<br />
SILENCE pipeline, which includes five product candidates in clinical development, consists of both partnered and internal programs.<br />
Silence’s lead compound Atu027 is currently in a Phase I clinical study for the treatment of solid tumours. 24 patients had been treated<br />
with Atu027. Interim data will be presented at the ASCO Annual Meeting in June 2011.<br />
In addition to Silence's partnerships with Quark/Pfizer ($95m milestone payments) and Quark/Novartis ($80m milestone payments),<br />
Silence has active collaborations with AstraZeneca ($15m upfront/$400m milestone payments) and Dainippon Sumitomo ($2m upfront).<br />
PROPRIETARY TECHNOLOGY<br />
The company has developed a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery systems for siRNA<br />
(AtuPLEX, DACC and DBTC).<br />
CORPORATE ALLIANCES<br />
SILENCE has established validating partnerships with AstraZeneca ($15m upfront payment & equity, $400m milestone payments),<br />
Pfizer/Quark ($95m milestone payments, so far $6m received) & Dainippon Sumitomo Pharma (delivery collaboration) and Quark<br />
Pharma/Novartis ($80m milestone payments, $1m received)<br />
INTELLECTUAL PROPERTY<br />
SILENCE’s strong IP position is based on patents issued in the US, Europe and other territories. SILENCE is one of only few biotech<br />
companies worldwide which own issued composition of matter patents in the field of siRNA therapeutics.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
PF-4523655 (AtuRNAi) Phase II, IIa, IIb Macular Edema: AMD & Diabetic Retinopathy<br />
QPI-1002 (AtuRNAi) Phase II, IIa, IIb Prevention of Delayed Graft Function, Acute<br />
Kidney Injury<br />
Atu027 (AtuRNAi) Phase I GI & Lung and Other Cancers Complete Phase I study<br />
Atu111 (AtuRNAi) Preclinical AcuteLung Injury<br />
Atu134 (AtuRNAi) Preclinical Solid Tumors Continue preclin. devel. and prepare for IND<br />
Atu195 (AtuRNAi) Preclinical Solid Tumors<br />
SENIOR MANAGEMENT<br />
Dr. Phil Haworth, Chief Executive Officer • Thomas Christély, Chief Operating Officer • Dr. Klaus Giese, Chief Scientific Officer • Max<br />
Herrmann, Chief Financial Officer • Mike Riley, Vice President • Dr. Joerg Kaufmann, Vice President<br />
BIO Business Forum 2011 299 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Jerry Randall, Chairman • Annette Clancy, Non-Executive Director • Phil Haworth, PhD, Chief Executive Officer • James Topper, PhD,<br />
Non-Executive Director • David Mack, PhD, Non-Executive Director • David U'Prichard, PhD, Non-Executive Director • Max Herrmann,<br />
Chief Financial Officer and Company Secretary<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Wolfgang Meyer-Sabellek, Chairman of SAB, former Medical Director AstraZeneca Germany • Prof. Bertram Wiedenmann,<br />
Director at the Charité, Chairman of the DSMB for the ongoing Atu027 phase I study • Prof. Dirk Strumberg, University Hospital Herne •<br />
Prof. Dr. A. Schneeweiss, University of Heidelberg • Prof. Dr. M. Thomas, University of Heidelberg<br />
BIO Business Forum 2011 300 Participating Company <strong>Profiles</strong>
Jinsheng Ren<br />
Chief Executive Officer<br />
502 Carnegie Center<br />
Princeton, NJ 08540<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jie Liu D'Elia<br />
Tien Lee<br />
Simcere Pharmaceutical Group<br />
Clinical Foci: Oncology • Infectious Disease • Cardiovascular Disease<br />
www.simcere.com/english/index.asp<br />
Phone: 1-858-336 0398<br />
Incorporated: 1995<br />
Employees: 4000<br />
Ownership: Public<br />
Market Cap: $600.00 million<br />
NYSE : SCR<br />
CORPORATE MISSION<br />
Established in 1995, Simcere has swiftly evolved from being a pure distributor of pharmaceutical products to become a leading R&D based<br />
company in the rapidly growing China pharmaceutical market, focusing on development, manufacturing, and commercialization of<br />
branded generics and proprietary pharmaceutical products. We now have eight certified GMP manufacturing facilities, two nationwide<br />
sales and marketing subsidiaries, a research and development center, and over 4,000 employees.<br />
In recent years, we have continued to refine our strategy to focus on the development of first-to-market generic and innovative<br />
pharmaceuticals in oncology, neuroscience, cardiovascular, inflammation, and infectious diseases. In 2007, we launched our first<br />
proprietary product, Endu, a human modified endostatin, for NSCLC. In 2011, Simcere received SFDA approval for biosimilar etanercept.<br />
We currently manufacture and sell over 45 principal pharmaceutical products and are the exclusive distributor of three additional<br />
pharmaceuticals that are manufactured by third parties but marketed under our brand. In addition, we have obtained approvals from the<br />
SFDA to manufacture and sell over 210 other generic products.<br />
In our research and development efforts, we concentrate on the treatment of diseases with high incidence and/or mortality rates and for<br />
which there is a clear demand for more effective pharmacotherapy. We have built a robust pipeline ranging from discovery to registration<br />
across multiple disease areas focused on our core disease areas. Our R&D efforts also span across multiple treatment modalities, with<br />
small molecules, proteins and peptides, and monoclonal antibodies in our pipeline. While committed to innovation, we focus on external<br />
collaboration to drive the continuous expansion of our pipeline. Active licensing deals with U.S. biotech companies and large pharma<br />
demonstrate our commitment and corporate mandate in cross-border collaborations.<br />
SENIOR MANAGEMENT<br />
Jinsheng Ren, Chief Executive Officer • Yehong Zhang, President • Xiaojin Yin, Senior Vice President • Peng Wang, Chief Scientific<br />
Officer • Jie Liu D'Elia, Vice President • Tien Lee, Director<br />
BIO Business Forum 2011 301 Participating Company <strong>Profiles</strong>
Mr. Grant Ferrier<br />
Chairman<br />
Suite 100, BBDC<br />
Edmonton, AB T6N 1H1<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Sinoveda Canada Inc.<br />
Clinical Foci: Drug Development • Drug Discovery • Biopharmaceuticals<br />
www.sinoveda.com<br />
Nuzhat Tam-Zaman, VP, International and Regulatory Affairs<br />
Yun K. Tam, President & CSO<br />
Phone: 1-780-435-2912<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Canadian Agricultural Adaptation Program has awarded the company $1.3 million dollars in<br />
March, 2011 for the R&D of one CNS product and dosage forms for three products: 3 for<br />
osteoporosis and 1 for cardiovascular condition.<br />
The company has successfully develop a solid dosage form for Effecti-Cal and the submission of<br />
a clinical trial protocol for Effecti-Cal to the local Ethics Review Board in May 2011.<br />
Formation of the Board of Directors including high profile members: Mr. Grant Ferrier, Founder<br />
of Nutritional Business Journal and Dr. Keith Chan, co-founder of GloboMax. Mr. Ferrier has<br />
recently joined agreed to serve as the executive chairman.<br />
Incorporated: 2006<br />
Employees: 7<br />
Ownership: Private<br />
To sign a distribution agreement with a<br />
Taiwan and Indian company.<br />
Obtain a self-affirmed GRAS for Effect-<br />
Cal.<br />
Completion of dosage form design for<br />
SCI-RC-1341 and a combination of<br />
Effecti-Cal and SCI-RC-1341.<br />
CORPORATE MISSION<br />
Sinoveda Canada Inc. was founded by two pharmaceutical scientists, 2006. The mission of the company is to use pharmaceutical<br />
technology to develop and/or standardize botanical medicines. These two scientists, a husband and wife team, has more than 50 years of<br />
experience in pharmaceutical research. One of the founders, Dr. Yun Tam, a former professor at the Faculty of Pharmacy &<br />
Pharmaceutical Sciences, University of Alberta, has spent most of his research life in developing pharmacokinetic theories and models for<br />
drug discovery and drug development.<br />
In the past ten years, Dr. Tam has focused on creating technologies for developing botanical medicines. He firmly believes that a safe and<br />
efficacious product should contain more than one entity. Instead of searching botanical libraries for new core structures, eventually<br />
leading to a single new chemical entity, a new platform technology has been invented to explore active entities and potential interactions.<br />
This patent pending technology, PPT®, is an in vitro and in silico physiological pharmacokinetic and pharmacodynamic model which is<br />
used for screening active moieties in a complex mixture, similar to that of a medicinal herb. This multiple ingredient/multiple target<br />
approach (MIMT) has been used successfully to develop two leads, which are projected to enter clinical trials at the end of 2011 and the<br />
middle of 2012. SCI-RC-1341 is a lead for the osteoporosis and SCI-CX-1240 is for cardiovascular conditions including angina. The<br />
characteristics of these products are unique in that they contain a small panel of active moieties with defined dosages. The company is<br />
currently seeking IP protection of these two products.<br />
PROPRIETARY TECHNOLOGY<br />
Essential to its product development, the company uses its patent pending Pharmaceutical Platform Technology, PPT®, as a new approach<br />
to design new candidates. PPT® was developed to identify active moieties in a complex mixture which include botanicals. The technology<br />
is based on physiologically based pharmacokinetic and pharmacodynamic models. Using specifically designed studies, in vitro and in<br />
silico parameters are generated to estimate the pharmacokinetic and efficacy profiles of individual components and their interactions in a<br />
complex mixture. An optimization routine is employed to estimate the optimal ratios of active components based on their<br />
pharmacokinetic and pharmacodynamic properties. The characteristic of products developed using this technology is multi-components.<br />
CORPORATE ALLIANCES<br />
Sinoveda Canada Inc. allies with the following institutions for R & D work:<br />
1. Cross Cancer Institute, University of Alberta: The company works jointly with Professor Jack Tuszynski, Allard Chair, to develop in<br />
silico models. Professor Tuszynski is a renowned biophysicist.<br />
2. Drug Development Innovation Center: The company works with Professor Raimar Lobenberg, Faculty of Pharmacy & Pharmaceutical<br />
Sciences, University of Alberta, to develop dosage forms for the company’s products.<br />
3. School of Biomedical Sciences, Chinese University of Hong Kong: The company works closely with Professor Ge Lin, a renowned<br />
botanical pharmacologist, in the development of Traditional Chinese Medicine.<br />
4. Alberta Agriculture: The company has developed a very good working relationship with Dr. Susan Lutz,<br />
BIO Business Forum 2011 302 Participating Company <strong>Profiles</strong>
INTELLECTUAL PROPERTY<br />
There are four patents filed. There status in various countries are listed below:<br />
1. Pharmaceutical Platform Technology For The Development Of Natural Products: US, Australia, Brazil, Canada, China, EP, Hong Kong,<br />
India, Japan, Korea, Mexico and Singapore applications.<br />
2. Formulas Comprising Highly Soluble Elements And Vitamins For The Prevention And Amelioration Of Osteoporosis: US, Canada, EP,<br />
Australia, China, Hong Kong, India, Japan, Korea, New Zealand and Singapore applications.<br />
3. Preparation Of Botanical Extracts Containing Absorbable Components Using Pharmaceutical Platform Technology: US application.<br />
4. Development Of A Red Clover Product For The Prevention Or Treatment Of Osteoporosis: US application.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Effecti-Cal Other Prevention of osteoporosis Enter Comparative (Phase IV) Trial in July,<br />
2011<br />
SCI-RC-1341 Other Prevention or Treatment of Osteoporosis Enter Proof of Principle Trial at the end of<br />
2011<br />
SCI-CX-1230 Preclinical Cardiovascular Enter Proof of Principle Trial in 2012<br />
SCI-RPC-2011 Preclinical Cholesterol Lowering Enter Proof of Principle Trial in 2012<br />
SCI-RHO-1545 Research Depression Preclinical ends at March 2013<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Seed Round: 12/16/2008 (US $2.92 million)<br />
Round A: 12/08/2009 (US $1.00 million)<br />
Round B: 02/16/2011 (US $1.23 million)<br />
Investors: Global Billion International Trading Ltd. (5 %) • Mr. Cho Kong Lam (5 %)<br />
SENIOR MANAGEMENT<br />
Mr. Grant Ferrier, Chairman • Dr. Yun K. Tam, Chief Scientific Officer • Mr. Al Gourley, Chief Financial Officer • Dr. Nuzhat Tam-<br />
Zaman, Vice President<br />
BOARD OF DIRECTORS<br />
Mr. Grant Ferrier, Founder, Nutritional Capital Network and President & CEO, Environmental Business International Inc. • Dr. Keith<br />
Chan, Founder of GloboMax; Professor, National Chengchi University, Taiwan • Mr. Paul Braconier, President & CEO, Global IQ • Mr.<br />
Alex Lee, Partner, Phoenix Capital, Hong Kong • Dr. Nuzhat Tam-Zaman, Sinoveda Canada Inc. • Dr. Yun K. Tam, Sinoveda Canada Inc.<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Jack Tuszynski, Cross Cancer Institute, University of Alberta • Dr. R. Venkataramanan, School of Pharmacy, University of Pittsburgh •<br />
Dr. Kerry Siminoski, Faculty of Medicine and Dentistry, University of Alberta (pending) • Dr. Raimar Lobenberg, Faculty of Pharmacy and<br />
Pharmaceutical Sciences, University of Alberta<br />
BIO Business Forum 2011 303 Participating Company <strong>Profiles</strong>
Spencer F. Robert<br />
Chief Executive Officer<br />
2 Davis Drive<br />
Research Triangle Park, NC 27709<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Robert Spencer, JD, MBA, CEO<br />
CORPORATE MISSION<br />
Sirga Advanced Biopharma, Inc<br />
Clinical Foci: Infectious Disease<br />
www.SirgaAB.com<br />
Phone: 1-919-354-1007<br />
Incorporated: 2007<br />
Ownership: Private<br />
Sirga is an early stage biotechnology company focused on the discovery and development of a new class of small molecule, anti-infective<br />
drugs that target tRNAs. Sirga has two drug discovery programs based on this platform technology, one for HIV and another for grampositive<br />
bacterial infections such as MRSA.<br />
PROPRIETARY TECHNOLOGY<br />
Sirga has used its proprietary assay to identify small molecule, bioactive hits against a host cell RNA interaction with HIV proteins critical<br />
to viral replication. These hits are now being optimized to develop a new class of HIV drug. Unlike the mechanisms of action of other drugs<br />
approved or in clinical trials to treat HIV, Sirga’s target of a tRNA/protein interaction: (1) does not occur in non-infected cells; (2) is critical<br />
to viral replication; (3) would be extremely difficult for the virus to develop resistance; and (4) to our knowledge is not being exploited by<br />
other companies.<br />
INTELLECTUAL PROPERTY<br />
Sirga has a portfolio of patent applications for both the screening assays for its unique targets as well as the resulting small molecule hits<br />
produced from them.<br />
SENIOR MANAGEMENT<br />
Spencer F. Robert, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Dr. Paul Agris, Director, RNA Institute<br />
BIO Business Forum 2011 304 Participating Company <strong>Profiles</strong>
Howard J. Verrico, MD<br />
Chief Executive Officer<br />
955-789 West Pender Street<br />
Vancouver, BC V6C 1H2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Geraldine Deliencourt-Godefroy, Chief Scientific Officer<br />
Mark Senner, President<br />
Sirona Biochem Corporation<br />
Clinical Foci: Drug Discovery • Metabolic Disease • Skin/Dermatological<br />
www.sironabiochem.com<br />
Phone: 1-604-641-4466<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Acquired TFChem, a France-based drug discovery company<br />
specializing in carbohydrate chemistry.<br />
Achieved positive preclinical results for lead compound, a sodium<br />
glucose co-transporter (SGLT) inhibitor for Type 2 diabetes.<br />
Recipient of Going Global Innovation Funding.<br />
Incorporated: 2009<br />
Ownership: Public<br />
Market Cap: $14.00 million<br />
TORONTO STOCK EXCHANGE: SBM<br />
Identify depigmenting lead compound.<br />
Safety and toxicology preclinical results expected for lead SGLT<br />
inhibitor program.<br />
Lead compound identified as an inducer for recombinant protein<br />
production.<br />
CORPORATE MISSION<br />
Sirona Biochem Corp. is a biotechnology company applying a proprietary chemistry technique towards the development of three<br />
carbohydrate-based programs including diabetes therapeutics, cosmeceuticals, and biological ingredients. Using our chemistry expertise,<br />
it is our aim to optimize the pharmaceutical properties of carbohydrate-based molecules to deliver stable, safe and effective compounds.<br />
Sirona Biochem’s sodium glucose co-transporter (SGLT) inhibitor for Type 2 diabetes recently achieved positive preclinical results.<br />
PROPRIETARY TECHNOLOGY<br />
In March 2011, Sirona Biochem acquired France-based TFChem, a drug discovery with expertise in the fluorination of carbohydrate-based<br />
molecules. With TFChem, Sirona Biochem uses fluorine atom properties to develop new glycomimetic compounds with an improved<br />
stability, bioavailability and safety profile. Sirona Biochem optimizes the potential of carbohydrate-based drugs with an aim to develop<br />
new, more potent and safer drugs.<br />
CORPORATE ALLIANCES<br />
Sirona Biochem acquired TFChem in March 2011. Our most advanced product is a sodium glucose co-transporter (SGLT) inhibitor for Type<br />
2 diabetes. Our lead SGLT compound recently achieved positive preclinical results. It is Sirona Biochem’s plan to complete preclinical<br />
studies of our SGLT inhibitor and seek a partner for clinical and commercial development activities. In vitro studies of Sirona Biochem’s<br />
dermatological and biological ingredients are ongoing and partnerships for these programs will be considered.<br />
INTELLECTUAL PROPERTY<br />
Sirona Biochem’s proprietary chemistry technology is protected through intellectual property firm Cabinet Regimbeau in Paris, France.<br />
Global patent expert Mr. Jacques Warcoin has been closely involved in the development of the French biotechnology sector since the late<br />
1970’s and is a world leader in the area of patentability of living organisms.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SGLT inhibitor Preclinical Type 2 diabetes Q2- Safety/Toxicology<br />
preclinical results<br />
Depigmenting Agent Research Skin/Dermatology Q2-Lead compound identified<br />
Inducer for Recombinant Protein Production Research Protein Expression Q2-Lead compound identified<br />
Anti-aging compound Research Skin/Dermatology, Anti-aging<br />
SENIOR MANAGEMENT<br />
Howard J. Verrico, MD, Chief Executive Officer • Mark Senner, President • Geraldine Deliencourt-Godefroy, PhD, Chief Scientific<br />
Officer • Christopher Hopton, Chief Financial Officer • Bertrand Plouvier, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Howard J. Verrico, MD, CEO, Sirona Biochem Corp. • Michael Rogers, President, Palmer Rogers Encore Ventures • Alex Marazzi, MD,<br />
Family & Emergency Physician • Geraldine Deliencourt-Godefroy, CSO, TFChem • Mark Senner, President, Sirona Biochem •<br />
Christopher Hopton, CFO, Sirona Biochem • Chris Verrico, Financial Consultant<br />
BIO Business Forum 2011 305 Participating Company <strong>Profiles</strong>
SCIENTIFIC ADVISORY BOARD<br />
Stuart Maddin, MD, FRCPC, Professor Emeritus, Dermatology, University of British Columbia • Mario Pinto, PhD, Vice President,<br />
Research, Simon Fraser University • Denis Richard, PhD, Professor, Department of Medicine, Laval University • Bruce Verchere, PhD,<br />
Head of Diabetes Research Program, Child & Family Research Institute • Michael Walker, PhD, CEO, Verona Pharma • Jacques Warcoin,<br />
CEO, Cabinet Regimbeau<br />
BIO Business Forum 2011 306 Participating Company <strong>Profiles</strong>
Jim Reid<br />
Chief Executive Officer<br />
Thomson Building<br />
Glasgow<br />
G12 8QQ<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Verna McErlane, Director of Commercial Operations<br />
HIGHLIGHTS<br />
Recent<br />
Sistemic Ltd<br />
Clinical Foci: Gene/Cell Therapy • Regenerative Medicine • Drug Development<br />
www.sistemic.co.uk<br />
Phone: 44-141-330 1683<br />
Incorporated: 2008<br />
Employees: 10<br />
Ownership: Private<br />
May 2011; Signed a Memorandum of Understanding with Roslin Cells to promote the development of new miRNA-based technologies for<br />
standardizing the manufacture of stem cells for applications in cell therapy and drug development.<br />
April 2011; Sistemic was selected by Redx Pharma as their in vitro screening partner using their SistemRNA suite of drug development<br />
tools.<br />
Signed several commercial agreements in early 2011 with Cell Therapy companies from both the US and Europe to use Sistemic's,<br />
SistemQC service for cell identity, purity and potency markers.<br />
CORPORATE MISSION<br />
Sistemic provide innovative miRNA-based product solutions to the drug development, cell therapy and bioprocessing markets, providing<br />
knowledge-rich & instructive data on your system.<br />
Our core focus and expertise is on applying miRNA profiling in context with the biology, to areas where there is currently an unmeet need<br />
for sophisticated tools which deliver actionable and robust knowledge of the cell system. MiRNAs are seen as the master controllers of a<br />
cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an<br />
isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual<br />
effect. From their SistemRNA platform they have derived a suite of Drug Development products in the areas of elucidation of<br />
mechanism of action studies, predictive & mechanistic toxicology (SistemTOX) and positioning/repurposing (SistemKB). In addition,<br />
there is an extensive suite of tools for the cell therapy and bioprocessing community using SistemQC, which characterises cells including<br />
stem cells as well as monitors the QC of production. More specifically the initial focus of SistemQC by clients has been on generation of<br />
miRNA-based ID markers, purity, potency and safety assays.<br />
Sistemic is a privately held Biotechnology company head-quartered in Glasgow, Scotland with offices in Boston, MA.<br />
PROPRIETARY TECHNOLOGY<br />
Sistemic have developed proprietary customised algorithms which analyse the miRNA dataset that is produced when a cell is perturbed by<br />
a stimulus or compound that define the phenotypic response and importantly use contextual analysis to inform on the fundamental<br />
biological impact of these miRNAs. In addition this approach can be utilised to generate fingerprints using a small number of key<br />
microRNAs (kmiRs) that can be used robustly as biomarkers of the system. This approach adds significant value to the drug development<br />
community through a deeper understanding of the compounds complete biological and therapeutic landscape and to the cell therapy<br />
markets by offering robust, sensitive and quantitative markers of phenotype and/or the process manufacture QC.<br />
SENIOR MANAGEMENT<br />
Jim Reid, Chief Executive Officer • Dr Verna McErlane, Director • Vincent O'Brien, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Jim Reid, Chairman & CEO • Karen Reid, Non-Executive Director • Vincent O'Brien, Non-Executive Director & CSO • Rosalyn Campbell,<br />
Non-Executive Director<br />
BIO Business Forum 2011 307 Participating Company <strong>Profiles</strong>
Sang Hoon Park<br />
Chief Executive Officer<br />
99, Seorin-dong, Jongro-gu<br />
Seoul 110-728<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
SK biopharmaceuticals<br />
Clinical Foci: CNS • Neurology • Drug Discovery<br />
http://eng.skbp.com/index.asp<br />
Phone: 82-2-2121-5379<br />
Duncan P. Taylor , PHD, Senior Director, Business Development<br />
Taegsang YOU, Manager<br />
Justis Cho<br />
Jeong Woo Cho, Executive Vice President<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
SK biopharmaceuticals has established on 1st April 2011 spun off from SK holdings.<br />
YKP10461(Neuroprotection) : Acquired IND approval from U.S. FDA (at 2011) the 12th IND<br />
approval.<br />
YKP3089: Multi-center epilepsy study for partial onset seizure has been initiated.(Phase 2b)<br />
Employees: 200<br />
Ownership: Private<br />
The phase 2 clinical trial of SKL-NP<br />
(Neurpathic pain) and YKP-GI(Chronic<br />
Constipatin/IBS) will be started soon in<br />
U.S.<br />
CORPORATE MISSION<br />
SK biopharmaceuticals has established on 1st April 2011 spun off from SK holdings.Based on the capability of life science business which<br />
has been incubated in SK Group as a new growth engine since 1993.<br />
SK biopharmaceuticals is a global development-stage pharmaceutical company focusing on drug discovery and development. The<br />
company has R&D facilities in Korea, China, and the US. SK biopharmaceuticals initiated research in the CNS area, and was the first<br />
Korean-based company to successfully file an IND in the US. Since then, the company has filed a total of 12 INDs for drugs for the<br />
treatment of anxiety, depression, epilepsy, neuropathic pain, and schizophrenia. SK Biopharmaceuticals is currently conducting clinical<br />
studies in the US in Phase 2b with YKP3089 (indicated for epilepsy, anxiety, and neuropathic pain), in Phase 2 with SKL-N05(Narcolepsy)<br />
and YKP509(Neuropathic pain), in Phase 2 ready with SKL-DEP (Depression) and YKP-GI (Chronic Constipation/Irritable Bowel Syndrome),<br />
and in Phase 1 with YKP10461(Neuroprotection).<br />
PROPRIETARY TECHNOLOGY<br />
SK biopharmaceuticals has an extensive, proprietary chemical library that it employs in high throughput screening to identify lead<br />
molecules. Its significant medicinal chemistry effort focuses on lead optimization to obtain key development candidates. SK<br />
biopharmaceuticals has a demonstrated ability to carry preclinical development activities from conception to the clinic.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
YKP3089 Phase II, IIa, IIb Epilepsy, Neuropathic Pain,Anxiety Seeking co-development partner<br />
SKL-N05 Phase II, IIa, IIb Narcolepsy, substance abuse Seeking co-development partner<br />
SKL-DEP Phase I Depression Seeking co-development partner<br />
YKP-GI Phase I Chronic Constipation/Irritable Bowel Syndrome Seeking co-development partner<br />
YKP10461 Phase I Neuroprotection Seeking co-development partner<br />
SKL2020 Preclinical Peripheral Artery Disease / Restenosis Seeking co-development partner<br />
SKL-PSY Preclinical Bipolar disorder Seeking co-development partner<br />
SKL-NP2 Preclinical Neuropathic pain Seeking co-development partner<br />
SKL-A4R Preclinical Alzheimer Seeking co-development partner<br />
YKP509 Phase II, IIa, IIb Neuropathic pain Seeking co-development partner<br />
FINANCING HISTORY<br />
Investors: SK holdings (100 %)<br />
SENIOR MANAGEMENT<br />
Sang Hoon Park, Chief Executive Officer • Junku Park, Vice President • S. James Lee, Vice President • Kiho Lee, Vice President • Marc<br />
Kamin, Vice President • Duncan Taylor, Business Development • Jeong Woo Cho, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Sang Hoon Park, CEO of SK biopharmaceuticals<br />
BIO Business Forum 2011 308 Participating Company <strong>Profiles</strong>
Siri Stabel Olsen<br />
Chief Executive Officer<br />
Smia, Ringaasen<br />
3512 Hønefoss<br />
Norway<br />
CONFERENCE PARTICIPANTS<br />
Siri Stabel Olsen, CEO<br />
Skannex<br />
Clinical Foci: Medical Device • Diagnostics • Food & Ag<br />
www.skannex.com<br />
Phone: 47-99-252274<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successful development of a software for image analysis utilizing traditional scanner or<br />
camera technology. Applications for a large number of lateral flow casettes adapted. Software<br />
also developed for ELISA, Microarray and Bacterial Colony Counting.<br />
Several customers/partners already in the market with the Skannex technology for their<br />
assays. Applications in the market include IVD, Drug of Abuse and GMO & Mycotoxin testing.<br />
The Skannex software is CE marked.<br />
Establishing a subsidary in China June 2011 to serve the Asian market.<br />
Incorporated: 2006<br />
Employees: 8<br />
Ownership: Private<br />
FDA 510(K) in submission in USA for<br />
Software and Instruments and similarly<br />
sFDA in China.<br />
Start active sales and marketing<br />
activities in the USA with local<br />
representatives<br />
Commercial introduction to India.<br />
CORPORATE MISSION<br />
Skannex is a Norwegian, privately owned company founded in 2006. We develop, manufacture and sell automated image reader solutions<br />
based on our proprietary software technology for accurate, robust and easy analysis of biological assays. The SkanX products are ideal for<br />
laboratory testing, Point-of-Care Diagnostic as well as for Drug of Abuse or Food/Feed testing. Skannex is a B2B company. Our customers<br />
distribute the SkanX products as part of their total biochemical assay testing package. Skannex is your partner if you look for cost<br />
effective and flexible automated reader solution.<br />
PROPRIETARY TECHNOLOGY<br />
Advanced Software and Barcode technology for image capture and automated quantitative or qualitative analysis of biochemical tests, as<br />
well as easy and compatible report generation. We are adapting the Software to benchtop or in-the-field instrumentation.<br />
INTELLECTUAL PROPERTY<br />
Patent "Immunoassay Analytical Method"<br />
* Assigning a unique barcode coded text segment together on a test device (single strip/casette etc)<br />
* Capture an image of the barcoded lateral flow assay by a scanner device or a digital camera or a mobile phone camera connected to a<br />
computer or network<br />
* Semi-quantitativ or quantitative analysis of the the assay using a computer to execute program instructions<br />
* Patent application in USA, Europe, China and nine additional territories<br />
PCT International Publication Date 30 April 2009<br />
(WO 2009/054729 A1)<br />
US Publication Date 27 January 2011<br />
(US 2011/0019883 A1)<br />
Priority from 23 October 2007<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SkanX MaxiRead S01 Diagnostics Benchtop instrument powered by Skannex<br />
proprietary software for analysis of lateral flow<br />
casettes or strips. Ideal for Point-of-care analysis.<br />
Can read various and numerous tests<br />
simultanously.<br />
Commercial available 4Q2011<br />
SkanX SmartRead P02 Diagnostics Portable instrument powered by Skannex<br />
proprietary software. Instrument built around<br />
commercial available smartphone. Ideal for inthe-field<br />
analysis of lateral flow casettes or strips.<br />
Results in seconds<br />
SkanX SmartRead P01 Diagnostics Commercial available smartphone powered by<br />
Skannex proprietary software. Ideal for in-thefield<br />
analysis of lateral flow casettes or strips.<br />
Results in seconds<br />
Commercial available 1Q2012<br />
Commercial available 1Q2012<br />
BIO Business Forum 2011 309 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Investors: Dag Bremnes (62 %) • Adeptio Invest Limited (10 %) • Christina Casen (6 %) • Investor Corporate (5 %) •<br />
Eivind Strøm (5 %)<br />
SENIOR MANAGEMENT<br />
Siri Stabel Olsen, Chief Executive Officer • Dag Bremnes, Chief Scientific Officer • Scott Clark, Vice President • Christina Casen,<br />
Manager • Eivind Strøm, Manager • Yang Zu, Managing Director<br />
BOARD OF DIRECTORS<br />
Haakon Sæterøy, Investor Corporate AS • Christina W. Casen, Tica Westby • Fang Liu, Norwegian Radium Hospital • Morten Sten<br />
Johansen, Diagenic ASA • Dag Bremnes, Skannex AS<br />
BIO Business Forum 2011 310 Participating Company <strong>Profiles</strong>
Axel Mueller<br />
Chief Executive Officer<br />
Eptingerstrasse 61<br />
4132 Muttenz (Basel)<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Yves Decadt<br />
CORPORATE MISSION<br />
SkyePharma PLC<br />
Clinical Foci: Drug Delivery • AutoImmune • CNS<br />
www.skyepharma.com<br />
Phone: 41-61-4675531<br />
Incorporated: 1997<br />
Ownership: Public<br />
Market Cap: $10.00 million<br />
LONDON STOCK EXCHANGE: SKYEY<br />
SkyePharma is a specialist drug delivery company developing oral and inhalation products. With a wide range of patented and proven<br />
technologies, SkyePharma helps to make good drugs better.<br />
We partner with a wide variety of companies from big Pharma, such as GlaxoSmithKline, Novartis, sanofi-aventis, AstraZeneca and Roche<br />
to a range of smaller speciality pharmaceutical companies. SkyePharma’s proprietary drug delivery technologies enable the development<br />
of new formulations of existing products as well as new chemical entities to provide a clinical benefit to patients.<br />
SkyePharma’s Geomatrix and Geoclock technologies enable controlled- or timed-release versions of immediate-release products to be<br />
developed providing advantages to both partner companies and patients.<br />
The Group’s inhalation technologies include formulation as well as device technologies and encompass metered dose inhalers and dry<br />
powder inhalers.<br />
With research and development facilities in Switzerland and manufacturing in France, SkyePharma offers a comprehensive range of<br />
services from feasibility through to commercial scale manufacture.<br />
SENIOR MANAGEMENT<br />
Axel Mueller, Chief Executive Officer • Yves Decadt, Business Development<br />
BIO Business Forum 2011 311 Participating Company <strong>Profiles</strong>
Knut Smerud<br />
President & CEO<br />
Unit 10 & 19 Enterprise House<br />
Manchester<br />
M15 6SE<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Paul Cronin, Business Development Manager<br />
CORPORATE MISSION<br />
Smerud Medical Research UK Ltd<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Service<br />
www.smerud.com<br />
Phone: 44-845-8039665<br />
Incorporated: 1993<br />
Employees: 80<br />
Ownership: Private<br />
The Smerud Medical Research Group (SMERUD) is a clinical Contract Research Organisation (CRO) operating in the European area with<br />
offices in Denmark, Finland, Norway, Poland, Russia, Sweden and the United Kingdom. Our activities are primarily focused on general drug<br />
development consulting to the biotech and pharma industries, and on executing clinical project management, monitoring of phase I-IV<br />
studies, regulatory affairs, data management and medical writing projects. The company employs about 80 persons, of whom 65 are<br />
clinical research, regulatory or biostatistical professionals. We have been operating since 1993 with involvement in more than 600 clinical<br />
trials and more than 300 regulatory projects, in addition to over 100 projects related to data management, biostatistics and medical<br />
writing. Our international management team consists of senior professionals with many years of experience from the international<br />
pharmaceutical industry, academia as well as the consultancy business. The local country operational units, each counting typically of 5-<br />
15 team members, are headed by country managers, all with several years’ practical experience from clinical research. International<br />
project managers are based in key cities around Europe.<br />
In particular, SMERUD has significant experience in working with Small-Medium sized Enterprises (SMEs). SMERUD has worked with these<br />
types of companies as a development partner rather than a simple service provider. We are also involved in a number of Eurostars and FP7<br />
grant applications not as a subcontractor but part of the consortium. We were actually the first company to get a clinical trial funded<br />
under the Eurostars programme. Indeed, earlier this year we received confirmation that we have won a second Eurostars grant to fund yet<br />
another clinical trial. We continue to aid SME companies to access non-dilutive funding to support their drug development activities.<br />
FINANCING HISTORY<br />
Investors: Knut Smerud (100 %)<br />
SENIOR MANAGEMENT<br />
Knut Smerud, President & CEO • Bob Macnair, Other • Yvonne Peltonen, Other • Paul Cronin, Other<br />
BIO Business Forum 2011 312 Participating Company <strong>Profiles</strong>
Ryoichi Nagata<br />
President & CEO<br />
St.Luke's Tower 12F, 8-1 Akashi-cho, Chuo-ku<br />
Tokyo 104-0044<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
SNBL, Ltd.<br />
Clinical Foci: Drug Delivery • Drug Discovery • Oncology<br />
www.snbl.com/en/index.html<br />
Phone: 81-35565-6148<br />
Takefumi Gemba, Director, Business Development, Translational Research Company<br />
HIGHLIGHTS<br />
Recent<br />
Incorporated: 1957<br />
Employees: 2039<br />
Ownership: Public<br />
Market Cap: $146.00 million<br />
TOKYO STOCK EXCHANGE: 2395<br />
License agreement with Kissei Pharmaceutical to develop pilocarpine hydrochloride for treatment of fibromyalgia (Mar.30,2011)<br />
Licensing Agreement with Pastorus LLC to develop intranasal oxytocin for treatment of autism (Feb.10,2011)<br />
CORPORATE MISSION<br />
SNBL established as the first Japanese contract research organization (CRO) in 1957. SNBL has started a new business model of<br />
Translational Research (TR), to find novel drug seeds or technology from academia and biotech ventures, and fully utilize the nonclinical/clinical<br />
development capabilities of SNBL's core CRO business to accelerate drug development. Our focus area is intranasal drug<br />
delivery technology, vaccines, oncology, immunology/allergy, and inflammatory diseases. Regarding intranasal delivery platform<br />
technology, TRG (intranasal granisetron), the one of our product, confirmed good efficacy in more than 100 patients in P2 in US. Regarding<br />
stereocontrolled oligonucleotide synthesis technology, the stereoregulated oligonucleotides enhanced activity and efficacy that can be<br />
applied to many types of oligonucleotide including antisense, siRNA, miRNA and nucleic acid adjuvant.<br />
PROPRIETARY TECHNOLOGY<br />
Intranasal drug delivery formulation and devices,<br />
Stereocontrolled synthesis of oligonucleotides,<br />
Oligonucleotide prodrug<br />
CORPORATE ALLIANCES<br />
1) License agreement with Kissei Pharmaceutical Co.,Ltd. to develop pilocarpine hydrochloride for treatment of fibromyalgia (Mar.30, 2011)<br />
2) Licensing Agreement with Pastorus LLC to develop intranasal oxytocin for treatment of autism (Feb.10, 2011)<br />
INTELLECTUAL PROPERTY<br />
1) Intranasal drug deliver: 7 IP for forumulation and 4 IP for device 4) Stereocontrolled synthesis of oligonucleotide: 12 IP<br />
2) Antibodies: 4 IP for osteoarthritis therapy<br />
5) Oligonucleotide prodrugi: 5 IP<br />
3) Fibromyalgia: 5 usage IP (license agreement with Kissei<br />
Pharmaceutical Co.,Ltd.)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TRG (Intranasal granisetron) Phase II, IIa, IIb Anti-emetics Complete. TRG has shown more than 90% of patients<br />
achieved complete control of CINV in P2 in US.<br />
TRZ (Intranasal zolmitriptan) Phase I Migraine P1 trial plan to initiate in August 2011.<br />
TR-Flu (Intranasal flu vaccine) Preclinical Pandemic influenza TR-Flu showed good results in both H1N1 and H5N1<br />
influenza viruses in monkey study.<br />
TRI (Intranasal insulin) Preclinical Diabetes<br />
Chiral oligonucleotide Target Validated Infectious disease, cancer,<br />
vaccine, allergy, immunology<br />
Oligonucleotide prodrug Research Cancer<br />
Stereoregulated chiral oligonucleotide enhanced<br />
adjuvant activitiy in vitro.<br />
SENIOR MANAGEMENT<br />
Ryoichi Nagata, President & CEO • Toshihiko Seki, Chief Financial Officer • Koichiro Fukuzaki, Executive Vice President • Ken<br />
Takanashi, Senior Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Takeshi Wada, Associate Professor, Department of Medical Genome Science, The University of Tokyo • Dr. Gregory Verdine, Erving<br />
Professor of Chemistry, Harvard University<br />
BIO Business Forum 2011 313 Participating Company <strong>Profiles</strong>
Josée Fortin<br />
Chief Executive Officer<br />
35 Radisson suite 100<br />
Sherbrooke, QC J1L 1E2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Chantal Michel<br />
CORPORATE MISSION<br />
SOCPRA<br />
Clinical Foci: Drug Discovery • Oncology • CNS<br />
Phone: 1-819-821-7961 Incorporated: 2007<br />
Employees: 7<br />
Ownership: Private<br />
Manage the intellectual property derived from research performed at the Université de Sherbrooke and its affiliated institutions.<br />
Advance technologies in order to attract partners.<br />
Apply valorization strategy to commercialize technologies, either as licenses or spin-off businesses, thus generating returns for the<br />
community.<br />
Our Vision<br />
Maintain the leadership position of the Université de Sherbrooke when it comes to exploiting and valorizing intellectual property.<br />
SENIOR MANAGEMENT<br />
Josée Fortin, Chief Executive Officer • Chantal Michel, Business Development • Guy Benoit, Business Development • Philippe Lapierre,<br />
Business Development<br />
BIO Business Forum 2011 314 Participating Company <strong>Profiles</strong>
Paul (Breck) Breckinridge Jones<br />
Chief Executive Officer<br />
4010 DuPont Circle, Suite L-07<br />
Louisville, KY 402075<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Patrick Murphy, Vice President Operations<br />
CORPORATE MISSION<br />
Solstice Neurosciences, Inc<br />
Clinical Foci: Neurology • CNS • Biopharmaceuticals<br />
www.solsticeneuro.com<br />
Phone: 1-650-243-4410<br />
Incorporated: 7<br />
Employees: 90<br />
Ownership: Private<br />
Solstice Neurosciences, LLC is a specialty biopharmaceutical company focused on the development, manufacturing, sales and marketing of<br />
specialty biopharmaceutical products.<br />
Solstice’s first product, MYOBLOC® (rimabotulinumtoxinB) Injection, represents the only botulinum toxin type B currently available to<br />
physicians and patients worldwide.<br />
CORPORATE ALLIANCES<br />
Eisai, Eisai Manufacturing Limited, DreamPharma<br />
PRODUCTS<br />
Name Phase Indication<br />
Myobloc Cleared for US Marketing Cervical Dystonia<br />
SENIOR MANAGEMENT<br />
Paul (Breck) Breckinridge Jones, Chief Executive Officer • Lee Warren, Chief Operating Officer<br />
BIO Business Forum 2011 315 Participating Company <strong>Profiles</strong>
Joseph N. Garner, PhD<br />
Chief Executive Officer<br />
1500 1st Avenue North<br />
Birmingham, AL 35203<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Joseph N Garner, Chief Executive Officer<br />
Soluble Therapeutics<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Service<br />
www.soluble-therapeutics.com<br />
Phone: 1-205-314-3577<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Soluble Therapeutics closed a Venture Capital investment deal with the Birmingham<br />
Technology Fund (administered by Greer Capital in Birmingham, AL) which supplied<br />
the capital required to expand service based operations.<br />
Soluble Therapeutics has expanded operation to include laboratory space at the<br />
Innovation Depot (The nationally recognized 2011 Technology Incubator of the Year).<br />
Incorporated: 2008<br />
Employees: 5<br />
Ownership: Private<br />
Soluble Therapeutics anticipates it will close a<br />
Venture Capital investment deal with Targeted<br />
Technology Ventures (administered by Incyte<br />
Ventures in San Antonio, TX) the which will supply<br />
the capital required to improve the speed of the<br />
Technology.<br />
CORPORATE MISSION<br />
Soluble Therapeutics, founded in 2008 in Birmingham, Alabama, was formed to commercialize the HSC Technology. This system will<br />
enhance and speed the research, development and production of protein-based therapeutics, vaccines and research tools that will<br />
improve the quality of life and overall state of public health.<br />
The HSC Technology is a powerful computational and analysis system that solves one of the pharmaceutical and vaccine development<br />
industry's' major problems...<br />
Identifying formulations that keep your protein soluble and stable at high concentrations for extended periods of time.<br />
How do we accomplish this?<br />
A protein arrives at Soluble Therapeutics's laboratory and, using the HSC Technology, we provide the client an optimized formulation<br />
within 45 days that will maximize the protein's solubility and stability.<br />
PROPRIETARY TECHNOLOGY<br />
The HSC Technology, can rapidly determine the optimal formulation that maximizes the stability and solubility of proteins designed to<br />
be used as therapeutics, vaccines, diagnostics, and research reagents.<br />
The HSC Technology can dramatically increase the solubility and physical stability of antibodies, water soluble proteins, peptides,<br />
membrane proteins and mutants, and complex mixtures. The HSC Technology is an improvement over traditional methods due to the<br />
low sample consumption and high-throughput amenability, while providing useful information for both crystallization and formulation<br />
optimization.<br />
CORPORATE ALLIANCES<br />
Soluble Therapeutics (ST) maintains a working relationship with Discovery BioMed (DBM), Inc. This relationship allows for the rapid<br />
assessment of the functionality of novel biologics (identified by DBM) that have been optimally formulated (via ST).<br />
Soluble Therapeutics (ST) maintains a working relationship with Vivo Bioscience (VB). The combined efforts of both organizations allow<br />
for:<br />
1. The confirmation of functionality of, client provided, protein-based, products post formulation<br />
2. The assessment of toxicity of, client provided, protein-based, products post formulation<br />
INTELLECTUAL PROPERTY<br />
Soluble Therapeutics holds patents and has pending patents on several components of the HSC Technology.<br />
PRODUCTS<br />
Name Phase Indication<br />
Initial Screen Other The identification of additives that will improve your protein's solublility and stability.<br />
Discovery Screen Other Optimization of additive concentrations that will improve your protein's solublility and stability.<br />
Formulation Screen Other The compilation and analysis of data derived from the Initial and Discovery Screens resulting in the<br />
optimized formulation that will be delivered to the client<br />
SENIOR MANAGEMENT<br />
Joseph N. Garner, PhD, Chief Executive Officer • Wilbur W. Wilson, PhD, Chief Scientific Officer • Lawrence J. DeLucas,PhD, O.D.,<br />
General Partner • Dr. Lawrence W. Greer,, Venture Capitalist • Alan H. Dean, Venture Capitalist<br />
BIO Business Forum 2011 316 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Joseph N. Garner, PhD, Soluble Therapeutics • Wilbur W. Wilson, PhD, Soluble Therapeutics • Lawrence J. DeLucas, PhD, O.D.,<br />
University of Alabama at Birmingham • Dr. Lawrence W. Greer,, Greer Capital Advisors • Alan H. Dean, Greer Capital Advisors<br />
SCIENTIFIC ADVISORY BOARD<br />
Lawrence J. DeLucas, PhD, O.D., University of Alabama at Birmingham • Wilbur W. Wilson, PhD, Soluble Therapeutics • David H.<br />
Johnson, Soluble Therapeutics<br />
BIO Business Forum 2011 317 Participating Company <strong>Profiles</strong>
Pat O'Flynn<br />
Chief Executive Officer<br />
225 Western Gateway Building<br />
Western Road<br />
Cork<br />
Ireland<br />
CONFERENCE PARTICIPANTS<br />
Mark Ledwidge, VP Strategy<br />
Pat O'Flynn, CEO<br />
Solvotrin Therapeutics Ltd<br />
Clinical Foci: Cardiovascular Disease • Chemistry • Oncology<br />
www.solvotrin.com<br />
Phone: 353-21-420 5340<br />
Incorporated: 2009<br />
Employees: 10<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
2011 results from non-human primate study confirmed efficacy and tolerability advantages of lead compounds over conventional<br />
therapies.<br />
Solvotrin won the Enterprise Ireland Life-science & Food Commercialisation Award 2010.<br />
Two posters presented at the American College of Cardiology (ACC) 60th Annual Scientific Session April 2011.<br />
CORPORATE MISSION<br />
Solvotrin is a pharmaceutical development company. Solvotrin’s initial focus has been on first-in-class technology developed in Trinity<br />
College Dublin from 2001 to 2007 and is directed at the global cardiovascular market. The company is developing this and other novel<br />
technologies in partnership with internationally leading chemistry, clinical, regulatory, business development and intellectual property<br />
organizations.<br />
Solvotrin’s strategy is to take its compounds to the end of Phase IIa and to partner the later development and commercialization phases<br />
with large pharmaceutical companies.<br />
PROPRIETARY TECHNOLOGY<br />
Solvotrin creates analogues of well-established therapies, by chemically modifying them in a way that targets them to a specific site of<br />
action and generates pharmacological synergy. This approach confers efficacy and tolerability advantages to address unmet clinical needs<br />
in large markets. It also reduces developmental risk, increases speed to market and complements existing treatment paradigms<br />
affordably.<br />
Solvotrin has two lead products; one which offers efficacy and safety advantages over niacin for treating cholesterol problems and a<br />
second product which will prevent tissue degeneration. Solvotrin’s intellectual property offers a major opportunity with novel, patent<br />
protected medicines at the cutting edge of therapeutics.<br />
CORPORATE ALLIANCES<br />
Initial funding has been provided by the promoters, and has taken the technology to an advanced stage of pre-clinical proof of concept.<br />
INTELLECTUAL PROPERTY<br />
Solvotrin has intellectual property underpinned with patent protection at the new chemical entity (NCE) level. It has also leveraged critical<br />
positions on repurposing of established drugs. New additions to the original patent (2007) have been filed in 2010 and 2011. No external<br />
research has been cited against Solvotrin’s patents.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ST0702 Preclinical Dyslipidaemia Non-human primate study - Efficacy results versus conventional<br />
niacin (Lp(a) and LDL).<br />
SI1004 Preclinical Hypertensive heart disease,<br />
Post MI and heart failure.<br />
Non-human primate study - Efficacy results on MMP inhibition.<br />
ST0703 Preclinical Orphan Non-human primate study. Thromboxane inhibition.<br />
SENIOR MANAGEMENT<br />
Pat O'Flynn, Chief Executive Officer • Dr. Mark Ledwidge, Senior Vice President • Dr. John Gilmer, Senior Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Michael Berndt, Biomedical Diagnostics Institute and Royal College of Surgeons. • Professor Marek Radomski, Trinity College<br />
Dublin • Professor David Kerins, University College Cork, Mercy University Hospital Cork.<br />
BIO Business Forum 2011 318 Participating Company <strong>Profiles</strong>
Riemergasse 14<br />
A-1010 Vienna<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Andreas Pfoestl, Patent Attorney<br />
HIGHLIGHTS<br />
Recent<br />
SONN & PARTNER Patentanwälte<br />
Phone: 43-1-512 8405 Incorporated: 1851<br />
Employees: 45<br />
Ownership: Private<br />
Our firm has been ranked in tier 1 of the World IP Survey published by the Journal "Managing Intellectual Property - MIP" (the leading<br />
independent worldwide IP survey) in both categories "Patents" and "Trade Mark/Copyright" for several years.<br />
"Sonn & Partner counts among Austria's oldest and most experienced IP firms" - "top tier position for the third consecutive year" -<br />
"undisputed leader in the Austrian IP market" - "there is no doubt about their position"<br />
“IP Firm of the Year 2010” (MIP)<br />
CORPORATE MISSION<br />
SONN & PARTNER is one of the leading Intellectual Property Attorneys Offices in Austria with more than 50 staff members including 9<br />
European and Austrian Patent and Trademark Attorneys ("Patentanwälte"). Our office, located in the centre of Vienna, serves the need of<br />
large and small international and local clients in all areas of technology and goods. Our service is particularly geared to a complete advice<br />
of highest standard in individual cases especially in patent, trademark and design matters under international, European and Austrian<br />
Law.<br />
SONN & PARTNER is well represented in International Associations including FICPI, INTA, AIPPI, ECTA, LES and CIPA.<br />
Our firm has been ranked in tier 1 of the World IP Survey published by the Journal "Managing Intellectual Property - MIP" (the leading<br />
independent worldwide IP survey) in both categories "Patents" and "Trade Mark/Copyright" for several years.<br />
"Sonn & Partner counts among Austria's oldest and most experienced IP firms" -<br />
"top tier position for the third consecutive year" -<br />
"undisputed leader in the Austrian IP market" -<br />
"there is no doubt about their position" -<br />
"tops the rankings again this year for both patents and trade marks"<br />
Our firm was awarded Austrian “IP Firm of the Year 2010” by "Managing Intellectual Property - MIP".<br />
BIO Business Forum 2011 319 Participating Company <strong>Profiles</strong>
Detlef Albrecht<br />
President & CEO<br />
710 Lakeway Dr Ste 290<br />
Sunnyvale, CA 94085<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Detlef Albrecht<br />
Giovanni Ferrara, Business Development<br />
Sorbent Therapeutics, Inc<br />
Clinical Foci: Cardiovascular Disease • Renal • Drug Development<br />
www.sorbent.com<br />
Phone: 1-408-857-5248<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successful removal of clinically significant amounts of sodium, potassium and<br />
fluid in ESRD patients during recently completed clinical proof of concept trial.<br />
Total of 74 subjects dosed with CLP, up to 30 grams and up to 14 days with no<br />
drug related serious adverse events while critical serum balances of Na, Ca, and<br />
Mg remain unchanged. Compound is non-absorbed-no systemic toxicities.<br />
Alternative administrative dosing forms near final development-sachet, gel,<br />
snack bar.<br />
Incorporated: 2005<br />
Employees: 3<br />
Ownership: Private<br />
Hyperkalemia prevention in CHF with CKD;<br />
optimization of RAAS blockade therapy; improved 6<br />
minute walk test; reduced blood pressure<br />
Ability to reduce interdialytic weight gain in dialysis<br />
patients<br />
CORPORATE MISSION<br />
Biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in<br />
large markets - Congestive Heart Failure (CHF), End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) and Hypertension.<br />
In Phase 1 studies, CLP 001 has been shown to remove up to 1.5g of potassium per day and to lower serum potassium by about 0.5mEq/L.<br />
CLP 001 also binds about 1g of sodium per day, which translated into the reduction of blood pressure and body weight (from water). The<br />
amount of K and Na bound represent approximately 30-40% of the daily dietary intake in HF and ESRD patients. Since CLP removes cations<br />
from the total body pool rather than simply binding dietary cations, CLP can be given with or independent of meals and dosed any time<br />
throughout the day.<br />
CLP offers a novel therapy for heart failure patients through two mechanisms:<br />
1. CLP’s capacity to remove potassium provides the opportunity to optimize RAAS inhibition and in particular aldosterone blockade<br />
without the concern of developing life threatening hyperkalemia, especially in HF patients with risk factors for elevated serum<br />
potassium (CKD, diabetes, older age).<br />
2. CLP’s capacity to remove body sodium and water through the gastrointestinal tract provides a kidney independent treatment option to<br />
manage sodium/fluid overload, especially in HF patients with concomitant kidney disease that has resulted in reduced effectiveness of<br />
diuretics.<br />
Ultimately, it is expected that the sodium and potassium removal effects of CLP will result in reduction of fluid overload related<br />
symptoms, and prevention of hospitalizations and re-hospitalizations of HF patients.<br />
PROPRIETARY TECHNOLOGY<br />
New generation of a family of super absorbent polymers that can be modified to either sequester or contribute targeted ions in targeted<br />
areas of the digestive tract. The polymers are taken orally and are non-absorbed, and offer flexibilty in dosing since they bind to cations<br />
independent of diet. The technology is covered by composition of matter patents out until 2028.<br />
CORPORATE ALLIANCES<br />
Geographic Alliances Pending; Currently seeking partnerships.<br />
INTELLECTUAL PROPERTY<br />
Composition and methods IP on new generation family of polymers until 2028. Novel composition of matter IP on second generation<br />
polymers will be filed summer of 2011.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
CLP 1001 Phase II, IIa, IIb End Stage Renal Disease (ESRD) Reduced Interdialytic Weight Gain (IDWG), Blood Pressure, Less<br />
Symptomatic Hypotension and Cardiopulmonary Edema<br />
CLP 1002 Phase I Heart Failure Alters Serum Potassium in Heart Failure patients<br />
CLP 1003 Phase II, IIa, IIb Heart Failure Reduced blood pressure, reduced signs of fluid overload,<br />
improved 6 minute walk, reduced hospitalization rate<br />
BIO Business Forum 2011 320 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Round A: 01/01/2006 (US $14.00 million)<br />
Round B: 09/30/2009 (US $7.00 million)<br />
Round C: 06/30/2010 (US $22.00 million)<br />
Investors: ARCH Venture Partners (1 %) • SOFINNOVAVENTURES (1 %) • CMEA VENTURES (1 %) • DOW VENTURES (1<br />
%) • AgeChem Venture Fund (1 %)<br />
SENIOR MANAGEMENT<br />
Detlef Albrecht, President & CEO • Linda de Young, Vice President • Julie Iwashita, Director • Giovanni Ferrara, Business<br />
Development<br />
BOARD OF DIRECTORS<br />
Detlef Albrecht, Sorbent Therapeutics,Inc. • Scott Minick, ARCH Venture Partners & BIND Biosciences • James I Healy, MD,PhD.,<br />
Sofinnova Ventures • David J. Collier, MD, CMEA Ventures • Ricardo "Richard" Fuentes, DOW Ventures • Donald Joseph, Independent<br />
Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Lee W. Henderson, MD,F.A.C.P., Chairman, Sorbent Therapeutics, Inc. • Alfred Cheung, MD, Department of Internal Medicine,<br />
Nephrology, University of Utah health Sciences Center • Maria Rosa Costanza, MD, Medical Director, Midwest Heart Specialists • Eli A.<br />
Friedman, MD, M.A.C.P., Chief of the Division of Renal Disease, State University of New York Downstate Medical Center • Allen<br />
Nissenson, MD, Chief Medical Officer, DaVita Corporation • Barry Massie, Chief of Cardiology, UCSF<br />
BIO Business Forum 2011 321 Participating Company <strong>Profiles</strong>
Henry Ji, PhD<br />
Chief Executive Officer<br />
6042 Cornerstone Court West, Suite B<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sorrento Therapeutics, Inc<br />
Clinical Foci: Drug Discovery • Immunology • Drug Development<br />
www.sorrentotherapeutics.com<br />
Phone: 1-858-210-3701<br />
Henry Ji, Interim Chief Executive Officer and Chief Scientific Officer<br />
HIGHLIGHTS<br />
Recent<br />
Incorporated: 2009<br />
Employees: 20<br />
Ownership: Public<br />
Market Cap: $75.00 million<br />
OTC BB: SRNE.OB<br />
Completion and validation of diverse libraries of fully human antibodies.<br />
Identification and isolation of high quality human antibody binders for approximately 2-3 dozens of antibody drug targets.<br />
Antibody discovery and development alliance with the Scripps Research Institute for the prevention and treatment of Staph aureus<br />
infections, including the MRSA.<br />
CORPORATE MISSION<br />
Sorrento Therapeutics, Inc. (STI) has one of the strongest antibody development platforms available in the industry - the G-MAB Platform -<br />
offering rapid development timeline and unmatched library diversity. STI’s libraries are comprised of fully human antibodies, designed to<br />
efficiently identify optimal antibody candidates against virtually any disease target. Importantly, STI’s G-MAB Platform is unencumbered<br />
by third party royalty obligations.<br />
The flexible G-MAB Platform allows STI to create human antibody libraries in different formats, such as single-chain variable fragment<br />
(scFv) as well as full-length IgG1. All of our libraries are fully human, constructed from mRNAs obtained from approximately 600 individual<br />
donors ensuring a high degree of diversity.<br />
STI's G-MAB Platform is validated by identification and isolation of high quality antibody binders against approximately 2-3 dozens of<br />
antibody drug targets.<br />
Antibody therapeutics that are not fully human can cause allergic-type reactions in the short-term and may only work the first time they<br />
are used due to the human body’s reaction to them, thus compromising their long-term use. Since all STI antibodies are fully human,<br />
therapeutics derived from them will not have these shortcomings. As noted by the American Cancer Society, fully human antibody<br />
therapeutics are likely to be safer and more effective.<br />
PROPRIETARY TECHNOLOGY<br />
As opposed to the Winter II technology, the STI Technology applies ribonucleic acid (RNA) transcription for amplification of the<br />
immunoglobulin variable domain sequences. RNA transcription is not sequence-dependent and is therefore ideal for the production of a<br />
large number of copies from a complex mixture of nucleic acid sequences. When used to amplify immunoglobulin variable domain<br />
sequences, RNA transcription can amplify virtually the entire genetic information encoding for the variable domains of human antibodies.<br />
These amplified variable domain sequences have been cloned into different antibody display systems to produce high complexity human<br />
antibody libraries. A U.S. patent covering the STI Technology was issued in July 2008.<br />
CORPORATE ALLIANCES<br />
The Scripps Research Institute (La Jolla)<br />
INTELLECTUAL PROPERTY<br />
Issued US patent for the process of using RNA transcription to generate human antibody libraries.<br />
SENIOR MANAGEMENT<br />
Henry Ji, PhD, Chief Executive Officer • Richard Vincent, Chief Financial Officer • Henry Ji, PhD, Chief Scientific Officer • Martina<br />
Molsbergen, Vice President<br />
BOARD OF DIRECTORS<br />
Glenn Halpryn, Transworld Investment Corporation • Henry Ji, PhD, Sorrento Therapeutics • Jane H. Hsiao, PhD, MBA, Director, OPKO<br />
Health, Inc. • Curtis Lockshin, PhD Director, Independent pharmaceutical and life science consultant • Kim Janda, PhD, The Scripps<br />
Research Institute<br />
SCIENTIFIC ADVISORY BOARD<br />
Richard A. Lerner, MD, Chairman, Scientific Advisory Board, The Scripps Research Institute • Kim Janda, PhD, Consultant, The Scripps<br />
Research Institute • Gunnar Kaufmann, PhD, Consultant, The Scripps Research Institute<br />
BIO Business Forum 2011 322 Participating Company <strong>Profiles</strong>
Alison Todd<br />
Managing Director<br />
Suite G16, National Innovation Centre<br />
Sydney, NSW 2015<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Caroline Fuery<br />
CORPORATE MISSION<br />
Speedx<br />
Clinical Foci: Diagnostics • Genetic Disorders • Pharmacogenetics<br />
www.speedx.com.au<br />
Phone: 61-2-9209 4170<br />
Incorporated: 2<br />
Employees: 12<br />
Ownership: Private<br />
At SpeeDx we license our catalytic nucleic acids (MNAzymes and DNAzymes) to provide cheap and robust multiplex diagnostics for the<br />
detection of genetic disease and pathogens. Nucleic acids are cheap and fast to manufacture, and can be easily designed to detect the<br />
presence of pathogens, diagnose genetic conditions such as those caused by acquired mutations (cancer, epigenetics) and inherited<br />
conditions (SNP, disease predisposition), chromosome disorders etc.<br />
We are interested in granting further licenses to MNAzymes, and in developing products in human in vitro diagnostics (IVD).<br />
SpeeDx is a venture capital-backed biotechnology company based in Sydney, Australia.<br />
PROPRIETARY TECHNOLOGY<br />
MNAzymes are catalytic nucleic acids that provide a platform detection technology that can be linked to a wide range of amplification<br />
techniques including PCR and isothermal methods.<br />
MNAzyme qPCR provides a superior alternative to other real time PCR detection methods providing greater specificity (with four levels of<br />
sensitivity) and a robust method of multiplex analysis of targets. We routinely multiplex four and five targets together.<br />
MNAzymes coupled to qPCR were used in a Phase II Gene Therapy clinical trial to measure expression of the gene construct (Nat Med. 2009<br />
Mar;15(3):285-92). This is a mature technology with products already on the market (sold by third party under license to SpeeDx).<br />
CORPORATE ALLIANCES<br />
SpeeDx has granted licenses for MNAzymes in the following fields: human in vitro diagnostics (IVD), Life Sciences Research and applied<br />
markets such as agricultural, veterinary, food and environmental testing.<br />
INTELLECTUAL PROPERTY<br />
Patents granted for MNAzymes and applications pending.<br />
SENIOR MANAGEMENT<br />
Alison Todd, Managing Director • Alison Todd, Chief Scientific Officer • Caroline Fuery, Chief Business Officer • Elisa Mokany, Chief<br />
Technology Officer<br />
BOARD OF DIRECTORS<br />
Andrew Denver, PFM Cornerstone Pty Ltd • Andrew Jane, CM Capital Pty Ltd • John Klopp<br />
BIO Business Forum 2011 323 Participating Company <strong>Profiles</strong>
Susanne Picard<br />
President<br />
1235 3rd ave<br />
Val-d'Or, QC J9P 6C3<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Susanne Picard, President<br />
SPharm Inc.<br />
Clinical Foci: Service • Drug Development • Other<br />
www.spharm.ca<br />
Phone: 1-819-824-6889<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
SPharm is pleased to be featured in the April edition of the<br />
European Life Science Journal. The editorial is entitled "Your<br />
Partner in North America",<br />
Incorporated: 2000<br />
Employees: 7<br />
Ownership: Private<br />
SPharm's new website will soon be online.<br />
Please visit www.spharm.ca to find out about our new wider range<br />
of services.<br />
CORPORATE MISSION<br />
SPharm is a consulting firm specialized in Pharmaceutical/Medical Regulatory Affairs and Product Development Services. SPharm's team<br />
of experts assists pharmaceutical, biological, natural health product and medical device companies from around the world throughout the<br />
various phases of their product development up to a successful and timely market access.<br />
With over 40 years of experience, SPharm can act as a integral member of your company's Regulatory team or as a consultant when<br />
needed. We can overlook and manage your products' life-cycle management, from clinical trials to post-market updates.<br />
Our expertise goes beyond the scope of simply providing regulatory consultation and dossier preparation. SPharm offers the advantages<br />
of a true partnership by ensuring that our services are fully integrated with our client’s strategies, procedures and objectives.<br />
CORPORATE ALLIANCES<br />
SPharm is part of a strategic alliance of 5 Canadian companies in the biopharmaceutical field. These companies represent an excellent<br />
potential of partnership for our clients who require expert services during their drug development process. All members of the alliance<br />
offer services that cover each stage of product development, from the end of the pre-clinical phase, all the way through the Canadian<br />
marketing after regulatory approval.<br />
SPharm has numerous partners in Canada, Europe and US offering complementary services in order to offer to our clients a wide range of<br />
personalized services corresponding to their specific needs.<br />
SENIOR MANAGEMENT<br />
Susanne Picard, President • Marie-Claude Gravel, Director • Mylène Lavoie, Director<br />
BIO Business Forum 2011 324 Participating Company <strong>Profiles</strong>
Claire Kruger, PhD<br />
Chief Executive Officer<br />
6430 Rockledge Drive<br />
Bethesda, MD 20817<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Claire L. Kruger, PhD<br />
Robert A. Lodder, PhD<br />
Leisa Dennehy<br />
Spherix, Inc<br />
Clinical Foci: Cardiovascular Disease • Metabolic Disease • Specialty Pharmaceutical<br />
www.spherix.com<br />
Phone: 1-301-897-2540<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
In the recently completed study, treatment of animals using<br />
combination therapy with twice-daily oral dosing significantly<br />
reduced triglycerides by 43 mg/dl compared with control animals<br />
with a mean triglyceride level of 118 mg/dl (p=0.01).<br />
The same therapy significantly reduced total cholesterol by 73<br />
mg/dl from a mean level of 378 mg/dl compared with control<br />
animals (p=0.01).<br />
The company has initiated development of SPX-106 and D-tagatose<br />
as a treatment for hypertriglyceridemia, and plans to start an<br />
initial human efficacy study in the late 2011 or early 2012.<br />
Incorporated: 1967<br />
Employees: 10<br />
Ownership: Public<br />
Market Cap: $8.60 million<br />
NASDAQ: SPEX<br />
D-tagatose is in preclinical development in combination with other<br />
agents including SPX-106 for prevention and treatment of<br />
atherosclerosis, hypertriglyceridemia, and related dyslipidemias.<br />
The company has initiated development of SPX-106 and D-tagatose<br />
as a treatment for hypertriglyceridemia, with an initial human<br />
efficacy study expected to start in 4Q2011 or 1Q2012. A partner is<br />
required to complete development in Type 2 diabetes.<br />
A new IND will be filed with the US FDA for use of SPX-106 and Dtagatose<br />
in 4Q2011 or 1Q2012. Spherix is expected to begin the<br />
first Phase 1 human study immediately afterward in 4Q2011 or<br />
1Q2012.<br />
CORPORATE MISSION<br />
Spherix Incorporated is clinical-stage, specialty pharma company dedicated to developing and licensing/marketing drugs as treatments<br />
for metabolic syndrome, including dyslipidemia, Type 2 diabetes, obesity, and hypertension. The newest drug is an oral compound, SPX<br />
10624258 designated “SPX-106”. SPX-106 is one of five small molecules licensed by Spherix last year. Spherix is co-developing this drug<br />
with D-tagatose as an oral small molecule with a novel mechanism of action on glucose and lipid homeostasis.<br />
D-tagatose is a novel, small molecule that has shown human proof of concept as a glycemic control agent in an initial Phase 3 clinical trial<br />
in Type 2 diabetes, and as an anti-dyslipidemic agent in a Phase 2 study in Type 2 diabetics. D-tagatose is an epimer of fructose and has a<br />
unique mechanism of action in glucose and lipid homeostasis. D-tagatose is believed to depress elevations of blood sugar levels in diabetic<br />
patients by increasing glycogen synthesis while decreasing glycogen utilization, resulting in an improvement of blood sugar control and<br />
modulation of HbA1c. D-tagatose may have a mechanism of action in adipocytes (fat cells), hepatocytes (liver cells) and enterocytes (gut<br />
cells) in the maintenance of lipid homeostasis.<br />
A development program in hypertriglyceridemia was initiated in 4Q2010, with a Phase 1 study expected to begin 4Q2011 or 1Q2012. Dtagatose<br />
is being used by Spherix as a platform for other drug products to treat atherosclerosis and the metabolic syndrome.<br />
D-tagatose has been approved by the FDA as a Generally Recognized As Safe (“GRAS”) agent for food use, and has been approved as a<br />
“novel food ingredient” in the European Union (EU) without any restriction on usage. Tagatose was previously used as a food ingredient in<br />
the U.S. and Europe, but is no longer being marketed for food use.<br />
CORPORATE ALLIANCES<br />
Spherix has signed a research contract with a leading global contract research organization to investigate the role of SPX-106 and Dtagatose<br />
in lowering triglycerides. Work will continue through at least 2012. In the first phase of this program, we will be working with the<br />
CRO to design and execute studies in cell culture, animal models, and humans to clarify the mechanism of action of SPX-106 and Dtagatose<br />
in modulating triglycerides and glucose in the metabolic syndrome. The first post-hoc analysis of the Phase 3 NEET clinical trial<br />
with D-tagatose for the treatment of Type 2 diabetes provided information that supports the role of adipocytes in the mechanism of<br />
action for D-tagatose. This information on potential mechanism of action will be incorporated into the development program.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
D-tagatose Phase III Glycemic control in Type 2 diabetes Use as monotherapy in mild Type 2 diabetes<br />
D-tagatose Other Reduction of triglycerides Monotherapy in hypertriglyceridemia-starting<br />
Phase 1 2011<br />
SPX 7233801 Preclinical Atherosclerosis Combination of D-tagatose and a natural product<br />
SPX 8522876 Preclinical Dyslipidemias, diabetes Combination of D-tagatose and a natural product<br />
BIO Business Forum 2011 325 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
SPX 10624258 (SPX-106) Preclinical Metabolic syndrome, dyslipidemia Combination of D-tagatose and a natural product<br />
SPX 8818309 Preclinical Obesity, metabolic syndrome Combination of D-tagatose and a natural product<br />
SPX 8818440 Preclinical Diabetes, obesity Combination of D-tagatose and a natural product<br />
SENIOR MANAGEMENT<br />
Claire Kruger, PhD, Chief Executive Officer • Robert Clayton, Chief Financial Officer • Robert Lodder, PhD, President • Katherine<br />
Brailer, Director • Robert J. Vander Zanden, Chairman<br />
BOARD OF DIRECTORS<br />
Robert Vander Zanden, Chairman of the Board • Mr. Douglas T. Brown, SVP Corp Banking-PNC Bank • Dr. Claire Kruger, CEO & COO •<br />
Robert A. Lodder, Jr., President • Aristides Melissaratos, Sr. Advisor to the President - JHU • Thomas B. Peter, Retired from Glaxo<br />
SmithKline<br />
BIO Business Forum 2011 326 Participating Company <strong>Profiles</strong>
Didier Scherrer<br />
Chief Executive Officer<br />
1919 Route de Mende<br />
34293 Montpellier<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Didier Scherrer<br />
CORPORATE MISSION<br />
Splicos<br />
Clinical Foci: Infectious Disease • Oncology • Metabolic Disease<br />
www.splicos.com<br />
Phone: 33-467-634952<br />
Incorporated: 2008<br />
Employees: 9<br />
Ownership: Private<br />
Recent discoveries have shown that modifications of RNA alternative splicing play a critical role in the alteration of key biological<br />
mechanisms implicated in various diseases, opening a brand new field for the search of new treatments for diseases with high medical<br />
needs.<br />
Based on breakthrough proprietary discoveries and innovative screening technologies, SPLICOS is developing a novel class of small<br />
molecules targeting RNA alternative splicing in the field of HIV-AIDS, oncology (metastatic invasion)<br />
SPLICOS is a cutting hedge company entirely focused on preclinical R&D in the field of RNA alternative splicing from discovery to in vivo<br />
validation of the NCEs on appropriate animal models. With three ongoing projects generating very promising results, such as a novel class<br />
of molecule in HIV showing excellent in vitro and in vivo efficacy, SPLICOS is actively looking for industrial partners to advance these<br />
projects to the clinical development stage.<br />
SENIOR MANAGEMENT<br />
Didier Scherrer, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Philippe Pouletty, Truffle Capital • Claude Bertrand, IPSEN • Jacques Raynaud, Cancer Research Association • Alain Chevallier •<br />
Michel Kackzoreck, Eurobiomed • Mark Wainberg, McGill Unversity<br />
SCIENTIFIC ADVISORY BOARD<br />
Jacques Reynes • Mark Wainberg • Vincent Calvez • Gilles Peytavin • Pierre Corbeau<br />
BIO Business Forum 2011 327 Participating Company <strong>Profiles</strong>
8 Saint Mary's Street<br />
Boston, MA 02215<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Frank Bobe<br />
Shobana Albrecht, VP Corporate Development<br />
Springleaf Therapeutics<br />
Clinical Foci: Drug Delivery • Biopharmaceuticals • Medical Device<br />
www.springleaftx.com<br />
Phone: 1-617-358-5659<br />
Incorporated: 2008<br />
Employees: 15<br />
Ownership: Private<br />
CORPORATE MISSION<br />
SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care.<br />
SpringLeaf was founded based on breakthrough science at MIT.<br />
PROPRIETARY TECHNOLOGY<br />
SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate<br />
injectable therapeutics.<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round B: 05/12/2011 (US $15.00 million)<br />
BIO Business Forum 2011 328 Participating Company <strong>Profiles</strong>
Laurier Schramm<br />
President & CEO<br />
125 - 15 Innovation Blvd.<br />
Saskatoon, SK S7N 2X8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Amy Friesen<br />
HIGHLIGHTS<br />
Recent<br />
SRC BioManufacturing<br />
Clinical Foci: Service • Veterinary • Biopharmaceuticals<br />
www.src.sk.ca<br />
Phone: 1-306-933-7920<br />
Incorporated: 1947<br />
Employees: 420<br />
Ownership: Other<br />
SRC BioManufacturing is the only shortcut worth taking in product development. We provide value to clients from idea to market:<br />
technology concepts, small-scale fermentation, process development, scale-up, product licensing, marketable products.<br />
SRC BioManufacturing has a Biosafety Level 2 fermentation facility with Canadian Food Inspection Agency approval for production of<br />
veterinary biologics. It is ideally suited for process development and supports bacterial and recombinant fermentation.<br />
SRC BioManufacturing has a multi-disciplinary team with expertise in microbiology, biochemistry and fermentation. We provide<br />
downstream processing and protein purification expertise and experience in non-regulated work in areas such as biofuels.<br />
CORPORATE MISSION<br />
SRC BioManufacturing accelerates innovation and commercialization through value-added product development and contract<br />
manufacturing services for the biotechnology industry. Our team offers substantial expertise in process development, optimization and<br />
scale-up, contract manufacturing, technology transfer, and regulatory affairs. For over 10 years we have been helping our clients develop<br />
and commercialize a diverse array of products including biologics, vaccines, biopharmaceuticals, biopesticides, crop inoculants, industrial<br />
enzymes, and biochemicals.<br />
We are a provider of fermentation and downstream process technologies for Biologics.<br />
As part of the Saskatchewan Research Council, SRC BioManufacturing contributes to the Council’s aim to enable innovation through<br />
applied research, development, design, scale-up, demonstration, and technology commercialization.<br />
SENIOR MANAGEMENT<br />
Laurier Schramm, President & CEO • Phillip Stephan, Vice President • Michael Best, Manager • Amy Friesen, Marketing<br />
BIO Business Forum 2011 329 Participating Company <strong>Profiles</strong>
Zielstattstrasse 44<br />
81379 Munich<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Irina Staatz-Granzer<br />
HIGHLIGHTS<br />
Recent<br />
Staatz Business Development & Strategy<br />
www.staatz.biz<br />
Phone: 49-89-7806 89810<br />
Ownership: Private<br />
Deal advisor to Molecular Partners for the license of their anti-VEGF DARPin for retinal diseases to Allergan. The contract comprises an<br />
upfront of USD 45MM, aggregated milestone paymentsof USD 375MM and double digit royalties.<br />
CORPORATE MISSION<br />
We provide strategic and operational business development support (sell and buy side) based on our long-standing healthcare industry<br />
experience, from both, the pharmaceutical and the biotechnology side. We have successfully prepared and negotiated a large number of<br />
various agreement types in a many indication areas: licensing contracts, R&D collaborations, marketing/distribution contracts,<br />
divestment/acquisition contracts. We liaise and negotiate with professionals from the global big pharma and medtech industry, from<br />
small biotech industry and academia. We operate on a global basis with target companies and clients from Europe, Japan and North<br />
America. Some of our recent accomplishments included the licensing agreement between Molecular Partners and Allergan for a head line<br />
value of USD 420MM or the sale of U3 Pharma to Daiichi-Sankyo for a one-time payment of USD 235MM. Our services range from the<br />
definition of your business development strategy, the sourcing of partners and projects, preparation for and management of due<br />
diligence processes, the assessment of business opportunities and the performance of all aspects of business development operations<br />
including creation of deal constructions and term sheets, negotiations and alliance management. Based on our sound experience, but also<br />
on our involvement in professional business development organizations, for which Dr. Irina Staatz-Granzer serves as past President<br />
(European Pharma Licensing Council) and Vice President (German Pharma Licensing Club) respectively, we can revert to a large<br />
international network of contacts to support you and your business. In co-operation with our partner company we add further value to<br />
your business by combining effectively the strategic / commercial services with an R&D service package, which includes strategic support<br />
in product development and regulatory strategy. Choose from our broad range of services and benefit from our expertise!<br />
CORPORATE ALLIANCES<br />
Granzer Regulatory Consulting & Services<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
rhX wound healing gel Phase I scalds, burns, diabetic ulcer, venous ulcer start of phase II / out-licensing<br />
BIO Business Forum 2011 330 Participating Company <strong>Profiles</strong>
Dr Barbara Domayne-Hayman<br />
Chief Executive Officer<br />
London BioScience Innovation Centre<br />
London<br />
NW1 0NH<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Donna Hackett, Commercial Director<br />
Barbara Domayne-Hayman, PhD<br />
Stabilitech Ltd<br />
Clinical Foci: Vaccines • Biopharmaceuticals • Biodefense<br />
www.stabilitech.com<br />
Phone: 44-771-4234705<br />
HIGHLIGHTS<br />
Recent<br />
Recently raised £2.2 million to assist the commercialisation of the platform.<br />
Incorporated: 2002<br />
Employees: 15<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Stabilitech has developed a novel proprietary stabilisation platform for vaccines, biopharmaceuticals and other biological products.<br />
Currently vaccines and biopharmaceuticals require storage and transport under strictly controlled temperatures (‘cold chain’).<br />
Stabilitech’s technology will enable the long term stable storage of vaccines and other biological products over a wide range of<br />
temperatures, and will protect the products against both heat and freeze damage. The technology has been successfully applied to live<br />
viral vaccines (enveloped and non-enveloped), inactivated viruses and sub-unit vaccines as well as to antibodies, growth factors and other<br />
proteins. Stabilitech’s approach involves the addition of carefully selected excipients at optimized concentrations and ratios, followed by<br />
freeze drying. The excipients have all been previously used in clinical settings and are inexpensive and readily available. The technology is<br />
easily incorporated into existing manufacturing processes, using standard equipment.<br />
Stabilitech is a private company based in London, in the Imperial College Incubator.<br />
PROPRIETARY TECHNOLOGY<br />
Stabilitech has developed a novel proprietary technology which stabilizes vaccines, biopharmaceuticals and other biological products.<br />
Stabilitech’s technology will enable the long term stable storage of vaccines and other biological products over a wide range of<br />
temperatures, protecting products against both heat and freeze damage. The technology has been successfully applied to live viral<br />
vaccines, inactivated viruses and sub-unit vaccines as well as to antibodies, growth factors and other proteins. Stabilitech’s approach<br />
involves the addition of carefully selected excipients (all previously used in clinical settings, which are inexpensive and readily avalable) at<br />
optimized concentrations and ratios, followed by freeze drying using standard equipment.<br />
CORPORATE ALLIANCES<br />
Feasibility studies are under way with a number of vaccine (both human and animal health) and biopharmaceutical companies.<br />
INTELLECTUAL PROPERTY<br />
Stabilitech has filed a broad range of patent families and continues to build the company's intellectual property portfolio.<br />
PRODUCTS<br />
Name Phase Indication<br />
Thermal stabilisation platform Other vaccines and biopharmaceuticals<br />
SENIOR MANAGEMENT<br />
Dr Barbara Domayne-Hayman, Chief Executive Officer • Dr Jeff Drew, Chief Scientific Officer • Dr Stephen Ward, Other • Donna<br />
Hackett, Business Development<br />
BOARD OF DIRECTORS<br />
Wayne Channon • Dr Barbara Domayne-Hayman, Stabilitech Ltd • Dr Jeff Drew, Stabilitech Ltd • Dr Peter Cozens, ProPharma<br />
Partners<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr John Tite (Chairman), Bicycle Therapeutics Ltd • Dr John Anderson, Formerly Institute of Animal Health UK • Professor Wendy<br />
Barclay, Imperial College London • Professor Tony Cass, Imperial College London • Professor Steven Myint, Moewin Associates •<br />
Professor David Rowlands, University of Leeds • Professor Nigel Slater, University of Cambridge • Professor Sir Greg Winter,<br />
University of Cambridge<br />
BIO Business Forum 2011 331 Participating Company <strong>Profiles</strong>
Dr Jackie Fairley<br />
Chief Executive Officer<br />
PO Box 6535<br />
Central, VIC 8008<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Malcolm McColl, Vice President Business Development<br />
Starpharma<br />
Clinical Foci: Drug Delivery • Oncology • Reproductive<br />
www.starpharma.com<br />
Phone: 61-3-8532 2721<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
May 23, 2011 Starpharma today announced successful results of a major phase<br />
2 clinical study that demonstrated efficacy of VivaGel® for the treatment of<br />
bacterial vaginosis (BV). Further clinical studies will be initiated in the second<br />
half of 2011.<br />
September 2010; Starpharma today announced the signing of a collaborative<br />
research agreement with Eli Lilly and Company. The new agreement relates to a<br />
co-development program for one of Starpharma’s dendrimer-drug conjugates.<br />
Incorporated: 1996<br />
Employees: 30<br />
Ownership: Public<br />
Market Cap: $409.00 million<br />
ASX: SPL<br />
Based on the results of this phase 2 study, Starpharma<br />
will undertake further discussions with regulatory<br />
authorities, with a view to initiating phase 3<br />
registration trials of VivaGel® for the treatment of BV<br />
in late 2011 or early 2012.<br />
CORPORATE MISSION<br />
Starpharma is a world leader in the development of nanotechnology based products for pharmaceutical and life-science applications.<br />
Starpharma's technology includes:<br />
1. VivaGel® (SPL7013 Gel) is a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide. VivaGel® has<br />
recently successfully completed a Phase 2 trial for the treatment of Bacterial Vaginosis and is also in development for the prevention of<br />
sexually transmitted infections including HIV, HSV2 and HPV.<br />
2. Drug delivery through conjugation of small molecules, peptides, proteins or biologicals such as monoclonal antibodies (or combinations<br />
thereof) to the Starpharma proprietary dendrimers to provide benefits such as: improved drug solubility, improved pharmacokinetics<br />
including an ability to lengthen half-life, reduced toxicity through mechanisms including release at targeted sites; with reproducible<br />
manufacture and and an ability to extend product lifecycle through improved presentations.<br />
Starpharma’s headquarters and research facilities are located in Melbourne, Australia. Starpharma principally consists of two operating<br />
companies, Starpharma Pty Ltd in Australia and Dendritic Nanotechnologies, Inc. in USA. both with a comprehensive intellectual property<br />
portfolio.<br />
Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US<br />
under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX: SPHRY).<br />
PROPRIETARY TECHNOLOGY<br />
1. VivaGel® (SPL7013 Gel) is a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide. VivaGel® has<br />
recently successfully completed a Phase 2 trial for the treatment of Bacterial Vaginosis. Further clinical trials will commence in this<br />
indication in 2011.<br />
2. Drug delivery through conjugation of small molecules, peptides, proteins or biologicals such as monoclonal antibodies (or combinations<br />
thereof) to the Starpharma proprietary dendrimers to provide benefits such as: improved drug solubility, improved pharmacokinetics<br />
including an ability to lengthen half-life, reduced toxicity through mechanisms including release at targeted sites; with reproducible<br />
manufacture and and an ability to extend product lifecycle through improved presentations.<br />
CORPORATE ALLIANCES<br />
The Starpharma dendrimer technology is being commercialised broadly, including:<br />
– Drug delivery advancing through collaborative research relationships with partners including Lilly, Elanco and GSK/Stiefel and several<br />
other world leading organisations.<br />
– Diagnostics including a license to Siemens Healthcare<br />
– Transfection technology including licenses to EMD Merck and Qiagen<br />
INTELLECTUAL PROPERTY<br />
Starpharma holds a central position in the dendrimer IP landscape with a wide portfolio of patents and patent applications covering both<br />
the composition and application of dendrimers in pharmaceutical, life-science industrial and other fields.<br />
The Starpharma patent portfolio currently has around 35 active patent families with over 70 granted patents and more than 100 patent<br />
applications pending.<br />
BIO Business Forum 2011 332 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
VivaGel® Phase II, IIa, IIb Treatment and prevention of bacterial<br />
vaginosis<br />
Drug delivery of various<br />
cytotoxic drugs<br />
Preclinical Development of a range of enhanced cytotoxics<br />
with proof of concept completed in paclitaxel,<br />
doxorubicin, methotrexate and several other<br />
un-named agents.<br />
VivaGel® Phase I Prevention of HIV and HSV<br />
SENIOR MANAGEMENT<br />
Successful completion of phase II in<br />
treatment of bacterial vaginosis in<br />
May 2011<br />
Dr Jackie Fairley, Chief Executive Officer • Dr Malcolm McColl, Business Development • Dr Paul Barrett, Business Development • Dr<br />
David Owen, Chief Scientific Officer • Nigel Baade, Chief Financial Officer • Dr Jeremy Paull, Other • Ben Rogers, Other<br />
BOARD OF DIRECTORS<br />
Peter Bartels AO • John Raff • Ross Dobinson • Richard A Hazleton • Peter Jenkins<br />
BIO Business Forum 2011 333 Participating Company <strong>Profiles</strong>
Dennis W. King<br />
President & CEO<br />
759 Wessel Dr<br />
Fairfield, OH 45014-3662<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Rod Lashley<br />
Statking Consulting Inc.<br />
Clinical Foci: Oncology • CNS • Cardiovascular Disease<br />
www.statkingclinical.com<br />
Phone: 1-513-858-2989<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
STATKING is working on an NDA submission for a radiopharmaceutical to detect<br />
breast, head and neck, and melanoma cancers. STATKING is providing data<br />
management, data analysis, statistical consulting, and clinical study monitoring<br />
services.<br />
STATKING provided statistical analysis and FDA support services for a recent PMA<br />
submission for a cardiac ablation device. STATKING has provided all analytical<br />
support for the submission, including providing responses to FDA questions.<br />
STATKING is providing clinical data management and statistical analysis support for<br />
two oncology projects for a small pharmaceutical company. The NDA for the first<br />
indication is expected to be completed by the end of 2011.<br />
Incorporated: 1989<br />
Employees: 30<br />
Ownership: Private<br />
STATKING expects to begin work on a diagnostic<br />
for detection of renal disease. STATKING will<br />
provide clinical trial management, clinical study<br />
monitoring, clinical data management, and<br />
statistical analysis for this study.<br />
STATKING expects to begin work a device to be<br />
used in knee replacement surgery. STATKING will<br />
provide clinical study management, clinical study<br />
monitoring, clinical data management, and<br />
statistical analysis.<br />
CORPORATE MISSION<br />
STATKING Clinical Services provides data related services for clinical trials for the pharmaceutical and medical device industry. STATKING<br />
provides statistical consulting, clinical data management, statistical programming, medical writing, clinical trial management, and<br />
clinical study monitoring for studies in all phases. For over 20 years, STATKING has assisted pharmaceutical companies and device<br />
manufacturers get their products through the regulatory approval process.<br />
CORPORATE ALLIANCES<br />
STATKING Consulting, Inc. has alliances with Community Research and Quest Research Institute to provide full Phase I services.<br />
SENIOR MANAGEMENT<br />
Dennis W. King, President & CEO • Roderick L. Lashley, Executive Vice President • Clare Geiger, Director<br />
BIO Business Forum 2011 334 Participating Company <strong>Profiles</strong>
CARLOS ARENAS WIEDFELDT<br />
Chairman<br />
Camino a Santa Teresa 1040 Mezzanine<br />
14210 Tlalpan DF,<br />
Mexico<br />
CONFERENCE PARTICIPANTS<br />
Gerardo Sanchez-Mejorada<br />
Stendhal<br />
Clinical Foci: Biopharmaceuticals • Specialty Pharmaceutical • Cardiovascular Disease<br />
www.stendhal.com.mx<br />
Phone: 52-55-2000 6630<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
rEVENUES OF 70 MILLION USD IN 2010<br />
SIGNED AGREEMENT WITH ONY PHARMACEUTICAL / SIRAEO FOR<br />
DISTRIBUTION OF INFASURF IN LATIN-AMERICA.<br />
Incorporated: 1974<br />
Employees: 170<br />
Ownership: Private<br />
REVENUES OF 152 MILLION USD IN 2011, GROWHT OF 104%<br />
AGAINST 2010.<br />
THROUGH EXTENSION OF LICENSING DEAL WITH GILEAD AND NEW<br />
DEALS WITH PROSPECTIVE PARTNERS, LAUNCH OF<br />
CARDIOVASCULAR BUSINESS UNIT IN 2012.<br />
START ACTIVE PARTICIPATION ON R&D PROJECTS.<br />
CORPORATE MISSION<br />
Stendhal, a Latin-American pharmaceutical company headquartered in Mexico City and Panama, with commercial operations in 14 Latin-<br />
American countries and the Caribbean, markets proprietary high-specialty pharmaceutical products for: HIV/Infectious Diseases;<br />
Neurology, Pain, Critical Care Medicine, Cancer and Obstetric conditions. Stendhal’s strategy is to in-license marketed or late-stage<br />
proprietary therapeutic products devoted to specialty medicine, complete any required development and regulatory submission of these<br />
products, and market them through the company’s highly-trained specialty sales and marketing team.<br />
PROPRIETARY TECHNOLOGY<br />
Through patent-license agreements, Stendhal has the rights to commercialize in part of all of our territories the following molecules:<br />
Tenofovir, Emtricitabine, Interferon Beta 1a, Natalizumab, Galsulfase.<br />
CORPORATE ALLIANCES<br />
With Gilead, for the marketing of VIREAD, EMTRIVA, TRUVADA and ATRIPLA (antiretrovirals); with Biogen-Idec, AVONEX and TYSABRI<br />
(Multiple Sclerosis); with Biomarin, NAGLAZYME (MPS VI), with ONY Pharmaceutical, INFASURF (galsulfase), with Ferring, for FIRMAGON<br />
(Prostate Cancer) and three other products in Venezuela.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VIREAD On Market HIV DISEASE<br />
TRUVADA On Market HIV DISEASE<br />
ATRIPLA On Market HIV DISEASE LAUNCHED 2011 IN MEXICO<br />
AVONEX On Market MULTIPLES SCLEROSIS<br />
TYSABRI On Market MULTIPLE SCLEROSIS<br />
COLMESDANT On Market LIFE-THREATENING GRAM NEGATIVE INFECTIONS LAUNCHED 2010<br />
AMBISOME On Market SISTEMIC OR LIFE-THREATENING FUNGAL INFECTIONS TO BE LAUNCHED 2011<br />
NAGLAZYME On Market MUCHOPOLYSACCARIDOSIS VI LAUNCHED 2010<br />
INFASURF On Market PULMONARY SURFACTANT DEFICIENCY IN NEONATE TO BE LAUNCHED 2011<br />
FIRMAGON On Market PROSTATE CANCER TO BE LAUNCHED 2012<br />
FINANCING HISTORY<br />
Investors: PRIVATELY OWNED (100 %)<br />
SENIOR MANAGEMENT<br />
CARLOS ARENAS WIEDFELDT, Chairman • JUAN PEDRO ANZUETO, President • ALEJANDRO GAYON, Chief Financial Officer •<br />
ANTONIETA ROMAN, Chief Scientific Officer • GERARDO SANCHEZ MEJORADA, Business Development • OSCAR CASTANEDA, Managing<br />
Director • ROMUALDO RODRIGUEZ, Managing Director • MARIA ELENA MARIN MD, Chief Medical Officer<br />
BOARD OF DIRECTORS<br />
CARLOS ARENAS WIEDFELDT, STENDHAL • PIERRE VERSTRAETE, INDEPENDENT • ROBERTO TAPIA. MD, INDEPENDENT • GUSTAVO<br />
ARENAS WIEDFELDT, GRUPO ARFELDT • JESUS ARENAS WIEDFELDT, GRUPO ARFELDT • ISABEL ARENAS WIEDFELDT, GRUPO ARFELDT<br />
BIO Business Forum 2011 335 Participating Company <strong>Profiles</strong>
Shantal Feltham<br />
President & CEO<br />
4575 Blakie Road, 2nd Floor<br />
London, ON N6L 1P8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Shantal Feltham<br />
CORPORATE MISSION<br />
Stiris Research Inc.<br />
www.stirisresearch.com<br />
Phone: 1-519-652-5327<br />
Ownership: Private<br />
Stiris Research is North America’s most client-focus Clinical Research Organization (CRO). Established in 2004, Stiris is privately held,<br />
Certified Woman-Owned and composed of 123 elite team members located throughout the United States and Canada with an average of<br />
14 years of industry experience.<br />
Stiris provides both integrated team support and full-service management for Phase I through Phase IV clinical trials for pharmaceutical,<br />
biotechnology and medical device companies.<br />
Stiris services include:<br />
• Project Management<br />
• Clinical Monitoring<br />
• Administrative Support<br />
• Program Planning<br />
• Program Management<br />
• Medical Monitoring<br />
• Medical Writin<br />
SENIOR MANAGEMENT<br />
Shantal Feltham, President & CEO • Amanda Carrera, Vice President • Julie Stover, Business Development<br />
BIO Business Forum 2011 336 Participating Company <strong>Profiles</strong>
Jerrold Gershone<br />
Chief Executive Officer<br />
710 South 2nd Street, 7th Floor<br />
Minneapolis, MN 55401<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Nikos Katopodis<br />
Judy Kessel<br />
Stonearch Creative<br />
Clinical Foci: Medical Device • Diagnostics • Medical Device<br />
www.stonearchcreative.com/<br />
Phone: 1-612-217-7603<br />
Incorporated: 1984<br />
Employees: 43<br />
Ownership: Private<br />
CORPORATE MISSION<br />
StoneArch Creative is a Minneapolis-based marketing communications agency specializing in the medical device industry. By tapping into<br />
the diverse skills and talents of the StoneArch team, we develop award-winning creative, dynamic content and engaging user experiences<br />
for brands across the globe.<br />
What makes us so invaluable to our clients is our medical expertise. Within our ranks are former marketing managers for medical device<br />
companies and hospital systems, pharmaceutical sales reps and healthcare practitioners. We understand your business, your target<br />
audiences and your market, and we’re fluent in the complexities of legal and regulatory, FDA requirements and HIPAA compliance.<br />
From interactive training and education programs to multi-platform product launches, StoneArch designs fully integrated marketing<br />
strategies and creative tactics to meet your business goals and objectives.<br />
SENIOR MANAGEMENT<br />
Jerrold Gershone, Chief Executive Officer • Judy Kessel, President • Jonathan Comito, Director • Jessica Boden, Director • Ellen<br />
Schuller, Director • Nikos Katopodis, Director<br />
BIO Business Forum 2011 337 Participating Company <strong>Profiles</strong>
Office of Technology Licensing & Industry<br />
Relations - Melville Library, N5002<br />
Stony Brook, NY 11794-3369<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Shiu Yie Hsieh, Assistant Director (Life Sciences)<br />
Sean Boykevisch , PhD, Licensing Specialist (Life Sciences)<br />
Adam DeRosa, Licensing Associate (Life Sciences)<br />
Stony Brook University<br />
Clinical Foci: Drug Delivery • Diagnostics • Drug Delivery<br />
www.stonybrook.edu/research/otlir/<br />
Phone: 1-631-632-1362<br />
Incorporated: 1951<br />
Employees: 10<br />
Ownership: Private<br />
CORPORATE MISSION<br />
The Office of Technology Licensing and Industry Relations at Stony Brook University identifies and protects faculty-developed intellectual<br />
property and creates partnerships with business and industry to further research and license inventions. Our team’s depth of experience<br />
— from successfully licensing emerging technologies to participating in active programs of research — is developing new industries and<br />
jobs for the public benefit. We work with biotechnology and pharmaceutical partners to help them license Stony Brook University facultydeveloped<br />
innovations that will become the foundation of new commercial products. - Fiscal 2010 Fast Facts — • 22 licenses • 67 invention<br />
disclosures • 26 issued patents • 76 patent applications filed • $10.7 million in licensing revenue • $200 million in research grants. -<br />
Successful Track Record — By creating partnerships with business and industry, we helped deliver the faculty developed science behind: •<br />
ReoPro® • Periostat® • Oracea® • 3-D Virtual Colonoscopy System • Yeast Two-Hybrid System - Broad Portfolio — Our team manages<br />
innovations developed by faculty whose activities cover a broad spectrum of scientific research: • Biomedical • Biotechnology • Oral<br />
Biology • Chemistry • Computer Science • Applied Mathematics • Engineering • Materials Science • Physics<br />
INTELLECTUAL PROPERTY<br />
Technologies available for OUT-Licensing are typically early stage, pre-clinical or phase 1. Additionally, many of our esteemed life sciences<br />
faculty have created platform technologies, including diagnostic screens for a wide variety of human diseases, and medical devices.<br />
BIO Business Forum 2011 338 Participating Company <strong>Profiles</strong>
Lynn Allen-Hoffmann, PhD<br />
Chief Executive Officer<br />
505 S. Rosa Road<br />
Madison, WI 53719<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Russell R. Smestad, President<br />
Stratatech Corporation<br />
Clinical Foci: Regenerative Medicine • Skin/Dermatological • Gene/Cell Therapy<br />
www.stratatechcorp.com<br />
Phone: 1-608-441-2750<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successfully completed first-time-in-human StrataGraft skin<br />
substitute Phase I/IIa clinical trial in severe burn patients. Provided<br />
important safety and immunological insights supporting further<br />
clinical progression. Results have been published.<br />
Launched StrataTest human skin research model for use in in vitro<br />
demal toxicity testing.<br />
Employees: 29<br />
Ownership: Private<br />
Commencement in 2011 of StrataGraft skin substitute proof-ofconcept<br />
clinical trial in patients with second degree deep partialthickness<br />
burns.<br />
Commencement in 2012 of ExpressGraft antimicrobial skin<br />
substitute Phase I clinical trial to treat non-healing diabetic foot<br />
ulcers.<br />
CORPORATE MISSION<br />
Stratatech Corp. is a clinical stage regenerative medicine company focused on commercializing next generation skin substitute products<br />
for therapeutic and research use. It is the only company that has a human keratinocyte progenitor cell line – NIKS® – that faithfully<br />
reproduces normal skin epidermal architecture. The company’s flagship product, StrataGraft® tissue, is a full-thickness resorbable skin<br />
substitute used to treat severe burns and other complex skin defects. Its companion suite of ExpressGraft tissues have been genetically<br />
enhanced to produce elevated levels of natural wound healing and antimicrobial factors, and will be used to treat chronic non-healing<br />
ulcers. These core competencies have the potential to drive a paradigm shift in wound care management. For the research market, the<br />
company commercializes StrataTest®, a three-dimensional human skin model for in vitro toxicity screening, product testing and drug<br />
discovery.<br />
PRODUCTS<br />
Name Phase Indication<br />
StrataGraft human skin substitute Phase II, IIa, IIb Severe burns<br />
ExpressGraft genetically enhanced skin substitutes Preclinical Non-healing ulcers (diabetic foot ulcers)<br />
ExpressGraft pro-angeogenic skin substitute Preclinical Non-healing ulcers (veneous leg ulcers)<br />
StrataTest human skin research model On Market in vitro toxicity screening assay<br />
SENIOR MANAGEMENT<br />
Lynn Allen-Hoffmann, PhD, Chief Executive Officer • Russell R. Smestad, President • Robert Barnard, Vice President • Allen Comer,<br />
PhD, Other<br />
BOARD OF DIRECTORS<br />
Lynn Allen-Hoffmann, PhD, Stratatech Corporation<br />
BIO Business Forum 2011 339 Participating Company <strong>Profiles</strong>
Patrick G. LePore<br />
President & CEO<br />
300 Tice Blvd<br />
Woodcliff Lake, NJ 07677<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Holly Chang, Director, Business Development<br />
CORPORATE MISSION<br />
Strativa Pharmaceuticals<br />
Clinical Foci: Specialty Pharmaceutical • Oncology • Gastroenterology<br />
www.strativapharma.com<br />
Phone: 1-201-802-4000<br />
Incorporated: 2005<br />
Employees: 700<br />
Ownership: Public<br />
Market Cap: $1200000.00 million<br />
NYSE : PRX<br />
Established in 2005, Strativa (www.strativapharma.com) is the proprietary branded products division of Par Pharmaceutical, a US based<br />
generics pharmaceutical company (www.parpharm.com). Total revenue for Par Pharmaceutical in 2010 was $1.0B. Par’s generis division<br />
markets >50 product families and is the 6th largest US generics firm.<br />
Strativa is a rapidly-growing specialty pharmaceutical business focused on specialist-driven markets. The company’s prescriber footprint<br />
includes high-prescribing PCPs, oncologists, HIV treaters and other select specialties. Strativa markets four branded products.<br />
Strativa/Par is seeking partnering opportunities in four areas:<br />
1) New branded product opportunities in oncology/hematology, supportive care oncology, gastroenterology (GI), long-term care and<br />
other select specialty markets for the US market in late phase 3 development.<br />
2) Worldwide partnerships for Nascobal in Canada and Asia with a partner with development capabilities in the local territory.<br />
3) Injectable versions of existing molecules, including long-acting versions (e.g., branded generic 505b2 or ANDA).<br />
4) Biosimilar / biogeneric opportunities.<br />
Strativa/Par is an ideal commercialization partner, combining a specialty product focus with large pharmaceutical resources. This<br />
includes our experienced management team, strong cash position, excellence in manufacturing/distribution/supply chain and high<br />
performing intellectual property expertise.<br />
Strativa currently markets four branded products in the US through a sales force of 200 field-based representatives.<br />
CORPORATE ALLIANCES<br />
Strativa is partnered with: 1) BioAlliance for commercialization of Oravig (miconazole) muco-buccal tablet for oropharyngeal candidiasis<br />
(thrush). 2) MonoSol Rx for commercialization of Zuplenz (ondansetron) oral thin film chemo-induced, radiation-induced and postoperative<br />
nausea and vomiting. 3) Swedish Orphan Biovitrum for development and commercialization of Nascobal (cyanocobalamin) in<br />
Europe.<br />
PRODUCTS<br />
Name Phase Indication<br />
Megace ES oral suspension (megestrol<br />
acetate)<br />
Cleared for US Marketing anorexia/cachexia due to HIV/AIDS<br />
Nascobal nasal spray (cyanocobalamin) Cleared for US Marketing vitamin B12 deficiency<br />
Oravig (miconazole) muco-buccal tablet Cleared for US Marketing oral candidiasis (thrush)<br />
Zuplenz (ondansetron) oral soluble thin<br />
film<br />
Cleared for US Marketing chemo-induced nausea and vomiting, post-operative<br />
nausea and vomiting, radiation-induced nausea and<br />
vomiting<br />
SENIOR MANAGEMENT<br />
Patrick G. LePore, President & CEO • Paul V. Campanelli, Executive Vice President • Thomas J. Haughey, General Counsel • Michael A.<br />
Tropiano, Chief Financial Officer • Allison Wey, Investor Relations<br />
BOARD OF DIRECTORS<br />
Patrick G. LePore, Par Pharmaceutical • Joseph E. Smith, Warner-Lambert Company, EVP, retired • Patrick J. Zenner, Hoffman-LaRoche<br />
Inc., Chief Operating Officer, retired • Melvin Sharoky, MD, Somerset Pharmaceuticals, Pres & CEO, retired • Peter S. Knight, Generation<br />
Investment Management--US, President • Thomas P. Rice, Columbia Investment LLC, Principal and Co-founder<br />
BIO Business Forum 2011 340 Participating Company <strong>Profiles</strong>
Michael Gilman, PhD<br />
Chief Executive Officer<br />
One Canal Park, Suite 1120<br />
Cambridge, MA 02141<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Michael Gilman<br />
HIGHLIGHTS<br />
Recent<br />
Stromedix<br />
Clinical Foci: Pulmonary • Renal • Regenerative Medicine<br />
www.stromedix.com<br />
Phone: 1-617-674-8400<br />
Initiating STX-100 Phase 2a trial in idiopathic pulmonary fibrosis.<br />
CORPORATE MISSION<br />
Incorporated: 2007<br />
Employees: 6<br />
Ownership: Private<br />
Stromedix is a clinical-stage company focused on fibrosis and organ failure. We have a strong focus on the use of clinical biomarkers to<br />
follow drug and disease activity.<br />
PROPRIETARY TECHNOLOGY<br />
STX-100: Humanized monoclonal antibody to integrin avb6, entering Phase 2 in idiopathic pulmonary fibrosis.<br />
STX-200: Antibody to integrin avb5 for both acute and chronic organ failure, preclinical.<br />
Proprietary biomarker panels of fibrosis and epithelial injury in kidney and lung<br />
INTELLECTUAL PROPERTY<br />
STX-100 covered by six patent families.<br />
PRODUCTS<br />
Name Phase Indication<br />
STX-100 Phase II, IIa, IIb Idiopathic Pulmonary Fibrosis<br />
STX-200 Preclinical Scleroderma, acute lung injury, sepsis<br />
SENIOR MANAGEMENT<br />
Michael Gilman, PhD, Chief Executive Officer • Brad Maroni, MD, Chief Medical Officer • Shelia Violette, PhD, Vice President • Daniel<br />
Lynch, Chairman<br />
BOARD OF DIRECTORS<br />
Daniel Lynch • Michael Gilman, Stromedix • Peter Barrett, Atlas Venture • Ron Hunt, New Leaf Venture Partners • Stephen Kraus,<br />
Bessemer Venture Partners<br />
BIO Business Forum 2011 341 Participating Company <strong>Profiles</strong>
Mr. Dilip Shanghvi<br />
Chief Executive Officer<br />
270 Prospect Plains Road<br />
Cranbury, NJ 08512<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sun Pharmaceutical Industries Ltd<br />
Clinical Foci: Neurology • Pulmonary • Ophthalmic<br />
www.sunpharma.com<br />
Phone: 1-609-495-2862<br />
James Hattersley, Vice President, Corp. Business Development<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
April 2011 - Merck and Sun Pharmaceutical Industries Establish<br />
Joint Venture to Develop and Commercialize Novel Formulations<br />
and Combinations of Medicines<br />
in Emerging Markets.<br />
April 2011 - Merck in India and Sun Pharmaceutical Industries<br />
Enter Strategic Partnership to Co-market Merck's Diabetes Drugs<br />
– Sitagliptin and Sitagliptin + Metformin - in India<br />
September 2010 - Sun Pharmaceutical Industries Acquires<br />
Controlling Stake in Taro Pharmaceutical Industries (dermatology).<br />
Incorporated: 1994<br />
Employees: 9500<br />
Ownership: Public<br />
Market Cap: $10000.00 million<br />
BOMBAY STOCK EXCHANGE: SUNPHARM<br />
Product approvals currently under development in key therapeutic<br />
areas - dermatology, neurology, oncology, opththalmology, and<br />
respiratory - both specialty and NCE.<br />
Corporate and asset acquisitions. Enabling intellectual property<br />
allowances.<br />
Sun seeks regional partnerships where it wishes to establish new<br />
commercial infrastructure.<br />
CORPORATE MISSION<br />
Sun Pharmaceutical Industries is seeking acquisition opportunities and strategic partnerships with other distinguished pharma / biotech<br />
companies in dermatology, neurology, oncology, ophthalmology, and respiratory therapeutic areas. In addition Sun seeks to partner,<br />
primarily for Japan territory, four (4) specific programs described in "Licensing Projects' within company directory. Strengthening market<br />
presence with its partners in key territories, while maintaining a strong customer focus, continues to be a high priority area for the<br />
company.<br />
Sun's commitment to the medical community coupled with its drive for growth has remained focal points since its inception in 1983.<br />
Since 1983, Sun has accomplished several milestones establishing itself as an important specialty pharma company with technically<br />
complex products in global markets. Sun is the top pharmaceutical company by market capitalization in India.<br />
Sun is a publicly traded international specialty pharma company, present in 30 markets, with an added ability to manufacture API's. In<br />
branded markets, Sun's products are prescribed in chronic therapy areas such as neurology, psychiatry, cardiology, gastroenterology,<br />
diabetology and respiratory.<br />
Highlights include 17 manufacturing plants in 3 continents, 2 world class research centers, several brands sold in markets worldwide, a<br />
growing presence in the U.S. pharmaceutical market, increased research investments, 60% of sales from international markets, and 9500<br />
employees worldwide.<br />
PROPRIETARY TECHNOLOGY<br />
Within the past 14 years Sun has used a combination of internal development and external acquisitions to drive growth. Important<br />
mergers include those in U.S. and Europe. Several internationally approved manufacturing plants are located in Europe, India, and U.S.<br />
Sun concentrates its work regarding new molecules and drug delivery systems into a subsidiary company, namely Sun Pharmaceuticals<br />
Advanced Research Company (SPARC) also listed on the Bombay Stock Exchange. Drug discovery platforms. Drug delivery systems.<br />
Manufacturing processes.<br />
CORPORATE ALLIANCES<br />
Large cap pharmaceutical company (e.g., Merck) for innovative branded products for emerging market territories.<br />
Small and mid capitalization pharmaceutical companies (as yet undisclosed) for strategic interest in region and technology.<br />
INTELLECTUAL PROPERTY<br />
Extensive estate covering NCE composition of matter. Drug delivery formulation technology. Manufacturing process design.<br />
SENIOR MANAGEMENT<br />
Mr. Dilip Shanghvi, Chief Executive Officer • Mr. Sudhir Valia, Chief Financial Officer • Mr. Kal Sundaram - Sun, President • Mr. Kirti<br />
Ganorkar, Business Development • Mr. James Kedrowski - Taro, President • Mr. James Hattersley, Business Development<br />
BIO Business Forum 2011 342 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Mr. Dilip Shanghvi, Sun Pharmaceutical Industries, Ltd. • Mr. Sudhir Valia, Sun Pharmaceutical Industries, Ltd. • Mr. Sailesh Desai, Sun<br />
Pharmaceutical Industries, Ltd. • Mr. Kal Sundaram, Sun Pharmaceutical Industries, Ltd. • Mr. Keki Mistry - Non Executive<br />
Independent, Housing Development Finance Corporation, Ltd. • Mr. Ashwin Dani - Non Executive Independent, Vice Chairman &<br />
Managing Director of Asian Paints, Ltd. • Mr. Hasmukh Shah - Non Executive Independent, Chairman of Gujarat Gas; Former Chairman<br />
& Managing Director IPCL • Mr. S. Mohanchand Dadha - Non Executive Independent, Former Chairman & Managing Director TDPL<br />
BIO Business Forum 2011 343 Participating Company <strong>Profiles</strong>
Michael Sundman<br />
Chief Executive Officer<br />
Spalenvorstadt 30 / Postfach<br />
CH-4003 Basel<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Michael Sundman, CEO<br />
CORPORATE MISSION<br />
Sundman Business Development Gmbh<br />
www.sbdg.ch<br />
Phone: 41-61-2633966<br />
Incorporated: 1999<br />
Ownership: Private<br />
Based in Basel, Sundman Business Development brings large company corporate development expertise to small and mid-sized<br />
companies on a project basis. Emphasis on strategic transactions such as acquisitons, divestitures, alliances and licensing. Strong track<br />
record in healthcare and other industries during times of consolidation. CEO is former Head Business Development Ciba Pharmaceuticals<br />
Division (now Novartis).<br />
FINANCING HISTORY<br />
Investors: Sundman Family (100 %)<br />
SENIOR MANAGEMENT<br />
Michael Sundman, Chief Executive Officer<br />
BIO Business Forum 2011 344 Participating Company <strong>Profiles</strong>
Robert Kann<br />
Managing Director<br />
125 Summer Street<br />
Boston, MA 02110<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Justin Huddleson<br />
Lisa M. Tittemore<br />
Sunstein Kann Murphy & Timbers LLP<br />
Clinical Foci: Chemistry • Neurology<br />
www.sunsteinlaw.com<br />
Phone: 1-617-443-9292<br />
Incorporated: 1979<br />
Employees: 81<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Representative cases: Sunstein secured a jury verdict for Abbott Laboratories, defeating an $11.5 million patent infringement claim<br />
relating to intravenous valve devices. The jury verdict and judgment of non-infringement was affirmed on appeal.<br />
Sunstein worked with a N.Y. firm to obtain a $65MM patent infringement verdict for Ariad Pharma. against Eli Lilly & Co. The team<br />
presented complex evidence. Witnesses included experts in molecular biology and two Nobel prize winning scientists.<br />
Sunstein patents include U.S. Patent Nos.: 6,358,738 (Polo Box Therapeutic Compositions); 5,762,876 (Automatic Genotype<br />
Determination); and 5,160,726 (Filter Sterilization for Production of Colloidal Superparamagnetic MR Contrast Agents)<br />
CORPORATE MISSION<br />
Sunstein Kann Murphy & Timbers LLP www.sunsteinlaw.com has an outstanding record of important wins for our life sciences clients<br />
through patent and trademark prosecution, intellectual property portfolio development, litigation and business transactions. We<br />
emphasize early identification of business goals and strategic planning to achieve them. We have a long track record of success in<br />
protecting and enforcing our clients' patent, trademark copyright and other IP-related assets. Our team of life science practitioners<br />
provides intellectual property counsel --patent prosecution, trademark protection, and litigation-- in a range of biomedical, medical device<br />
and pharmacologic areas. Our patent lawyers have a broad range of science degrees and technical expertise in such areas as biochemistry,<br />
biomedical engineering, biotechnology, chemistry, molecular biology, systems biology, medical devices, pharmaceuticals and drug<br />
discovery. We provide our clients with strategic counsel in patent prosecution and portfolio development, clearance strategies, use of<br />
patents to maximize product life and exclusivity, trademark prosecution, patent and other IP litigation, and interference, re-examination,<br />
and inventorship disputes. Our life sciences clients are active in such diverse fields as pharmaceuticals, medical devices, health care,<br />
biotechnology, food, packaging, biofuels, publishing, and education.<br />
SENIOR MANAGEMENT<br />
Robert Kann, Managing Director • Bruce Sunstein, Attorney • Timothy Murphy, Attorney • Kerry Timbers, Attorney • Justin<br />
Huddleson, Ph. D., Attorney • Robert Asher, Attorney • Lisa Tittemore, Attorney • Robert Hess, Ph. D., Attorney • Jonathon Lovely,<br />
Attorney • Kate Noll, Attorney<br />
BIO Business Forum 2011 345 Participating Company <strong>Profiles</strong>
Tsang-Bin Tzeng<br />
President & CEO<br />
4F-1, No. 268, Liancheng Rd.<br />
New Taipei City 235<br />
Taiwan<br />
CONFERENCE PARTICIPANTS<br />
Tsang-Bin Tzeng, President &CEO<br />
Sunten Phytotech Co., Ltd.<br />
Presenting Company<br />
Clinical Foci: Gastroenterology • Skin/Dermatological • Cardiovascular Disease<br />
www.stpt.com.tw<br />
Phone: 886-2-8227-8111<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
SunTen Phytotech Co. Ltd. received the highest honor of Gold Prize<br />
in the Year 2010 of the “Pharmaceutical Technology Research and<br />
Development Award – Drug Development Section” for STD07 from<br />
the Department of Health (DOH), Executive Yuan, Taiwan.<br />
SunTen Phytotech Co. Ltd. (STPT) received the Bronze Award in the<br />
Year 2010 of Taipei Biotech Award for STD07<br />
SunTen Phytotech Co. Ltd. (STPT) received Choice Award in the Year<br />
2010 of Taiwan Healthcare and Agricultural Biotech Industries<br />
Innovation and Excellence Awards<br />
Incorporated: 2001<br />
Employees: 30<br />
Ownership: Private<br />
SunTen Phytotech Co. Ltd. (STPT) is to enter the phase II clinical<br />
study in the USA for STD07- an active small molecule discovered<br />
from botanical source to treat Inflammatory Bowel Diseases (IBD)<br />
SunTen Phytotech Co. Ltd. (STPT) is to enter the phase I clinical<br />
study in Taiwan for STD06- an active small molecule discovered<br />
from botanical source to treat Diabetic Foot Ulcer (DFU)<br />
SunTen Phytotech just discovered a thrombolytic agent with<br />
potency slight better than tPA, yet, no bleeding side effects.<br />
CORPORATE MISSION<br />
SunTen Phytotech Co., Ltd (STPT), an herbal-based biotechnology company in Taiwan, is striving to unravel the miracle of nature to develop<br />
novel botanical medicine and functional dietary products. STPT was the R&D division that spun off from Sun Ten Pharmaceuticals in 2000.<br />
Sun Ten Pharmaceutical Co., Ltd. is a renowned GMP manufacturer of concentrated herbal extracts conforming to international standards.<br />
It is named the largest Chinese herbal extract manufacturing company in Taiwan by the Commercial Times with annual revenues of<br />
approximately $40 million USD.<br />
STPT has inherited more than 60 years of technical platform and experiences on sourcing, authentication, research and development,<br />
quality control and manufacturing in botanical drugs from Sun Ten Pharmaceuticals. In addition, STPT has established a new drug<br />
development platform in-line with international norms through years of experiences in new drug development. This platform<br />
incorporates the technology, process, regulation and clinical trials used by advanced Western nations on new drug development to<br />
develop plant-based drugs and functional foods. Together with the inheritance of Sun Ten tradition, the integration of current<br />
techniques, a steady corporate growth, and the search for strategic alliance partnership with domestic and foreign companies for<br />
cooperation STPT sets the goal of developing effective and safe medicinal products.<br />
With core competence, STPT's product development strategy hence focuses on unmet medical demands of specific disease populations,<br />
including cardiovascular diseases, allergic asthma, chronic gastrointestinal disorders, and skin diseases for both therapeutic and health<br />
promoting remedies.<br />
PROPRIETARY TECHNOLOGY<br />
The inheritance of more than 60 years of R&D experience and more than 600 marketed products in traditional Chinese herbs with a strong<br />
foundation on the authentication of natural products and understanding of the pharmacological activities and research methods.<br />
Collection of more than two hundred herbal HPLC fingerprint, tissue section, and construction of rigid specification for each species of<br />
herbs.<br />
The capability to integrate modern drug development knowledge into the development of botanical drugs based on international<br />
standards.<br />
The capability to develop and validate analytical method and animal models for botanical drug products.<br />
The ability to professionally manage R&D in drug development to effectively control progress and to attain set goals.<br />
CORPORATE ALLIANCES<br />
Sun Ten Pharmaceutical Co. Ltd.<br />
SunTen Herbs. Co. Ltd<br />
Yung Shin Pharm Co., Ltd.<br />
Beijing Capital Medical University<br />
INTELLECTUAL PROPERTY<br />
All products are filed patents in US and other major countries. Currently, more than 20 patents have been granted and 20+ patents are<br />
pending for approval.<br />
BIO Business Forum 2011 346 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
SB221 NDA/BLA filed, or in process Endothelial/ Anti-hypertensive Market<br />
STA36 Phase II, IIa, IIb Chronic Asthma Phase III<br />
STD07 Phase I Inflammable Bowel Disease Phase II<br />
STD06 Preclinical Diabetic Wound Healing/<br />
Dermatitis<br />
BIO Business Forum 2011 347 Participating Company <strong>Profiles</strong><br />
Phase I<br />
STD12 Research Thrombolytic Therapy Preclinical<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Seed Round: 05/10/2002 (US $1.70 million)<br />
Round A: 06/25/2002 (US $1.80 million)<br />
Round B: 05/20/2004 (US $2.50 million)<br />
Round C: 12/17/2004 (US $3.70 million)<br />
Investors: Sun Ten Pharmaceutical Co., Ltd. (15 %) • Sun Ten International Investment Co., Ltd. (11 %) • Shin Yang<br />
Ventures Capital Co., Ltd. (6 %)<br />
SENIOR MANAGEMENT<br />
Tsang-Bin Tzeng, President & CEO • Shiau-Fen Jung, Director • Yi-Wei Chang, Manager • Ming-Chung Lee, Manager • Catherine Lee,<br />
Manager<br />
BOARD OF DIRECTORS<br />
David D.F. Hsieh, Sun Ten Group • Chau Shin Hsu, Sun Ten Pharmaceutical Co., Ltd. • Lee Chiou Chang, Sun Ten Pharmaceutical Co.,<br />
Ltd. • Herb Shen, Ben You Investment Company • Hsiu-Ling Wang, Sun Ten International Investment Co., Ltd. • Gordon Ho, Pac Link<br />
BioVentures • Dr. Charleston C. Hsu, Sun Ten Group • Chung-Guang Shen, Sun Ten Group • Hong-Jen Chang, Taiwan BioVenture<br />
Company • Dr. J. H. Ho, PAC-LINK Bio.<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Hylar Friedman, Neurogen Corporation, USA • Dr. Tom Davies, STA Preclinical Services LLC, USA • Dr. Harry Olson, STA Preclinical<br />
Services LLC, USA • Dr. Li-Pin Kung, MegaMed International Co., USA
Dr Sanjeev Chowdhary<br />
Chief Executive Officer<br />
Plot No. D-3,A wing,2nd floor,District Centre<br />
Delhi 110017<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Super Religare Laboratories<br />
Clinical Foci: Diagnostics • Drug Development • Drug Discovery<br />
www.srl.in/<br />
Phone: 91-22-67801222<br />
Sujoy Ghosh, Head-Business Development-Clinical Research Services<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Religare SRL is coming up with a IPO soon & we will become public.<br />
We have been audited by several Global Sponsors & auditory bodies like CAP,<br />
Randox international, Bio-Rad, R&D systems, CDC Lipid standardization,<br />
NGSP etc.<br />
Won prestigious FICCI Healthcare Excellence Award for Operational<br />
Excellence in Healthcare Delivery in 2010.<br />
• Received Frost & Sullivan Award in 2007 and 2009 in the recognition of<br />
being the Diagnostics Company for the respective years.<br />
Our Commitment to Quality :Our laboratories conform to the highest<br />
Accreditation Standards.Our Quality Systems are compliant with the<br />
requirements of College of American Pathologist (CAP, USA), National<br />
Accreditation Board for Testing and Calibration<br />
Incorporated: 1996<br />
Employees: 1800<br />
Ownership: Private<br />
We have supported 500 Clinical Trials in last 13 years<br />
Largest logistics network covering more than 500<br />
cities/towns through 5 reference labs supported by 45<br />
Satellite labs and 1200 Collection Centers across India<br />
which offers specimen transport at Ambient,<br />
Refrigerated & Frozen condition in min TAT<br />
•We cover extensive disciplines in Central lab services<br />
such as Hematology, Coagulation, Clinical Chemistry<br />
including Protein chemistry, Flow Cytometry,<br />
Immunology, Serology, Endocrinology, Microbiology,<br />
Mycology, Metal testing , Oncology<br />
CORPORATE MISSION<br />
Super Religare Laboratories Limited (Formerly SRL Ranbaxy Ltd.) is one of the leading pathology laboratory network in India, servicing<br />
nearly 1550 hospitals/path labs and over 50,000 doctors. SRL along with its subsidiary Piramal Diagnostic Services Private Limited<br />
performs over 33,000 tests/day and catered to approximately 4.20 million customers during the nine month period ended December 31,<br />
2010, offering a comprehensive range of over 3,300 diagnostic tests, from the routine to the highly specialized tests. The tests are based on<br />
more than 200 technologies covering most known diseases.<br />
Super Religare Laboratories Limited (Formerly SRL Ranbaxy Ltd.) is one of the company, in the pathology testing sector, to have an R&D<br />
unit. It develops innovative assays in new drug development support, enables study of test dynamics and results vis-à-vis geographical<br />
races, epidemiological distribution and other demographic considerations.<br />
Super Religare Laboratories Limited (Formerly SRL Ranbaxy Ltd.) commenced operations in 1996, with business extending to United Arab<br />
Emirates, Oman, Qatar, Kuwait, Bahrain, SriLanka, Bangladesh, Nepal, the Maldives, Tanzania and Zambia<br />
PROPRIETARY TECHNOLOGY<br />
USP of Our Central Lab :<br />
•India’s Largest & No.1 Central Lab meeting Global Standards to offer services to support the need of Global drug development for various<br />
phases of Multi centric Clinical trials across India as well as with other Asian countries<br />
•We are the First Central Lab to get accredited by CAP ( College of American Pathologist) in 2002;<br />
•We are the First Central Lab to get accredited by NABL in 1999, in accordance with ISO 15189:2007<br />
•Achieved NGSP Level I certification in 2007<br />
•Adjudged as “Best Central Lab “ by Frost & Sullivan under the category of Partner of Choice in Clinical Research in 2007 & 2008<br />
•Dedicated to serve our Global Clinical Research Community with Comprehensive test menu with more than 3600 investigations, new<br />
assay development<br />
CORPORATE ALLIANCES<br />
We are the preferred Central lab partners in Indian & APAC region for Major Domestic & MNC Pharma,Bio pharma,CROs,Central lab<br />
palyers across the Globe for their Central lab outsourcing requirement<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Central Laboratories Services Diagnostics Clinical Trials of any phase & any disease<br />
areas<br />
We have supported more than 500<br />
Clinical trials in Indian Continent<br />
BA/BE services Phase I Phase I & all generic BA/BE services We have US FDA ,EMEA,MHRA,DCGI<br />
,ANVISA approved & audited facility<br />
Project Management Services Diagnostics Any Clinical Phase Trials<br />
BIO Business Forum 2011 348 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Logistics Support Phase II, IIa,<br />
IIb<br />
Data Management Diagnostics SAS based data management in Central<br />
Lab areas<br />
SENIOR MANAGEMENT<br />
Any Clinical Trials Phase we have been sucessfully utilising our<br />
Logistics capabilities & offering cost<br />
effective,reduced TAT & IATA compliant<br />
services<br />
All phase clinical trials<br />
Dr Sanjeev Chowdhary, Chief Executive Officer • Dr B.R.Das, President • Mr Kiran vaidya, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Mr. Shivinder Mohan Singh, SRL,Fortis Group Chairman • Mr. Malvinder Mohan Singh • Mr. Sunil Godhwani • Dr. Sanjeev K.<br />
Chaudhry • Dr. Brian Tempest • Mr. Harpal Singh • Dr. Amit Varma • Dr. Sunita Naidoo • Dr. Ranjit Roy Chaudhury • Dr. P. S.<br />
Joshi<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr B.R. Das, President Research & Innovation<br />
BIO Business Forum 2011 349 Participating Company <strong>Profiles</strong>
Dr. James Manuso<br />
Chief Executive Officer<br />
4140 Dublin Boulevard<br />
Dublin, CA 94568<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Stuart Hwang, Exec. Director, Business Development<br />
HIGHLIGHTS<br />
Recent<br />
SuperGen, Inc<br />
Clinical Foci: Oncology • Specialty Pharmaceutical • Oncology<br />
www.supergen.com<br />
Phone: 1-925-560-0100<br />
6 April 2011: SuperGen and Astex Therapeutics enter definitive merger agreement<br />
5 Jan 2011: Enrollment of first patient in first in human trial of SGI-110 in MDS & AML<br />
CORPORATE MISSION<br />
Incorporated: 1991<br />
Employees: 90<br />
Ownership: Public<br />
Market Cap: $160.00 million<br />
NASDAQ: SUPG<br />
SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies with a focus on epigenetic<br />
and cell signaling modulation. SuperGen develops products through biochemical and clinical proof of concept to partner for further<br />
development and commercialization. The company receives royalty revenue from Dacogen® (decitabine) partnerships with Eisai Co., Ltd.<br />
and Johnson & Johnson. For more information, please visit www.supergen.com.<br />
CORPORATE ALLIANCES<br />
SuperGen has a commercial and research alliances. Through a commercial partnership with Dacogen® (decitabine) the company receives<br />
royalty revenue from Eisai Co., Ltd. and Johnson & Johnson. SuperGen has a drug discovery and development collaboration with<br />
GlaxoSmithKline in the field of epigenetics.<br />
PRODUCTS<br />
Name Phase Indication<br />
Amuvatinib (MP-470) Phase II, IIa, IIb Cancer: Small cell lung cancer (SCLC)<br />
SGI-110 Phase I Cancer: AML & MDS<br />
SENIOR MANAGEMENT<br />
Dr. James Manuso, Chief Executive Officer • Dr. Mohammad Azab, Chief Medical Officer • Mr. Michael Molkentin, Chief Financial<br />
Officer<br />
BIO Business Forum 2011 350 Participating Company <strong>Profiles</strong>
Jack Khattar<br />
Chief Executive Officer<br />
1550 East Gude Drive<br />
Rockville, MD 20850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jones Woody W. Bryan Jr., PhD<br />
HIGHLIGHTS<br />
Recent<br />
Supernus Pharmaceuticals, Inc<br />
Clinical Foci: CNS • Neurology • Specialty Pharmaceutical<br />
www.supernus.com<br />
Phone: 1-301-838-2681<br />
Two NDAs to be filed in 2011 in neurology<br />
Two additional programs with POC data in ADHD and IA in ADHD<br />
Depression Program ready for late stage in 2012<br />
Incorporated: 2005<br />
Employees: 75<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Supernus is a privately funded late stage CNS company with five programs in its portfolio that span neurology and specialty psychiatry<br />
with plans to file two NDAs in 2011 and commercialize its first product in 2012.<br />
PROPRIETARY TECHNOLOGY<br />
CNS portfolio and drug delivery expertise<br />
CORPORATE ALLIANCES<br />
Afecta, Daewoong and others<br />
INTELLECTUAL PROPERTY<br />
IP filed or issued on all portfolio assets<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SPN538 NDA/BLA filed, or in process Epilepsy Approval<br />
Epliga Phase III Epilepsy NDA Filing in 2011<br />
SPN810 Phase II, IIa, IIb IA in ADHD Compelling POC data and Phase 2b next<br />
SPN812 Phase II, IIa, IIb ADHD Compelling POC data and Phase 2b next<br />
SPN809 IND Filed Depression Phase 2b ready in 2012<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Round A: 12/23/2005 (US $45.00 million)<br />
SENIOR MANAGEMENT<br />
Jack Khattar, Chief Executive Officer • Rip Wilson, Chief Financial Officer • Woody Bryan, Vice President<br />
BIO Business Forum 2011 351 Participating Company <strong>Profiles</strong>
Prof. Dr. Peter Buckel<br />
Chief Executive Officer<br />
Am Klopferspitz 19<br />
D-82152 Martinsried/Munich<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Robert C. Phelps<br />
SuppreMol, GmbH<br />
Clinical Foci: AutoImmune • Hematology • Immunology<br />
www.suppremol.com<br />
Phone: 49-89-309050680<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Phase I clinical trial with SM101 successfully completed and Phase Ib/IIa in ITP started<br />
Orphan Drug Designation for SM101 granted by the European Commission and the FDA<br />
EUR 15.5 M series C financing round and public research funding of more than EUR 3.5<br />
million secured<br />
Employees: 16<br />
Ownership: Private<br />
To start Phase IIa Clinical Trial in SLE with<br />
SM101<br />
Expecting topline results of ongoing Ph 2a<br />
study in ITP mid 2011<br />
CORPORATE MISSION<br />
SuppreMol GmbH is focusing on the development of novel therapeutics for the treatment of autoimmune diseases. The company’s lead<br />
program SM101, a recombinant human therapeutic protein, is based on a soluble form of the Fc gamma receptor IIb, which possesses<br />
immunoregulatory properties demonstrated in acute and chronic disease models where the protein proved strong anti-inflammatory and<br />
immunosuppressive efficacy. SuppreMol has successfully completed a Phase I study with SM101 and started a proof of concept study in<br />
Primary Immune Thrombocytopenia (ITP) early this year. Orphan Drug Designation for SM101 in ITP has been granted by the European<br />
Commission and the FDA. The company plans to initiate a Phase IIa study in Systemic Lupus Erythematosus (SLE) early in 2011 and is<br />
currently evaluating Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD). SuppreMol also has two additional early<br />
stage programs: a monoclonal antibody targeting specifically the Fc gamma receptor IIb and a soluble dimeric protein of the Fc gamma<br />
receptor IIb.<br />
SuppreMol GmbH is a privately-owned biotechnology company located in Martinsried near Munich, Germany and was founded in 2002 as<br />
a spin-off from the Max-Planck-Institute of Biochemistry in Martinsried, out of the laboratories of Prof. Dr. Robert Huber who received the<br />
Nobel Price in chemistry in 1988.<br />
PROPRIETARY TECHNOLOGY<br />
SM 101 is a soluble Fc receptor which has been shown to effectively block autoimmune diseases like ITP, SLE, RA and MS in acute and<br />
chronic animal models at a key position of the B-cell activation and inflammatory pathways. In a Phase I study, SM101 was safe and well<br />
tolerated in more than 40 healthy individuals. SuppreMol started a proof of concept study in Primary Immune Thrombocytopenia (ITP)<br />
with topline results expected by the mid-2011. Orphan Drug Designation for SM101 in ITP has been granted by the European Commission<br />
and the FDA. The company plans to initiate a Phase II study in Systemic Lupus Erythematosus (SLE) in early 2011 and is currently<br />
evaluating Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD).<br />
CORPORATE ALLIANCES<br />
Various academic collaborations<br />
INTELLECTUAL PROPERTY<br />
Matter of composition patent for SM101 granted in key markets. 5 patent families covering the field.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SM101 Phase II, IIa, IIb Autoimmune Disease topline data in ITP expected in Q3/11<br />
SENIOR MANAGEMENT<br />
Prof. Dr. Peter Buckel, Chief Executive Officer • Dr. Peter Sondermann, Chief Scientific Officer • Sascha Tillmanns, Director • Dr.<br />
Robert Phelps, Business Development<br />
BOARD OF DIRECTORS<br />
Dr. Thomas Hecht, Chairman • Prof. Dr. Dr. Ernst-Günter Afting, Former President and CEO of the National Research Centre, GSF in<br />
Munich, Germany • Michael Motschmann, Executive partner of MIG AG • Dr. Markus Hosang, General Partner at BioMedPartners •<br />
Ulrich Mahr, Member of General Management of Max Planck Innovation<br />
BIO Business Forum 2011 352 Participating Company <strong>Profiles</strong>
SCIENTIFIC ADVISORY BOARD<br />
Prof. Dr. Robert Huber, chairman • Dr. Uwe Jacob, co-founder • Prof. Dr. Fritz Melchers, Professor of Immunology at the University<br />
Basel • Dr. Zoltan Nagy, former Head of Immunology at Hoffmann-La Roche Inc • Prof. Dr. Falk Nimmerjahn, Professor for<br />
Experimental Immunology and Immune Therapy at the University of Erlangen-Nürnberg, Germany • Prof. Dr. Jeffrey V. Ravetch,<br />
Professor of Molecular Genetics and Immunology at the Rockefeller University, NY, USA • Dr. Helmut Lenz, Expert for immune assays and<br />
antibodies (Boehringer Mannheim / Roche) • Prof. Dr. Christoph Huber, Director of the III. Medical School, Mainz<br />
(Hematology/Immunotherapy), Germany<br />
BIO Business Forum 2011 353 Participating Company <strong>Profiles</strong>
756 Tom Martin Drive<br />
Birmingham, AL 35211<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas R. Tice, PhD<br />
Art Tipton, PhD, President<br />
Deborah A. Fox, PhD<br />
SurModics Pharmaceuticals<br />
Clinical Foci: Drug Delivery • Biopharmaceuticals • Biomaterials<br />
www.surmodicspharma.com<br />
Phone: 1-205-917-2200<br />
Ownership: Public<br />
Market Cap: $262.00 million<br />
NASDAQ: SRDX<br />
CORPORATE MISSION<br />
SurModics Pharmaceuticals is a drug delivery company that develops extended-release parenterals for its clients. SurModics<br />
Pharmaceuticals has a wide-range of drug-delivery technologies particularly for extended-release parenterals such as bioresorbable<br />
injectable microparticles, nanoparticles, implants, coatings, films, and fibers for the delivery of small molecules, peptides, proteins,<br />
antibodies, and nucleic acids -- systemic delivery and local delivery. Partnered programs range from proof-of-concept studies, product<br />
development and optimization, process scale up, clinical trial manufacturing, and commercial contract manufacturing of drug-delivery<br />
formulations and biomaterials. Manufacturing includes microparticles, nanoparticles, liposomes, and resobable implants. Commercial<br />
supply of Lakeshore Biomaterials cGMP poly(lactide-co-glycolide) polymers and contract manufacturing of biodegradable and nonbiodegradable<br />
excipients is available.<br />
BIO Business Forum 2011 354 Participating Company <strong>Profiles</strong>
William Newell<br />
Chief Executive Officer<br />
310 Utah Avenue South<br />
South San Francisco, CA 94080<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Lesley A. Stolz<br />
William J. Newell<br />
Sutro Biopharma, Inc<br />
www.sutrobio.com<br />
Phone: 1-650-392-8412<br />
Incorporated: 2003<br />
Employees: 34<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Sutro Biopharma discovers and develops a new generation of protein therapeutics with improved properties utilizing a proprietary<br />
technology to introduce non-natural amino acids providing either a handle for designer modifications or unique adjustments to active<br />
site and binding regions to dial in desired properties. The company’s scalable cell-free protein synthesis gives unprecedented access to a<br />
broad range of non-natural amino acids in a manner that allows for rapid entrance into a world of proteins of interest followed by<br />
virtually guaranteed ability to scale to desired amounts for in-vivo, clinical and commercial applications with a speed that has never been<br />
imagined in the biopharmaceutical industry.<br />
PROPRIETARY TECHNOLOGY<br />
The basis of Sutro's technology is its scalable cell free protein synthesis technology which has proven to be versatile in its ability to enable<br />
the synthesis of complex eukaryotic proteins rapidly. The technology allows us to go from DNA template to protein in days. The<br />
adaptation of the technology to the incorporation of non-natural amino acids is proving to be just as versatile with the ability to<br />
incorporate amino acids of almost any type into the protein of interest in a site specific manner.<br />
CORPORATE ALLIANCES<br />
The company has been and is currently collaborating with multiple large pharmaceutical companies; however, the identity of the partners<br />
in these relationships have not been disclosed.<br />
SENIOR MANAGEMENT<br />
William Newell, Chief Executive Officer • Lesley Stolz, PhD, Vice President • Trevor Hallam, PhD, Chief Scientific Officer • Henry<br />
Heinsohn, Vice President • Christopher J. Murray, PhD, Vice President<br />
BIO Business Forum 2011 355 Participating Company <strong>Profiles</strong>
Kennet Rooth<br />
Chief Executive Officer<br />
Tomtebodavägen 23A<br />
11276 Stockholm<br />
Sweden<br />
CONFERENCE PARTICIPANTS<br />
Peter Selin, Business Development Director<br />
Christina Herder , PHD, Director, Business Development<br />
HIGHLIGHTS<br />
Recent<br />
Swedish Orphan Biovitrum<br />
Clinical Foci: Hematology • AutoImmune • Metabolic Disease<br />
www.sobi.com<br />
Phone: 46-8-697 2000<br />
Incorporated: 2001<br />
Employees: 500<br />
Ownership: Public<br />
Market Cap: $700.00 million<br />
STOCKHOLM STOCK EXCHANGE: STO:SOBI<br />
Sobi agrees with Fresenius Biotech to distribute Removab in 15 European countries.<br />
Sobi signs distribution agreement with BL&H for South Korea.<br />
Sobi's long lasting Hemophilia A therapy receives Orphan Drug Designation in the US (collaboration project with Biogen Idec).<br />
CORPORATE MISSION<br />
Swedish Orphan Biovitrum (Sobi) is a Swedish based pharmaceutical company with an international market presence. The product<br />
portfolio consists of several orphan and specialty pharmaceutical products. Sobi has an emerging late stage clinical development orphan<br />
and specialty pharmaceutical pipeline. Sobi's focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer<br />
and inherited metabolic disorders.<br />
Sobi has a pan-European commercial organization, an emerging organization in North America, and partners in the Middle East and Asia.<br />
The organization possesses a high level of expertise and resources within all areas of the value chain, from pre-clinical research and<br />
development, business development and production to market access, marketing, distribution and customer support. Sobi has about 500<br />
employees.<br />
PRODUCTS<br />
Name Phase Indication<br />
Kiobrina (rhBSSL) Phase III Enzyme replacement therapy to improve growth and development in<br />
preterm infants<br />
Kineret (anakinra) On Market Rheumatoid arthritis<br />
Orfadin (nitisinone) On Market Hereditary Tyrosinemia Type 1 (HT-1)<br />
Kepivance (palifermin) On Market Oral Mucositis for Bone Marrow Transplant patients<br />
Multiferon On Market Malignant melanoma<br />
FIX:Fc Phase III Hemophilia B<br />
FVIII:Fc Phase III Hemophilia A<br />
SENIOR MANAGEMENT<br />
Kennet Rooth, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Bo Jesper Hansen<br />
BIO Business Forum 2011 356 Participating Company <strong>Profiles</strong>
Dr Nigel Lindner<br />
Chief Executive Officer<br />
Priory Business Park<br />
Bedford<br />
MK44 3UP<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Swiss Precision Diagnostics<br />
Clinical Foci: Diagnostics • Medical Device • Reproductive<br />
www.swissprecisiondiagnostics.com<br />
Phone: 44-01234-835 472<br />
Adam Hajjar, External Opportunity & Business Intelligence Manager<br />
CORPORATE MISSION<br />
Incorporated: 2007<br />
Employees: 170<br />
Ownership: Private<br />
Swiss Precision Diagnostics (SPD) is an OTC consumer diagnostics company, formed in May 2007 as a 50/50 joint venture (JV) between the<br />
world leading diagnostics and consumer products companies Alere (formerly Inverness Medical Innovations) and Procter & Gamble (P&G).<br />
SPD already maintains a leading position in pregnancy, fertility and contraception related products (sold under the Clearblue, Accu-Clear,<br />
CLEAR PLAN, Fact Plus and PERSONA brands), but is now looking to develop further new innovative consumer diagnostic products for<br />
women's, children's and family health.<br />
SPD's head office is based at P&G's European headquarters in Geneva, Switzerland, with its research and development being carried out at<br />
separate facilities in Bedford, UK (SPD Development Company Ltd) and Shanghai, China (Inverness Medical Shanghai Co Ltd).<br />
PROPRIETARY TECHNOLOGY<br />
Under the terms of the JV, SPD has worldwide rights (for consumer diagnostic product applications) to a large number of diagnostic<br />
related patents held by its parent company Alere, including key patents covering the 'lateral flow' immunoassay technology platform<br />
widely used by the industry for both OTC and Point-of-Care diagnostic products.<br />
SPD also has a portfolio of its own patents covering some of its consumer diagnostic related technologies/products.<br />
CORPORATE ALLIANCES<br />
SPD would be particularly interested to talk to research organisations and companies that have technologies with potential diagnostic<br />
product applications. Examples could include novel sampling/extraction technologies, disease/condition biomarkers, assay reagents,<br />
assay methods, signal creation and detection systems, as well as alternative diagnostic technology platforms.<br />
SPD would also be interested to talk to companies that have consumer diagnostic technologies/products that need further development<br />
and/or that could be sold by SPD through its parent company P&G's extensive worldwide sales and distribution networks.<br />
INTELLECTUAL PROPERTY<br />
SPD has worldwide rights (for consumer diagnostic product applications) to a large number of diagnostic related granted patents and<br />
pending applications held by its parent company Alere, as well as having its own portfolio of pending applications and granted patents<br />
covering some of its consumer diagnostic technologies/products.<br />
FINANCING HISTORY<br />
Investors: Alere Inc (50 %) • Procter & Gamble Co (50 %)<br />
SENIOR MANAGEMENT<br />
Dr Nigel Lindner, Chief Executive Officer • Dr Stewart Wilson, Chief Technology Officer • Mrs Hazel Polka, General Counsel<br />
BIO Business Forum 2011 357 Participating Company <strong>Profiles</strong>
Olivier Rickmers<br />
Chief Executive Officer<br />
Route de l'Ile-au-Bois 1A<br />
CH-1870 Monthey Valais<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Olivier Rickmers, CEO<br />
Massimo Nobile, Business Development Manager<br />
Laurent Michel, Project Manager<br />
Freddy Boehmwald, Research Manager<br />
Swissaustral Biotech SA<br />
Clinical Foci: Industrial Biotech • Biology • Service<br />
www.swissaustral.ch<br />
Phone: 41-24-4710494<br />
Incorporated: 2009<br />
Employees: 5<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
With more than 50 new organisms isolated every year in various extreme habitats, our collection is permanently growing and the isolates<br />
are routinely screened for the qualitative presence of different enzymatic activities or other biocompounds.<br />
CORPORATE MISSION<br />
Swissaustral Biotech SA is a worldwide specialist in Extreme Biotechnology developing innovative solutions for non standard<br />
technological challenges in Life Sciences and Industry. Our company exploits the potential of Extremophiles, high-performance<br />
enzymes, ultrastable biocompounds, and unexplored metabolic pathways as a unique and diverse natural resource for industrial<br />
applications. As a key for your success, Swissaustral offers: - Access to Extreme Diversity, with a large and growing proprietary<br />
collection of unique extremophilic microorganisms available. - Highly Specialized Research Services related to “Extreme” Biotechnology,<br />
with a unique know-how and research capabilities available to you. - Specialized Enzymes and Biomolecules, including enzymes<br />
working in harsh industrial conditions, as well as Biostabilizers, pigments and antioxidants.<br />
PROPRIETARY TECHNOLOGY<br />
Following the principle “From the Sample to the Product”, our R&D is focused on: - A proprietary collection of unique extremophiles -<br />
Sampling of extreme biohabitats - Growth media development for isolating and culturing novel extremophiles - Biocatalysis with<br />
"extremophilic" enzymes, ranging from discovery up to complete enzyme purification and cloning - Discovery/development of other types<br />
of special bio-compounds such as bio-stabilizers, biopolymers, pigments, and antioxidants.<br />
CORPORATE ALLIANCES<br />
Swissaustral Biotech SA holds the exclusive license for commercialization and further downstream development of the extremophile<br />
biotechnology platform of Foundation Biociencia, a research institute located in Chile, pioneer in extremophiles R&D.<br />
PRODUCTS<br />
Name Phase Indication<br />
Targeted Research Services related to<br />
"Extreme" Biotechnology<br />
On Market Access to Extreme Biodiversity, Assay Development and Screening, Isolation,<br />
Purification, and Characterization of Enzymes and Biomolecules, Technical<br />
Support and Consulting, Bioprospection and Microbiological Assessment on<br />
Site<br />
Ectoin Research Biostabilizer<br />
Specialized Enzymes "Extremozymes" Research Ultrastable, performant<br />
Carotenoids and Violacein Research Pigments, Antioxidants<br />
Nanoparticles Research Different sizes and shapes<br />
Collection of extremophiles On Market novel metabolic tools and pathways<br />
FINANCING HISTORY<br />
Investors: Jenny Blamey (30 %) • Olivier Rickmers (30 %) • Other Investor (30 %)<br />
SENIOR MANAGEMENT<br />
Olivier Rickmers, Chief Executive Officer • Jenny Blamey, Chief Scientific Officer<br />
BIO Business Forum 2011 358 Participating Company <strong>Profiles</strong>
Colin MacKay<br />
Chief Executive Officer<br />
Unit 10, Scion House<br />
Stirling<br />
FK9 4NF<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
John Porter, Business Development Director<br />
Colin Mackay, Chief Executive<br />
Symbiosis Pharmaceutical Services<br />
Clinical Foci: Service • Oncology • Biopharmaceuticals<br />
Phone: 44-07703-194 351 Incorporated: 2010<br />
Employees: 5<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Symbiosis is building a world-class sterile fill/finish capability in the heart of Scotland. We are building on the expectations and views of<br />
our clients. Symbiosis will manufacture liquid and lyophilised drug product for clinical trials. Expertise includes manufacture of biologic<br />
and small molecule drugs with specialist handling capability for cytotoxic and highly potent drugs.<br />
SENIOR MANAGEMENT<br />
Colin MacKay, Chief Executive Officer • Dr John Porter, Director • Murray McKay, Director • Simon Bath, Director • Dr Howard<br />
Marriage, Chairman<br />
BIO Business Forum 2011 359 Participating Company <strong>Profiles</strong>
Kristen Drejer, PhD<br />
Chief Executive Officer<br />
Elektrovej Building 375<br />
DK2800 Lyngby<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Jette Asboe Lassen<br />
Gayle M. Mills, MBA<br />
Kirsten Drejer, PhD<br />
Symphogen, A/S<br />
Clinical Foci: Oncology • Infectious Disease • Hematology<br />
www.symphogen.com<br />
Phone: 45-45-265050<br />
Incorporated: 2000<br />
Employees: 80<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Initiation of Phase 1b study of SYM004 (Anti-EGFr) in Colorectal Completion of SYM001 Phase 2 study<br />
Cancer Patients<br />
Completion of SYM004 Phase Ib/2 studies<br />
Closing of 100 million euro financing<br />
Additional publications and key industry presentations supporting<br />
Reacquisition of full development rights for SYM001 (ITP)<br />
the mechanism of action and utility of SYM001 (ITP) and SYM004<br />
(Anti-EGRr)<br />
CORPORATE MISSION<br />
Symphogen is developing superior antibody mixture therapeutics to treat cancer and infectious diseases. With its proprietary, unique<br />
Symplex discovery, SymSelect lead selection and Sympress manufacturing platforms, the company captures the diversity and<br />
specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a<br />
diversified pipeline of internal and partnered products across multiple indications.<br />
PROPRIETARY TECHNOLOGY<br />
Symphogen has developed an integrated platform for discovery, lead generation and manufacturing of antibody therapeutics:<br />
*Symplex generates recombinant and target specific antibodies which reflect the diversity, affinity, selectivity and safety profile of<br />
naturally occuring antibodies. This automated process rapidly generates large repertoires of high-quality antibodies.<br />
*SymSelect is a high throughput method to rationally test and rank thousands of antibody mixtures with regard to their biological<br />
activity.<br />
*Sympress uses a proprietary mammalian expressional platform enabling consistent, reproducible single-batch manufacture of<br />
recombinant polyclonal antibodies.<br />
CORPORATE ALLIANCES<br />
Meiji Pharmaceuticals: Development & License Agreement for a recombinant antibody mixture product candidate against an undisclosed<br />
bacterial target.<br />
Genentech: Development & License Agreement for development of antibody therapeutics against three undisclosed infectious disease<br />
targets.<br />
INTELLECTUAL PROPERTY<br />
Symphogen has a broad set of filed and issued patents covering the Symplex, SymSelect and Sympress technologies.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
SYM001 Anti-Rhesus D Antibody<br />
Mixture<br />
Phase II, IIa, IIb Immune Thrombocytopenia Purpura<br />
(ITP)<br />
Completion of Phase II Study in ITP<br />
Patients<br />
SYM004 Anti-EGFr Phase II, IIa, IIb Cancer Completion of Efficacy Study in Cancer<br />
Patients<br />
SYM005 her-2 Research Cancer<br />
Various RTK Programs Research Cancer<br />
SENIOR MANAGEMENT<br />
Kristen Drejer, PhD, Chief Executive Officer • Thomas Felthus, Chief Financial Officer • Ivan Horak, Chief Medical Officer • Gayle M<br />
Mills, Chief Business Officer • Torben Frandsen, Vice President<br />
BOARD OF DIRECTORS<br />
Goran Ando, ex-Celltech, Pharmacia • Samuel Broder, ex-NCI, Celera • John B. Landis, ex-Schering-Plough • Jeppe Christiansen, CEO<br />
LD Invest A/S • Tom Bork Petersen, IP/Life Science Group, Norrbom Vinding • Ian Nicholson, CEO, Chroma Therapeutics • Jeff<br />
Himawan, Essex Woodlands • Kirsten Drejer, CEO, Symphogen<br />
BIO Business Forum 2011 360 Participating Company <strong>Profiles</strong>
SCIENTIFIC ADVISORY BOARD<br />
James Marks, MD, PhD, UCSF • Daniel Levitt, MD, PhD, CMO Dynavax • Stanley Falkow, PhD, Stanford • Harry Greenberg, MD,<br />
Stanford • Ron Levy, MD, Stanford • Henrik Rassmussen, MD, PhD, Consultant<br />
BIO Business Forum 2011 361 Participating Company <strong>Profiles</strong>
Pierre Warffemius MBA<br />
Chief Executive Officer<br />
Paasheuvelweg 30<br />
1105 BJ Amsterdam<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Djamel Deken<br />
Marcel Thalen<br />
Synco Bio Partners B.V.<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Biodefense<br />
www.syncobiopartners.com<br />
Phone: 31-20750-3606<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
SynCo Bio Partners to manufacture Syntaxin’s SXN101959 novel<br />
drug for treatment of Acromegaly<br />
SynCo Bio Partners finalized the Process Conformance lots for two<br />
products in 2010 for market registration in the US<br />
Incorporated: 2000<br />
Employees: 125<br />
Ownership: Private<br />
SynCo Bio Partners expects 1 FDA PAI in 2011, 3 FDA PAIs in 2012<br />
and 1 FDA PAI in 2013<br />
CORPORATE MISSION<br />
SynCo Bio Partners B.V. is a biopharmaceutical GMP Contract Manufacturing Organization located in Amsterdam, the Netherlands,<br />
licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products. As a truly global player, SynCo<br />
offers a fully integrated range of biopharmaceutical development and manufacturing services supporting small biotech to large<br />
pharmaceutical organizations worldwide from the earliest stages in process development, through pre-clinical and clinical trials, biologic<br />
license approval and market supply.<br />
SynCo’s product dedicated facilities offer batch and campaign manufacturing with up to 1,500L microbial fermentation capacity,<br />
mammalian and virus production suites, aseptic fill/finish and lyophilisation up to 20,000 vials per batch. As a privately owned,<br />
financially stable and independent company, SynCo is one of the few CMOs with an established track record and in a position to support<br />
long term strategic manufacturing relationships.<br />
SynCo can assist its customers with:<br />
- process development of microbial and mammalian produced products<br />
- analytical development<br />
- consultation on process and analytical development<br />
- technology transfer and scale-up from lab to clinical and commercial production scale<br />
- pre-clinical manufacturing (toxicology batches)<br />
- clinical manufacture for all phases<br />
- market supply manufacturing<br />
- aseptic filling and lyophilization<br />
- stability studies<br />
- process validation<br />
- regulatory support.<br />
By selecting SynCo Bio Partners as your Bulk Drug Substance and/or Drug Product contract manufacturing partner, you will benefit from<br />
over 10 years of biopharmaceutical manufacturing experience for both clinical and commercial supply of vaccines and biotherapeutics.<br />
Over the years SynCo has assisted more than 50 companies with their process development, GMP manufacturing and aseptic filling needs,<br />
on route to the market.<br />
CORPORATE ALLIANCES<br />
Publically announced<br />
Novartis - manufacture of 2 x commercial APIs,<br />
Cleveland Biolabs - manufacture of radioprotectant for defence<br />
use,<br />
HAL - filling of commercial allergy products,<br />
Oncomed - filling of antibodies for Phase I and II clinical trials,<br />
FINANCING HISTORY<br />
Investors: William Rutter (100 %)<br />
Versartis - process development, manufacture and filling of two<br />
different fusion protein products,<br />
Syntaxin - manufacture and filling of protein,<br />
Actogenix - manufacture and filling of live biotherapeutic.<br />
Including many other companies which have not been publically<br />
announced.<br />
BIO Business Forum 2011 362 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Pierre Warffemius MBA, Chief Executive Officer • Richard van Rijnsoever, Director • Paul Ives PhD, Director • Rob Sprenkels, Director<br />
• Sandra Verhaagh PhD, Director<br />
BIO Business Forum 2011 363 Participating Company <strong>Profiles</strong>
Mr. Peter Bains<br />
Chief Operating Officer<br />
Biocon Park Plot#2 &3<br />
Karnataka 560099<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Nita Roy, Research Director, Biology<br />
Sivaram Venkat, General Manager, Business Development<br />
Syngene International Ltd<br />
Clinical Foci: Drug Discovery • Drug Development • Service<br />
www.syngeneintl.com<br />
Phone: 91-080-2808 2808<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Syngene was declared as Best Bioservices company in India<br />
consecutively 2007, 2008 & 2009 in a survey conducted by<br />
BioSpectrum - a leading biopharmaceutical magazine in India.<br />
Incorporated: 1994<br />
Employees: 1500<br />
Ownership: Private<br />
Syngene is planning to make additional investments to the tune of<br />
over $ 10 Mn in creating new infrastructure and additional<br />
capabilites in biologics, drug discovery and development.<br />
CORPORATE MISSION<br />
Syngene International Ltd., a wholly owned subsidiary of Biocon, is an internationally reputed contract research and manufacturing<br />
organization with multidisciplinary skills in chemistry, biology, pre-clinical, biologics and formulation development. We provide<br />
customized services to pharmaceutical and biotechnology majors, from early stage discovery and process development through to cGMP<br />
manufacturing, on a strong platform of confidentiality and intellectual property protection. Our highly experienced scientists and strong<br />
project management team together ensures the timelines, quality standards, consistent review and interaction with the clients’. We<br />
provide state-of-the-art research facilities certified with ISO 9001: 2008, ISO 14001:2004, OHSAS 18001:2007, National and German GLP<br />
Federal Bureau Certified and AAALAC accredited animal lab research facilities. Over the past 17 years, we have successfully partnered from<br />
startup companies to Big Pharmas, offering a wide range of challenging services and collaborating on discovery programs, both in the<br />
large and small molecule space.<br />
CORPORATE ALLIANCES<br />
BMS: FTEs for Discovery, Libraries, Process, AI Manufacturing Merck: FTEs for Discovery, Custom Manufacturing<br />
DuPont: Research alliance with DuPont in Discovery<br />
Creative Antibiotics: Development and manufacturing of virulence blockers to counteract bacterial diarrhoeal disease<br />
Endo Pharmaceuticals: Discovery and Development of novel biological therapeutic molecules against cancer<br />
INTELLECTUAL PROPERTY<br />
Syngene being a Contract Research Organization assigns all the IP generated to its partners.<br />
SENIOR MANAGEMENT<br />
Mr. Peter Bains, Chief Operating Officer • Mr. M B Chinappa, Chief Financial Officer • Dr. Manoj Nerurkar, Vice President • Dr. Nita<br />
Roy, Director • Dr. Dhananjay Patankar, Vice President • Mr. Sivaram V, Business Development<br />
BOARD OF DIRECTORS<br />
Dr. Kiran Mazumdar Shaw, Biocon Ltd. • Dr. Kiran Mazumdar Shaw, Biocon Ltd. • Dr. Neville Bain, Chairman, Institute of Directors, UK<br />
• Prof. Charles L. Cooney, Professor, Chemical & Biochemical • Dr. Bala S. Manian, Chairman and Founder, Reametrix Inc • Mr. Suresh<br />
Talwar, Partner, Talwar Thakore & Associates • Mr. Peter Bains, COO of Syngene International Limited • Mr. John Shaw, Vice Chairman,<br />
Biocon • Prof. Ravi Mazumdar, University Research Chair Professor, University of Waterloo, Canada • Mr. Russell Walls, Additional<br />
Director, Biocon<br />
BIO Business Forum 2011 364 Participating Company <strong>Profiles</strong>
Ute Steinbusch<br />
Managing Director<br />
Dennewartstraße 25-27<br />
52477 Aachen<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Ute Steinbusch<br />
HIGHLIGHTS<br />
Recent<br />
Syntab Therapeutics<br />
Clinical Foci: Drug Development • Oncology<br />
www.syntab-therapeutics.com<br />
Phone: 49-241-9631555<br />
Ownership: Private<br />
Syntab Therapeutics offers "me-too-but-synthetic" APIs combining the advantages of monoclonal antibodies and small molecules. Our<br />
products are fully chemically synthesized.<br />
Syntab Therapeutics’ lead synthetic antibody candidate, yet in preclinical development, is applied in cancer therapy. Its target structure is<br />
the epidermal growth factor receptor (EGFR).<br />
CORPORATE MISSION<br />
Syntab Therapeutics is doing research and development of innovative pharmaceuticals. The company strives for early out-licensing of<br />
product candidates after completion of preclinical development.<br />
PROPRIETARY TECHNOLOGY<br />
Syntab Therapeutics owns a proprietary technology platform for the development and production of synthetic antibodies. The technology<br />
platform enables the company to synthesize highly effective drugs against cancer and other diseases. These drugs show the positive<br />
effects of monoclonal antibodies (high specificity for the target molecule, activation of the immune system), but they are much smaller<br />
and simpler in manufacturing.<br />
INTELLECTUAL PROPERTY<br />
Syntab's technology platform is broadly patented. It enables Syntab Therapeutics to identify and develop drug candidates on its own or<br />
with the help of partner companies.<br />
PRODUCTS<br />
Name Phase Indication<br />
SAB-Y1 Preclinical oncology<br />
SENIOR MANAGEMENT<br />
Ute Steinbusch, Managing Director<br />
BIO Business Forum 2011 365 Participating Company <strong>Profiles</strong>
Bruno Tillier<br />
Chief Executive Officer<br />
5 avenue du Grand Sablon<br />
38700 LA TRONCHE<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Bruno Tillier<br />
CORPORATE MISSION<br />
Synthelis<br />
Clinical Foci: Service • Drug Development • Biopharmaceuticals<br />
www.synthelis.com<br />
Phone: 33-4-76549537<br />
Incorporated: 2011<br />
Employees: 6<br />
Ownership: Private<br />
Synthelis is a young start-up company providing a solution to a well known challenge in terms of biotechnological production, namely the<br />
development, characterization and production of customized membrane proteins and associated service offerings.<br />
The technology at the heart of the Synthelis offering originates from the University Joseph Fourier’s and the company started its life in<br />
commercial terms as a Business Unit of Floralis (the UJF’s technology transfer subsidiary) in 2008 before recently spinning off as a<br />
company.<br />
The company is also working on its own R&D programs with a view to developing innovative therapeutic and vaccine approaches.<br />
Synthelis intends to develop therapeutic proteoliposomes until stage I clinical trial and to then out-license these products to<br />
pharmaceutical companies capable of further developing these biopharmaceuticals.<br />
Synthelis is already working with a variety of big pharma clients, proof in itself of the quality and the potential that they see in the<br />
company’s offering.<br />
Synthelis has won three important awards for innovation including the Credit Agricole Innovation Award organized by the Grenoble<br />
School for Management, followed by the Emergence category of the national OSEO award for new businesses in 2009 and a second OSEO<br />
prize in the “Creation-Development” category in 2010.<br />
PROPRIETARY TECHNOLOGY<br />
The Synthelis technology is based on a cell-free system using cell extracts optimized to specifically express membrane proteins. This<br />
patented system has been already used to successfully produce more than 50 membrane proteins (GPCR, ion channels, human, bacterial<br />
and plant porins and also proteins from viral envelopes) with structure and functionality preserved.<br />
INTELLECTUAL PROPERTY<br />
A French patent application was filed on April 26, 2007 under number FR 07.54701 to protect the technology and its applications. An<br />
international application was filed in April 2008 under the priority of the above-mentioned French patent application. The patent<br />
application is currently in the national and regional phases in EU, US, CA, JP and AUST.<br />
PRODUCTS<br />
Name Phase Indication<br />
LipoBak Preclinical Anti-Glioblastoma<br />
SENIOR MANAGEMENT<br />
Bruno Tillier, Chief Executive Officer • Jean-Luc Lenormand, Chief Scientific Officer • Dr Bruno Marques, Chief Technology Officer •<br />
Remy Beroud, Business Development • Floralis - UJF Filiale, Executive Partner<br />
SCIENTIFIC ADVISORY BOARD<br />
Pr Jean-Luc Lenormand, University of Grenoble • Pr Don Martin, University of Technology, Sydney • Pr Benoit Polack, Hospital of<br />
Grenoble / University of Grenoble • Pr Bertrand Toussaint, Hospital of Grenoble / University of Grenoble • Pr Emmanuel Drouet,<br />
University of Grenoble<br />
BIO Business Forum 2011 366 Participating Company <strong>Profiles</strong>
Chandler D. Robinson<br />
Chief Executive Officer<br />
1007 Church Street, Suite 307<br />
Evanston, IL 60201<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Chandler D. Robinson, CEO<br />
HIGHLIGHTS<br />
Recent<br />
Tactic Pharma, LLC<br />
Clinical Foci: Oncology • CNS • None<br />
Phone: 1-847-733-0940 Ownership: Private<br />
With ATN-658, we recently received a very large grant from the NCI NExT program because of intriguing preclinical data this antibody has<br />
for pancreatic and ovarian cancer. NCI is paying for its development through Phase II on a milestone basis.<br />
CORPORATE MISSION<br />
Tactic Pharmaceuticals acquires and develops pre-clinical and clinical stage compounds. Tactic currently has three development stage<br />
compounds in its portfolio: ATN-161, ATN-224, and ATN-658.<br />
PROPRIETARY TECHNOLOGY<br />
ATN-658 is a monoclonal antibody about to enter Phase I with intriguing data in pancreatic and ovarian cancer.<br />
ATN-291 is a monoclonal antibody which gets internalized into certain cancer cells. We have completed antibody-doxorubicin-conjugate<br />
studies showing ATN-291 has potential as a platform for antibody-drug conjugates.<br />
ATN-161 an integrin inhibitor peptide in Phase II with potential in head and neck cancer as well as glioblastoma multiforme.<br />
INTELLECTUAL PROPERTY<br />
We have composition of matter patents already approved for some, and currently in prosecution for others.<br />
PRODUCTS<br />
Name Phase Indication<br />
ATN-658, a monoclonal antibody to uPAR IND Filed pancreatic cancer, ovarian cancer<br />
ATN-291, a monoclonal antibody that gets<br />
internalized into certain cancer cells<br />
Preclinical Antibody-drug-conjugate platform for cancer<br />
ATN-161, integrin inhibitor peptide Phase II, IIa, IIb Head and Neck cancer, Glioblastoma Multiforme, pancreatic cancer<br />
SENIOR MANAGEMENT<br />
Chandler D. Robinson, Chief Executive Officer • Andrew P. Mazar, Chief Scientific Officer • Tom O'Halloran, Director<br />
BIO Business Forum 2011 367 Participating Company <strong>Profiles</strong>
Lee, Tae Young / Lee, Joon Youb<br />
Chief Executive Officer<br />
657-87 Hannam-dong Yongsan-gu<br />
Seoul 140-210<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Tae-Soo Won<br />
Sung Won Moon<br />
Taejoon Pharm<br />
Clinical Foci: Ophthalmic • Gastroenterology • Cardiovascular Disease<br />
www.taejoon.co.kr<br />
Phone: 82-2-799 0150<br />
Incorporated: 1978<br />
Employees: 400<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Taejoon signed a supply agreement of Xalost (latanoprost ophthalmic solution) for EU markets in 2007 and became the first company<br />
which exports ophthalmic product to EU countries in Korea.<br />
Taejoon contracted an in-license agreement on oral dissolving tablet of Lansoprozole with Salvat S.A. in 2010.<br />
CORPORATE MISSION<br />
TAEJOON PHARM Co., LTD is much interested in in-licensing innovative and superior products which are related to the field of ophthalmic<br />
agents, contrast media, and gastrointestinal agents.<br />
TAEJOON PHARM Co., LTD founded in 1978 has grown to become an expert pharmaceutical company with the advanced technology in<br />
ophthalmic agents and contrast media and the resources have made endless endeavor on research & development.<br />
Taejoon produces and supplies indispensible medicines closely associated with national health, such as mainly ophthalmic medicines,<br />
contrast media, and gastrointestinal medicines. Especially, we have taken a lead in the ophthalmic field of the domestic pharmaceutical<br />
industry by manufacturing the highest quality of products. In addition, we have been exporting ‘Xalost ophthalmic solution’ which is<br />
indicated for glaucoma to several EU countries and will continue to expand exporting products through quality improvement.<br />
Now, Taejoon has tried its utmost effort for the continual improvement of its research ability by leading the creation of advanced<br />
pharmaceutical business through collaboration with global pharmaceutical companies.<br />
Based on these, Taejoon is trying to leap again for the goal of "Bio Tech Company based on R&D in 2020", "Global Pharmaceutical Company<br />
in specialized area in 2030". To achieve these goals, long term visions are being established and actualized under the company slogan,<br />
'Company, always devoting".<br />
We will never slow down developing to be the reliable health provider by constantly making efforts on research and we will keep our<br />
innovative and creative Entrepreneurship by consistantly challenging. Again, Taejoon will fulfill the mission that it will do its best to meet<br />
customers' needs.<br />
PROPRIETARY TECHNOLOGY<br />
Taejoon obtained the certificate of EU GMP for sterile ophthalmic solution, and its proprietary technology provides the highest<br />
convenience for treating ophthalmic diseases.<br />
CORPORATE ALLIANCES<br />
Senju in Japan, Santen in Japan, Nippon Shinyaku in Japan, Salvat in Spain<br />
PRODUCTS<br />
Name Phase Indication<br />
Hyalein ophthalmic solution (sodium<br />
hyaluronate)<br />
Flumetholon ophthalmic solution<br />
(fluorometholone)<br />
On Market Dry eye syndrome<br />
On Market Inflammatory disease<br />
Xalost ophthalmic solution (latanoprost) On Market Glaucoma<br />
Cravit ophthalmic solution (levofloxacin) On Market Inflammatory disease<br />
Combisopt ophthalmic solution<br />
(dorzolamide+timolol)<br />
On Market Glaucoma<br />
Iobrix (Iohexol) On Market Contrast medium for angiography<br />
Iosense (Iodixanol) On Market Nonionic dimeric iodinated radiographic contrast medium<br />
MRBester (gadopentetate dimeglumine) On Market contrast medium in magnetic resonance imaging<br />
Gaslon N tablet (irsogladin maleate) On Market 1.Peptic ulcer, 2.Improvement of gastric mucous membrane lesion for<br />
acute and chronic gastritis<br />
Lamina-G solution (sodium alginate) On Market 1.Peptic ulcer, 2.Improvement of gastric mucous membrane lesion for<br />
acute and chronic gastritis<br />
BIO Business Forum 2011 368 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Lee, Tae Young / Lee, Joon Youb, Chief Executive Officer • Won, Tae Soo, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Lee, Tae Young<br />
BIO Business Forum 2011 369 Participating Company <strong>Profiles</strong>
Ming-Chu Hsu, PhD<br />
Chief Executive Officer<br />
7F, 138 Shin Ming Road, Neihu District<br />
Taipei 11470<br />
Taiwan<br />
CONFERENCE PARTICIPANTS<br />
John Fenyu Jin, Vice President, Business Development<br />
TaiGen Biotechnology Company, Ltd<br />
Clinical Foci: Infectious Disease • Hematology • Oncology<br />
www.taigenbiotech.com<br />
Phone: 886-2-8177 7072<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
On Oct 14, 2010, TaiGen Biotechnology amended its license agreement with Warner<br />
Chilcott plc, thereby WC acquired Nemonoxacin rights for US/EU/Japan based on the<br />
exceptional clinical outcome of 2 phase II trials in CAP and DFI.<br />
In March 2010, TaiGen Announced Nemonoxacin (TG-873870) Once-A-Day Oral<br />
Dosing in Diabetic Foot Infection Met Primary Endpoints and Showed Promising<br />
Anti-MRSA Activity and Excellent PK Profile in a Phase II Proof of Concept trial.<br />
In December 2009, TaiGen initiated a randomized, open-label, multi-center Phase II<br />
study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell<br />
mobilization of TG-0054 in patients with Multiple Myeloma, NHL or Hodgkin<br />
Disease.<br />
Incorporated: 2001<br />
Employees: 86<br />
Ownership: Private<br />
Completion of Nemonoxacin Phase III clinical trial<br />
in Commnity-acquired pneumonia (CAP) in China<br />
and Taiwan and submit NDA.<br />
Completion of Phase II study of TG-0054 in Stem<br />
Cell Transplantation patients. Initiation of trials<br />
in ischemic tissue repair and chemosensitization.<br />
Initiation of global Phase I study for TG-2349, a<br />
HCV protease inhibitor.<br />
CORPORATE MISSION<br />
Founded in 2001 and backed by well-known venture capital investors, TaiGen Biotechnology is a research-based and product-driven<br />
biotechnology company engaging in the development of novel therapeutics in the field of infectious diseases, cancer and cardiovascular<br />
diseases. TaiGen has built a fully-integrated drug development platform that capitalizes on the senior management team's expertise in<br />
drug discovery, development, global regulatory approval, and commercialization in China. The company focuses on in-licensing innovative<br />
programs targeting Asian-prevalent diseases to complement its internal pipeline, as well as partnering its own drug programs for global<br />
markets. TaiGen is headquartered in Taipei, Taiwan with 90 FTEs including 70 R&D staff, and has a wholly-owned Beijing China subsidiary.<br />
TaiGen's pipeline includes three "first-in-class" or "best-in-class" programs. Nemonoxacin is an once-a-day, novel non-fluorinated<br />
quinolone in both oral and IV formulation with a broad spectrum of anti-gram-positive and -negative bacteria, as well as MRSA, QRSA and<br />
VRSA activities. It has completed Phase II studies in Community-Acquired Pneumonia and Diabetic Foot Infection under a US IND and is in<br />
Phase III studies under China INDs.<br />
TG-0054 is a potent and selective chemokine receptor CXCR4 antagonist with therapeutic potential for stem cell transplantation, chemosensitization,<br />
and ischemic tissue repair. TG-0054 demonstrated excellent safety and PK/PD data in phase I and has entered phase II for<br />
stem cell transplantation in cancer patients. TG-0054 has shown promising data in animal models for chemo-sensitization and acute<br />
myocardial infarction. TaiGen is seeking a global development and commercialization partner(s).<br />
TG-2349, a HCV NS3-4A Protease Inhibitor, has demonstrated best-in-class potential with once-daily dosing, superior anti-viral activity and<br />
improved safety profile. TaiGen filed an US FDA IND in April 2011 and PhaseI/IIa trial is targeted for 2H2011.<br />
PROPRIETARY TECHNOLOGY<br />
1. TaiGen carries out innovative R&D at low cost and with high efficiency and develops first-in-class or best-in-class NCEs with worldwide<br />
IP protection.<br />
2. TaiGen achieves sustained growth driven by global vision and strategy: 1) Parallel in-license and internal discovery for Asian and global<br />
markets; 2) Perform multi-national trials under US IND authority; 3) Perform clinical trials under Chinese IND authority using Subsidiary in<br />
Beijing; and 4) Provide a platform for US/EU companies to develop and market products in China; and 5) Risk and reward sharing through<br />
alliances and partnering.<br />
CORPORATE ALLIANCES<br />
In Aug. 2010, TaiGen amended Global License Agreement with Warner Chilcott for Development and Commercialization of Nemonoxacin,<br />
under which, Warner Chilcott retains development and commercialization rights in the non-TaiGen territory. TaiGen received an upfront<br />
payment from Warner Chilcott and is eligible for certain regulatory milestone payments, as well as a royalty on net sales.<br />
In Dec, 2004, TaiGen signed a licensing agreement with P&G and obtained exclusive development and commercialization rights to<br />
Nemonoxacin in Asia including China and Korea. TaiGen became responsible for the conduct of a Phase Ib and two Phase II trials in CAP<br />
and DFI. Upon its purchase of the drug business of P&G in 2009, Warner Chilcott assumed P&G’s interest. TaiGen has since completed the<br />
clinical trials.<br />
INTELLECTUAL PROPERTY<br />
TaiGen files and owns worldwide IP rights for all of its internally developed programs.<br />
BIO Business Forum 2011 370 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Nemonoxacin Phase III Community Acquired Pneumonia; Diabetic Foot<br />
Infection, Hospital Acquired Pneumonia;<br />
Complicated Skin and Skin Structure Infection.<br />
TG-0054: CXCR4 Antagonist Phase II, IIa, IIb Stem cell transplantation, Chemosensitization,<br />
Ischemic Tissue Repair in Acute Myocardiac<br />
Infarction<br />
NDA Filing of Nemonoxacin in<br />
Greater China<br />
Completion of Phase II for Stem<br />
Mobilization in cancer patients.<br />
TG-2349 IND Filed HCV Infection Initiation of Phase I/IIa<br />
FINANCING HISTORY<br />
Most Recent Round: C Round<br />
Round A: 05/01/2001 (US $37.00 million)<br />
Round B: 03/01/2004 (US $38.00 million)<br />
Round C: 02/11/2010 (US $40.00 million)<br />
Investors: MPM Capital (16 %) • YFY Group (19 %) • Development Fund (13 %) • TaiSugar (11 %) • YaoHwa Glass (7<br />
%) • Area Pharmaceuticals (5 %) • China Steel Corp. (5 %)<br />
SENIOR MANAGEMENT<br />
Ming-Chu Hsu, PhD, Chief Executive Officer • John Jin, PhD (Business Development), Vice President • Max Chan, Chief Financial<br />
Officer • Richard King, PhD (Research), Senior Vice President • David Chung, MD (Clinical Development), Vice President • Yi-Jong Lin,<br />
PhD (Regulatory Affairs), Vice President • Philip Huang (GM for China), Vice President • Joseph Hsueh (Operation), Vice President •<br />
Ada Kung, PhD (Preclinical Development), Senior Vice President<br />
BOARD OF DIRECTORS<br />
Ming-Chu Hsu, PhD, CEO, TaiGen Biotechnology • Michael Steinmetz, PhD, Managing Director, Clarus Ventures • Show-Chung Ho,<br />
Chairman, SinoPac Bank • Steve Lee, Vice President, China Steel Corp. • Jack Lief, CEO, Arena Pharmaceuticals<br />
BIO Business Forum 2011 371 Participating Company <strong>Profiles</strong>
Akira Uehara<br />
Chief Executive Officer<br />
24-1, Takada 3-chome Toshima-ku<br />
Tokyo 170-8633<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Haruhisa Ogita, Assistant Manager<br />
Ryuichi Shoji, Deputy General Manager<br />
Tetsuya Tanikawa, Research Scientist<br />
Hideto Kawano, Manager<br />
Taisho Pharmaceutical Co., Ltd.<br />
Clinical Foci: Infectious Disease • Metabolic Disease • Musculoskeletal<br />
www.taisho.co.jp/en/index.html<br />
Phone: 81-3-3985 1183<br />
Incorporated: 1912<br />
Employees: 5622<br />
Ownership: Public<br />
Market Cap: $6500.00 million<br />
TOKYO STOCK EXCHANGE: 4535<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Approval (Jan 21, 2011) and Launch (April 11,2011) of Edirol* (eldecalcitol), an active Vitamin D3<br />
derivative, in Japan. (Co-Marketing with Chugai)<br />
*Edirol® is a registered trademark of Chugai<br />
FY 2010 Taisho Toyama Pharmaceutical's share of the antibacterial agent market** was 17% in<br />
Japan. (**J01 antibacterial market)<br />
(©2011 IMS Japan, JPM April 2010 ~ March 2011, Unauthorized reproduction prohibited.)<br />
Execution of Agreement to acquire Hoepharma Holdings (Malaysia) shares (2011)<br />
Incorporation of Holding<br />
Company through Sole-Share<br />
Transfer (2011)<br />
We will celebrate 100th<br />
anniversary in 2012.<br />
CORPORATE MISSION<br />
Taisho's corporate mission is to contribute to society by creating and offering superior pharmaceuticals and health-related products as<br />
well as healthcare-related information and services in socially responsible ways that enrich people's lives by improving health and beauty.<br />
Taisho's R&D activity has focused on 3 areas such as CNS, metabolic disease, infection diseases.<br />
PROPRIETARY TECHNOLOGY<br />
Taisho is an originator of Clarithromycin, a macrolide antibiotics.<br />
CORPORATE ALLIANCES<br />
Co-Development: Chugai (CT-064)<br />
Tokuhon (TT-063)<br />
Co-Marketing:Chugai (Edirol)<br />
Out-license:Abbott (Clarithromycin)<br />
Esteve (topical steroid preparation)<br />
BrainCells (new drug candidate for CNS indications)<br />
In-license: Nycomed Austria (lornoxicam)<br />
MIkasa (topical preparation containing felbinac)<br />
Three-way Strategic Alliance: Toyama Chemical, FujiFilm<br />
Joint Venture:Taisho Toyama Pharmaceutical (established with Toyama Chemical)<br />
INTELLECTUAL PROPERTY<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TS-071 Phase II, IIa, IIb type1 &2 diabetes<br />
CT-064 (injection) Phase III Osteoporosis Co-developed with Chugai<br />
NT-072 Phase II, IIa, IIb Bronchial asthma Co-developed with Nissan Chemical<br />
NT-702 Phase II, IIa, IIb Intermittent claudication Co-developed with Nissan Chemical<br />
CT-064 (oral) Phase II, IIa, IIb Osteoporosis Co-developed with Chugai<br />
Palux inj. (injection) Phase II, IIa, IIb new indication for intermittent claudication<br />
BIO Business Forum 2011 372 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
TT-063 Phase II, IIa, IIb Topical plaster formulation containing sflurbiprofen<br />
for OA, etc.<br />
Zosyn On Market Injectable Antibiotic Combination Product<br />
Geninax On Market Oral Quinolone Antimicrobial Agent<br />
Co-developed with Tokuhon<br />
Edirol (eldecalsitol) On Market Osteoporosis Co-marketed with Chugai<br />
SENIOR MANAGEMENT<br />
Akira Uehara, Chief Executive Officer • Sigeru Uehara, Executive Vice President<br />
BOARD OF DIRECTORS<br />
Akira Uehara, Chariman & CEO<br />
BIO Business Forum 2011 373 Participating Company <strong>Profiles</strong>
Keelung Hong, PhD<br />
Chairman<br />
11F-1, 3 Yuanqu Street<br />
Taipei 11503<br />
Taiwan<br />
CONFERENCE PARTICIPANTS<br />
George Yeh, President<br />
Keelung Hong, Chairman & CEO<br />
Taiwan Liposome Company Co., Ltd. (TLC)<br />
Clinical Foci: Drug Delivery • Oncology • Ophthalmic<br />
www.tlcbio.com<br />
Phone: 886-2-2655 7377<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Drug license granted for ProFlow (Improved Prostaglandin E1<br />
emulsion) in Taiwan; ANDA submitted in Japan, China, and to be<br />
submitted in Korea<br />
Bio-IND submitted for Doxisome in the US<br />
Distribution Agreement for ProFlow signed for Japan and Korea<br />
territories<br />
Incorporated: 1997<br />
Employees: 80<br />
Ownership: Private<br />
Establish branch offices in Japan and China<br />
Submit ANDA for Doxisome (generic form of Doxil/Caelyx) and<br />
AmBiL (generic form of Ambisome)<br />
Submit IND for ProDex (Macular Edema)<br />
CORPORATE MISSION<br />
Taiwan Liposome Company (TLC) is a specialty biopharmaceutical company focused on the research, development and commercialization<br />
of pharmaceutical products based on its proprietary drug delivery technologies for improving the treatment of cancers, pheripheral<br />
arterial disease (PAD), ophthalmology and infectious diseases. Our strengths lie in utilizing lipid-based formulation to optimize the<br />
pharmacokinetics for better efficacy and lower toxicity. TLC currently operates from the headquarter in Taiwan with branch offices in the<br />
U.S. and Netherlands.<br />
PROPRIETARY TECHNOLOGY<br />
(1) NanoEmulsion: Patented formulation and manufacturing know-how to stabilize active ingredient in parenteral emulsions<br />
(2) Polymeric Micelle: Nano-sized drug carrier to incorporate high content of water insoluble drugs<br />
(3) NanoX: A proprietary technology for fast and complete drug loading in the new generation of nano-particles<br />
(4) Targeted Delivery: Receptor-targeted nano-particles for intracellular delivery of therapeutics by antibody-mediated or peptidemediated<br />
route<br />
(5) BioSeizer: A lipid-based technology to carry bio-therapeutics or small molecule agents to control the drug releasing profile to reduce<br />
the frequency of administration.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ProFlow® NDA/BLA filed, or in process Peripheral Arterial Disease (PAD), Diabetic<br />
Neuropathy & Ulcers<br />
Lipotecan® Phase II, IIa, IIb Oncology drug Phase II in 2011<br />
AmBiL® Other Systemic fungal infection ANDA in 2012<br />
Doxisome Other AIDS-related Kaposi’s sarcoma, Breast<br />
Cancer, Ovarian Cancer<br />
Drug License granted in Taiwan;<br />
ANDA filed in Japan, China and<br />
to be filed in Korea<br />
ANDA in 2012<br />
ProDex Preclinical Macular Edema IND in 2012<br />
TLC178 Phase II, IIa, IIb NSC lung cancer, breast cancer, colorectal<br />
cancer, Head and Neck cancer<br />
SENIOR MANAGEMENT<br />
Keelung Hong, PhD, Chairman • George Yeh, MBA, President • Yunlong Tseng, PhD, Director<br />
BOARD OF DIRECTORS<br />
Dr. Keelung Hong, Taiwan Liposome Company, Ltd. • Dr. Ann Hanham, Burrill and Company • Dr. Hong-Jen Chang, YFY Biotech<br />
Management Company • Yu-Bei Wang, Nang Kuang Pharmaceutical Co., Ltd. • Thomas H. Bliss, Jr., Ex-Amgen Inc.<br />
BIO Business Forum 2011 374 Participating Company <strong>Profiles</strong>
One Takeda Parkway<br />
Deerfield, IL 60015<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Takeda Pharmaceutical Company<br />
Sponsor, Presenting Company<br />
Clinical Foci: AutoImmune • Metabolic Disease • CNS<br />
www.tpna.com<br />
Phone: 1-224-554-6500<br />
Natalie Mirutenko, PhD, Director, Business Development<br />
Nicholas Manusos, VP, Global Licensing and Business Development<br />
Rosie Gonzalez, Project Coordinator, GLBD<br />
Brent Bankosky, Sr. Director, Global Licensing and Business<br />
Development<br />
John Bathery, Director, Global Licensing<br />
Jill Fischer, PhD, Director, Global Business Development<br />
Joseph Luminiello, VP, Business Development - North and Latin<br />
Americas<br />
Michael Broxson, Sr. Director, Global Licensing and Business<br />
Development - Europe<br />
Dave Brady, VP, Global Licensing and Business Development -<br />
Europe<br />
Nicholas Plumeridge, VP, Global Licensing and Business<br />
Development - Asia<br />
Daaron Dohler, VP, Global Licensing and Strategic Partnering<br />
Catherine Sazdanoff, VP, Global Licensing and Business<br />
Development<br />
Tariq Kassum, Director, Global Business Development<br />
Midori Yokoyama, Director, Global Business Development<br />
Ian Moules, Sr. Director of Business Development - Europe<br />
Brad Scheidhaur, Director, Global Business Development<br />
Ownership: Public<br />
Market Cap: $30800.00 million<br />
TOKYO STOCK EXCHANGE: -4502.T<br />
Marina Balasanov, Project Coordinator, GLBD<br />
Dan Orlando, VP, Business Development - North and Latin Americas<br />
Maria Dzaleta, Sr. Director, Global Licensing and Business<br />
Development - Europe<br />
Bhaskaran Rajendran, Manager, Business Development - Asia<br />
Ronald E. Law, PhD, JD<br />
Thomas Frommel<br />
Tolga Uz, MD, PhD<br />
Masatoyo Kojima<br />
Minori Masago<br />
Takuya Tamatani<br />
Tomoyuki Fujisawa, MBA<br />
Graeme R Martin<br />
Kentaro Hashimoto<br />
Juan M. E. Harrison<br />
Tsuneaki Hida<br />
Yo Omata, Research Alliance Member<br />
CORPORATE MISSION<br />
Takeda continues to accelerate its global pharmaceutical operations by establishing operations in new geographic areas with a focus on<br />
emerging markets, and other countries and regions where high market growth is expected. In the past three years, Takeda established<br />
operations in Canada, Mexico, Brazil, South Korea, Turkey, Spain, Portugal, Belgium, Luxembourg and the Nordics. With significant<br />
commercial offices in Tokyo, Chicago, Boston, London and Singapore, Takeda has created a strong international platform for growth.<br />
Takeda next plans to target Russia, Poland and the CEE and CIS countries. Takeda’s targeted expansion plans in Asia include India and<br />
Australia. Takeda recently established a new sales and marketing company in China which when integrated with the established sales<br />
and marketing operations of Tianjin Takeda will ensure that Takeda is poised for significant expansion in China and North Asia.<br />
In addition to growing its geographic footprint, Takeda is interested in collaborating with external partners to make available products in<br />
established and new therapeutic areas. Specifically, the defined business areas of interest for the Americas, Europe and Asia include<br />
differentiated products in late-stage development as well as marketed products/divestitures. Products with exclusive sales and marketing<br />
rights in China, Thailand, Korea, Australia, Taiwan, Indonesia, Philippines, Singapore, Malaysia and Hong Kong are of interest.<br />
Takeda is also actively seeking new alliances that accelerate the discovery and development process, improve R&D productivity, and<br />
increase the probability of successfully commercializing novel therapeutics and vaccines. Takeda will augment its portfolio through inlicensing<br />
innovative products in these therapeutic areas: Cardiometabolic Diseases, Autoimmune Diseases, Neurological Diseases,<br />
Oncology, Gastrointestinal Disorders and Vaccines.<br />
CORPORATE ALLIANCES<br />
As part of our commitment to bring innovative therapeutics to patients, Takeda continues to partner with biopharmaceutical companies,<br />
institutions and academics. Our creative deal structures are tailored to the needs and ambitions of our partners. Takeda’s alliance<br />
managers are committed to build a strong foundation of trust between the partners in order to advance the mutual goals of the<br />
collaboration. Takeda recently announced collaborations with: AMAG, AMYLIN, AMGEN, AFFYMAX, LUNDBECK, DAINIPPON SUMITOMO and<br />
OREXIGEN.<br />
BIO Business Forum 2011 375 Participating Company <strong>Profiles</strong>
285 E. Grand Avenue<br />
South San Francisco, CA 94080<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Mary Haak-Frendscho, President and CSO<br />
Michael Buckley, Vice President, Process Science<br />
Takeda San Francisco<br />
Sponsor<br />
www.takedasf.com<br />
Phone: 1-650-745-9332<br />
Ownership: Public<br />
Market Cap: $30800.00 million<br />
Tokyo Stock Exchange: -4502.T<br />
CORPORATE MISSION<br />
Takeda San Francisco<br />
Center for Excellence and Therapeutic Antibody IND Engine<br />
Takeda San Francisco, Inc. (TSF) is Takeda's global center for excellence for biologics. TSF was established in 2008 and supports Takeda's<br />
therapeutic antibody research through our antibody technology platform. This platform is based on Ab target discovery and Ab drug<br />
discovery, optimization and non-clinical development technologies used to efficiently generate Investigational New Drug (IND) candidates<br />
for the treatment of cancer, inflammatory and metabolic diseases.<br />
Takeda is also interested in novel biologics and biobetters with marked differentiation that fit with the therapeutic areas of interest, to<br />
include:<br />
Antibody drug conjugate linker systems, payloads and platforms, Technologies that enhance expression, production, formulation, stability<br />
and bioavailability (via SQ admin) of proteins, Bi-specific platforms with promising stability and manufacturing yield, Targeted delivery<br />
technologies that overcome the blood brain barrier or glycan medicated targeting, Fc engineering to improve half-life, effector functions.<br />
With these therapeutic areas, Takeda will consider: Targets with in vivo proof of concept, Molecules with a defined mechanism of action,<br />
Validated Biomarker(s), Technologies with patent protection that provide a competitive advantage, Novel patented chemical or biological<br />
entities or vaccines in discovery and development.<br />
BIO Business Forum 2011 376 Participating Company <strong>Profiles</strong>
Steven R. Deitcher, MD<br />
Chief Executive Officer<br />
2207 Bridgepointe Parkway<br />
San Mateo, CA 94404<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gradon Knotts<br />
CORPORATE MISSION<br />
Talon Therapeutics, Inc<br />
Clinical Foci: Oncology • Hematology • Specialty Pharmaceutical<br />
www.talontx.com<br />
Phone: 1-650-588-6404<br />
Incorporated: 2002<br />
Employees: 28<br />
Ownership: Public<br />
Market Cap: $9.98 million<br />
OTC BB: TLON<br />
Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc.), is a San Francisco Bay Area-based biopharmaceutical company dedicated to<br />
seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring<br />
value to patients, patient care providers, shareholders, corporate partners and employees.<br />
PROPRIETARY TECHNOLOGY<br />
OPTISOME Nanoparticle Technology encapsulates cell cycle specific chemotherapeutics for enhanced delivery. Current encapsulated<br />
agents are vincristine (Marqibo), vinorelbine (Alocrest) and topotecan (Brakiva).<br />
CORPORATE ALLIANCES<br />
Optisomal compounds were in-licensed from Tekmira Pharmaceutical Corporation.<br />
Menadione was in-licensed from the Albert Einstein College.<br />
INTELLECTUAL PROPERTY<br />
Talon has worldwide rights and the right to sublicense for all portfolio drug candidates.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Marqibo (vincristine sulfate<br />
liposome injection, OPTISOME)<br />
NDA/BLA filed, or in<br />
process<br />
Acute Lymphoblastic Leukemia<br />
(ALL), Hodgkin's Disease, Non-<br />
Hodgkin's Lymphoma and Multiple<br />
Melanoma<br />
Menadione Topical Lotion Phase I Skin rash associated with EGFR<br />
inhibitors<br />
Alocrest (vinorelbine liposomes<br />
injection, OPTISOME)<br />
Brakiva (topotecan liposomes<br />
injection, OPTISOME)<br />
NDA filing expected 1H2011.<br />
Presentation of rALLy complete data<br />
at ASCO 2010. Presentation of<br />
Marqibo integrated efficacy data and<br />
PK at ASH 2010.<br />
Phase 1 completed. Phase 2 study<br />
plans ongoing.<br />
Phase I Breast Cancer and Lung Cancer Phase 1 trial completed. Product is<br />
ready for Phase 2 activation.<br />
Phase I Small-Cell Lung Cancer and<br />
Ovarian Cancer<br />
Phase 1 dose escalation study is<br />
nearing completion.<br />
SENIOR MANAGEMENT<br />
Steven R. Deitcher, MD, Chief Executive Officer • Craig Carlson, Chief Financial Officer • Tom Tarlow, Vice President • Nandan Oza,<br />
Vice President • Gradon Knotts, Vice President • Jeffrey Silverman, Vice President<br />
BOARD OF DIRECTORS<br />
Steven R. Deitcher, MD, President & CEO, Talon Therapeutics, Inc. • Howard Furst, MD, Partner, Deerfield Management • Paul Maier,<br />
Chief Financial Officer, Sequenom, Inc. • Andrew Ferrer, Associate, Warburg Pincus • Nishan de Silva, MD, Principal, Warburg Pincus •<br />
Jonathan S. Leff, Managing Director, Warburg Pincus • Leon Rosenberg, MD, Professor of Molecular Biology, Princeton University •<br />
Robert Spiegel, MD, Independent • Leon Rosenberg, Chairman of the Board<br />
SCIENTIFIC ADVISORY BOARD<br />
Kenneth C. Anderson , MD, Dana-Farber Cancer Institute • Bruce D. Cheson, MD, FACP, FAAS, Georgetown University Hospital • Pieter<br />
R. Cullis , PhD, FRSC, University of British Columbia • Hagop M. Kantarjian , MD, University of Texas MD Anderson Cancer Center •<br />
Thomas J. Lynch , MD, Yale Cancer Center • Maurie Markman , MD, Cancer Treatment Centers of America<br />
BIO Business Forum 2011 377 Participating Company <strong>Profiles</strong>
Don deBethizy, PhD<br />
President & CEO<br />
200 East First Street<br />
Winston-Salem, NC 27101-4165<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Targacept, Inc<br />
Clinical Foci: CNS • Neurology • Gastroenterology<br />
www.targacept.com<br />
Phone: 1-336-480-2100<br />
Jeffrey Brennan, SVP, Business and Commercial Development, Chief Business Officer<br />
Beth Fordham-Meier, Vice President, Licensing and Intellectual Property<br />
Scott Cullison, Senior Director, Business and Commercial Development<br />
Patrick M. Lippiello, PhD, Senior Principal Scientist, Preclinical Research<br />
Leslie Rogers, Senior Director Regulatory Affairs & Quality Assurance<br />
J. Donald deBethizy, PhD, President and CEO<br />
Alan A. Musso, CPA, SVP, Finance and Administration, CFO and Treasurer<br />
HIGHLIGHTS<br />
Recent<br />
Ownership: Public<br />
Market Cap: $667.00 million<br />
NASDAQ: TRGT.O<br />
5/20/11 - Targacept announces pricing of underwritten public offering of 3,658,537 shares of its common stock at a public price of<br />
$20.50/share. Targacept net proceeds from the sale, after deductions, are expected to be approximately $70.2 million.<br />
5/2/11 - Targacept retains full rights to the TC-5619 compound, a highly selective alpha7 neuronal nicotinic receptor modulator, after<br />
AstraZeneca opts not to exercise its option to license this product candidate.<br />
3/3/11- Targacept will have full rights to its program subject after the end of it's alliance with GSK, ultimately resulting from GSK's<br />
significant changes and refocusing in the neurosciences area.<br />
CORPORATE MISSION<br />
Targacept is developing a diverse pipeline of innovative NNR Therapeutics for difficult-to-treat diseases and disorders of the nervous<br />
system. NNR Therapeutics selectively modulate activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate<br />
vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with<br />
AstraZeneca and is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder. Targacept leverages its scientific<br />
leadership and proprietary drug discovery platform Pentad to generate novel small molecule product candidates to fuel its pipeline and<br />
attract significant collaborations with global pharmaceutical companies.<br />
PROPRIETARY TECHNOLOGY<br />
Pentad, a proprietary drug discovery platform.<br />
CORPORATE ALLIANCES<br />
Currently partnered with AstraZeneca on neuropathic subjects, specifically on AZD3480 where they are currently determining next steps<br />
after Phase 2 results in ADHD and Alzheimer's Disease, as well as on AZD1446 where the Alzheimer's Disease study will complete Phase 2 in<br />
1H11. AstraZeneca will not exercise its option to license Targacept’s product candidate TC-5619. As a result, Targacept retains full rights to<br />
the compound, a highly selective alpha7 neuronal nicotinic receptor modulator to treat negative and cognitive symptoms of<br />
schizophrenia.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TC-5214 Phase III Adjunct Treatment for Major<br />
Depressive Disorder<br />
TC-5619 Phase II, IIa, IIb Cognitive dysfunction in<br />
schizophrenia (CDS), ADHD and<br />
Alzheimer's Disease<br />
* 1st top-line results from P3 RENAISSANCE Program<br />
(adjunct therapy) expected 4Q11 *NDA filing for<br />
adjunct therapy planned 2H12 *Progress P2b "switch"<br />
monotherapy study (initiated 1Q11)<br />
*Achieved pre-defined success criteria in P2 study in<br />
CDS; planning for next development steps ongoing<br />
*Reported top-line results from P2 study in adults with<br />
ADHD 1Q11 *Complete studies designed to enable<br />
potential P2 trial in Alzheimer's<br />
TC-6987 Phase II, IIa, IIb Inflammatory Disorders *Goal of top-line results from initial P2 studies (asthma<br />
and Type 2 diabetes) by year end<br />
AZD3480 Phase III ADHD, Alzheimer's Disease *Targacept exploring potential additional P2 study in<br />
Alzheimer's * AstraZeneca decision regarding future<br />
development in ADHD expected 2Q11<br />
BIO Business Forum 2011 378 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
AZD1446 Phase II, IIa, IIb Alzheimer's Disease *Completion by AstraZeneca of pharmacodynamic<br />
study in Alzheimer's patients, advancement decision<br />
expected 3Q11<br />
SENIOR MANAGEMENT<br />
Don deBethizy, PhD, President & CEO • Alan Musso, Chief Financial Officer • Merouane Bencherif, MD, PhD, Senior Vice President •<br />
Jeffrey Brennan, Chief Business Officer • William Caldwell, PhD, Senior Vice President • Geoffrey Dunbar, MD, Chief Medical Officer •<br />
Peter Zorn, General Counsel • Mauri Hodges, Vice President • Karen Hicks, Vice President<br />
BOARD OF DIRECTORS<br />
Mark Skaletsky, Fenway Pharmaceuticals • M. James Barrett, PhD, New Enterprise Associates • Charles A. Blixt, Esq, Former General<br />
Counsel, Reynolds American (Retired) • Julia R. Brown, Former Executive VP and Advisor to the CEO, Amylin Pharmaceutical (Retired) •<br />
G. Steven Burrill, Burrill & Company, LLC • J. Donal deBethizy, PhD, Targacept, Inc • Errol B. De Souza, PhD, Biodel, Inc. • Alan W.<br />
Dunton, MD, Danerius • John P. Richard, Georgia Ventura Partners • Ralph Snyderman, MD, Duke University<br />
BIO Business Forum 2011 379 Participating Company <strong>Profiles</strong>
Sil Lutkewitte<br />
President & CEO<br />
475 West Governor Road<br />
Hershey, PA 17033<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sil Lutkewitte<br />
Targepeutics<br />
Clinical Foci: Oncology<br />
www.targepeutics.com<br />
Phone: 1-717-571-2402<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Licesning agreement with ImmunoCellular Therapeutics, for<br />
IL13Ra2 vaccine.<br />
Completed saftey and distribution studies at UCSF.<br />
Held successful pre-IND meeting with FDA<br />
Incorporated: 1997<br />
Employees: 4<br />
Ownership: Private<br />
Survival study at UCSF, using CED as method of delivery.<br />
File IND within 12 months of funding.<br />
CORPORATE MISSION<br />
Targepeutics is a privately held company specializing in targeting disease restricted biomarkers with molecular therapeutics and imaging<br />
agents.<br />
We are currently seeking financing to complete a Phase I clinical trial in brain cancer and to complete pre-clinical testing on successive<br />
drug candidates. We would also be amenable to an out-license of this technology<br />
PROPRIETARY TECHNOLOGY<br />
Targepeutics is in advanced preclinical stages of developing GB13, a novel proteinaceous chimeric molecule, for treatment of patients with<br />
malignant brain tumors, specifically high-grade astrocytomas (HGA). We genetically combined this discriminating tumor targeted<br />
ligand with a potent bacterial toxin derivative (PE4E) and have shown that the resultant product, GB13, potently kills HGA cells in vitro and<br />
in vivo via the tumor associated biomarker IL13RA2, which is present in the majority of high-grade astrocytomas but not in normal brain.<br />
Furthermore, in contrast to wtIL3 based cytotoxins, GB13 does not kill cells expressing the physiologically abundant IL13RA1, which is<br />
present in elements of normal brain.<br />
CORPORATE ALLIANCES<br />
Technology License agreement with ImmunoCellular Therapeutics, Inc.<br />
INTELLECTUAL PROPERTY<br />
Exclusive license from Penn State<br />
Background rights from Public Health Service<br />
FTO on lead compound, GB-13<br />
PRODUCTS<br />
Name Phase Indication<br />
GB13 Preclinical Brain Cancer, others<br />
SENIOR MANAGEMENT<br />
Sil Lutkewitte, President & CEO • Dr. Steve Abramson, Vice President • Dr. Lynn Maines, Vice President • Dr. Akiva Mintz, Consultant<br />
• Dr. Waldemar Debinski, Consultant<br />
BIO Business Forum 2011 380 Participating Company <strong>Profiles</strong>
Jeffrey N. Peterson<br />
Chief Executive Officer<br />
4030 Fabian Way<br />
Palo Alto, CA 94303<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jeffrey N. Peterson<br />
Luke Schneider, PhD<br />
Kent Koeninger<br />
Target Discovery, Inc<br />
Clinical Foci: Diagnostics • Oncology • Systems Biology<br />
www.targetdiscovery.com<br />
Phone: 1-650-812-8100<br />
Incorporated: 1999<br />
Employees: 7<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Veritomyx spin-out to commercialize Oedipus protein sequencing software.<br />
In-licensing of isoform biomarkers for anti-mitotic chemotherapy treatment guidance in non-small cell lung cancer.<br />
ProteoSolve-TD reagents licensed to Pressure Biosciences for manufacture and marketing of Research Use Only product line, and ongoing<br />
product co-development.<br />
CORPORATE MISSION<br />
Target Discovery, Inc. (TDI) discovers, validates and utilizes protein isoform biomarkers to present the next generation of clinical<br />
diagnostics (Isonostics), offering higher-value insights for therapy guidance applications, initially in cancer. Isonostics are specific to<br />
the post-translational modifications that control most biochemical pathway changes, while also capturing SNPs and splice variants<br />
expressed in proteins. These personalized medicine diagnostic applications are designed to improve patient outcomes and lower the<br />
overall costs of treatment. TDI also offers its unique stable-isotope-ratio mass spec metabolomics (MetaSIRMS) platform in support of<br />
biomarker research, diagnostics and other applications.<br />
Outside of our initial oncology focus, TDI collaborates with partners on application of our unique Isonostic and MetaSIRMS<br />
technologies in other disease areas, where protein isoforms or metabolites are known or suspected to be useful biomarkers. Development<br />
of assays to determine patient-specific response profiles relative to drug efficacy or toxicology (personalized medicine or theranostic<br />
applications) is an area of partnering interest.<br />
PROPRIETARY TECHNOLOGY<br />
Isonostic isoform-specific diagnostic assays (immunoaffinity capillary electrophoresis isoform separation and quantitation). ~90% of<br />
isoforms are post-translational modifications, and are inaccessible to current immunodiagnostic and nucleic acid clinical assays.<br />
EOTrol dynamic coatings for capillary electrophoresis<br />
IDBEST mass defect tags for assays (immunoaffinity mass spectrometry) for discovery and validation of low-abundance, clinicallyrelevant<br />
isoforms.<br />
Proteosolve TD integral membrane protein extraction for immunoaffinity enrichment and study.<br />
Oedipus de novo protein sequencing and isoform identification.<br />
MetaSIRMS stable isotope ratio mass spec metabolomics platform for direct monitoring of metabolic fluxes and pathways in patients<br />
and cell culture<br />
CORPORATE ALLIANCES<br />
Veritomyx-Protein Sequencing Software<br />
M. D. Anderson Cancer Center<br />
- ovarian cancer treatment guidance (platin/taxol resistance)<br />
- breast cancer treatment guidance<br />
Virginia Prostate Center (Eastern Virginia Medical School)<br />
- prostate cancer treatment guidance (tumor aggressiveness)<br />
Pressure Biosciences<br />
- manufacture and market TDI’s membrane protein extraction reagents<br />
Groton Biosystems<br />
- TDI EOTrol reagents incorporated into Groton products<br />
INTELLECTUAL PROPERTY<br />
Patents: 14 issued US patents, and numerous international counterparts.<br />
Trade Secrets: EOTrol, UltraTrol, and Proteosolve reagent product lines.<br />
BIO Business Forum 2011 381 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
EOTrol & UltraTrol On Market Dynamic coating reagents for capillary electrophoresis<br />
(selectable EOF control and elimination of non-specific<br />
binding)<br />
Proteosolve TD On Market Extraction of intact, functional proteins from cell<br />
membranes during tissue processing.<br />
Isonostics On Market Protein isoform diagnostics, specific to post-translational<br />
modification state, coupled with affinity enrichment for low<br />
abundance biomarkers.<br />
Theranostic Assays On Market Use of Isonostics (above) as a companion diagnostic to<br />
qualify or disqualify patients for specific therapeutic<br />
treatments.<br />
MetaSIRMS On Market Patient or cell culture in vivo monitoring of metabolic fluxes<br />
in biochemical pathways, for biomarker discovery and<br />
diagnostics.<br />
Oedipus Other De novo sequencing identification of unknown proteins and<br />
characterization of post-translational modifications.<br />
Resolves 65-90% error rate of current methods.<br />
Available for partnering or<br />
licensing on client projects.<br />
Available for partnering or<br />
licensing on client projects.<br />
Available for partnering or<br />
licensing on client projects.<br />
Available for partnering or<br />
licensing on client projects.<br />
Available for partnering or<br />
licensing on client projects.<br />
In final development for 2010<br />
services introduction.<br />
SENIOR MANAGEMENT<br />
Jeffrey N. Peterson, Chief Executive Officer • Luke V. Schneider, Chief Scientific Officer • David C. Bomberger, Director<br />
BOARD OF DIRECTORS<br />
Jeffrey N. Peterson, CEO • Luke V. Schneider, CSO • Clayton A. Struve, Independent Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Juan G. Santiago, Stanford University • Dr. John E. Shively, City of Hope • Dr. Alan J. Smith, Stanford University (Emeritus) • Dr.<br />
Evan R. Williams, UC Berkeley • Dr. Leon S. Yengoyan, San Jose State University<br />
BIO Business Forum 2011 382 Participating Company <strong>Profiles</strong>
John Yao, PhD<br />
President & CEO<br />
2011 - 94th Street NW<br />
Edmonton, AB T6N 1H1<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
John J. Yao, President & CEO<br />
CORPORATE MISSION<br />
TC Scientific, Inc.<br />
www.tcscientific.com<br />
Phone: 1-780-577-0288<br />
Ownership: Private<br />
TC Scientific Inc. is an Edmonton, Canada-based CRO that provides medicinal chemistry related contract research services. Scientists at TC<br />
Scientific Inc. are appreciated for their excellent synthetic chemistry talents and knowledge of structure-activity relationships (SAR). They<br />
have extensive experience in anticancer, antifungal reagents, antibiotics, central nervous system (CNS), infective disease, inflammatory<br />
disease and cardiovascular (CV) disease drug discovery. These unique characteristics make it possible for TC Scientific Inc. to deliver<br />
solutions and inventions for complex problems and challenging targets in a timely and cost-effective manner. The intellectual property<br />
developed is carefully protected, and fully assigned to the client.<br />
We also provide custom synthesis services such as the synthesis of stable isotope-labeled compounds, reference compounds, impurities,<br />
pharmaceuticals and their metabolites. TC Scientific’s greatest strength is our people: each of our scientists has an average of 13 years of<br />
experience in the area of drug discovery and organic synthesis.<br />
PROPRIETARY TECHNOLOGY<br />
stable isotope-labeled compounds, reference compounds.<br />
PRODUCTS<br />
Name Phase Indication<br />
stable isotope-labeled compounds Other stable isotope-labeled compounds<br />
reference compounds Other reference compounds as bioactivity stardand<br />
gold nanoparticles (GNP) Other gold nanoparticles (GNP) for medical use<br />
building blocks Other building blocks for organic synthesis<br />
SENIOR MANAGEMENT<br />
John Yao, PhD, President & CEO • Qizhu Ding, PhD, Chief Operating Officer • Tingsheng Li, PhD, Chief Scientific Officer • Joe Zhou,<br />
PhD, Senior Vice President<br />
BIO Business Forum 2011 383 Participating Company <strong>Profiles</strong>
Ran Vigdor<br />
Chief Executive Officer<br />
Alberto Aguilera 7<br />
28015 Madrid<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Ran Vigdor<br />
TCD Pharma<br />
Clinical Foci: Oncology • Drug Development • Diagnostics<br />
www.tcdpharma.com<br />
Phone: 34-91-267 0900<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
September, 2010 - the FDA has approved its Investigational New<br />
Drug (IND) application to begin a Phase I clinical study with its<br />
Choline Kinase Alpha inhibitor, TCD-717, for the treatment of solid<br />
tumors.<br />
October, 2010 - TCD has been chosen as one of Spain’s top 5<br />
investment opportunities in Biotechnology by a panel of experts as<br />
part of the Investors’ Forum in BioSpain international Conference.<br />
February, 2011 - the first patient was treated with TCD-717 in a<br />
Phase I study performed in patients with advanced solid tumors.<br />
Ownership: Private<br />
Financing - TCD expects to close its third round of finance before<br />
the end of 2011<br />
In-licensing - TCD is expected to in-license at least one additional<br />
program from a Spanish research institution before the end of<br />
2011 in order to expand its pipeline.<br />
CORPORATE MISSION<br />
Chosen by an international panel as one of Spain’s top 5 biotech investment opportunities, TCD is focused on creating the future of<br />
Oncology by developing innovative therapies that address unmet medical needs.<br />
Established in 2005 and with one product, TCD-717, already in clinical trials the company is positioning itself as Spain’s Partner of Choice<br />
for Oncology drug discovery and development opportunities.<br />
TCD’s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources<br />
through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug<br />
development while significantly lowering risks and costs.<br />
PROPRIETARY TECHNOLOGY<br />
TCD is developing its pipeline by in-licensing breakthrough cutting-edge technologies after proof-of-concept. Currently the company’s<br />
efforts are focused on two main programs.<br />
TCD’s leading program is based on Choline Kinase Alpha (ChoK Alpha), a key enzyme regulating the formation of the cell’s membrane.<br />
With ChoK Alpha TCD is implementing a novel approach of exploiting phospholipid metabolism for the treatment of cancer using a<br />
Personalized and Targeted treatment strategy. TCD-717, the company’s first ChoK Alpha inhibitor, is currently undergoing evaluation in<br />
Phase I clinical trial as treatment for advanced solid tumors. The study has been approved by the FDA as part of an Investigational New<br />
Drug (IND) application, and is being conducted in two medical centers in the U.S.<br />
INTELLECTUAL PROPERTY<br />
TCD enjoys strong IP protection: various patent families both granted and pending for major world markets including EU, USA and Japan.<br />
PRODUCTS<br />
Name Phase Indication<br />
TCD-717 Phase I Cancer - Solid Tumors<br />
Early Stage NSCLC Prognostic Test Diagnostics Early Stage NSCLC<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round A: 12/01/2008 (US $)<br />
Round B: 03/01/2010 (US $)<br />
SENIOR MANAGEMENT<br />
Ran Vigdor, Chief Executive Officer • Beatriz Palacios, Director • Nicholas L. Occleston, Director • Javier Cascos, Chief Financial Officer<br />
BOARD OF DIRECTORS<br />
Pablo Cabello Albendea, Cross Road Biotech<br />
BIO Business Forum 2011 384 Participating Company <strong>Profiles</strong>
Swapan Bhattacharya<br />
Managing Director<br />
Block BN, Sector V, Salt Lake City<br />
Kolkata 700 091<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Garrett Dilley<br />
HIGHLIGHTS<br />
Recent<br />
TCG Lifesciences Limited<br />
Clinical Foci: Drug Discovery • Drug Development • CNS<br />
www.tcgls.com<br />
Phone: 91-33-2367 3151<br />
TCG Lifesciences enters into a research collaboration with ENDO Pharmaceuticals<br />
Pfizer And TCG Lifesciences Announce A Collaboration To Develop Portfolio Of Preclinical Candidate Molecules<br />
Frost & Sullivan 2009 India Excellence in Healthcare Award<br />
CORPORATE MISSION<br />
Incorporated: 2001<br />
Employees: 1100<br />
Ownership: Private<br />
Chembiotek, a TCG Lifesciences Enterprise, is a leading provider of drug discovery and development services and has received recognition<br />
for being the preferred supplier to a number of the largest pharmaceutical companies in the world. Our services focus on hit to lead Drug<br />
Discovery and Development and include Medicinal Chemistry, Parallel Synthesis, Custom Synthesis, Computational Molecular Modeling,<br />
Gene-amplification, cloning and expression, assay development and screening, ADME, Pharmacokinetics, In-vivo Pharmacology, Process<br />
Development, Analytical Development, Impurity Identification, Stability Studies, Scale-up, Intermediates Production, and GMP Production<br />
of API’s. In its 10 years of operation Chembiotek has come to be known as a trusted partner which works closely with its clients and builds<br />
value beyond simply delivering on time an on-budget. Chembiotek has a staff of over 600 scientists, 15% of whom hold PhD degrees.<br />
CORPORATE ALLIANCES<br />
Pfizer<br />
Endo<br />
Forest Laboratories<br />
Carna Biosciences<br />
Mantrax<br />
Constella Group<br />
SENIOR MANAGEMENT<br />
Swapan Bhattacharya, Managing Director • Garrett Dilley, Business Development • Ashis Saha, Vice President • Sourav Basu, Vice<br />
President • Subho Roy, Director<br />
BOARD OF DIRECTORS<br />
Pernendu Chatterjee, Chairman<br />
BIO Business Forum 2011 385 Participating Company <strong>Profiles</strong>
STEFANINI Philippe<br />
Chief Executive Officer<br />
400 promenade des anglais<br />
6204 Nice<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Céline Jacquet<br />
CORPORATE MISSION<br />
Team Cote D'Azur<br />
Clinical Foci: Skin/Dermatological • Ophthalmic • Medical Device<br />
www.investincotedazur.com<br />
Phone: 33-4-9217 5185<br />
Ownership: Public<br />
Côte d’Azur, a vibrant environment for science and industry<br />
Sophia Antipolis provides a vibrant environment for R&D activities. This leading science and technology park hosts 1,400 companies, 8<br />
major public research institutes and 30 dedicated labs, 3.000 researchers in life sciences. You will find here acknowledged academic and<br />
industrial expertise in dermatology, ophthalmology, nutrition and metabolism, immunology, ageing and neurological diseases.<br />
Our international success companies: Arkopharma, Galderma, Lundbeck, Virbac etc<br />
Examples of innovative SME’s: TxCell, Median and Nicox<br />
Public research, a strong innovative impulse:<br />
-IPMC (Institute of Molecular and Cellular Pharmacology)<br />
-CNRS (The molecular and Cell Pharmacology Institute)<br />
-INRIA (National Institute of research in Computer Science and Control)<br />
-C3M: (Mediterranean research centre for Molecular medicine)<br />
Team Côte d'Azur provides free, personalized and confidential assistance to companies that are looking to set up on the Côte d'Azur.<br />
1/Check your idea<br />
-Law and Tax information, visa applications<br />
-Economic information: Potential suppliers; customers, R&D, laboratories, specific training…<br />
-Simulation of costs (Wages, public incentives, set-up costs, utilities…)<br />
2/Launch your project<br />
-Pre-selection of suitable real estate solutions<br />
-Connection to investor pools –Assistance to apply to public funding<br />
-Support for your recruitment<br />
3/Develop your business<br />
- Promotion, communication and media<br />
- Introduction to local and professional networks<br />
SENIOR MANAGEMENT<br />
STEFANINI Philippe, Chief Executive Officer • JACQUET Celine, Business Development<br />
BIO Business Forum 2011 386 Participating Company <strong>Profiles</strong>
Jordi Girona, 29<br />
08034 Barcelona<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Elisabet Del Valle Alvaro, Licensing Manager<br />
CORPORATE MISSION<br />
Technical University of Catalonia<br />
Clinical Foci: Biomaterials • Medical Device • Diagnostics<br />
www.upc.edu/patents<br />
Phone: 34-93-413 4070<br />
Ownership: Public<br />
Market Cap: $43.00 million<br />
The Universitat Politècnica de Catalunya (UPC) is one of the leading research universities in Spain. It specializes in the fields of health<br />
sciences, engineering, ICT, architecture, optics among others. In order to take advantage of all its assets the UPC works diligently in<br />
transferring technology and knowledge to private companies and to society.<br />
The Patent and Licensing Office is the unit responsible for managing and protecting the UPC’s intellectual property, identifying its<br />
commercial potential and stimulating economic development through the licensing of all these patented technologies to the commercial<br />
market.<br />
PRODUCTS<br />
Name Phase Indication<br />
New nanostructured material for tissue<br />
regeneration<br />
Research Technology available for licensing<br />
New inorganic cement for biomedical<br />
applications<br />
Method for the automatic detection of<br />
calcium release events through image<br />
proce<br />
Biopolymer-containing calcium phosphate<br />
foam for bone regeneration<br />
Recombinant protein polymer useful for<br />
bone implants<br />
Research Technology available for licensing<br />
Diagnostics Technology available for licensing<br />
Research Technology available for licensing<br />
Research Technology available for licensing<br />
New device for laboratory animal telemetry Other Technology available for licensing<br />
New device for measuring pelvic floor<br />
muscle strength<br />
Other Technology available for licensing<br />
BIO Business Forum 2011 387 Participating Company <strong>Profiles</strong><br />
NA
Technion city<br />
32000 Haifa<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Joseph Nathan, Director of New Ventures<br />
HIGHLIGHTS<br />
Recent<br />
Technion Technology Transfer Company<br />
Clinical Foci: Drug Discovery • Diagnostics • Drug Development<br />
http://t3.technion.ac.il/<br />
Phone: 972-54-208 0101<br />
Ownership: Private<br />
Technion professors and Teva Pharmaceuticals to develop a sophisticated drug that offers real hope for PD patients. Azilect® (rasagiline),<br />
the breakthrough drug for Parkinson’s disease, is now being marketed worldwide.<br />
CORPORATE MISSION<br />
T³ is a wholly owned company of the Technion - Israel Institute of Technology, it offers a special combination of science and engineering;<br />
with 11 affiliated hospitals, a high-tech entrepreneurial incubator and the world-class Rappaport Faculty of Medicine. Technion's power<br />
for innovation and application has shaped a successful high-tech nation and has left its imprint on the global evolution of science and<br />
high-technology.<br />
As the commercialization arm of the Technion - T³ has vast expertise in IP development rights, patenting and licensing inventions and<br />
forming win-win business agreements, bringing together groundbreaking ideas with investors and entrepreneurs. Transforming<br />
scientific discovery and technological innovation into real-life applied solutions, T³ has the skill, experience and wisdom to build powerful<br />
bridges so that science, technology and pure brainpower become problem-solving solutions available to all.<br />
By contacting T³, you can become part of a growing community of entrepreneurs, industrialists and investors who are involved in the<br />
commercialization of Technion's ground-breaking technologies.<br />
CORPORATE ALLIANCES<br />
Top tier VC's, Fortune 500 companies, Leading entrepreneurs, various types of investors, mid-size companies.<br />
BIO Business Forum 2011 388 Participating Company <strong>Profiles</strong>
5200 Soquel Avenue<br />
Santa Cruz, CA 95062-7800<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Technology Vision Group, LLC<br />
www.techvision.com<br />
Rebecca Angelos, Managing Director<br />
Oliver Duchamp, Business Development, European Advisor<br />
Annie Chen, Business Development<br />
Chandini Kalsy<br />
Loreta M. Klivecka, Business Developer<br />
Robert Lee Kilpatrick, PhD, Partner<br />
Phone: 1-831-464-4230<br />
Employees: 19<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Technology Vision Group LLC (TVG) is a life science networking company that is built on industry expertise and long-standing<br />
relationships. We provide our clients with the connections, the venues, and the access they need to succeed in a global life science world.<br />
Since 1992, TVG has been connecting innovators and leaders in the life science industry across the US, Canada, China, Europe, Australia,<br />
Latin America, and India. TVG enables a global network that supports life science companies as they build new relationships, enter new<br />
markets, and create new products. Our 19-year track record (1992-2011) of success is founded on our deep industry knowledge, our<br />
integrity in business, and our powerful network of valuable relationships. We are judged by the company we keep and have helped over<br />
3,200 life science companies achieve their business goals. We continue to expand our network into new markets in Latin America, China,<br />
and India — fulfilling our vision to be Your Global Life Science Network.<br />
TVG’s Global Conference Network is powered by biopartnering.com and allows life science companies to access global innovation, raise<br />
new sources of capital, and tap into skilled workforces around the world. Connect with your global partners at these industry leading<br />
conferences in 2011:<br />
C21 BioVentures | Napa, CA, USA<br />
BioPartnering India | Bangalore, India<br />
BioPartnering Latin America | São Paulo, Brazil<br />
BioPartnering Europe | London, United Kingdom<br />
AusBiotech 2011 | Adelaide, Australia<br />
BioPartnering China | China<br />
BioPartnering North America | Vancouver, BC, Canada<br />
BIO Business Forum 2011 389 Participating Company <strong>Profiles</strong>
Miguel Garcia<br />
Chief Executive Officer<br />
Av. Professor Egas Moniz<br />
Lisbon 1649-028<br />
Portugal<br />
CONFERENCE PARTICIPANTS<br />
Miguel Garcia, MBA, PhD, CEO<br />
Nuno Afonso, Business Unit Manager<br />
TechnoPhage, SA<br />
Clinical Foci: Biopharmaceuticals • Drug Discovery • Drug Development<br />
www.technophage.pt<br />
Phone: 351-21-799 9472<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
May, 2011:<br />
TechnoPhage and UCB sign a collaborative protocol, under which UCB is funding Technophage to develop new therapeutic agents using<br />
TechnoPhage’s small-domain antibody proprietary technology<br />
CORPORATE MISSION<br />
TechnoPhage is a Biotechnology company focused on the discovery and development of biopharmaceuticals, using different proprietary<br />
technologies. TechnoPhage is engaged in three main R&D programs: 1. Recombinant single domain antibody fragments (sdAbs), for<br />
therapeutic applications. Ongoing projects in the areas of inflammation, oncology, cardiology and neurodegenerative diseases. 2. Drug<br />
discovery using the zebrafish as an in vivo screening system. Ongoing programs in the areas of bone and neurodegenerative disorders. 3.<br />
Novel bacteriophage-based products for the treatment and diagnosis of bacterial infections caused by antibiotic-resistant bacteria. The<br />
company laboratories are located at the campus of the Institute of Molecular Medicine of the Faculty of Medicine of the University of<br />
Lisbon.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TA_101 Preclinical Inflammation CTA filing expected in Q4 2011<br />
SENIOR MANAGEMENT<br />
Miguel Garcia, Chief Executive Officer<br />
BIO Business Forum 2011 390 Participating Company <strong>Profiles</strong>
Maurizio Cunico<br />
Chief Technology Officer<br />
Via Scuderlando, 89/b<br />
37135-Verona<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Michele Montanari<br />
CORPORATE MISSION<br />
Techorizon Srl<br />
Clinical Foci: Informatics • Service • Other<br />
www.techorizon.com<br />
Phone: 39-045-822 2888<br />
Incorporated: 2009<br />
Employees: 15<br />
Ownership: Private<br />
TecHorizon wants to be a benchmark of the technological services through the development and/or integration of products that support<br />
business processes and project management.<br />
Expertise in technology, Ten-year expertise in Medical Technology, Management and operational reporting, tailored custom solutions.<br />
PROPRIETARY TECHNOLOGY<br />
- Efficient and rapid tracking solution implementation<br />
-Integrations of complex heterogeneus data (IVR,RDC, Internal Excel, databases) for operational and top management reporting<br />
-Extending corporate data system on mobile devices<br />
-ePRO<br />
-Expertise in Computerized Systems Validation (GAMP 5)<br />
-Expertise in Virtualized Systems<br />
-Microsoft Server and Desktop and others (Windowsphone, Android, iOS)<br />
CORPORATE ALLIANCES<br />
Cooperation with an Italian leader company in telecommunications about the extension of mobile services and RFID.<br />
SENIOR MANAGEMENT<br />
Maurizio Cunico, Chief Technology Officer • Silvio Severini, Manager • Michele Montanari, Business Development<br />
BIO Business Forum 2011 391 Participating Company <strong>Profiles</strong>
Subbaraju Sagi<br />
Managing Director<br />
3194, Milton Jenson CT<br />
Tracy, CA 95377<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Fahd Khan<br />
Techsol Corporation<br />
Clinical Foci: Informatics • Specialty Pharmaceutical • Drug Development<br />
www.techsolcorp.com<br />
Phone: 91-40-4900-8858<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Partner of Oracle Health Sciences<br />
Worked with Leading Pharma and CRO Companies Globaly<br />
Became Leaders in our niche area.<br />
CORPORATE MISSION<br />
Ownership: Private<br />
Become end to end IT life sciences service provider.<br />
Techsol is a Global Technology Service provider for the Life Sciences, Pharmaceutical, Biotechnology, Clinical Research Organizations (CRO)<br />
and Healthcare. We are certified Gold Partner of Oracle health sciences and offer full range of Clinical Development,<br />
Safety/Pharmacovigilance and Healthcare Analytics technology services to the global companies.<br />
We offer the following technology services:<br />
• Implementation, Validation and Upgrade of Oracle Health Sciences Applications :<br />
Argus Safety Suite, AERS e-Submission Gateway<br />
Sibel Clinical<br />
Oracle Clinical RDC Suite<br />
ePedigree and Serialization Manager<br />
Clinical Development Manager LSH<br />
Enterprise Healthcare Analytics<br />
• Managed Support and Maintenance (Both Level 1 Help desk and Level 2 Technical)<br />
• EDC Help Desk 24x7 English and Multilingual<br />
• Disaster Recovery and Associated Infrastructure services including Application Hosting<br />
• Application Training<br />
• Resource Augmentation<br />
Web: www.techsolcorp.com<br />
Contact: Sales@techsolcorp.com<br />
CORPORATE ALLIANCES<br />
Oracle Health Sciences<br />
SENIOR MANAGEMENT<br />
Subbaraju Sagi, Managing Director<br />
BIO Business Forum 2011 392 Participating Company <strong>Profiles</strong>
Kentaro Arao<br />
Chief Executive Officer<br />
Kasumigaseki Common Gate West Tower<br />
Tokyo 100-8585<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Yasuhiro Takano<br />
Daishiro Miura<br />
Yuichi Kunori<br />
Teijin Pharma Limited<br />
Clinical Foci: Musculoskeletal • Pulmonary • Metabolic Disease<br />
www.teijin.co.jp<br />
Phone: 81-3-3506 4107<br />
Incorporated: 1918<br />
Employees: 1863<br />
Ownership: Private<br />
TOKYO STOCK EXCHANGE: 3401<br />
HIGHLIGHTS<br />
Recent<br />
Teijin Pharma annouced on April 18th that it will launch Feburic® (febuxostat, TMX-67), in Japan on May 17th, 2011.<br />
Teijin Pharma announced on April 6th that it will launch Alvesco® (ciclesonide) 100 microgram Inhaler 56 Puff for use in both adults and<br />
children with bronchial asthma, in Japan on April 7th, 2011.<br />
Teijin Pharma announced on December 9th, 2010 that it will launch Synvisc® (hylan G-F 20), a cross-linked hyaluronic acid discovered by<br />
Genzyme for the treatment of patients with knee osteoarthritis, in Japan on December 14th, 2010.<br />
CORPORATE MISSION<br />
Teijin Pharma Limited is one of the principal subsidiaries of Teijin Limited which was established in 1918 in Japan. Total net sales of Teijin<br />
Limited is about ¥816 billion (ca. USD$9.1 billion) (2010, consolidated) with its businesses of high-performance fibers, films, resins, and<br />
medical & pharmaceutical products. It has about 17,542 employees (March, 2011, consolidated). Teijin Pharma started its medical &<br />
pharmaceutical business in 1973 which was spin off as Teijin Pharma Limited, 100% subsidiary of Teijin Limited, as of October 1st, 2003. In<br />
fiscal year 2008, Teijin Pharma’s net sales is about ¥136.4 billion (ca. USD$1.5 billion), and has about 1,863 employees. Teijin Pharma is<br />
committed to contributing to total healthcare through being a proprietary R&D-oriented company, and providing advanced medical<br />
services by means of pharmaceuticals and home healthcare businesses. For more information, visit our website: www.teijinpharma.co.jp/english/index.html<br />
PROPRIETARY TECHNOLOGY<br />
Teijin Pharma focuses its R&D activities on the three core therapeutic areas: respiratory, bone & joint and cardiovascular & metabolic<br />
diseases. Teijin Institute for Bio-Medical Research, the main R&D facility of Teijin Pharma, was established in 1973 in Tokyo, and dedicates<br />
to proprietary pharmaceutical research. Teijin Pharma also has a research laboratory (MRC/London), which specializes in target-finding &<br />
validation research.<br />
CORPORATE ALLIANCES<br />
Teijin Pharma has established numbers of alliances with various pharmaceutical companies, biotechnology companies, universities and<br />
research institutes. License-in from: Boehringer Ingelheim, Nycomed, Solvey/Aska, Ipsen, Merck&Co., Eli Lilly, Glenmark, Nissan Chemical,<br />
Genzyme, etc. License-out to: Takeda Pharmaceutical North America (TAP Pharmaceutical Products Inc.), Ipsen, GlaxoSmithKline Biologicals<br />
S.A., Hermal, Isdin, Merck Sante, Sanofi Pasteur, Abiogen, Rottapharm, Angelini, SK Chemicals, Ilsung, Dong Wha, Taiwan Astellas (Taiwan<br />
Fujisawa), Berli Jucker, Martin Dow, Shanghai Pharmaceutical, Profex Healthcare, Croma, PT Dipa, Somedico, Pharmacon, CSC, Janata<br />
Trading, Minapharma, Hind Wing.<br />
PRODUCTS<br />
Name Phase Indication<br />
Bonalon On Market Osteoporosis<br />
Onealfa On Market Osteoporosis<br />
Synvisc On Market Knee osteoarthritis<br />
Mucosolvan On Market Expectorant<br />
Alvesco On Market Asthma<br />
Venilon On Market Severe Infectious Diseases<br />
Febuxostat (TMX-67) On Market Gout, Hyperuricemia<br />
ITM-077 Phase II, IIa, IIb Type-2 diabetes<br />
NTC-801 Phase II, IIa, IIb Atrial Fibrillation<br />
ITM-058 Phase I Severe Osteoporosis<br />
SENIOR MANAGEMENT<br />
Kentaro Arao, Chief Executive Officer • Hiroshi Uno, Managing Director • Kiyoshi Bannai, Managing Director • Hidekazu Kuribayashi,<br />
Director • Takashi Kamimura, Director • Tamotsu Koyama, Director • Tetsuya Yano, Director • Osamu Nishikawa, Director<br />
BIO Business Forum 2011 393 Participating Company <strong>Profiles</strong>
Mark Murray<br />
President & CEO<br />
100-8900 Glenlyon Parkway<br />
Burnaby, BC V5J 5J8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Paul Brennan<br />
HIGHLIGHTS<br />
Recent<br />
Tekmira Pharmaceuticals Corp.<br />
Clinical Foci: Infectious Disease • Oncology • Metabolic Disease<br />
www.tekmirapharm.com<br />
Phone: 1-604-419-3200<br />
Employees: 75<br />
Ownership: Public<br />
Market Cap: $30.00 million<br />
NASDAQ: TKMR<br />
Concluded its ApoB LNP Phase 1 human clinical trial. ApoB SNALP is designed to reduce the production of apolipoprotein B (ApoB), a<br />
protein produced in the liver that plays a central role in cholesterol metabolism.<br />
Commenced Phase I human clinical trial for PLK1 LNP program which is being developed as a treatment for cancer<br />
Developed LNP formulations which can which can be nebulised and delivered for inhalation<br />
CORPORATE MISSION<br />
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on the development of a new class of proprietary<br />
compounds called RNA interference (RNAi) therapeutics. The company’s two lead RNAi products target cholesterol management and<br />
cancer. In addition to its pipeline products, Tekmira has partnership agreements with leading pharmaceutical companies to provide its<br />
innovative RNAi delivery technology for the development of its partners’ RNAi product candidates.<br />
PROPRIETARY TECHNOLOGY<br />
Small interfering RNAs (siRNA) are the therapeutic agents that exert the effect of RNAi to treat diseases at the genetic level. In order to be<br />
effective, the siRNA compound must get to the target cell, penetrate the cell and be released in an active form. Tekmira’s proprietary siRNA<br />
delivery technology accomplishes these three objectives using Lipid Nanoparticle or LNPs. These specialized LNPs completely encapsulate<br />
the siRNA and protect it from natural degradation within the body. Preclinical studies have shown that administered systemically, LNPs<br />
are effective in delivering siRNA to the target organs and silencing the target genes, with the desired efficacy and minimal toxicity.<br />
CORPORATE ALLIANCES<br />
Tekmira has licensed its LNP delivery technology to a number of leading RNAi developers, including Merck, Takeda and Alnylam. By<br />
licensing its leading LNP delivery technology, Tekmira derives near term research and manufacturing revenues and has the opportunity to<br />
earn milestone payments and sales royalties. These partnerships validate the potential of Tekmira’s LNP platform and provide near term<br />
revenues to lower Tekmira’s burn rate as the company focuses on advancing its proprietary pipeline of RNAi drugs.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ApoB SNALP Phase I Hypercholesterolemia or elevated LDL<br />
cholesterol<br />
commence Phase 1 for nextgeneration<br />
ApoB SNALP<br />
PLK1 SNALP Phase I Cancer IND in 2010; Phase 1 in 2010<br />
TKM-Ebola Preclinical Anitviral against ebola<br />
TKM-Hep C Target Validated Hepatitis C<br />
TKM-Hep B Target Validated Hepatitis B<br />
SENIOR MANAGEMENT<br />
Mark Murray, President & CEO • Ian Mortimer, Chief Financial Officer • Ian MacLachlan, Chief Scientific Officer • Paul Brennan, Senior<br />
Vice President • Pete Lutwyche, Senior Vice President<br />
BOARD OF DIRECTORS<br />
Daniel Kisner, MD, Previously Aberdare Ventures, Isis Pharmaceuticals • Frank Karbe, Exelixis, Inc. • Ken Galbraith, CA, Ventures West<br />
• Michael J. Abrams, PhD, Inimex Pharmaceuticals • Arthur M. Bruskin, PhD, Biotechnology Consultant, previously at OSI • Donald<br />
Jewell, CA, Director, previously at KPMG • Ian Lennox, Ricerca • Mark J. Murray, PhD, CEO, Tekmira<br />
BIO Business Forum 2011 394 Participating Company <strong>Profiles</strong>
Johanna Holldack<br />
Chief Executive Officer<br />
Via della Posta 10<br />
CH - 6934 Bioggio<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Nadia Passini<br />
Johanna Holldack<br />
TELORMEDIX SA<br />
Clinical Foci: Oncology • AutoImmune • Vaccines<br />
www.telormedix.com<br />
Phone: 41-91-610 7038<br />
Employees: 9<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Telormedix focuses on Toll Like Receptor 7 (TLR-7) as therapeutic target in oncology and dermatology for the development of both agonists<br />
and antagonists compounds. The first compound, a TLR-7 agonists, entered phase I clinical trial in June 2010 for the treatment of bladder<br />
cancer. The second product, TMX-202, is in preclinical trials for topical treatments for skin and bladder cancers and a third product, TMX-<br />
201, is in development for use as a vaccine adjuvant. Telormedix also has an additional pipeline of programmes for inflammatory<br />
diseases, which is called TMX-30X.<br />
Business Development<br />
Telormedix welcomes enquiries from potential partners interested in finding out more about its product pipeline.<br />
PRODUCTS<br />
Name Phase Indication<br />
TMX 101 Phase I Bladder Cancer<br />
TMX-202 Preclinical skin cancer bladder cancer<br />
TMX-201 Preclinical adjuvant vaccines<br />
TMX-30X Research autoimmune/inflammatory diseases<br />
SENIOR MANAGEMENT<br />
Johanna Holldack, Chief Executive Officer<br />
SCIENTIFIC ADVISORY BOARD<br />
Dennis Carson, Moores Cancer Centre, UCSD • Rolf Zingernagel, University of Zurich • Alberto Mantovani, IC Humanitas<br />
BIO Business Forum 2011 395 Participating Company <strong>Profiles</strong>
Av/Font i Sague', 55 Parc Cientific<br />
08227 Barcelona-Catalunya<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Nuria Batet, Product Manager<br />
HIGHLIGHTS<br />
Recent<br />
Telstar<br />
Clinical Foci: Gene/Cell Therapy • Medical Device • Other<br />
www.telstar.eu<br />
Phone: 34-937-361600<br />
Incorporated: 1963<br />
Employees: 1000<br />
Ownership: Private<br />
Telstar is introducing into the market the HEXASCREEN, a completely innovative minibioreactor model to perform animal cell culture<br />
screening studies on a scale applicable to R&D.<br />
Telstar presents the LYOQUEST, the state-of-the-art laboratory freeze-drier capable of making recipes with temperature and vacuum<br />
control. The device is the perfect solution, for research and development.<br />
CORPORATE MISSION<br />
Telstar has focused its business in the field of Life Science and Health through its Telstar Life Science Solutions division to provide<br />
equipment solutions for the pharmaceutical, medical-hospital, biotech, laboratories and related industries.<br />
With over 45 years of experience and an international presence in more than 100 countries, Telstar Life Science Solutions has a broad<br />
range of references in the major companies and is established as a worldwide leader in the field.<br />
Each market needs the best customer-focused sales team and for this reason Telstar has a trained, highly qualified and expert sales force<br />
to provide the best advice and service to the customer base:<br />
The focus of Telstar Life Science Solutions in Pharmaceutical Industry is the design, manufacture, sales and support of high technology<br />
equipment solutions for the pharmaceutical, biotech and related industries. The range of product offerings includes GMP lyophilizers with<br />
integrated automatic loading/unloading systems, equipment for contamination control and production of water for injection and pure<br />
steam, moist heat autoclaves, dry heat ovens, water stills, pure steam generators, industrial down-flow booths, containment isolators and<br />
weighing cabinets among others.<br />
The focus of Telstar Life Science Solutions in Laboratory Field is the design, manufacture, sales and after sales of Laboratory Equipment for<br />
R&D, quality control and analysis in sectors related to Life and Health Sciences. Telstar offers to the market an extensive range of products<br />
such as vertical and horizontal laminar flow benches, bio-safety cabinets, lyophilizers, containment and sterile isolators and ultrafreezers<br />
among others.<br />
Telstar Life Science Solutions offers the Medical Sectors and Hospitals advanced technology in the design and installation of laminar flow<br />
systems for operating theatres, and ventilation systems that minimize the risk of postoperative infections.<br />
PROPRIETARY TECHNOLOGY<br />
Biorreactors, GMP lyophilizers with integrated automatic loading/unloading systems, equipment for contamination control and<br />
production of water for injection and pure steam, moist heat autoclaves, dry heat ovens, water stills, pure steam generators, industrial<br />
down-flow booths, containment isolators and weighing cabinets among others, vertical and horizontal laminar flow benches, bio-safety<br />
cabinets, laboratory lyophilizers, containment and sterile isolators and ultrafreezers among others.<br />
CORPORATE ALLIANCES<br />
With HexaScreen Culture Technologies, S.L. for developing and marketing a minibiorreactor called HexaScreen®.<br />
This is a bencth top minibiorreactor and is an excellent solution to optimize biotechnological processes that uses Animal Cell Culture such<br />
us:Cell screening, Cell characterization, Cell adaptation, Media definition and optimization, Cell toxicity test or Process optimization.<br />
PRODUCTS<br />
Name Phase Indication<br />
HexaScreen Minobiorreactor On Market bench top bioreactor for animal cell culture<br />
Laboratory Freeze Dryers On Market Freeze Dryers for R&D<br />
BioSafety Cabinets On Market Biological Safety Cabinets for R&D<br />
Laboratory Isolators On Market Isolators for R&D & Hospitals<br />
Sterilization Systems On Market Laboratory autoclaves<br />
GMP Production Freeze Dryers On Market Freeze Dryers for pharmaceutical Industry<br />
PW, WFI & Pharmaceutical Steam On Market Purification of drinking water or purified water<br />
Laminar airflow systems On Market Laminar air flow benches & laminar airflow booths<br />
Clean Rooms On Market arquitecture, air treatment, associated equipment & control and monitoring<br />
Turnkey projects On Market Engineering services, consultancy, procurement, project management &<br />
validation master plan<br />
BIO Business Forum 2011 396 Participating Company <strong>Profiles</strong>
Patricia May<br />
President & CEO<br />
17870 Irons Court<br />
Minneapolis, MN 55044<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Patricia May, President/CEO<br />
HIGHLIGHTS<br />
Recent<br />
Tembua: The Precision Language Solution<br />
Clinical Foci: Service • Other • Service<br />
www.tembua.com<br />
Phone: 011-952-435-8178<br />
Certification to ISO-9001:2008 and EN 15038:2006, our industry's international quality standard.<br />
Litigation support for cross-national European infringement issue.<br />
Interpreters and all equipment for Soyatech International conference.<br />
Incorporated: 18<br />
Employees: 35<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Tembua: The Precision Language Solution is an ISO-9001 and EN 15038 certified company. We provide a broad range of high-quality<br />
linguistic services targeting clients in the technology, scientific and legal sectors. Offerings include document translation and website<br />
localization as well as expertise with multi-lingual desktop publishing. Using state-of-the-art technology in the hands of highly-skilled,<br />
professional native linguists, we manage both glossary development and translation memories in over 100 languages by client,<br />
department, language, and topic. Of course, confidentiality is addressed with our own private, password-protected file transfer site. For<br />
legal firms, we produce prior art patent translations, contracts, agreements,and litigation support. Technology clients request fullytypeset<br />
manuals and packaging translations. Other clients need research outcomes and survey information in many languages. In<br />
addition, our interpreters and sound equipment serve international conferences and foreign dignitary visits. Tembua also offers custom<br />
authoring and editing into and out of English. This service is heavily used by people writing for the web in their 2nd or 3rd language who<br />
want their text to sound like native speaker output. Tembua serves such clients as Boston Scientific, Medtronic, General Mills, 3M, Piper<br />
Jaffray, and numerous law firms around the world.<br />
CORPORATE ALLIANCES<br />
Tembua's client list includes Boston Scientific, Medtronic, Lion Precision Technologies, Hypertension Diagnostics, Daniel Defense, General<br />
Mills, Target, Sally Beauty, the State of Minnesota, Canadian Fisheries and Oceans, UL-DQS and many law firms.<br />
INTELLECTUAL PROPERTY<br />
Trademarked logos and taglines only<br />
PRODUCTS<br />
Name Phase Indication<br />
Translation Other All scientific, technological and legal documents<br />
Website localization Other All scientific, technological and legal websites<br />
Conference Interpreting Other Staff and equipment, all languages for international conferences and<br />
foriegn dignitary visits.<br />
Custom authoring and editing Other All scientific, technological and legal industries, all languages<br />
Multi-lingual desktop publishing Other All scientific, technological and legal publications<br />
FINANCING HISTORY<br />
Investors: Patricia May (100 %)<br />
SENIOR MANAGEMENT<br />
Patricia May, President & CEO • Robert May, Chief Technology Officer • Sam Broberg, Business Development • Donna Lange, Business<br />
Development<br />
BIO Business Forum 2011 397 Participating Company <strong>Profiles</strong>
Steven Nichtberger, MD<br />
President & CEO<br />
2900 Potshop Lane, Suite 100<br />
East Norriton, PA 19403<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Steven Nichtberger, MD<br />
Mark Stejbach<br />
Tengion, Inc<br />
Clinical Foci: Regenerative Medicine • Gene/Cell Therapy • Renal<br />
www.tengion.com<br />
Phone: 1-267-960-4800<br />
Incorporated: 2003<br />
Employees: 60<br />
Ownership: Public<br />
Market Cap: $63.50 million<br />
NASDAQ: TNGN<br />
CORPORATE MISSION<br />
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables the company to create<br />
proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of nativelike<br />
organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which<br />
they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the company’s<br />
lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder<br />
tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The company’s lead preclinical program is the<br />
Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.<br />
Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic<br />
bladder. Tengion has worldwide rights to its product candidates.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Neo-Urinary Conduit Phase I Regenerative urinary conduit following<br />
cystectomy for bladder cancer<br />
Neo-Kidney Augment Preclinical Prevent or delay dialysis in CKD stage 4<br />
SENIOR MANAGEMENT<br />
Interim data 12/2011<br />
Steven Nichtberger, MD, President & CEO • Tim Bertram, DVM, PhD, Chief Scientific Officer • Mark Stejbach, Chief Business Officer •<br />
Brian Davis, Chief Financial Officer • Sunita Sheth, MD, Chief Medical Officer • Sunita Sheth, MD, Chief Medical Officer<br />
BOARD OF DIRECTORS<br />
David Scheer, President, Scheer & Company • Steven Nichtberger, MD, President & CEO, Tengion, Inc. • Carl-Johan Dalsgaard, MD,<br />
PhD, Partner, HealthCap Venture Capital • Brenda D. Gavin, DVM, Managing Partner, Quaker BioVentures • Richard E. Kuntz, MD,<br />
MSc, Sr. Vice President & Chief Scientific, Clinical and Regulatory Officer, Medtronic • Gary J. Kurtzman, MD, Managing Director, Life<br />
Sciences Group, Safeguard Scientifics, Inc. • Lorin J. Randall, Financial Consultant<br />
BIO Business Forum 2011 398 Participating Company <strong>Profiles</strong>
Evan Hurwitz<br />
Chief Executive Officer<br />
Wren House, 43 Hatton Garden<br />
London<br />
EC1N 8EL<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Marc Rhys-Evans, Business Development Manager<br />
David Bull, Commercial Manager<br />
Neil Darkes, General Manager, Life Sciences<br />
CORPORATE MISSION<br />
Terrapinn Ltd.<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Drug Discovery<br />
www.terrapinn.com<br />
Phone: 44-207-827 5945<br />
Incorporated: 1987<br />
Employees: 387<br />
Ownership: Private<br />
LONDON STOCK EXCHANGE:<br />
Terrapinn is a global B-2-B organisation with offices in North America, Latin America, Europe, South Africa, Dubai, Singapore, China and<br />
Australia.<br />
Our purpose is to give our customers the relationships and big ideas to do different and better business. We’ve been doing it for more<br />
than 20 years.<br />
We want you to come away from one of our events with eight big ideas and eight new key contacts. That’s how we contribute to the<br />
business communities we serve.<br />
Our experience, skill, creative vision and commercial drive have built a portfolio of successful international brands. The kind of brands that<br />
ensure your world class brand gets maximum value from a global stage.<br />
PROPRIETARY TECHNOLOGY<br />
Terrapinn's core focus is on the development of industry defining brands supporting the Biopharmaceutical industry.<br />
Terrapinn's core brands include the World Vaccine Congress series, the World's largest and longest running international Vaccine<br />
congresses for senior commercial and scientific stakeholders in North America, Europe and Asia.<br />
Additionally, Terrapinn organise the industry's leading congress brands within the areas of Stem Cells and Regenerative Medicine,<br />
Antibodies, Orphan Drugs, Cell Culture and the newest addiiton Pharma Innovation, industry's leading R&D innovation forum.<br />
CORPORATE ALLIANCES<br />
Terrapinn work closely with industry Associations and Alliances to co-develop brands that best meet the needs of their members and<br />
stakeholders.<br />
Terrapinn brands gain support and affiliation with national and domestic partners to represent the requirements of global industries.<br />
SENIOR MANAGEMENT<br />
Evan Hurwitz, Chief Executive Officer • Neil Darkes, Managing Director • Marc Rhys-Evans, Business Development • David Bull,<br />
Business Development • Debbie Tagg, Business Development • Enrique Schindelheim, Business Development • Danny Featherstone,<br />
Business Development<br />
BIO Business Forum 2011 399 Participating Company <strong>Profiles</strong>
Prof. Maree Smith<br />
Managing Director<br />
Steele Building, Staffhouse Rd, St Lucia<br />
Brisbane, QLD 4072<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Maree Smith<br />
Kris Dyszynski<br />
TetraQ<br />
Clinical Foci: Drug Development • Neurology • CNS<br />
www.tetraq.com.au<br />
Phone: 61-7-3346-9933<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
CIPDD is searching for a pharmaceutical company, involved in pain drug development and marketing, to collaborate on a grant to develop<br />
drug leads for the treatment of pain.<br />
CORPORATE MISSION<br />
TetraQ is the commercial arm of the University of Queensland's Centre for Preclinical Drug Development (CIPDD). The CIPDD collaborates<br />
with industry partners in the pain area in projects funded by state and federal grants. TetraQ is a leading Australian Contract Research<br />
Organisation (CRO) that provides integrated preclinical drug development services and advice to companies that are in the early stages of<br />
drug development also assisting by bridging the gap between drug discovery and early stage clinical trials. TetraQ is focused to<br />
understand your business needs with comprehensive and tailored solutions that represent a very strong value proposition at competitive<br />
rates.<br />
PROPRIETARY TECHNOLOGY<br />
CIPDD/TetraQ Services:<br />
ADME<br />
•GLP recognized bioanalytical services<br />
•Pharmacokinetic & bioavailability studies<br />
•Assay development & validation<br />
•Metabolite identification & profiling<br />
Efficacy<br />
•Many models of efficacy<br />
Incl; various pain models, sensitivity & perception, acute stimulus, acute & chronic inflammatory pain, Neuropathic pain, CNS models<br />
include; Alzheimer’s, Parkinson’s & MS Other models include; Obesity, diabetes, IBD, Arthritis & Stroke.<br />
Toxicology<br />
•Genotoxicity assays (AMES, MLA, Micronucleus)<br />
•Dose range finding<br />
•Repeat dose<br />
•Safety Pharmacology<br />
Pharmaceutics<br />
•Characterization<br />
•Stability studies<br />
•Formulation development<br />
•Analytical method development &validation<br />
Novel drug delivery system for pain drugs/drug candidates<br />
CORPORATE ALLIANCES<br />
The CIPDD is collaborating with Eli Lilly on a novel drug delivery system for pain drugs. TetraQ, and Q-Pharm, a leading early phase clinical<br />
trial facility in Australasia, have formed a strategic alliance to enhance the delivery of bioanalytical services to clients in the biotechnology<br />
and pharmaceutical industries. The alignment of the two organizations at the interface of the preclinical and early phase clinical stages of<br />
the drug development pathway presents significant opportunities for capturing operational economies, co-marketing of services, crossreferral<br />
of potential clients and providing a more complete and streamlined service.<br />
PRODUCTS<br />
Name Phase Indication<br />
ADME testing Preclinical all<br />
Efficacy testing Preclinical all<br />
BIO Business Forum 2011 400 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
Toxicology testing Preclinical all<br />
Pharmaceutics Preclinical all<br />
Program management Preclinical all<br />
Consultancy services Preclinical all<br />
Pain drug development grant opportunitiy Preclinical pain<br />
SENIOR MANAGEMENT<br />
Prof. Maree Smith, Managing Director • Otto Damsma, Manager • Kris Dyszynski, Vice President • Bruce Wyse, Manager<br />
BIO Business Forum 2011 401 Participating Company <strong>Profiles</strong>
5 Bazel Street<br />
00000 Petach-Tikva<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Martin Eglitis, Senior Director<br />
William P. Watson, Senior Partnering Director<br />
Gavin Samuels, Senior Director<br />
Teva Innovative Ventures<br />
Sponsor<br />
Clinical Foci: Neurology • AutoImmune • Oncology<br />
www.tevapartners.com<br />
Phone: 972-3-9148157<br />
Employees: 38000<br />
Ownership: Public<br />
Market Cap: $45000.00 million<br />
NASDAQ: TEVA<br />
CORPORATE MISSION<br />
In Licensing: Pre-Clinical/Clinical stage<br />
Building on it's successes in developing proprietary therapies such as the blockbuster COPAXONE® for Multiple Sclerosis and AZILECT® for<br />
Parkinson's disease, Teva Innovative group is looking to in-license Pre-Clinical and Clinical opportunities in it's targeted therapeutic areas<br />
(Neurology, Autoimmune/Inflammatory, Oncology, Women’s Health, and Respiratory) as well as additional specialty areas (products<br />
marketed to medical specialists) that have the following attributes:<br />
New chemical/biological entities with strong IP, satisfy high unmet medical need, and demonstrated in vivo pharmacological proof of<br />
concept with potential advantages over existing drugs.<br />
Pre-Clinical stage projects:<br />
Martin Eglitis, PhD Senior Partnering Director, US, Central-West Coast Opportunities (TIV)<br />
Gavin Samuels, MD, MBA- Senior Partnering Director, US, Central-East Coast Opportunities (TIV)<br />
Will Watson, PhD, MBA Senior Partnering Director ,EU and ROW Opportunities (TIV)<br />
Clinical stage progets:<br />
Michael McHugh, Clinical Stage, Respiratory, and Women’s Health opportunities<br />
Karl Strohmeier, Clinical Stage, Oncology and Autoimmune opportunities<br />
Ken Wentzel, Clinical Stage, Neurology, MS, and Orphan diseases opportunities.<br />
TEVA's Biosimilar Products<br />
Teva BioSimilar Biopharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is committed to the discovery<br />
and development of improved, next generation and novel biopharmaceuticals for the treatment of disease and serious medical<br />
conditions. Using our proprietary albumin fusion technology, Teva Biopharmaceuticals can improve and expand the use of established<br />
and novel biopharmaceutical by developing drug candidates with reduced dosing and increased safety.<br />
Ivan Cohen-Tanugi,MD,MBA, Vice President,General Manager North American Biologics and specialty products<br />
Mark Rampy,PhD,Vice President, Business Development and Strategy, North American Biologics & Specialty Products<br />
BIO Business Forum 2011 402 Participating Company <strong>Profiles</strong>
5 Bazel Street<br />
49131 Petach-Tikva<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Ken Wentzel<br />
Karl Strohmeier<br />
James Updike<br />
Michael G. McHugh<br />
Michael Fetell<br />
Teva Pharmaceuticals-Global Branded Products<br />
Sponsor<br />
Clinical Foci: Neurology • Oncology • AutoImmune<br />
www.tevapharm.com<br />
Phone: 1-972-3914 8157<br />
Employees: 40000<br />
Ownership: Public<br />
Market Cap: $45000.00 million<br />
NASDAQ: TEVA<br />
CORPORATE MISSION<br />
In Licensing: Clinical<br />
Building on it's successes in developing proprietary therapies such as the blockbuster COPAXONE® for Multiple Sclerosis and<br />
AZILECT® for Parkinson's disease, ProAir, and Qvar in our Respiratory franchise, and Seasonique and Plan B in the Women's Health<br />
Franchise.<br />
Clinical stage projects:<br />
Michael McHugh, Vice President, Business Development and Alliance Management;<br />
Ken Wentzel, Clinical Stage, Neurology, MS, and Orphan diseases opportunities;<br />
Karl Strohmeier, Clinical Stage, Oncology and Autoimmune opportunities;<br />
Jim Updike, Clinical Stage, Respiratory, and Women’s Health opportunities<br />
BIO Business Forum 2011 403 Participating Company <strong>Profiles</strong>
Theresa Fossum, DVM, MS, PhD<br />
Director<br />
800 Raymond Stotzer Parkway, Ste 2060<br />
College Station, TX 77843<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Theresa Fossum<br />
HIGHLIGHTS<br />
Recent<br />
Texas A&M Institute for Preclinical Studies<br />
Clinical Foci: Medical Device • Drug Discovery • Cardiovascular Disease<br />
http://tips.tamu.edu<br />
Phone: 1-979-845-3374<br />
Ownership: Other<br />
Selected member of the A&M System team of the world’s finest scientists, engineers, corporations, and educators created to seek the<br />
establishment of a National Center for Innovation in Advanced Development and Manufacturing in College Station, Texas.<br />
Recipient of the 2010 TurnKey Facility of the Year Award, recognized for its state-of-the-art facility design, construction and operation of a<br />
new GLP laboratory animal facility.<br />
CORPORATE MISSION<br />
The Texas A&M Institute for Preclinical Studies (TIPS) is working to improve human and animal health by accelerating medical device and<br />
drug development. TIPS is a state-of-the-art large animal GLP facility offering a full range of collaborative and support services that are<br />
critical to the success of drug and medical device development.<br />
From basic research/design, to biomedical imaging and preclinical testing, TIPS uses an interdisciplinary approach to seamlessly improve<br />
the effectiveness and efficiency of drug and device development. Through its multi-disciplinary service, TIPS has become a premier leader<br />
in helping medical device, pharmaceutical and biotechnology companies readily meet international regulatory requirements by<br />
shortening the pathway to FDA approval and making the translational process more cost effective.<br />
TIPS was created to fill a need in both the international medical community and the state of Texas, by providing access to the highest<br />
quality pre-clinical research services, unique resources and world-renowned researchers and surgeons in a GLP-compliant environment.<br />
Located in the emerging One Health Plus Biocorridor in the Research Valley, Texas, TIPS is a component of the critical infrastructure in<br />
place for “one-stop-shop” biomedical development. The One Health Plus Biocorridor has become the nation’s premier destination to<br />
discover new therapies, perform pre-clinical evaluations, and manufacture them in one convenient location.<br />
PROPRIETARY TECHNOLOGY<br />
Comprehensive large animal preclinical research services and biomedical imaging.<br />
CORPORATE ALLIANCES<br />
Texas A&M University, Texas A&M College of Veterinary Medicine and Biomedical Sciences (CVM), Texas A&M Institute for Innovative<br />
Therapeutics (IIT), Texas A&M Institute for Genomic Medicine (TIGM), National Center for Therapeutics Manufacturing (NCTM), Texas<br />
A&M Health Science Center, MD Anderson, Texas Brain & Spine Institute, DARPA, NASA, Bayer HealthCare, GlaxoSmithKline, Pfizer,<br />
Boehringer Ingelheim, Texas Instruments, Boston Scientific.<br />
SENIOR MANAGEMENT<br />
Theresa Fossum, DVM, MS, PhD, Director<br />
BIO Business Forum 2011 404 Participating Company <strong>Profiles</strong>
Daniel Spasic<br />
Chief Executive Officer<br />
Ruben Rausingsgatan 11<br />
SE-22355 Lund<br />
Sweden<br />
CONFERENCE PARTICIPANTS<br />
Spasic Daniel<br />
Mariska Van Der Heijden<br />
TFS Trial Form Support International<br />
Clinical Foci: Drug Development • Medical Device • Biopharmaceuticals<br />
Phone: 46-46-280 1800 Employees: 500<br />
Ownership: Private<br />
CORPORATE MISSION<br />
TFS offers four distinct business solutions:<br />
TFS Explore<br />
Early stage clinical trials in Phases 0, I and IIa.<br />
TFS Develop<br />
Operations and services supporting the registration-based Phase II, III, and IV clinical trials.<br />
TFS People<br />
Clinical research professionals available whenever and wherever you need them.<br />
TFS Academy<br />
Specialist training for clinical research professionals.<br />
These business areas cover the complete clinical development cycle, and operate as independent centres of excellence within the TFS<br />
Group.<br />
Since 1996, TFS has served the Life Science Industry by outlining, initiating, conducting and reporting the clinical trials in all clinical phases<br />
and in the majority of clinical disciplines. We have had the privilege of collaborating with the leading companies in each separate<br />
industrial segment, such as big pharmaceutical, biotech, medical device, diagnostic, generics and functional food companies - all with<br />
unique needs. This broad range of experience and capability is one of the main reasons why so many companies trust TFS. It is also the<br />
reason that we are invited to conduct trials with some of the most reputed hospitals in the world and have gained access to so many<br />
patient populations throughout Europe.<br />
SENIOR MANAGEMENT<br />
Daniel Spasic, Chief Executive Officer • Christian Lindholm, Chief Financial Officer • Alistair Bone, Director • Eva Lundqvist, Director •<br />
Mariska van der Heijden, Director<br />
BOARD OF DIRECTORS<br />
Ulf Rosén • Daniel Spasic • Wenche Rolfsen • Anders Leijon • Fredrik Herslow<br />
SCIENTIFIC ADVISORY BOARD<br />
Markus Jerling • Toni Perez<br />
BIO Business Forum 2011 405 Participating Company <strong>Profiles</strong>
Stephen Gately, PhD<br />
President<br />
13208 E. Shea Blvd<br />
Scottsdale, AZ 85259<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Stephen Gately<br />
Tara Franks<br />
HIGHLIGHTS<br />
Recent<br />
Strategic Partnership with Horizon Discovery<br />
Tgen Drug Development (TD2)<br />
Clinical Foci: Oncology<br />
www.td2.org/<br />
Phone: 1-602-358-8315<br />
Ownership: Private<br />
CORPORATE MISSION<br />
TGen Drug Development (TD2) is an oncology drug development group (oncology CRO) with an integrated suite of tools for more<br />
predictive preclinical oncology models (tumor xenografts, orthotopic cancer models, isogenic cell lines, etc.) TD2 focuses on tumor<br />
xenograft cancer models, preclinical oncology models, and TD2 is recognized as a leading cancer CRO.<br />
TD2 can facilitate proof of concept/mechanism of action studies, developing strategies for more rapid regulatory approval, and innovative<br />
clinical trial designs. In doing so TD2 is accelerating oncology drug development in a way that will define the future of oncology drug<br />
approvals. Lead by world-class oncology experts, including Dr. Daniel Von Hoff, TD2 is uniquely positioned to assist companies with the<br />
development of their oncology portfolio drugs.<br />
TD2 is located in Scottsdale, Arizona on the campus of the Mayo Clinic and is a wholly owned subsidiary of the Translational Genomics<br />
Research Institute (TGen). Since its inception TD2, as the premiere oncology CRO, has assisted over 120 pharmaceutical and biotechnology<br />
companies and has successfully transitioned numerous oncology compounds from preclinical development into first in human Phase I<br />
clinical trials.<br />
CORPORATE ALLIANCES<br />
TD2 is an Affiliate of the Translational Genomics Research Institute (TGEN) The Translational Genomics Research Institute (TGen) and the<br />
Van Andel Research Institute (VARI) forged a strategic alliance that will enable both to maximize their worldwide contributions to science<br />
and health.<br />
INTELLECTUAL PROPERTY<br />
None- strictly a fee for service organization<br />
PRODUCTS<br />
Name Phase Indication<br />
Preclinical Service Offerings Preclinical Oncology<br />
Regulatory Service Offerings IND Filed Oncology & Other Indications<br />
Clinical Service Offerenings Phase I Oncology<br />
Clinical Service Offerings Phase II, IIa, IIb Oncology<br />
Preclinical Service Offerings Preclinical Oncology<br />
Regulatory Service Offerings IND Filed Oncology & Other Indications<br />
Clinical Service Offerings Phase I Oncology<br />
Clinical Service Offerings Phase II, IIa, IIb Oncology<br />
SENIOR MANAGEMENT<br />
Stephen Gately, PhD, President • Tara Franks, Director • Linda Vocila, Director • Paul Gonzales, Director<br />
BIO Business Forum 2011 406 Participating Company <strong>Profiles</strong>
Hillary Theakston<br />
Chief Executive Officer<br />
7514 Girard Avenue, Suite 218<br />
La Jolla, CA 92037<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Hillary Theakston<br />
The Clearity Foundation<br />
Clinical Foci: Oncology • Diagnostics • None<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Presentation at AACR 2011: Molecular profiling in recurrent<br />
ovarian cancer patients: considerations for the design of clinical<br />
studies to validate profiling for therapy selection.<br />
The Clearity Foundation is featured in O, The Oprah Magazine to<br />
increase public awareness of molecular profiling for ovarian<br />
cancer.<br />
Clearity hires Hillary Theakston as Executive Director<br />
Phone: 1-858-735-2224 Incorporated: 4<br />
Employees: 4<br />
Ownership: Private<br />
Presentation at ASCO: Expression profiles in matched primary and<br />
recurrent serous ovarian carcinomas.<br />
Clearity educational event at ASCO: Accelerating Progress Toward<br />
Individualized Treatment for Ovarian Cancer sponsored by Nektar,<br />
Abbott and Sanofi Aventis<br />
CORPORATE MISSION<br />
The Clearity Foundation is the only foundation in America dedicated to improving therapeutic options for women with ovarian cancer<br />
now. We believe we are the first organization making personalized medicine a reality for women with this disease. We do this using<br />
molecular profiling technology to analyze a patient’s tumor coupled with Clearity’s Diane Barton Database to determine which drugs are<br />
most likely to be effective. By improving the information used in making treatment decisions, our goal is for women with ovarian cancer<br />
to live longer, healthier lives.<br />
Every year, more than 14,000 women die of ovarian cancer and approximately 21,000 are newly-diagnosed. When a patient’s ovarian<br />
cancer returns after standard chemotherapy, a chance for a cure is less than 15%, or less than 3% if she did not respond to initial<br />
treatment. Ovarian cancer survivor and scientist Laura Shawver, PhD, established The Clearity Foundation to improve treatment options<br />
for ovarian cancer patients and change the one-size-fits-all approach.<br />
PROPRIETARY TECHNOLOGY<br />
Ovarian cancer tumors are very different from patient to patient, which means they are likely to respond differently to FDA approved and<br />
investigational drugs. By identifying the alterations in each tumor’s information pathways, molecular profiling enables the<br />
individualization of a patient’s treatment by matching those tumor alterations with one or more drugs. The Clearity Foundation has<br />
developed a process for generating this personalized diagnostic information using commercially-available molecular profiling<br />
technologies and then analyzing the results using its Diane Barton Database. Armed with this analysis, patients are able to work with their<br />
medical teams to make better-informed treatment decisions.<br />
CORPORATE ALLIANCES<br />
Current Foundation partners include Morphotek, Nektar, Abbott, Sanofi Aventis, Clarient, Ventana and IlluminaDX, McKesson<br />
Corporation, Credit Suisse, Blueprint Life Science Group, CMEA Capital, Goodwin Procter and 5AM Ventures<br />
SENIOR MANAGEMENT<br />
Hillary Theakston, Chief Executive Officer • John Crawford, Chief Financial Officer • Laura K. Shawver, PhD, Chairman • Deborah<br />
Zajchowski, PhD, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Laura K. Shawver, PhD, 5am Ventures • Rachel Leheny, PhD, Caxton Advantage Life Sciences Fund • Kerry Kelly, JD, Ambit Biosciences<br />
• Susan Atkins • John E. Crawford • Aimee Jungman, frogdesign<br />
SCIENTIFIC ADVISORY BOARD<br />
Beth Karlan, MD, Director of the Women's Cancer Research Institute, Cedars-Sinai Medical Center • Douglas A. Levine, MD, Memorial<br />
Sloan Kettering Cancer Center • Julie Cherrington, PhD, Pathway Therapeutics, • Ursula A. Matulonis, MD, Dana-Farber Cancer<br />
Institute, Harvard Medical School • Deborah Zajchowski, PhD, Scientific Director, The Clearity Foundation<br />
BIO Business Forum 2011 407 Participating Company <strong>Profiles</strong>
Andrew Romans<br />
President & CEO<br />
1001 Bayhill Drive<br />
San Bruno, CA 94066<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Andrew Romans, General Partner<br />
The Founders Club<br />
Clinical Foci: Other<br />
www.founders-club.com<br />
Phone: 1-650-475-6877<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
If you are a CEO, CxO or founder of a privately held VC backed company,<br />
we want to meet you in DC or Silicon Valley. We will be in London and<br />
Europe for meetings in mid-June. Contact us if you want to meet there.<br />
The Founders Club Moves Headquarters to Silicon Valley<br />
http://www.founders-club.com/news-and-events/club-news.html<br />
Signed first 10 members to Healthcare & Life Science Fund I. We will<br />
close this fund when we reach 20 companies. >> Technology &<br />
Cleantech Fund I Closed >> Technology & Cleantech Fund II Now Open<br />
Incorporated: 2010<br />
Employees: 2<br />
Ownership: Private<br />
http://bit.ly/lseXk0<br />
More VCs and entrepreneurs in the process of joining The<br />
Founders Club<br />
Launch of Israel only fund with participation of Israeli angels<br />
making a powerful network in Israel connected to our global<br />
network<br />
CORPORATE MISSION<br />
The Founders Club is a unique fund where VC backed entrepreneurs agree to invest a small percentage of their future cash exit into a fund<br />
in return for ownership in the fund and membership in the club.<br />
Our members have collectively raised over $321 million in funding from leading Venture Capital funds.<br />
Joining takes a minimal amount of time and the process is dead simple. There is no cash cost to join. Members only contribute cash from<br />
proceeds at the time they sell or liquidate their equity position in their company. Members receive cash distributions from each exit in<br />
their specific fund. Each fund comprises 20 high potential venture backed portfolio companies, thereby affording any single entrepreneur<br />
a strategy to create wealth while accomplishing portfolio diversification. Portfolio companies are selected by committees comprised of<br />
Venture Advisors from premier venture capital firms in the US, Europe and Israel. Entrepreneurs accepted into the club on this basis have<br />
access to other members as well as the venture capitalists serving on our Venture Advisory committees.<br />
We are a club. We organize an annual conference, periodic meetings, dinners, breakfasts, cocktail networking events, 1:1 meetings and<br />
web conferences. We access powerful global contact networks, start companies, recruit teams, raise cash and build great ventures. All<br />
applications, company information and participants are strictly confidential.<br />
Happy to speak before or after the event via phone or in person.<br />
Andrew Romans<br />
ar (at) founders-club.com<br />
+1 (650) 475-6877<br />
+44 7815 901 066 (mid June when in UK and EU)<br />
PROPRIETARY TECHNOLOGY<br />
Venture Capital Equity Exchange Fund with over 20 VCs on the advisory board nominating entrepreneurs to join and forming our<br />
selection committees evaluating candidates and determining who joins.<br />
Strong group of industry shaping angel investors who actively add value to the club.<br />
International position with members, VCs and angels scattered across key technology corridors in the US, Europe and Israel.<br />
CORPORATE ALLIANCES<br />
20+ VC firms<br />
FINANCING HISTORY<br />
Investors: Edmund Truell (0 %) • Jon Moulton (0 %) • André Jaeggi (0 %) • Chris Burke (0 %) • Gordon Waldron (0<br />
%) • Martin Steiner (0 %) • Kai Petersen (0 %) • Morrison & Foerster (0 %) • Andrew Romans (0 %)<br />
SENIOR MANAGEMENT<br />
Andrew Romans, President & CEO • André Jaeggi, Chairman • Martin Steiner (investor & advisor), Venture Capitalist • Michael B.<br />
Sheffery OrbiMed Advisors, Venture Capitalist • Anja Koenig Novartis Venture Fund, Venture Capitalist • Roel Bulthuis<br />
MerckSerono, Venture Capitalist • Nissim Darvish OrbiMed-Israel, Venture Capitalist • Karl Naegler Ventech, Venture Capitalist •<br />
Hans Kuepper Global Life Science Ventures, Venture Capitalist • Stephen Reeders, MVM Life Science Partners, Venture Capitalist<br />
BOARD OF DIRECTORS<br />
André Jaeggi, Adveq ($5.5 billion fund of funds)<br />
BIO Business Forum 2011 408 Participating Company <strong>Profiles</strong>
Mary Jo Haddad<br />
Chief Executive Officer<br />
555 University Avenue<br />
Toronto, ON M5G1X8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Arlene Yee<br />
CORPORATE MISSION<br />
The Hospital for Sick Children<br />
Clinical Foci: Genetic Disorders • Oncology • Regenerative Medicine<br />
www.sickkids.ca<br />
Phone: 1-416-813-8858<br />
Ownership: Other<br />
The Hospital for Sick Children (SickKids) is recognized as one of the world’s foremost paediatric health-care institutions and is Canada’s<br />
leading centre dedicated to advancing children’s health through the integration of patient care, research and education. Founded in 1875<br />
and affiliated with the University of Toronto, SickKids is one of Canada’s most research-intensive hospitals and has generated discoveries<br />
that have helped children globally. Its mission is to provide the best in complex and specialized family-centred care; pioneer scientific and<br />
clinical advancements; share expertise; foster an academic environment that nurtures health-care professionals; and champion an<br />
accessible, comprehensive and sustainable child health system. SickKids is proud of its vision of Healthier Children. A Better World. For<br />
more information, please visit www.sickkids.ca.<br />
PROPRIETARY TECHNOLOGY<br />
Genetic markers for cystic fibrosis. Gene modifiers for cystic fibrosis disease spectrum. Novel sweat test and device for cystic fibrosis.<br />
Diagnostic biomarkers for autism and ADHD. Mouse models for breast cancer (PIK3C-alpha). Mouse model and cell lines for glucose<br />
uptake for preclinical testing. Compounds for treating Tay-Sachs Disease and Gauchers Disease. Compounds for treating brain cancer<br />
(glioblastoma, medulloblastoma). Brain cancer stem cell lines for cancer therapeutics. Prognostic test for cancer risk (p53 mutation).<br />
Research reagents for regenerative medicine. Wound healing and scar treatment agent. Human cell lines for V-ATPase activity for drug<br />
discovery. Bioreactor and scaffolds for urinary bladder tissue reconstruction.<br />
CORPORATE ALLIANCES<br />
MaRS Innovation<br />
Centre for Commercialization of Regenerative Medicine<br />
INTELLECTUAL PROPERTY<br />
Patent applications filed.<br />
In-licensing opportunities.<br />
SENIOR MANAGEMENT<br />
Mary Jo Haddad, Chief Executive Officer • Jim Garner, Senior Vice President<br />
BIO Business Forum 2011 409 Participating Company <strong>Profiles</strong>
Prof Alan Ashworth<br />
Chief Executive Officer<br />
Enterprise Unit, 123 Old Brompton Road<br />
London<br />
SW7 3RP<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Jennifer Hodgson, Business Development Manager<br />
Jennifer Watts, Contracts Manager<br />
The Institute of Cancer Research<br />
Clinical Foci: Drug Discovery • Oncology • Drug Development<br />
www.icr.ac.uk<br />
Phone: 44-20735-28133<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
We have several drugs on the market or in clinical trials as well as research<br />
reagents, books and radiotherapy and ultrasound software.<br />
Drugs invented at the ICR currently in trials include Abiraterone, ONX0801<br />
(an alpha-folate receptor targeted TS inhibitor), Hsp90, a PI3k inhibitor,<br />
PARP inhibitors, Picoplatin, Satraplatin and PKB inhibitors.<br />
CORPORATE MISSION<br />
Incorporated: 1909<br />
Employees: 2000<br />
Ownership: Other<br />
We have an unparalleled record in the development of new<br />
anticancer drugs. Looking forward we have great hopes for<br />
Abiraterone which was invented at the ICR and ICR and the<br />
Royal Marsden are leading the clinical trials.<br />
The ICR is Europe’s leading cancer research centre, it has been ranked the UK’s top academic research centre, based on the results of the<br />
Higher Education Funding Council’s Research Assessment Exercise. The ICR works closely with its partner The Royal Marsden NHS<br />
Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest<br />
comprehensive cancer centre in Europe.<br />
Over its 100-year history, the ICR’s achievements include identifying the potential link between smoking and lung cancer which was<br />
subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any<br />
other organisation in the world.<br />
PROPRIETARY TECHNOLOGY<br />
The ICR is a world leader in cancer genetics, cancer epidemiology and advanced radiotherapy techniques. The ICR is unrivalled in its record<br />
in cancer drug discovery and development.<br />
CORPORATE ALLIANCES<br />
The ICR is partnered with the Royal Marsden NHS Foundation Trust. Together the ICR and RMH are the only National Institute of Health<br />
Research (NIHR) Biomedical Research Centre specialising in cancer in the UK.<br />
INTELLECTUAL PROPERTY<br />
The Enterprise Unit at the ICR manage all the ICR's and the Royal Marsden's intellectual property. We currently have a number of licensing<br />
and collaboration opportunities and are looking to discuss these with interested parties.<br />
SENIOR MANAGEMENT<br />
Prof Alan Ashworth, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Lord Ryder of Wensum OBE<br />
BIO Business Forum 2011 410 Participating Company <strong>Profiles</strong>
610 Main Street<br />
Bar Harbor, ME 04609<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
The Jackson Laboratory<br />
Clinical Foci: Biology • Oncology • Genetic Disorders<br />
www.jax.org<br />
Gabriele Proetzel, Associate Director Technology Transfer<br />
Phone: 1-207-288 6736<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
April 2011 - Maine State Science Fair at The Jackson Laboratory.<br />
July 2010 - New Importation and Isolation Facility for Reproductive<br />
Sciences operations. The three-story, 22,500 square foot facility<br />
allows the Laboratory to receive, house and process all “imported”<br />
mice of unknown health status.<br />
September 2010 - Professor Emeritus Douglas Coleman wins 2010<br />
Lasker Award<br />
CORPORATE MISSION<br />
Incorporated: 1929<br />
Employees: 1344<br />
Ownership: Private<br />
July 2011 National Council Discovery Days<br />
The Jackson Laboratory is an independent, nonprofit organization focusing on mammalian genetics research to advance human health.<br />
Our mission is to discover the genetic basis for preventing, treating and curing human disease, and to enable research for the global<br />
biomedical community. Our work uses the mouse as a research tool. Because the mouse genome is 95 percent identical to the human<br />
genome, mice are an effective and efficient model for human diseases. Along with our research we provide scientific resources,<br />
techniques, software and data to scientists around the world. The Laboratory has 36 principal investigators leading research groups in<br />
cancer, neurobiology, ophthamology, immunology, metabolic diseases, reproductive sciences, stem cells, aging and computational<br />
biology. We breed and manage colonies of mice to supply other research institutions and laboratories. We have over 5000 varieties of mice<br />
including over 2,100 targeted and 1,000 transgenic mutant mouse lines, many of which are models for cancer, heart disease, Alzheimer’s<br />
disease, ALS, diabetes, Parkinson's disease, spinal muscular atrophy, Huntington's disease and various autoimmune diseases. More than<br />
500 new lines are imported annually.<br />
PROPRIETARY TECHNOLOGY<br />
Humanized Mouse Models: NSG, NRG, FCRN (US patents 6,992,234 and 7,358,416)<br />
Sperm Cryopreservation Mouse<br />
Genetic Stability Program to maintain inbred rodent strains (US patent 7,592,501)<br />
Collection of over 5,000 JAX® Mice strains<br />
CORPORATE ALLIANCES<br />
Charles River Laboratories, Janvier<br />
INTELLECTUAL PROPERTY<br />
US patents<br />
6,992,234; 7,358,416; 7,592,501; 7,881,873; 7,822,556; 7,772,569; 7,191,734<br />
PRODUCTS<br />
Name Phase Indication<br />
Humanized FcRn Mouse Modles for Antibody PK On Market Antibody Pharmacokinetics<br />
Humanized Mouse Models for Human Cell/Tissue Engraftments On Market Stem Cells, Cancer, Infectious Disease,<br />
Diabetes<br />
Mouse Sperm Cryo Kit On Market Research Tool<br />
JAX® GEMM® Mouse Strains - genetically engineered mice On Market Research Tool<br />
JAX® Cryopreservation and Recovery Services On Market Research Tool<br />
JAX® Breeding and Rederivation Services On Market Research Tool<br />
BIO Business Forum 2011 411 Participating Company <strong>Profiles</strong>
John Walter<br />
Chief Executive Officer<br />
1311 Mamaroneck Avenue<br />
White Plains, NY 10605<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Allison Formal<br />
HIGHLIGHTS<br />
Recent<br />
The Leukemia & Lymphoma Society<br />
Clinical Foci: Oncology • Hematology<br />
www.lls.org<br />
Phone: 1-425-216-3559<br />
Incorporated: 60<br />
Employees: 100<br />
Ownership: Private<br />
5/2011- Acetylon and LLS will jointly support a Phase I/II clinical trial of Acetylon’s oral selective HDAC6 inhibitor drug candidate, ACY-<br />
1215, in multiple myeloma through LLS’s commitment to fund up to $4.85 million.<br />
12/2010 Ascenta Therapeutics and LLS entered into an agreement whereby the LLS will support clinical development of Ascenta’s oral<br />
small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406. LLS supports up to $1.7 million<br />
7/2010 The LLS and Shape Pharmaceuticals announced today they entered into a partnership to advance Shape’s novel topical treatment<br />
SHP-14 for cutaneous T-Cell lymphoma (CTCL) into clinical development. LLS will support up to $3.3 million.<br />
CORPORATE MISSION<br />
The Leukemia & Lymphoma Society (LLS) is the largest voluntary health agency dedicated to curing leukemia, lymphoma and myeloma,<br />
and to improving the quality of life of patients and their families. LLS was established in 1949 as The de Villiers Foundation. In 2000, LLS<br />
changed its name from The Leukemia Society of America to The Leukemia & Lymphoma Society to emphasize its commitment to fighting<br />
all blood cancers.<br />
Today, LLS supports the following major programs: research, patient services, public and professional education, advocacy and community<br />
services. With headquarters in White Plains, NY, LLS has chapter offices across the United States and is a single corporation doing business<br />
under New York State nonprofit corporate laws.<br />
Nearly 1 million volunteers from all walks of life give generously of their time and talents to implement LLS's programs. They provide<br />
professional guidance and help raise vitally-needed funds. LLS's activities are directed and supervised by its national Board of Directors<br />
and chapter boards of trustees.<br />
CORPORATE ALLIANCES<br />
Acetylon- $4.8 million for a phase I/II trial in multiple myeloma<br />
Shape Pharmaceuticals- $3.3 million for phase I/II trial in cutaneous T cell Lymphoma<br />
Ascenta- $1.7 million for a phase I trial in AML<br />
Avila- US$3.3 million for phase I/II trial- B-cell lymphomas;<br />
Forma- Up to US$5 million for drug discovery and development for inhibitors of Bcl-6;<br />
Celator- Up to US$3.7 million for phase II in relapsed refractory AML patients;<br />
Shape- Up to US$3.3 million for a phase I trial for a topical HDACi for CTL;<br />
Aegera- Up to US$3.4 million for phase I/II for antisense therapy for follicular lymphoma;<br />
Memgen- Phase I trial for immunotherapy aimed at Cd40+ cells in CLL;<br />
Onconova- Up to US$10 million for trial in relapsed MDS patients.<br />
SENIOR MANAGEMENT<br />
John Walter, Chief Executive Officer • Louis J. DeGennaro, Executive Vice President • Richard Winneker, Senior Vice President • Allison<br />
Formal, Vice President<br />
BIO Business Forum 2011 412 Participating Company <strong>Profiles</strong>
Todd Sherer<br />
Chief Executive Officer<br />
90 Broad Street<br />
Manhattan, NY 10004<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
The Michael J. Fox Foundation<br />
Clinical Foci: Neurology • Drug Development • Drug Discovery<br />
www.michaeljfox.org<br />
Phone: 1-212-509-0995<br />
Tracey Marren Mumford, Associate Director, Research Partnerships<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
MJFF is sponsoring a landmark clinical biomarker study - the<br />
Parkinson's Progression Markers Initiative - designed to identify<br />
markers of progression for PD. This is a pre-competitive publicprivate-partnership<br />
and is co-funded with industry.<br />
MJFF currently has four open funding programs focused on<br />
biomarker development, LRRK2 and dyskinesia. Applications can<br />
be submitted throughout the year from industry and academic<br />
labs.<br />
MJFF generated monoclonal LRRK2 antibodies and has made these<br />
available to the research community free of charge. MJFF has also<br />
generated open-source animal models that can be accessed easily<br />
by the research community.<br />
Ownership: Private<br />
Upcoming deadline dates for our Pipeline Program will be<br />
announced in early June. Please check<br />
http://www.michaeljfox.org/research for details.<br />
On Oct 26, MJFF will host the 2011 PD Therapeutics Conference in<br />
partnership with The New York Academy of Sciences. The event will<br />
showcase innovative research, as well as identify recent research<br />
highlights that impact PD therapeutic development.<br />
CORPORATE MISSION<br />
The Michael J. Fox Foundation for Parkinson’s Research was founded with a single goal in mind — to accelerate the development of<br />
improved and effective treatments and, hopefully, a cure for Parkinson’s disease. Recognizing that significant private resources and an<br />
aggressive, risk-taking research program are critical to fulfill this mission, the Foundation has amassed extraordinary scientific, business<br />
and media assets to aid in the pursuit of an ambitious research agenda that reflects the urgency and hope felt by people with Parkinson’s<br />
and their families. The Foundation, with its Scientific Advisory Board (SAB), has developed a strategy for evaluating and prioritizing<br />
potential research investments likely to yield treatments that make a difference in the lives of patients — the ultimate measure of all<br />
Parkinson’s research. The Foundation today implements its research strategy through a diverse portfolio that includes (1) driving critical<br />
paths research; (2) funding development of translational research tools; and (3) seeding pipeline programs to ensure the continued<br />
generation of new and novel investigative approaches. In each area, the focus is on transformative ideas with the potential to<br />
fundamentally change the landscape of Parkinson’s disease research. To date, MJFF has funded over $238 million in Parkinson's research.<br />
PROPRIETARY TECHNOLOGY<br />
Not applicable.<br />
CORPORATE ALLIANCES<br />
We fund pre-clinical and clinical research in industry and academia.<br />
INTELLECTUAL PROPERTY<br />
The Foundation does not claim IP on research conducted with grants it awards.<br />
SENIOR MANAGEMENT<br />
Todd Sherer, Chief Executive Officer • Debi Brooks, Other • Joanne Martz, Chief Financial Officer • Sohini Chowdhury, Vice President •<br />
Laxmi Wordham, Other<br />
BOARD OF DIRECTORS<br />
George E. Prescott, GP Management Services • David Golub, Golub Capital • Holly S.Andersen, MD, Cornell Cardiology Associates •<br />
Eva Andersson-Dubin, MD, NBC Medical • Jon Brooks, JMB Capital Partners • Barry J. Cohen, Apollo Capital Management • Donny<br />
Deutsch, Deutsch Inc. • David Einhorn, Greenlight Capital • Karen Finerman, Metropolitan Capital Advisors, Inc. • Michael J. Fox, The<br />
Michael J. Fox Foundation<br />
SCIENTIFIC ADVISORY BOARD<br />
Gene Johnson, PhD, Washington University School of Medicine • Franz Hefti, PhD, Avid Radiopharmaceuticals, Inc. • Irene Hegeman<br />
Richard, MD, University of Rochester • Joseph Jankovic, MD, Baylor College of Medicine • Jeffrey Kordower, PhD, Rush University<br />
Medical Center • Peter Reinhart, PhD, Proteostasis Therapeutics • Andrew Singleton, National Institute of Aging • Mark Cookson,<br />
PhD, National Institute on Aging<br />
BIO Business Forum 2011 413 Participating Company <strong>Profiles</strong>
Jackie Ballard<br />
Chief Executive Officer<br />
19-23 Featherstone St<br />
London<br />
EC1Y 8SL<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Denise R Goldman, Translational Research Manager<br />
CORPORATE MISSION<br />
The Royal National Institute for Deaf People<br />
Clinical Foci: Drug Discovery • Drug Development • Regenerative Medicine<br />
www.rnid.org.uk/businessdevelopment<br />
Phone: 44-020-7294 3742<br />
Ownership: Private<br />
Looking for lucrative untapped markets? Want to get advice, support and market intelligence absolutely FREE? RNID can help you now...<br />
London-based RNID is the largest not-for-profit organisation representing deaf and hard of hearing people. We are working to ensure that<br />
treatments are developed to protect, improve and restore hearing, and alleviate tinnitus. We do this by<br />
• Compiling novel otology market intelligence reports<br />
• Providing consultancy to companies wishing to enter hearing loss and tinnitus markets<br />
• Brokering relationships between academia and pharma/biotech companies<br />
• Funding high quality academic science<br />
SENIOR MANAGEMENT<br />
Jackie Ballard, Chief Executive Officer • Ralph Holme, Director • Denise Goldman, Manager • Sohaila Rastan, Chief Scientific Officer<br />
BIO Business Forum 2011 414 Participating Company <strong>Profiles</strong>
William Brody<br />
President<br />
10010 North Torrey Pines Road<br />
La Jolla, CA 92037<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Paul Roben, PhD, Director, Business Development<br />
Rachel Mullen, Marketing and Licensing Associate<br />
The Salk Institute for Biological Studies<br />
www.salk.edu<br />
Phone: 1-858-453-4100<br />
Ownership: Private<br />
CORPORATE MISSION<br />
In 1960, just five years after developing the first safe, effective vaccine against polio, Jonas Salk, MD founded the institute that today bears<br />
his name. Home to 11 Nobel laureates since its founding, the Salk Institute for Biological Studies is a global leader in life science research<br />
and is advancing our understanding of disease and helping to drive new cures for patients. With a research budget approaching $100<br />
million per year, the Institute employs over 1100 faculty, staff and research associates, plus post-doctoral fellows and pre-doctoral<br />
students.<br />
The Institute's areas of major focus are Neurobiology, Oncology, Metabolism and Plant Science. The 60 laboratories that make up Salk are<br />
devoted to basic research in molecular, cellular, cognitive, systems and computational neurobiology; chemical biology and proteomics;<br />
infectious diseases; gene expression; gene therapy; molecular, cell, structural and regulatory biology, plant biology and genetics.<br />
Further information and links to scientist/laboratory websites can be found at www.salk.edu.<br />
PROPRIETARY TECHNOLOGY<br />
As a non-profit research institute focused on biological discovery and early stage research, we depend on collaborations and partnerships<br />
with commercial entities to translate our discoveries into products and cures for patients that ultimately improve human health. We are<br />
seeking to advance our technologies through new corporate partnerships, spin-out company formation and out-licensing opportunities.<br />
For a list of technologies available for licensing, see: http://www.salk.edu/faculty/technologies.html<br />
SENIOR MANAGEMENT<br />
William Brody, President • Marsha Chandler, Executive Vice President • Kim Witmer, Chief Financial Officer • Julia Miller, General<br />
Counsel • William Brody, President<br />
BIO Business Forum 2011 415 Participating Company <strong>Profiles</strong>
1840 Century Park East, Suite 400<br />
Los Angeles, CA 90067<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Samuel Renwick, Managing Director<br />
CORPORATE MISSION<br />
The Salter Group<br />
www.saltergroup.com<br />
Phone: 1-310-552-3774<br />
Incorporated: 2002<br />
Employees: 20<br />
Ownership: Private<br />
For the past nine years, Salter Group has been a leading financial and strategic advisory firm specializing in providing independent<br />
forecasting services, valuations, financial opinions, financial and strategic advisory services and transaction support. In our life sciences<br />
group, our professionals have completed in excess of 330 engagements totaling over $7 billion in asset and transaction values specific to<br />
the biopharmaceutical, device and diagnostic and research tool sectors for companies, private equity, venture and hedge funds, and<br />
capital markets constituents. Across all industry sectors, our firm has completed in excess of 1000 engagements totaling more than $105<br />
billion in asset and transaction values.<br />
We offer a unique perspective for the development of forecasts, valuations and advisory services by combining the analytical and<br />
modeling rigor of a capital markets constituent with a robust data-intensive primary and secondary research capability that spans<br />
100,000’s of thought leaders, care providers, payors and other experts through our partners. We do this in a flexible and cost-efficient<br />
manner. Rather than relying on a significant up-front fee regardless of whether a transaction closes (the model for many consulting<br />
firms), we have the flexibility to earn our fees in a different fashion, charging less up front but earning a fee if a transaction is successfully<br />
completed. The end result is a cost-effective integrated research and model solution that can help your company be better prepared in<br />
your discussions with licensing partners, investors, lenders or acquirers.<br />
BIO Business Forum 2011 416 Participating Company <strong>Profiles</strong>
5801 South Ellis Avenue<br />
Chicago, IL 60637<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Robert Forgey<br />
The University of Chicago<br />
Clinical Foci: Oncology • Metabolic Disease • Pharmacogenetics<br />
http://corporate.uchicago.edu/<br />
Phone: 1-773-834-4815<br />
Incorporated: 1892<br />
Employees: 2500<br />
Ownership: Private<br />
CORPORATE MISSION<br />
At the University of Chicago, we take seriously our part in the enormous task of generating new knowledge for the benefit of present and<br />
future generations. Our agenda-setting faculty crosses traditional disciplinary boundaries to transform the way we understand business,<br />
economics, history, law, literature, religion, physics, chemistry, and biology and medicine, among other fields. In this spirit of discovery, we<br />
train future generations of scholars, scientists, educators, and world leaders.<br />
BIO Business Forum 2011 417 Participating Company <strong>Profiles</strong>
Sydnovate, SIT Building J12<br />
The University of Sydney, NSW 2006<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Kailing Wang, Business Development Manager<br />
Gregory N. Ward<br />
The University of Sydney<br />
Clinical Foci: Other<br />
www.sydney.edu.au<br />
Phone: 61-02-9351 4000<br />
Ownership: Private<br />
CORPORATE MISSION<br />
The University of Sydney, founded in 1850, is Australia's first university, and has an international reputation as a centre of research<br />
excellence in Australia. It offers an extensive portfolio of novel and exciting technologies, expertise and services that cover the entire<br />
spectrum of modern science and technology. The University also has close alliances with leading Australian research institutes and<br />
hospitals, contributing to its reputation as Australia's leading research University. Sydnovate is the commercial arm of the University of<br />
Sydney, responsible for the commercialisation of Intellectual Property (IP) developed at the University. The main mission of Sydnovate is to<br />
ensure that technologies, innovations and expertise from the University of Sydney will be used to develop successful products for the<br />
benefit of the public. Our key objective at BIO2011 is to seek potential licensees for our research innovation, to establish partnerships with<br />
industry and to collaborate with them in turning the University’s research excellence into useful and successful products. We also<br />
welcome speculative inquiries as we have a wide range of research interests and early stage technologies which may strategically fit<br />
industry requirements.<br />
PROPRIETARY TECHNOLOGY<br />
Sydnovate offers a patent portfolio covering a broad range of innovative biotechnologies including therapeutics, diagnostics, medical<br />
devices, drug delivery, veterinary products, enabling technologies and biomaterials. We assist industry and government to access the<br />
University's research, expertise and IP. Some of the key licensing opportunities include: • Lead series targeting cancer • Lead series<br />
targeting neurodegenerative diseases • Demibody technology • Wound healing technology for chronic ulcers and burns • Anti-fungal and<br />
anti-bacterial lead series • Nano-particle drug delivery<br />
PRODUCTS<br />
Name Phase Indication<br />
Lead series targeting cancer Preclinical cancer<br />
Lead series targeting CNS disorders Preclinical CNS<br />
Wound Healing technology Phase II, IIa, IIb Wound care<br />
anti-infective agents Preclinical fungal and bacteria species<br />
Iron chelators Lead Series iron overload disease<br />
Demibody technology Research cancer<br />
Nanopartical drug delivery Phase I drug delivery<br />
bioactive hydrogels Research process<br />
Prevention of neurotropic Virus Transport Target Validated HSV<br />
tissue enginerring scaffolds Research drug delivery<br />
BIO Business Forum 2011 418 Participating Company <strong>Profiles</strong>
Steve Gillis, PhD<br />
President<br />
1124 Columbia Street<br />
Seattle, WA 98104<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Kristine Swiderek<br />
Theraclone Sciences, Inc<br />
Clinical Foci: Infectious Disease • Oncology • Drug Discovery<br />
www.theraclone-sciences.com<br />
Phone: 1-206-805-1600<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
In January 2011, Theraclone anounced collaboration with Pfizer for<br />
the discovery of therapeutic antibodies in oncology and infectious<br />
disease indications.<br />
In a July 2010 publication of PNAS, Theraclone announced the<br />
discovery of novel human antibodies against a highly conserved<br />
epitope on influenza A viruses.<br />
In Otober 2009 we announced that we entered into a collaboration<br />
with Zenyaku Kogyo to use our I-STAR for the discovery of broadly<br />
protective monoclonal antibodies for the treatment of pandemic<br />
influenza and severe seasonal influenza.<br />
Ownership: Private<br />
Enter clinic in H211 with TCN-032, the lead anti-influenza<br />
therapeutic antibody drug candidate.<br />
IND filing 2H11 for TCN-202, the lead anti-HCMV therapeutic<br />
antibody drug candidate.<br />
Additional corporate partnerships in influenza, HCMV, or other<br />
indications and for technology platform in 2011-2012<br />
CORPORATE MISSION<br />
Headquartered in Seattle, Theraclone Sciences is a discovery-stage biotechnology company developing novel therapeutic antibodies for<br />
the treatment of infectious disease and oncology. Our proprietary discovery platform allows us to comprehensively screen and identify the<br />
rare antibodies that select individuals produce to successfully ward off disease. Central to our discovery approach, we identify antibodies<br />
produced naturally by human memory B cells in response to disease. This allows us to identify monoclonal antibodies that are likely to be<br />
highly effective in combating disease in a broad patient population. The antibodies identified through our discovery process can be<br />
further studied as tools for vaccine development. Our most advanced development programs are focused on infectious disease including<br />
novel antibodies to fight pandemic and severe seasonal influenza and cytomegalovirus infections. We have also partnered with the<br />
International AIDS Vaccine Initiative (IAVI) to identify two of the most potent and broadly neutralizing anti-HIV antibodies yet discovered,<br />
despite more than 10 years of intensive research by investigators worldwide. Theraclone is a venture-funded company founded in 2005.<br />
Our investors include ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM, and AREE. We are actively<br />
seeking development partners in the U.S., Europe, and Japan to help us create and commercialize antibody therapeutic products.<br />
PROPRIETARY TECHNOLOGY<br />
I-STAR Technology. The human immune system responds to pathogens, like viruses and bacteria, by evolving in real time highly<br />
protective proteins called antibodies. The immunological history of these protective responses is archived in human memory B cells, a<br />
specialized type of blood cell. The I-STAR platform allows comprehensive interrogation of this memory B cell archive. Theraclone's<br />
technology is unique because it enables us to rapidly test the function of tens of thousands of natural human antibodies to find those<br />
with exceptional biological activities. The antibodies identified through our discovery process are appropriate for further study as novel<br />
therapies to help patients fight existing disease.<br />
CORPORATE ALLIANCES<br />
Funded collaboration agreement with Zenyaku Kogyo for the discovery and development of antibodies for the treatment of pandemic and<br />
severe seasonal influenza. Funded collaboration agreement with Pfizer for the discovery of therapeuitc antibody candidates for<br />
indications in oncology and infectious disease. Funded collaboration agreement with IAVI for the discovery of anti-HIV antibodies.<br />
INTELLECTUAL PROPERTY<br />
Patents and patent applications filed for various infectious disease, inflammation, cancer and technology assets.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TCN-032 Preclinical Severe seasonal and pandemic influenza Clinical Entry H2 2011<br />
TCN-202 Preclinical HCMV infection IND Filing H2 2011<br />
TCN-350 Optimized Lead Asthma<br />
FINANCING HISTORY<br />
Investors: ARCH Venture Partners (0 %) • Canaan Partners (0 %) • HealthCare Ventures (0 %) • MPM (0 %) •<br />
Amgen (0 %) • Alexandria Real Estate Equities (0 %) • Zenyaku Kogyo (0 %)<br />
BIO Business Forum 2011 419 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Steve Gillis, PhD, President • Russ Hawkinson, Chief Financial Officer • Kristine Swiderek, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Steve Gillis, PhD (Chairman), President, Theraclone Sciences; Managing Director, ARCH Venture Partners • Wende Hutton, Canaan<br />
Partners • Chris Mirabelli, PhD, HealthCare Ventures<br />
SCIENTIFIC ADVISORY BOARD<br />
K. Frank Austen, MD, Harvard Medical School • Laurie Glimcher, MD, Harvard Medical School • Robert Schooley, MD, UCSD • Robert<br />
Lamb, PhD, Northwestern University<br />
BIO Business Forum 2011 420 Participating Company <strong>Profiles</strong>
David Dellamonica<br />
Chief Executive Officer<br />
2229, route des Crêtes<br />
06560 Valbonne Sophia Antipolis<br />
France<br />
CONFERENCE PARTICIPANTS<br />
David Dellamonica, CEO<br />
Theralpha SAS<br />
Clinical Foci: Biopharmaceuticals • Specialty Pharmaceutical • CNS<br />
www.theralpha.com<br />
Phone: 33-6-25183239<br />
Incorporated: 2009<br />
Employees: 4<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Theralpha entered recently into a collaboration and business agreement with Flamel Technologies to<br />
develop controlled-release formulation of one of our analgesic peptide<br />
Recent developments have demonstrated that THA902 is more powerful than classical drugs in postoperative<br />
pain models.<br />
In January 2011, we have applied for a new patent (PCT) for THA903.<br />
Theralpha is looking to<br />
raise €8million for its first<br />
round<br />
CORPORATE MISSION<br />
Theralpha is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the<br />
treatment pain. Our lead product, THA903, is designed to address acute pain by sublingual administration. We have three additional<br />
product candidates in preclinical development. We are advancing next generation pain drugs based on scientifically validated Acid<br />
Sensing Ion Channel (ASIC) pathways.<br />
Current therapies are often inadequate, have side effects, or are under-prescribed due to the dangers of addiction. There has been a lack<br />
of clinical breakthroughs in recent years, instead of Current therapies are often inadequate or have side effects, and there has been lack of<br />
clinical breakthroughs.<br />
PROPRIETARY TECHNOLOGY<br />
The company’s founding assets originate from worldwide exclusive licenses from IPMC (Institut de Pharmacologie Moleculaire, CNRS,<br />
Sophia Antipolis, France) and Singapore University. Specifically, the IPMC-originating assets represent discoveries made by Professor M.<br />
Lazdunski and his team at IPMC, who have pioneered for more than 10 years the discovery of peptides found in animal venoms that<br />
selectively inhibit Acid Sensing Ion Channels (ASICs) which are directly implicated in pain signal transmission.<br />
CORPORATE ALLIANCES<br />
Theralpha SAS today announced that it has entered into a joint development program with Flamel Technologies (NASD: FLML) for a<br />
Medusa®-enabled, long-acting formulation of Theralpha’s THA-902. THA902 is a natural peptide that is a potent and highly specific Acid<br />
Sensing Ion Channel 3 (ASIC 3) inhibitor.<br />
It is effective in inflammatory pain animal models following subcutaneous injection and has a number of possible indications, including<br />
post-operative pain, osteoarthritis pain and fibromyalgia. The development agreement has been structured to leverage Theralpha’s<br />
pioneering intellectual property regarding Acid Sensing Ion Channels (ASICs)<br />
INTELLECTUAL PROPERTY<br />
Six patent families supporting drug candidates<br />
Extensive agreement with IPMC for right of first refusal on any pain therapeutics discovered at IPMC.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
THA902 Preclinical Inflammatory pain, (RA, OA, POP)<br />
THA903 Preclinical Acute and chronic non-neuropathic pain SubAlgic Project<br />
THA901/904 Preclinical Chronic intractable pain, neuropathic pain<br />
FINANCING HISTORY<br />
Investors: David Dellamonica (0 %) • Marc Vasseur (0 %) • Michel Lazdunski (0 %)<br />
SENIOR MANAGEMENT<br />
David Dellamonica, Chief Executive Officer • Marc Vasseur, President • Michel Lazdunski, Chief Scientific Officer • Cyril, Chief<br />
Technology Officer • Brigitte, Chief Medical Officer<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Carlos Belmonte, president IBRO, Director of the Instituto de Neurociencias de Alicante • Christian Jorgensen, Inflammatory<br />
pain specialist, Head of the Service d'Immuno-Rhumatologie of Hôpital Lapeyronie, head of INSERM unit 844 • Professor Michel Lanteri-<br />
Minet, Head of the Unit for Evaluation and Pain Treatment (CHU, Nice) , President of the Société Française d'Etude et d<br />
BIO Business Forum 2011 421 Participating Company <strong>Profiles</strong>
Glenn D Hoke, PhD<br />
President & CEO<br />
15010 Broschart Road<br />
Rockville, MD 20850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ronald Hencin<br />
CORPORATE MISSION<br />
Theranostics Health<br />
Clinical Foci: Oncology • Diagnostics • Other<br />
www.theranosticshealth.com<br />
Phone: 1-301-251-4443<br />
Incorporated: 2007<br />
Ownership: Private<br />
Theranostics Health is a leading provider of proteomic services whose resources and capabilities offer unique opportunities for pursuing<br />
protein-based biomarker discovery or translational research strategies. Our technologies are of particular value for biomarker discovery<br />
and translational research efforts involving Molecular Targeted Therapies, and allow for insights into the phospho-activation status of<br />
drug targets and receptors, their downstream signal transduction pathways, as well as potential survival or adaptive mechanisms within<br />
targeted cell populations.<br />
PROPRIETARY TECHNOLOGY<br />
Reverse-phase Protein Microarray (RPMA) is a proteomic platform that allows for the simultaneous analysis of hundreds of clinical or<br />
experimental samples in the presence of proteomic calibration standards. The RPMA assay’s sensitivity allows for the measurement of<br />
analytes from picogram to attogram amounts of protein lysates. Currently, several hundred assays are available that target surface<br />
receptors, signaling pathways, transcriptional factors, nuclear proteins, etc.<br />
Laser Capture Microdissection (LCM) selectively capturing specific cells of interest (e.g. tumor, stromal, epidermal cells, etc.) for proteomic<br />
analysis. Pathologist-directed LCM services are available for liquid nitrogen frozen and FFPE-prepared tissues, as well as for excised tissue<br />
and core needle biopsy samples.<br />
CORPORATE ALLIANCES<br />
George Mason University's Center for Applied Proteomics and Molecular Medicine<br />
Duke University<br />
SENIOR MANAGEMENT<br />
Glenn D Hoke, PhD, President & CEO • Ronald S. Hencin, PhD, Vice President<br />
BIO Business Forum 2011 422 Participating Company <strong>Profiles</strong>
Rick E Winningham<br />
Chief Executive Officer<br />
901 Gateway Boulevard<br />
South San Francisco, CA 94080<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
David L. Brinkley<br />
William Martin<br />
Clint Rogers , PHD,MBA, Director, Business Development<br />
CORPORATE MISSION<br />
Theravance, Inc<br />
Clinical Foci: Pulmonary • Infectious Disease • Gastroenterology<br />
www.theravance.com<br />
Phone: 1-650-808-6000<br />
Discovery and early development of significantly differentiated medicines.<br />
PROPRIETARY TECHNOLOGY<br />
Application of multivalent drug design to discover and develop signficantly improved therapies.<br />
CORPORATE ALLIANCES<br />
GSK (two alliances), Astellas, AstraZeneca<br />
INTELLECTUAL PROPERTY<br />
Over 200 granted U.S. patents.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Incorporated: 1996<br />
Employees: 200<br />
Ownership: Public<br />
Market Cap: $2000.00 million<br />
NASDAQ: THRX<br />
TD-1792 Phase II, IIa, IIb Serious Gram-positive infections Completed Phase 2 vs, vancomycin<br />
TD-5108 Phase III Chronic constipation Phase 3 ready<br />
TD-4208 Phase II, IIa, IIb COPD in Phase 2<br />
TD-1607 Preclinical Serious Gram-positive infections IND-enabling safety<br />
TD-1211 Phase II, IIa, IIb Opioid-induced constipation in Phase 2<br />
TD-5108 Phase I Alzheimer's Disease Phase 2 ready<br />
ARNI Preclinical Hypertension, CHF<br />
MARIN Phase I Chronic pain in Phase 1<br />
Heterodimeric NS5A inhibitor Preclinical HCV<br />
PRIZM Preclinical CHF, HTN, CKD, PAH<br />
SENIOR MANAGEMENT<br />
Rick E Winningham, Chief Executive Officer • Mike Aguiar, Chief Financial Officer • Brad Shafer, General Counsel • Leonard Blum,<br />
Chief Business Officer • David Brinkley, Business Development • Mathai Mammen, Senior Vice President<br />
BIO Business Forum 2011 423 Participating Company <strong>Profiles</strong>
Xiaoming Zhang, PhD<br />
Chief Executive Officer<br />
365 San Aleso Avenue<br />
Sunnyvale, CA 94085<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Xiaoming Zhang, PhD<br />
Terence G. Porter, Business Development Advisor<br />
Theron Pharmaceuticals Inc<br />
Clinical Foci: Pulmonary • Drug Discovery • Drug Development<br />
www.theronpharma.com<br />
Phone: 1-408-792-7424<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Theron Pharmaceuticals Presented at the American Thoracic<br />
Society Conference on May 15th, 2011 in Denver, Colorado<br />
Theron Pharmaceuticals Presented at the BIO-Europe Spring<br />
Conference on March 16, 2011 in Milan, Italy<br />
CORPORATE MISSION<br />
Incorporated: 2008<br />
Employees: 6<br />
Ownership: Private<br />
Theron's CEO, Xiaoming Zhang, will present at the 11th Annual US-<br />
Japan Health Sciences Dialogue on June 6th-7th in Philadelphia.<br />
Theron Pharmaceuticals is a private, preclinical stage, Biotechnology company developing a best-in-class long acting M3 muscarinic<br />
antagonist (LAMA) targeting the multi-billion dollar chronic obstructive pulmonary disease (COPD) and asthma disease markets.<br />
PROPRIETARY TECHNOLOGY<br />
TRN-157, Theron’s lead development candidate is a best-in-class, once-a-day, long acting M3 muscarinic antagonist (LAMA) targeting the<br />
multi-billion dollar chronic obstructive pulmonary disease (COPD) and asthma disease markets. TRN-157 has the exciting potential to<br />
overcome the multi-drug combination and delivery device compatibility limitations of tiotropium the only approved LAMA. TRN-157 is as<br />
potent and long-acting as tiotropium with the versatility to be used in drug combinations and inhaled delivery systems of choice. Theron<br />
feels strongly that a versatile, once-a-day, LAMA such as TRN-157 will be a critical requirement for any strong COPD portfolio, being a key<br />
component of future combination products. Recent evidence also suggests the value of a LAMA for severe asthma.<br />
SENIOR MANAGEMENT<br />
Xiaoming Zhang, PhD, Chief Executive Officer • Jurg Pfister, PhD, Chairman • M. (Venkat) Venkatraman, PhD, Director • Agnes<br />
Choppin, PhD, Director<br />
BOARD OF DIRECTORS<br />
James Larrick, MD, PhD, Founder, Panorama Research Institute and Venture Partner, Life Sciences, CMEA Capital • Cary Queen, PhD,<br />
President, Galaxy Biotech and Co-founder, PDL • Allan Kramer, MD, Chairman, Bridge Bank<br />
SCIENTIFIC ADVISORY BOARD<br />
Douglas Hay, PhD, President, Hay Drug Discovery Consulting, LLC Former VP of COPD Drug Discovery, GSK • Phil Haywood, PhD,<br />
Managing Director, Haywood Consulting; Former Head of Inhalation Development, Novartis and GlaxoWelcome • Jeffrey Edelson, MD<br />
FRCPC MHSc, Chief Medical Officer, Palatin Technologies; Principal, Aequanimitas Consulting • Tim McGovern, PhD,<br />
Toxicology/Regulatory Consultant, Scilucent; Former Supervisory Pharmacologist, FDA, Division of Pulmonary and Allergy • Terry Porter,<br />
PhD, Managing Director, Aqua Partners Former VP External Science & Technology, Worldwide Business Development, GSK<br />
BIO Business Forum 2011 424 Participating Company <strong>Profiles</strong>
77 Hatton Garden<br />
London<br />
EC1N 8JS<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Jeff Levine<br />
Joseph D. McCarthy<br />
THOMSON REUTERS<br />
Clinical Foci: Drug Development • Drug Discovery • Biopharmaceuticals<br />
www.thomsonreuters.com<br />
Phone: 44-207-434 000<br />
Ownership: Public<br />
Market Cap: $33000.00 million<br />
NYSE : TRI<br />
CORPORATE MISSION<br />
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals.<br />
We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal,<br />
tax and accounting, healthcare, science and media markets, powered by the world’s most trusted news organization.<br />
Thomson Reuters Pharma and Forecast<br />
Competitor intelligence database integrating more than 40 pharmaceutical data sources, unique abstracts, commentaries and analysis.<br />
PROPRIETARY TECHNOLOGY<br />
Analyst Research, Drug Sales Data, pharmacy drug pricing data, Biosimilars database, Drug revenue models, indication investment<br />
analysis<br />
PRODUCTS<br />
Name Phase Indication<br />
Thomson Reuters Pharma Other all<br />
Thomson Reuters Forecast Other all<br />
BIO Business Forum 2011 425 Participating Company <strong>Profiles</strong>
Ramon Bejar<br />
President<br />
CIF: B-63753800, P.Medit. Tecnologia<br />
08860 Castelldefels Barcelona<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Ramon Bejar<br />
Ignasi Miquel, Strategic Alliances Director<br />
Juan Ramon Rodriguez<br />
Pila Sanchez, Commercial Operations<br />
Thrombotargets Europe SL<br />
Clinical Foci: Hematology • Biopharmaceuticals • Diagnostics<br />
www.thrombotargets.com<br />
Phone: 34-936-642040<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
FDA Orphan Drug Extension for TT-173. At present, TT-173 has<br />
Orphan Drug Designation for its use in the topical treatment of<br />
hemorrhages due to cutaneous injuries or dental procedures both<br />
in Hemophilicas and von Willebrand patients<br />
Preclinical Data Accepted by Spanish Drug Agency (AEMPS).<br />
Proposed Phase I clinical protocol accepted. According to AEMPS, it<br />
will support Phase II clinical trials in minor/major surgery<br />
Innovative 3 Dimensional biosensors technology in licensed<br />
Incorporated: 2005<br />
Ownership: Private<br />
Clinical Phase I for TT-173 Q4 2011.<br />
Alzheimer diagnostic kit prototipe Q4 2012. Multianalyte simple<br />
and reliable assay based on in-licensed 3D Biosensor technology.<br />
NTRs first commercial use in transfection reagent Q2-Q3 2013.<br />
Additional applications in Drug Delivery, Imaging, and Transient<br />
Gene Therapy afterwards.<br />
CORPORATE MISSION<br />
Thrombotargets Europe is a Biotechnology company incorporated in 2005, and focused on the development of new therapeutics on the<br />
hemostasis and thrombosis field (TT-173, a Tissue Factor-based topical hemostat, entering clinical trials Q4 2011). Thrombotargets is<br />
interested in in-licensing medical devices, in vitro diagnostics and dental products and devices for its comercialization in Spain, the 7th<br />
largest pharmaceutical market worldwide. Thrombotargets is offering services in recombinant protein production at small, medium and<br />
large scale. This service includes protein production in E.coli, Yeast, Mammalian and insect cells. Thrombotargets is developing 3D-IDEA<br />
biosensor-based diagnosis platform, that is now developing with different biomarkers.<br />
PROPRIETARY TECHNOLOGY<br />
3D-IDEA are 3D Biological Sensors for the detection of analytes in biological samples. It van be used for the detection of biomarkers for<br />
prognosis or diagnosis, but also in the detection of residues in food, enviromental control...<br />
NTRs are self-assembling peptide based nanoparticles that can be loaded with different molecules, or functionalized in their surface, for<br />
targeted drug delivery, transient gene therapy, transfection reagents, imaging...<br />
Bioplatformscreen is a HTS of Pathway Activity platform. It works in physiological-like humat matrix. and provides highly relevant<br />
biological information in 4 activities simultaneously: procoagulation, anticoagulation, fibrinolysis, antifibrinolysis.<br />
Recombinant protein production at all scales in diverse expression systems.<br />
CORPORATE ALLIANCES<br />
National Center for Biotechnology, CNB-CSIC (Madrid, Spain)<br />
CNM-CSIC (Barcelona, Spain)<br />
SPECS (Delft, NL)<br />
LIPPSO, Univ. Girona (Girona, Spain)<br />
IUCT (Mollet, Spain)<br />
PPQF (UAH, Alcalá, Spain)<br />
AMRg-CIBER (Barcelona, Spain)<br />
INTELLECTUAL PROPERTY<br />
IPRs for all products and technologies that are being developed are protected in the most convenient way according to their particulart<br />
status.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TT-173 Preclinical Topical Hemostat Clincial I, Q3 2011<br />
3D-IDEA Diagnostic Platform Diagnostics Biosensor technology useful for<br />
biomarker detection in all conditions<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Seed Round: 10/04/2005 (US $0.85 million)<br />
Round A: 12/31/2006 (US $2.73 million)<br />
POC on a multianalyte simple and<br />
highly sensible diagnostic kit, 2012<br />
Round B: 11/05/2007 (US $6.44 million)<br />
Round C: 10/08/2009 (US $3.78 million)<br />
BIO Business Forum 2011 426 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Ramon Bejar, President • Juan Ramon Rodriguez, Chief Scientific Officer • Ignasi Miquel, Chief Business Officer • Pilar Sanchez,<br />
Business Development • Luis Motje, Chief Financial Officer<br />
BIO Business Forum 2011 427 Participating Company <strong>Profiles</strong>
Thomas A. Tóth von Kiskér<br />
Chief Executive Officer<br />
Baslerstrasse 15<br />
4310 Rheinfelden<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Tillotts Pharma AG<br />
Clinical Foci: Gastroenterology<br />
www.tillotts.com<br />
Mr. Dirk Reckert, Business Development & Licensing Director<br />
CORPORATE MISSION<br />
Phone: 41-61-9352 622<br />
Employees: 150<br />
Ownership: Other<br />
Tillotts Pharma is a fast-growing speciality pharma company with over 150 employees in Switzerland and abroad. We are dedicated to the<br />
development, in/out-licensing and marketing of innovative pharmaceutical products, medical devices and diagnostics, all in the field of<br />
gastroenterology.<br />
We successfully market our own products Asacol® and Colpermin® as well as in-licensed products in over 55 countries through our<br />
affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world.<br />
PROPRIETARY TECHNOLOGY<br />
ASACOL<br />
Thanks to its sophisticated delivery system Tillotts’ ASACOL (Mesalazine) is the first choice drug for the treatment of Ulcerative Colitis and<br />
is also widely used in Crohn’s Disease.<br />
COLPERMIN<br />
COLPERMIN for irritable bowel syndrome (IBS) is a natural product containing peppermint oil presented in enteric coated capsules.<br />
COLPERMIN is a recognised and safe treatment for some of the troublesome symptoms of IBS. Since its first launch in 1981, over 1 billion<br />
capsules have been sold worldwide.<br />
CORPORATE ALLIANCES<br />
Tillotts products are successfully introduced in more than 54 countries through our established marketing and sales infrastructure and a<br />
network of carefully selected distributors as well as licensees.<br />
PRODUCTS<br />
Name Phase Indication<br />
ASACOL On Market IBD<br />
COLPERMIN On Market IBS symptoms<br />
SENIOR MANAGEMENT<br />
Thomas A. Tóth von Kiskér, Chief Executive Officer<br />
BIO Business Forum 2011 428 Participating Company <strong>Profiles</strong>
Stuart Collinson, PhD<br />
Chief Executive Officer<br />
9393 Towne Centre Drive Ste. 200<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
David Urso, COO & General Counsel<br />
Stuart Collinson, Chairman and CEO<br />
Tioga Pharmaceuticals<br />
Clinical Foci: Gastroenterology<br />
www.tiogapharma.com<br />
Phone: 1-858-677-6077<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
In 2011 Tioga initiated Phase 3 development of asimadoline for D-IBS.<br />
In 2011 Tioga reached agreement with FDA on a Special Protocol Assessment (SPA) governing the<br />
design, execution and analysis of the Phase 3 clinical trials of asimadoline for D-IBS.<br />
In 2011 Tioga raised $18 million to fund Phase 3 development of asimadoline for D-IBS.<br />
In the first half of next year (2012)<br />
Tioga anticipates receiving the data<br />
from its first Phase 3 clinical trial of<br />
asimadoline for D-IBS.<br />
CORPORATE MISSION<br />
Tioga Pharmaceuticals, Inc. is a private, venture backed company developing novel therapies for the treatment of gastrointestinal<br />
diseases. Tioga's lead compound, asimadoline, is currently in Phase 3 clinical development for the treatment of diarrhea predominant<br />
irritable bowel syndrome (D-IBS).<br />
Data from the first Phase 3 D-IBS trial is expected 1H 2012.<br />
Asimadoline is a proprietary, small molecule, a peripherally restricted highly selective kappa opioid agonist. To date, asimadoline has<br />
been administered to over 1200 subjects and has an excellent safety profile.<br />
Tioga has a Special Protocol Assessment with FDA governing the design, execution and analysis of the Phase 3 protocols for the treatment<br />
of D-IBS.<br />
Tioga acquired all worldwide rights to asimadoline by assignment from Merck KGaA in 2005.<br />
PROPRIETARY TECHNOLOGY<br />
In a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical trial involving 596 subjects, asimadoline demonstrated<br />
statistically significant results in the treatment of Irritable Bowel Syndrome (IBS). Asimadoline produced significant improvement in<br />
diarrhea-predominant (D-IBS) and alternating (A-IBS) patients across multiple parameters including the primary endpoint of pain, as well<br />
as secondary endpoints of urgency, frequency and bloating in both males and females. In D-IBS patients, therapeutic benefit was observed<br />
within the first month of treatment and was sustained for the three month duration of the trial. Asimadoline was well tolerated with no<br />
adverse events occurring in a dose-dependent manner throughout the trial<br />
CORPORATE ALLIANCES<br />
Tioga has an alliance with Ono Pharmaceutical Co. to develop and commercialize asimadoline in Japan, South Korea and Taiwan.<br />
Tioga retains all other worldwide rights to asimadoline.<br />
INTELLECTUAL PROPERTY<br />
Tioga owns 170 issued patents and 87 pending patents around the world relating to asimadoline.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
asimadoline Phase III Diarrhea Predominant IBS Data from first Phase 3 D-IBS trial is expected 1H 2012<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Seed Round: 06/15/2005 (US $1.00 million)<br />
SENIOR MANAGEMENT<br />
Round A: 12/31/2005 (US $23.00 million)<br />
Round B: 04/15/2011 (US $18.00 million)<br />
Stuart Collinson, PhD, Chief Executive Officer • David Urso, Chief Operating Officer • Allen Mangel MD, PhD, Chief Medical Officer •<br />
Gareth Hicks PhD, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Stuart Collinson PhD, Forward Ventures • David Urso, Tioga COO & General Counsel • Jim Niedel MD, PhD, New Leaf Venture Partners<br />
• Martin Meunchbach, PhD, BB Biotech Ventures • Arno Hartmann PhD, Merck Serono<br />
BIO Business Forum 2011 429 Participating Company <strong>Profiles</strong>
Dr. Morag McFarlane<br />
Chief Scientific Officer<br />
Titan Enterprise, Suite 29, 1 Aurora Ave<br />
Clydebank Glasgow<br />
G81 1BF<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Ann Cooreman, COO<br />
CORPORATE MISSION<br />
TISSUE SOLUTIONS LTD<br />
Clinical Foci: Biomaterials • Biomaterials<br />
www.tissue-solutions.com<br />
Phone: 44-141-951 7885<br />
Incorporated: 2007<br />
Employees: 6<br />
Ownership: Private<br />
TISSUE SOLUTIONS – HIGH QUALITY HUMAN TISSUES AND BIOMATERIALS<br />
Tissue Solutions offers a single point to access the entire range of human biological materials, diseased and normal tissues, body fluids<br />
(e.g. blood, serum, plasma, CSF, ascites, synovial fluid), etc.<br />
We find the material our clients require for pre-clinical drug discovery and drug development supporting:<br />
• Diagnostics,<br />
• Biomarkers research,<br />
• Xenograft models,<br />
• Translational medicine.<br />
BANKED HUMAN TISSUES: frozen tissues, formalin preserved paraffin embedded human tissues (FFPE): e.g. FDA/EMEA panel of Normal<br />
Tissues, cancer, autoimmune diseases, etc.<br />
FRESH AND HARD TO OBTAIN Human Tissues, such as:<br />
• psoriasis skin,<br />
• DRG’s fresh from transplant donors, frozen from post mortem or transplant donors<br />
• fresh skin<br />
• cancer samples with short Cold Ischemia Times<br />
• Fresh Cancer Tissue & Bloods (e.g. Prostate, Melanoma, Colon, Lung, Kidney, Ovary, Head and Neck, Liver, Pancreas,<br />
Glioblastoma, etc.)<br />
• PBMCs from a range of leukemias and lymphomas: AML, MM, ALL, CLL & CML when donors are available<br />
• CNS brain samples (e.g. PD, AD, schizophrenia, bipolar, Lewy body and controls)<br />
HUMAN ISOLATED CELLS: e.g. Pancreatic Islets, hepatocytes<br />
PROSPECTIVE COLLECTIONS with Ethics Approval – Clinical Collaborations<br />
SERVICES:<br />
• Immunohistochemistry (IHC)<br />
• FDA Ab Cross-reactivity studies<br />
• Non-Invasive Biomarker Studies<br />
• Primary Cell Lines<br />
SENIOR MANAGEMENT<br />
Dr. Morag McFarlane, Chief Scientific Officer • Dr. Ann Cooreman, Chief Operating Officer<br />
BIO Business Forum 2011 430 Participating Company <strong>Profiles</strong>
Sunil Bhonsle<br />
President<br />
400 Oyster Point Boulevard, Suite 505<br />
South San Francisco, CA 94080<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Titan Pharmaceuticals, Inc<br />
Presenting Company<br />
Clinical Foci: CNS • Drug Delivery<br />
www.titanpharm.com<br />
Phone: 1-650-244-4990<br />
Sunil Bhonsle, MBA, President<br />
Marc Rubin , MD, Executive Chairman<br />
Katherine Beebe, PhD, Executive Vice President and Chief Development Officer<br />
John Selig<br />
Michael Mischke-Reeds<br />
Jeff Karan<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Publication in JAMA in Q4 2010 on Probuphine clinical results from<br />
the first controlled Phase 3 study.<br />
Completed $20 million debt financing in Q1 2011<br />
Completion of confirmatory Phase 3 study of Probuphine in opioid<br />
addiction – June 2011<br />
Incorporated: 1992<br />
Employees: 10<br />
Ownership: Public<br />
Market Cap: $120.00 million<br />
OTC BB: TTNP<br />
Pre-NDA meeting with FDA – Q3 2011<br />
Probuphine data presentations – International Society of Addiction<br />
Medicine – Nov 2011<br />
Announce commercial partnership deal for Probuphine<br />
CORPORATE MISSION<br />
Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous<br />
system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May<br />
2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled<br />
to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents. Titan's second product, Probuphine, is<br />
nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel,<br />
subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This<br />
product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction<br />
PROPRIETARY TECHNOLOGY<br />
Titan is currently developing its long term drug delivery technology and its first product using this technology, Probuphine, is in Phase 3<br />
testing for the treatment of opioid addiction. The technology can provide 24 hour drug release for up to one year and deliver stable blood<br />
levels of drug which are advantageous in many CNS diseases.<br />
Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single<br />
treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid<br />
addiction and the data from its second Phase 3 trial is expected later this month (June 2011).<br />
CORPORATE ALLIANCES<br />
Titan’s first marketed drug, Fanapt (iloperidone) is currently marketed by Novartis Pharma, AG.<br />
Titan is currently exploring a commercial partner for its second drug, Probuphine, for the treatment of opiate addiction and secondarily,<br />
chronic pain.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Probuphine Phase III Opioid<br />
Addiction<br />
Completion of confirmatory Phase 3 study of<br />
Probuphine in opioid addiction – June 2011<br />
SENIOR MANAGEMENT<br />
Sunil Bhonsle, President • Marc Rubin, MD, Chairman • Katherine L. Beebe, PhD, Executive Vice President • Brian Crowley, Vice<br />
President • Raj Patel, PhD, Vice President • Sunil Sreedharan, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Marc Rubin, MD, Titan Pharmaceuticals, Inc. • Victor J. Bauer, PhD • Eurelio M. Cavalier • Hubert E. Huckel, MD • M. David<br />
MacFarlane, PhD • Ley S. Smith<br />
BIO Business Forum 2011 431 Participating Company <strong>Profiles</strong>
Utrechtseweg 48<br />
3704HE Zeist<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
TNO Life Sciences, Inc.<br />
Clinical Foci: Drug Development • Biopharmaceuticals • Metabolic Disease<br />
www.tno.nl<br />
Peter Van Dijken, PhD<br />
Robert Ostendorf, Business Development Manager Pharma<br />
Tineke Meijers, VP Business Development<br />
Phone: 31-88-866 6000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Launch of an Accelarator Mass Spectrometer (AMS) to support<br />
phase 0 microdosing studies following the current ICH M3 (R2)<br />
guideline. The machine is equipped for 14C, 41Ca and 129I.<br />
Safety testing:<br />
- Photosafety testing by using human skin models or ex vivo<br />
human skin (from surgery) as follow-up for the in vitro 3T3 NRU<br />
phototoxicity test.<br />
- Zebrafish model for safety testing and screening (livertox,<br />
pathology, reproductive tox)<br />
Mechanistic insights on efficacy and safety mechanism using<br />
systems toxicology and bioinformatics<br />
Incorporated: 1932<br />
Employees: 4200<br />
Ownership: Other<br />
Introduction of a diabetic nephropathy model induced in a<br />
metabolic disease model.<br />
Human 3D reconstituted tissue models (airway- and skin models)<br />
or ex vivo human skin to obtain more route specific exposure and<br />
relevant toxicological information.<br />
Development of toolbox for the prediction of immunogenicity of<br />
biologicals<br />
CORPORATE MISSION<br />
TNO is an independent research institute with its focus on 1) metabolic health and approaches towards personalized risk benefit analysis<br />
of drug interventions and development and 2) implementation of better predictive models by using innovative 3R methods (reduction,<br />
refinement and replacement of animal testing) for safety, efficacy and pharmcokinetics.<br />
TNO’s ambition is to help introducing Personalized Health approaches, with a focus on metabolic diseases together with more efficient<br />
safety testing. TNO has established first in class translational disease models for metabolic diseases and their complications and fort<br />
assessment of safety and PK parameters. These models are instrumental in “understanding” metabolic diseases, understanding efficacy<br />
and side effects of current drugs and in predicting responders vs. non-responders.<br />
Moreover, TNO offers a minimum safety testing strategy in which innovative methods such as omics and QSAR are combined with<br />
regulatory toxicity testing and expert judgment.<br />
We can perform all experimental work required, for underpinning the safety and efficacy of NCE’s and biopharmaceuticals, in compliance<br />
with international guidelines. This includes bioavailability, mass balance, active transporter and metabolism studies. We furthermore<br />
focus on reliable prediction of human bioavailability and organ concentration using unique in vitro gastrointestinal models (TIM) in<br />
combination with mucosal cell lines, ex vivo tissues, a variety of transporter and metabolizing assays, and in silico modelling.<br />
The in vitro and in vivo efficacy models TNO has to offer are for inflammatory and autoimmune diseases (inflammatory bowel disease,<br />
psoriasis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and fibrosis) and models to study lipid metabolism, atherosclerosis,<br />
insulin resistance and metabolic health / disease.<br />
PROPRIETARY TECHNOLOGY<br />
- Proprietary transgenic and conventional animal models for cardiovascular, metabolic and inflammatory diseases<br />
- Gastrointestinal models (TIM) predictive of drug bioavailability, drug-nutrient interactions and digestion<br />
- State-of-art systems biology and bioinformatics<br />
- TNO has an extensive track record performing in vitro transporter studies for regulatory purposes with human drug transporters such as<br />
MDR1, BCRP, MRP2 and OCT2. Among those all clinically relevant transporters as indicated in the white paper from the International<br />
Transporter Consortium, and in the draft guidance of the FDA and EMA as well as a wide range of other human, rat and murine uptake<br />
and efflux transporters.<br />
TNO recently generated HEK-cells stably overexpressing human OATP1B1*15, the natural variant of OATP1B1.<br />
CORPORATE ALLIANCES<br />
It is possible to collaborate with TNO in several business models with a strong scientific focus on preclinical and early clinical research. In<br />
addition to contract research services, we can also closely collaborate in development alliances. Through spin out companies and licenses<br />
we commercialize IP.<br />
TNO collaborates with top 10 Pharma and Biotech worldwide.<br />
BIO Business Forum 2011 432 Participating Company <strong>Profiles</strong>
Andrew Hindman<br />
President & CEO<br />
198 US Highway 9 North<br />
Manalapan, NJ 07726<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Kathleen McGowan, Vice President of Finance<br />
Robert Jacks<br />
Andrew A Hindman<br />
Tobira Therapeutics, Inc<br />
Clinical Foci: Infectious Disease<br />
www.tobiratherapeutics.com<br />
Phone: 1-732-863-5980<br />
HIGHLIGHTS<br />
Recent<br />
Initiation of Phase 2b clinical trial for Cenicriviroc in previously untreated HIV infected patients.<br />
Closing of $31M Series B financing.<br />
Incorporated: 2007<br />
Employees: 12<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Tobira Therapeutics acquires, develops and commercializes innovative products for the treatment of important and unmet medical needs<br />
in infectious diseases, with a current focus on HIV/AIDS. At Tobira, we are committed to creating value for patients, healthcare providers<br />
and other important stakeholders by building a world-class team, accelerating the development of our lead product candidate and<br />
expanding our pipeline through acquisitions and alliances.<br />
PROPRIETARY TECHNOLOGY<br />
Cenicriviroc (TBR-652) is an oral, dual CCR5/CCR2 antagonist currently in a Phase 2b clinical trial in previously untreated HIV infected<br />
individuals.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Cenicriviroc Phase II, IIa, IIb HIV Phase 2b data expected Q2 2012<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Seed Round: 10/01/2006 (US $1,000,000.00 million)<br />
Round A: 07/31/2007 (US $31,000,000.00 million)<br />
Round B: 07/31/2010 (US $31,000,000.00 million)<br />
SENIOR MANAGEMENT<br />
Andrew Hindman, President & CEO • Sandra M. Palleja, MD, Senior Vice President • David Martin, Senior Vice President • Kathleen<br />
McGowan, Vice President • Richard Ogden, Chief Scientific Officer • Robert Jacks, Senior Vice President<br />
BOARD OF DIRECTORS<br />
Laurent Fischer, MD, President and CEO, Ocera Therapeutics • Patrick Heron, General Partner, Frazier Healthcare Ventures • Dan<br />
Turner, General Partner/Managing Member, Mongreux Equity Partners • Michael Kamdar, EVP & CBO, VentiRx Pharmaceuticals •<br />
Andrew Hindman, President and CEO, Tobira Therapeutics • Carol Brosgart, MD, SVP & CMO, Children's Hospital & Research • Eckard<br />
Weber, MD, Partner, Domain Associates • Jack Nielsen, Partner, Novo Ventures<br />
SCIENTIFIC ADVISORY BOARD<br />
Dani Bolognesi, PhD, Chairman and CEO, B3Bio, Inc. • Paul Grint, MD, CMO and Head of Dev., Kalypsys • Gail Skowron, MD, Chief, Div.<br />
of Infectious Diseases, Roger Williams Medical Center • Michael Varney, PhD, VP, Small Molecule Drug Discovery, Genentech • Israel F.<br />
Charo, MD, PhD, Associate Director, Gladstone Institute of Cardiovascular Disease Translational Research and Development<br />
BIO Business Forum 2011 433 Participating Company <strong>Profiles</strong>
Harry Gruber MD<br />
President & CEO<br />
3030 Bunker Hill Street, #230<br />
San Diego, CA 92109<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Tocagen, Inc<br />
Clinical Foci: Oncology • Biopharmaceuticals • Gene/Cell Therapy<br />
www.tocagen.com<br />
Phone: 1-858-412-8400<br />
Nicholas A Boyle, PhD, MBA, Head Business Development and Product Manager<br />
Incorporated: 2007<br />
Employees: 35<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Advancing enrollment in our Phase I/II first-in-man trial of Toca 511<br />
Completed highly successfull rounds of financing each with an increase in valuation and over subscribed.<br />
Established commercially viable manufacturing processes<br />
Clinical POC within 12<br />
months<br />
CORPORATE MISSION<br />
Tocagen Inc. is a US based, clinical stage, biopharmaceutical company with a focus in oncology. Tocagen is initially focusing on treatments<br />
for patients with advanced cancer for which we believe no adequate treatment currently exists.<br />
Our technology platform has demonstrated safety and efficacy in fatal cancers such as lung, breast, liver, colon, prostate, brain, and<br />
metastastic disease. Our lead program is for the treatment of the most lethal form of brain cancer: high grade gliomas including<br />
glioblastoma multiforme. Tocagen has started a Phase I/II study at premier brain cancer centers in the US and clinical POC is expected<br />
within 12 months. A registrational program is planned for 2012 and FDA approval is expected in 2014.<br />
PROPRIETARY TECHNOLOGY<br />
Our Controlled Active Gene Transfer Technology (CAGT) platform is a unique gene transfer technology that is designed to carry a<br />
therapeutic gene (e.g. prodrug activator, immunotherapeutic, or siRNA) and selectively kill cancer cells while not harming healthy tissue.<br />
Our lead program, Toca 511 is currently in Phase I/II clinical trials.<br />
CORPORATE ALLIANCES<br />
UCLA<br />
UCSF<br />
Cleveland Clinic<br />
Major NIH grant<br />
ABC2 grant<br />
INTELLECTUAL PROPERTY<br />
A worldwide portfolio of issued and pending patents<br />
NBTS grant<br />
ABTA grant<br />
Christian Doppler Research Association<br />
Other prestigeous grants (undisclosed)<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Toca 511 with Prodrug Phase II, IIa, IIb glioblastoma multiforme Clinical POC within 12 months<br />
Toca 511 with Prodrug Preclinical Brain metastasis<br />
Toca 511 with Prodrug Preclinical breast, colorectal, liver, prostate, lung<br />
CAGT vector with siRNA Preclinical cancer - not determined<br />
CAGT vector with<br />
immunotherapeutic<br />
SENIOR MANAGEMENT<br />
Preclinical cancer - not determined<br />
Harry Gruber MD, President & CEO • Tom Darcy, Chief Financial Officer • Dennis Berman, Corporate Finance • Doug Jolly PhD,<br />
Executive Vice President • Dan Pertschuk, MD, Vice President • Debra Gessner, MS, Vice President • Omar Perez, Director • Joan<br />
Robbins, Director • Nicholas Boyle, Director • Carlos Ibanez, Director<br />
SCIENTIFIC ADVISORY BOARD<br />
John Coffin PhD, Tufts Univ. & NIH faculty, National Academy Science • Joe Sodroski MD, Harvard Medical School faculty • Stephen<br />
Russell MD, PhD, Mayo Clinic, Chair Molecular Medicine • Nori Kasahara MD/PhD, Professor of Medicine UCLA • Thomas Chen<br />
MD/PhD, USC Neurosurgery Faculty<br />
BIO Business Forum 2011 434 Participating Company <strong>Profiles</strong>
Takafumi Yamamoto<br />
Chief Executive Officer<br />
3rd Fl., Sangakurenkei-Plaza<br />
Tokyo 113-0033<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Kazuo Adachi<br />
Bernadette Oreski<br />
Takafumi Yamamoto<br />
Tomoo Ishida<br />
TODAI TLO, Ltd.<br />
www.casti.co.jp<br />
Phone: 81-3580-57661<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Through disseminating “knowledge” to industry, TODAI TLO’s mission is to contribute in creating a society in which people can live<br />
harmoniously in health and safety.<br />
PROPRIETARY TECHNOLOGY<br />
TODAI TLO is a technology licensing organization for the University of Tokyo; we have more than 1,200 inventions for licensing.<br />
INTELLECTUAL PROPERTY<br />
The statuses of the intellectual properties vary from invention to invention, but it is mostly protected by patent. Please ask the<br />
representatives for details.<br />
PRODUCTS<br />
Name Phase Indication<br />
Oncolytic virus as cancer therapeutics Phase I Cancer<br />
Novel recombinant virus bearing the full length of HSV-2 genome Preclinical Infectious Diseases<br />
Diagnostic method for autoimmune disease Research Diagnostics<br />
Efficient System to Deliver Proteins into Cytoplasm Optimized Lead DDS<br />
Therapeutic medicine for impairment of brain function Preclinical CNS<br />
Artificial Blood Vessel Research Tissue engineering<br />
Therapeutic agent for ischemic diseases Preclinical Diabetes<br />
Novel fluorescent probe(rapid cancer imaging during surgery) Preclinical Diagnostics<br />
Effective INHIBITORS OF miRNA – Custom design and effective<br />
expression of stable<br />
FINANCING HISTORY<br />
Investors: The University of Tokyo (100 %)<br />
SENIOR MANAGEMENT<br />
Research Research Tool<br />
Takafumi Yamamoto, Chief Executive Officer • Tomoo Ishida, Director • Keiko Honda, Director • Yusaku Tenjin, Director<br />
BOARD OF DIRECTORS<br />
Yoichiro Matsumoto, Managing Director of the University of Tokyo • Hikaru Ishiguro, The University of Tokyo controller<br />
SCIENTIFIC ADVISORY BOARD<br />
Kazuo Adachi, Adachi Consulting Corporation<br />
BIO Business Forum 2011 435 Participating Company <strong>Profiles</strong>
2-1-1 Katahira<br />
Sendai 980-8577<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Takanobu Mizuta<br />
Kyoko Matsumoto<br />
Tohoku Techno Arch Co., Ltd<br />
Clinical Foci: Oncology • Metabolic Disease • CNS<br />
Phone: 81-22-222 3049 Incorporated: 1998<br />
Ownership: Other<br />
CORPORATE MISSION<br />
Tohoku Techno Arch is a tech transfer office of Tohoku University which is one of the best leading national universities in Japan. We are<br />
proud to present the latest technologies and academic research fruits in life science field from Tohoku University’s researchers, with the<br />
aim of promoting technology transfer and joint research. We hope we have opportunities to introduce such technologies to companies<br />
finding “Seeds” for creating new business and worldwide innovation. Our exhibition booth (#5123) is also open and welcome to check<br />
details of our technologies and to discuss any possibilities about linkage with Tohoku University.<br />
PROPRIETARY TECHNOLOGY<br />
Here are some of technologies we can present in this exhibition. More technologies and detail information are available by PC<br />
presentation in our booth (#5123).<br />
(1) Exigolide and its analogs specifically inhibit growth of lung cancer cells<br />
(2) Bis(arylmethylidene)acetone, a curcumin derivative for anti-cancer agent<br />
(3) CNV markers for prediction of onset/prognosis of type 2 diabetes<br />
(4) TSLP-overexpressing cell line for R&D on anti-allergic drugs<br />
(5) Myotube cell line with highly activated sugar metabolism via insulin for R&D on diabetic drugs<br />
INTELLECTUAL PROPERTY<br />
All of the technologies presented have completed or are currently undergoing PCT filing for the purpose of global applications.<br />
PRODUCTS<br />
Name Phase Indication<br />
Exigolide and its analogs specifically inhibit growth of lung cancer<br />
cells<br />
Bis(arylmethylidene)acetone, a curcumin derivative for anti-cancer<br />
agent<br />
Research oncology, compound, pharmaceutical<br />
Research oncology, compound, pharmaceutical<br />
CNV markers for prediction of onset/prognosis of type 2 diabetes Research diabetes, genetic marker, diagnostics<br />
TSLP-overexpressing cell line for R&D on anti-allergic drugs Research allergy, screening, research tool<br />
Myotube cell line with highly activated sugar metabolism via insulin Research diabate, screening, research tool<br />
Simultaneous fMRI/EEG/NIRS measuring for analyzing animal brain<br />
activities<br />
Research device, research tool<br />
BIO Business Forum 2011 436 Participating Company <strong>Profiles</strong>
2-1-1 Katahira<br />
Sendai Miyagi 980-8577<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Tohoku University<br />
www.tohoku.ac.jp/english/<br />
Phone: 81-22-217 6035<br />
Akihisa Matsuno, Coodinator, International Cooperation Division<br />
CORPORATE MISSION<br />
Incorporated: 2004<br />
Employees: 5800<br />
Ownership: Public<br />
Tohoku University was founded in 1907 as the third Imperial University of Japan, following Tokyo Imperial University and Kyoto Imperial<br />
University. From its start, it displayed to the world an unswerving commitment to an “Open Door” policy. Departing from the norms of<br />
other imperial universities, it accepted graduates from technical schools and higher normal schools, and despite opposition from the<br />
government at that time, became Japan's First University to admit female students in 1913 (admitting three in that year).<br />
At the time of its founding, Tohoku University was able to attract a group of young and brilliant researchers who had trained around the<br />
world to serve on its faculty. For this reason, a “Research First” principle was established, calling upon scholars to not only pursue highly<br />
productive research but to also put their findings to work in the teaching of their students. In addition to this, Tohoku University has<br />
nurtured a tradition of “Practice Oriented Research and Education,” in which the results of cutting edge research are being put to use for<br />
the good of society and the improvement of living standards. Evidence of our pioneering practice (before the Second World War) includes<br />
the establishment of local venture businesses which have contributed to regional industry, and our status as the nation's center for<br />
research on family law; the domestic branch of law which is closely associated with our daily lives.<br />
This spirit, which continued strongly through World War II and the rapid economic growth of the postwar period, remains alive and can be<br />
seen in today's new era of advanced globalization.<br />
Today, the university has approximately 18 thousand students, 3 thousand faculty members, and 3 thousand administrative and technical<br />
staff members.<br />
CORPORATE ALLIANCES<br />
Tohoku University carries out collaborative research projects with wide ranges of research institutions and private corporations<br />
worldwide. In 2009, the number of such projects totaled more than 600 and approximately one-third of it is in the field of Life Sciences.<br />
The university attracts about 10 billion yen (approx. one thousand million US dollar) of external funding in total each year. The university<br />
also welcomes collaborative research with global corporations located outside Japan.<br />
BIO Business Forum 2011 437 Participating Company <strong>Profiles</strong>
1-3 Kagurazaka, Shinjujuku<br />
Tokyo 162-8601<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Tokyo University of Science<br />
Clinical Foci: Immunology • Oncology • Diagnostics<br />
www.tus.ac.jp/tlo/english/index.html<br />
Phone: 81-35225-1089<br />
Yasunobu Funakoshi, Division Manager, International Division<br />
HIGHLIGHTS<br />
Recent<br />
Nature Immunology May 2011 Vol 12 No.5<br />
The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells - pp450 - 459<br />
Professor Masato Kubo et al<br />
Phys. Rev. Lett. 106, 153401 (2011) [4 pages]<br />
Photodetachment of Positronium Negative Ions<br />
Professor Y. Nagashima<br />
Incorporated: 1881<br />
Employees: 742<br />
Ownership: Private<br />
AMSTERDAM STOCK EXCHANGE:<br />
CORPORATE MISSION<br />
Tokyo University of Science was established in 1881 and is one of the oldest private science universities in Japan. There are 742 faculty<br />
members and 300 doctor course students, therefore around 1000 scientists are working on area such as Physics, Material Science,<br />
Nanotechnology and Bio Science.<br />
Dr. Fujishima, who is the president of our University, is the inventor of oxidized titanium application as a catalytic agent. Material Science,<br />
such as semiconductors like solar panel and electricity generation by heat, and Bio Science, such as the regeneration of teeth and thymus,<br />
and antibodies as immunology are being studied.<br />
We began to do some research collaborations with overseas companies recently.<br />
We, Technology Licensing Organization, offer research collaboration of basic patented technology, or licensing it to your company.<br />
PROPRIETARY TECHNOLOGY<br />
Today, we introduce cutting-edge technologies as follows:<br />
PROTEIN ENGINEERING:<br />
Enhanced Antibody technology(Tandem Fc),<br />
Anti TNIIIA2-antibody,<br />
Anti FNIII14-Antibody,<br />
Enhanced TNFalphaReceptor protein,<br />
Antibody production by B Cell,<br />
REGENERATION:<br />
Regeneration of thymus,<br />
Transfection with trivalent Fe,<br />
AGRICULTURE:<br />
Plant immune activator,<br />
NANOTECHNOLOGY:<br />
Particle concentration apparatus in micro device,<br />
IMAGING<br />
Image Restoring Device,<br />
CORPORATE ALLIANCES<br />
We began to do some research collaboration with oversees companies recently.<br />
Some patents were licensing and are under negotiation also.<br />
INTELLECTUAL PROPERTY<br />
We offer you research collaboration or licensing.<br />
Most technologies we have are covered by PCT patents or provisional patents. Others are in the middle of entry into the national phase.<br />
BIO Business Forum 2011 438 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Anti TNIIIA2-antibody : LSP75 Target Validated Antibody for Breast Cancer and stomach<br />
cancer?Anti Tenascin-antibody<br />
Anti FNIII14-Antibody : LSP105 Target Validated Antileukemic Enhancing Activator?Anti<br />
Fibronectin-Antibody , FNIII14 was<br />
modified<br />
Enhanced TNFaReceptor protein<br />
: LSP104<br />
Antibody production by B Cell :<br />
LSP62<br />
Target Validated Biological activity is higher than that of<br />
Etanercept, Both ADCC and CDC are<br />
effective.<br />
Pre-Target Validation This method can produce the antibody<br />
to highly toxic antigen in vitro by<br />
human B cell.<br />
Research collaboration or<br />
License<br />
Research collaboration or<br />
License<br />
Research collaboration or<br />
License<br />
Research collaboration or Nonexclusive<br />
license<br />
Regeneration of thymus : LSP74 Research Research Research collaboration<br />
Transfection with trivalent Fe :<br />
LSP61<br />
Pre-Target Validation High efficiency of gene transfection to<br />
inside of cell is achieved with liposome<br />
by fusion.<br />
Plant immune activator : LSP80 Lead Series More wider application compounds<br />
than Probenazole of Meiji Seika and<br />
Tiadimil of Nippon Nouyaku Co., Ltd will<br />
be found by this methods.<br />
Particle concentration<br />
apparatus in micro device :<br />
LSP78<br />
Research Concentration microscopic particles in a<br />
liquid<br />
Image Restoring Device : LSP77 Pre-Target Validation Calculation time is shorter and figure is<br />
more clear than that of Kalman Filter<br />
algorithm. Useful for Imaging.<br />
Enhanced Antibody<br />
Technology,Tandem Fc : LSP1<br />
Pre-Target Validation Enhancing Method of the effector<br />
activity with two or three human Fc.<br />
Non-exclusive license<br />
Research collaboration or Nonexclusive<br />
license<br />
Research collaboration or Nonexclusive<br />
license<br />
Non-exclusive license<br />
Non-exclusive licence<br />
BIO Business Forum 2011 439 Participating Company <strong>Profiles</strong>
Ron Demuth<br />
President<br />
6605 Nancy Ridge Drive<br />
San Diego, CA 92121<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Nikolay Savchuk, PhD, Director & Managing Partner<br />
HIGHLIGHTS<br />
Recent<br />
Torrey Pines Investment<br />
Clinical Foci: CNS • Oncology • Infectious Disease<br />
www.torreypinesinvestment.com<br />
Phone: 1-858-794-4860<br />
Ownership: Private<br />
06-25-2011<br />
TeaRx Ltd. (TeaRx), Member of ChemRar High Tech Center, and Roche have signed a license agreement for innovative drugs fighting<br />
Thrombosis, Stroke, and Embolism<br />
03-16-2011<br />
ChemRar and Genzyme Announce Collaboration for Development of Orphan Drugs<br />
12-01-2010<br />
ChemRar announced alliance with Akrihin, expanded R&D collaborations with Sanofi-Aventis and Novartis.<br />
CORPORATE MISSION<br />
Torrey Pines Investment, founded in 2002, is a specialty life-science investment company located in San Diego. Torrey Pines has a team of<br />
investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has created biopharma<br />
incubators investing in early development stage assets from international pharma and biotech partners in CNS, oncology, and virology<br />
area to bring them to commercial success through pharma partnering and M&A. Our philosophy centers on maximizing the potential for<br />
capital gains and confining the risk of loss by:<br />
potential positioning as first on the market or best on the market therapy or potential for generating value through combination with<br />
such positions,<br />
the value orientation starting at pre-clinical candidate level exiting at clinical proof of concept,<br />
stream lining the development through an embedded collaboration with co-owned global CRO network based on aligned incentives,<br />
minimizing the fixed cost through managing asset portfolios by proven professional drug hunters and drug developer management<br />
teams,<br />
maintaining a pro-active pharma partner oriented exit strategy through call options and other mechanisms of early partner participation.<br />
We are committed to capitalizing on the unique opportunities in biotech and pharma, where we can add value in development or<br />
regulatory strategy by utilizing resources of our portfolio CRO companies. We seek to leverage our industry knowledge, network of<br />
industry and financial contacts, and internal resources to assist our portfolio management in developing and executing their business<br />
strategy. Our bottom line is to help our companies achieve growth, build value and realize wealth.<br />
PROPRIETARY TECHNOLOGY<br />
Our Partfolio Includes:<br />
Avineuro Pharmaceuticals, Viriom, ChemRar High Tech Center, iDialog, Afraxis, iPharma, Aviron, Biointegrator Ltd., TeaRx, NewVac<br />
Pharma, GXP Engineering, Avionco, Recoverex, Drug Technology, Pharmoslavl, SatRx<br />
CORPORATE ALLIANCES<br />
Partners: Avalon Ventures, HealthCare Ventures LLC; Russian Venture Company; Rusnano.Skolkovo Foundation, ChemRar Ventures<br />
SENIOR MANAGEMENT<br />
Ron Demuth, President • Michael Palfreyman, Vice President • Uwe Peukert, Vice President • Nikolay Savchuk, Managing Director •<br />
Ian Wisenberg, Consultant • Christopher J. Cummings, Consultant • Nicholas A. Saccomano, Consultant<br />
BIO Business Forum 2011 440 Participating Company <strong>Profiles</strong>
Andrea Paolini<br />
Managing Director<br />
Via Fiorentina, 1<br />
53100-Siena<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Francesco Maria Senatore, Business Development<br />
HIGHLIGHTS<br />
Recent<br />
Toscana Life Sciences Foundation<br />
Clinical Foci: Diagnostics • Drug Development • Medical Device<br />
www.toscanalifesciences.org<br />
Phone: 39-0577-231 207<br />
Incorporated: 2004<br />
Employees: 20<br />
Ownership: Other<br />
TLS is the managing body of the new born Life Science Regional Cluster putting together more than 200 companies in the sector.<br />
CORPORATE MISSION<br />
The Toscana Life Sciences Foundation (TLS) is a non-profit organization founded in 2004 by a group of public and private institutions in<br />
Tuscany with the mission to support research activities in the field of Life Sciences and in particular to foster the development of projects<br />
from basic research to industrial application. The main project of the Foundation has been the development of the Science and Technology<br />
Park (STP) that offers equipped buildings, services and financing opportunities, thus creating a fertile ground for the development of new<br />
biotech companies focused on pharmaceutical, biotech, diagnostic and innovative biomedical technologies. TLS is today the third STP in<br />
Italy in terms of number of companies located, investment attracted and number of specialized employee. On top of the incubation<br />
activities TLS is committed to the development of new therapies for orphan diseases and technology transfer from Tuscany Universities in<br />
the red biotech sector. According to its mission in the technology transfer support, TLS will manage the centralized activities of the new<br />
born Life Sciences Regional Cluster putting together over 200 companies in the field and 6 Universities representing one of the most active<br />
and interesting biotech hub in Italy.<br />
PROPRIETARY TECHNOLOGY<br />
The area, where the TLS Science Park is located, has been hosting research and industrial activities in the field of vaccines for more than<br />
one hundred years. In this location, facilities and skills in microbiology, immunology, molecular biology and cell biology have been<br />
growing and consolidating. Recently, further competences have been established in bioinformatics, computational chemistry, small drug<br />
design and discovery thanks to the expansion of the research activities of Chiron Vaccines, now Novartis Vaccines and Diagnostics<br />
(www.novartisvaccines.com) , the establishment of Siena Biotech (www.sienabiotech.it) and the presence of the Molecular Biology<br />
Department of the Siena University (www.biologiamolecolare.unisi.it).<br />
SENIOR MANAGEMENT<br />
Andrea Paolini, Managing Director • Francesco Maria Senatore, Business Development<br />
BOARD OF DIRECTORS<br />
Maurizio Cenni, Monte dei Paschi di Siena Bank<br />
BIO Business Forum 2011 441 Participating Company <strong>Profiles</strong>
Giorgio Soldani<br />
Chief Executive Officer<br />
V.le Vittorio Emanuele II 62-64<br />
50134-Florence<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Marco Perrone, Officer<br />
Stefano Giovannelli<br />
Toscana Promozione - Invest In Tuscany<br />
Clinical Foci: Biosensing • Biopharmaceuticals • Diagnostics<br />
www.toscanapromozione.it<br />
Phone: 39-055-462 8096<br />
Incorporated: 2000<br />
Employees: 50<br />
Ownership: Public<br />
Market Cap: $1500.00 million<br />
CORPORATE MISSION<br />
Born from an agreement between Tuscany Region, the Regional Organization of the Chambers of Commerce, the National Institute for the<br />
Foreign Commerce (ICE) and the National Body for the Tourism (ENIT), Toscana Promozione is an Agency that has the main purpose to<br />
support the undertaking of Tuscan businesses to compete on the different world markets.<br />
A task that the Agency carries out through the organization of events, seminars, workshops, pointing on the image and supporting the<br />
Tuscan businesses that participate to national and international trade fairs, but not only. Toscana Promozione implements initiatives of<br />
international cooperation; it financially and technically supports projects of economic promotion proposed by private subjects; it provides<br />
a service of assistance and first approach to foreign businesses that want to establish themselves in Tuscany, and through the Counter for<br />
Internationalization (Sprint Toscana), it offers to Tuscan businessmen insurance, financial, promotional services and consultancy.<br />
The Agency activity sectors are three: Agriculture and Food Industry; small and medium industrial businesses and quality craftsmanship;<br />
tourism.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Cardiovascular Suite Optimized Lead A set of 4 products for the assessment of<br />
cardiovascular risk markers.<br />
BioBlender Optimized Lead A complete instrument to elaborate the movement of<br />
proteins and to display their surface features using a<br />
visual code based on texturing and particles special<br />
effects.<br />
Innovative product for<br />
treatment of chronic skin<br />
lesions<br />
SENIOR MANAGEMENT<br />
Pre-Target<br />
Validation<br />
A new product for the treatment of chronic skin<br />
lesions that combines the features of an advanced<br />
biologically active dressing with the property to<br />
monitor the progression of wound healing and tissue<br />
regeneration.<br />
FDA for products 1-2;<br />
Complete the<br />
development of<br />
products 3-4;<br />
Commercialization<br />
Giorgio Soldani, Chief Executive Officer • Monica Zoppè, Chief Scientific Officer • Francesco Faita, Chief Business Officer • Vincenzo<br />
Gemignani, Managing Director • Elisabetta Bianchini, Chief Technology Officer<br />
BOARD OF DIRECTORS<br />
Vincenzo Gemignani, Managing Director • Francesco Faita, Sales Manger • Elisabetta Bianchini, Senior researcher<br />
SCIENTIFIC ADVISORY BOARD<br />
Monica Zoppè, National Resarch Council • M.F. Zini, National Resarch Council • R. Andrei, National Resarch Council • Giorgio Soldani,<br />
National Resarch Council • Enrica Briganti, National Resarch Council<br />
BIO Business Forum 2011 442 Participating Company <strong>Profiles</strong>
Akio Toyoda<br />
President<br />
1 Toyota-cho<br />
Toyota 471-8572<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
TOYOTA MOTOR CORPORATION<br />
Clinical Foci: Other • Industrial Biotech • Environmental<br />
www.toyota-global.com/<br />
Phone: 81-565-72-9981<br />
Chikara Ohto, Group Manager, Bio Research Laboratory, Future Project Division<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Improving seed oil content and/or plant biomass using artificial<br />
transcription factors (chimeric repressor silencing technology), and<br />
plant biomass using a protein phosphatase 2C gene.<br />
Developing genome-wide marker technology for a complicated and<br />
undetermined genome such as sugarcane.<br />
Developing a genetically modified yeast that can produce prenyl<br />
alcohols of farnesol and/or geranylgeraniol.<br />
Incorporated: 1937<br />
Employees: 320590<br />
Ownership: Public<br />
TOKYO STOCK EXCHANGE: 7203<br />
Determining specific markers for sugarcane QTLs<br />
Developing a new technology for rearrangement of plant<br />
chromosomes in vivo.<br />
Protein engineering of enzymes for bio-fuel cell.<br />
CORPORATE MISSION<br />
Toyota is a Japanese automotive company researching and developing not only in the field of automotive-related technology but<br />
biotechnology and bioscience. Bio Research Laboratory, Future Project Division is in charge of cutting-edge R&D with plants,<br />
microorganisms and enzymes. We are interested in favorable technologies for sustainability in the future.<br />
PROPRIETARY TECHNOLOGY<br />
Plant genes for increasing biomass (areal plant, seed oil or seed protein).<br />
Restructuring chromosomes in vivo using specific restriction enzymes.<br />
Genome-wide marker technology for complicated and undetermined genomes, in particular useful for QTL analyses.<br />
Metabolic engineering of microorganisms for producing target compounds.<br />
Enzyme Energy-conversion technology for bio fuel cell.<br />
INTELLECTUAL PROPERTY<br />
Plant biomass, seed oil or seed protein increasing, WO 2010 140682 WO/2010/140672 WO/2010/140388 WO/2010/104092<br />
WO/2010/055837 WO/2010/035784 WO/2009/113684 WO/2009/110466 WO/2009/107822 WO/2009/107820 WO/2009/072609<br />
WO/2009/072608;<br />
Plant stress or agrichemical resistance, WO/2011/052169 EP1514941 EP1715050 US7402732;<br />
Marker technology for complicated and undetermined genomes, WO/2011/004594 WO/2010/131768;<br />
Metabolic engineering of microorganisms, WO/2011/013352 WO/2002/053751 WO/2002/053747 WO/2002/053746 WO/2002/053745;<br />
Bio-fuel cell, WO/2011/016102 WO/2010/147111 WO/2008/032871<br />
FINANCING HISTORY<br />
Investors: Japan Trustee Services Bank, Ltd. (10 %) • Toyota Industries Corporation (6 %) • The Master Trust Bank<br />
of Japan, Ltd. (6 %) • Nippon Life Insurance Company (4 %) • State Street Bank and Trust Company (3 %)<br />
• Trust & Custody Services Bank, Ltd. (3 %) • The Bank of New York Mellon as Depositary Bank for<br />
Depositary Receipt (2 %) • Tokio Marine & Nichido Fire Insurance Co., Ltd. (2 %) • Mitsui Sumitomo<br />
Insurance Co, Ltd. (2 %)<br />
SENIOR MANAGEMENT<br />
Akio Toyoda, President • Takeshi Uchiyamada, Vice President • Yukitoshi Funo, Vice President • Atsushi Niimi, Vice President •<br />
Shinichi Sasaki, Vice President • Yoichiro Ichimaru, Vice President • Satoshi Ozawa, Vice President • Soichiro Okudaira, Other<br />
BIO Business Forum 2011 443 Participating Company <strong>Profiles</strong>
Charles Theuer<br />
Chief Executive Officer<br />
8910 University Center Lane<br />
San Diego, CA 92122<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Charles P. Theuer, MD, PhD<br />
Tracon Pharmaceuticals, Inc<br />
Clinical Foci: Biopharmaceuticals • Oncology • Ophthalmic<br />
www.traconpharma.com<br />
Phone: 1-858-550-0780<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
ASCO 2011 presentation of final TRC105 Phase 1 data<br />
ASCO 2011 presentation of TRC150 Phase 1 biomarker data<br />
ASCO 2010 presentation of final TRC102 Phase 1 data<br />
Incorporated: 2004<br />
Employees: 8<br />
Ownership: Private<br />
2012-2013: Phase 2 data for TRC105 in prostate, bladder, kidney,<br />
liver, brain, breast and ovarian cancer<br />
CORPORATE MISSION<br />
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer<br />
and age-related macular degeneration.<br />
PROPRIETARY TECHNOLOGY<br />
TRC105 is an antibody to CD105 (endoglin) that inhibits angiogenesis and complements VEGF inhibition and is in Phase 2 testing<br />
TRC102 is a small molecule that reverses resistance to alkylating and antimetabolite chemotherapy and is Phase 2 ready<br />
CORPORATE ALLIANCES<br />
Roswell Park Cancer Institute<br />
Case Western Reserve University<br />
INTELLECTUAL PROPERTY<br />
Global composition of matter and use patents have been issued<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TRC105 (antibody) to CD105<br />
(endoglin)<br />
Phase II, IIa, IIb multiple onoclogy indications and AMD Multiple Phase 1b and Phase 2<br />
readouts in 2011-13<br />
TRC102 (small molecule) Phase I lung cancer and brain cancer Phase 1 completed<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 03/28/2011 (US $22.00 million)<br />
SENIOR MANAGEMENT<br />
Charles Theuer, Chief Executive Officer • Bryan Leigh, Chief Medical Officer • Sharon Real, Vice President • Bonne Adams, Vice<br />
President • Suzanne Benedict, Director<br />
BOARD OF DIRECTORS<br />
Hironori Hozoji, JAFCO • Kenji Harada PhD, JAFCO • Myoung Kwon PhD, Nextech • J. Rainer Twiford JD PhD, Brookline • Charles<br />
Theuer MD PhD, TRACON<br />
SCIENTIFIC ADVISORY BOARD<br />
Charles Sawyers MD, Memorial Sloan Kettering • William Kaelin MD, Dana Farber • Stanton Gerson MD, Case Cancer Center<br />
BIO Business Forum 2011 444 Participating Company <strong>Profiles</strong>
10490 SW Village Center Drive<br />
Port Saint Lucie, FL 34987<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Andrew Favata<br />
CORPORATE MISSION<br />
Tradition Center For Innovation<br />
Clinical Foci: Drug Discovery • Gene/Cell Therapy • Drug Development<br />
www.tciflorida.com/<br />
Phone: 1-772-345-3515<br />
Incorporated: 2006<br />
Ownership: Private<br />
Tradition Center for Innovation (TCI) is a 150-acre, privately owned research park in the master-planned community of Tradition in Port St.<br />
Lucie, Florida. TCI is in the heart of southeast Florida’s “Research Coast,” a biotech and life sciences hub strategically located between key<br />
life science organizations in Orlando and Palm Beach.<br />
Key Members<br />
TCI’s first member was Torrey Pines Institute for Molecular Studies in 2006, when the institute moved its headquarters from San Diego.<br />
The president of Torrey Pines Institute then recruited long-time collaborator Oregon Health & Science University’s Vaccine and Gene<br />
Therapy Institute (VGTI), which announced it would open a facility at TCI in 2008. Another member is Mann Research Center, which is<br />
planning a 410,000 square-foot life sciences complex adjacent to both facilities. Martin Memorial Health Systems is also planning on<br />
building a medical campus at the park.<br />
Culture of Collaboration and Commercialization<br />
One of TCI’s chief goals is to translate innovations from lab to the marketplace, with a focus on attracting world-class institutions. The<br />
expertise and research programs of TCI’s current members provide a solid foundation<br />
along the translational research continuum, from Torrey Pines Institute’s rapid drug discovery methods to Martin Memorial Health<br />
Systems’ experience in conducting clinical trials.<br />
A culture of entrepreneurism is also critical to moving an idea to the marketplace. VGTI and Torrey Pines Institute both encourage<br />
technology transfer and help their researchers obtain patents and spin off companies. In 2010, members of TCI formalized their culture of<br />
collaboration and commercialization by forming Florida Innovation Partners (FIP). FIP will direct TCI’s growth by recruiting institutions<br />
that complement existing research programs, promoting collaborations with world-class institutions outside the park and promoting the<br />
commercialization of new discoveries<br />
made within the park.<br />
CORPORATE ALLIANCES<br />
Current Alliances: Scripps Florida, Sanford-Burnham Medical Research Institute, Max Planck Florida Institute, United States Department of<br />
Agriculture, Smithsonian Marine Station, Harbor Branch Oceanographic Institute, University of Florida, University of Miami, Florida<br />
Atlantic University, Indian River State College, Keiser University<br />
BIO Business Forum 2011 445 Participating Company <strong>Profiles</strong>
Tony Cruz<br />
Chief Executive Officer<br />
220- 101 College Street<br />
Toronto, ON M5G 1L7<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Elie Farah<br />
Carl Damiani<br />
Transition Therapeutics, Inc<br />
Clinical Foci: CNS • Metabolic Disease<br />
www.transitiontherapeutics.com<br />
Phone: 1-416-263-1206<br />
Incorporated: 1999<br />
Employees: 30<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
NASDAQ: TTHI<br />
HIGHLIGHTS<br />
Recent<br />
Transition Announces Licensing and Collaboration Agreement with Lilly for next generation diabetes therapies<br />
Elan and Transition Therapeutics Announce Modification of their Collaboration Agreement for the development and commercialization of<br />
ELND005<br />
CORPORATE MISSION<br />
Transition is a publicly traded biopharmaceutical company, traded on the NASDAQ Global market and the Toronto Stock Exchange<br />
(NASDAQ: TTHI; TSX: TTH). Transition's lead product is ELND005 (AZD-103) for the treatment of Alzheimer's disease. Transition has an<br />
emerging pipeline of drug candidates targeting metabolic and inflammatory diseases.<br />
PROPRIETARY TECHNOLOGY<br />
Alzheimers Disease<br />
ELND005 (AZD-103)<br />
Phase 3 Clinical Development<br />
CORPORATE ALLIANCES<br />
Elan Pharmaceuticals<br />
- License for the development and commercialization of Alzheimer's disease drug candidate ELND005 (AZD-103)<br />
Eli Lilly & Company<br />
- Global licensing agreement to develop and commercialize next generation diabetes therapies<br />
PRODUCTS<br />
Name Phase Indication<br />
ELND005 (AZD-103) Phase III Alzheimer's disease<br />
TT-301 Phase I CNS<br />
TT-302 Preclinical CNS<br />
TT-401 Preclinical Type 2 Diabetes<br />
SENIOR MANAGEMENT<br />
Tony Cruz, Chief Executive Officer • Elie Farah, President • Carl Damiani, Business Development • Aleksandra Pastrak, Chief Medical<br />
Officer<br />
BIO Business Forum 2011 446 Participating Company <strong>Profiles</strong>
Eric Ostertag MD, PhD.<br />
Chief Executive Officer<br />
201 East Main St. Suite 1405<br />
Lexington, KY 40507<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jack Crawford<br />
Transposagen Biopharmaceuticals, Inc<br />
Clinical Foci: Drug Discovery • Metabolic Disease • Gene/Cell Therapy<br />
www.transposagenbio.com<br />
Phone: 1-315-351-9115<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
2008: Launch of first products and hiring of key technical scientists<br />
2009: Moved headquarters to Lexington, KY. Agreements with<br />
multiple strategic alliances and client contracts<br />
2010: Company becomes cash positive. Agreements are signed for<br />
distribution of animal models by Taconic and Charles River.<br />
CORPORATE MISSION<br />
Incorporated: 2003<br />
Ownership: Private<br />
2011: Investment to move and increase capacity of vivairium in<br />
Lexington, KY. New custom transgenic models, knockout and<br />
knock-in rats<br />
2012: Launch of humanized rats, AAALAC certification<br />
Company:<br />
Location: Lexington, KY<br />
Number of employees:
SENIOR MANAGEMENT<br />
Eric Ostertag MD, PhD., Chief Executive Officer • Joe Ruiz PhD., Chief Scientific Officer • Craig Morley, Marketing • Gerry Walsh, Chief<br />
Operating Officer • Jack Crawford, Business Development<br />
SCIENTIFIC ADVISORY BOARD<br />
Haig H. Kazazian, MD, University of Pennsylvania • Jef Boeke, Ph.D, Johns Hopkins Univeristy • Aron Geurts, Ph.D, Medical College of<br />
Wisconsin<br />
BIO Business Forum 2011 448 Participating Company <strong>Profiles</strong>
4170 Mendenhall Oaks Parkway<br />
High Point, NC 27265<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Carmen Valcarce<br />
Nura Strong, Associate Director, Business Development<br />
TransTech Pharma, Inc<br />
www.ttpharma.com<br />
Phone: 1-336-841-0300<br />
Ownership: Private<br />
CORPORATE MISSION<br />
TransTech Pharma is a privately held clinical-stage pharmaceutical company focused on the discovery, development, and<br />
commercialization of human therapeutics to fill unmet medical needs. The company’s high-throughput drug discovery platform,<br />
Translational Technology®, translates the functional modulation of human proteins into safe and effective medicines. TransTech Pharma<br />
has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases, including<br />
central nervous system disorders, Type I and Type II diabetes, obesity, cardiovascular and cancer<br />
PROPRIETARY TECHNOLOGY<br />
TTP Translational Technology® is a highly automated and fully integrated drug discovery process, which translates genomic and proteomic<br />
data into safe and effective small molecule therapeutics in high throughput fashion, bypassing most of the classical requirements and<br />
bottlenecks in drug discovery. We have used our technology to discover and develop drugs for our own internal pipeline and in research<br />
collaborations with pharmaceutical and biotechnology companies. The technology already has delivered clinical drug candidates against a<br />
wide range of biological targets including protein-protein interactions, receptor modulators, and enzyme inhibitors.<br />
CORPORATE ALLIANCES<br />
Forest Laboratories, Novo Nordisk, Pfizer<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
11ßHSD1 Inhibitor Phase I Primary Open Angle Glaucoma HPP851 is currently in a multi-center Phase 1<br />
study in patients with elevated IOP or POAG<br />
BACE 1 Inhibitor Phase I Alzheimer's disease HPP854 entering phase 1 in AD patients in<br />
2011<br />
Oral GLP-1r Agonists Phase II, IIa, IIb Type II Diabetes TTP054 entering phase 2 in type 2 diabetic<br />
population in 2011<br />
Oral H3 Antagonist Phase I Obesity HPP404 entering phase 2 in 2011<br />
Oral PPARd Agonist Phase I Dyslipidemia, obesity,<br />
Osteoporosis and Osteoarthritis<br />
and Muscle Function<br />
HPP593 entering phase 1 studies in 2011<br />
Oral PTP-1b Inhibitor Phase II, IIa, IIb Type II Diabetes TTP814 entering phase 2 in type 2 diabetic<br />
population in 2011<br />
RAGE Ligands Decoy IND Filed Alzheimer's Disease TTP4000 entering phase 1 in AD patients in<br />
2011<br />
BIO Business Forum 2011 449 Participating Company <strong>Profiles</strong>
Vipin Garg, PhD<br />
Chief Executive Officer<br />
4819 Emperor Boulevard<br />
Durham, NC 27703<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Jennifer Filbey, PhD<br />
Helmut Thomas, PhD<br />
Tranzyme, Inc<br />
Clinical Foci: Gastroenterology • Metabolic Disease • Drug Discovery<br />
www.tranzyme.com<br />
Phone: 1-919-313-4760<br />
Incorporated: 1998<br />
Employees: 40<br />
Ownership: Public<br />
Market Cap: $96.00 million<br />
NASDAQ: TZYM<br />
CORPORATE MISSION<br />
Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class<br />
small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. Our two most<br />
advanced product candidates, ulimorelin (in Phase 3) and TZP-102 (in Phase 2), are being evaluated for the treatment of predominantly<br />
upper GI motility disorders. We believe approximately 20% of adults worldwide are affected by conditions these product candidates are<br />
designed to tract. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are<br />
currently a limited number of treatment options for patients suffering from these conditions. Ulimorelin and TZP-102 target the ghrelin<br />
receptor, a novel mechanism of action, with a highly potent and direct role in the stimulation of GI motility. Current and formerly<br />
available drugs targeted the GI function primarily through either the serotonin or dopamine receptors and have had significant safety<br />
issues, resulting in product recalls. We believe our product candidates have the potential to offer a safe and effective treatment for GI<br />
motility disorders, an area of significant unmet medical need.<br />
PROPRIETARY TECHNOLOGY<br />
Tranzyme’s product candidates have been discovered using our proprietary chemistry technology platform, MATCH (Macrocyclic<br />
Template Chemistry), which enables us to construct synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient<br />
manner. MATCH compounds mimic the favorable binding characteristics of proteins and peptides such as tight receptor binding for high<br />
potency and selectivity, while eliminating the drawbacks associated with these biomolecules—poor metabolic stability, low oral<br />
bioavailability, lack of membrane permeability, high manufacturing costs and antigenicity. As part of our business strategy, we continue<br />
to leverage our technology platform to discover, develop and commercialize first-in-class products in collaboration with discovery<br />
partners.<br />
CORPORATE ALLIANCES<br />
In December, 2009, Tranzyme entered into a strategic collaboration with BMS to discover, develop and commercialize novel compounds<br />
discovered using our proprietary chemistry technology platform, against a limited number of targets of interest to BMS. BMS is funding<br />
our early lead discovery efforts on these targets and is also responsible for optimizing the identified lead compounds.<br />
In June 2010, Tranzyme entered into a license agreement with Norgine B.V., a leading, GI-focused European specialty pharmaceutical<br />
company that provides Norgine with exclusive rights to develop and commercialize ulimorelin in Europe and other select territories.<br />
Tranzyme retained rights to ulimorein in North & South America and Asia. Norgine will share the cost of our development.<br />
INTELLECTUAL PROPERTY<br />
Our patent portfolio contains patents and patent applications relating to our products and our MATCH drug discovery technology.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Ulimorelin (TZP-101) Phase III Management of postoperative ileus Complete Phase III program<br />
TZP-102 Phase II, IIa, IIb Diabetic gastroparesis Initiate Phase IIb<br />
TZP-201 Preclinical Chemo-induced diarrhea<br />
TZP-301 Lead Series Metabolic disease<br />
Chemistry Research Available for collaboration<br />
SENIOR MANAGEMENT<br />
Vipin Garg, PhD, Chief Executive Officer • Richard Eisenstadt, Chief Financial Officer • Helmut Thomas, PhD, Senior Vice President •<br />
Gordana Kosutic, MD, Vice President • Jennifer Filbey, Business Development • Mark Peterson, Vice President<br />
BOARD OF DIRECTORS<br />
John H. Johnson, Savient Pharmaceuticals, Inc. • Jean-Paul Castaigne, Angiochem, Inc. • Aaron Davidson, H.I.G. BioVentures • Brenda<br />
D. Gavin, Quaker BioVentures • Anne M. VanLent, AMV Advisors • Alex Zisson, Thomas, McNerney & Partners<br />
BIO Business Forum 2011 450 Participating Company <strong>Profiles</strong>
Maxine Gowen<br />
President & CEO<br />
1018 West 8th Avenue<br />
King of Prussia, PA 19406<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Maxine Gowen, PhD<br />
Art Fratamico<br />
Trevena, Inc<br />
BIO Board Member, Presenting Company<br />
Clinical Foci: Cardiovascular Disease • CNS • Drug Discovery<br />
www.trevenainc.com<br />
Phone: 1-610-354-8840<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Initiated a phase 2 trial assessing the hemodynamic effects of<br />
TRV027 in heart failure patients which include blood pressure,<br />
pulmonary capillary wedge pressure (surrogate for dyspnea),<br />
cardiac output and renal effects.<br />
Selected the clinical mu opioid candidte for the treatment of post<br />
operative surgical pain.<br />
Incorporated: 2008<br />
Employees: 34<br />
Ownership: Private<br />
Completion of the phase 2 heart failure trial in Q1 2012. The trial is<br />
assessing the hemodynamic parameters of blood pressure,<br />
pulmonary capilary wedge pressure (measure of dyspnea), cardiac<br />
output and renal effects using creatinine and cystatin C.<br />
Initiation of the phase 1 trial for TRV130 assessing it effects in<br />
healthy volunteers.<br />
CORPORATE MISSION<br />
Trevena, Inc. is a leader in the discovery and development of GPCR biased ligand drugs. Trevena combines a powerful and efficient drug<br />
discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines. Approximately 40% of<br />
modern medicinal products target GPCRs and GPCRs remain the largest class of targets under clinical evaluation. However, currently<br />
marketed GPCR drugs suffer significant problems such as limited efficacy and undesirable adverse effects, which often limit their overall<br />
use. Furthermore, there are many GPCRs linked to disease that cannot be translated into medicines because of specific target-related<br />
adverse effects. Trevena’s novel drug discovery approach is focused on discovering and developing a linked portfolio of GPCR ligands that<br />
are “biased” toward either activating or blocking specific signaling pathways mediated through individual GPCRs. Unlike traditional,<br />
broad GPCR approaches, the enhanced focus and specificity of these biased ligands enables Trevena to engage only the desired signaling<br />
pathway and deliver optimal therapeutic effects - without many of the unwanted effects seen with less selective GPCR approaches.<br />
Trevena’s lead program TRV027 is in phase 2a clinical trials and is being developed to treat patients with acute heart failure. TRV027 is a<br />
first-in-class agent that, due to its unique spectrum of biological effects, could provide a major advance in the treatment of acute heart<br />
failure. It targets AT1R, which plays a central role in the pathophysiology of heart failure. Based on its profile in animals, TRV027 is<br />
expected to rapidly provide symptomatic benefit while promoting an improvement in target organ function in patients suffering from<br />
acute heart failure. Trevena is also developing a pain franchise, in which the lead program has demonstrated morphine-like in vivo<br />
efficacy with reduced side effects.<br />
PROPRIETARY TECHNOLOGY<br />
Trevena’s proprietary Advanced Biased Ligand Explorer, or ABLE, platform is the first ever fully assembled set of integrated tools for<br />
identifying and characterizing functionally selective biased ligands for a wide range of GPCRs. The platform includes customized assays,<br />
proprietary software, animal models and unique biological signaling information across multiple GPCRs. Trevena uses ABLE to generate<br />
proprietary biological information highlighting the specific biological pathways and their role in producing either the beneficial or adverse<br />
effects of an agent.<br />
CORPORATE ALLIANCES<br />
Trevena recently concluded a successful collaboration with Ligand Pharmaceuticals (NASDAQ: LGND) to screen targets using Ligand’s five<br />
million compound ultra high throughput chemistry platform based on data derived from Trevena’s ABLE platform. Under the alliance,<br />
Trevena has exclusive, royalty-free worldwide rights to sublicense active compounds resulting from the collaboration and Ligand expects<br />
to screen 24 targets over two years.<br />
INTELLECTUAL PROPERTY<br />
Trevena’s proprietary Advanced Biased Ligand Explorer, or ABLE, platform is the first ever fully assembled set of integrated tools for<br />
identifying and characterizing functionally selective biased ligands for a wide range of GPCRs. The platform includes customized assays,<br />
proprietary software, animal models and unique biological signaling information across multiple GPCRs. Trevena uses ABLE to generate<br />
proprietary biological information highlighting the specific biological pathways and their role in producing either the beneficial or adverse<br />
effects of an agent.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TRV027 Phase II, IIa, IIb Acute heart failure Phase 2 data in Q1, 2012<br />
Mu-opioid biased ligand Optimized Lead Treatment of post surgical pain relief IND to be filed Q1, 2012<br />
Kappa-opioid biased ligand Optimized Lead Treatment of neuropathic pain<br />
BIO Business Forum 2011 451 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Delta-opioid biased ligand Lead Series Depression, Parkinson's and pain<br />
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round A: 01/01/2008 (US $25.00 million)<br />
Round B: 07/01/2010 (US $35.00 million)<br />
Investors: Alta Partners (1 %) • HealthCare Ventures (1 %) • New Enterprise Associates (1 %) • Polaris Venture<br />
Partners (1 %) • Yasuda Enterprise Development Company (1 %)<br />
SENIOR MANAGEMENT<br />
Maxine Gowen, President & CEO • Rosamond Deegan, Vice President • Art Fratamico, Chief Business Officer • Mike Lark, Chief<br />
Scientific Officer • David Soergel, Vice President<br />
BOARD OF DIRECTORS<br />
Farah Champsi, Alta Partners • Robert Garland. MD, New Enterprise Associates • Maxine Gowen, PhD, Trevena • Terrance G<br />
McGuire, Polaris Venture Partners • Robert R Ruffolo, Jr., PhD, Former President R&D, Wyeth Pharmaceuticals • Ralph Snyderman,<br />
MD, Chancellor Emeritus, Duke University Medical Center<br />
SCIENTIFIC ADVISORY BOARD<br />
Robert J. Lefkowitz, MD, Duke University Medical Center • Howard A. Rockman, MD, Duke University Medical Center • John L.<br />
LaMattina, PhD, Permer President, Global R&D Pfizer • Robert R. Ruffolo, Jr., PhD, Former President R&D, Wyeth Pharmaceuticals<br />
BIO Business Forum 2011 452 Participating Company <strong>Profiles</strong>
Dr. Niclas Stiernholm<br />
President & CEO<br />
96 Skyway Avenue<br />
Toronto, ON M9W 4Y9<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Niclas Stiernholm, PhD, CEO<br />
Trillium Therapeutics, Inc<br />
Clinical Foci: Immunology • AutoImmune • Oncology<br />
www.trilliumtherapeutics.com<br />
Phone: 1-416-595-5967<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
On March 11, 2010, Trillium signed license agreements with two<br />
Toronto research institutions, granting it exclusive worldwide<br />
rights to commercialize two immunology programs in the areas of<br />
hematopoietic stem cell transplantation and cancer.<br />
On March 18, 2010, the FDA provided clearance for Trillium to<br />
commence clinical studies in its lead program, TTI-1612. The first<br />
trial will be in healthy volunteers, thus providing support for both<br />
indications under consideration.<br />
On March 8, 2011, Trillium closed a financing that will allow the<br />
company to advance TTI-1612 into clinical trials in interstitial<br />
cystitis patients.<br />
Employees: 12<br />
Ownership: Private<br />
We plan to submit a clinical trial application for the use of TTI-1612<br />
in the treatment of IC patients by September 2011.<br />
We will start fundraising for a phase II trial in IC in Q4/11, as well<br />
as seeking a potential partner in parallel.<br />
The CD47Fc and SIRPaFc programs will be introduced as potential<br />
early-stage collaboration opportunities in Q4/2011.<br />
CORPORATE MISSION<br />
Trillium Therapeutics Inc. (TTI) is a privately-owned, Toronto-based biopharmaceutical company with two main areas of focus:<br />
cytoprotection and immune regulation. The company's cytoprotection programs are based upon a recombinant form of heparin-binding<br />
epidermal growth factor-like growth factor (HB-EGF). In the immune regulation space, Trillium is developing a suite of innovative<br />
immunomodulatory products that are capable of either suppressing the immune system, for the treatment of autoimmunity,<br />
inflammation and hematopoietic stem cell transplantation (HSCT), or activating the immune system, for the treatment of cancer.<br />
Specifically, Trillium’s portfolio includes: a)Two cytoprotective programs around TTI-1612, a recombinant growth factor that is being<br />
developed as a treatment for interstitial cystitis (IC) and for the prevention of necrotizing enterocolitis (NEC). Trillium recently received<br />
clearance from the FDA to commence clinical studies in the NEC program, but for strategic reasons the company is advancing the IC<br />
program into the clinic first; b)Three pre-clinical cancer programs, including a fully human CD200-specific monoclonal antibody, which is<br />
being co-developed with a pharma partner, as well as two early-stage Fc fusion proteins that target the CD47Fc-SIRPa immunoregulatory<br />
pathway; and c) Two autoimmune/inflammatory programs, including CD200Fc, which recently entered formal development and was<br />
licensed to a large biotech partner, and TTI-314, an anti-CD32a specific antibody that has completed an acute toxicology study in<br />
nonhuman primates and is currently subject to partnering discussions.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TTI-1612 IND Filed Interstitial cystitis (IC) Start of Phase I<br />
TTI-1612 IND Filed Necrotising enterocolitis (NEC) Start of Phase I<br />
CD200Fc Preclinical Inflammation/autoimmune Start of IND-enabling studies<br />
CD47Fc Preclinical Hematopoietic stem cell transplantation Start of IND-enabling studies<br />
SIRPaFc Research Cancer Start of IND-enabling studies<br />
SENIOR MANAGEMENT<br />
Dr. Niclas Stiernholm, President & CEO • Dr. Bob Uger, Chief Scientific Officer • Dr. Penka Petrova, Manager<br />
BIO Business Forum 2011 453 Participating Company <strong>Profiles</strong>
David Woodland<br />
President<br />
154 Algonquin Avenue<br />
Saranac Lake, NY 12983<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Stephen Smiley, Director, Corporate Relations<br />
CORPORATE MISSION<br />
TRUDEAU INSTITUTE<br />
Clinical Foci: Immunology • Infectious Disease • Biodefense<br />
www.trudeauinstitute.org<br />
Phone: 1-518-891-3080<br />
Incorporated: 1894<br />
Employees: 135<br />
Ownership: Private<br />
Trudeau Institute is committed to discovering new ways to prevent and treat infection, inflammation and sepsis. We are an independent,<br />
non-profit, biomedical research organization. Our scientists are available for Sponsored Research, Grant Partnering, Contract Research,<br />
and Consulting.<br />
PROPRIETARY TECHNOLOGY<br />
For over a century, Trudeau Institute scientists have studied the immune system and its roles during infection and inflammation. Our<br />
expertise and enthusiasm for modeling infection, immunity, vaccination, and inflammation have led to many pioneering discoveries.<br />
Mouse models available for sponsored research include influenza, influenza-associated bacterial pneumonia, tuberculosis, sepsis,<br />
listeriosis, toxoplasmosis, pneumonic plague, schistosomiasis, and chronic herpesvirus infection. We have especially strong expertise in<br />
pulmonary immunity, cellular immunity, and infection-associated coagulation.<br />
INTELLECTUAL PROPERTY<br />
Property available for licensing: Nucleoprotein-specific antibodies to treat or prevent influenza infection; Chemokine signaling<br />
antagonists as therapeutics for inflammatory disease; Vaccines and therapeutics for schistosomiasis; Interleukin-15 antagonists for the<br />
treatment of anemia; A novel IL-12 receptor splice variant; Use of live bacteria to induce type 1-17 responses; Vaccination to prime T cells<br />
that combat plague; A mouse model of thrombocytopenia resulting from chronic viral infection<br />
SENIOR MANAGEMENT<br />
David Woodland, President • Nelson Pleau, Vice President • Terry Gach, Vice President • Lisa Shovan, Chief Financial Officer •<br />
Stephen Smiley, Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Vincent A. Fischetti, PhD, Rockefeller University • Christine Biron, PhD, Brown University • Eric G. Pamer, MD, Memorial Sloan-<br />
Kettering Cancer Center • F. Alan Sher, PhD, National Institutes of Health • Maureen Howard, PhD • Ralph M. Steinman, MD,<br />
Rockefeller University • William E. Paul, MD, National Institutes of Health • Robert A. Seder, MD, National Institutes of Health • David<br />
L. Woodland, PhD, Trudeau Institute<br />
BIO Business Forum 2011 454 Participating Company <strong>Profiles</strong>
John Hilfinger<br />
President<br />
540 Avis Drive<br />
Ann Arbor, MI 48108<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Elke Lipka, PhD, Vice President Business Development<br />
TSRL, Inc.<br />
Presenting Company<br />
Clinical Foci: Drug Delivery • Infectious Disease • Specialty Pharmaceutical<br />
www.tsrlinc.com<br />
Phone: 1-734-663-4233<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completed proof-of-feasibility for influenza challenge model (in<br />
vivo mouse model for TSR-026/zanamivir).<br />
Secured ~$3 million in funding from NIH (Phase 2 SBIR grant) for<br />
TSR-026/zanamivir program.<br />
First US patents issued, additional patents filed.<br />
Ownership: Private<br />
Complete pre-IND meeting for TSR-026/zanamivir by 3Q11.<br />
File IND for TSR-026/zanamivir by 3Q12.<br />
Extend IP internationally.<br />
CORPORATE MISSION<br />
TSRL, Inc. is a biopharmaceutical company focused on enabling oral delivery of approved drugs and investigational drug candidates that<br />
are characterized by poor absorption across biological membrane, such as the intestine. Using its proprietary transporter-facilitated<br />
absorption technology, TSRL has demonstrated improved oral bioavailability and preclinical efficacy of a number of antiviral therapeutics<br />
which are currently delivered by non-oral routes, including its lead candidates, TSR-026, an oral prodrug of zanamivir, and TSR-462, an oral<br />
prodrug of guanidine-oseltamivir for influenza. TSR-026 demonstrated effectiveness against recent oseltamivir-resistant virus strains<br />
thus enabling development of a new generation of oral medicines targeting all recent strains of seasonal and pandemic influenza.<br />
In addition, TSRL has developed oral prodrugs of cidofovir for the treatment of human cytomegalovirus infections (hCMV), of vidarabine<br />
for the treatment of HSV, hCMV and smallpox and of triciribine for the treatment of AKT-overexpressing malignancies. TSRL’s oral<br />
therapeutics will be marketed to and partnered with large pharmaceutical firms with pipeline gaps in these therapeutic areas.<br />
We expect most of the new drugs resulting from our approach to be developed using the 505(b)(2) pathway, which lowers development<br />
cost and increases speed of approval. As a result, our business approach is to develop part of our own portfolio of compounds up to Phase I<br />
PK proof-of-concept, i.e. until we achieve systemic exposure levels equal to non-enteral routes of administration. We will then partner<br />
drug candidates for Phase III clinical development, approval, and global commercialization. In addition, we make early stage prodrugs<br />
available for license and are seeking to apply our technology to partners’ compounds at all stages of development.<br />
PROPRIETARY TECHNOLOGY<br />
TSRL has developed a proprietary medicinal chemistry approach for enhancing the absorption of such charged or highly polar small<br />
molecules by targeting endogenous intestinal transporters and has proof of feasibility for its platform technology from several anti-viral<br />
drugs in preclinical animal models. Specifically, TSRL has demonstrated that analogs of zanamivir, a drug marketed as Relenza® and<br />
administered via inhalation have commercially and clinically feasible oral bioavailability. TSR-026, the zanamivir lead candidate, has<br />
demonstrated complete protection in a preclinical fatal influenza challenge mouse model with an oral bioavailability of close to 100%.<br />
TSRL’s proprietary technology has been successfully employed pre-clinically for oral delivery of other anti-viral drugs.<br />
CORPORATE ALLIANCES<br />
TSRL’s technology is broadly applicable to hydrophilic, small molecule compounds with poor bioavailability and to other therapeutic areas,<br />
including oncology. We expect that many of the new drugs resulting from our approach will be based on currently marketed products and<br />
will be developed using the 505(b)(2) pathway, given their proven safety and efficacy. As a result, our business approach is to develop our<br />
own portfolio of compounds up to Phase 1 PK proof-of-concept, and then partner drug candidates for Phase 3 clinical development,<br />
approval, and global commercialization. In addition, we are seeking to apply our technology to partners’ compounds at all stages of<br />
development. TSRL is in active, early stage discussion with a number of pharmaceutical companies.<br />
INTELLECTUAL PROPERTY<br />
TSRL owns full rights to the initial seminal patent application PCT/US2009/040660, published 22 October 2009. This patent application,<br />
with a priority date of 2008, claims a number of specific chemical compositions with utility as neuraminidase inhibitors as well as a<br />
number of chemical modifications to zanavimir, oseltamivir, or peramivir and a number of methods to treat influenza with such<br />
compositions. Full international rights are still available to TSRL through the PCT process. TSRL expects to generate additional patent<br />
protectable IP from optimized synthetic routes for key compounds, formulations manufacturing processes. Full international rights would<br />
be available.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
TSR-026 Preclinical Influenza IND 3Q12<br />
TSR-462 Preclinical Influenza IND 4Q12<br />
BIO Business Forum 2011 455 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
TSR-243 Preclinical Human cytomegalovirus infection, hCMV Lead selection 4Q11<br />
TSR-272 Preclinical Smallpox, hCMV, HSV Lead optimization<br />
TSR-826 Preclinical Akt-overexpressing malignancies Lead optimization<br />
TSR-423 Preclinical inflammatory bowel disease, IBD, Crohn's disease, ulcerative colitis Lead optimization<br />
SENIOR MANAGEMENT<br />
John Hilfinger, President • Elke Lipka, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Grodon Amidon, PhD, Professor of Pharmaceutical Sciences and Charles R. Walgreen Jr. Professor of Pharmacy, University of Michigan •<br />
Arnold Monto, MD, Professor of Epidemiology and Thomas Francis, Jr. Collegiate Professor of Public Health, University of Michigan •<br />
Chris McGuigan, PhD, Professor of Medicinal Chemistry and Deputy Pro Vice Chancellor of Research, Cardiff University • John Drach,<br />
PhD, Professor Emeritus of Biologic and Materials Sciences, Dentistry and Pharmacy, University of Michigan<br />
BIO Business Forum 2011 456 Participating Company <strong>Profiles</strong>
Prof. Pier Giuseppe Pelicci<br />
President & CEO<br />
via Adamello, 16<br />
20139-Milano<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Germano Ferrari<br />
CORPORATE MISSION<br />
TTFactor<br />
Clinical Foci: Oncology • Diagnostics • Gene/Cell Therapy<br />
www.ttfactor.com<br />
Phone: 39-02-9437 5140<br />
Incorporated: 2010<br />
Ownership: Private<br />
TTFactor S.r.l. is the technology transfer company of the FIRC Institute for Molecular Oncology (IFOM) and the European Institute of<br />
Oncology (IEO) incorporated for the purposes of advancing scientific results arising from the IFOM and IEO through technology licensing,<br />
sponsored research and spin off creation.<br />
PROPRIETARY TECHNOLOGY<br />
Early stage cancer diagnostic and therapeutic technologies available for licensing, including:<br />
-Tumor immunotherapy<br />
Method to improve the tumoral antigen presentation to dendritic cells by Salmonella infection for melanoma therapy or prophylaxis<br />
-Biologics<br />
A novel “dual action” type of inhibitor of the urokinase-type plasminogen activator receptor (uPAR)<br />
-Biomarkers / Diagnostics<br />
1) A novel cancer “signature” (10 genes or 80 genes) which helps to predict the course of disease and the choice of treatment in early<br />
stages of Lung Cancer<br />
2) Method for establishing susceptibility to drug treatment in breast cancer for drugs acting on Numb gene<br />
3) A serum circulating miRNAs diagnostic test to identify asymptomatic high-risk individuals with early stages lung cancer (NSCLC)<br />
CORPORATE ALLIANCES<br />
Siemens AG, Pfizer, Myriad Genetics, EOS - Ethical Oncology Science, Abcam, Millipore<br />
INTELLECTUAL PROPERTY<br />
TTFactor provides licensing / co-development opportunities for the project currently in pipeline and for the antibodies developed by the<br />
two institutions.<br />
TTFactor is the connection for industrial partners to IFOM-IEO Institutes for research collaborations in the field of oncology / basic research.<br />
Please, visit our website (www.ttfactor.com For Companies) for a detailed list of patents available for licensing<br />
PRODUCTS<br />
Name Phase Indication<br />
A novel prognostic “gene signature” for early stage Lung Cancer Diagnostics Lung Cancer (Early stage)<br />
Method to establish susceptibility to treatment for drugs acting<br />
on Numb gene<br />
A miRNAs diagnostic test to identify asymptomatic high-risk<br />
early stage NSCLC<br />
Diagnostics Breast Cancer<br />
Diagnostics Non-small Cell Lung Cancer<br />
Novel anti-cancer compounds with anti-tubulin effect Pre-Target Validation Cancer<br />
Novel compounds inhibiting LSD1 and LSD2 histone<br />
demethylases<br />
Hybridomes available for MAb production (detailed catalog on<br />
www.ttfactor.com)<br />
Method to improve the tumoral antigen presentation to DCs by<br />
Salmonella infect.<br />
Pre-Target Validation Cancer / Viral infections<br />
Research Research Tools<br />
Preclinical Melanoma (Therapy, Prophylaxis)<br />
A novel “dual action” type of inhibitor of uPAR Preclinical Neoplasm / Cancer / Oncology<br />
Novel radiopharmaceuticals with extended half-life fo diagnosis<br />
and therapy<br />
Diagnostics Cancer / Breast cancer<br />
SENIOR MANAGEMENT<br />
Prof. Pier Giuseppe Pelicci, President & CEO • Daniela Bellomo, PhD, MBA, Managing Director • Germano Ferrari, PhD, MBA, Business<br />
Development • Marzia Fumagalli, PhD, Other<br />
BIO Business Forum 2011 457 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Pier Giuseppe Pelicci, (President) Scientific co-Director, Chairman, Department of Experimental Oncology, IEO • Mr. Andrea Cuomo,<br />
Executive VP & Chief Strategy & Technology Officer at ST Microelectronics • Prof. Claudio Basilico, Jan T. Vilcek Professor of Molecular<br />
Pathogenesi, New York University • Mr. Domenico Triarico, Management Control Resp., IEO • Ms. Elisabetta Petrucci, General<br />
Manager, FIRC Foundation • Prof. Isaac Kohlberg, Senior Associate Provost and Chief Technology Development Officer at Harvard<br />
University • Prof. Marco Foiani, Scientific Director, IFOM • Ms. Raffaella Zoboli, CFO, IFOM • Mr. Stefano Michelini, General Manager,<br />
European Institute of Oncology • Mr. Tomas Lindhal, FRS-Cancer Research UK<br />
BIO Business Forum 2011 458 Participating Company <strong>Profiles</strong>
Rikumatti Levonmaki<br />
Chief Executive Officer<br />
Itainen Pitkakatu 4 B<br />
20520 Turku<br />
Finland<br />
CONFERENCE PARTICIPANTS<br />
Tero Karhi<br />
Tero M. Piispanen<br />
Turku Science Park Ltd<br />
Phone: 358-2-880 3100 Ownership: Other<br />
CORPORATE MISSION<br />
Turku Science Park Ltd is a regional development company for the biotech actors in the BioTurku® cluster in Finland. The cluster includes<br />
about 100 biotechnology companies, 3 universities and several educational, service and research institutes. The focus areas of BioTurku<br />
are cancer and hormonal diseases, inflammatory and infectious diseases, diseases of the CNS and regenerative medicine including<br />
biomaterials.<br />
CORPORATE ALLIANCES<br />
Karolinska Developmant, Heidelberg Technologiepark GmbH<br />
SENIOR MANAGEMENT<br />
Rikumatti Levonmaki, Chief Executive Officer • Tero Piispanen, Director<br />
BIO Business Forum 2011 459 Participating Company <strong>Profiles</strong>
Chih-Ming Chen<br />
Chairman<br />
4F, No. 41, Lane 221, Kang Chien Rd., NeiHu<br />
Dist.<br />
Taipei 114<br />
Taiwan<br />
CONFERENCE PARTICIPANTS<br />
Sherry Ku, President & CSO<br />
Albert Lin, Business Development Manager<br />
TWi Biotechnology, Inc.<br />
Clinical Foci: Metabolic Disease • Oncology • Ophthalmic<br />
www.twipharma.com<br />
Phone: 886-2-26573350<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
for AC-201, the Phase IIa study showed a mean reduction of 0.63% for HbA1c (N=56, p
PRODUCTS<br />
Name Phase Indication Milestone<br />
AC-501 Preclinical Acute Myeloid<br />
Leukemia<br />
AC-101 Preclinical A prodrug of<br />
gabapentin<br />
SENIOR MANAGEMENT<br />
AC-501 is a multi-kinase inhibitor with inherent low systemic toxicity<br />
during late stage of preclinical study.<br />
Chih-Ming Chen, Chairman • M. Sherry Ku, President • Chaur-Ming (Steve) Jan, Senior Vice President • Calvin Chen, Business<br />
Development • Ling-Ying Liaw, Vice President • Yu-Jen (Kan) Chien, Vice President • Shou-Chiung Chen, Vice President<br />
BOARD OF DIRECTORS<br />
Chih-Ming Chen<br />
BIO Business Forum 2011 461 Participating Company <strong>Profiles</strong>
Henrik Luessen, PhD<br />
Managing Director<br />
Van der Kaaijstraat 64<br />
1815 VM Alkmaar<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Henrik Luessen, PhD, CEO<br />
Tytonis Bv<br />
Clinical Foci: Drug Delivery • Pulmonary • Biopharmaceuticals<br />
www.tytonis.com<br />
Phone: 31-6-2156 6415<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Founded Tytonis Operations, Dresden (www.tytonis-operations.com) to serve<br />
businesses in Germany and Eastern Europe more efficiently, help start-up utilizing<br />
the financial favorable environment for Hi-tech start-ups in Saxonia & provide<br />
QA/RA support<br />
Served as interim CBO of Activaero and assisted the company in their licensing of a<br />
new product to Bayer and their recent financing rounds.<br />
Appointed as CBO of Inscreenex, a company founded under the guidance of Tytonis<br />
as a spin out from the Helmholtz Center in Brunswig. Core technology: Cell based<br />
efficacy and tox screening with primary cell lines<br />
Incorporated: 2006<br />
Employees: 3<br />
Ownership: Private<br />
Outlicensing of Activaero's high dose steroid<br />
inhalative product for treatment of severe OCS<br />
dependent asthma<br />
Outlicensing of OncoHist, respectively finding<br />
financing / M&A partner for Symbiotec.<br />
Establishing the platform of Inscreenex that allow<br />
rational drug screening and tox testing using<br />
standarized primary cells<br />
CORPORATE MISSION<br />
Tytonis is providing advisory services in the field of licensing transactions (including full legal services), valuations (corporate and product<br />
based), portfolio strategy and valuations, financing support, M&A as well as intellectual properties evaluations and strategies. Tytonis<br />
operates within a group of international recognized experts and advisors (see also www.tytonis.com). We have affiliated partners in the<br />
US and in Asia to facilitate product and technology transfer oversees in the highest professional quality with people that know the local<br />
cultures and have established a track record of relevant contacts in the industry. On demand we could also fill interim senior level<br />
positions in business/corporate development and product development.<br />
As of 2009 Tytonis Operations in Dresden (www.tytonis-operations.com) was added to our organisation to serve our customers that like to<br />
get advice on operational issues (quality, manufacturing) as well as business start-up support in Saxonia.<br />
PROPRIETARY TECHNOLOGY<br />
We are dedicated to excel the technology of our partners and may present them to interested parties on their behalf. See also Product<br />
section for more information.<br />
CORPORATE ALLIANCES<br />
We cooperate with a network of international experts available on a consultancy basis within Europe, US and Asia. For more information<br />
please refer to our website www.tytonis.com.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
High-dose steriods for OCS weaning Phase II, IIa, IIb severe OCS dependent<br />
asthma<br />
Outlicensing after finalization of CP II (Q4/2011);<br />
Owner: Activaero<br />
OncoHist Phase II, IIa, IIb Cancer, AML and ALL Outlicensing immediately available including<br />
clinical IIa in AML, Owner: Symbiotec<br />
T-Guard Phase II, IIa, IIb Acute Graft vs Host<br />
Disease (aGVHD)<br />
Tech platform: HTS for<br />
biopharmaceutical formulations<br />
Monosphere process technology<br />
platform (by Nanomi BV)<br />
Na/H channel blocker (by Peacock<br />
Pharma GmbH)<br />
Topical tacrolimus formulation with<br />
improved skin penetration<br />
Outlicensing, immediately available, Owner:<br />
Xenikos BV<br />
On Market any Finding co-development partners with<br />
biopharmaceuticals for product development<br />
Other any Finding co-development partners for sustained<br />
release microsphere formulations<br />
Phase I Cardiology: ventricular<br />
fibrillation<br />
financing until end of Phase II<br />
Phase III Psoriasis vulgaris Outlicensing to Japanese/Korean partner prior to<br />
start of multicenter Phase III trials<br />
SENIOR MANAGEMENT<br />
Henrik Luessen, PhD, Managing Director • Sam Dylan Moré, PhD, Tytonis Operations, Managing Director<br />
BIO Business Forum 2011 462 Participating Company <strong>Profiles</strong>
David Winwood, PhD<br />
Chief Executive Officer<br />
701 20th Street South<br />
Birmingham, AL 35294<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Deborah J. Bidanset, Assistant Director<br />
Dugald Hall, Licensing Associate<br />
UAB Research Foundation<br />
www.uab.edu/uabrf<br />
Phone: 1-205-934-9911<br />
Incorporated: 1986<br />
Ownership: Public<br />
HIGHLIGHTS<br />
Recent<br />
• 34 startup companies based on UAB technologies.<br />
• Over 400 option and license agreements executed generating approximately $46 million in revenues for UAB.<br />
• More than $29 million in research agreements for the University negotiated through UABRF.<br />
CORPORATE MISSION<br />
The UAB Research Foundation (UABRF) is the technology transfer and commercialization office for The University of Alabama at<br />
Birmingham (UAB). It was formed in 1987 as a non-profit corporation with a mission to identify, evaluate, market and license technology<br />
createded at UAB. UABRF is the assignee of all intellectual property developed at UAB and is responsible for managing all aspects of its<br />
transfer and commercialization.<br />
UABRF's primary responsiblity is to identify, evaluate, protect and market intellectual property created at UAB. The office reviews<br />
intellectual property disclosures submitted by UAB employees and students, evaluates the commercial potential of these discoveries and<br />
seeks appropriate protection for selected technologies. In addition, UABRF markets and licenses technologies to commercial entities and<br />
monitors compliance with contractual terms.<br />
PROPRIETARY TECHNOLOGY<br />
UAB has technologies in every medical therapeutic area, including but not limited to technologies for the diagnosis and treatment of<br />
cancer, autoimmune diseases, cardiovascular diseases, and central nervous system disorders. They encompass every type of technology,<br />
from platform technology and research tools to diagnostics and therapeutics (such as gene therapy and vaccines), and every stage, from<br />
very early stage to late stage (including clinical trials). UAB also has a strong portfolio of engineering, biomaterials and computer<br />
technologies with a wide variety of industrial and medical applications.<br />
INTELLECTUAL PROPERTY<br />
Portfolio of patent applications and granted patents for US, EU, and often worldwide.<br />
SENIOR MANAGEMENT<br />
David Winwood, PhD, Chief Executive Officer • Leona Fitzmaurice, PhD, Director • Deborah Bidanset, PhD. MBA, Assistant<br />
BIO Business Forum 2011 463 Participating Company <strong>Profiles</strong>
Stephen Rudy<br />
Other<br />
160 Fifth Avenue<br />
New York, NY 10010<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Stephen M. Rudy<br />
UAM Global<br />
Clinical Foci: Medical Device • Service<br />
www.uamglobal.org<br />
Phone: 1-212-537 0325<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Universal Anesthesia Machine in use at three UK hospitals: Southampton General,<br />
Poole, and Royal Hospital for Sick Children. Four machines in clinical use in Nepal. Two<br />
additional placements are expected this summer.<br />
The Universal Anesthesia Machine becomes the first anesthesia machine designed<br />
specifically for low income environments to receive the CE Mark.<br />
UAM Global receives financing from the Nick Simons Foundation, a New York<br />
philanthropy dedicated to health services in low income countries.<br />
Incorporated: 2010<br />
Employees: 5<br />
Ownership: Private<br />
Additional clinical studies in the UK to provide<br />
independent validation of the Universal<br />
Anesthesia Machine.<br />
A long term clinical evaluation in the US and<br />
Africa to be conducted by a major US teaching<br />
hospital. Announcement expected in this<br />
summer.<br />
CORPORATE MISSION<br />
UAM Global is an arm of the Nick Simons Foundation, a NY based philanthropy dedicated to improving health in low income countries.<br />
UAMG had developed a CE marked anesthesia machine designed to safely deliver standard anesthetic agents in austere environments<br />
characterized by power shortages and disruptions in the supply of compressed medical gases. The Universal Anesthesia Machine has been<br />
installed in hospitals in the UK and Nepal, with near term placements expected in sub-Saharan Africa.<br />
The goal of UAMG is the provision of anesthesia services which in turn enable emergency and urgent surgery in district hospitals. The<br />
organization is targeting improvements in maternal health through the availability of emergency obstetric surgery, as well as surgery for<br />
trauma and urgent interventions.<br />
UAMG will develop training, service and support activities to ensure the anesthesia machine will be used by trained, local personnel and<br />
supported to ensure long term use. The company is looking for partners with an existing footprint in low income hospitals to participate<br />
in securing grants, distributing the machine and its associated products, training personnel and establishing service and support<br />
capabilities.<br />
PROPRIETARY TECHNOLOGY<br />
The Universal Anesthesia Machine is designed for austere environments characterized by intermittent electrical power and shortages of<br />
compressed medical gases. The UAM can operate on battery backup and is compatible with a variety of gas sources, including room air in<br />
the event no other source is available.<br />
CORPORATE ALLIANCES<br />
Nick Simons Institute, Nepal<br />
Southampton General Hospital, UK<br />
Royal Hospital for Sick Children, UK<br />
Poole Hospital, UK<br />
INTELLECTUAL PROPERTY<br />
One patent pending<br />
PRODUCTS<br />
Name Phase Indication<br />
Universal Anesthesia Machine On Market General anesthesia<br />
FINANCING HISTORY<br />
Investors: Nick Simons Foundation (100 %)<br />
SENIOR MANAGEMENT<br />
Stephen Rudy, Other • Erica Frenkel, Other • Andy Gyenes, Other<br />
BOARD OF DIRECTORS<br />
James Simons, The Nick Simons Foundation • Marilyn Simons, The Nick Simons Foundation<br />
SCIENTIFIC ADVISORY BOARD<br />
Paul Fenton, MD • David Acker<br />
BIO Business Forum 2011 464 Participating Company <strong>Profiles</strong>
Jane C. Moores, PhD<br />
Director<br />
9500 Gilman Drive, MC-0910<br />
La Jolla, CA 92093-0910<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Denise Lew<br />
HIGHLIGHTS<br />
Recent<br />
UC San Diego<br />
Clinical Foci: Biology • Chemistry<br />
http://invent.ucsd.edu<br />
Phone: 1-858-534-5815<br />
Incorporated: 1960<br />
Ownership: Other<br />
FY2010: UCSD licensed patent rights to 13 new start-up companies (>25% of 47 start-ups in the UC system.) The UC system is first<br />
nationally in start-up company formation (source: AUTM)<br />
FY2009: 151 patents issued and 42 invention licenses completed.<br />
The UC system holds the most US patents of any academic institution in the nation. UCSD manages over 700 active US & over 800 foreign<br />
patents.<br />
See our website http://invent.ucsd.edu for technology descriptions available for licensing from UCSD.<br />
FY2008, FY2009 and FY2010: Over 350 invention and copyright disclosures were submitted to the UCSD Technology Transfer Office. As the<br />
first step in the IP management process, this serves as a positive indicator for future activity.<br />
CORPORATE MISSION<br />
The UC San Diego Technology Transfer Office (TTO) evaluates, patents, markets and out-licenses innovations developed at UCSD for<br />
commercial applications in the global marketplace. Through licensing to local businesses, including start-up companies, TTO promotes<br />
the economic development of the greater Southern California area. We also license to companies internationally, from North and South<br />
America, Europe, Asia and Australia, to commercialize in their business ventures.<br />
PROPRIETARY TECHNOLOGY<br />
biofuels, cancer, cardiovascular, CNS, dermatological, ophthalmic, otological diseases, endocrine, GI, infectious disease, inflammation,<br />
immunology, plants, stem cells, urology; genomics, proteomics, bioinformatics, software, biochips, BioMEMS, cell culture, tissue<br />
engineering, research tools, nanotechnology; see our website http://invent.ucsd.edu for technology descriptions.<br />
INTELLECTUAL PROPERTY<br />
1400+ patents and technologies available for licensing in agriculture, biomedicine, bioinformatics, plants, stem cells, engineering and<br />
physical sciences, nanotechnology and other fields<br />
SENIOR MANAGEMENT<br />
Jane C. Moores, PhD, Director • Denise Lew, PhD, Business Development • Grai Andreason, PhD, MBA, Business Development •<br />
Dominic Montisano, PhD, Business Development • Rose Murphy, MBA, Business Development • Donna Shaw, PhD, Business<br />
Development • Wendy Shih, PhD, Business Development<br />
BIO Business Forum 2011 465 Participating Company <strong>Profiles</strong>
Dr Anne Lane<br />
Executive Vice President<br />
The Network Building<br />
London<br />
W1T4TP<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Richard Joseph Fagan, Director BioPharm<br />
CORPORATE MISSION<br />
UCL Business PLC<br />
Clinical Foci: Drug Discovery • Medical Device • Regenerative Medicine<br />
www.uclb.com<br />
Phone: 44-0207-679 9000<br />
Incorporated: 2006<br />
Employees: 40<br />
Ownership: Private<br />
University College London Business (UCLB) is the technology transfer organisation for University College London, responsible for<br />
technology development and commercial transactions for University College London (UCL).<br />
We work to make commercial connections between the expertise and innovations of UCL's academics and the needs of industry. For<br />
businesses seeking specific technology solutions, UCLB provides the commercial expertise, legal and administrative support required to<br />
broker licensing agreements.<br />
PROPRIETARY TECHNOLOGY<br />
UCLB has a range of projects in development utilising novel intellectual propert eminating from UCL ranging from therapeutics, small<br />
molecule, biologics and stem cells, medical imaging, imaging software to a range of novel medical devices.<br />
CORPORATE ALLIANCES<br />
Ocera Therapeutics<br />
Coronado Biosciences<br />
GSK<br />
Technology Automation Partners<br />
Pfizer<br />
Stanmore Implants Worldwide<br />
AstraZeneca<br />
Becton Dickinson<br />
Novartis<br />
INTELLECTUAL PROPERTY<br />
Ondine<br />
UCLB has a total number of 22 drug discovery projects in development. Intellectual property has been filed on all projects. We currently<br />
have 214 patent families<br />
PRODUCTS<br />
Name Phase Indication<br />
ProAxon Lead Series neuroprotection - MS, Galucoma, Stroke<br />
dimethylarginine dimethylaminohydrolase,<br />
DDAH<br />
Lead Series Sepsis<br />
Naturetic Peptide Receptor C Agonists Lead Series Myocardial Infarction<br />
Detection of Apoptosing Retinal Cells Optimized Lead glaucoma, Alzheimers', Parkinsons',<br />
Antibody Tablet Research glaucoma, would healing<br />
Abcodia Research Serum BioBanks, Biomarker discovery and validation, oncology,<br />
cardiovascular, metabolic, CNS, respiratory<br />
SENIOR MANAGEMENT<br />
Dr Anne Lane, Executive Vice President • Ms Karen Cheetham, Director • Mr Cengiz Tarhan, Managing Director • Dr Steven<br />
Schooling, Director • Dr Richard Fagan, Director<br />
BIO Business Forum 2011 466 Participating Company <strong>Profiles</strong>
Dr. Marc Zabeau<br />
Managing Director<br />
Bollebergen 2 B<br />
B-9052 Gent<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Philippe Jacobs, European Patent Attorney<br />
Piet De Vos<br />
UGent Tech Transfer<br />
Clinical Foci: Diagnostics • Vaccines • Food & Ag<br />
Phone: 32-926-49981 Ownership: Other<br />
CORPORATE MISSION<br />
UGent is one of the largest universities in Belgium (31,000 students, 7100 staff members) having -amongst others- a strong research<br />
community within the field of biotechnology. The technology transfer office of the university, together with its business development<br />
centers and the Ghent University Hospital, wishes to identify suitable strategies -such as research partnerships and out-licensing- for the<br />
commercialization of its innovative research.<br />
PROPRIETARY TECHNOLOGY<br />
UGent has proprietary technology in the fields of 1) industrial biotech and biocatalysis (phosphorylases), 2) biomarkers in cancer, heart<br />
disease, lung disease and sepsis, 3) agrobiotech (folate production and plant-based antibodies), 4) aquaculture, 5) (veterinary) infections,<br />
6) delivery and 7) vaccines.<br />
CORPORATE ALLIANCES<br />
UGent has a framework agreement with VIB (the Flemish Institute for Biotechnology) and has agreements with several Pharma and<br />
Biotech companies.<br />
INTELLECTUAL PROPERTY<br />
UGent actively applies for patent protection for all its technologies. Currently UGent possesses about 270 patent families.<br />
SENIOR MANAGEMENT<br />
Dr. Marc Zabeau, Managing Director<br />
BIO Business Forum 2011 467 Participating Company <strong>Profiles</strong>
1 Victoria St<br />
London<br />
SW1H 0ET<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Hilary Glidden<br />
Christina Bergstrand<br />
Joe Dodd, Manager, Trade & Investment<br />
UK Trade & Investment<br />
Clinical Foci: Oncology<br />
www.ukti.gov.uk<br />
Phone: 44-20-7215 8000<br />
Ownership: Other<br />
CORPORATE MISSION<br />
UK Trade & Investment is the British government department that assists UK-based companies to succeed globally and assists overseas<br />
companies to bring high quality investment to the UK.<br />
BIO Business Forum 2011 468 Participating Company <strong>Profiles</strong>
Sylvain Duvernay<br />
Chief Executive Officer<br />
100, de l'Industrie<br />
Candiac, QC J5R1J1<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Alain Huneault, Director, Business Development<br />
CORPORATE MISSION<br />
UMAN PHARMA Inc.<br />
Clinical Foci: Oncology • Drug Development • Generics<br />
www.umanpharma.com<br />
Phone: 1-514-220-4304<br />
Employees: 85<br />
Ownership: Private<br />
STERILE MANUFACTURING –<br />
The sterile facility, located in its own separate building, is designed to manufacture sterile forms of cytotoxic and high potency products.<br />
The site is equipped to fill pre-filled syringes and vials, either in solution or lyophilized forms, with capabilities for low and high<br />
temperature processing and disperse systems such as liposomes.<br />
ORAL SOLID DOSAGE –<br />
The oral solid dosage manufacturing facility is integrated into the main complex. It is suitably equipped for the manufacturing and<br />
packaging tablets and hard gelatine capsules at clinical and commercial scales.<br />
UMAN IS A FULL-SERVICE PROVIDER<br />
Research & Development<br />
Formulation Design<br />
API Evaluation<br />
Process development and optimization<br />
Lyophilization cycle development<br />
Quality and Compliance<br />
Approved on-site laboratories<br />
Chemistry and microbiology<br />
Analytical method development and validation<br />
Stability testing programs<br />
Technology transfer<br />
CMC documents and CTD support<br />
Pre-clinical and clinical development<br />
Drug formulation development and scale-up<br />
Complete clinical manufacturing (Phase I to Phase IV)<br />
Sterile fill: pre-filled syringes and vials<br />
Lyophilization<br />
Terminal sterilization (vials)<br />
Tablet and capsule production.<br />
Manufacturing of placebo<br />
Release testing<br />
Packaging and labelling of blinded and open label materials<br />
Commercialization<br />
Technology transfer<br />
Scale-up to commercial<br />
Validation of manufacturing process<br />
Packaging and labelling<br />
QUALITY<br />
Quality is of the utmost importance at Uman Pharma. From incoming materials to finished goods, our professional quality control and<br />
quality assurance groups ensure the highest pharmaceutical quality standards.<br />
Uman Pharma is an integrated pharmaceutical company offering products and services to the global health sciences industry. Through a<br />
combination of flexibility, excellent product quality and a professional team, we are the partner of choice for clients worldwide.<br />
SENIOR MANAGEMENT<br />
Sylvain Duvernay, Chief Executive Officer • Alain Hubert, Chief Operating Officer • Luc Charbonneau, Chief Financial Officer<br />
BIO Business Forum 2011 469 Participating Company <strong>Profiles</strong>
Kikwon Doh<br />
Chief Executive Officer<br />
4 Fl. 68-22 Chungdam-dong<br />
Seoul 135-953<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Kay Doh, Team Lead<br />
Kikwon Doh<br />
Jaehan Park<br />
Jeong-Gu Kang<br />
Unhwa Corporation<br />
Clinical Foci: Biomaterials • Drug Development • Drug Discovery<br />
www.unhwa.com<br />
Phone: 82-2-61901122<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Unhwa's article titled "Cultured cambial meristematic cells as a<br />
source of plant natural products" was published in Nature<br />
Biotechnology November 2010. This article introduces Unhwa's<br />
plant stem cell technology and its implications.<br />
Unhwa has been selected by the Korean government Ministry of<br />
Knowledge Economy in a project to develop botanical drug<br />
targeting global market. Especially Unhwa aims to develop an AIDS<br />
therapy targeting phase II clinical trial in the U.S. by 2014.<br />
Discovery Channel and Unhwa has jointly produced a set of three<br />
documentaries introducing Unhwa's pioneering plant stem cell<br />
isolation and culture technology and Discovery has broadcasted<br />
them in over 30 countries worldwide this year.<br />
Incorporated: 2005<br />
Employees: 120<br />
Ownership: Private<br />
Unhwa has partnered with global cosmetic and nutrition<br />
companies to develop cosmetic/ nutrition products using plant<br />
stem cell ingredient. By the end of 2011, many plant stem cell<br />
cosmetic/ nutrition products will be introduced in the global<br />
market.<br />
Unhwa plans to partner with a well renowned botanical drug<br />
company in China to develop botanical drugs for Chinese market<br />
and abroad.<br />
Unhwa has few botanical drug candidates in the areas of anti-viral,<br />
anti-inflammation, and anti-cancer in the pipeline. Through<br />
research with pharmaceutical companies and research institutions,<br />
Unhwa plans to develop them into botanical drugs.<br />
CORPORATE MISSION<br />
Unhwa Corporation is a privately-held biotechnology company in Korea having secured the world's first patent technology in isolation and<br />
culture of plant stem cells. Using this proprietary technology, Unhwa Corporation is developing and producing new biomaterials for<br />
pharmaceutical, nutrition, and cosmetic ingredients and developing botanical drug.<br />
PROPRIETARY TECHNOLOGY<br />
Unhwa Corporation has succeeded in isolation and culture of cambial meristematic cells (CMCs) for the first time in the world and this<br />
platform technology has been published in Nature Biotechnology in Nov. 2010. Unlike the dedifferentiated callus, plant stem cell clearly<br />
demonstrates its “stem cell” nature, with an amazing capability to maintain viability and stemness in the long term suspension culture.<br />
Therefore, plant stem cell culture technology actualizes an optimal cell culture system which is outstandingly homogeneous, stable,<br />
controllable and reproducible in the long term and large scale culture. This technology enables the utmost quality management and<br />
standardization of natural products.<br />
CORPORATE ALLIANCES<br />
Unhwa Corporation is currently working with University of Edinburgh, University of Maryland and other renowned research institutes in<br />
Korea to research and develop this new biomaterial as pharmaceutical, nutrition, and cosmetic ingredients. Unhwa Corporation is also<br />
working with industrial partners, renowned global nutrition and cosmetic companies to develop products using world's first plant stem<br />
cell.<br />
INTELLECTUAL PROPERTY<br />
Secured an extensive international patent portfolio by applying for patents for plant stem cell isolation and culture technology in major<br />
15 countries<br />
A total of 122 material, usage, and method patents applied (approx. 10 patents per patent type)<br />
Plant stem cell exclusive intellectual property rights acquired:<br />
- Plant stem cell isolation and culture technology verified as a platform technology by the Korean Intellectual Property Office (KIPO)<br />
- Platform technology patents registered in South Korea (2011), Russia (2010), Singapore (2011), and South Africa (2011)<br />
FINANCING HISTORY<br />
Investors: Kikwon Doh (46 %) • Youngwoo Jin (18 %) • Eunkyong Lee (10 %)<br />
SENIOR MANAGEMENT<br />
Kikwon Doh, Chief Executive Officer • Young-woo Jin, Chief Technology Officer • Eunkyong Lee, Chief Scientific Officer • Jaehan Park,<br />
Business Development<br />
BIO Business Forum 2011 470 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Kikwon Doh, Unhwa Corporation • Young-woo Jin, Unhwa Corporation • Eun Kyong Lee, Unhewa Coporation • Hyo-sung Won,<br />
Unhwa Life Corporation • Jaehan Park, Unhwa Corporation<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Gary Loake, Institute of Cell & Molecular Biology, University of Edinburgh • Professor Mun-shik Yang, Department of Life<br />
Science, Chonbuk University • Dr. M.B. Ali, Founder of Chinese Preventative Medicine Association, Advisor of the Chinese Ministry of<br />
Health<br />
BIO Business Forum 2011 471 Participating Company <strong>Profiles</strong>
Ashleigh Palmer<br />
President & CEO<br />
81 Fulton St.<br />
Boonton, NJ 07005<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Ali Bolat, Asst Director, Business Development<br />
Gregory Mayes, Corporate Development<br />
Unigene Laboratories, Inc<br />
Clinical Foci: Drug Delivery • Metabolic Disease • Veterinary<br />
www.unigene.com<br />
Phone: 1-973-882-0860<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Unigene announces manufacturing and clinical supply agreement<br />
with Cara Therapeutics for Phase 1 study of Novel Kappa Receptor<br />
Agonist.<br />
Unigene completes patient enrollment of oral PTH Phase 2 study<br />
for the treatment of osteoporosis in postmenopausal women.<br />
Unigene’s oral peptide drug delivery technology validated with<br />
positive top-line Phase 3 results from Tarsa’s ORACAL trial of Oral<br />
Calcitonin.<br />
Incorporated: 1982<br />
Employees: 70<br />
Ownership: Public<br />
Market Cap: $103.00 million<br />
OTC BB: UGNE.OB<br />
Tarsa's plans for New Drug Application (NDA) submission of Oral<br />
Calcitonin to the Food and Drug Administration (FDA) targeted<br />
before the end of 2011.<br />
Unigene expects Tarsa to announce Phase 3 oral calcitonin top-line<br />
results.<br />
Unigene expects Cara's Phase 1 study to begin in the second half of<br />
2011.<br />
CORPORATE MISSION<br />
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The company is<br />
building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence platform. Peptelligence<br />
encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development<br />
expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral<br />
and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.<br />
PROPRIETARY TECHNOLOGY<br />
Unigene’s patented oral delivery technology has been shown to effectively deliver therapeutically important peptides. Oral Peptide<br />
Delivery: Peptides and proteins possess several inherent properties that limit oral bioavailability.<br />
Unigene’s technology has overcome these physiological barriers by several mechanisms resulting in excellent bioavailability:<br />
Enteric coating permits passage of the tablet or capsule through the stomach into the small intestine;<br />
Novel excipients prevent proteolytic cleavage and enhance transport of drug into the blood stream; and<br />
Absolute bioavailability from 1% to greater than 20% compared to IV infusion.<br />
CORPORATE ALLIANCES<br />
Unigene’s technologies have extensive clinical and partner validation. The company’s first product to market, Fortical®, a nasal calcitonin<br />
product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis.<br />
Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of<br />
osteoporosis. Other validating relationships include an oral parathyroid hormone in Phase 2 and licensed to GlaxoSmithKline. In addition,<br />
Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the<br />
treatment of osteoporosis and osteoarthritis.<br />
INTELLECTUAL PROPERTY<br />
Our oral delivery technology can provide patent protection up to 2028. In addition, Unigene has patented recombinant manufacturing<br />
technologies for production of peptides and proteins.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Fortical On Market Osteoporosis<br />
Oral Calcitonin Phase III Osteoporosis Phase 3 results expected 2Q11.<br />
Oral PTH Phase II, IIa, IIb Osteoporosis Commence Phase 2; 1Q11, Complete<br />
patient enrollment; 2Q11, Top-line<br />
results 4Q11.<br />
Satiety Peptides Preclinical Obesity<br />
Anti-inflammatory Peptides Preclinical Inflammation and reperfusion injury<br />
BIO Business Forum 2011 472 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Satiety Peptides Research Obesity for Veterinary Use<br />
SENIOR MANAGEMENT<br />
Ashleigh Palmer, President & CEO • Alex Martin, Business Development • Gregory T. Mayes, Esq, General Counsel • Nozer Mehta,<br />
PhD, Vice President • Paul Shields, PhD, Vice President • William Steinhauer, CPA, Vice President • Roxanne Tavakkol, Vice President •<br />
Jenene Thomas, Investor Relations<br />
BOARD OF DIRECTORS<br />
Richard Levy, Victory Park Capital Advisors • Ashleigh Palmer, President & CEO, Unigene Laboratories • Allen Bloom, PhD, Board<br />
Secretary • Zvi Eiref, Board Treasurer • Marvin L. Miller, Independent Consultant • Joel A. Tune, President, JTune Consulting LLC<br />
BIO Business Forum 2011 473 Participating Company <strong>Profiles</strong>
David Henderson<br />
Managing Director<br />
The University of Queensland<br />
Brisbane, QLD 4072<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
UniQuest Pty Limited<br />
Clinical Foci: Drug Discovery • Biopharmaceuticals • Medical Device<br />
www.uniquest.com.au<br />
Dean Moss<br />
Judy Halliday, Group Manager<br />
Don Kakuda, Commercialisation Manager, Life Sciences<br />
Robin Fieldhouse, Commercialisation Manager, Life Sciences,<br />
University of Tasmania<br />
Ben Phillis<br />
Craig Belcher, Manager of Business Development<br />
Mark Ashton, Commercialisation Manager, Health Sciences<br />
Pamela Blaikie, Commercialisation Manager, University of<br />
Technology Sydney<br />
Phone: 61-07-3365 4037<br />
Incorporated: 1984<br />
Employees: 85<br />
Ownership: Private<br />
Gavin Dixon, Commercialisation Manager, University of<br />
Wollongong<br />
David Markwell, Commercialisation Associate<br />
Paul Sernia, Commercialisation Manager, James Cook University<br />
Aoife Cullen, Research, Innovation & Commercial Development<br />
Associate<br />
David Henderson<br />
Carrie Hillyard<br />
HIGHLIGHTS<br />
Recent<br />
Cancer vaccine concept - licensed to RNAi developer Alnylam Pharmaceuticals, Inc., https://www.uniquest.com.au/news/uq-vaccineinnovation-licensed-global-biopharmaceutical-company<br />
Medication safety website - commercial agreement with NPS - better choices, better health (formerly the National Prescribing Service).<br />
https://www.uniquest.com.au/news/medication-safety-website-aims-reduce-medication-errors<br />
OzID lipid molecule characterization method - patent granted by the United States Patent and Trademark Office.<br />
https://www.uniquest.com.au/news/us-patented-oz-idea-improve-understanding-disease<br />
CORPORATE MISSION<br />
Established by The University of Queensland in 1984, UniQuest is widely recognised as one of Australia’s largest and most successful<br />
university commercialisation groups. With more than 80 staff and group revenues exceeding A$320 million in the past five years, the<br />
company is also benchmarked in the top tier of technology transfer worldwide. From an intellectual property portfolio of 1,500+ patents it<br />
has created over 60 companies, and since 2000 UniQuest and its start-ups have raised more than $400 million to take university<br />
technologies to market. UniQuest's innovation portfolio includes Australia's first blockbuster vaccine Gardasil®, Australia's largest biotech<br />
IPO QRxPharma Ltd, the Triple P Positive Parenting Program, and superconductor technology used in two-thirds of the world's MRI<br />
machines. Sales of products using UQ technology and licensed by UniQuest have passed $5.2 billion. UniQuest now commercialises<br />
innovations developed at The University of Queensland and its commercialisation partner institutions: the University of Wollongong,<br />
University of Technology Sydney, James Cook University, University of Tasmania, and the Mater Medical Research Institute. UniQuest also<br />
provides access to an expansive and exclusive network of independent academics to tailor a consulting or project R&D solution to meet<br />
the diverse needs of industry and government, facilitating some 500 consulting, expert opinion, testing, and contract research services<br />
each year. UniQuest is also a leading Australasian provider of international development assistance recognised for excellence in technical<br />
leadership, management and research. Working with agencies such as AusAID, NZAID, the Asian Development Bank and the World Bank,<br />
UniQuest has developed and implemented more than 400 projects in 46 countries throughout the Pacific, South-East Asia, the Indian subcontinent<br />
and Africa.<br />
PROPRIETARY TECHNOLOGY<br />
biopharmaceuticals, novel targets and novel treatments for multiple diseases across the spectrum<br />
CORPORATE ALLIANCES<br />
The University of Queensland<br />
University of Technology, Sydney<br />
Merck/GSK<br />
University of Tasmania<br />
Pfizer<br />
TetraQ<br />
University of Wollongong<br />
QPharm<br />
Mater Medical Research Institution<br />
Ausbiotech<br />
James Cook University<br />
INTELLECTUAL PROPERTY<br />
Life Sciences Queensland<br />
UniQuest manages an intellectual property portfolio of more than 1,500 patents and patent applications.<br />
BIO Business Forum 2011 474 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
Biomarkers and treatments for peripheral<br />
vascular diseases<br />
Research Cardiovascular diseases<br />
Enogesia Preclinical neuropathic pain<br />
immunomodulation Research autoimmune disorders<br />
VacK4 Research hormone dependent cancers<br />
SENIOR MANAGEMENT<br />
David Henderson, Managing Director • Dr Dean Moss, Manager • Dr Judy Halliday, Manager • Dr Craig Belcher, Business<br />
Development • Dr Ben Phillis, Manager • Dr Pamela Blaikie, Manager • Dr Mark Ashton, Manager • Dr Robin Fieldhouse, Manager •<br />
Dr Paul Sernia, Manager • Dr Gavin Dixon, Manager<br />
BOARD OF DIRECTORS<br />
Dr Carrie Hillyard, Independent • Professor Gordon Dunlop, University of Queensland • Dr Chris Rawlings, Independent • Ms Mary<br />
Boydell, Independent • Mr David Henderson, UniQuest • Mr Rob Hewitt, UniQuest<br />
BIO Business Forum 2011 475 Participating Company <strong>Profiles</strong>
Eureka Building. Campus UAB<br />
08193 Bellaterra (Cerdanyola del Vallès) BCN<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Maite Ibern, IP and Innovation Manager<br />
Universitat Autònoma De Barcelona<br />
Clinical Foci: Industrial Biotech • Drug Delivery • Gene/Cell Therapy<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
New molecule to bind a wide<br />
range of biomolecules to obtain<br />
radiopharmaceuticals<br />
platelet-rich-plasma gel for<br />
volumetric reconstruction<br />
Embryotag Other Encoded microparticles<br />
for isolated cell and<br />
embryo tracking<br />
Phone: 34-93-5868922 Ownership: Other<br />
Market Cap: $400.00 million<br />
Other Cancer diagnostic nearly 97% yield of the resultant Tc-99m derivatives, high<br />
stability even at low concentration and in presence of<br />
aminoacids<br />
Phase I breast cancer 50 patients - Nearly 100 % of the patients remain with the<br />
same volume along 2 year of monitoring and any recidives<br />
were found<br />
Barcodes have been successfully adhered to the zona pellucida<br />
of mouse embryos and encoded embryos have been tracked in<br />
vitro during their pre-implantation development. Encoded<br />
embryos can be frozen and develop normally after thawing.<br />
BIO Business Forum 2011 476 Participating Company <strong>Profiles</strong>
Marc Le Gal<br />
Director<br />
37, rue du repos<br />
69007 Lyon<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Sandrine Carteau<br />
CORPORATE MISSION<br />
Université de Lyon<br />
Clinical Foci: Oncology • Infectious Disease • Drug Delivery<br />
www.universite-lyon.fr/lst<br />
Phone: 33-4-3737 4297<br />
Incorporated: 2006<br />
Ownership: Other<br />
Lyon Science Transfert is a French Technology Transfer Office. It supports the University of Lyon by transferring basic research discoveries<br />
made in the laboratories to the marketplace for commercial development.<br />
Lyon Science Transfert works in synergy with the CNRS, INSERM, INRA and INRIA. It offers numerous innovative products, processes,<br />
softwares, services, know-how, etc. in all scientific domains and particularly life sciences.<br />
Missions of Lyon Science Transfert are:<br />
• Raising awareness of technology transfer among researchers<br />
• Detection of inventions in partner laboratories<br />
• Maturation of inventions (proof of concept and prototype)<br />
• Licensing and transfer to players in the socio-economic world<br />
• Industrial property management.<br />
INTELLECTUAL PROPERTY<br />
Lyon Science Transfert looks for industrial partners and offers to grant patents licences.<br />
PRODUCTS<br />
Name Phase Indication<br />
A new predictive and prognostic breast cancer biomarker Diagnostics Oncology, diagnostics<br />
New antiviral treatment against human enterovirus Lead Series Infectious diseases<br />
Electro-therapeutic wound mapping and healing system Other Medical device, wound healing<br />
Stable chitosan based cationic particles for encapsulation Lead Series Drug delivery, encapsulation<br />
A new targeted treatment against cancer: tyrosine kinase inhibitors<br />
of ALK<br />
Lead Series Oncology<br />
Influenza virus production optimisation Research Vaccines, infectious diseases<br />
Hyaluronic acid long fiber production for cosmetics and biomedical<br />
applications<br />
SENIOR MANAGEMENT<br />
Marc Le Gal, Director • Christian Mally, Director • Sandrine Carteau, Other<br />
Research Cosmetics, drug delivery, wound healing<br />
BIO Business Forum 2011 477 Participating Company <strong>Profiles</strong>
Faculty of Medicine & Dentistry<br />
Edmonton, AB T6G 2H5<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Deborah James, Director, Industry Relations<br />
Philip Baker, Dean, Faculty of Medicine & Dentistry<br />
Elizabeth Nanak<br />
David Bressler , PhD<br />
University of Alberta<br />
Clinical Foci: Diagnostics • Metabolic Disease • Drug Development<br />
www.ualberta.ca<br />
Phone: 1-780-492-6988<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The Faculty of Medicine & Dentistry at the University of Alberta is home to the Alberta Centre for Personalized Medicine (ACPM). The ACPM<br />
creates a portal of entry - for industry - into our research programs, technology platforms and integrated academic health sciences<br />
network for industry investment and partnerships as it relates to precision diagnostics (biomarkers) discovery, validation and application.<br />
Technologies available encompass those in metabolomics, transcriptomics, proteomics, advanced pathology, computational biology and<br />
bioinformatics, and in vivo imaging. Therapeutic applications span our programs of research excellence - both basic and clinical. A unique<br />
feature is our pan-Alberta health system that affords studies across the majority of disease states.<br />
BIO Business Forum 2011 478 Participating Company <strong>Profiles</strong>
Science Park 904, B0.160<br />
1098 XH Amsterdam<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Ingrid Y.T. Van Es, Project Manager<br />
CORPORATE MISSION<br />
University of Amsterdam<br />
www.amsterdambiomed.nl/lsca<br />
Phone: 31-20-525 2092<br />
Ownership: Other<br />
Life Sciences Center Amsterdam (LSCA) represents the full range of life sciences research in the Amsterdam region. LSCA includes two<br />
universities (University of Amsterdam and VU University), their academic medical centers (AMC and VUmc), the highly-respected<br />
Netherlands National Cancer Institute (NKI), the Netherlands National Blood Supply Foundation (Sanquin), and finally ACTA, which<br />
recently opened the most advanced dental education and research facility in the world.<br />
Although each member research institution controls the legal and strategic efforts of their individual research and clinical efforts, the<br />
scale and marketing provided by LSCA, improves the likelihood of inventions making economic, social, and medical impact. LSCA provides<br />
access to all academic Amsterdam science in one visit.<br />
BIO Business Forum 2011 479 Participating Company <strong>Profiles</strong>
University of California, Irvine, Office of Corporate Relations<br />
5171 California Avenue, Suite 150<br />
Irvine, CA 92697-7700<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Megha Patel<br />
Holger Roehl<br />
Clinical Foci: Biopharmaceuticals • Pharmacogenetics • Drug Discovery<br />
www.uci.edu<br />
Phone: 1-949-824-2920<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The UCI Office of Technology Alliances provides UC Irvine faculty and researchers with guidance and support in matters of intellectual<br />
property and commercialization of inventions with a focus on university services, resources, and policies that guide industry/university<br />
interactions and an emphasis on establishing industry-funded collaborative research programs to further develop early-stage UC Irvine<br />
inventions. The Office of Technology Alliances operates within delegated authorities to protect, manage, and license the university’s<br />
intellectual property (patents, copyrights, trademarks, and tangible research products) and to enhance access to university research for<br />
commercialization.<br />
BIO Business Forum 2011 480 Participating Company <strong>Profiles</strong>
12635 E. Montview Blvd.<br />
Aurora, CO 80045<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Paul Tabor, Licensing Manager<br />
CORPORATE MISSION<br />
University of Colorado<br />
Clinical Foci: Oncology • Diagnostics • Drug Discovery<br />
www.cu.edu/techtransfer/<br />
Phone: 1-303-724-0221<br />
Ownership: Other<br />
We are an academic technology transfer office interested in advancing the work of our scientists and seeing that their discoveries are<br />
commercialized and publicized in the most efficient way possible.<br />
PROPRIETARY TECHNOLOGY<br />
We have a wide variety of technologies in the life sciences, chemical sciences, engineering, mechanical engineering, software and multidepartmental<br />
fields. Devices, diagnostics, therapeutics, vaccines, materials and research tools are all available.<br />
BIO Business Forum 2011 481 Participating Company <strong>Profiles</strong>
319 Ceramics Building, 105 South Goodwin<br />
Ave<br />
Champaign, IL 61801<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Nancy Sullivan<br />
Shayan Sartipi<br />
David Klick, Technology Manager<br />
University of Illinois at Chicago<br />
www.innovations.uillinois.edu<br />
Phone: 1-217-244-5011<br />
Employees: 23000<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
The University of Illinois spends more than $716 million annually on research. Researchers at the University have produced revolutionary<br />
innovations and advances such as Illini Super Sweet corn, the Mosaic web browser, and robotic transplant surgery.<br />
The research parks associated with the Urbana and Chicago campuses together host more than 100 companies, 1,700 employees and 300<br />
student interns.<br />
Each year, the University of Illinois system produces more than $13 billion in direct and indirect economic impact on the state of Illinois,<br />
including the creation of more than 150,000 jobs.<br />
CORPORATE MISSION<br />
With an annual funded research budget of more than $700 million dollars, the University of Illinois is a leader in generating products and<br />
services that have a profound impact on human lives. The University's accomplishments include one of the largest medical schools in the<br />
country, twenty-two Nobel Laureates among its faculty and alumni, and a history of ground-breaking research.<br />
CORPORATE ALLIANCES<br />
Information regarding alliances may be found at www.corporaterelations.illinois.edu<br />
INTELLECTUAL PROPERTY<br />
The mission of the Offices of Technology Management on the Urbana and Chicago campuses is to encourage innovation, enhance<br />
research, and facilitate economic development through the transfer of intellectual property.<br />
For information on specific technologies, please visit www.innovations.uillinois.edu<br />
BIO Business Forum 2011 482 Participating Company <strong>Profiles</strong>
319 Ceramics Building, 105 South Goodwin<br />
Ave<br />
446 COM West MC682<br />
Champaign, IL 61801<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
University of Illinois at Urbana-Champaign<br />
www.innovations.uillinois.edu<br />
Phone: 1-217-244-5011<br />
Olof Westerstahl, Assistant Director<br />
Lesley Millar, Director, Office of Technology Management Urbana<br />
Lisa Dhar, Senior Technology Manager<br />
Roger VanHoy, Associate DIrector, Corporate Relations<br />
Employees: 23000<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
The University of Illinois spends more than $716 million annually on research. Researchers at the University have produced revolutionary<br />
innovations and advances such as Illini Super Sweet corn, the Mosaic web browser, and robotic transplant surgery.<br />
The research parks associated with the Urbana and Chicago campuses together host more than 100 companies, 1,700 employees and 300<br />
student interns.<br />
Each year, the University of Illinois system produces more than $13 billion in direct and indirect economic impact on the state of Illinois,<br />
including the creation of more than 150,000 jobs.<br />
CORPORATE MISSION<br />
With an annual funded research budget of more than $700 million dollars, the University of Illinois is a leader in generating products and<br />
services that have a profound impact on human lives. The University's accomplishments include one of the largest medical schools in the<br />
country, twenty-two Nobel Laureates among its faculty and alumni, and a history of ground-breaking research.<br />
CORPORATE ALLIANCES<br />
Information regarding alliances may be found at www.corporaterelations.illinois.edu<br />
INTELLECTUAL PROPERTY<br />
The mission of the Offices of Technology Management on the Urbana and Chicago campuses is to encourage innovation, enhance<br />
research, and facilitate economic development through the transfer of intellectual property.<br />
For information on specific technologies, please visit www.innovations.uillinois.edu<br />
BIO Business Forum 2011 483 Participating Company <strong>Profiles</strong>
Garold Breit<br />
Director<br />
631 Drake Centre<br />
Winnipeg, MB R3T 5V4<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Garold Breit, Executive Director<br />
Odd Bres, Technology Manager<br />
Neeraj Visen, Technology Manager<br />
University of Manitoba<br />
www.umanitoba.ca/research/tto<br />
Phone: 1-204-474-6200<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The University of Manitoba’s Technology Transfer Office (TTO) is one of Canada's most productive intellectual asset programs.<br />
The TTO oversees a Intellectual Property estate of over 400 patents covering 300 university developed technologies. We manage over onehundred<br />
technology-based alliances with local and global partners. Over the past two decades, the TTO has launched forty new start-up<br />
ventures, creating over 1200 jobs in the local economy.<br />
PROPRIETARY TECHNOLOGY<br />
Please refer to individual licensing projects<br />
CORPORATE ALLIANCES<br />
The TTO oversees an Intellectual Property estate of over 400 patents covering 300 university developed technologies. These technologies<br />
comprise physical and life science, and information and communications technology discoveries including; human and animal health<br />
technologies, medical devices, diagnostics and software.<br />
We manage over one-hundred technology-based alliances with our local and global partners. The TTO seeks to partner in technology<br />
development, technology licensing and research-focused partnerships.<br />
In fact, the TTO co-invests with our industry partners to accelerate the movement of these important platform Technologies to the market.<br />
PRODUCTS<br />
Name Phase Indication<br />
Enhancing medication with directed drug convection using magnetic<br />
nano-particles<br />
Research Drug Delivery to CNS<br />
Improved diagnostic test for estrogen receptor status in breast cancer Diagnostics Breast Cancer Diagnostic<br />
Novel antibiotic chemistries: Aminoglycoside-based cationic amphiphiles Optimized<br />
Lead<br />
Prevention and treatment of microvascular disease in diabetes Research Diabetes<br />
PTX3: BioMarker for allergic asthma Research Asthma<br />
Antibiotics, Anti infectives<br />
Scleraxis: a transcription factor involved in congestive heart failure Research Congestive Heart Failure, Fibrosis<br />
Topical method for treating skin irritation, inflammation and scarring Preclinical Dermatology<br />
SENIOR MANAGEMENT<br />
Garold Breit, Director • Dr. Odd Bres, Manager • Dr. Neeraj Visen, Manager<br />
BIO Business Forum 2011 484 Participating Company <strong>Profiles</strong>
Mary Sue Coleman<br />
President<br />
2800 Plymouth Road<br />
Ann Arbor, MI 48109<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
University of Michigan<br />
Clinical Foci: Drug Discovery • Oncology • Medical Device<br />
www.umich.edu<br />
Phone: 1-734-936-1531<br />
Connie Chang, Director Business Development, Univ. of Michigan Medical School<br />
HIGHLIGHTS<br />
Recent<br />
Over $1.1Bn in research for FY2010, with over 40% in biomedical sciences<br />
Strong Tech Transfer productivity (FY10):<br />
10 start-ups launched.<br />
$39.8M in royalties, equity sales.<br />
290 new invention disclosures.<br />
97 new license agreements<br />
Master Agreements in place with key industry and other external partners.<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The University of Michigan, located in Ann Arbor, MI, is one of the world's leading research institutions. Its diverse schools and colleges are<br />
consistently ranked among the best, including its schools of Business, Education, Engineering, Information, Law, Medicine, Music, Nursing,<br />
Public Health, and Social Work. The University is known for its ability to foster collaboration among schools, and drive innovation across<br />
disciplines.<br />
The University of Michigan focuses on the translation of discoveries into impactful innovations. The University has a robust $1 billion<br />
research program, with world-class researchers and programs. Since 2001, over 700 innovations have been licensed to industry and over<br />
80 new start-up companies have been launched, creating opportunity, jobs and economic benefits. The University pro-actively seeks<br />
productive engagements with industry, connecting its research, talent and knowledge resources to our business and venture partners.<br />
PROPRIETARY TECHNOLOGY<br />
Please see websites for:<br />
University of Michigan Office of Technology Transfer<br />
http://www.techtransfer.umich.edu/index.php,<br />
and Business Development at the University of Michigan Medical School<br />
http://www.med.umich.edu/bd/index.htm<br />
SENIOR MANAGEMENT<br />
Mary Sue Coleman, President • Steve Forrest, PhD, Vice President • Ora Hirsch Pescovitz, MD, Executive Vice President<br />
BIO Business Forum 2011 485 Participating Company <strong>Profiles</strong>
501 North Columbia Road Stop 9037, Rm<br />
1701B<br />
Grand Forks, ND 58202-9037<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Kumi Nagamoto-Combs, Licensing Assistant<br />
University of North Dakota<br />
Clinical Foci: CNS • Immunology • Oncology<br />
www.und.edu/<br />
Phone: 1-701-777-2559<br />
Ownership: Other<br />
CORPORATE MISSION<br />
As a state academic research institution with the only medical school in the area, the University of North Dakota takes pride in its group of<br />
innovative researchers, especially in the areas of neuroscience, cancer research and immunology. The University holds a number of<br />
patents available for licensing, including research tools, diagnositcs, therapeutics and medical devices. Our researchers are also seeking<br />
industry partners for development and discovery of potential therapeutic drugs and diagnostic and research tools in various areas.<br />
BIO Business Forum 2011 486 Participating Company <strong>Profiles</strong>
David Grimmett<br />
Business Development<br />
Enterprise Office. P O Box 56<br />
Dunedin North 9054<br />
New Zealand<br />
CONFERENCE PARTICIPANTS<br />
David Grimmett, Business Manager<br />
Bret Morris, Director<br />
University of Otago<br />
Clinical Foci: Diagnostics • Drug Discovery • Drug Development<br />
www.otago.ac.nz<br />
Phone: 64-3-4798471<br />
Employees: 1500<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
CORPORATE MISSION<br />
New Zealand’s top-ranked research university, established in 1869 1,600 academic & research staff, 18,000 undergraduate / 4,000<br />
postgraduate students, including 1100 PhDs, 700 Research only staff. Medicine, Sciences, Business and Humanities. The University of<br />
Otago - Enterprise Office facilitates research collaborations, manages intellectual property and assists in the process of commercialising<br />
ideas and technologies<br />
PROPRIETARY TECHNOLOGY<br />
We are Seeking Partnerships and Collaborations.<br />
Research Areas include:<br />
We can offer:<br />
Cancer,<br />
Preclinical and Clinical R&D and Consulting.including:<br />
Neuroscience,<br />
Pharmaceutical Preformulation R&D Expertise and Consulting, Cardiovascular,<br />
Drug and Vaccine Delivery,<br />
Renal,<br />
Rational Drug Design and Synthesis,<br />
Inflammatory disease,<br />
Drug and Diagnostic Discovery,<br />
Infectious disease,<br />
Clinical Trial Design,.<br />
Vaccines,<br />
Participation in Clinical Trials (Cardio, Renal, Neuroscience),<br />
Dental<br />
INTELLECTUAL PROPERTY<br />
NITRIC OXIDE CARRIERS - Targeted delivery of Nitric oxide (NO)<br />
(Rob Smith, UoO, Mike Murphy, MRC Cambridge)<br />
Clinical Applications:<br />
• Treatment for cardiac damage in ischaemic reperfusion<br />
• Vasorelaxant increasing blood flow in angina.<br />
Technology:<br />
• Molecules accumulate within isolated mitochondria where it reversibly slows respiration and S-nitrosates mitochondrial proteins.<br />
• Related MitoQ® shown to load up the heart, liver and kidney 5min post IV injection and exhibit drugability and safety and<br />
pharmacokinetics in Phase II trial.<br />
Publication: Smith et al. PNAS 100: 5407 (2003). Prime et al. PNAS 106: 10764–10769 (2009).<br />
International PatentFilings 2009<br />
SENIOR MANAGEMENT<br />
David Grimmett, Business Development • Dr Bret Morris, Director<br />
BIO Business Forum 2011 487 Participating Company <strong>Profiles</strong>
200 Gardner Steel Conference Center<br />
Pittsburgh, PA 15260<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
University of Pittsburgh<br />
Clinical Foci: Drug Discovery • Biomaterials • Regenerative Medicine<br />
www.otm.pitt.edu/<br />
Phone: 1-412-624-3160<br />
Andrew Remes, Associate Director, Office of Enterprise Development<br />
Marc S. Malandro, PhD, CLP<br />
Alexander Ducruet<br />
Michelle P. Booden<br />
Amy Brunetto-Phillips, MBA<br />
Incorporated: 1787<br />
Ownership: Other<br />
CORPORATE MISSION<br />
The University of Pittsburgh has a history of 220 years of groundbreaking research and innovation development and is ranked fifth in the<br />
country in research funding from the NIH. The University is supported by $737M in sponsored research funding and is affiliated with<br />
UPMC, one of the largest medical centers in the world. Pitt is placed in the top cluster of 7 leading U.S. public research universities.<br />
BIO Business Forum 2011 488 Participating Company <strong>Profiles</strong>
University of Pittsburgh, Center for Biotechnology & Bioengineering<br />
300 Technology Drive<br />
Pittsburgh, PA 15219<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Sam N. Rotshtein, Chief Scientific Officer<br />
HIGHLIGHTS<br />
Recent<br />
Clinical Foci: Drug Delivery • Biomaterials • Regenerative Medicine<br />
www.littlelab.pitt.edu<br />
Phone: 1-412-383-9700<br />
Ownership: Other<br />
Review article by Rothstein and Little, “A 'tool box' for rational design of degradable controlled release formulations” featured on the cover<br />
of the Journal of Materials Chemistry. (http://pubs.rsc.org/en/content/articlelanding/2011/jm/c0jm01668c)<br />
Little Lab selected as one of 6 finalists in the 2011 Charite International Biomedical Entrepreneurial competition for their new start-up<br />
ChroKnow, Inc.<br />
CORPORATE MISSION<br />
The Little Lab is the University of Pittsburgh's go-to group for custom controlled release formulations. Its success comes from a team that<br />
integrates expertise in medicine, material science and chemical engineering with a forward thinking approach to formulation design.<br />
This team has developed patent-pending algorithms that transform the design of controlled release formulations from a lengthy<br />
experimental process into a rapid, robust mathematical one. Since these algorithms were developed just 3 years ago, the Little Lab has<br />
used them to design and produce over 15 controlled release formulations to precise specifications. Of these, novel treatments for<br />
periodontisis, transplant rejection, and neonatal immunization have already tested successfully in animal models.<br />
The Little Lab is presently spinning out its predictive algorithms into a new start-up company, ChroKnow Inc, and is eager to engage<br />
potential strategic partners that can help it address the following questions:<br />
- Can formulations be precisely designed to improve pharmacological properties of fledgling drug candidates?<br />
- How much can the Little Lab's algorithms speed up the reformulation of off patent and orphaned drugs?<br />
- Can the Little Lab's algorithms make controlled release a cost-effective research tool for basic scientific studies and the development of<br />
novel treatments?<br />
PROPRIETARY TECHNOLOGY<br />
The patent-pending algorithms developed in Pitt's Little Lab are unique among models of controlled release because they allow a wide<br />
range of drug or biomolecule delivery schedules to be “preprogrammed” into hydrolyzable polymer microparticles or implants by simple<br />
adjustment of the matrix composition and geometry. Initial validation of the mathematics behind these algorithms predicted in vitro<br />
release behavior for 22 different drug delivery formulations whereas the best alternative models can only predict performance for two or<br />
three such systems. The platform provided by Pitt's algorithms enables the rapid and cost effective design of custom controlled release<br />
formulations practically any drug candidate or novel treatment.<br />
CORPORATE ALLIANCES<br />
McGowan Institute for Regenerative Medicine,<br />
ChroKnow Inc.,<br />
Idea Foundry<br />
INTELLECTUAL PROPERTY<br />
International Patent Application WO/2011/031996<br />
BIO Business Forum 2011 489 Participating Company <strong>Profiles</strong>
Joel Seligman<br />
President & CEO<br />
601 Elmwood Avenue<br />
Rochester, NY 14642-0001<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
University of Rochester<br />
www.urmc.rochester.edu/techtransfer/<br />
Phone: 1-585-784-8850<br />
Michael Rusnak, Deputy Director, New Ventures and Technology Development<br />
Harl Tolbert<br />
Ownership: Other<br />
HIGHLIGHTS<br />
Recent<br />
University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer,<br />
providing data to support a new investigational treatment that targets those same genes.<br />
Two proteins that are abnormally modified in the brains of patients with Alzheimer disease collude, resulting in ill effects on the crucial<br />
energy centers of brain cells, according to new findings published online in Neurobiology of Aging.<br />
A molecule that lies dormant until it encounters a cancer cell, then suddenly activates and rouses the body’s immune system to fight<br />
cancer cells directly, marks the latest step in scientists’ efforts to tap the body’s own resources to fight the dise<br />
CORPORATE MISSION<br />
The University of Rochester is one of the country's top-tier research universities. Our 158 buildings house more than 200 academic majors,<br />
more than 2,000 faculty and instructional staff, and some 9,300 students. One of the nation's top academic medical centers, the University<br />
of Rochester Medical Center forms the centerpiece of the University's health research, teaching, patient care, and community outreach<br />
missions. With more than $300 million in federal research funding, UR School of Medicine research funding ranks in the top one-quarter<br />
of U.S. medical centers, while the School of Nursing ranks 12th highest in funding. The University's health care delivery network is<br />
anchored by Strong Memorial Hospital—a 739-bed, University-owned teaching hospital—which boasts programs that consistently rank<br />
among "America's Best Hospitals," according to U.S. News & World Report. Our patients benefit from the Medical Center's robust teaching<br />
and biomedical research programs.<br />
PROPRIETARY TECHNOLOGY<br />
First in the country in Orthropedics funding with a stong focus in vaccines, neurology, infectious discase, and genetics.<br />
INTELLECTUAL PROPERTY<br />
Managing over 300 active technologies and associated patents<br />
SENIOR MANAGEMENT<br />
Joel Seligman, President & CEO • Bradford C. Berk, MD, PhD, Chief Executive Officer • Ralph W. Kuncl, PhD, MD, Other<br />
BOARD OF DIRECTORS<br />
Ron Zarrella, Chairman of the Board of Trustees<br />
BIO Business Forum 2011 490 Participating Company <strong>Profiles</strong>
IFSC-USP, CP 369, São Carlos/SP, Brazil<br />
São Carlos 13560-970<br />
Brazil<br />
CONFERENCE PARTICIPANTS<br />
Osvaldo N. Oliveira, Professor<br />
CORPORATE MISSION<br />
University of São Paulo<br />
Clinical Foci: Biopharmaceuticals • Biomaterials • Gene/Cell Therapy<br />
www.usp.br<br />
Phone: 55-16-339 825<br />
Incorporated: 1934<br />
Employees: 21073<br />
Ownership: Other<br />
Market Cap: $1000.00 million<br />
The University of Sao Paulo - USP is the largest higher education and research institution in Brazil. It has outstanding projection around<br />
the world, especially in Latin America, and develops a large number of Brazilian masters and doctors who work in higher education and<br />
research institutes. It is a public and free university, with open access for students selected by the 'vestibular' (Brazilian entrance exam for<br />
universities). Many of these students, after graduation, hold strategic and leading functions in different segments of public and private<br />
industries.<br />
USP is composed of seven campi, 40 learning and research units, five hospitals, five museums, five specialized institutes, besides multiple<br />
experimental laboratories and centers of scientific and cultural diffusion. It comprises all areas of the human activity and offers<br />
approximately 700 regular courses. There are 230 undergraduate courses (including different habilitations), with more than 3,400<br />
disciplines, and an average of 5,500 students graduate annually. Graduate studies at USP, with more than 500 fields of concentration<br />
areas (MAs and PhDs), are an international point of reference in Science and Technology.<br />
2010 Ranking of 500:<br />
74th Scientific Works of World Universities, the Higher Education Evaluation and Accreditation Council of Taiwan<br />
143th position of the Institute of Higher Education Shanghai JiaoTong University, established in 2003,<br />
232th position of "The Time"<br />
PROPRIETARY TECHNOLOGY<br />
The University deposits 100 patents per year in Brazil, nowadays we have a portfolio of 664, with more than 50% in health and personal<br />
care.<br />
CORPORATE ALLIANCES<br />
The university R & D Maintains alliances with leading companies in Brazil and the World.<br />
Examples:<br />
Petrobras (http://www.petrobras.com.br/en/), Vale (http://www.vale.com/enus<br />
/ pages / default.aspx), Embraer, Braskem, BRF - Brazil Foods, Hewlett-Packard, IBM, Microsoft, BASF, Natura Cosmetics, Bunge,<br />
Monsanto, Biolab, Cristalia, Ache, Medley, Roche.<br />
The university also maintains partnerships with major research centers in the world.<br />
Examples:<br />
CNRS, Institut Pasteur, MIT, Harvard, Oxford, Cambridge, University of Tokyo, University of California, Yale University, Stanford, Columbia,<br />
University of Paris, Cornell.<br />
PRODUCTS<br />
Name Phase Indication<br />
Gomesin can be obtained by extraction of<br />
Acanthoscurria Gomesiana Spider<br />
Preclinical ANTIMICROBIAL PEPTIDE, COMPOSITIONS, AND USES THEREFOR<br />
Brazilian plant extract with anti-aging<br />
property<br />
Pharmaceutical composition comprising<br />
lectin KM+ to prevent and heal epithelial<br />
Expression of the amyloid polypeptide from<br />
human pancreatic islets.<br />
PHARMACEUTICAL COMPOSITION AND<br />
METHOD FOR TREATING MALARIA<br />
Preclinical Composições dermocosmética para o tratamento e / ou prevenção de<br />
fotoenvelhecimento da pele, envelhecimento cutâneo.<br />
Preclinical Lectins are proteins, or glycoproteins of distribution located in the<br />
nature, that if the sugars bind selectively and reversibly. Two lectins<br />
had been isolated of seeds of Artocarpus integrifolia (jaca): jacaline<br />
and KM+, also called artocarpine.<br />
Other Method for cloning, expression and purification of the amyloid<br />
polypeptide from human pancreatic islets (IAPP). Potentia treatment<br />
for a large number of important human diseases particularly type II<br />
diabetes.<br />
Research Phamarceutical composition comprising one or more compounds that<br />
bind to serpentine receptors existent in parasites of genus<br />
Plasmodium besides pharmaceutically acceptable excipients.<br />
GENES ASSOCIATED TO SUCROSE CONTENT Research Sucrose content is a highly desirable trait in sugarcane as the<br />
worldwide demand for cost-effective biofuels surges.<br />
BIO Business Forum 2011 491 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication<br />
GENERATION/REPRODUCTION OF DNA<br />
SEQUENCES AND ANALYSIS OF<br />
POLYMORPHISMS/MUTATIONS<br />
Research Method that uses error-coding codes for validating polymorphisms<br />
and mutations/alterations in a DNA sequence which encodes a<br />
polypeptide sequence. Method that can be useful for the predictive<br />
analysis of diseases originated by mutations or polymorphisms.<br />
Treatment of severe sepsis. Research Development of pharmacologic inhibitors against the acute phase<br />
proteins hemopexin and alpha-1-acid glycoprotein for the treatment<br />
of severe sepsis<br />
Drug Development for the Treatment of<br />
Chagas´Disease.<br />
Preclinical Novel Therapeutic Application: Compound, used in clinical treatment<br />
of humans, is effective against Trypanosoma brucei and Trypanosoma<br />
cruzi cells in culture.<br />
BIO Business Forum 2011 492 Participating Company <strong>Profiles</strong>
3802 Spectrum Blvd., Suite 100<br />
Tampa, FL 33612<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
University of South Florida Research Foundation<br />
Clinical Foci: CNS • Medical Device • Oncology<br />
www.research.usf.edu/pl<br />
Phone: 1-813-974-0994<br />
Valerie McDevitt, Asst. Vice President, Division of Patents & Licensing<br />
CORPORATE MISSION<br />
Ownership: Private<br />
Established in 1956, University of South Florida is the second largest university in the state of Florida and a Research I institution. USF<br />
researchers received $360 million in research contracts and grants in fiscal year 2008.<br />
The Divison of Patents and Licensing at USF directs the movement of ideas, tools, new discoveries and innovations resulting from research<br />
and scholarly activities at USF into the commerical and the public sectors.<br />
BIO Business Forum 2011 493 Participating Company <strong>Profiles</strong>
Dr. Norbert Buzas<br />
Director<br />
13. Dugonics Sq.<br />
Szeged 6720<br />
Hungary<br />
CONFERENCE PARTICIPANTS<br />
Norbert Buzas, PhD<br />
CORPORATE MISSION<br />
University of Szeged<br />
Clinical Foci: Drug Development • Neurology • Diagnostics<br />
www.u-szeged.hu<br />
Phone: 36-62-546 702<br />
Ownership: Other<br />
Market Cap: $500.00 million<br />
The University of Szeged has 12 faculties; 88 BSc majors; 117 MSc majors; 19 PhD schools; almost 30,000 students and 2,149 tutors. The<br />
University of Szeged is the 124th best university in the Central European region according to the Academic Ranking of World Universities,<br />
and has turned in 21 successful grant applications within the Seventh Framework Programme of the European Community for Research<br />
and Technological Development. In 2010 the Hungarian Ministry of Education and Culture conferred the honorable Research University<br />
title on our institution.<br />
PROPRIETARY TECHNOLOGY<br />
Apart from educating the scientists of the future the University’s major objective is to be a strong link between science and society. In<br />
order to fulfill this role in the past 5 years our research groups accomplished 422 industrial R&D projects in the fields of neurobiology, preclinical<br />
pharmacology, clinical pharmacology, genetics, nanotechnology and materials science, laser physics, bio- and environmental<br />
technology and software engineering.<br />
INTELLECTUAL PROPERTY<br />
The University of Szeged lays great emphasis on IP commercialisation.The IP portfolio of the University comprises 23 patents, including<br />
those in PCT phase, and for 7 of them a licence has been issued.<br />
One of the University's main goals is to actively enhance the regional, national and international economy.<br />
This approach is supported by a dedicated technology transfer office and a revenue-sharing policy that brings significant benefits to<br />
inventors.<br />
The main areas of research include silicate nanocomposites of polymer hydrogels, diagnosing of susceptibility of post-traumatic scar<br />
tissue formation, stimulating muscle regeneration, methods for increased production of biogas and sustained release bionanocomposites.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
sustained release<br />
bionanocomposites<br />
New type of layer silicate<br />
nanocomposites of polymer<br />
hydrogels and their use of<br />
Method and diagnostic kit for<br />
diagnosing of susceptibility of<br />
post-traumatic sca<br />
Methods for stimulating muscle<br />
regeneration<br />
Method for increased<br />
production of biogas<br />
SENIOR MANAGEMENT<br />
Dr. Norbert BUZAS, Director<br />
Other the formulation of biologically active proteins scale-extendation of the process<br />
for preparation<br />
Phase I Osmotic skin expander producing, skin selftransplantation,<br />
skin yield, cosmetic implants,<br />
dermatology<br />
Diagnostics PCR based diagnosing of susceptibility of posttraumatic<br />
scar tissue formation, diagnostic kit,<br />
diagnostics<br />
Research New biochemical pathway for stimulating muscle<br />
regeneration, genetic muscle diseases, sport<br />
muscle damages<br />
On Market A new method for increasing biogas production of<br />
thermophillic anaerobe systems, biogas<br />
production.<br />
prepare of manufacturing,<br />
optimization of manufacturing<br />
prepare of manufacturing,<br />
optimization of manufacturing<br />
Prepare of preclinical/clinical<br />
trials<br />
Using of method in fermentors<br />
BIO Business Forum 2011 494 Participating Company <strong>Profiles</strong>
Brent Sternig<br />
President & CEO<br />
UVic Industry Partnerships<br />
Victoria, BC V8W 3W2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Jocelyn P Milburn, Industry Liaison Officer<br />
CORPORATE MISSION<br />
University of Victoria<br />
Clinical Foci: Biopharmaceuticals • Vaccines • Drug Discovery<br />
http://web.uvic.ca/industry/<br />
Phone: 1-250-721-8868<br />
Ownership: Other<br />
The University of Victoria (UVic), located in Victoria, British Columbia, Canada, is consistently ranked in the top tier of Canada’s researchintensive<br />
universities. UVic Industry Partnerships is the industry liaison office for the University of Victoria. Our primary focus is to<br />
promote University / Industry research collaborations at the University.<br />
Our work includes evaluating and protecting intellectual property for the benefit of both researchers and industrial partners, developing<br />
University/Industry contracts, identifying opportunities for leveraging industry funding, licensing/optioning University IP, and assisting<br />
UVic entrepreneurs with the development of spin-off companies through our Greater Victoria Accelerator Centre.<br />
To date, over 680 inventions have been disclosed to UVic Industry Partnerships, leading to 350 filed patents, 55 patents issued, and 50 new<br />
spin-off companies. Currently, UVic Industry Partnerships is interested in developing collaborative research and/or licensing relationships<br />
with industrial partners.<br />
PROPRIETARY TECHNOLOGY<br />
• Nanoparticles for imaging and diagnostics<br />
• Antigens for syphilis diagnosis<br />
• Neuraminidase inhibitor chemical scaffold<br />
• Vaccine comprising heat sensitive transgene<br />
• Transcription factors and antimicrobial peptides for transgenic plants<br />
• Thyroid hormone depleted serum for cell culture<br />
• Small-molecule chemists<br />
• Medical device engineers<br />
INTELLECTUAL PROPERTY<br />
The University of Victoria’s intellectual property policy is a “creator-owned’ policy designed to promote a supportive climate for the<br />
development of IP and the provision of services based upon mutually beneficial partnerships that respect the interests of researchers and<br />
the creators, the University, and the wider community.<br />
PRODUCTS<br />
Name Phase Indication<br />
Lanthanide-doped nanoparticles Research Lanthanide-doped nanoparticles with potential applications in<br />
biolabeling, imaging, and diagnostics<br />
Novel syphilis diagnostic Research Novel antigen to improve the sensitivity and specificity of current<br />
syphilis diagnostic tests<br />
Chemical scaffold for neuraminidase<br />
inhibitor<br />
Research Improved neuraminidase inhibitor with potential therapeutic<br />
applications<br />
Apicomplexan crystal structure Research Crystal structures from Apicomplexan parasites for the strategic design<br />
of vaccines and therapeutics<br />
Low thyroid hormone serum Research A patented serum naturally low in thyroid hormone that still contains all<br />
cofators for normal cell growth.<br />
Proteomics Centre Research Offering a wide variety of services, including bioinformatics,<br />
metabolomics, structural proteomics, MALDI imaging and protein<br />
characterization and identification.<br />
Temperature-sensitive vaccine platform Research A technique for creating temperature-sensitive bacterial vaccines.<br />
SENIOR MANAGEMENT<br />
Brent Sternig, President & CEO • Kathy Veldhoen, Vice President<br />
BIO Business Forum 2011 495 Participating Company <strong>Profiles</strong>
620 W. Lexington St., 4th floor<br />
Baltimore, MD 21201-1508<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Brian Darmody<br />
Stephen Kinsey<br />
Jane Shaab<br />
Nancy Cowger<br />
University System of Maryland<br />
Clinical Foci: Drug Development • Infectious Disease • Medical Device<br />
www.research.umaryland.edu<br />
Phone: 1-410-706-6723<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
UM licensee, Bali BioSciences, will develop an antibody-enriched colostrum product to aid<br />
patients with burns, trauma, and HIV. UM’s anti-sepsis vaccine, which has already proven safe<br />
in human trials, was developed by Dr. Alan Cross and colleagues.<br />
Institute of Human Virology (IHV) at the University of Maryland School of Medicine will receive<br />
$23.4 million from a consortium of funding sources to support the next phase of research into<br />
a promising HIV/AIDS preventive vaccine candidate.<br />
A new public-private partnership for developing and manufacturing stem cell therapies for<br />
regenerative medicine funded in part by Maryland Biotechnology Center has been formed<br />
between the University of Maryland and Paragon Bioservices, Inc.<br />
Employees: 7500<br />
Ownership: Other<br />
UM licensee, Blnk Medical<br />
Technologies, is rolling out its new<br />
product. The Blnk server communicates<br />
vital lab data to the critical point-ofcare.<br />
Technology co-inventors from UM<br />
are Dr. Marcelo Cardarelli, Dr. Yan Xiao<br />
and Dr. Vinay Vaidya.<br />
CORPORATE MISSION<br />
The University of Maryland (UM) is a thriving academic medical center with over 2,500 faculty conducting $570 million in funded research<br />
last year in its schools of Medicine, Dentistry, Nursing, and Pharmacy. Cores of UMB’s cutting edge research are exemplified by its NCIdesignated<br />
Greenebaum Cancer Center and the Institute for Genome Sciences, as well as the work of UMB’s Center for Vaccine<br />
Development and Institute for Human Virology to prevent deadly infectious diseases including cholera, typhoid fever, and HIV/AIDS.<br />
PROPRIETARY TECHNOLOGY<br />
UM has a portfolio of hundreds of technologies available for licensing that are a mix of vaccines, drug targets, therapeutics, devices, and<br />
cutting-edge techniques that promise to make a quantifiable impact on human health and the environment. The internationally<br />
recognized medical, dental, and pharmaceutical research underway at UM provides a robust pipeline of more than 100 new innovations<br />
each year.<br />
CORPORATE ALLIANCES<br />
UM is engaged in a broad range of research and development programs with collaborators all over the world, including other academic,<br />
government, and non-profit institutions and with industry, for example, via licensing, sponsored research, and clinical trials.<br />
INTELLECTUAL PROPERTY<br />
UM has an active patent portfolio related to the technologies available for licensing and partnering. Forming UM's tech transfer team are<br />
in-house patent attorneys and licensing officers well versed in the portfolio.<br />
PRODUCTS<br />
Name Phase Indication<br />
Salmonella Typhi Vaccines (UMB ref. FN-98-001) Phase II, IIa, IIb Vaccine, infectious disease<br />
Load-Bearing Bone Repair with Injectable Matrix (UMB ref. HX-<br />
2010-041)<br />
Preclinical Orthopedics, dentistry<br />
SILCS: Method for binding site identification Research Drug design<br />
Novel Fluorinated Dendrimers for Quantitative Imaging (UMB ref.<br />
BY-2008-043; BY-<br />
Research Imaging, oncology<br />
Vaccine against Clostridium difficile Preclinical Vaccine, infectious disease<br />
Vaccine, diagnostic and detection of MRSA Biofilms Preclinical MRSA Biofilm Infection<br />
DMXAA for the treatment of infection Optimized Lead Anti-infectives<br />
Modulation of bitter taste receptors for pulmonary and metabolic<br />
disease<br />
Research Pulmonary and Metabolic Disease<br />
Inhibition of S100 Proteins Target Validated Cancer<br />
EPR Imaging Probes Diagnostics Imaging, Clinical tools<br />
BIO Business Forum 2011 496 Participating Company <strong>Profiles</strong>
3551 31 St. NW<br />
Calgary, AB T2L 2K7<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Jaswinder Kaur<br />
Chris Nicholls<br />
University Technologies International Inc.<br />
www.uti.ca<br />
Phone: 1-403-270-7027<br />
Incorporated: 1989<br />
Employees: 45<br />
Ownership: Other<br />
CORPORATE MISSION<br />
University Technologies International (UTI) is the University of Calgary’s technology transfer, commercialization and incubation center<br />
servicing the Calgary region. UTI was founded in 1989 and consistently ranks in the top 4 centers of its kind in Canada and is recognized as<br />
an innovation leader in commercializing technology. UTI works with inventors to evaluate, protect, market, and commercialize<br />
technology.<br />
BIO Business Forum 2011 497 Participating Company <strong>Profiles</strong>
Mariann Fee<br />
Chief Executive Officer<br />
University of Melbourne, 205-211 Grattan<br />
Street<br />
Carlton, VIC 3053<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Ruth Park-Jones, Business Development<br />
Christophe Demaison, Snr Business Development Manager<br />
UoM Commercial Ltd.<br />
Clinical Foci: Infectious Disease • CNS • Vaccines<br />
Phone: 61-383-443198 Ownership: Private<br />
CORPORATE MISSION<br />
UoM Commercial Ltd is a wholly-owned subsidary company of the University of Melbourne (Australia) and provides commercial<br />
engagement services to the University relating to intellectual property management and licencing, start-up creation, academic consulting<br />
and customised education programs.<br />
The University of Melbourne is one of the top 40 universities in the world (Times Higher Education 2010) and is Australia's leading<br />
comprehensive research university (Excellence in Research for Australia 2010). The University has more than 47,000 students and over<br />
7,000 academic and professional staff with a strong focus in human health.<br />
FINANCING HISTORY<br />
Investors: University of Melbourne (100 %)<br />
SENIOR MANAGEMENT<br />
Mariann Fee, Chief Executive Officer • Jason Coonan, Managing Director • Christophe Demaison, Business Development<br />
BIO Business Forum 2011 498 Participating Company <strong>Profiles</strong>
6701 Evenstad Drive<br />
Maple Grove, MN 55369<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Mike McBride, Sr. Director, Industry Relations<br />
Rich Fisher, Sr. Director, Strategy and Business Development<br />
Lori Freese, Director, Strategic Portfolio Management<br />
Upsher-Smith Laboratories, Inc.<br />
Sponsor, Presenting Company<br />
Clinical Foci: CNS • Neurology • Biopharmaceuticals<br />
www.upsher-smith.com<br />
Phone: 1-763-315-2173<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Novo Nordisk Inc. announces exclusive agreement with Upsher-Smith to market Vagifem® 10 mcg (August 23, 2010)<br />
Upsher-Smith adds ITI-111 (nasal midazolam) to CNS development pipeline (June 28, 2010)<br />
Upsher-Smith signs agreement to sublicense tonabersat (April 12, 2010)<br />
CORPORATE MISSION<br />
Upsher-Smith is looking for strong and trusted partnerships through licensing, profit sharing, co-development and co-marketing<br />
arrangements. Upsher-Smith has a wide US distribution network and an experienced sales force with established customer relationships.<br />
Looking to the future, Upsher-Smith is focused on: building our current product pipeline; co-promoting and acquiring women’s health<br />
products ready for commercialization; and developing, in-licensing and acquiring CNS products focused primarily on treatments for<br />
epilepsy, Parkinson’s disease and Alzheimer's disease. Our vision is to become a leader in providing therapies that empower people<br />
suffering from central nervous system diseases to lead healthy, productive lives. Our focus is simple: Advancing pharmacotherapy.<br />
Improving life.<br />
PRODUCTS<br />
Name Phase Indication<br />
USL255 Phase III Adjunctive therapy in the treatment of partial-onset seizures in adults with<br />
epilepsy<br />
USL261 Phase III Rescue treatment of seizures in patients who require control of<br />
intermittent bouts of increased seizure activity (ARS/cluster seizures)<br />
USL260 Phase I Epilepsy<br />
BIO Business Forum 2011 499 Participating Company <strong>Profiles</strong>
750 E Adams St<br />
Syracuse, NY 13210<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Upstate Medical University<br />
Clinical Foci: Infectious Disease • Oncology • Metabolic Disease<br />
www.upstate.edu<br />
Phone: 1-315-464-4398<br />
Cynthia Dowd Greene, Associate Vice President for Industry Relations<br />
CORPORATE MISSION<br />
Incorporated: 1834<br />
Employees: 7000<br />
Ownership: Other<br />
Upstate Medical University, one of only 127 academic medical centers in the nation, is located in Syracuse, New York. It is built around a<br />
rapidly expanding biomedical research enterprise, four colleges and its own teaching hospital. As a research enterprise, Upstate’s<br />
investigations are aimed specifically at improving human health. Its research growth is currently the second-fastest among the 64<br />
campuses of the State University of New York (SUNY).<br />
Upstate is one of the co-founders of SUNY REACH, a network of research scientists and clinicians. 75% of Upstate’s own research is aligned<br />
around four disease centric research pillars: Disorders of the Nervous System; Diabetes, Metabolic Disorders, and Cardiovascular Disease;<br />
Cancer and Infectious Diseases.<br />
As a clinical enterprise, Upstate’s service area covers one-third of New York state and has a diverse patient population of 1.8 million<br />
people. Upstate has the region’s only Level-1 trauma center and dedicated children’s hospital, Golisano Chilrdren's Hospital. Upstate is a<br />
New York State Designated Center for Trauma, Burn, SAFE services, Poison Control, AIDS and Stroke. Its 80 specialty clinics include Joslin<br />
Diabetes Center -a New York State Center of Excellence- and a level 4 Epilepsy Center.<br />
Upstate continues to grow with three major capital projects under construction: a cancer center; a 100,000 square foot expansion that will<br />
provide cross departmental research space for Disorders of the Nervous System and a new bio-incubator, CNY BRC.<br />
CORPORATE ALLIANCES<br />
CNY BRC's, a new bio-incubator,mission is to support university-industry partnerships that discover, develop and deploy innovative<br />
products for the biological and medical marketplaces. The CNY BRC will provide growth-oriented companies essential business<br />
acceleration services and access to industry-specific development resources. Located in Syracuse, CNY BRC is a joint collaboration between<br />
Upstate and SUNY College of Environmental Science and Forestry (ESF). Clients will be part of a professional, research rich environment<br />
that will help them benefit fully from this highly-specialized setting. The CNY BRC goal is clear: to help biotech entrepreneurs and new<br />
companies succeed by providing focused, affordable and collaborative environment with company office and wet laboratory space.<br />
BIO Business Forum 2011 500 Participating Company <strong>Profiles</strong>
Gregory Hayer<br />
Senior Vice President<br />
1100 Orthodox Street<br />
Philadelphia, PA 19124<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gregory Hayer<br />
Jason Laufer, Global Business Development<br />
URL Pharma<br />
Clinical Foci: Specialty Pharmaceutical • AutoImmune • Drug Development<br />
www.urlpharma.com<br />
Phone: www.sickkids.ca 973-723-9000<br />
Incorporated: 1946<br />
Employees: 550<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Colcrys® (colchicine, USP) - Prophylaxis and treatment of acute gout flares. Familial Mediterranean<br />
fever (FMF)<br />
Launch: Q4 ’09<br />
$100M allocated for Business Development<br />
Fibricor (fenofibric acid tabs)- reduces triglyceride (TG) levels in patients with severe<br />
hypertriglyceridemia (= 500 mg/dl).<br />
Reduces elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and<br />
apolipoprotein.<br />
Launch: Q4 09<br />
Deploy US sales force: 300+ representatives.<br />
Seeking to in-license Phase II-III small molecules.<br />
Seeking to in-license Phase II-III<br />
small molecules.<br />
CORPORATE MISSION<br />
URL Pharma is a best-in-class specialty pharmaceutical company<br />
achieving sustainable growth by developing and commercializing<br />
safe, innovative, and exclusive medications and technologies.<br />
Established 1946 - privately held.<br />
550 employees<br />
300+ Sales Representatives - calling on PCP's and Rheumatologists<br />
Profitable - with $100 million available for in-licensing and business development.<br />
Four branded products and robust pipeline:<br />
) Bactrim (sulfamethoxazole and trimethoprim ).<br />
) Qualaquin® (quinine sulfate).<br />
) Colcrys® (colchicine, USP) - Launched Q4 ’09.<br />
) Fibricor (fenofibric acid tablets) - Launched Q4 ‘09.<br />
) 12 pipeline products in development<br />
Multi-Dimensional strategy: 505(b)2s, existing brands.<br />
Two NDA's approved in 2009.<br />
Significant medically driven pipeline.<br />
URL Pharma leverages a portfolio of 274 ANDAs.<br />
FACILITIES:<br />
350,000 sq ft manufacturing. 3 campuses - two in Phila, one in Chicago.<br />
49 manufacturing suites.<br />
7 packaging lines.<br />
4.0+ billion units capacity; tablets and capsules.<br />
"Quality First, Always"…recent four FDA cGMP inspections.... no 483’s<br />
INNOVATION:<br />
Success in solving product challenges…. URL Pharma’s innovative proprietary technologies have demonstrated success in improving drug<br />
solubility, eliminating food effect, delivering drug combinations, identifying new drug interactions, targeting delivery in the GI tract and<br />
improving a drug’s safety profile……these technologies can be applied to an NCE or an existing product<br />
BIO Business Forum 2011 501 Participating Company <strong>Profiles</strong>
PROPRIETARY TECHNOLOGY<br />
Technology Platforms<br />
) Multi-Burst Multi-Particulate Technology- Targeted delivery of drug along GI tract<br />
) NanoBurst Nanoparticle Technology- Increase bioavailability of poorly water soluble molecules<br />
) Z-BurstZero Order Release Technology - Zero order sustained release<br />
)PRISM (Program To Improve The Safety Of Medications) - Based upon discoveries on metabolic pathways<br />
CORPORATE ALLIANCES<br />
King Pharmaceuticals and other pharma companies<br />
INTELLECTUAL PROPERTY<br />
Broad patent estate:<br />
9 issued patents.<br />
75+ patent applications.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Colcrys® (colchicine, USP) Cleared for US Marketing Gout - pain relief Approved by the FDA for the<br />
prophylaxis of gout flares<br />
Bactrim (sulfamethoxazole and<br />
trimethoprim )<br />
Cleared for US Marketing Reduce development of drug<br />
resistant bacteria<br />
Qualaquin® (quinine sulfate) Cleared for US Marketing Malaria<br />
Fibricor® (fenofibric acid<br />
tablets)<br />
SENIOR MANAGEMENT<br />
Gregory Hayer, Senior Vice President<br />
Cleared for US Marketing Treatment of severe<br />
hypertriglyceridemia (= 500<br />
mg/dl)<br />
Low cost alternative to TriCor<br />
and TriLipix<br />
BIO Business Forum 2011 502 Participating Company <strong>Profiles</strong>
Dr. Bernd Eisele<br />
Chief Executive Officer<br />
Mellendorfer Strasse 9<br />
30625 Hannover<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Leander Grode, Director Business Development<br />
Vakzine Projekt Management, GmbH<br />
Clinical Foci: Vaccines • Biopharmaceuticals • Immunology<br />
www.vakzine-manager.de<br />
Phone: 49-511-16990811<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
VPM1002-Tuberculosis Vaccine is being tested since September<br />
2008 in a Phase I Open Label, randomized, controlled, doseescalation<br />
study to evaluate safety and immunogenicity of<br />
VPM1002 in comparison with BCG in healthy male volunteers.<br />
VPM5001-Soluferon®: Phase I to be initiated in 2009.<br />
VPM4001-Prostate Cancer: Due to the favourable clinical phase I/II<br />
experience with the current material, it is VPM’s goal to streamline<br />
the clinical development process in 2009.<br />
CORPORATE MISSION<br />
Incorporated: 2002<br />
Employees: 9<br />
Ownership: Private<br />
Phase II of TB vaccine with two populations: First one, newborns<br />
with the goal to provide protection against primary infection<br />
and/or disease in high-risk endemic areas. Second one, already<br />
infected adolescents living in a high-risk environment.<br />
Vakzine Projekt Management GmbH (VPM) is a vaccine and biopharmaceutical development company with a high potential for value<br />
creation. It acquires promising vaccine candidates from academia, develops them with a consortium of partners and commercializes the<br />
results. VPM develops its products by applying industrial standards (GxP) up to proof of concept. We have four promising projects in our<br />
pipeline: an improved, better soluble ß-interferon and three vaccines, of which one is a therapeutic vaccine against prostate cancer. The<br />
other vaccines are targeted against human cytomegalovirus and tuberculosis. VPM holds exclusive rights for all four products.<br />
VPM’s team has over 50 years of experience in management positions in the pharmaceutical and chemical industry.<br />
INTELLECTUAL PROPERTY<br />
VPM holds worldwide exclusive licenses for vaccine candidates against cancer (prostate, renal cell carcinoma, melanoma), tuberculosis,<br />
cytomegalo virus, and for the second generation beta-interferon, in total seven patent families. Most patents are granted in Europe, US<br />
and other countries. VPM has filed one own patent application.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VPM1002 Tuberculosis Vaccine Phase II, IIa, IIb Live vaccine against tuberculosis Clinical Phase I trial in healthy volunteers<br />
was finished in March 2010<br />
VPM4001 Prostate Cancer<br />
Vaccine<br />
Phase II, IIa, IIb An allogeneic therapeutic vaccine<br />
for treatment of prostate<br />
carcinoma<br />
VPM2001 HCMV Vaccine Preclinical A safe, well tolerated and<br />
efficacious vaccine (dense bodies<br />
of human cytomegalovirus)<br />
against infection with HCMV after<br />
transplantation and during<br />
prenatal life<br />
VPM5001 SOLUFERON® Preclinical A 2nd generation interferon-ß<br />
with increased bioavailability for<br />
the treatment of Multiple Sclerosis<br />
and use as antiviral therapy.<br />
Successful completion of a phase I/II clinical<br />
study in prostate cancer with an allogeneic<br />
vaccine. Improved manufacturing process to<br />
be developed.<br />
A novel vaccine for Human Cytomegalovirus<br />
is in preclinical phase. It consists of dense<br />
bodies, which contain all major antigens of<br />
HCMV but lack the viral genome.<br />
Soluferon®, a 2nd generation interferon-ß<br />
with increased bioavailability. GMP process<br />
including proprietary cell line in place.<br />
Preclinical studies ongoing.<br />
FINANCING HISTORY<br />
Investors: Ascenion GmbH (70 %) • Association for funding the Helmhotz Center for Infection Research (20 %) • Dr.<br />
Läufer GmbH (10 %)<br />
SENIOR MANAGEMENT<br />
Dr. Bernd Eisele, Chief Executive Officer • Dr. Leander Grode, Business Development • Dr. Clemens Oertelt, Manager • Inge Jacobi,<br />
Assistant<br />
BIO Business Forum 2011 503 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Dr. Christian Stein, Ascenion GmbH • Professor Dr. Joachim Klein, Association for funding the Helmholtz Center for Infection Research<br />
• Dr. Albrecht Läufer, Dr. Läufer GmbH<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Dr. Carlos Alberto Guzmán, Helmhotz Centre for Infection Research • Prof. Dr. Ulrich Kalinke, Twincore,Centre for Experimental<br />
and Clinical Infection Research • Prof. Dr. Stefan H.E. Kaufmann, Max Planck Institute for Infection Biology • Prof. Dr. Michel Klein,<br />
VaxiBio Inc • Dr. Peter Lange • Prof. Dr. John Oxford, Retroscreen Virology Ltd. • Dr. Christian Stein, Ascenion • Prof. Dr. Tobias<br />
Welte, Medical School Hannover<br />
BIO Business Forum 2011 504 Participating Company <strong>Profiles</strong>
J. Michael Pearson (Chief Executive Officer)<br />
Chief Executive Officer<br />
700 Route 202/206 North<br />
Bridgewater, NJ 08807<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Barry L. Levinson, PhD<br />
Joe Smith<br />
Benjamin Alt, Business Development Analyst<br />
Warren Lei<br />
Valeant Pharmaceuticals International, Inc<br />
Clinical Foci: Neurology • Skin/Dermatological • Ophthalmic<br />
www.valeant.com<br />
Phone: 1-866-246-8245<br />
Ownership: Public<br />
Market Cap: $15000.00 million<br />
NYSE : VRX<br />
HIGHLIGHTS<br />
Recent<br />
Recently acquired AB Sanitas (NASDAQ OMX: SAN1L) for approximately EUR314 million in cash. Company based in Kaunas, Lithuania, has a<br />
broad branded generics product portfolio consisting of 390 products in nine countries throughout Central and EEU.<br />
Recently received a commitment in principle to license Elidel (pimecrolimus 1% cream) from Meda in the U.S., Canada and Mexico. Elidel is<br />
a patent protected specialty focused product for the treatment of atopic dermatitis (AD).<br />
Recent agreement with Promius for Cloderm® (clocortolone pivalate 0.1%) Cream. Promius made an attractive upfront payment and will<br />
pay future royalties as the consideration for the right to manufacture, distribute and market Cloderm in the U.S.<br />
CORPORATE MISSION<br />
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops and<br />
markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients' lives. Valeant is<br />
focused in the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Australia, Switzerland<br />
and Central Europe.<br />
CORPORATE ALLIANCES<br />
Valeant has an exclusive worldwide partnership agreement with GlaxoSmithKline (GSK) for retigabine, its Phase III compound for the<br />
treatment of partial on-set seizures in adult patients and refractory epilepsy. Valeant has a joint venture agreement with Meda AB to<br />
strengthen its presence in Australia, Canada and Mexico through the development, marketing and commercialization of certain current<br />
and future products. Valeant Pharmaceuticals International has a partnership with Spear Pharmaceuticals, Inc. for rights to commercialize<br />
Refissa®, a prescription-based topical tretinoin cream used to diminish fine wrinkles and fade irregular pigmentation due to sun damage.<br />
PRODUCTS<br />
Name Phase Indication<br />
Acanya On Market Acne Vulgaris<br />
Atralin On Market Acne Vulgaris<br />
CeraVe On Market Skin Care<br />
Retigabine NDA/BLA filed, or in process Epilepsy<br />
Taribavirin Phase II, IIa, IIb Hepatitis C<br />
Cesamet On Market Chemotherapy Induced Nausea and Vomiting<br />
IDP108 Phase III Onychomycosis<br />
Zovirax, non ophthalmic On Market herpes labialis<br />
Wellbutrin XL On Market Major Depressive Disorder<br />
Migranal On Market Migraine<br />
SENIOR MANAGEMENT<br />
J. Michael Pearson (Chief Executive Officer), Chief Executive Officer • Rajiv De Silva, Chief Operating Officer • Philip W. Loberg, Chief<br />
Financial Officer • Robert Chai-Onn, General Counsel • Richard K. Masterson, President • Mark Durham, Senior Vice President<br />
BOARD OF DIRECTORS<br />
J. Michael Pearson (Chairman), Chairman • G. Mason Morfit, Partner, ValueAct Capital • Kate Stevenson, Corporate Director • Dr.<br />
Laurence Paul, Founding Principal, Laurel Crown Capital LLC • Robert A. Ingram, General Partner, Hatteras Venture Partners • Theo<br />
Melas-Kyriazi, Chief Financial Officer, Levitronix LLC • Robert N. Power, Corporate Director • Norma A. Provencio, President and<br />
Owner, Provencio Advisory Services Inc. • Lloyd Segal, Equity Partner, Persistence Capital Partners • Michael R. Van Every, Retired<br />
Partner of Price Waterhouse Coopers LLP<br />
BIO Business Forum 2011 505 Participating Company <strong>Profiles</strong>
Irene Gonzalez, PhD.<br />
Chief Executive Officer<br />
1450 South Rolling Road<br />
Baltimore, MD 21227<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Irene Gonzalez<br />
CORPORATE MISSION<br />
Valens Therapeutics, Inc.<br />
Clinical Foci: Oncology • Ophthalmic • Infectious Disease<br />
www.valenstherapeutics.com<br />
Phone: 1-410-455-5858<br />
Ownership: Private<br />
Valens Therapeutics Inc, a small privately held pharmaceutical company located in Baltimore, MD, owns a technology platform of<br />
molecules and is developing the next-generation of medicines for the ocular, oncology and infectious diseases markets. The company is<br />
currently seeking funding to develop its early stage unique and novel proprietary technology.<br />
PROPRIETARY TECHNOLOGY<br />
The IP is owned by the founder, president, and CEO. It consists of a technology platform of molecules that are being developed into unique,<br />
novel multi-targeted compounds with a delivery system for the treatment of human diseases in areas of ophthalmology, oncology,<br />
infectious diseases (HIV), and neurology.<br />
INTELLECTUAL PROPERTY<br />
Utility and PCT pending patents covering the technology platform<br />
FINANCING HISTORY<br />
Investors: Irene Gonzalez, PhD (96 %) • University of Maryland Baltimore County (4 %)<br />
SENIOR MANAGEMENT<br />
Irene Gonzalez, PhD., Chief Executive Officer • Donald Fallon, Chief Financial Officer • Richard Thorn, PhD, Other<br />
SCIENTIFIC ADVISORY BOARD<br />
Rachel Joseph, Life Bridge Health • Steve Dordunno, Kydes Pharmaceuticals<br />
BIO Business Forum 2011 506 Participating Company <strong>Profiles</strong>
Sabin Boily, PhD<br />
President & CEO<br />
550 Sherbrooke West suite 230<br />
Montreal Quebec, QC H3A1B9<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Valeo Management, L.P.<br />
Clinical Foci: Oncology • Infectious Disease • Drug Development<br />
www.valeosec.com<br />
Alain Richard , PHD, Director, Commercialization Life Sciences<br />
CORPORATE MISSION<br />
Phone: 1-514-840-1226<br />
Employees: 9<br />
Ownership: Private<br />
Valeo Management L.P. is a limited partnership whose mission is to commercialize the results of research carried out by its limited<br />
partners. The limited partners of Valeo Management L.P. are the member universities of the Université du Québec network (Université du<br />
Québec à Montréal, École de Technologie Supérieure, Université du Québec à Rimouski, Université du Québec à Trois-Rivières, Université<br />
du Québec en Outaouais, Université du Québec en Abitibi-Témiscamingue) and Concordia University.<br />
PROPRIETARY TECHNOLOGY<br />
Biotechnology, Pharmaceuticals, Health, Nutraceuticals, Telecom, IT, Industrial Technologies, Nanotechnology, Technologies in the Arts.<br />
CORPORATE ALLIANCES<br />
Various programs from the Governments of Québec and Canada<br />
INTELLECTUAL PROPERTY<br />
More than 150 patents (pending & issued). Various fields.<br />
PRODUCTS<br />
Name Phase Indication<br />
Estrogen-linked platinum (II) complexes as anticancer agents Preclinical Breast, Ovarian & Uterine Cancer<br />
New Anticancer Conjugates Preclinical Prostate Cancer<br />
Anticancer Agents Based on Amino Acid Derivatives Preclinical Breast, Ovarian & Uterine Cancer<br />
Expression Vectors in Aspergillus Other Protein Production<br />
HIV Gene Therapy Preclinical HIV<br />
Targeted Fat Loss (Adipotronics) Other Weight Management, Obesity<br />
SENIOR MANAGEMENT<br />
Sabin Boily, PhD, President & CEO<br />
BOARD OF DIRECTORS<br />
Luc Tanguay, CFO, Theratechnologies<br />
BIO Business Forum 2011 507 Participating Company <strong>Profiles</strong>
9605 Medical Center Drive<br />
Rockville, MD 20850<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gunther Birznieks<br />
CORPORATE MISSION<br />
Vanda Pharmaceuticals Inc<br />
Clinical Foci: CNS • Neurology • Specialty Pharmaceutical<br />
www.vandapharmaceuticals.com<br />
Phone: 1-301-599-4500<br />
Vanda is a specialty pharmaceutical company focused on developing therapeutics for CNS indications.<br />
PRODUCTS<br />
Name Phase Indication<br />
Incorporated: 2003<br />
Employees: 30<br />
Ownership: Public<br />
Market Cap: $200.00 million<br />
NASDAQ: VNDA.OQ<br />
Fanapt Cleared for US Marketing Schizophrenia<br />
Tasimeleteon Phase III Insomnia/Major Depression<br />
BIO Business Forum 2011 508 Participating Company <strong>Profiles</strong>
NUGGEHALLY R SRINIVAS<br />
Chief Executive Officer<br />
Phoenix Pinnacle, 3rd Floor, No. 46,<br />
Bangalore 560042<br />
India<br />
CONFERENCE PARTICIPANTS<br />
Vanthys Pharmaceutical Dev Pvt Ltd<br />
Clinical Foci: Drug Development<br />
www.vanthys.net<br />
Phone: 91-80-6662 8327<br />
NUGGEHALLY SRINIVAS, Chief Executive Officer and Chief Scientif Officer<br />
CORPORATE MISSION<br />
Incorporated: 2009<br />
Employees: 17<br />
Ownership: Private<br />
Vanthys Pharmaceutical Development Pvt Ltd is a 50-50 joint venture of Eli Lilly and Company (USA) and Jubilant Life Sciences (formerly<br />
Jubilant Organosys), India. Company was incorporated in May 2009 and is an autonomus organisation with a mission of accelerating<br />
global drug development. Vanthys is modeled after Lilly's early stage development division Chorus (www.choruspharma.com), which<br />
provides fast and efficient drug development exculisively through the utilisation of external contract companies. The goal of Vanthys is<br />
to provide proof of concept answers during early phase drug development with the ultimate aim to privide high quality scientific answers<br />
to our business partners faster, and in a cost efective manner, so as to aid in decision for further investment and advancement of the<br />
compound.<br />
CORPORATE ALLIANCES<br />
Eli Lilly and Company, USA and Jubilant Life Scineces (formerly Jubilant Organosys)<br />
SENIOR MANAGEMENT<br />
NUGGEHALLY R SRINIVAS, Chief Executive Officer • NUGGEHALLY R SRINIVAS, Chief Scientific Officer<br />
BIO Business Forum 2011 509 Participating Company <strong>Profiles</strong>
Danguole Altman<br />
Chief Executive Officer<br />
8285 El Rio Street<br />
Houston, TX 77054<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Danguole Altman, MBA<br />
CORPORATE MISSION<br />
Vapogenix, Inc<br />
Clinical Foci: Drug Development • Skin/Dermatological • Neurology<br />
www.vapogenix.com<br />
Phone: 1-713-748-3903<br />
Incorporated: 2006<br />
Employees: 4<br />
Ownership: Private<br />
Vapogenix is an innovator of superior medicines for preventing and treating localized pain through transforming approved therapeutics<br />
into novel products. Our technology is based on new routes of administration & new indications for a class of off-patent drugs, with<br />
broad potential to treat many painful disorders without the side effects of narcotics. We combine the rapid development path of an<br />
existing drug with the patent protection of a new one. Our first product will be a rapidly acting topical analgesic for minor procedural<br />
pain– “orajel for the skin”. Such a product has strong unmet demand and can be developed relatively rapidly. Subsequent products will<br />
focus on longer duration acute and chronic pain.<br />
Vapogenix has preliminary animal and human data showing reversible analgesia and rapid skin penetration of its drug. We have<br />
developed several candidate formulations which meet preliminary criteria for commercialization. In addition, the company has<br />
completed a detailed analysis of the potential market for its first product. We will obtain preliminary proof of efficacy in humans in our<br />
first clinical study. We plan to submit an IND for our first product by the end of this year and begin clinical trials in early 2012.<br />
PROPRIETARY TECHNOLOGY<br />
Our API is approved by the FDA and available in generic form. It cannot be used for localized delivery without formulation. Our patents<br />
cover novel formulations of the API as well as method of use. The technology was initially developed at UT-MD Anderson Cancer Center<br />
and exclusively licensed to Vapogenix.<br />
CORPORATE ALLIANCES<br />
Vapogenix does not currently have any alliances with pharmaceutical companies.<br />
INTELLECTUAL PROPERTY<br />
All patents are pending. Vapogenix has filed for broad patent protection in the US, Canada, Europe, Japan and other countries.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VPX-595-001 Preclinical Quick acting topical analgesic for minor<br />
procedural pain for adults and children<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 11/01/2007 (US $2.53 million)<br />
Plan to submit IND by<br />
12/31/2011<br />
Investors: Pamoja Capital (48 %) • Danguole Altman (15 %) • Allen Burton, MD (14 %) • Phillip Phan, MD (14 %) •<br />
UT-MD Anderson Cancer Center (5 %) • Others (4 %)<br />
SENIOR MANAGEMENT<br />
Danguole Altman, Chief Executive Officer • Heather Giles, PhD, Chief Scientific Officer • Clarice Motter, Chief Financial Officer • Terry<br />
Farmer, PhD, Other<br />
BOARD OF DIRECTORS<br />
Danguole Altman, President and CEO, Vapogenix • George Davitt, Pamoja Capital • Chris Jorgenson, Pamoja Capital<br />
SCIENTIFIC ADVISORY BOARD<br />
Allen Burton, MD, Scientific Founder, Former Chair, Dept of Pain Medicine, MD Anderson Cancer Center • Phillip Phan, MD, Scientific<br />
Founder, Former asst. Prof UT-MDACC and Baylor College of Medicine • Patrick Dougherty, PhD, Professor, Dept of Pain Medicine, UT-<br />
MDACC • William Zempsky, MD, Prof of Pediatrics, University of Connecticut School of Medicine, Interim Head, Div of Pain Medicine,<br />
Conn Children's • Peter LaCouture, PhD, former Executive Director, Magidom Discovery, regulatory expert, pain • Jay Birnbaum, PhD<br />
(pending), consultant, former VP Dermatology Novartis<br />
BIO Business Forum 2011 510 Participating Company <strong>Profiles</strong>
Christian Wandersee<br />
Chief Executive Officer<br />
Friedrich-Bergius-Ring 15<br />
97076 Wuerzburg<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Christian Wandersee, CEO<br />
Frank Tegtmeier, CSO<br />
Andrew Clark, Chairman of the Board<br />
vasopharm GmbH<br />
Clinical Foci: CNS • Cardiovascular Disease<br />
www.vasopharm.com<br />
Phone: 49-931-3590990<br />
Incorporated: 1998<br />
Ownership: Private<br />
CORPORATE MISSION<br />
vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebroand<br />
cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits steering<br />
the bioavailability of biological NO, covering the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm’s drug<br />
candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life<br />
threatening rises in intracranial pressure after a traumatic brain injury.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VAS203 Phase II, IIa, IIb Traumatic Brain Injury Completion of IIa phase<br />
VAS2870 Preclinical Cardiovascular<br />
SENIOR MANAGEMENT<br />
Christian Wandersee, Chief Executive Officer • Frank Tegtmeier, PhD, Chief Scientific Officer • Reinhard Schinzel, PhD, Director •<br />
Peter Scheurer, PhD, Director<br />
BOARD OF DIRECTORS<br />
Andrew Clark, PhD, Independent Consultant • Clemens Doppler, PhD, HeidelbergCapital • Thomas Lander, MD, Independent<br />
Consultant • Klaas de Boer, Entrepreneurs Fund<br />
BIO Business Forum 2011 511 Participating Company <strong>Profiles</strong>
Anders Wangby<br />
Director<br />
Assistentgatan 23<br />
93185 Skellefteå<br />
Sweden<br />
CONFERENCE PARTICIPANTS<br />
Björn Ursing<br />
CORPORATE MISSION<br />
Västerbotten Investment Agency<br />
Clinical Foci: Infectious Disease • Drug Development • Food & Ag<br />
www.viavasterbotten.se<br />
Phone: 46-708-111 268<br />
Employees: 4<br />
Ownership: Other<br />
Västerbotten Investment Agency (VIA) is a regional investment promotion agency dedicated to make the Västerbotten province the most<br />
attractive choice for foreign investors and companies thinking about establishing or expanding their business operations in Sweden. With<br />
expertise in several key sectors, VIA offers information about business opportunities as well as assistance throughout the investment and<br />
establishment process. VIA is a regional partner to the government agency Invest Sweden and works free of charge.<br />
With the life science sector the city of Umeå in Västerbotten, is particulary strong in infectious diseases and forest biotechnology. Other<br />
areas where we have strong research and startups are medtech and sports medicine.<br />
SENIOR MANAGEMENT<br />
Anders Wangby, Director • Björn Ursing, Manager • Olof Norberg, Manager<br />
BIO Business Forum 2011 512 Participating Company <strong>Profiles</strong>
Nancy Bouveret, MD<br />
Chief Medical Officer<br />
245 First Street<br />
Cambridge, MA 02142<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Mr. Brian Rosen<br />
CORPORATE MISSION<br />
VBI Vaccines<br />
Clinical Foci: Vaccines • Infectious Disease • Biodefense<br />
www.vbivaccines.com<br />
Phone: 1-617-830-3031<br />
Incorporated: 2006<br />
Employees: 35<br />
Ownership: Private<br />
VBI Vaccines is a vaccine development company dedicated to the innovative formulation, development and delivery of thermostable<br />
vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine<br />
development and growing pipeline of vaccine programs address significant market opportunity and are designed to answer critical<br />
unmet medical need.<br />
Founded in 2001, VBI is a privately held company headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Canada.<br />
PRODUCTS<br />
Name Phase Indication<br />
Thermostable IM Technology Research Influenza Prevention<br />
Thermostable IM Technology Research MMR<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Seed Round: 12/01/2005 (US $0.60 million)<br />
Round A: 12/28/2005 (US $36.50 million)<br />
Investors: Clarus Ventures (0 %) • Arch Venture Partners (0 %) • 5AM Partners (0 %)<br />
SENIOR MANAGEMENT<br />
Nancy Bouveret, MD, Chief Medical Officer • David Anderson, PhD, Vice President • Marc Kirchmeier, PhD, Vice President • Egidio<br />
Nascimento, CA, Chief Financial Officer • Adam Buckley, Vice President • Brian Rosen, Vice President • Jeff Baxter, Chief Executive<br />
Officer<br />
BOARD OF DIRECTORS<br />
Jeff Leiden, Clarus Ventures • Steve Gillis, Arch Venture Partners • Scott Rocklage, 5AM Partners • Jeff Baxter, Variation<br />
Biotechnologies Inc. • Steve Vignau, Former Merck EVP • Jeffrey Leiden, MD, Ph.D, Managing Director Clarus Ventures • Steven Gillis,<br />
PhD, Managing DIrector ARCH Venture Partners • Scott M. Rocklage, PhD, Managing Partner 5AM Ventures • Steve Vignau, Merck &<br />
Co. (Retired) • Jeff Baxter, President & CEO VBI Vaccines<br />
SCIENTIFIC ADVISORY BOARD<br />
Gary Nabel, MD, PhD - Chair, Director of the NIH Vaccine Institute • Mike Levine, MD, DTPH, Director of the Vaccine Research Center,<br />
University of Maryland • Stanley Plotkin, MD, Ex Sanofi-Aventis SVP and Emeritus Professor at Wistar & at the University of Pennsylvania<br />
• Florian Schodel, MD, Former VP Infectious Disease & Vaccine Clinical Research at Merck Research Laboratories • Francisco Diaz-<br />
Mitoma, MD, PhD, Founder & Senior Advisor, VBI Founder, VP Research Sudbury Regional Hospital & Professor at Northern Ontario<br />
School of Medicine • Rahul Singhvi, Sc.D., Former CEO of Novavax & Founder of Axella Solutions • Richard Ulevitch, PhD, 5AM<br />
Ventures, former Chairman of Department of Immunology at the Scripps Research Institute • Alex Sette, PhD, Director of the<br />
Immunology and Vaccine Center, University of San Diego<br />
BIO Business Forum 2011 513 Participating Company <strong>Profiles</strong>
Yi-Qian Sun<br />
Chief Scientific Officer<br />
Postboks 1262 Sluppen<br />
7462 Trondheim<br />
Norway<br />
CONFERENCE PARTICIPANTS<br />
Trond Erik Vee Aune<br />
CORPORATE MISSION<br />
Vectron Biosolutions AS<br />
Clinical Foci: Drug Development • Service<br />
www.vectronbiosolutions.com<br />
Phone: 47-950-27449<br />
Incorporated: 2008<br />
Employees: 3<br />
Ownership: Private<br />
Vectron Biosolutions’ business idea is to use its proprietary and unique technology platform to develop, sell and out-license superior<br />
technology solutions for production of recombinant proteins in bacteria.<br />
We are currently developing outstanding production processes for 14 different biosimilars and will have these available to the<br />
pharmaceutical industry in late 2011/early 2012.<br />
PROPRIETARY TECHNOLOGY<br />
The basis for Vectron Biosolutions AS is its proprietary expression vector platform technology which has been developed in Professor Svein<br />
Valla’s research group at the Norwegian University of Science and Technology (NTNU) in collaboration with SINTEF Biotechnology. This<br />
technology utillizes unique promoters (Pm) with associated genetic elements harboured on a broad-host-range plasmid vectors based on<br />
the RK2 plasmid. This constitutes a powerful vector platform for production of any non-glycosylated protein in E. coli and other Gram<br />
negative bacteria,<br />
CORPORATE ALLIANCES<br />
SARomics Biostructures AS<br />
Dualsystems Biotech<br />
SINTEF<br />
INTELLECTUAL PROPERTY<br />
Patented technology.<br />
SENIOR MANAGEMENT<br />
Yi-Qian Sun, Chief Scientific Officer • Trond Erik Vee Aune, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Gaute Moldestad, LEN<br />
SCIENTIFIC ADVISORY BOARD<br />
Professor Svein Valla, NTNU<br />
BIO Business Forum 2011 514 Participating Company <strong>Profiles</strong>
Christopher Blackwell<br />
Chief Executive Officer<br />
1 Prospect West<br />
Chippenham Wiltshire<br />
SN14 6FH<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Peter Hirst<br />
Roger Heerman<br />
Vectura Group Plc<br />
Clinical Foci: Pulmonary • Neurology<br />
www.vectura.com<br />
Phone: 44-1249-667 700<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Phase III data show NVA237 significantly improves lung function<br />
with good safety profile in COPD patients (April 2011).<br />
VR496 demonstrates anti-inflammatory and mucolytic activity in<br />
cystic fibrosis patients (March 2011).<br />
Positive outcome for VR040 in Parkinson’s trial (November 2010).<br />
CORPORATE MISSION<br />
Incorporated: 1997<br />
Employees: 180<br />
Ownership: Public<br />
Market Cap: $330.00 million<br />
LONDON STOCK EXCHANGE: VEGPF.PK<br />
NVA237 (COPD). Novartis expects launch in 2012.<br />
QVA149 (COPD). $7.5m (£5.1m) milestone triggered by start of<br />
Phase III studies received in May 2010. Novartis expects launch in<br />
2013.<br />
VR315 (asthma/COPD). Next milestones expected on approval in<br />
EU. Licensing discussions ongoing for US and ROW.<br />
Vectura Group plc is a product development company focused on the development of a range of inhaled therapies principally for the<br />
treatment of respiratory diseases.<br />
Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have<br />
been licensed to major pharmaceutical companies. The company seeks to develop certain programmes further through development to<br />
optimise value through licensing at a later stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical<br />
companies on a licensing basis where this complements Vectura’s business strategy.<br />
Vectura is based in the UK, with headquarters and development operations in Chippenham, Wiltshire. The company has a device<br />
development group in Cambridge and a small office in Boston, US.<br />
Vectura's shares trade on the London Stock Exchange under the symbol VEC.<br />
PROPRIETARY TECHNOLOGY<br />
Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities,<br />
addressing large and fast-growing market sectors, as well as a portfolio of revenue generating, marketed products.<br />
Vectura has proprietary inhalation device and formulation technologies, which it uses to develop products in-house and with its<br />
pharmaceutical company partners.<br />
CORPORATE ALLIANCES<br />
Vectura's partners include GlaxoSmithKline (GSK), Sandoz, Novartis, Otsuka Pharmaceutical Co Ltd, ProFibrix BV, Sosei Group Corporation<br />
/ Arakis Ltd, Baxter and Recipharm.<br />
INTELLECTUAL PROPERTY<br />
Vectura’s patent portfolio includes over 120 families of granted patents and patent applications, covering inventions made by the Group’s<br />
researchers as well as inventions the Group has acquired or licensed from third parties. The Group actively maintains and protects this<br />
patent estate. Significant effort is also directed to other intellectual property rights including trade mark and design rights, and knowhow.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
NVA 237 Phase III COPD Partnered with Novartis<br />
QVA149 Phase III COPD Partnered with Novartis<br />
VR315 EU Other Asthma/COPD Partnered with Sandoz<br />
VR315 US and RoW Other Asthma/COPD Available for partnering in US and RoW<br />
VR632 EU Other Asthma COPD Partnered with Sandoz<br />
VR632 US Other Asthma/COPD<br />
VR506 Other Asthma<br />
VR496 Phase II, IIa, IIb Cystic Fibrosis Available for partnering<br />
BIO Business Forum 2011 515 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
VR040 Phase II, IIa, IIb Parkinson's disease Available for partnering<br />
SENIOR MANAGEMENT<br />
Christopher Blackwell, Chief Executive Officer • Anne Hyland, Chief Financial Officer • Tim Wright, Other • Mark Main, Other •<br />
Stephen Eason, Other • Martin Shott, Other • Colin Dalton, Other • Trevor Phillips, Other<br />
BOARD OF DIRECTORS<br />
John "Jack" Cashman, Non-Executive Chairman • Andrew Richards, Non-Executive Director • John Brown, Non-Executive Director •<br />
Susan Foden, Non-Executive Director • Neil Warner, Non-Executive Director • Christopher Blackwell, Chief Executive and Executive<br />
Director • Anne Hyland, Chief Financial Officer, Company Secretary and Executive Director<br />
BIO Business Forum 2011 516 Participating Company <strong>Profiles</strong>
Scott E. Deeter<br />
Chief Executive Officer<br />
320 East Vine Drive<br />
Fort Collins, CO 80524<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Scott E. Deeter, MBA, MSc, Chief Executive Officer<br />
Randy Semadeni<br />
Ventria Bioscience<br />
Clinical Foci: Gastroenterology • Hematology • Infectious Disease<br />
www.ventria.com<br />
Phone: 1-800-916-8311<br />
Incorporated: 2002<br />
Employees: 27<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Ventria Bioscience is a privately held biopharmaceutical company with a human health product pipeline enabled by ExpressTec. Ventria’s<br />
most advanced human health product (Ven100) is an orally delivered treatment for antibiotic-associated diarrhea (AAD) including C.<br />
difficile. Ven100 is scheduled to begin dosing in a 336 patient multi-center Phase III clinical study in late 2011. Ven100 has peak revenue<br />
potential of $1.8 billion for its first two target markets; 1) “at-risk” adults in long term care ($560 million) and 2) hospital in-patients ($1.2<br />
billion). Additional indications being developed by Ventria include ulcerative colitis and osteoporosis. Encouraging animal data and initial<br />
human data has been developed for these indications. Phase II pilot studies are being planned for both indications and will commence<br />
upon successful development of Ven100 for AAD.<br />
Ventria’s product pipeline also includes Recombinant Albumin, a safer and more reliable albumin to replace plasma-derived human<br />
albumin. Plasma-derived human albumin is an estimated $1 billion revenue product today with therapeutic and non-therapeutic<br />
applications. Current suppliers of plasma-derived human albumin include Baxter, CSL, Grifols and Talecris. The therapeutic market for<br />
Recombinant Albumin represents $350 million of potential peak revenue in the US alone.<br />
PROPRIETARY TECHNOLOGY<br />
ExpressTec has at least a ten-fold higher protein yield than other plant-based systems, and plant-based production provides scale and cost<br />
advantages compared to other manufacturing systems. Ventria believes it can offer a sustainable competitive advantage and unique<br />
intellectual property position to biologic product development customers as a contract manufacturer and/or as a co-development partner.<br />
Ventria has several potential targets for this strategy, including biosimilars.<br />
CORPORATE ALLIANCES<br />
NIH; CDC; Thermo-Fisher Scientific; Sigma-Aldrich; Kerry Bioscience; Merck Millipore;<br />
INTELLECTUAL PROPERTY<br />
23 Issued patents; 27 pending patents<br />
PRODUCTS<br />
Name Phase Indication<br />
Ven100 Phase III Anti-infective (antibiotic-associated diarrhea including C. difficile)<br />
Ven105 Phase II, IIa, IIb Inflammatory Bowel Disease<br />
Ven110 Phase II, IIa, IIb Osteoporosis in Post-menopausal women<br />
Ven200 Preclinical Hematology<br />
FINANCING HISTORY<br />
Investors: William J. Rutter (0 %) • Thomas N. Urban (0 %) • William H. Rutter (0 %) • Vista Ventures (0 %) • Melvin<br />
D. Booth (0 %) • Pablo Valenzuela (0 %) • Scott E. Deeter (0 %)<br />
SENIOR MANAGEMENT<br />
Scott E. Deeter, Chief Executive Officer • Randy J. Semadeni, Vice President • Ning Huang, Vice President • Greg Unruh, Vice President<br />
BOARD OF DIRECTORS<br />
Thomas N. Urban, Private Investor • William J. Rutter, Synergenics, LLC • William H. Rutter, Private Investor • Melvin D. Booth, Booth<br />
Partners • William W. Crouse, HealthCare Ventures • Pablo Valenzuela, Ciencia Para La Vida - Chile • David Dwyer, Vista Ventures •<br />
Scott E. Deeter, CEO, Ventria Bioscience<br />
BIO Business Forum 2011 517 Participating Company <strong>Profiles</strong>
Patrik Frei<br />
Chief Executive Officer<br />
Kasernenstrasse 11<br />
8004 Zurich<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Patrik Frei, PhD, CEO<br />
Jost Renggli, COO<br />
Venture Valuation<br />
www.venturevaluation.com<br />
Phone: 41-43-321 8660<br />
Incorporated: 1999<br />
Employees: 8<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Launch of new version of Biotechgate with over 20,000 company profiles, 1,200 licensing deals containing financial information and other<br />
licensing opportunities.<br />
CORPORATE MISSION<br />
Venture Valuation specializes in independent assessment and valuation of technology-driven companies in Biotechnology and Life<br />
Sciences. Our comprehensive Valuation Reports contain a detailed assessment of the value drivers of the company and the possible<br />
development of the value based on reaching certain milestones. We also provide detailed Product Valuations based on an assessment of<br />
therapeutics currently in development (sciences/technology and market environment). We carry out a detailed calculation of the risk<br />
adjusted net present value for the licensee and licensor. This can then serve as a basis for negotiations or to structure different deal<br />
scenarios (front-loaded, milestone based or back loaded).<br />
Clients include investors, biotech, pharma and medtech companies as well as economic development agencies.<br />
In addition to valuation products, Venture Valuation offers high-quality, focused information services, such as the global Biotech and Life<br />
Sciences database Biotechgate (www.biotechgate.com).<br />
Venture Valuation is owner and provider of Biotechgate, a global, comprehensive, Life Science database encompassing the Biotechnology,<br />
Pharmaceutical and Medical Device industries as well as Professional Service firms and Investors. Over 20,000 high-quality profiles as well<br />
as over 1,200 Licensing Deals are available for viewing. <strong>Profiles</strong> are regularly updated by the companies themselves and an experienced<br />
database team to ensure the accuracy and relevance of the data.<br />
Licensing Candidate Search<br />
Based on unique valuation and industry expertise, and leveraging access to the proprietary client and products database, Venture<br />
Valuation also offers individual, tailor-made solutions to customers. Our Licensing Candidate Search includes licensing partner<br />
identification and an evaluation of potential products for licensing.<br />
PROPRIETARY TECHNOLOGY<br />
Global Biotechnology Database Biotechgate and country databases:<br />
Canadian Life Sciences Database (www.canadianlifesciences.com)<br />
German Biotech Database (www.germanbiotech.com)<br />
Indian Biotech Database (www.indianbiotech.com)<br />
Scandinavian Life Sciences Database (www.scandinavianlifesciences.com)<br />
Swiss Life Sciences Database (www.swisslifesciences.com)<br />
UK Biotech Database (www.ukbiotech.com)<br />
USA Life Sciences Database (www.usalifesciences.com)<br />
SENIOR MANAGEMENT<br />
Patrik Frei, Chief Executive Officer • Jost Renggli, Chief Operating Officer<br />
BIO Business Forum 2011 518 Participating Company <strong>Profiles</strong>
999 West Hastings Street<br />
Vancouver, BC V6C2W2<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Gary J. Bridger, PhD<br />
Ken Galbraith<br />
Ventures West Capital<br />
www.ventureswest.com<br />
Phone: 1-604-688-9495<br />
Ownership: Private<br />
BIO Business Forum 2011 519 Participating Company <strong>Profiles</strong>
Ian Garland<br />
Chief Executive Officer<br />
Oakdene Court<br />
Winnersh<br />
RG41 5UA<br />
United Kingdom<br />
CONFERENCE PARTICIPANTS<br />
Nerida Scott<br />
CORPORATE MISSION<br />
Vernalis plc<br />
Clinical Foci: CNS • Oncology • Other<br />
www.vernalis.com<br />
Phone: 44-01189-773 133<br />
Ownership: Public<br />
Market Cap: $60.00 million<br />
LONDON STOCK EXCHANGE: VER.L<br />
One of the UK’s leading development stage pharmaceutical companies, Vernalis takes promising product candidates along a<br />
commercially-focused path to market. We derive pipeline candidates both from our own research activities, and from successful<br />
collaboration with a number of global pharmaceutical businesses. Our pipeline focuses on several key areas of disease in CNS and<br />
oncology.<br />
Pipeline includes clinical and pre-clinical programmes in pain, Parkinson's Disease and cancer.<br />
PROPRIETARY TECHNOLOGY<br />
Structure-based drug discovery research technology<br />
CORPORATE ALLIANCES<br />
Novartis, GSK, Servier, Lundbeck,<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Frovatriptan On Market acute migraine<br />
HSP90 inhibitors Phase II, IIa, IIb oncology successful completion by our partner<br />
Novartis of Ph II POC studies<br />
V81444 Phase I Parkinson's Disease Shortly starting Phase I studies<br />
V158866 Phase I Pain and other indications (FAAH<br />
inhibitor)<br />
completion of Phase I<br />
V158411 Preclinical oncology (Chk1 inhibitor) completion of PC studies<br />
SENIOR MANAGEMENT<br />
Ian Garland, Chief Executive Officer • David Mackney, Chief Financial Officer • Nerida Scott, BD&L, Business Development • Stephen<br />
Pawsey, Development, Director • Mike Wood, Research, Director • Kevin Kissane, Attorney<br />
BOARD OF DIRECTORS<br />
Peter Fellner<br />
BIO Business Forum 2011 520 Participating Company <strong>Profiles</strong>
Adityo Prakash<br />
Chief Executive Officer<br />
48820-100B Kato Road<br />
Fremont, CA 94538<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Adityo Prakash, CEO<br />
Verseon Corporation<br />
Presenting Company<br />
Clinical Foci: Drug Discovery • Biopharmaceuticals • Cardiovascular Disease<br />
www.verseon.com<br />
Phone: 1-510-225-9000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Discovery, development, and optimization of first<br />
known small molecule allosteric thrombin inhibitors.<br />
These inhibitors show a remarkably different<br />
functional profile in coagulation assays compared to<br />
current DTIs, promising a novel clinical profile.<br />
CORPORATE MISSION<br />
Incorporated: 2002<br />
Employees: 20<br />
Ownership: Private<br />
Completion of regulatory toxicity studies and IND application.<br />
Results from ongoing studies on the effect of Verseon compounds on PAR-1<br />
related cancers – breast and prostate.<br />
Results from ongoing studies on the neuro-protective effect of Verseon’s<br />
compounds. Thrombin accumulation in the brain is toxic and has been detected<br />
immunohistochemically in senile plaques of human Alzheimer's patients.<br />
Verseon is a bio-pharmaceutical company leveraging its novel drug design platform to discover, develop, and commercialize new small<br />
molecule medicines that address unmet medical needs. The company has built a drug discovery platform that can reliably engineer novel<br />
drug candidates for any target with available 3D molecular structure. The company has utilized its platform to design and test multiple<br />
novel Direct Thrombin Inhibitors (DTIs) in a short span of one year, and is currently advancing its compounds towards IND application.<br />
DTIs have cardiovascular applications in prevention of thrombosis and strokes in patients with atrial fibrillation, and in oncology for<br />
treating solid tumors. The company is leveraging its platform efficiencies to launch multiple new programs in the next two years in the<br />
areas of oncology, diabetes / obesity, and Alzheimer’s disease.<br />
PROPRIETARY TECHNOLOGY<br />
Verseon platform screens a large virtually designed drug-like, novel, and synthesizable chemical space (~200M+ molecules for any<br />
program) for novel drug candidates. The platform uses highly accurate predictions of intermolecular interactions which are based on<br />
proprietary advances in modeling of relevant physics and chemistry, novel mathematical optimization algorithms and high-performance<br />
computing. The large drug-like and synthesizable chemical space is created by Verseon’s unique library technology. Computational<br />
methods are tightly integrated with feedback from laboratory testing. Verseon platform’s combination of proprietary computational<br />
design coupled with focused synthesis and bio-assays has resulted in a rapid and reliable discovery and optimization pipeline.<br />
INTELLECTUAL PROPERTY<br />
Growing patent portfolio covers novel candidates from Verseon’s drug discovery programs. Verseon’s core technology is also proprietary<br />
and completely built in-house and is covered by a mixed strategy of patents and trade secrets which affords the best mix of IP protection<br />
while preventing others from replicating the platform.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VE-04051645 Preclinical CVD, Oncology<br />
SENIOR MANAGEMENT<br />
Adityo Prakash, Chief Executive Officer • Eniko Fodor, Chief Operating Officer • David Kita, Managing Director • Kevin Short,<br />
Managing Director<br />
SCIENTIFIC ADVISORY BOARD<br />
Robert W. Karr, GTx, Inc, Idera Pharmaceuticals, ex-Pfizer, ex-Warner Lambert • John McCall, PharMac LLC, ex-Pfizer, ex-Pharmacia •<br />
John Leonard, Abbott Labs<br />
BIO Business Forum 2011 521 Participating Company <strong>Profiles</strong>
Peter Soelkner<br />
Managing Director<br />
Eywiesenstraße 5<br />
88212 Ravensburg<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Peter Soelkner<br />
Thomas Otto<br />
Max Horn<br />
Wolfgang Kerkhoff<br />
Udo Vetter<br />
Vetter Pharma International GmbH<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Drug Delivery<br />
www.vetter-parma.com<br />
Phone: 49-751-3700-0<br />
Gunther Strothe<br />
Brigitte Reutter-Haerle<br />
Simon Walter<br />
John Moore<br />
Incorporated: 1953<br />
Employees: 2400<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Vetter announced that its new Chicago facility is now accepting client projects. Located in Skokie, the site supports preclinical through<br />
phase II products. The facility provides cGMP filling for vials, syringes and cartridges.<br />
Vetter will build a state-of-the-art high bay warehouse for cold-storage and room-temperature goods. Space will also be dedicated for<br />
automatic and manual visual inspection as well as for stability chambers designed to the highest standards.<br />
CORPORATE MISSION<br />
For more than 25 years, the Vetter name has stood for quality, innovation and strategic partnership. An independent, leading provider of<br />
aseptically prefilled syringes, cartridges and vials, Vetter supports pharmaceutical and biotech clients throughout a product’s lifecycle –<br />
from preclinical development through regulatory approval and market supply worldwide. Vetter is headquartered in Ravensburg,<br />
Germany<br />
Biotechnology drugs, in particular, are highly sensitive complex compounds that are very expensive to produce. Vetter has extensive<br />
experience working with biotech substances, including monoclonal antibodies, peptides, interferons and vaccines. Type of stopper, type of<br />
glass, and degree of siliconization can all potentially interact with a product’s active ingredient. Knowing how to match drug product to<br />
delivery system is critical, along with designing an appropriate manufacturing process. So is maximizing API yield. Vetter’s state-of-theart<br />
technology preserves API during the filling process, and Vetter’s experience in the industry minimizes wasteful trial and error.<br />
Vetter is an acknowledged leader in aseptic filling:<br />
- Vetter works with the world´s leading pharmaceutical and biotech companies.<br />
- Vetter is a leader in the use of RABS technology in cleanrooms.<br />
- Vetter invented dual-chamber technology, including the Vetter Lyo-Ject® dual-chamber syringe and V-LK® cartridge.<br />
- Vetter holds nearly 140 patents on drug-delivery system processes and components.<br />
- Vetter is an expert in lyophilization (freeze-drying), often required to prolong product shelf-life.<br />
Service divisions<br />
- Vetter Development Service: product management from preclinical development to market launch<br />
- Vetter Commercial Manufacturing: large-scale production and packaging of aseptic prefilled drug-delivery systems<br />
- Vetter Solutions: proprietary innovations, from dual-chamber technology to anti-counterfeiting measures<br />
PROPRIETARY TECHNOLOGY<br />
Patented products<br />
> Vetter Lyo-Ject® dual-chamber syringe<br />
> V-LK® dual-chamber cartridge<br />
> V-OVS® tamper-evident closure system<br />
Prefilled WFI syringe with V-OVS® tamper-evident closure and registration documents<br />
CORPORATE ALLIANCES<br />
Preferred partnership with Sentry, provider for clinical packaging solutions & supply chain management<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Vetter Lyo-Ject® dual-chamber syringe On Market varoius Support end-user convenience and more<br />
accurate dosing for lyophilized and other<br />
drugs<br />
BIO Business Forum 2011 522 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
V-LK® dual-chamber cartridge On Market varoius Support end-user convenience and more<br />
accurate dosing for lyophilized and other<br />
drugs<br />
Prefilled WFI syringe registration<br />
documents<br />
V-OVS® tamper-evident closure<br />
system<br />
On Market varoius Differentiate your lyophilized products and<br />
support a faster time to clinic<br />
On Market various Support drug safety and product differentiate<br />
your prefilled syringes<br />
Development Services On Market complex biopharmaceutical<br />
products<br />
Commercial Manufacturing On Market complex biopharmaceutical<br />
products<br />
secondary packaging On Market pen, autoinjector, safety<br />
device assembly<br />
SENIOR MANAGEMENT<br />
Peter Soelkner, Managing Director • Oskar Gold, Vice President<br />
pre-clinical - phase II<br />
phase III - market supply, life cycle<br />
management<br />
clinical and commercial<br />
BIO Business Forum 2011 523 Participating Company <strong>Profiles</strong>
Bryan Kim<br />
Chief Executive Officer<br />
2700 Research Forest Drive, Suite 180<br />
The Woodlands, TX 77381<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
David Colvin, Sales Manager<br />
Henry Hebel, COO<br />
VGXI, Inc.<br />
Clinical Foci: Vaccines • Gene/Cell Therapy • None<br />
www.vgxii.com<br />
Phone: 1-281-296-7300<br />
Incorporated: 13<br />
Employees: 44<br />
Ownership: Private<br />
CORPORATE MISSION<br />
VGXI is a contract manufacturing organization that specializes in the production of DNA plasmids under GMP for human clinical trials.<br />
With over 13 years experience, VGXI has produced products for numerous clinical trials in the U.S., Europe and Asia. Its patented AIRMIX®<br />
manufacturing technology produces the highest quality plasmids in the industry with supercoil percentages up to 99% and final product<br />
concentrations as high as 15 mg/ml. VGXI’s highly experienced team can work with your project’s unique requirements to create a<br />
manufacturing solution that ensures the success of your clinical program.<br />
PROPRIETARY TECHNOLOGY<br />
AIRMIX® Technology<br />
INTELLECTUAL PROPERTY<br />
Patented<br />
SENIOR MANAGEMENT<br />
Bryan Kim, Chief Executive Officer • Henry Hebel, Chief Operating Officer • Jerry Brandewie, Director • Dorothy Peterson, Director •<br />
David Colvin, Marketing<br />
BIO Business Forum 2011 524 Participating Company <strong>Profiles</strong>
Rudy Dekeyser<br />
Managing Director<br />
Rijvisschestraat 120<br />
B-9052 Zwijnaarde<br />
Belgium<br />
CONFERENCE PARTICIPANTS<br />
Jan Albert Demolder, European Patent Attorney<br />
Aurelie Huser, Licensing manager<br />
VIB<br />
Clinical Foci: Drug Discovery • Diagnostics • Systems Biology<br />
www.vib.be/en/Pages/default.aspx<br />
Phone: 32-9-2446611<br />
Incorporated: 1996<br />
Employees: 1200<br />
Ownership: Private<br />
CORPORATE MISSION<br />
VIB is a research institute with 1200 employees. VIB’s main objective is gathering innovative basic knowledge on the normal and abnormal<br />
or pathological processes occurring in a cell, an organ and an organism (humans, plants, micro organisms), using gene technological<br />
research. That is why VIB conducts strategic basic research in the various life science domains.<br />
Recent VIB research led to breakthroughs in molecular and cell biology, developmental biology, genetics, cancer biology and cell death,<br />
blood vessel formation, inflammatory diseases, immunology, microbiology, neurobiology and Alzheimer’s disease, signal transduction,<br />
gene expression and regulation, functional genomics and proteomics, plant growth and development, plant systems biology and<br />
integrative biology, structure biology, glycobiology, and protein structure-function relations.<br />
The VIB researchers work in research departments of four Flemish universities: Ghent University, K.U.Leuven, the University of Antwerp<br />
and the Vrije Universiteit Brussel. The groups were selected on the basis of their excellence. Through close cooperation with these<br />
universities and a solid funding program for strategic basic research, VIB joins the forces of 1200 scientists and technologists in one single<br />
institute.<br />
VIB pursues an active technology transfer policy. VIB’s innovative research is a continuous source of new technologies and findings that<br />
can form the basis of new social and industrial applications, such as diagnostics or medicine. The ambition of VIB is to translate its<br />
scientific discoveries and insights to applications that lead to an increase in society’s quality of life. That is why VIB’s inventions are<br />
intellectually protected by patents. These are actively licensed out to national and international companies, who want to convert the<br />
inventions into useful products or applications. VIB also brings new findings to technology platforms that are the basis for setting up new<br />
bio high-tech companies.<br />
PROPRIETARY TECHNOLOGY<br />
VIB its proprietary technology is mainly situated in the biomedical and plant biotechnology field, with a focus on biologicals, targets,<br />
assays, genes important for plant growth and stress resistance and technology platforms.<br />
CORPORATE ALLIANCES<br />
VIB has executed over 600 agreements since 1996 with (bio) parmaceutical, (ag) biotech and food comapnies worldiwide. These<br />
agreements consist mainly of R&D and License agreements and yielded over 89 Mio Euro income for VIB so far. VIB also spun out 5 venture<br />
capital backed start-ups (deVGen, Cropdesign, Ablynx, Promota and ActoGeniX) and exploits three incubator facilities for biotech<br />
companies.<br />
INTELLECTUAL PROPERTY<br />
We actively pursue patent protection for our technologies and inventions, the status of which varies according to the technologie and the<br />
stage of protection.<br />
SENIOR MANAGEMENT<br />
Rudy Dekeyser, Managing Director • Jo Bury, Managing Director<br />
BIO Business Forum 2011 525 Participating Company <strong>Profiles</strong>
Dr. Stefan Beyer<br />
Managing Director<br />
Zeppelinstrasse 2<br />
27472 Cuxhaven<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Stefan Beyer<br />
CORPORATE MISSION<br />
Vibalogics GmbH<br />
Clinical Foci: Vaccines • Gene/Cell Therapy • Oncology<br />
www.vibalogics.com<br />
Phone: 49-4721-565400<br />
Ownership: Private<br />
Live viruses and bacteria as well as aseptic filling is Vibalogics’ expertise.<br />
We work on therapeutic and prophylactic vaccines, gene vectors and oncolytic viruses and are a partner for companies committed to<br />
developing innovative drugs for live-threatening diseases.<br />
Our one-stop-shop services include filling, lyophilization, cGMP-compliant manufacturing, formulation, and QC testing of drugs based on<br />
recombinant and attenuated viruses and bacteria.<br />
We offer a highly competent team of experts and a biosafety level 2 state-of-the-art facility. Four independent production suites with<br />
cleanroom class areas A-D provide a unique grade of flexibility to develop manufacturing processes and QC assays. We deliver clinical trial<br />
material including comprehensive GMP documentation and Certificates of Analysis to enable straightforward product development.<br />
PROPRIETARY TECHNOLOGY<br />
Services encompass:<br />
Cell and Seed banking, process development, cGMP manufacturing, fermentation using single-use technology and stainless steel<br />
bioreactors, aseptic filling, lyophilization, vacuum drying / foam drying, QC and stability testing (TCID50, PCR, viable cell count, Western<br />
blotting, Elisa, etc.)<br />
Experience with numerous viruses using different cell lines growing in suspension or adherently. Bacteria such as Mycobacteria,<br />
Salmonella, Listeria, can be manufactured using single-use bioreactors. Pichia cloning has recently been added to our service portfolio.<br />
SENIOR MANAGEMENT<br />
Dr. Stefan Beyer, Managing Director • Thomas Hermann, Chief Financial Officer<br />
BIO Business Forum 2011 526 Participating Company <strong>Profiles</strong>
Matt Heck<br />
Chief Executive Officer<br />
11682 El Camino Real<br />
San Diego, CA 92130<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas Heck<br />
Kevin B McAdams<br />
Victory Pharma, Inc<br />
Clinical Foci: CNS • Neurology • Specialty Pharmaceutical<br />
www.victorypharma.com<br />
Phone: 1-919-459-3930<br />
Incorporated: 2004<br />
Employees: 210<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Victory was founded in 2003 by an experienced management team that has previously built other successful specialty pharmaceutical<br />
companies. Over time, Victory has acquired a series of pain management products which we currently market to rheumatologists,<br />
orthopedists, pain specialists and selected primary care physicians. At Victory, our experienced sales representatives use their knowledge<br />
of pain and related conditions as a resource to support healthcare professionals in tailoring pain solutions to the needs of individual<br />
patients.<br />
Our lead product is NAPRELAN®, a non-steroidal anti-inflammatory drug (NSAID) acquired in late 2006. NAPRELAN, the only branded, oncedaily<br />
naproxen sodium product on the market, contains the gold standard NSAID. With the well-publicized cardiovascular toxicity<br />
concerns regarding COX-2 inhibitors, the treatment paradigm is shifting back to traditional NSAID therapies. NAPRELAN is well positioned<br />
for this shift, as it has the lowest NSAID-associated cardiovascular risk.(1,2) It also has a patent-protected delivery system that may<br />
minimize the GI irritation seen with NSAID therapies among certain patients.(3) We have significantly increased NAPRELAN sales since its<br />
re-launch in January 2007, and we believe that NAPRELAN is poised for further growth. We recently launched two additional strengths of<br />
NAPRELAN, providing physicians with greater titration flexibility for the treatment of pain.<br />
In addition to acquiring and marketing pain relief products, we have also established a development pipeline focused on meeting current<br />
challenges in pain management and related conditions. These development programs will be NDA submissions utilizing the FDA 505(b)(2)<br />
pathway and involve novel formulations, alternative delivery forms and patented combinations of prescription products that have already<br />
received U.S. regulatory approval. This development approach significantly reduces development time, cost and risk.<br />
PROPRIETARY TECHNOLOGY<br />
NAPRELAN has a patent-protected delivery system that may minimize the GI irritation seen with NSAID therapies among certain patients.<br />
CORPORATE ALLIANCES<br />
Drug Delivery and CMO's<br />
INTELLECTUAL PROPERTY<br />
Not disclosed<br />
PRODUCTS<br />
Name Phase Indication<br />
MGX-006 NDA/BLA filed, or in process Emesis<br />
MGX-001 Phase II, IIa, IIb Opiod induced sedation/ Pain<br />
Naprelan On Market Pain<br />
Xodol On Market Pain<br />
Magnacet On Market Pain<br />
Fexmid On Market Muscle relaxer<br />
Dolgic Plus On Market Headache<br />
Other NDA/BLA filed, or in process Pain<br />
Rybix ODT On Market Moderate to severe pain<br />
Moxatag On Market Anti-infective<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Round A: 03/14/2009 (US $45,000,000.00 million)<br />
SENIOR MANAGEMENT<br />
Matt Heck, Chief Executive Officer • Dan Stokely, Corporate Finance • Jim Newman, Director • Shawn Scranton, Chief Scientific Officer<br />
• Tom Heck, Business Development • Mike Goolsby, Vice President • Mike Cvijanovich, Vice President<br />
BOARD OF DIRECTORS<br />
Jim Newman, Founder • Scott Barry, Essex Woodland Health Ventures • Herb Hooper, Ampersand Ventures • David Snyder, Pillsbury<br />
Winthrop LLP • Tom Wiggins, B.O.D.<br />
BIO Business Forum 2011 527 Participating Company <strong>Profiles</strong>
Bala Venkataraman<br />
Chief Executive Officer<br />
2403 Bonshaw Lane<br />
Atlanta, GA 30064<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Rick McElheny<br />
CORPORATE MISSION<br />
Vidara Therapeutics<br />
Clinical Foci: Specialty Pharmaceutical • Skin/Dermatological • Oncology<br />
www.vidararx.com/<br />
Phone: 1-732-648-3654<br />
Incorporated: 1<br />
Employees: 4<br />
Ownership: Private<br />
Vidara Therapeutics is a specialty pharmaceutical company, which aims to execute on the proven business model of creating value<br />
through accretive product acquisitions, license agreements and life cycle management. Vidara plans to focus on therapeutic specialties<br />
including but not limited to critical care, central nervous system, oncology, urology and dermatology. These specialty markets can be<br />
effectively marketed via a specialty sales force with a specialized commercial team. Other therapeutic areas will also be strongly<br />
considered. Our goal at Bio is to connect with companies and organization that have late stage or commercialized assets that are available<br />
for divestiture or in-licensing.<br />
Vidara was founded and is led by an experienced managed team who has experience in building pharmaceutical companies, acquiring<br />
and licensing products and extending the life-cycle of these products. Vidara is financed by management, Altiva Capital, DFW Capital,<br />
Greyrock Capital Group and GE HealthCare Finance.<br />
CORPORATE ALLIANCES<br />
Altiva Capital, DFW Capital, Greyrock Capital Group and GE HealthCare Finance.<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 04/30/2010 (US $50.00 million)<br />
Investors: Bala Venkataraman (70 %) • Virinder Norhia (10 %) • Rick McElheny (10 %) • Adam Mathis (10 %)<br />
SENIOR MANAGEMENT<br />
Bala Venkataraman, Chief Executive Officer • Virinder Nohria, President • Adam Mathis, Chief Financial Officer • Rick McElheny,<br />
Chief Business Officer<br />
BOARD OF DIRECTORS<br />
Bala Venkataraman, CEO • Keith Pennell, General Partner DFW Capital Partners • Steve Dempsey, Principal Greyrock Capital Group<br />
BIO Business Forum 2011 528 Participating Company <strong>Profiles</strong>
Bill Finneran<br />
President<br />
1215 Main Street<br />
Tewksbury, MA 01876-4708<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
William A. Finneran Jr., RPh, President<br />
Kevin J. Donlan, Managing Partner<br />
Viking Healthcare Solutions, Inc<br />
Clinical Foci: Service • Specialty Pharmaceutical • Biopharmaceuticals<br />
www.vikinghcs.com<br />
Phone: 1-978-640-6300<br />
Incorporated: 2001<br />
Employees: 15<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
Viking Healthcare solutions recently reached the ten year milestone in our company history.<br />
Viking Healthcare has partnered with over 30 pharmaceutical companies in our ten year history. Numerous partners have leveraged our<br />
reimbursement insights to to achieve maximum corporate goals including IPO's, acquisition, and growth..<br />
Viking Healthcare has conducted over 50 reimbursement advisory boards to validate corporate partner reimbursement strategies and<br />
gain vital insights on pricing and managed care optimization.<br />
CORPORATE MISSION<br />
Viking HealthCare Solutions is the leader in the provision of reimbursement solutions for new and emerging pharmaceutical products.<br />
Our approach is based on a proven (10 year) track record of employees (not consultants) who average 25 years in the navigation of<br />
managed markets.<br />
We stake our claim on the continued ability to access and negotiate on our clients behalf with the highest level of reimbursement decision<br />
makers..<br />
We are the only provider of managed care account services that provides a list of full spectrum payer references to assure our access and<br />
associated relationships.<br />
We do so with a constant view on a proprietary ratio of ROI for our clients.<br />
PROPRIETARY TECHNOLOGY<br />
Viking HealthCare Solutions has developed several mechanisms to assure maximum return on investment within the reimbursement<br />
space.<br />
We do so via access to reimbursement executives (vs traditional market research participants) and leverage those contacts to create<br />
predictable scenarios for pricing and product evidence investment.<br />
We complete the cycle by providing dedicated managed care account coverage to assure continuity of reimbursement..<br />
CORPORATE ALLIANCES<br />
Viking Healthcare Solutions has been fortunate to work with over thirty pharmaceutical companies in our ten year history.<br />
We have a dedicated group of current PhRMA partners, two of whom have been with us throughout our corporate history<br />
INTELLECTUAL PROPERTY<br />
Viking Healthcare Solutions has developed several proprietary mechanisms to track PhRMA partner return on investment metrics in the<br />
managed markets space.<br />
In addition, we have proven pricing models that maximize revenue relative to traditional rebate ratios.<br />
SENIOR MANAGEMENT<br />
Bill Finneran, President • Kevin Donlan, Vice President • Bill Grunick, Vice President<br />
BIO Business Forum 2011 529 Participating Company <strong>Profiles</strong>
Bryan Dulhunty<br />
Managing Director<br />
Level 2 Suite 1b Grandview Street<br />
Sydney, NSW 2075<br />
Australia<br />
CONFERENCE PARTICIPANTS<br />
Bryan Dulhunty<br />
Viralytics Ltd<br />
Presenting Company<br />
Clinical Foci: Oncology • Immunology • Vaccines<br />
www.viralytics.com<br />
Phone: 61-2-998 84000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion of intratumoral Phase I study in late stage melanoma<br />
Commencment of Intravenious Phase I study in late stage Breast,<br />
Prostate and Melanima in Australia<br />
Commencment of intraturoral Phase I study in late stage head and<br />
Neck cancer in Australia<br />
Incorporated: 1986<br />
Employees: 15<br />
Ownership: Public<br />
Market Cap: $60.00 million<br />
ASX: VLA<br />
Phase II melanoma IND application lodged<br />
Completion of Intravenious Phase I study in late stage Breast,<br />
Prostate and Melanima in Australia.<br />
Completion of intraturoral Phase I study in late stage head and<br />
Neck cancer in Australia<br />
CORPORATE MISSION<br />
Phase II clinical development of coxsackie A21 virus for the treatment of a range of cancers under an authorised IND (Oncolytic<br />
virotheraphy)<br />
Preclinical development of other Oncolytic viruses<br />
Listed on the Australian Securities Exchange (vla) and trading under an pink sheets ADR program (VRACY)<br />
PROPRIETARY TECHNOLOGY<br />
patent famalies covering the coxsackie and echo viruses<br />
INTELLECTUAL PROPERTY<br />
Coxsackie family patents granted in USA and Europe as well as other world jurusidictions<br />
Echo family patents granted in USA and Europe as well as other world jurusidictions<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Cavatak (coxsackievirus A21) Phase II, IIa, IIb metatastic tumours FDA IND application made for<br />
Phase II trial<br />
Evatak (echo virus) Preclinical ovarian and prostate cancer<br />
SENIOR MANAGEMENT<br />
Bryan Dulhunty, Managing Director • Professor Darren Shafren, Chief Scientific Officer • Stephen Goodall, Chief Operating Officer<br />
BOARD OF DIRECTORS<br />
Paul Hopper, Chairman • Peter Molley, Non-excecutive director • Phillip Altman, Non-executive director • Bryan Dulhunty,<br />
Managing director<br />
BIO Business Forum 2011 530 Participating Company <strong>Profiles</strong>
Mr. Eric Marée<br />
President & CEO<br />
BP 27<br />
06511 CARROS CEDEX<br />
France<br />
CONFERENCE PARTICIPANTS<br />
VIRBAC LABORATORIES<br />
Clinical Foci: Veterinary • Drug Development<br />
www.virbac.com<br />
Phone: 33-4-92087100<br />
Dominique Saunier<br />
Virginie ALLIX, Licensing Manager, Corporate Product Innovation<br />
Benoit CHATRENET<br />
Incorporated: 1968<br />
Employees: 3150<br />
Ownership: Public<br />
Market Cap: $1100.00 million<br />
PARIS STOCK EXCHANGE: VIRP<br />
HIGHLIGHTS<br />
Recent<br />
Strong sales growth in the first quarter: Virbac consolidated sales in the first quarter reached 159.9 M€, a +17.7% change compared to the<br />
same period of 2010. Sales increased by +14.1% excluding exchange rates impacts and +12.3% at constant scope.<br />
2010 RESULTS: Historic growth of sales and net earnings<br />
CORPORATE MISSION<br />
Founded in 1968 by a French veterinarian, Virbac is the first independant laboratory worldwide, exclusively dedicated to animal health.<br />
Present in more than 100 countries, the company offers a comprehensive range of products and services intended for veterinarians,<br />
farmers and animal owners.<br />
8th veterinary pharmaceutical company in the world<br />
Production site in 7 countries<br />
Research centres in 5 countries<br />
3150 employes<br />
Among our flagship products, many are coming from working with biotech companies: Leucogen (the first vaccine produced by genetic<br />
engineering against a retrovirus), Virbagen omega (the first veterinary interferon), Ypozane (hormonal treatment against benign prostatic<br />
hyperplasia ), Sphérulites (microspheres to deliver actives ingredients used in many dermatological products or cosmetics),… For a<br />
biotechnology company working on animal models is often a mandatory step whatsoever for obtaining "proof of concept" or during the<br />
various phases of human development (toxicity studies, pharmacology, ..). Virbac may be a partner to develop a parallel project for<br />
animals through its expertise in the veterinary field, whether regulatory, development, production, marketing or sales to veterinarians<br />
and animal owners. The veterinary treatment being on the market more quickly, it helps to valorize the results, and also, to finance the<br />
development in human medicine. Virbac is always looking for new projects from the field of biotechnology to develop products and<br />
services for pets, livestock and horses. Our areas of expertise and interest are numerous: internal and external pest control, vaccines,<br />
antibiotics, food, food supplements, dermatology, cosmetic and hygiene, immunology, cardiology, oncology, behavior, geriatrics, ... We are<br />
open to any project in phase of development, whatever its stage, whether it is a product or an active ingredient, a pharmaceutical process<br />
or a new technology/process.<br />
SENIOR MANAGEMENT<br />
Mr. Eric Marée, President & CEO<br />
BOARD OF DIRECTORS<br />
Mr. Eric Marée, Chairman of the Executive Board • Mr. Pierre Pagès, Chief Operating Officer and Member of the Executive Board • Mr<br />
Christian Karst, Corporate development director and Member of the Executive Board • Mr Michel Garaudet, Chief Financial Officer and<br />
Member of the Executive Board • Mr Jean-Pierre Dick, Responsible for special projects, Chairman of the Virbac Foundation, and Member<br />
of the Executive Board<br />
BIO Business Forum 2011 531 Participating Company <strong>Profiles</strong>
Yong-Soo Kim<br />
Chief Executive Officer<br />
5th Floor, Bldg 203<br />
Seoul National University<br />
599 Gwanak-ro Gwanak-gu Seoul 151-747<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Paul Kim, Vice President, Chief Business Officer<br />
Youngtae Hong, Section Chief, Strategic Business Dev.<br />
ViroMed Co., Ltd.<br />
Clinical Foci: Drug Development • Cardiovascular Disease • Hematology<br />
www.viromed21.com<br />
Phone: 82-2-2102-7200<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Completion of patient enrolment in Phase I / II trials of VM202 for<br />
Diabetic Peripheral Neuropathy in the US.<br />
Progression of patient enrollment in Phase II trial of VM202 for<br />
Critical Limb Ischemia in the US and Korea.<br />
Commencement of Phase I trial of VM206 ( Her2 / neu DNA cancer<br />
vaccine ) for breast cancer in Korea.<br />
Incorporated: 1996<br />
Employees: 71<br />
Ownership: Public<br />
Market Cap: $5.55 million<br />
KOREA STOCK EXCHANGE: 084990<br />
IND approval of Phase II trial of VM202 for Diabetic Peripheral<br />
Neuropathy in the US.<br />
Completion of patient enrollment in Phase II trial of VM202 for<br />
Critical Limb Ischemia in the US.<br />
IND approval of Phase II trial of VM202 for Critical Limb Ischemia in<br />
China.<br />
CORPORATE MISSION<br />
ViroMed Co., Ltd. [KOSDAQ: 084990] (to be known as VM BioPharma in the US from July 2011 onwards) is a leading biotechnology<br />
company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus:<br />
DNA/protein-based biopharmaceuticals and phytotherapeutics (botanical drugs/nutraceuticals). ViroMed has in its pipeline products<br />
targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials in the US, Korea, and China. The company has<br />
established several key partnerships with global firms including Johnson & Johnson (Biologics Delivery Systems Group of Cordis Corp.,<br />
USA), Beijing Northland Biotech (China), SBI Biotech (Japan), and Reyon Pharmaceutical (Korea).<br />
PROPRIETARY TECHNOLOGY<br />
ViroMed's proprietary technology includes: naked DNA plasmid vector, HGF-X7 (two isoforms of HGF protein naturally expressed from a<br />
single HGF gene), recombinant proteins, therapeutic cancer vaccine targeting Her2 / neu antigen, phytotherapeutic compounds.<br />
CORPORATE ALLIANCES<br />
Viromed is in co-development with Biologics Delivery System Systems group of Cordis Corporation, a Johnson & Johnson company, to<br />
deliver the company’s VM202 using the NOGA Cardiac Navigation System and the Myostar injection catheter. The company has ongoing<br />
partnerships with Beijing Northland Biotech (China), Cobra Biomanufacturing Plc (UK), Efficas, Inc. (US), Oxford Biomedica Plc (UK), and SBI<br />
Biotech (Japan). In Korea the company has ongoing and scheduled clinical trials in collaboration with PMG Pharm, Reyon Pharm and Yuhan<br />
Corporation, all of which are among the largest and most respected pharmaceutical companies in Korea.<br />
INTELLECTUAL PROPERTY<br />
As of May 31st, 2011, ViroMed has 79 issued patents and 90 pending patents worldwide, including US, EU and Japan, for technologies in<br />
therapeutic genes, gene delivery vectors and phytotherapeutic compounds.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VM 202 Phase II, IIa, IIb Critical Limb Ischemia, Coronary Artery Disease, Diabetic<br />
Peripheral Neuropathy<br />
Phase II US trial commenced (May 2010)<br />
VM 501 Phase II, IIa, IIb Chemotherapy-induced thrombocytopenia Phase III commencement (Summer 2011)<br />
VM 206 Phase I Her2 / neu positive breast and ovarian cancer Phase I commenced (2010)<br />
PG 201 Phase III Arthritis (RA and OA) NDA submission by 2011<br />
SENIOR MANAGEMENT<br />
Yong-Soo Kim, Chief Executive Officer • Brian Ahn, Chief Operating Officer • Paul Kim, Vice President • Sungchul Kim, Chief Financial<br />
Officer • Seung Shin Yu, PhD, Director • Jong-Mook Kim, PhD, Director • Sheila Yi, Director • Seon-Hee Kim, PhD, Director<br />
BOARD OF DIRECTORS<br />
Yong-Soo Kim, CEO • Jong-Mook Kim, PhD, Director • Brian Ahn, COO • Sungchul Kim, CFO<br />
SCIENTIFIC ADVISORY BOARD<br />
Ken-ichi Arai, University of Tokyo • Chang-Yuil Kang, Seoul National University<br />
BIO Business Forum 2011 532 Participating Company <strong>Profiles</strong>
Jeffrey S. Hatfield<br />
Chief Executive Officer<br />
502 West Office Center Drive<br />
Fort Washington, PA 19034<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Christine Brennan, PhD, Chief Business Officer<br />
Andrew Hardy<br />
Vitae Pharmaceuticals, Inc<br />
Presenting Company<br />
Clinical Foci: Renal • Metabolic Disease • Chemistry<br />
www.vitaepharma.com<br />
Phone: 1-215-461 2000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Successful end of Phase I meeting with FDA for VTP-27999 (Nov.<br />
2010)<br />
Animal (rodent and monkey) proof-of-principle established within<br />
12 months of start of the LXR modulator program for<br />
atherosclerosis (Dec. 2010)<br />
Completion of Phase I for Vitae’s renin inhibitor, VTP-27999 (Oct.<br />
2010)<br />
Incorporated: 8<br />
Employees: 55<br />
Ownership: Private<br />
Initiation of the Phase 2b trial for VTP-27999 (expected in 4Q 2011).<br />
Initiation of GLP preclinical development for the atherosclerosis<br />
program (expected by 3Q 2011).<br />
Establishing in vivo reverse cholesterol transport for the LXR<br />
modulator program (expected 4Q 2011)<br />
CORPORATE MISSION<br />
Vitae is a clinical-stage biopharmaceutical company building a portfolio of novel, small molecule, best-in-class compounds that address<br />
large markets with significant unmet medical needs, including chronic kidney disease, diabetes, Alzheimer’s disease and atherosclerosis.<br />
Vitae is financially sound with multiple years of cash runway; our last venture round was in 2004.<br />
• Vitae’s lead compound, VTP-27999, is a novel, potent and selective renin inhibitor designed to offer a best-in-class therapeutic<br />
profile for kidney protection compared to current therapeutics (ACE, ARBs, aliskiren). VTP-27999 will enter Phase IIb in 4Q2011<br />
• Vitae has partnered two of its programs, in diabetes (11beta-HSD-1 in Phase I studies) and Alzheimer’s disease (BACE inhibitor in<br />
preclinical development), with Boehringer Ingelheim. To date, the two partnerships have generated more than $100 million for Vitae in<br />
upfront, research and milestone payments and are expected to enable a steady flow of additional, contingent milestone payments.<br />
• Vitae's fourth program is a selective LXR modulator for atherosclerosis. It was initiated in 1Q2010 and has progressed rapidly<br />
with novel chemistry discovered and preclinical (rodent and monkey) proof-of-concept data within 12 months.<br />
Each of Vitae’s programs were generated via our proprietary, structure-based drug discovery engine. Vitae's engine plus the experience<br />
and insights of a world-class R&D team address the 3 main issues facing small molecule discovery - novelty, speed and capital efficiency.<br />
PROPRIETARY TECHNOLOGY<br />
Vitae’s proprietary, structure-based drug discovery engine delivers novelty, speed and capital efficiency, enabling the discovery of potent,<br />
bioavailable compounds active against hard-to-drug yet validated therapeutic targets. The platform contributes to lead optimization,<br />
enhancing appropriate drug-like characteristics related to bioavailability, potency and pharmacokinetics.<br />
Vitae’s engine has produced our pipeline of 4 programs, tackling very hard to drug targets such as renin and beta-secretase. Vitae has<br />
consistently been able to produce novel, patentable, compound leads within 2-6 months and been able to generate animal proof-ofconcept<br />
data within 14-16 months from the start of a program.<br />
CORPORATE ALLIANCES<br />
Vitae’s 11beta-hydroxysteroid dehydrogenase (HSD)-1 inhibitor program for diabetes was partnered with Boehringer Ingelheim in 2007<br />
and is currently in Phase I development.<br />
In 2009, Vitae’s beta-secretase (BACE) program for Alzheimer’s disease is partnered with Boehringer Ingelheim. The BACE program is on<br />
track.<br />
INTELLECTUAL PROPERTY<br />
The lead program, VTP-27999, for chronic kidney disease has extensive worldwide patent filings. Composition of matter patent<br />
applications are pending and/or allowed in 32 countries, including all major markets. Worldwide composition protection is expected<br />
through 2026 with the potential for extension.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
VTP-27999 renin inhibtor for<br />
chronic kidney disease<br />
LXR Modulator for<br />
Atherosclerosis<br />
Phase I Chronic kidney disease / diabetic<br />
nephropathy<br />
Phase IIb will start in 4Q2011<br />
Preclinical Atherosclerosis Preclinical candidate selected by 1Q 2010<br />
BIO Business Forum 2011 533 Participating Company <strong>Profiles</strong>
FINANCING HISTORY<br />
Most Recent Round: B Round<br />
Round B: 01/12/2004 (US $15.00 million)<br />
SENIOR MANAGEMENT<br />
Jeffrey S. Hatfield, Chief Executive Officer • Richard E. Gregg, MD, Chief Scientific Officer • Tina L. Fiumenero, Chief Financial Officer •<br />
Christine Brennan, PhD, Chief Business Officer • David Claremon, PhD, Vice President • Jerry McGeehan, PhD, Vice President • Joanna<br />
Balcarek, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Donald Hayden • Robert V. Gunderson, Jr., Senior Partner Gunderson, Dettmer, Stough, Villeneuve, Franklin & Hachigian, LLP • Jeffrey<br />
S. Hatfield, CEO, Vitae Pharmacueticals • Charles Newhall, III, General Partner, New Enterprise Associates • Bryan Roberts, Ph.D,<br />
General Partner, Venrock Associates • James Tananbaum, MD, Founder and CEO, Foresite Capital Management • Peter Barrett, PhD,<br />
Senior Partner, Atlas Venture<br />
SCIENTIFIC ADVISORY BOARD<br />
Eugene Shakhnovich, PhD, Professor of Chemistry, Harvard University • William L. Jorgenson, PhD, Whitehead Professor of Chemistry,<br />
Yale University • Michael Milburn, PhD, Chief Scientific Officer, Metabolon, Inc. • Brian Shoichet, PhD, Professor, University of<br />
California, San Francisco • Pierre Corvol, MD, PhD, Professor of Experimental Medicine, Collège de France, Paris • Norman K.<br />
Hollenberg, MD, PhD, Professor of Medicine, Harvard Medical School / Brigham & Women's Hospital, Boston, MA • Domenic A. Sica, MD,<br />
Professor of Medicine and Pharmacology, Virginia Commonwealth University Health System<br />
BIO Business Forum 2011 534 Participating Company <strong>Profiles</strong>
Pascal BRETON<br />
Chief Executive Officer<br />
31 avenue Monge<br />
37200 Tours<br />
France<br />
CONFERENCE PARTICIPANTS<br />
Pascal Breton, PhD, Chief Executive Officer<br />
VitamFero<br />
Clinical Foci: Vaccines • Veterinary • Infectious Disease<br />
Phone: 33-2-4736 7047 Incorporated: 2005<br />
Employees: 9<br />
Ownership: Private<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
VitamFero raised €1.1 million (seed round) from CapDecisif Management and G1J<br />
Ile-de-France two well-regarded venture funds on January 28, 2011 operating in<br />
Paris area<br />
VitamFero is the first organization in the world who has held a live and attenuated<br />
strain of Neospora caninum, a vaccine candidate for which it can precisely describe<br />
and document the molecular origin of the attenuation.<br />
To reinforce its technology and Know-How in the modification of apicomplexa<br />
parasite genome, VitamFero recently executed an Research and Licensing<br />
Agreement with Cellectis (Romainville, France). VitamFero has now an access to<br />
Cellectis' meganucleases<br />
Hopefully, VitamFero will raise €0.8 million from<br />
French VCs before 2011 ends<br />
VitamFero is to file a patent application to cover<br />
the results it obtained with its bovine<br />
cryptosporidiosis vaccine<br />
VitamFero is to confirm the efficacy of its feline<br />
toxoplasmosis vaccine<br />
CORPORATE MISSION<br />
VitamFero is a young French biotech company which is developing proprietary anti-parasite live attenuated vaccines (ovine<br />
toxoplasmosis, bovine neosporosis and cryptosporidiosis, etc) primarily dedicated to animal health. Incorporated in 2005 in Tours (France),<br />
in the heart of the magnificient Loire Valley and its famous Renaissance Châteaux, VitamFero is also aiming at opportunely developing its<br />
anti-parasite vaccines against human parasitoses such as toxoplamosis (congenital toxoplasmosis ans acquired ocular toxoplasmosis),<br />
cryptosporidiosis or malaria, the prevention of which remains a huge medical unmet need. Founded and headed by Dr. Pascal Breton<br />
(CEO), who holds 20 years of experience in the pharma and biopharma industry in Europe and in North-America and Dr. Edouard Sèche<br />
(CSO), who started is carreer within the company, VitamFero has currently 10 employees, mostly scientists with a strong expertise in<br />
molecular biology, immunology and vaccinology. Since inception, VitamFero has received more than €2 million in subsidies and grants<br />
from public organizations as well as about €1.5 million capital venture from founders, Business Angels and very well-regarded French VCs.<br />
PROPRIETARY TECHNOLOGY<br />
VitamFero's anti-parasite vaccine technology is based on a proprietary, live and attenuated Toxoplasma gondii strain called Toxo KO which<br />
was established by a deletion of two genes encoding for microneme proteins that ease asexual parasite growth in mammal host cells. This<br />
well-documented, fully described and controlled double deletion process meets requirements of regulatory dossier and, contrarily to most<br />
of other animal live attenuated vaccines available, prevents any chance of return to virulence. Futhermore, Toxo KO appears as a very<br />
promising platform of technology to elaborate novel vaccines directed against other apicomplexa parasites (Neospora caninum,<br />
Cryptosporidium parvum,...) and other infectious agents.<br />
CORPORATE ALLIANCES<br />
VitamFero is looking for industrial partners to co-develop, license and distribute its animal vaccines and, possibly, its human vaccines<br />
against toxoplasmosis (congenital toxoplasmosis and acquired ocular toxoplasmosis), cryptosporodiosis, malaria, etc. Currently,<br />
VitamFero has alliances with French academic research laboratories and institutes (INRA, CNRS and French universities of Tours, Bordeaux<br />
and Burgundy in Dijon). In addition VitamFero just recently executed an R&D collaboration and license agreement with Cellectis<br />
(Alternext: ALCLS) to get access to the proprietary meganuclease-based technology.<br />
INTELLECTUAL PROPERTY<br />
VitamFero holds worldwide and exclusive rights on patents and patent applications covering, a live attenuated strain of Toxoplasma<br />
gondii (Toxo KO), its use as a toxoplasmosis vaccine and pharmaceutical compositions containing it. Patents are issued in Europe (16<br />
countries), the US, Australia, New-Zealand and South-Africa and are pending in Japan, Canada, India and Brazil. In Europe, it covers not<br />
only Toxo KO, but all other double knocked-out apicomplexa parasites such as Neospora caninum. VitamFero also holds rights from<br />
Cellectis to use proprietary meganucleases. Shortly, VitamFero will file a patent application to cover a novel and innovative bovine<br />
cryptosporidiosis vaccine. Within the next 24 months, VitamFero should be in a position to file 5 additional patent applications.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Ovine toxoplasmosis vaccine Phase I Ovine toxoplasmosis Completion of pharmaceutical development (end of<br />
2011/beginning of 2012)<br />
Bovine neosporosis vaccine Preclinical Bovine neosporosis Proof-of-Concept established in ruminants (end of 2011 /<br />
beginning of 2012)<br />
BIO Business Forum 2011 535 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Feline toxoplasmosis vaccine Preclinical Feline toxoplasmosis Confirmed Proof-of-Concept established in cats (end of 2011<br />
/ beginning of 2012)<br />
Bovine cryptosporidiosis<br />
vaccine<br />
Preclinical Bovine cryptosporidiosis Proof-of-Concept established in ruminants (end of 2011)<br />
Canine leishmaniosis vaccine Research Canine leishmaniosis Proof-of-Concept established in dogs (2013)<br />
Avian coccidiosis vaccine Research Avian coccidioses Proof-of-Concept established in chicken (2013)<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 01/28/2011 (US $0.90 million)<br />
Investors: CapDecisif Management (34 %) • Val de France Angels (a group of Business Angels) (28 %) • Founders<br />
(Pascal BRETON, Edouard SECHE and Alain DE LA BIGNE) (27 %) • G1J Ile-de-France (8 %) • Technology<br />
Inventors (3 %)<br />
SENIOR MANAGEMENT<br />
Pascal BRETON, Chief Executive Officer • Edouard SECHE, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Pascal BRETON, VitamFero • Edouard SECHE, VitamFero • Catherine BOULE, CapDecisif Management • Jérôme SNOLLAERTS,<br />
CapDecisif Management • Patrice MESNIER, CapDecisif Management / G1J Ile-de-France • Alain DE LA BIGNE, Lafarge / Independent<br />
advisor • Michel PAILLAT, Entrepreneur<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Isabelle DIMIER-POISSON, PhD, François-Rabelais University of Tours, Tours, France • Prof. Marie-Laure DARDE, PhD, University of<br />
LImoges, Limoges, France • Dr. Thierry BARDON, DVM, Former CSO of CEVA Santé Animale (Libourne, France) • Dr. Elskild PETERSEN,<br />
MD, Aarhus University Hospital, Aarhus, Denmark • Dr. Andrew HEMPHILL, PhD, University of Bern, Bern, Switzerland<br />
BIO Business Forum 2011 536 Participating Company <strong>Profiles</strong>
Joan Ballesteros, PhD<br />
President<br />
Plaza de Madrid no. 6, Entreplanta<br />
47004 Valladolid<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Andres Ballesteros<br />
Joan Ballesteros<br />
Vivia Biotech<br />
Clinical Foci: Hematology • Oncology • Drug Development<br />
www.viviabiotech.com<br />
Phone: 34-649-985942<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Vivia is launching at the end of this 2011 a novel Personalized<br />
Medicine test for hematological malignancies, validated by Spain’s<br />
hematologists and the public health system.<br />
Vivia009 intravenous is a drug candidate for NHL that will initiate<br />
Phase I-II trials Q4 2011, with a unique profile lacking<br />
hematotoxicity and previously unachieved lymph node<br />
distribution and efficacy. Vivia009 is positioned for the largest<br />
market.<br />
Vivia has entered into and is currently developing a research<br />
collaboration agreement with a top 20 multinational<br />
pharmaceutical company, directly with its US headquarters.<br />
Employees: 26<br />
Ownership: Private<br />
Enter market in Q4 2011 personalized medicine test in HMs<br />
capable of identifying, ahead of treatment, the protocol treatments<br />
to which the patient is more likely to respond/be resistant to,<br />
among all approved and experimental protocols for a given HM<br />
Vivia expects to start Phase I-II trials in Q4 2011 of Vivia009<br />
intravenous for NHL.<br />
Vivia expects to validate at preclinical level a non-cytotoxic<br />
candidate in rheumatoid arthritis by Q-3 2011.<br />
CORPORATE MISSION<br />
Vivia pioneers Systems Biology screening of thousands of drugs directly in patient samples, focused on Hematological Cancers (HC) and<br />
Autoimmune Disorders. Vivia offers two distinct applications:<br />
PERSONALIZED MEDICINE:<br />
Vivia has developed a novel ex vivo test that identifies the optimal treatment for each individual patient evaluating the efficacy of all<br />
potential treatments in fresh patient samples. This is the first test able to evaluate the efficacy of multidrug treatments, including<br />
mixtures of biologics with small molecules, the clinical reality that molecular tests cannot manage. Hundreds of drug combinations are<br />
screened for their ability to eliminate tumor cells in whole blood samples. Actionable data for the hematologist include classifying<br />
treatments as highly resistant or highly sensitive. Vivia has achieved a rather unique alliance with a medical association and a public<br />
health system to make reality the promise of Personalized Medicine in HCs.<br />
The company is extending these ex vivo tests to autoimmune diseases such as Rheumatoid Arthritis.<br />
Related to testing a drug combined with all other drugs in a disease area, we offer as a service profiling your existing drugs directly in<br />
human patient samples, alone and in combination with approved drugs, in several indications of Hematological Malignances and in<br />
Autoimmune Diseases. Our screening provides human sample data with the highest legal, ethical and traceability standards required for<br />
regulatory submission to the FDA or the EMEA. Our research model has proven its capacity to efficiently identify new drug candidates. Our<br />
ex-vivo test can also be used as a biomarker of efficacy in clinical trials.<br />
NEW INDICATIONS FOR DRUG ENANTIOMERS<br />
Vivia is pioneering screening of 2.000 known drugs per day per patient sample of HCs and autoimmune diseases such as RA. This enables<br />
the company to identify the very best candidates ex vivo. A new indication of an existing drug facilitates quick clinical PoC.<br />
PROPRIETARY TECHNOLOGY<br />
We have developed a proprietary ex vivo screening technology called ExviTech based on automating the standard clinical technique to<br />
evaluate blood and bone marrow samples for diagnosis of HCs: flow cytometry. ExviTech is able to analyze the effect of thousands of<br />
existing drugs (or combinations) directly on a patient's sample while it is still fresh (24/48 hours after its extraction). In our research in<br />
HCs, we use gold standard measurements of apoptosis by Annexin V in whole blood samples. We distinguish malignant and healthy cells<br />
using gold standard antibodies, to quantify the level of selective elimination of malignant cells of a given compound or combination.<br />
CORPORATE ALLIANCES<br />
Vivia Biotech has outstanding colaborations with large mutinational US pharma companies.<br />
INTELLECTUAL PROPERTY<br />
Vivia has patents granted with respect to the core exclusivity of it ExviTech Platform. Vivia has patent applications submitted for its<br />
personalized medicine test and its candidate for NHL.<br />
BIO Business Forum 2011 537 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Vivia 009 Preclinical Chronic Lymphocytic Leukemia,<br />
Multiple Myeloma and Non-<br />
Hodgkin Lymphoma<br />
Drug Profiling in Patient<br />
Samples<br />
Research Hematological Malignances and<br />
Autoimmune Disorders<br />
Personalized Medicine Test Diagnostics Multiple Myeloma, CLL & AML Sales start Q4 2011<br />
FINANCING HISTORY<br />
Most Recent Round: A Round<br />
Seed Round: 07/20/2007 (US $1.00 million)<br />
Round A: 08/20/2008 (US $4.00 million)<br />
Phase I Clinical Trial Q-4 2010 - Available for<br />
partnering or outlicensing<br />
Efficient identification of synergies of your drug<br />
candidate with existing treatments and phase III<br />
candidates<br />
SENIOR MANAGEMENT<br />
Joan Ballesteros, PhD, President • Andrés Ballesteros, Chief Executive Officer • Fernando Rodriguez, Vice President • Luis Caveda,<br />
PhD, Vice President • Teresa Bennett, PhD, Vice President • Julieta Montejo PhD, Chief Medical Officer<br />
BIO Business Forum 2011 538 Participating Company <strong>Profiles</strong>
Leland Wilson<br />
Chief Executive Officer<br />
1172 Castro Street<br />
Mountain View, CA 94040-2552<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Timothy Morris<br />
VIVUS, Inc<br />
Clinical Foci: Metabolic Disease • Urological • Drug Development<br />
www.vivus.com<br />
Phone: 1-650-934-5200<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
FDA meeting on April 14, 2011 and reached agreement on the<br />
design elements of FORTRESS, a retrospective study of fetal<br />
outcomes of infants born to mothers exposed to topiramate during<br />
pregnancy<br />
Publication of phase 3, CONQUER study in Lancet<br />
Presentation of long-term safety and efficiacy study of avanafil at<br />
2011 AUA meeting<br />
Incorporated: 1991<br />
Employees: 45<br />
Ownership: Public<br />
Market Cap: $650.00 million<br />
NASDAQ: VVUS.O<br />
Submission of avanafil NDA Q2 2011<br />
Top-line results of TA-303, Study of the Safety and Efficacy of<br />
Avanafil in the Treatment of Erectile Dysfunction Following<br />
Bilateral, Nerve-sparing, Radical Prostatectomy<br />
Top-line results of FORTRESS Q4 2011<br />
CORPORATE MISSION<br />
VIVUS, Inc. is a biopharmaceutical company, incorporated in 1991 as a California corporation and reincorporated in 1996 as a Delaware<br />
corporation, dedicated to the development and commercialization of therapeutic drugs for large underserved markets, including obesity<br />
and related morbidities, such as sleep apnea and diabetes, and men’s sexual health. With respect to obesity, it is estimated that the<br />
potential worldwide pharmaceutical market for obesity could approach $5 billion annually. Annual sales of approved drugs for diabetes<br />
currently exceed $10 billion. There are currently no approved pharmaceutical therapies for sleep apnea; however, the sales of devices and<br />
related consumables used to treat sleep apnea exceed $2 billion annually. Annual sales of approved drugs for erectile dysfunction<br />
currently exceed $4 billion. The indications targeted by our investigational drug candidate as a treatment for erectile dysfunction<br />
represent a projected market greater than $1 billion annually.<br />
Currently, we have one investigational drug candidate, QNEXA, which is under review by regulators has been submitted for approval as a<br />
treatment for weight loss in the U.S. and the European Union. In the U.S., we received a CRL for QNEXA in October 2010, which contained<br />
requests for additional information. We held a meeting with the FDA on April 14, 2011 to discuss their request to complete a retrospective<br />
study of fetal outcomes in infants born to women exposed to topiramate during pregnancy. We have agreed to the design elements of the<br />
study, dubbed FORTRESS, which should be completed in Q4 2011. Our goal is to resubmit the QNEXA NDA in Q4 2011.<br />
We also have investigational drug candidates in various stages of clinical development for various indications related to obesity, erectile<br />
dysfunction and other diseases.<br />
PROPRIETARY TECHNOLOGY<br />
QNEXA is our proprietary oral investigational drug candidate for the treatment of obesity, incorporating low doses of active ingredients<br />
from two previously approved drugs, phentermine and topiramate. We believe that by combining these compounds, QNEXA targets<br />
excessive appetite and high threshold for satiety, or the feeling of being full, the two main mechanisms that impact eating behavior.<br />
QNEXA is a once-a-day capsule containing a proprietary formulation of controlled release phentermine and topiramate.<br />
CORPORATE ALLIANCES<br />
Avanafil is an oral PDE5 inhibitor investigational drug candidate that we licensed from Tanabe Seiyaku Co., Ltd., or Tanabe, in 2001. In<br />
October 2007, Tanabe and Mitsubishi Pharma Corporation completed their merger and announced their name change to Mitsubishi<br />
Tanabe Pharma Corporation, or MTPC.<br />
INTELLECTUAL PROPERTY<br />
Our first U.S. patent on QNEXA (U.S. 7,056,890 B2) and our EU patent on QNEXA (EU EP 1187603) both expire in 2020.<br />
Our U.S. patent on avanafil (U.S. 6,656,935) expires in 2020.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
QNEXA NDA/BLA filed, or in process Obesity Refilling NDA Q4 2011<br />
Avanafil NDA/BLA filed, or in process Erectile Dysfunction NDA filing Q2 2011<br />
SENIOR MANAGEMENT<br />
Leland Wilson, Chief Executive Officer • Peter Tam, President • Tim Morris, Chief Financial Officer • Mike Miller, Chief Business Officer<br />
BIO Business Forum 2011 539 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Mark Logan, past CEO Visx • Chuck Casamento, SAGE Group • Linda Shortliff, Stanford • Leland Wilson, CEO • Peter Tam, President<br />
BIO Business Forum 2011 540 Participating Company <strong>Profiles</strong>
Martin Simonetti<br />
Chief Executive Officer<br />
307 Westlake Avenue North<br />
Seattle, WA 98109<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
VLST Corporation<br />
Presenting Company<br />
Clinical Foci: Immunology • AutoImmune<br />
www.vlstcorp.com<br />
Teresa Foy, Chief Scientific Officer<br />
Ron Myers, JD, VP, Corporate Development & Legal Affairs<br />
Martin A. Simonetti, MS, MBA, CEO & President<br />
Brian Blackman<br />
Phone: 1-206-262-5500<br />
Incorporated: 2004<br />
Employees: 33<br />
Ownership: Private<br />
CORPORATE MISSION<br />
VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel<br />
therapeutics for the treatment of inflammatory and autoimmune disorders.<br />
PROPRIETARY TECHNOLOGY<br />
VLST has developed a streamlined and efficient proprietary platform that rapidly yields novel biological therapeutic compositions of<br />
matter with a far greater likelihood of success in clinical trials, particularly in autoimmune and inflammatory disorders.<br />
The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying<br />
new targets for the development of novel biologic therapies. Moreover, the process used to identify targets also provides a clear path to<br />
developing biologic molecules that can be used for target validation studies. The VLST approach reduces the time to clinical development<br />
and improves the likelihood of clinical success.<br />
CORPORATE ALLIANCES<br />
In December 2008, VLST announced its collaboration with Novo Nordisk to develop novel theurapeutics for the treatment of inflammatory<br />
disorders.<br />
In March 2010, VLST entered into a collaboration with Takeda San Francisco on early target discovery.<br />
In December 2010, VLST entered into a collaboration with UCB on early target discovery.<br />
INTELLECTUAL PROPERTY<br />
VLST has several pending patent applications which cover its propietary platform and lead programs.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
AntiKine Preclinical Autoimmune IND Filing - 2012<br />
FINANCING HISTORY<br />
Most Recent Round: C Round<br />
Round A: 05/01/2004 (US $4.75 million)<br />
Round B: 06/01/2006 (US $35.10 million)<br />
Round C: 12/01/2008 (US $5.00 million)<br />
Investors: ARCH Ventures (18 %) • OVP Partners (17 %) • MPM Capital (9 %) • TPG Growth (9 %) • Amgen<br />
Ventures (7 %) • Novo Nordisk Ventures (8 %) • MedImmune Ventures (4 %) • WRF Capital (2 %) •<br />
Versant (1 %)<br />
SENIOR MANAGEMENT<br />
Martin Simonetti, Chief Executive Officer • Brian Blackman, Vice President • Ron Myers, MS, J.D., Vice President • Dr. Teresa Foy,<br />
PhD., Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Dr. Steven Gillis, PhD, Arch Venture • Gerard Langeler, OVP Venture Partners • Greg Sessler, Spiration • Martin Simonetti, VLST Corp<br />
• Dr. David Urdal, PhD, Dendreon Corporation<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Craig Smith, PhD, Sr. Scientific Fellow, Founder<br />
BIO Business Forum 2011 541 Participating Company <strong>Profiles</strong>
Dr. Hans-Rainer Jaenichen, Dipl.-Biol.<br />
Partner<br />
Siebertstrasse 3<br />
81675 81675 Munich<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Hans-Rainer Jaenichen<br />
Juergen Meier<br />
Georg Andreas Rauh<br />
HIGHLIGHTS<br />
Recent<br />
50 Years anniversary in 2011<br />
Vossius & Partner<br />
www.vossiusandpartner.com<br />
Phone: 49-89-413040<br />
Incorporated: 1961<br />
Employees: 230<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Vossius & Partner is a partnership of patent attorneys and attorneys-at-law with offices in Munich, Berlin and Basel. Established in Munich<br />
in 1961, it is today one of Europe‘s leading IP firms with clients from all over the world. The firm focuses on high-end advice for innovative<br />
companies concerning all questions associated with the protection of industrial property rights. The firm‘s areas of expertise comprise all<br />
IP fields (patents, trademarks, copyrights, design rights, SPCs etc.), as well as competition law, pharmaceutical law, media law and food<br />
law.<br />
SENIOR MANAGEMENT<br />
Dr. Hans-Rainer Jaenichen, Dipl.-Biol., Partner • Baroness Alexa von Uexküll, B.Sc. M.Sc., Ph.D, Partner • Dr. Joachim Wachenfeld,<br />
Biol., Partner • Dr. Friederike Stolzenburg, Dipl.-Biol., Partner • Dr. Jürgen Meier, Dipl.-Biol., Partner • Frank Bollmann, Managing<br />
Director<br />
BIO Business Forum 2011 542 Participating Company <strong>Profiles</strong>
POB 1500<br />
02044 VTT Espoo<br />
Finland<br />
CONFERENCE PARTICIPANTS<br />
VTT Technical Research Centre of Finland<br />
Clinical Foci: Oncology • Systems Biology • Metabolic Disease<br />
www.vtt.fi/mbt<br />
Phone: 358-20-722111<br />
Timo Pulli, Business Development Manager, PhD<br />
Sampo Sammalisto, Key Account Manager, Ph.D, Drug Development and Diagnostics<br />
Incorporated: 1942<br />
Employees: 3167<br />
Ownership: Other<br />
CORPORATE MISSION<br />
VTT is the biggest multi-technological applied research organisation in Northern Europe with more than 3.000 employees. Our mission is<br />
to collaborate with industrial partners in order to help them bring better products to the market faster.<br />
VTT ranks among the top4 most productive research organisations in Europe and produces more than 500 peer-reviewed scientific articles<br />
each year.<br />
In molecular biology our focus areas are:<br />
- Discovery and study of novel cancer drugs and drug targets<br />
- Development and application of systems biology approaches to metabolic and neuropsychiatric diseases<br />
- Development of recombinant antibodies for diagnostic and therapeutic applications<br />
PROPRIETARY TECHNOLOGY<br />
We actively develop innovative proprietary technologies that help our partners in gaining a competitive edge in their market. In molecular<br />
biology our main proprietary technologies are:<br />
- 3D Organotypic Cell Models: provides unique understanding in small compound testing and drug/drug target validation.<br />
- Cell Spot Microarray: ultra high-throughput platform for RNAi screening in cells<br />
- Protein Lysate Microarray: miniaturized platform for analysing protein levels from cell lysates<br />
CORPORATE ALLIANCES<br />
In 2010 VTT worked with more than 1.500 industrial partners either in long-term collaborations or short-term projects. In the<br />
pharmaceutical sector some of our partners include Roche, GlaxoSmithKline and Bayer Schering Pharma.<br />
INTELLECTUAL PROPERTY<br />
VTT patent portfolio includes more than 1.100 patents and patent applications which we actively seek to out-licence.<br />
BIO Business Forum 2011 543 Participating Company <strong>Profiles</strong>
Michael Koncar<br />
Chief Executive Officer<br />
Parkring 18<br />
8074 Grambach<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Thomas Purkarthofer, Head of Business Development<br />
Roland Weis, Chief Operating Officer<br />
VTU Technology<br />
Clinical Foci: Biopharmaceuticals • Service • Industrial Biotech<br />
www.vtu.com/proteins<br />
Phone: 43-316-4009 4017<br />
Incorporated: 2008<br />
Employees: 15<br />
Ownership: Private<br />
CORPORATE MISSION<br />
VTU Technology is a leading provider of comprehensive services around exclusive and innovative Pichia pastoris protein expression<br />
technologies. With exclusive know-how and extensive experience VTU´s skilled team delivers fast-track development of high-performance<br />
industrial protein expression strains enabling high expression yields and economically attractive production processes from lab to pilot<br />
scale suitable for pharma, life sciences and other industries.<br />
VTU´s Pichia pastoris expression system - built around the technology´s stronghold, a library of synthetic promoter variants - is best suited<br />
for economic biologics production furnishing expression titers of >10 g/L of secreted target proteins with up to 90% initial purity within a<br />
few weeks of development for various proteins (e.g. serum proteins, cytokines, Fabs and other antibody derived fragments, scaffold<br />
proteins, (HSA&Fc)fusion proteins, enzymes).<br />
VTU researchers apply cutting-edge technologies and elaborated time saving procedures to maximize both throughput and output and<br />
thereby drastically shorten the development time from the gene to gram quantities of different proteins. VTU Technology provides<br />
effective solutions for economic protein production accompanied by sound technology transfer and comprehensive documentation<br />
ensuring regulatory compliance.<br />
PROPRIETARY TECHNOLOGY<br />
Our exclusive proprietary promoter library of synthetic variants of AOX1 spans a wide range of activities and expression characteristics<br />
which allows an ideal match of promoter properties and specific requirements for efficient expression of a given target protein. The<br />
potential of this particular technology is further boosted by co-expression of auxiliary proteins as a finely-tuned balance between helper<br />
and target is the key to highest levels of protein production.<br />
INTELLECTUAL PROPERTY<br />
FTO<br />
SENIOR MANAGEMENT<br />
Michael Koncar, Chief Executive Officer • Roland Weis, Chief Operating Officer • Thomas Purkarthofer, Business Development<br />
BIO Business Forum 2011 544 Participating Company <strong>Profiles</strong>
Dr. Thomas Maier<br />
Managing Director<br />
Hans-Knöll-Str. 3<br />
07745 JENA<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
Silvana Di Cesare, Business Development Manager<br />
Thomas Maier, Managing Director<br />
HIGHLIGHTS<br />
Recent<br />
Wacker Biotech AG<br />
Clinical Foci: Biopharmaceuticals • Other<br />
www.wacker.com/biologics<br />
Phone: 49-3-64153 48150<br />
Employees: 82<br />
Ownership: Other<br />
2010: the GMP facility in Jena re-started operations for the production of biopharmaceuticals, following an expansion phase with a 18 mio<br />
EUR investment<br />
CORPORATE MISSION<br />
Wacker Biotech GmbH is an experienced contract manufacturer of biopharmaceuticals in microbial systems. The company was founded in<br />
1999 as a spin-off from the Hans-Knöll Institute in Jena and is a 100% subsidiary of Wacker Chemie AG since 2005.<br />
Wacker’s integrated service portfolio covers molecular biology, process and analytical development, and the GMP manufacturing of<br />
biologics for clinical trials and commercial supply. WACKER’s state-of-the-art facility in Jena has been successfully audited by international<br />
customers and regulatory authorities, and op-erates in compliance with FDA and EMA requirements.<br />
Wacker has segregated facilities for process development, cGMP production and quality control.<br />
The process development department has 900-sqm dedicated lab space. Fermenta-tion, downstream processing and analytical<br />
development are performed in separate labs. The lab equipment is highly aligned with that for GMP production.<br />
The multi-product cGMP facility for contract manufacturing was recently renovated and expanded after an 18 mio € investment. The<br />
1,500-sqm cGMP unit has 3 clean rooms for fermentation, primary recovery and downstream process-ing.<br />
The quality control department operates in 1,000-sqm dedicated labs and performs a broad variety of analytical methods for in-process<br />
controls and release testing.<br />
Wacker Biotech has an established track record and more than 20 years of experi-ence in process development and manufacturing of<br />
therapeutic proteins. Our expertise includes projects from preclinical development to process validation and API delivery for clinical phase<br />
III.<br />
PROPRIETARY TECHNOLOGY<br />
Wacker offers cutting-edge proprietary technologies for the efficient and cost-effective production of biologics:<br />
ESETEC®: proprietary E .coli based secretion system:<br />
Wacker’s secretion system allows the high-yield production of correctly folded pro-teins in the culture broth. It comprises an engineered E.<br />
coli K12-based host strain and a set of proprietary plasmids.<br />
DENSETEC®: proprietary technology for high-cell-density fermentation:<br />
Wacker holds IP for a high-cell density fermentation technology that allows optimal volumetric productivity in robust and highly<br />
reproducible fermentation regimes. High product amounts are reached.<br />
INTELLECTUAL PROPERTY<br />
Wacker's ESETEC and DENSETEC proprietary E. coli technologies are protected by several international patents.<br />
SENIOR MANAGEMENT<br />
Dr. Thomas Maier, Managing Director<br />
BIO Business Forum 2011 545 Participating Company <strong>Profiles</strong>
Thomas J. Dietz, PhD<br />
Chief Executive Officer<br />
26 Egret Way<br />
Mill Valley, CA 94941<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Thomas J. Dietz, PhD<br />
SENIOR MANAGEMENT<br />
Thomas J. Dietz, PhD, Chief Executive Officer<br />
Waypoint Holdings, LLC<br />
Phone: 1-415-425-7155 Ownership: Private<br />
BIO Business Forum 2011 546 Participating Company <strong>Profiles</strong>
P.O. Box 16067<br />
2500 BB The Hague<br />
Netherlands<br />
CONFERENCE PARTICIPANTS<br />
Lissa Culbertson Boxy, International Business Advisor<br />
West Holland Foreign Investment Agency<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Vaccines<br />
www.leidenbiosciencepark.nl<br />
Phone: 31-70-3115555<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Numerous deals were closed by Leiden companies in 2010:<br />
J & J and Crucell announced the takeover of Crucell by J & J. /<br />
To-BBB - Research collaboration with GlaxoSmithKline on to-BBB's<br />
G-technology in delivering a biological compound to the brain.<br />
ProteoNic and ORYZON Genomics joined forces to develop new<br />
antibodies again prostate cancer.<br />
Pharming and Swedish Orphan biovitrum started the sale of<br />
Ruconest, the first recombinant C1 esterase inhibitor for<br />
treatment of angioedema attacks.<br />
Prosensa started a phase I/II clinical study for PRO044 in patients<br />
with Duchenne Muscular Dystrophy.<br />
ProFibrix entered into an agreement with CSL Behring for the<br />
clinical and commercial supply of plasma-based fibrinogen and<br />
thrombin.<br />
Employees: 14<br />
Ownership: Other<br />
The CEO of Astellas and the Mayor of Leiden drilled the first pillar of<br />
the new building of Astellas which will be completed at the end of<br />
2012. The building will house a state-of-the-art laboratory for<br />
scientifc research and development.<br />
Bio Simulation Factory is in the planning to give students a chance<br />
to train in a state-of-the-art pharmaceutical plant<br />
New companies on the park in 2010:<br />
Miltenyi Biotec, Batavia BioSciences, TLC BioPharmaceuticals, iSOFT<br />
News: May 2011 , Leiden,<br />
ISA Pharmaceuticals closes a License Agreement with Transgene<br />
aimed at the development of novel vaccines for TB<br />
CORPORATE MISSION<br />
The WestHolland Region, home to the Leiden Bio Science Park (www.leidenbiosciencepark.nl) and Medical Delta, is a dynamic region for<br />
Biomedical activity with many companies and research institutes focused on innovative medical technology and drug development. If<br />
your company is considering a location in Europe, we invite you to join the more that 60 life science companies already located on the park<br />
like Janssen Biologics, Crucell, Mentor, Galapogos as well as the The Leiden University and its Medical Center along with numerous other<br />
research institutions such as TNO, the Center of Drug Research and Top Institute Pharma all offer world class medical and<br />
biopharmaceutical research. Leiden Bio Science Park offers office space for companies in all phases of their life cycle, from small start-up<br />
to well established companies. Companies can locate in existing office space, or develop their own premises on the 90 acres under<br />
development for new companies.<br />
Leiden is conveniently located near Schiphol airport (15 min by train), and within easy reach of the major cities of The Hague and<br />
Amsterdam as well as the rest of Europe.<br />
PROPRIETARY TECHNOLOGY<br />
The West Holland Foreign Investment Agency (WFIA) and the Leiden Bio Science Park provide free services to companies interested in R & D<br />
partnerships or establishing a presence in the region. On the Leiden Bio Science Park your company can benefit from: a highly stimulating<br />
environment for bioscience and bio-business, access to state-of-the-art science and research, a cohesive program for structured<br />
development, excellent office and lab facilities, an enthusiastic, well-trainied and internationally oriented workforce, a central location in<br />
Europe, with good accessibility and infrastructure and a good quality of life.<br />
CORPORATE ALLIANCES<br />
Leiden University, Leiden University Medical Center, Technical University of Delft, Science Port Holland, and companies at the Leiden Bio<br />
Science Park such as<br />
Janssen Biologics,Crucell,Octoplus,Pharming,Galapagos, Genomics, Genencor/Danisco, BaseClear, Xendo, Bio-Imaging Technologies,<br />
Microsafe,<br />
Flexgen, Promega, Proxy Laboratories,TNO, To-BBB, Astellas, DNAge, ProSensa, Top Institute Pharma, ZoBio, CAM Implants, Mentor Medical<br />
Systems and more.............<br />
SCIENTIFIC ADVISORY BOARD<br />
Nettie Buitelaar, Leiden Bio Science Park • Ellen Smit, Leiden Bio Science Park • Lissa Culbertson Boxy, West Holland Foreign<br />
Investment Agency<br />
BIO Business Forum 2011 547 Participating Company <strong>Profiles</strong>
801 West Baltimore St<br />
Baltimore, MD 21210<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Catherine Vorwald<br />
HIGHLIGHTS<br />
Recent<br />
Wexford Science & Technology, LLC<br />
Clinical Foci: Other<br />
www.wexfordequities.com<br />
Phone: 1-443-844-4172<br />
Incorporated: 2005<br />
Employees: 27<br />
Ownership: Private<br />
UMLSTP<br />
Contemporary laboratory space available at UMLSTP, gateway to the second largest health district in the USA serving life science<br />
companies involved in bioinformatics, regenerative medicine, tissue engineering, diabetes, cancer, #1 eye inst.<br />
Innovation Center<br />
Small laboratories and offices for emerging companies with shared autoclave, ice machine, sterilizing dishwasher, conference and break<br />
rooms, offered on a short-term basis. Business support access and networking create community en<br />
UMLSTP Soft Landing<br />
Enter USA and international markets through the gateway city Miami from the Soft Landing Center designed to provide companies easy<br />
office/lab terms, support services, and community environment to increase operational efficiency,<br />
CORPORATE MISSION<br />
University of Miami Life Science and Technology Park (UMLSTP), the Beacon Council of Miami-Dade County (Beacon Council), and Wexford<br />
Miami, LLC (Wexford), collaborate to provide real estate solutions for life science and technology commercialization resulting in cluster<br />
and economic development. This public-private-academic collaboration specifically provides financial incentives, collaborative<br />
opportunities, and location benefits that meet the specialized space needs of for-profit and non-profit institutions, including regional<br />
universities, emerging local companies, and entities entering the USA and international markets through the gateway city of Miami.<br />
CORPORATE ALLIANCES<br />
UMLSTP, the Beacon Council , and Wexford work together with the local, county, and State economic development agencies, namely,<br />
Greater Miami Chamber of Commerce, the Economic Development Corporation of South Florida, Enterprise Florida, and BIO Florida, to<br />
actualize the commitment of the State of Florida to the life science and technology cluster and economic development.<br />
BIO Business Forum 2011 548 Participating Company <strong>Profiles</strong>
Christina Sylvester-Hvid<br />
Partner<br />
Boge Alle 5<br />
2970 Horsholm<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Christina Sylvester-Hvid, DR, Partner<br />
HIGHLIGHTS<br />
Recent<br />
Wiborg ApS<br />
Clinical Foci: Oncology • Immunology • CNS<br />
www.wiborg.com<br />
Phone: 45-45-45871966<br />
Incorporated: 9<br />
Employees: 6<br />
Ownership: Private<br />
Completed license agreement with Perkin Elmer concering new marker for Down syndrom (ADAM12)<br />
License and development agreement with GSK concerning development of Piboserod in heart failure indication<br />
Completed more than 35 license agreements for clients since 2003<br />
CORPORATE MISSION<br />
WIBORG is an international consulting firm located in Denmark specializing in complex market analysis, licensing and business<br />
development in the biotechnological and pharmaceutical area. We provide our services to biotech and pharma companies, investors and<br />
research institutions in the areas of IPR, technology licensing, company start-up, market analysis, business development and project<br />
management. Our goal is clear: When a client drops a project on our table, we give it the optimal attention it requires in order to become a<br />
commercial success, or - we will honestly tell you why it will not be worthwhile pursuing it. If we do not have all the necessary<br />
competencies in-house, we can access them in our network and among our partners of regulatory professionals, clinical CRO’s, law and<br />
patent firms, etc. We always find workable and pragmatic solutions to everyday business problems as well as to highly complex challenges<br />
involving scientific, legal and financial aspects. We analyze the technology and markets, find the partners, negotiate and make the<br />
contracts – and manage the deals. Since the foundation of WIBORG in 2002 we have been working with more than 50 customers in<br />
Scandinavia, Europe and USA. We have a dedicated staff of 6 people (4 PhDs), all of which are experienced professionals with long industry<br />
experience. In addition, we have a local and international network of highly skilled professionals so we can handle large projects requiring<br />
a variety of scientific and commercial skills. We currently manage various projects and IP for clients. Both pharma and diagnostics.<br />
Typically, we assess the value, manage the projects and find license and development partners<br />
PROPRIETARY TECHNOLOGY<br />
With our partner, Avance GmbH, we offer proprietary software solutions for complex but user-friendly valuation of drug development<br />
projects and portfolios. Wiborg is managing important IP from the Danish Cancer Research Foundation covering a variety of uses related<br />
to Plasminogen Activator Inhibitor 1 (PAI-1) and the Urokinase Plasminogen Activator Receptor (uPAR) system.<br />
CORPORATE ALLIANCES<br />
Wiborg has entered into several agreements concering the development of therapeutic compounds for the treatment of cancer and other<br />
diseases based on interference with PAI-1 and the uPA/uPAR system.<br />
SENIOR MANAGEMENT<br />
Christina Sylvester-Hvid, Partner • Ole Wiborg, Partner<br />
BIO Business Forum 2011 549 Participating Company <strong>Profiles</strong>
1700 K Street, NW<br />
Washington, DC 20006<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Vern Norviel JD<br />
Jeffrey Guise<br />
Lou Lieto<br />
Wilson, Sonsini, Goodrich & Rosati, LLP<br />
www.wsgr.com<br />
Phone: 1-202-973 8800<br />
Employees: 1000<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Wilson Sonsini Goodrich & Rosati has developed a broad expertise in the field of life sciences. The firm's life sciences practice includes<br />
representation of more than 500 companies in biotechnology, biopharmaceuticals, drug discovery technology, genomics, medical devices,<br />
diagnostics, and health care services.<br />
We regularly advise life sciences companies on both public and private equity and debt financings, mergers and acquisitions, research and<br />
development financings, technology licensing and contracts, as well as day-to-day securities and corporate governance matters.<br />
Since 1998, Wilson Sonsini Goodrich & Rosati has served as counsel to companies and investment banks in more than 50 public offerings<br />
involving life sciences companies, raising more than $7 billion. The life sciences attorneys maintain close ties with venture capital funds<br />
most active in the space, and have represented more life sciences companies in the process of securing venture capital financing than any<br />
other law firm. Over the last five years, we have assisted our life sciences clients in raising more than $1.5 billion in venture capital<br />
financing.<br />
To assist life sciences companies with the protection and exploitation of their intellectual property, the firm maintains a dedicated team<br />
of intellectual property attorneys led by industry veterans with significant experience securing and defending patent positions. The firm<br />
runs a dedicated healthcare regulatory law practice to help life sciences clients successfully navigate complex regulatory mazes, secure<br />
timely approvals and comply with strictly enforced regulatory laws in the U.S. and international markets.<br />
The firm adapts its services to account for the different conditions in the life sciences industry, such as longer product development<br />
timetables, regulatory and reimbursement issues, and unique relationships with the scientific and medical communities. Our team<br />
includes attorneys with advanced degrees and industry training.<br />
BIO Business Forum 2011 550 Participating Company <strong>Profiles</strong>
Masatoshi Watabe<br />
Chief Executive Officer<br />
246-4 Inume-cho<br />
Tokyo 193-0802<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Masatoshi Watabe, CEO<br />
HIGHLIGHTS<br />
Recent<br />
Winered Chemical Corporation<br />
Clinical Foci: Diagnostics • Immunology • Drug Discovery<br />
www.winered.jp<br />
Phone: 81-4262-43755<br />
Incorporated: 2005<br />
Employees: 4<br />
Ownership: Private<br />
Palladium colloid (oligopeptide reduction) for POC immuno-assay<br />
Palladium chloride aqua solution + peptide -> New Palladium Colloid.<br />
Test line on the palladium colloid specimen can be seen more clearly than gold colloid specimen.<br />
Gold colloid (oligopeptide reduction) for POC immuno-assay<br />
Can be preserved for as long as six months at room temperature.<br />
With the ability to produce colloids with higher solution concentrations (more than 2 in OD525) it will be possible to down<br />
CORPORATE MISSION<br />
Name: Winered Chemical Corporation<br />
Location: 246-4 Inumemachi Hachiojishi Tokyo Japan 193-0802<br />
Home page: http://www.winered.jp/<br />
E-mail :watabe@cc.kogakuin.ac.jp<br />
Establishment: April 15, 2005<br />
Capital: 125 thousand dollar<br />
Business activity: Manufacturing and selling of Immuno-assay Palladium and Gold colloid<br />
Producer: Winered Chemical Corporation<br />
Tel: 81-(0)42-624-3755 Fax: 81-(0)42-624-3732<br />
e-mail:watabe@winered.jp URL: www.winered.jp<br />
Overseas Agent: Tatsuno Company Limited<br />
Tel: 81-(0)3-3263-7811 Fax: 81-(0)3-3263-7815<br />
e-mail: mail@tatsunojapan.com<br />
PROPRIETARY TECHNOLOGY<br />
• Develop new immuno-assay markers (palladium colloid and gold colloid).<br />
Palladium or gold chloride aqua solution + peptide -> New Palladium or Gold Colloid. Test line on the palladium colloid specimen can be<br />
seen more clearly than gold colloid specimen under the same condition.<br />
• Degrees of conjugation of antibodies to metal colloids depend on the palladium or gold colloids applied.<br />
• Can be preserved for as long as six months at room temperature.<br />
• Lower incidence of agglutination due to higher negative charge than conventional metal colloids<br />
• With the ability to produce colloids with higher solution concentrations (more than 12 in OD525 it will be possible to downsize<br />
the manufacturing devices and instruments, thus reducing manufacturing costs.<br />
INTELLECTUAL PROPERTY<br />
US pattent No.7,928,149<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
palladium colloid for POC<br />
immuno-assay<br />
gold colloid for POC immunoassay<br />
Diagnostics high sensitivity, high concentration (OD=6),<br />
long stable,and, oligopeptide reduced<br />
palladium colloid<br />
Diagnostics high sensitivity, high concentration (OD=12),<br />
and long stable, and, oligopeptide reduced gold<br />
colloid<br />
This is the first palladium<br />
colloid for POC immuno-assay.<br />
This is the first oligopeptide<br />
reduced gold colloid for POC<br />
immuno-assay.<br />
BIO Business Forum 2011 551 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
gold colloid for TEM imaging Research high sensitivity, high concentration (OD=12),<br />
and long stable oligopeptide reduced gold<br />
colloid<br />
FINANCING HISTORY<br />
Investors: Masatoshi Watabe (100 %)<br />
SENIOR MANAGEMENT<br />
Masatoshi Watabe, Chief Executive Officer • Nozomu Arai, Business Development<br />
BOARD OF DIRECTORS<br />
narrow dispersion of radius and<br />
easy conjugation of antigen and<br />
gold<br />
Masatoshi Watabe, Winered Chemical Corporation • Junji Tatsuno, Tatsuno Company • Nozomu Arai, Tatsuno Company<br />
BIO Business Forum 2011 552 Participating Company <strong>Profiles</strong>
590 Madison Ave., 21st Fl<br />
New York, NY 10022<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
WOMBAT CAPITAL, LTD.<br />
www.WombatCapital.com<br />
Phone: 1-212-521-4165<br />
Michel Cousineau, Head of BioPharma Licensing and Strategic Alliances<br />
CORPORATE MISSION<br />
Ownership: Private<br />
Wombat Capital is a New York-based mid-market corporate finance advisory firm focusing on M&A, JV, licensing and co-development<br />
deals for the life sciences industry. The Wombat Capital team has a vast network of international relationships and solid expertise in dealmaking<br />
to assist our clients in reaching strategic growth goals. Wombat Capital serves a diverse client base and has a focus on crossborder<br />
transactions and significant execution capabilities in the Americas, Europe, Asia/Pacific Rim, Africa and Middle East.<br />
Our healthcare group, with a vast and long-term life sciences expertise and background, provides professional services for transactions in<br />
the sectors of Biotechnology, Pharmaceutical, Drug Delivery, Specialty Pharma, Drug Discovery, CMOs/CROs, Molecular/Companion/IVD<br />
Diagnostics, Biomarker discovery, FineChemical/APIs, OTC Products, Generic Drugs, Medical Devices and Animal Health.<br />
PROPRIETARY TECHNOLOGY<br />
The Wombat Capital team has a vast network of international management level relationships and solid expertise in deal-making.<br />
Wombat Capital provides advice on a comprehensive range of strategic and financial transactions including sales, divestitures, merger<br />
advisory, capital raising, joint ventures and strategic alliances.<br />
Wombat Capital also offers the OptimEx service to prepare companies for a transaction process, 6-24 months in advance.<br />
BIO Business Forum 2011 553 Participating Company <strong>Profiles</strong>
Paul Paolatto<br />
Director<br />
100 Collip Circle, Suite 105<br />
London, ON N6G 4X8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Kirk Brown<br />
Souzan Armstrong<br />
Bryce Pickard, PhD<br />
Sandy Gian Vascotto<br />
Worldiscoveries<br />
Clinical Foci: Biopharmaceuticals • Diagnostics • Medical Device<br />
www.worldiscoveries.ca<br />
Phone: 1-519-661-4183<br />
Employees: 16<br />
Ownership: Other<br />
CORPORATE MISSION<br />
WORLDiscoveries is the business development arm of London Ontario’s research institutions; the University of Western Ontario<br />
(Western), Robarts Research Institute (Robarts) and Lawson Health Research Institute (Lawson). Collectively, these institutions employ<br />
1,800 researchers, attract $330 million in research investment and generate over $5 million in licensing revenue on an annual-basis from<br />
their existing IP portfolio. Over the last 10 years, WORLDiscoveries and its predecessor business development offices have started over 30<br />
new startup or spin-off companies have been formed in order to commercialize products and services based on discoveries that have been<br />
made by researchers within our community. Our mission and vision is to be recognized as one of the most innovative and productive<br />
business models for the commercialization of research discoveries on behalf of our partner institutions and inventors within all of Canada<br />
if not the World.<br />
Western (www.uwo.ca) is ranked as one of the top-ten research intensive universities within Canada and is home to the Schulich School of<br />
Medicine & Dentistry and the world-class medical research facilities of Robarts (www.robarts.ca). Lawson (www.lawsonresearch.com) is<br />
the integrated research arm of the London Health Sciences Centre (LHSC) and St. Joseph’s Health Care (SJHC) London, including Parkwood<br />
Hospital, Children’s Hospital of Southwestern Ontario and the London Regional Cancer Program.<br />
Western, Robarts and Lawson maintain their own research contracts function for administration of industry-sponsored and collaborative<br />
research and development agreements on behalf of their researchers.<br />
Contract Research at Western (including Robarts): http://www.uwo.ca/research/rds.html. Lawson:<br />
http://www.lawsonresearch.com/v1.0/website/clinical_trials.html. WORLDiscoveries staff can assist you in making the right connection<br />
to meet your specific needs.<br />
PROPRIETARY TECHNOLOGY<br />
Core life science basic and clinical research capabilities and strengths of Western, Lawson and Robart's include neurosciences and mental<br />
health; diabetes and infectious disease; imaging; musculoskeletal health; innovations in healthy aging; biomedical engineering;<br />
transplantation and immunology; cancer research; maternal newborn, child, family health and development; cardiac and vascular biology<br />
and respiration; physical activity sciences and robotic surgery.<br />
CORPORATE ALLIANCES<br />
WORLDiscoveries is the primary contact point for the participation of Western, Robarts and Lawson in C4 (www.c4ontario.ca) and ACCT<br />
Canada (www.acctcanada.ca). C4 is a regional consortium formed to support commercialization of the research interests of multiple<br />
institutions located within South Western Ontario. Membership of C4 includes Western, McMaster, Waterloo and Guelph University and<br />
all affiliated teaching hospitals and research institutes. ACCT Canada is the national organization for technology transfer within Ontario<br />
and Canada.<br />
INTELLECTUAL PROPERTY<br />
WORLDiscoveries promotes its available technologies, new startups/spinoffs, through its participation in industry specific partnering<br />
events such as BIO 2011, our website (www.worldiscoveries.ca) and posting to relevant technology exchanges such as Flintbox<br />
(www.flintbox.com).<br />
SENIOR MANAGEMENT<br />
Paul Paolatto, Director • Kirk Brown, Business Development • Sandy Vascotto, Business Development • Bryce Pickard, Business<br />
Development • Souzan Armstrong, Business Development<br />
BOARD OF DIRECTORS<br />
Ted Hewitt, University of Western Ontario • Dwyane Martins, Robarts Research Institute • David Hill, Lawson Health Research Institute<br />
• Kevin Roberstson, PriceWaterhouseCoopers • Janice McMichael, Bluewater Power<br />
BIO Business Forum 2011 554 Participating Company <strong>Profiles</strong>
Ge Li<br />
Chief Executive Officer<br />
288 Fute Zhong Road, Waigaoqiao Free Trade<br />
Zone<br />
200131 Shanghai<br />
China<br />
CONFERENCE PARTICIPANTS<br />
Richard M. Soll, Senior Vice President of Integrated Services<br />
Hui Cai, Vice President of Business Development<br />
Bill Farley, Vice President of Key Accounts, China Services<br />
WuXi AppTec, Inc<br />
Presenting Company<br />
Clinical Foci: Drug Discovery • Drug Development • Biopharmaceuticals<br />
www.wuxiapptec.com<br />
Phone: 86-21-5046-1111<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
02/23/2010<br />
Press Release 03/31/2009<br />
WuXi PharmaTech Passes EMEA Inspection of Its GMP<br />
Manufacturing and Analytical Testing Facilities in Shanghai<br />
12/22/2009<br />
WuXi PharmaTech Included in the Deloitte Technology Fast 500<br />
Asia Pacific 2009 List for the Sixth Consecutive Year<br />
In 2009, WuXi received many outstanding service awards from its<br />
biotech and pharma partners such as Schering-Plough, Eli Lilly,<br />
BASF, Astrazeneca, ...<br />
Incorporated: 2000<br />
Employees: 4200<br />
Ownership: Public<br />
Market Cap: $1000.00 million<br />
NYSE : WX<br />
WuXi AppTec announced its Bioanalytical Services (BAS) business<br />
unit has been inspected by the U.S. Food and Drug Administration<br />
(FDA) without the issuance of a Form 483, after an on site<br />
inspection of the China BAS operation<br />
02/22/2010<br />
WuXi PharmaTech Receives AAALAC Accreditation for Suzhou<br />
Toxicology Facility<br />
Press Relese 7/112008 -- WuXi PharmaTech (NYSE: WX) today<br />
proudly announced that it has won the 2008 Frost & Sullivan<br />
Award for Best in Class Outsourced R&D in Pharmaceuticals and<br />
Biotechnology.<br />
CORPORATE MISSION<br />
WuXi AppTec is a leading global pharmaceutical, biotechnology and medical device outsourcing company with operations in China and<br />
the U.S. Research-driven and customer-focused, with comprehensive capability and capacity, WuXi AppTec provides a broad and<br />
integrated portfolio of laboratory and manufacturing services throughout the R&D process and beyond. Our services are designed to<br />
assist our customers worldwide in shortening the time and lowering the cost of R&D by providing cost-effective and efficient outsourcing<br />
solutions.<br />
WuXi AppTec’s primary China-based facilities include a 782,000-square-foot R&D center and a 291,000-square-foot process<br />
development/cGMP-quality manufacturing plant in Shanghai; a 253,000-square-foot R&D center in Tianjin that focuses mainly on<br />
discovery chemistry services; and a 314,000-square-foot facility in Suzhou that is dedicated to GLP toxicology. U.S.-based facilities include<br />
a 75,000-square-foot testing and manufacturing facility in Philadelphia, PA; a 83,000-square-foot testing and manufacturing facility in St.<br />
Paul, MN; and a 50,000-square-foot testing facility in Atlanta, GA.<br />
CORPORATE ALLIANCES<br />
Below are several recent, publicly release collaborations announced. Other collaborations are on going or not publicly announced<br />
March 2010: WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and<br />
Training<br />
December 2009: WuXi PharmaTech Selects Labcyte POD 810 Platform for High-Throughput Screening<br />
In-Vitro ADME Collaboration with Pfizer through 2011.<br />
Integrated Pharmaceutical Research and Development collaboration with Johnson & Johnson Pharmaceutical Research & Development<br />
(J&JPRD) for discovery chemistry, discovery biology, chemical and analytical development, formulation and preclinical and bio-analytical<br />
services.<br />
SENIOR MANAGEMENT<br />
Ge Li, Chief Executive Officer • Edward Hu, Chief Operating Officer • Shu-Hui Chen, Chief Scientific Officer • Suhan Tang, Chief<br />
Medical Officer • Xiaozhong Liu, Executive Vice President • Felix Hsu, Senior Vice President • Richard Soll, Senior Vice President<br />
BOARD OF DIRECTORS<br />
Ge Li, Chairman<br />
BIO Business Forum 2011 555 Participating Company <strong>Profiles</strong>
Sheridan G. Snyder<br />
Chief Executive Officer<br />
505 South Flagler Drive, Suite 1330<br />
West Palm Beach, FL 33401<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Xcovery, Inc<br />
Clinical Foci: Oncology • Ophthalmic • Drug Development<br />
www.xcovery.com<br />
Cheryl Calhoun<br />
Teri Ardleigh Swift, VP Business Development Xcovery Vision<br />
Phone: 1-561-835-9356<br />
Incorporated: 2006<br />
Employees: 10<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Xcovery develops proprietary small molecule kinase therapeutics targeting oncology and inflammation. Xcovery's approach to drug<br />
development is to generate lead compounds with greater selectivity, better efficacy, and reduced toxicity, and to facilitate rapid discovery<br />
via one of the shortest paths from discovery to preclinical stages in the industry. Xcovery's best in class therapeutics are targeted for<br />
partnerships with leading biotechnology and pharmaceutical companies.<br />
CORPORATE ALLIANCES<br />
Xcovery is looking to partner / out-license our compounds with a suitable pharma partner<br />
INTELLECTUAL PROPERTY<br />
Xcovery has a robust oncology pipeline with several novel, potent, and selective inhibitors (VEGFR/PDGFR, ALK, c-MET, mTOR, PI3K delta<br />
and pan PI3K/mTor) that have demonstrated excellent in vivo efficacy and tolerability. The most advanced program, X-82, a VEGFR/PDGFR<br />
inhibitor, is in Phase I clinical trials.<br />
PRODUCTS<br />
Name Phase Indication<br />
ALK Inhibitor Preclinical Oncology<br />
c-Met inhibitor Preclinical Oncology<br />
PI3k alpha/mtor inhibitor Preclinical Oncology<br />
PI3k delta selective inhibitor Preclinical Oncology<br />
mTor inhibitor Preclinical Oncology<br />
X-82 (VEGFR/PDGFR) Phase I Oncology<br />
FINANCING HISTORY<br />
Investors: BioCatalyst International (70 %)<br />
SENIOR MANAGEMENT<br />
Sheridan G. Snyder, Chief Executive Officer • Dr. Chris Liang, Chief Scientific Officer • Dr. Jay Gibbons, Vice President • Cheryl<br />
Calhoun, Vice President • Teri Swift, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
Dr. Brian Druker • Dr. Sydney Brenner • Sir David Lane • Sir Philip Cohen<br />
BIO Business Forum 2011 556 Participating Company <strong>Profiles</strong>
Bassil Dahiyat, PhD<br />
President & CEO<br />
111 West Lemon Avenue<br />
Monrovia, CA 91016<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Edgardo Baracchini, CBO<br />
Bassil I. Dahiyat, PhD, CEO<br />
Xencor, Inc<br />
Clinical Foci: Biopharmaceuticals • AutoImmune • Oncology<br />
www.xencor.com<br />
Phone: 1-626-305-5900<br />
Incorporated: 1997<br />
Employees: 35<br />
Ownership: Private<br />
CORPORATE MISSION<br />
At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics for cancer, inflammation, and<br />
autoimmune disease – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve<br />
patient outcomes and quality of life. Our XmAb® engineering technologies have resulted in a robust pipeline of antibody drug candidates,<br />
including four in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics<br />
products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help<br />
reduce costs. We exploit the bioactivity of our unique portfolio of XmAb® engineered Fc domains to create highly selective immunemodulators<br />
for our autoimmune candidates and targeted, highly cytotoxic cancer therapies.<br />
PROPRIETARY TECHNOLOGY<br />
• ADCC Technology – Enhancing Fc Cell Cytotoxicity Effector Function<br />
• Xtend Technology – Enhanced Half-life Antibodies<br />
• Fv Optimization Technology – Enhanced Affinity and Humanized Antibodies<br />
• IIb (CD32b) Technology – Immunomodulation<br />
CORPORATE ALLIANCES<br />
Broad Alliances:<br />
Our antibody development partnerships with major pharmaceutical and biotechnology companies are testament to the power of our<br />
technologies and provide funding to advance clinical development of our proprietary drug candidates.<br />
Partnereships<br />
Amgen, Morphosys, Boehringer Ingelheim, Centocor, CSL Ltd., Human Genome Sciences, Genentech, MedImmune, Merck, Pfizer<br />
INTELLECTUAL PROPERTY<br />
>30 issued U.S. patents<br />
>30 foreign patents<br />
>400 patent applications<br />
•Seven XmAb® partnerships with major biotech and pharma companies<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
XmAb2513 (anti-CD30) Phase I Hodgkin's Lymphoma Completion of Phase 1 with biological activity<br />
XmAb5574 (anti-CD19) Phase I B-cell malignancies License and codevelopment partnership with<br />
Morphosys<br />
PF-4691502 Phase I Oncology Pfizer antibody with Xencor's ADCC technology<br />
Undisclosed Phase I Oncology Boehringer Ingelheim antibody with Xencor's<br />
ADCC technology<br />
XmAb5817 (anti-CD19/CD-32) Preclinical Autoimmune Diseases License option and codevelopment partnership<br />
with Amgen<br />
XmAb7195 (anti-IgE) Preclinical Asthma and Allergies Positive animal pharmacology in several disease<br />
models<br />
XmAb5592 (anti-HM1.24) Lead Series Myeloma Addiitve antitumor activities with current<br />
therapies<br />
XmAb5485 (anti-CD40) Lead Series B-cell malignancies<br />
XPro1595 (DN-TNF) IND Filed Autoimmune and<br />
Neurodegenerative Diseases<br />
Open IND<br />
Xtend anti-TNF Biosuperior Lead Series Autoimmune Diseases 3-fold increase in half-life<br />
BIO Business Forum 2011 557 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Bassil Dahiyat, PhD, President & CEO • Ed Baracchini, PhD, MBA, Chief Business Officer • John Desjarlais, PhD, Vice President • John<br />
Kuch, Vice President<br />
BOARD OF DIRECTORS<br />
Bruce L.A. Carter, PhD, Independent • Bassil I. Dahiyat, PhD, Xencor, Inc. • Douglas M. Fambrough, PhD, Oxford Bioscience Partners •<br />
Don Foster, PhD, Novo Nordisk • Tim Pearson, MedImmune • John S. Stafford III, Ronin Capital, LLC • Charles K. Stewart,<br />
Independent • Harold R. Werner, HealthCare Ventures<br />
SCIENTIFIC ADVISORY BOARD<br />
Jeffrey Ravetch, MD, PhD, The Rockefeller University • Richard Lerner, MD, The Scripps Research Institute<br />
BIO Business Forum 2011 558 Participating Company <strong>Profiles</strong>
Simon Pimstone<br />
President & CEO<br />
3650 Gilmore Way<br />
Burnaby, BC V5G 4W8<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Simon Pimstone, MD, PhD<br />
CORPORATE MISSION<br />
Xenon Pharmaceuticals, Inc<br />
Clinical Foci: Drug Development • Drug Discovery • Other<br />
www.xenon-pharma.com<br />
Phone: 1-604-484-3300<br />
Incorporated: 1996<br />
Employees: 70<br />
Ownership: Private<br />
Our mission is to “discover, develop and commercialize innovative and differentiated medicines based on genetically derived targets.”<br />
Xenon is a privately held small to mid-sized enterprise.<br />
We are a life sciences company focused on developing innovative therapeutics based on clinically and genetically validated drug targets.<br />
We conduct research and development activities on a number of novel drug products with the potential to significantly transform patient<br />
care in the areas of pain, metabolic and cardiovascular disease.<br />
Xenon’s science has been validated by numerous peer reviewed publications, government funding grants and corporate awards as well as<br />
through successful partnerships with leading pharmaceutical companies including Merck, Novartis, Pfizer, Roche and Takeda.<br />
CORPORATE ALLIANCES<br />
Novartis, Roche, Takeda, Merck, ISIS<br />
PRODUCTS<br />
Name Phase Indication<br />
Oral XEN402 Phase I Pain<br />
Topical XEN402 Phase II, IIa, IIb Pain<br />
Oral XEN403 Phase I Pain<br />
FINANCING HISTORY<br />
Investors: MX Associates, LLP (0 %) • Lipoterx Ltd. (0 %) • InterWest Partners (0 %) • Fidelity Management &<br />
Research Co. (0 %) • Invesco Private Capital (0 %) • Novartis Pharma AG (0 %) • Growthworks Capital<br />
Ltd. (0 %) • Roche (0 %) • Ventures West (0 %)<br />
SENIOR MANAGEMENT<br />
Simon Pimstone, President & CEO • Michael Hayden, Chief Scientific Officer • Tarek Mansour, Executive Vice President • Robin<br />
Sherrington, Vice President • Paul Goldberg, Vice President<br />
BOARD OF DIRECTORS<br />
Michael Tarnow, Past President & CEO, Merck Frosst Canada • Mohammad Azab, Supergen, Inc. • Chris Ehrlich, InterWest Partners •<br />
John Evans, Invesco Private Capital • Frank Holler, Lions Capital Corp. • Gary Patou, MPM Capital • August Troendle, Medpace, Inc. •<br />
Simon Pimstone, Xenon Pharmaceuticals Inc. • Michael Hayden, Centre for Molecular Medicine and Therapeutics<br />
BIO Business Forum 2011 559 Participating Company <strong>Profiles</strong>
Ron Barret<br />
Chief Executive Officer<br />
3410 Central Expressway<br />
Santa Clara, CA 95051<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Peter Virsik<br />
XenoPort, Inc<br />
Clinical Foci: Neurology • CNS • Other<br />
www.xenoport.com<br />
Phone: 1-408-616-7151<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
XenoPort announced FDA approval of Horizant (gabapentin enacarbil) for the<br />
treatment of RLS.<br />
XenoPort announced a renegotiated agreement with GSK regarding its lead<br />
compound, gabapentin enacarbil, which is seeking approval for the treatment of<br />
RLS. The compound is available for licensing in the EU and other ex-US territories.<br />
Initiation of IND-enabling studies for XP23829, a fumaric acid ester prodrug, in<br />
development for multiple sclerosis. Prior animal studies showed superior efficacy<br />
and gastrointestinal tolerability than DMF, the active ingredient of BG12.<br />
Incorporated: 1999<br />
Employees: 120<br />
Ownership: Public<br />
Market Cap: $275.00 million<br />
NASDAQ: XNPT<br />
Filing of Horizant for post-herpetic neuralgia in the<br />
US.<br />
EU regulatory guidance on the EU approvability of<br />
gabapentin enacarbil for RLS with the existing data<br />
package.<br />
PMDA response to our submitted NDA for<br />
gabapentin enacarbil for the treatment of RLS in<br />
Japan.<br />
CORPORATE MISSION<br />
XenoPort is a US-based publicly-owned biopharmaceutical company focused on developing a portfolio of internally discovered product<br />
candidates for the potential treatment of central nervous system (CNS) disorders. XenoPort focuses on the creation of prodrugs that utilize<br />
the nutrient transport system to improve the absorption and ultimately clinical profile of molecules.<br />
PROPRIETARY TECHNOLOGY<br />
XenoPort focuses on the creation of prodrugs that utilize the nutrient transport system to improve the absorption and ultimately clinical<br />
profile of molecules.<br />
CORPORATE ALLIANCES<br />
GlaxoSmithKline is our partner for the US (XNPT copromotes in US) .<br />
Astellas is our partner for Asia for XP13512.<br />
INTELLECTUAL PROPERTY<br />
Each compound developed at XenoPort is covered by an issued or pending composition of matter patent as well as other method of use,<br />
formulation, synthetic route, etc. patents.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
XP19986 Phase III Spasticity due to multiple<br />
sclerosis<br />
SPA agreement reached with FDA - Phase 3 studies<br />
started<br />
XP21279 Phase II, IIa, IIb Parkinson's Disease Completing head-to-head against Sinemet Phase 2<br />
study in Parkinson's patients<br />
XP21510 Preclinical Reduce blood transfusions<br />
during orthopedic surgeries<br />
IND-enabling studies ongoing<br />
XP13512 NDA/BLA filed, or in<br />
process<br />
Fumaric acid ester<br />
prodrugs<br />
Restless legs syndrome and<br />
neuropathic pain<br />
XenoPort discovered and fully development XP13512 for<br />
restless legs syndrome. The NDA has been filed at the<br />
FDA for the treatment of restless legs syndrome.<br />
Preclinical Multiple sclerosis (MS), psoriasis Announced initiation of IND-enabling studies; animal<br />
models show better efficacy and GI tolerability than<br />
BG12<br />
Transpoerter assays Other Research Tool Developed assays to qunatitatively assess molecule<br />
affinity and uptake by panels of transporters to aid in<br />
research approach.<br />
SENIOR MANAGEMENT<br />
Ron Barret, Chief Executive Officer • Bill Harris, Chief Financial Officer • David Savello, Senior Vice President • Vincent Angotti, Senior<br />
Vice President • Gia Bosko, Senior Vice President • Peter Virsik, Vice President • Richard Farley, Vice President<br />
BIO Business Forum 2011 560 Participating Company <strong>Profiles</strong>
Steven B. Engle<br />
Chief Executive Officer<br />
2910 Seventh Street<br />
Berkeley, CA 94710<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Steven B. Engle<br />
Svetlana Lucas, Director Business Development<br />
Jim Neal<br />
XOMA Ltd.<br />
Clinical Foci: Ophthalmic • Metabolic Disease • Cardiovascular Disease<br />
www.xoma.com<br />
Phone: 1-510-204-7200<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Servier regional agreemt. for XOMA 052: XOMA retains US/Japan<br />
rights for Behcet's uveitis, inflamm. diseases and cancer & option<br />
to reacquire US/Japan rights to diabetes & CVD; US$35 million<br />
upfront, $50+ million for Behcet's; advance diabetes & CVD.<br />
XOMA 052 in Behcet's uveitis: positive Phase 2 proof-of-concept<br />
study; 7/7 patients had rapid, sustained improvement in<br />
intraocular inflammation and visual acuity after one treatment,<br />
and 5/5 were successfully retreated; entering Phase 3 in 2011<br />
Incorporated: 1981<br />
Employees: 220<br />
Ownership: Public<br />
Market Cap: $100.00 million<br />
NASDAQ: XOMA<br />
XOMA 052 initiation of Phase 3 program in Behcet's uveitis<br />
New license and collaboration agreements based on proprietary<br />
XOMA antibody discovery and development technologies<br />
CORPORATE MISSION<br />
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline, under its contracts with the U.S.<br />
government, and through license and collaborative agreements with pharmaceutical and biotechnology companies, The company's<br />
proprietary product pipeline includes:<br />
• XOMA 052, a potent anti-IL-1 beta antibody entering Phase 3 clinical development in Behcet’s uveitis, for which it has been<br />
designated an orphan drug, and with potential for the treatment of a wide range of inflammatory conditions. XOMA has signed a<br />
regional development and license agreement with Servier for XOMA 052.<br />
• XOMA 3AB, an antibody candidate in Phase 1 studies to neutralize the botulinum toxin, among the most deadly potential bioterror<br />
threats, under development through funding provided by the National Institute of Allergy and Infectious Diseases of the National<br />
Institutes of Health (Contract # HHSN266200600008C).<br />
• A preclinical pipeline with candidates in development for cardio-metabolic, oncology, and fibrosis indications.<br />
PROPRIETARY TECHNOLOGY<br />
The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage<br />
display libraries, proprietary antibody engineering technologies (Human Engineering and TAE which allow optimization of affinity,<br />
immunogenicity, stability, and other biophysical properties of antibodies), and Kinetic Modulating Drug Technology (KMD). These<br />
technologies and unique know how have recently allowed XOMA to successfully generate antibody leads against GPCR targets, as well as<br />
sensitizing and agonizing antibodies with unique disease-modifying properties against targets like Insulin Receptor. XOMA is currently<br />
looking for discovery collaboration partners for its KMD and GPCR technologies, as well as phage display libraries.<br />
CORPORATE ALLIANCES<br />
Servier: XOMA 052;<br />
Takeda: antibody discovery and development;<br />
Novartis: antibody development.<br />
INTELLECTUAL PROPERTY<br />
XOMA has a patent portfolio covering bacterial and mammalian expression technologies for monoclonal antibodies and other<br />
recombinant proteins. In addition, XOMA has patents granted in the U.S. and Europe related to XOMA 052 compositions of matter and<br />
uses that provide coverage into 2026/2027.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
XOMA 052 Phase II, IIa, IIb Behcet's uveitis Initiation of Phase 3<br />
development in 2011.<br />
XOMA 052 Phase II, IIa, IIb Type 1 diabetes Trial completion<br />
XOMA 052 Optimized Lead Multiple myeloma<br />
BIO Business Forum 2011 561 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
XOMA 052 Optimized Lead Cardiovascular disease<br />
XOMA 3AB Optimized Lead anti-botulinum toxin antibody<br />
XMetS Lead Series Type II Diabetes, Metabolic Syndrome<br />
XmetA Optimized Lead Type I & II Diabetes<br />
XMetD Lead Series Severe Hypoglyecemia<br />
Anti-TGFb mAb Optimized Lead Oncology and Fibrosis<br />
Anti-RON mAb Lead Series Oncology<br />
SENIOR MANAGEMENT<br />
Steven B. Engle, Chief Executive Officer • Fred Kurland, Chief Financial Officer • Jim Neal, Business Development • Pat Scannon, Chief<br />
Scientific Officer • Svetlana Lucas, Business Development • Carol DeGuzman, Investor Relations<br />
BOARD OF DIRECTORS<br />
Steven B. Engle, Chief Executive Officer, XOMA Ltd. • William Bowes, U.S. Venture Partners • Charles Fisher, MD, Cardiome Pharma •<br />
Peter Barton Hutt, Covington & Burling • Patrick Scannon, MD, PhD, XOMA Ltd. • W. Denman Van Ness, Hidden Hill Advisors • John<br />
Varian, Aryx Therapeutics • Timothy Walbert, Horizon Pharma • Jack Wyszomierski, Former VWR, Schering-Plough EVP & CFO<br />
BIO Business Forum 2011 562 Participating Company <strong>Profiles</strong>
Uffe Boesen<br />
Partner<br />
Naverland 1C<br />
2600 Glostrup<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Uffe Boesen, Partner<br />
www.xplico.com<br />
Xplico A/S<br />
Phone: 45-0-4499 1000<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Number of European biotech and pharma companies have recently<br />
decided to use Xplico Evaluator including Leo Pharma, Ferring and<br />
Norgine. The standardized and easy-to-use approach, the analysis<br />
functions and our support package were the main reasons.<br />
Xplico has a.o. supported Bavarian Nordic and Zealand Pharma in<br />
deal making and portfolio analysis.<br />
Xplico has developed the forecasting tool for Nycomed for their<br />
product launch of Daxas (COPD) and fundanalyzer tool for Novo<br />
Ventures. Novo Ventures is one of the world largest Funds<br />
dedicated to life science investmests.<br />
Incorporated: 2005<br />
Employees: 3<br />
Ownership: Private<br />
Launching Xplico Portfolio in Autum 2011. Xplico Portfolio will<br />
enable you in a very easy way to do portfolio analysis of your<br />
pipeline. Xplico Portfolio could be used as an add-on to Xplico<br />
Evaluator.<br />
Establishing presence in the US in 2011/2012.<br />
Launching Xplico Pricing in 2012. Xplico Pricing will enable you in<br />
no time to see the consequences of a price change in one market<br />
for all the other markets. Further it will suggest market launch<br />
strategies for new products.<br />
CORPORATE MISSION<br />
Xplico provides valuation tool and valuation support for the pharma and biotech industry. Our standard toolbox Xplico Evaluator is easyto-use,<br />
Excel-based and flexible with integrated risk assessment and powerful analysis features which supports the needs of business<br />
development.<br />
In just a few years Xplico Evaluator has become the valuation tool of choice in Europe and the successful launch has given a solid<br />
foundation for our international expansion.<br />
Xplico provides also new product forecasting tool and support.<br />
SENIOR MANAGEMENT<br />
Uffe Boesen, Partner • Finn Nikolajsen, Partner<br />
BIO Business Forum 2011 563 Participating Company <strong>Profiles</strong>
Kyoungrak Kim<br />
President & CEO<br />
Gyeonggi BioCenter 14F, 864-1 Iui-dong<br />
Suwon 443-766<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Jong-Hoon Kim, Senior Researcher<br />
HIGHLIGHTS<br />
Recent<br />
2006 Designation as INNO-BIZ by SMBA<br />
1998 Establishment of R&D center<br />
1994 Establishment of YANIKEM s.a.r.l. in France<br />
CORPORATE MISSION<br />
Yangji Chemical<br />
Clinical Foci: Drug Delivery • AutoImmune • Skin/Dermatological<br />
Phone: 82-31-888 6612 Incorporated: 1987<br />
Employees: 26<br />
Ownership: Private<br />
YangJi Chemical is a research focused subsidiary of Han Wha Pharma in Korea. YangJi's discovery programs focus on anti-inflammatory<br />
and vascular diseases with unmet medical needs. The main areas include the development of new chemical entities from synthesis or<br />
plant extracts. In addition, R&D center also pursues the collaboration for incrementally modified drugs with domestic and foreign<br />
partners. At present, YangJi Chemical has a preclinical program for allergic diseases.<br />
PROPRIETARY TECHNOLOGY<br />
YangJi's discovery programs focus on anti-inflammatory and vascular diseases with unmet medical needs. The main areas include the<br />
development of new chemical entities from synthesis or plant extracts. In addition, R&D center also pursues the collaboration for<br />
incrementally modified drugs with domestic and foreign partners.<br />
CORPORATE ALLIANCES<br />
Seoul National University; University of Strassbroug; KAIST<br />
INTELLECTUAL PROPERTY<br />
4 PCT applications are currently maintained.<br />
PRODUCTS<br />
Name Phase Indication<br />
CCR2 antagonists Preclinical allergic diseases; auto-immune diseases<br />
herbal medicine Preclinical endothelial dysfunction; cardivascular diseases<br />
SENIOR MANAGEMENT<br />
Kyoungrak Kim, President & CEO • Nam Hak Kim, Chairman<br />
BIO Business Forum 2011 564 Participating Company <strong>Profiles</strong>
Yaacov Michlin<br />
President & CEO<br />
Hebrew University of Jerusalem<br />
91390 Jerusalem<br />
Israel<br />
CONFERENCE PARTICIPANTS<br />
Yaacov Michlin, President & CEO<br />
CORPORATE MISSION<br />
Yissum<br />
Clinical Foci: Drug Delivery • CNS • Oncology<br />
www.yissum.co.il<br />
Phone: 972-2-658 6688<br />
Incorporated: 1964<br />
Employees: 26<br />
Ownership: Private<br />
Yissum the technology transfer company of the The Hebrew University, Israel’s leading academic institution, carries out more than 1/3 of<br />
all academic scientific research in Israel and 43% of all Israeli academic biotech research.<br />
Yissum was founded in 1964 and is ranked among the top technology transfer companies in the world. The company has many<br />
collaborations in the biotechnology field, including with industry leaders such as Novartis, Johnson & Johnson, Roche, Merck, Teva, and<br />
many more.<br />
Products based on inventions of HU's researchers, that were commercialized by Yissum, generate over $2 billion in worldwide sales every<br />
year. Yissum owns the rights to 8 pharmaceutical products which are currently on the market, 15 products in human clinical stages and<br />
many more in pre-clinical stages. To date, Yissum has registered over 7,000 patents covering 2023 inventions and has licensed out 530<br />
technologies in many fields, mainly medicine and pharmaceuticals, agriculture and nutrition.<br />
In addition, Yissum founded 72 spin-off companies, most of them in the BIO area among them BioCancell, Intec Pharma, Collplant, Nasvax,<br />
Tiltan, Atox Bio, Avraham Pharmaceuticals and Novagali – each of which is a success story in its respective field.<br />
PROPRIETARY TECHNOLOGY<br />
Yissum currently offers for licensing more than 350 technologies. More details on Yissum Life science technologies can be found at:<br />
http://www.yissum.co.il/search_proj.php.<br />
These technologies and patents cover noval technologies in the fields of drug delivery, CNS, Metabolic Diseases, Cancer, Medical Devices,<br />
siRNA and many more.<br />
CORPORATE ALLIANCES<br />
Yissum is currently looking for licensees to its clinical and pre-clinical stages products, as well as for investments in its spin-off companies<br />
and its new Holding Company.<br />
INTELLECTUAL PROPERTY<br />
Yissum has registered over 7,000 patents which cover 2,023 inventions.<br />
SENIOR MANAGEMENT<br />
Yaacov Michlin, President & CEO • Sharon Cohen, Chief Financial Officer • Bob Trachtenberg, General Counsel • Shoshi Keynan,<br />
Business Development • Ariela Markel, Business Development<br />
BOARD OF DIRECTORS<br />
S. Morry Blumenfeld, PhD, Ex-Managing Director of GE Medical Systems in Israel • Mr. Martin Gerstel, Chairman of Compugen Ltd,<br />
Evogene Ltd, and Keddem Bioscience • Mr. Reuven Behar, Fisher Behar Chen & Co. • Ron Hadar, PhD, IVCH - Israel Healthcare Ventures<br />
(IHCV) • Prof. Hermona Soreq, Professor of molecular biology • Prof. Shai Arkin, Vice President for Research and Development<br />
Chairman of the Authority of the Hebrew University of Jerusalem. • Mr. Amos Mar-Haim<br />
BIO Business Forum 2011 565 Participating Company <strong>Profiles</strong>
Nick Glover, PhD<br />
President & CEO<br />
5045 Orbitor Drive, Building 11, Suite 400<br />
Mississauga, ON L4W 4Y4<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
David Kennard, Vice President, Strategic Alliances<br />
Ernest Wong, Vice President, Business Development<br />
Heather Stokes<br />
YM BioSciences Inc.<br />
Clinical Foci: Oncology • Hematology • Drug Development<br />
www.ymbiosciences.com<br />
Phone: 1-905-629-9761<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Positive interim data including substantial anemia response from Phase I/II trial of<br />
JAK1/JAK2 inhibitor CYT387 presented at American Society of Hematology (ASH)<br />
Annual Meeting, December 2010.<br />
Dr. Nick Glover appointed as Chief Executive Officer, effective November 18, 2010.<br />
Positive results from Phase I trial of vascular disrupting agent CYT997 published in<br />
British Journal of Cancer, September 2010.<br />
Incorporated: 1994<br />
Employees: 45<br />
Ownership: Public<br />
Market Cap: $350.00 million<br />
TORONTO STOCK EXCHANGE: YM<br />
Target completion of CYT387 Phase II study<br />
enrollment in 1Q11.<br />
Data from CYT997 Phase II trial in glioblastoma<br />
multiforme expected in 2Q11.<br />
CORPORATE MISSION<br />
YM BioSciences Inc. is a drug development company advancing a diverse portfolio of promising hematology and cancer-related products.<br />
The company was established in Canada in 1994, and its shares are listed on the Toronto Stock Exchange (TSX:YM) and the New York Stock<br />
Exchange (NYSE Amex:YMI).<br />
YM BioSciences is currently advancing three clinical-stage products: CYT387, an oral small molecule oral dual inhibitor of the JAK1/JAK2<br />
kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent oral vascular disrupting agent (VDA).<br />
CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of immune cell<br />
disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II<br />
trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile.<br />
Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small<br />
molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma<br />
multiforme. In addition to YM's three clinical stage products, the company has a library of more than 4,000 novel compounds identified<br />
through internal research conducted at YM BioSciences Australia which are currently being evaluated.<br />
We are actively searching for new in-licensing opportunities to enhance YM’s portfolio. Our preferred indications are oncology,<br />
hematology and inflammation. We are looking for drug candidates with strong IP and commercial potential that have at least reached the<br />
‘optimized lead’ stage, have a defined route to clinic and for which there is a validated mechanism of action.<br />
CORPORATE ALLIANCES<br />
YM BioSciences and its subsidiaries have established collaborations for product development and commercialization with companies<br />
around the world, including Daiichi-Sankyo Pharmaceutical Co. Ltd., Kuhnil Pharmaceutical Company, Innogene Kalbiotech, Oncoscience<br />
AG, the Center of Molecular Immunology in Cuba, Pulmokine, and Cancer Therapeutics CRC (CTx) in Australia.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
CYT387 Phase II, IIa, IIb Myeloproliferative neoplasms (MPNs),<br />
myelofibrosis<br />
Detailed initial safety and activity data<br />
presented at the American Society of<br />
Hematology (ASH) meeting in December 2010.<br />
Nimotuzumab Phase III non-small cell lung cancer, pediatric and adult<br />
glioma, gastric cancer, esophageal cancer,<br />
pancreatic cancer, head & neck cancer<br />
CYT997 Phase II, IIa, IIb glioblastoma multiforme (GBM), solid tumors Data from Phase II trial in glioblastoma<br />
multiforme expected in 2Q11.<br />
BIO Business Forum 2011 566 Participating Company <strong>Profiles</strong>
SENIOR MANAGEMENT<br />
Nick Glover, PhD, President & CEO • Vincent Salvatori, PhD, President • Mark Kowalski, MD, PhD, Chief Medical Officer • Wendy<br />
Chapman, Vice President • Ernest Wong, PhD, MBA, CLP, Vice President • Gregg Smith, PhD, MBA, Vice President • Len Vernon, BSc,<br />
CA, Vice President • James Smith, MSc (Eng), Vice President • Christopher J. Burns, PhD, Chief Scientific Officer • David A. Kennard,<br />
PhD, MBA, Vice President<br />
BOARD OF DIRECTORS<br />
David G. P. Allan, Former President & CEO, YM BioSciences Inc. • Thomas I.A. Allen, QC, FCIArb, Counsel to Ogilvy Renault • Mark<br />
Entwistle, MA, Former Canadian Ambassador to Cuba • Henry Friesen, CC, MD, FRSC, Distinguished Professor Emeritus, University of<br />
Manitoba • Philip Frost, MD, PhD, President, Calesca Pharmaceuticals • Nick Glover, PhD, President & CEO, YM BioSciences Inc. •<br />
François Thomas, MD, Senior Advisor, Bryan Garnier • Gilbert Wenzel, PhD, Chairman, Quisisana Holding AG • Tryon M. Williams, BSc<br />
(Math), Chairman, CEO & Director, Bingo.com Ltd.<br />
BIO Business Forum 2011 567 Participating Company <strong>Profiles</strong>
Richard Fritschi<br />
Chief Executive Officer<br />
Brunnmattstrasse 6<br />
CH-3401 Burgdorf<br />
Switzerland<br />
CONFERENCE PARTICIPANTS<br />
Ralf Künzi, Business Development Manager<br />
Ypsomed AG<br />
Clinical Foci: Medical Device • Drug Delivery<br />
www.ypsomed.com<br />
Phone: 41-34-4243157<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
The newly developed reusable ServoPen® insulin pen is launched in China<br />
together with Tonghua Dongbao Pharmaceutical Co., Ltd. a leading<br />
pharmaceutical company and insulin manufacturer in China.<br />
Ypsomed is partnering with Insulet as OUS distributor of the OmniPod<br />
insulin patch pump.<br />
Ypsomed is rolling out its new click-on Clickfine pen needle and Clickfine<br />
AutoProtect safety pen needle.<br />
Incorporated: 1984<br />
Employees: 1000<br />
Ownership: Public<br />
Market Cap: $700.00 million<br />
OTHER: YPSN<br />
Ypsomed is working with various leading international<br />
pharmaceutical companies to develop state-of-the-art<br />
cartridge-based pen injectors and syringe-based<br />
autoinjectors for a range of applications.<br />
CORPORATE MISSION<br />
Ypsomed is a worldwide leading independent developer and manufacturer of injection systems for custom-made self-administration and<br />
supplier of pen needles for the treatment of diabetes, growth disorders or infertility, as well as for further therapeutic areas. Ypsomed is<br />
headquartered in Burgdorf, Switzerland, and employs over 1000 employees at several production sites in Switzerland and throughout a<br />
European sales and distribution network.<br />
PROPRIETARY TECHNOLOGY<br />
Innovative and reliable devices for self-injection such as:<br />
Multidose pen injectors<br />
Autoinjectors<br />
Mono-dose injectors for dual-chamber cartridges<br />
Pen needles and safety pen needles<br />
Insulin infusion pumps<br />
CORPORATE ALLIANCES<br />
Ypsomed has well-established partnerships with numerous leading pharmaceutical and biotech companies such as Sanofi-Aventis, Eli<br />
Lilly, Pfizer, Roche/Genentech, Merck Serono, Amylin, Nycomed, Dongbao and others.<br />
INTELLECTUAL PROPERTY<br />
Ypsomed owns one of the largest IP portfolios in the field of self-injection devices covering the range of pen injectors, dual-chamber<br />
injectors and syringe based autoinjector systems<br />
PRODUCTS<br />
Name Phase Indication<br />
ServoPen (reusable multidose pen e.g. for insulin) On Market Diabetes, growth disorders, infertility, osteoporosis, others<br />
YpsoPen Twist (reusable multidose pen e.g. for insulin) Other Diabetes, growth disorders, infertility, osteoporosis, others<br />
UnoPen (disposable multidose pen e.g. for insulin) Other Diabetes, growth disorders, infertility, osteoporosis, others<br />
LyoTwist (disposable single-dose pen for dual-chamber<br />
cartridges)<br />
Other Diabetes, autoimmune, antiviral and cancer therapies, others<br />
YpsoJect (disposable auto-injector) Other Diabetes, autoimmune, antiviral and cancer therapies, others<br />
YpsoMate Other Diabetes, autoimmune, antiviral and cancer therapies, others<br />
SENIOR MANAGEMENT<br />
Richard Fritschi, Chief Executive Officer • Niklaus Ramseier, Chief Financial Officer • Simon Michel, Senior Vice President • Ian<br />
Thompson, Business Development<br />
BOARD OF DIRECTORS<br />
Willy Michel, Majority shareholder • Anton Kraeuliger, Board vice-chairman • Prof. Dr. rer. pol. Dr. h.c. mult. Norbert Thom, Board<br />
member • Gerhart Isler, Board member<br />
BIO Business Forum 2011 568 Participating Company <strong>Profiles</strong>
S.H. Choi, Y.S. Kim<br />
President & CEO<br />
49-6, Daebang-dong, Dongjak-gu<br />
Korea - South Korea<br />
CONFERENCE PARTICIPANTS<br />
Seola Kim<br />
Myung-Ho Bae<br />
Su Youn Nam<br />
Yuhan Corporation<br />
Clinical Foci: Gastroenterology • Metabolic Disease • Oncology<br />
www.yuhan.co.kr<br />
Phone: 82-2-828-0434<br />
HIGHLIGHTS<br />
Recent<br />
Jul. 2009: License agreement of Revanex for the India market.<br />
Mar. 2008: License agreement of Revanex for the China market.<br />
CORPORATE MISSION<br />
Incorporated: 1926<br />
Employees: 1500<br />
Ownership: Public<br />
Market Cap: $2116.00 million<br />
KOREA STOCK EXCHANGE: 000100<br />
Yuhan is one of the leading pharmaceutical company in Korea with the sales revenue of US$649 million in 2010. Yuhan has longstanding<br />
experience in R&D, production, marketing and sales since its foundation in 1926. We also have an extensive history of successful<br />
collaboration with global pharmaceutical companies. Yuhan has marketed its own NCE, Revanex, in Korea since Jan. 2007.<br />
PROPRIETARY TECHNOLOGY<br />
- Discovery & development of NCEs: Revanex(APA), 2nd generation APAs, IBS, diabetes.<br />
- Bio pharmaceuticals: RA Antibody, peptide drug (Degenerative disc disease, osteoarthritis)<br />
CORPORATE ALLIANCES<br />
JV Partners: Janssen, SP, Wyeth, Kimberly Clark etc.<br />
Licensing Partners: Gilead, SP, GSK, AZ, Grunenthal, Shire, Almirall, MTPC, DSP, Astra Tech etc.<br />
PRODUCTS<br />
Name Phase Indication<br />
Revanex On Market GU, DU, Gastritis<br />
APA Phase II, IIa, IIb GERD<br />
monoclonal antibody(anti-TNF alpha) Phase I Rheumatoid Arthritis<br />
YHD-1044 Phase II, IIa, IIb Premature Ejaculation<br />
Medi Fence Phase III Anti Adhesive Agent<br />
YH14618 Preclinical Degenerative Disc Disease<br />
YHD1023 Phase II, IIa, IIb Erectile Dysfunction<br />
YHD001 Phase II, IIa, IIb Asthma, anti-cough mucolytics<br />
YH14671 Phase II, IIa, IIb Type 2 Diabetes Mellitus<br />
YH14642 Phase II, IIa, IIb Chronic Periodontal Disease<br />
SENIOR MANAGEMENT<br />
S.H. Choi, Y.S. Kim, President & CEO<br />
BIO Business Forum 2011 569 Participating Company <strong>Profiles</strong>
Dr. Steffen Kammradt<br />
Chief Executive Officer<br />
Steinstrasse 104-106<br />
14480 Potsdam<br />
Germany<br />
CONFERENCE PARTICIPANTS<br />
ZAB Brandenburg Economic Development Board<br />
www.zab-brandenburg.de<br />
Phone: 49-331-660 3838<br />
Stefan Bauer, Dep. Director Health Care Industry/Life Sciences<br />
Ute Hartmann<br />
Incorporated: 2001<br />
Employees: 86<br />
Ownership: Private<br />
CORPORATE MISSION<br />
The Brandenburg Economic Development Board (ZAB) is the State of Brandenburg´s central contact point for investors, local companies<br />
and technology-orientated start-ups. The ZAB´s service profile includes financial, innovation, technological and foreign trade assistance,<br />
supporting technology transfer and company networks. We offer you all information on the business location Brandenburg and develop<br />
together with you tailor-made solutions. The ZAB works closely with the Investment Bank of the State of Brandenburg (ILB) an BC<br />
Brandenburg Capital GmbH. In this way we can offer our customers detailed consultancy about the funding available from the State of<br />
Brandenburg, from the Federal Government and the EU, as well as financing possibilities. Our objective is your success.<br />
PROPRIETARY TECHNOLOGY<br />
SENIOR MANAGEMENT<br />
Dr. Steffen Kammradt, Chief Executive Officer • Dr. Rolf Strittmatter, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Ralf Christoffers, Minister for Economic and European Affairs of the German Land of Brandenburg • Dr.-Ing. Victor Stimming (Dep.<br />
Chairman of the supervisory board), President of Potsdam Chamber of Commerce and Industry<br />
BIO Business Forum 2011 570 Participating Company <strong>Profiles</strong>
Mark H.N. Corrigan, MD<br />
President & CEO<br />
245 First Street<br />
Cambridge, MA 02142<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Mario Orlando<br />
Colin Moran<br />
Justin Renz<br />
Grant Zimmermann, VP, Strategic Alliances<br />
Zalicus Inc<br />
Presenting Company<br />
Clinical Foci: CNS • Musculoskeletal • Drug Discovery<br />
www.zalicus.com<br />
Phone: 1-617-425-7000<br />
Incorporated: 2000<br />
Employees: 55<br />
Ownership: Public<br />
Market Cap: $250.00 million<br />
NASDAQ: ZLCS<br />
CORPORATE MISSION<br />
Zalicus, Inc (ZLCS) is committed to advancing innovative therapeutics to treat pain and inflammation to improve the lives of patients.<br />
Zalicus creates value by discovering and advancing novel pharmaceutical products with the goal of establishing revenue generating<br />
partnerships. The company applies its combination drug discovery and selective ion channel modulation platforms, leveraging the power<br />
of cell-based systems, to generate innovative therapeutics. To learn more about Zalicus, please visit www.zalicus.com.<br />
PROPRIETARY TECHNOLOGY<br />
Zalicus has two unique technologies that fuel its product pipeline and revenue generating collaborations. cHTS provides a highthroughput<br />
capability to identify synergistic interactions between small-molecule drugs, or biologicals to better address the systems<br />
biology of disease, and can also be deployed to define genetic determinants of sensitivity to identify responder populations and<br />
companion diagnostics. Additionally, ZLCS is developing orally-available voltage-gated ion-channel modulators for the treatment of<br />
inflammatory and neuropathic pain. State-dependent modulators of either the Nav1.7 sodium channel or the N- and T-type calcium<br />
channels have the potential to produce a new class of analgesics with substantial safety and efficacy advantages relative to existing pain<br />
therapies.<br />
CORPORATE ALLIANCES<br />
Mallinckrodt, Inc, (Covidien) - The U.S. commercial rights to Zalicus' once-daily hydromorphone product, Exalgo, were acquired by<br />
Mallinckrodt in June '09.<br />
Fovea Pharmaceuticals SA - Prednisporin (FOV1101) was exclusively licensed to Fovea by ZLCS. Fovea was subsequently aquired by Sanofi-<br />
Aventis in 2009.<br />
Novartis Institutes for BioMedical Research - NVS and ZLCS have a strategic alliance focused on the discovery of novel anti-cancer<br />
combinations. Screening a unique library of molecules, including NVS compounds, in multiple cell lines representing a broad spectrum of<br />
cancers to discover novel single agent and combination therapies.<br />
Amgen Inc - ZLCS and AMGN entered a research collaboration to discover synergistic combinations for two oncology targets of interest to<br />
Amgen.<br />
PRODUCTS<br />
Name Phase Indication<br />
Synavive (Z-102) Phase II, IIa, IIb Rheumatoid Arthritis<br />
N-type Calcium Channel Blocker (Z-160) Phase I Pain<br />
T-type Calcium Channel Blocker (Z-944) Optimized Lead Pain<br />
Nav1.7 / SCN9A Slow-Inactivation Blockers Lead Series Pain<br />
Cav2.2 / N-type Calcium Channel Blockers Lead Series Pain<br />
SENIOR MANAGEMENT<br />
Mark H.N. Corrigan, MD, President & CEO • Christopher C. Gallen, MD, PhD, Executive Vice President • Terrance Snutch, PhD, Chief<br />
Scientific Officer • Justin Renz, Chief Financial Officer • Jason F. Cole, Esq, General Counsel<br />
BOARD OF DIRECTORS<br />
Frank Haydu, Independent Consultant • Mark H.N. Corrigan, MD, President & CEO, Zalicus Inc. • Sally W. Crawford, Healthcare<br />
Consultant • Todd Foley, Managing Director, MPM Asset Management LLC • Christopher C. Gallen, MD, PhD, Exec. Vice President R&D,<br />
Zalicus Inc. • Bill Hunter, MD, President & CEO, Angiotech Pharmaceuticals, Inc. • Michael G. Kauffman, MD, President & CEO,<br />
Karyopharm Therapeutics Inc. • W. James O'Shea, Former President & COO, Sepracor Inc. • Hartley T. Richardson, President & CEO,<br />
James Richardson & Sons, Ltd.<br />
BIO Business Forum 2011 571 Participating Company <strong>Profiles</strong>
David H. Solomon<br />
President & CEO<br />
Smedeland 36<br />
2600 Glostrup<br />
Denmark<br />
CONFERENCE PARTICIPANTS<br />
Arvind Hundal<br />
Marie Skovgaard<br />
Helle Storum<br />
Zealand Pharma A/S<br />
Clinical Foci: Metabolic Disease • Gastroenterology • Specialty Pharmaceutical<br />
www.zp.dk<br />
Phone: 45-88-773 600<br />
Incorporated: 1998<br />
Employees: 90<br />
Ownership: Public<br />
Market Cap: $300.00 million<br />
COPENHAGEN STOCK EXCHANGE: ZEAL<br />
HIGHLIGHTS<br />
Recent<br />
Zealand Pharma was listed on the Danish Stock Exchange in November 2011 raising gross proceeds of USD 70 million<br />
CORPORATE MISSION<br />
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and<br />
growing pipeline of novel peptide drugs. The company's lead product candidate is Lyxumia® (lixisenatide), a once-daily GLP-1 completing<br />
Phase III development for the treatment of type 2 Diabetes under collaboration with Sanofi. Zealand Pharma also has other collaboration<br />
and licensing partnerships, including a license agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of<br />
Chemotherapy and Radiotherapy Induced Diarrhea.<br />
Zealand Pharma have unique expertise in peptide discovery and optimization and specialize in the development of novel peptide drug,<br />
targeting disease areas, where existing treatments fail to adequately serve patient needs and where the market potential for improved<br />
treatments through the use of peptide drugs is high. All of Zealand Pharma's product candidates have been identified through the<br />
company's own drug discovery activities.<br />
PRODUCTS<br />
Name Phase Indication<br />
Lyxumia Phase III Type 2 Diabetes<br />
Lyxumia + Lantus Phase I Type 2 Diabetes<br />
ZP2929 Preclinical Type 2 Diabetes and Obesity<br />
ZP1848 Phase I Infalmmatory Bowel Disease<br />
ZP1846 Phase I Chemotheapy Induced Diarrhea<br />
Danegaptide Phase I Atrial Fibrillation<br />
ZP1480/AP214 Phase II, IIa, IIb Acute Kidney Injury<br />
SENIOR MANAGEMENT<br />
David H. Solomon, President & CEO • Mats Blom, Chief Financial Officer • Christian Grøndal, Chief Scientific Officer • John Hyttel,<br />
Chief Operating Officer • Arvind Hundal, Chief Business Officer • Hanne Leth Hillmann, Investor Relations<br />
BOARD OF DIRECTORS<br />
Daniel Jan Ellens, Partner at Life Sciences Partners, Amsterdam • Jørgen Lindegaard, Independent Board member • Peter Benson,<br />
Managing Partner of Sunstone Capital • Alain Munoz, AGF Private Equity • Florian Reinaud, Partner at CDC Innovation • Jutta af<br />
Rosenborg, Independent Board Member • Christian Thorkildsen, Employee Representative • Helle Størum, Employee Representative<br />
BIO Business Forum 2011 572 Participating Company <strong>Profiles</strong>
via Petrella 22<br />
20124-Milano<br />
Italy<br />
CONFERENCE PARTICIPANTS<br />
Marija Zecevic<br />
CORPORATE MISSION<br />
Zebra Ventures S.r.L.<br />
Phone: 39-02-2104 7411 Ownership: Private<br />
Zebra Ventures, a boutique consultancy firm, addresses the overwhelming need in the start up biotech sector to build and realize<br />
commercial value out of scientific excellence. Zebra Ventures is a complete service provider with an established network of experts that<br />
have a proven track record in all functional areas that are on the critical path for commercializing therapeutics. This approach makes<br />
Zebra Ventures the partner of choice to a variety of stakeholders including innovative life-science companies, investors, researchers,<br />
entrepreneurs and governmental agencies.<br />
CORPORATE ALLIANCES<br />
Areta International (Italy), National Tumor Institute (Milan, Italy), undisclosed US private biotech<br />
BIO Business Forum 2011 573 Participating Company <strong>Profiles</strong>
K. Hashimoto<br />
Chief Executive Officer<br />
33-7, Ohizumi-Machi 2-Chome, Nerima-Ku<br />
Tokyo 178-0062<br />
Japan<br />
CONFERENCE PARTICIPANTS<br />
Ryogo Yui, Director<br />
Zenyaku Kogyo Co., Ltd.<br />
Clinical Foci: Oncology • Infectious Disease • AutoImmune<br />
www.zenyaku.co.jp<br />
Phone: 81-3-3922-5131<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Incorporated: 1950<br />
Employees: 700<br />
Ownership: Private<br />
Zenyaku looks for antibodies and small molecule drugs in oncology. Therapeutics for lymphoma in preclinical or phase 1stage.<br />
Antibodies for solid tumors.<br />
CORPORATE MISSION<br />
Zenyaku Kogyo (Zenyaku) is a Tokyo-based pharmaceutical company focuced on acquiring and developing innovative therapuetic<br />
products in the field of oncology, hematology, immunology, CNS and infectious diseases. It also has an OTC consumer health care<br />
business.<br />
CORPORATE ALLIANCES<br />
Zenyaku is the exclusive licensee of Rituxan, an anti-CD20 mAb, in Japan. In March 2010, it signed a license-in agreement on certain<br />
influenza program with a Seattle-based bio-pharmaceutical company, Theraclone Sciences, Inc.<br />
PRODUCTS<br />
Name Phase Indication<br />
Rituxan On Market Anti-CD20 monoclonal antibody<br />
ZSTK-474 Phase I PI3K inhibitor<br />
SENIOR MANAGEMENT<br />
K. Hashimoto, Chief Executive Officer • Jumpei Enami, PhD, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
K. Hashimoto, CEO • K. Hashimoto, CEO • J. Enami, CSO • K. Kitagawa, Executive Director • T. Okamura, Managing Director<br />
BIO Business Forum 2011 574 Participating Company <strong>Profiles</strong>
Andoni Cruz<br />
Chief Executive Officer<br />
Pol. Marismas No 5<br />
39740 Santona Cantabria<br />
Spain<br />
CONFERENCE PARTICIPANTS<br />
Antonio Cruz Pacheco<br />
Roberto Hernan, PhD<br />
ZF BIOTOX<br />
Clinical Foci: Drug Discovery • Biopharmaceuticals • Other<br />
www.zfbiotox.com<br />
Phone: 34-610-958 858<br />
Incorporated: 2010<br />
Employees: 4<br />
Ownership: Private<br />
CORPORATE MISSION<br />
ZF BIOTOX is committed to develop innovative High Throughput Screening (HTS) tools that aim to add value and reduce costs in the drug<br />
discovery segment.<br />
ZF BIOTOX is also engaged in developing novel in vivo HTS technologies to help reducing the current high attrition rate in drug<br />
development, using the solid emerging zebrafish model.<br />
PROPRIETARY TECHNOLOGY<br />
Among ZF BIOTOX´s assets, we have developed proprietary in vitro technologies that provide frozen cells in microplates ready-to-use in<br />
cell-based assays, reducing this way the cell culturing time and costs associated to cell handling. Furthermore, we have also developed an<br />
innovative microplate design that enables an effective, fast, safe and economic microplate washing solution without the use of any pins,<br />
reducing this way the time and costs associated to liquid handling in the HTS industry.<br />
INTELLECTUAL PROPERTY<br />
European patent application for the technology that allows freezing cells in microplates.<br />
Spanish patent application for a tubeless washing plate design.<br />
PRODUCTS<br />
Name Phase Indication<br />
Cell in well Other Cell-based assays for drug discovery<br />
Evacuum Research Tubeless microplate washing design<br />
SENIOR MANAGEMENT<br />
Andoni Cruz, Chief Executive Officer • Roberto Hernan, Chief Scientific Officer<br />
BIO Business Forum 2011 575 Participating Company <strong>Profiles</strong>
Jonathan Lewis, MD, PhD<br />
Chief Executive Officer<br />
One First Avenue<br />
Boston, MA 02129<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Steven Bloom<br />
Richard Bagley<br />
ZIOPHARM Oncology, Inc<br />
Presenting Company<br />
Clinical Foci: Oncology • Gene/Cell Therapy<br />
www.ziopharm.com<br />
Phone: 1-617-259-1978<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Three financings in past 10 months has significantly improved the<br />
cash position of the company and allows for further development<br />
of late stage pipeline<br />
Two partnering deals during Q1'11 have validated current asset<br />
(darinaparsin) and company as a drug development engine.<br />
Palifosfamide is currently enrolling the Phase III soft tissue sarcoma<br />
trial (PICASSO 3) and has almost completed the Phase I trial in<br />
anticipation of beginning a Phase II trial in small cell lung cancer<br />
Incorporated: 2004<br />
Employees: 50<br />
Ownership: Public<br />
Market Cap: $420.00 million<br />
NASDAQ: ZIOP<br />
Anticipated completion of enrollment in palifosfamide Phase III<br />
soft tissue sarcoma trial (PICASSO 3) by 12/30/11and beginning of<br />
Phase II small cell lung cancer trial during Q4'11<br />
Begin enrollment of darinaparsin pivotal trial in peripheral T-cell<br />
lymphoma during Q4'11<br />
CORPORATE MISSION<br />
ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse group of cancer<br />
therapeutics. The company is focused on several clinical programs and our mission is:<br />
1. To advance patient treatment in cancer<br />
2. To apply new insights from molecular and cancer biology to understand<br />
how to improve the efficacy and safety of cancer medicines<br />
3. To develop therapies for diseases of high unmet medical need<br />
CORPORATE ALLIANCES<br />
1. Intrexon Corporation, Germantown, MD<br />
2. Solasia Pharma, Tokyo, Japan<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
Palifosfamide Phase III Soft tissue sarcoma, small cell lung<br />
cancer (Ph 1)<br />
Complete enrollment in sarcoma trial by<br />
12/30/11<br />
Darinaparsin Phase II, IIa, IIb Peripheral T cell Lymphoma Begin pivotal Trial in Fall of 2011<br />
Indibulin Phase I Breast Cancer Complete Phase I/II Trial<br />
SENIOR MANAGEMENT<br />
Jonathan Lewis, MD, PhD, Chief Executive Officer • Richard Bagley, President • Mark Thornton, MD, PhD, Executive Vice President •<br />
Robert Morgan, JD, PhD, Senior Vice President • Mike King, Senior Vice President • Bob Newman, Senior Vice President • Brian<br />
Hamilton, MD, PhD, Chief Scientific Officer • Chris Smyth, PhD, MBA, Senior Vice President • Steven Bloom, Vice President • Chris<br />
Piper, Vice President<br />
SCIENTIFIC ADVISORY BOARD<br />
James Armitage, MD, University of Nebraska Medical Center • Joseph Bertino, MD, Institute of New Jersey • George Demetri, MD,<br />
Dana Farber Cancer Institute/Harvard Medical School • Lawrence Einhorn, MD, Indiana University • Alan Houghton, MD, Memorial<br />
Cloan-Kettering Cancer Center • Alberto Pappo, MD, St. Jude Research Hospital • John F. Smyth, MD, University of Edinburgh Medical<br />
School • David Spriggs, MD, Memorial Sloan-Kettering Cancer Center<br />
BIO Business Forum 2011 576 Participating Company <strong>Profiles</strong>
David Perryman<br />
Chief Executive Officer<br />
1384 Buford Business Blvd., N.E.<br />
Buford, GA 30518-9206<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
David E. Huizenga, JD, PhD<br />
Zirus, Inc.<br />
Clinical Foci: Infectious Disease • Drug Discovery • Biodefense<br />
www.zirus.net<br />
Phone: 1-770-601-9356<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Identification of small molecules having activity against ebola and<br />
dengue<br />
Validation of complete RSV target platform<br />
Validation of Vaccine overproduction concept<br />
Major corporate deal<br />
Formation of Vaccine partnership<br />
Lead molecules for Dengue identified<br />
Incorporated: 2007<br />
Employees: 5<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Our mission is to provide keys to conquer viruses. Zirus provides a unique and extensive platform of host targets and an efficient process<br />
for finding additional targets and drugs to treat viruses for which we do not have effective vaccines. These host targets collectively provide<br />
the foundation to develop completely novel antiviral agents to treat virtually any commercially relevant virus, pandemic virus, neglected<br />
disease virus, or bioterrorist designed virus.<br />
PROPRIETARY TECHNOLOGY<br />
Zirus has exclusive rights to hundreds of human host gene targets that provide an extensive platform for blocking viral infection. Zirus<br />
scientists are currently using the cost effective and efficient gene trap to discover on average one additional gene target each day. These<br />
numbers greatly increase the potential for success in creating new blockbuster antiviral drugs including repurposed drugs.<br />
Inhibiting these targets blocks infection of all commercially important viruses tested to date in vitro. The targets provide a platform to<br />
develop drugs to block pandemic flu. The targets also provide an extensive platform for the development of broad spectrum antivirals<br />
(Zirus Antivirotics) for the treatment and prevention of virtually any virus created by nature or by a terrorist.<br />
CORPORATE ALLIANCES<br />
Given the broad platform of targets and potential antiviral drugs, it is most efficient and practical for Zirus to collaborate with the many<br />
experts in viruses and drug discovery and development. Zirus currently has collaborations/ agreements with the Brigham & Women's<br />
Hospital (Harvard afflliate), Centers for Disease Control and Prevention (CDC), National Institutes of Health/ National Institute of Allergy<br />
and Infectious Disease (NIH/NIAID) BioDefense, SouthWest Foundation, University of Texas Medical Branch at Galveston, Vanderbilt<br />
University, drug discovery research organizations, and companies in the biotech industry. Zirus is actively seeking additional<br />
collaborations to maximize the chance of success and value of its platform.<br />
INTELLECTUAL PROPERTY<br />
Twenty percent of the Zirus’s veteran workforce is devoted to patents and patent strategy. Broad protection of the Zirus platform in ways<br />
made available by the science and case law is a company mandate.<br />
The result is a broad, international, multilayered and constantly expanding portfolio of patents, patent applications and trade secrets to<br />
protect the Zirus assets.<br />
The various layers of Zirus patent protection fall into several general categories including gene trap, targets, the screening of drugs to the<br />
targets, methods to prevent infection, and drugs that bind the targets and prevent viral infection. Since these categories provide<br />
independent and overlapping protection, the combination provides more certainty and value to the company.<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
100+ of Host targetss Target Validated Influenza Drug discovery<br />
100+ Host Targets Target Validated RSV Drug discovery<br />
Repurposed Drugs On Market Influenza Approval for Influenza<br />
100+ Host targets Target Validated Pox Drug discovery<br />
110+ host targets Target Validated Rhinovirus Common Cold Drug discovery<br />
100+ Host Targets Target Validated Dengue Virus Drug discovery<br />
Host targets Pre-Target Validation Plague drug discovery<br />
Host targets Pre-Target Validation HCV<br />
Virus resistant animals Research Agriculture Animal development<br />
BIO Business Forum 2011 577 Participating Company <strong>Profiles</strong>
PRODUCTS<br />
Name Phase Indication Milestone<br />
Vaccine Production Research Systems for enhanced vaccine production Scale up<br />
SENIOR MANAGEMENT<br />
David Perryman, Chief Executive Officer • James Kelly, PhD, Chief Scientific Officer • David E. Huizenga, PhD, Chief Technology Officer<br />
• Tom O'Toole, Business Development<br />
BOARD OF DIRECTORS<br />
MARK S. GERMAIN, Merchant Banker • DON RUBIN, MD, Vanderbilt University • ANDREW SORENSEN, PHD, University of South<br />
Carolina. • JOHN P. RICHARD, Georgia Venture Partners, • DAVID PERRYMAN, President & CEO and a founder of Zirus<br />
SCIENTIFIC ADVISORY BOARD<br />
Dennis C. Liotta, PhD, Emory University • Christine Debouck, PhD,, Biotechnology Consultant • Eric Freed, PhD, NIH/NCI • T. (Teo)<br />
Forcht Dagi, M.D, HLM Venture Partners • Tom Folks, PhD, Southwest Foundation for Biomedical Research<br />
BIO Business Forum 2011 578 Participating Company <strong>Profiles</strong>
François Miceli<br />
Chief Executive Officer<br />
c/o Sofimac Partners<br />
69001 Lyon<br />
France<br />
CONFERENCE PARTICIPANTS<br />
François Miceli<br />
CORPORATE MISSION<br />
Zophis<br />
Clinical Foci: Vaccines • Infectious Disease • Biopharmaceuticals<br />
Newly incorporated, Zophis is seeking to in-license preclinical vaccine projects<br />
FINANCING HISTORY<br />
Most Recent Round: Seed Round<br />
Seed Round: 03/01/2011 (US $0.75 million)<br />
SENIOR MANAGEMENT<br />
François Miceli, Chief Executive Officer<br />
BOARD OF DIRECTORS<br />
Michel Finance<br />
Phone: 33-6-7369 12373 Ownership: Private<br />
BIO Business Forum 2011 579 Participating Company <strong>Profiles</strong>
Gail Schulze<br />
Chief Executive Officer<br />
34790 Ardentech Court<br />
Fremont, CA 94555<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Gail Schulze, CEO<br />
John Wulf, Head of Business Development<br />
Zosano Pharmaceutical, Inc<br />
Clinical Foci: Drug Delivery • Metabolic Disease • Hematology<br />
www.zosanopharma.com<br />
Phone: 1-510-745-1200<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Zosano entered in to a substantial Asian partnership for the ZP-PTH<br />
patch (parathyroid hormone) for treatment of severe osteoporosis<br />
in Q1 2011 with a partner to be disclosed in Q4.<br />
Vaccine collaboration (with undisclosed big pharma company)<br />
mAb collaboration (with undisclosed big pharma company )<br />
Incorporated: 5<br />
Employees: 20<br />
Ownership: Private<br />
Execute US and EU partnership(s) for ZP-PTH patch.<br />
Execute partnerships around ZP patch technology for delivery of<br />
EPO and GCSF.<br />
Execute technology collaborations around ZP microneedle patch<br />
with partners.<br />
CORPORATE MISSION<br />
Zosano was spun out of JNJ in 2006 around its microneedle transdermal patch delivery technology that was developed over a period of 8<br />
years by ALZA. The company has demonstrated success with the patch through its development of ZP-PTH patch (microneedle delivery of<br />
parathyroid hormone) which is has been partnered in Asia and is advancing to Ph III clinical trials.<br />
PROPRIETARY TECHNOLOGY<br />
The ZP transdermal microneedle patch is the most advanced microneedle patch delivery technology and can be used for transdermal<br />
delivery of small molecules, peptides, proteins, mAbs and vaccines. It offers single step therapeutic drug delivery, high patient acceptance,<br />
is user friendly, and is cost effective. We have a highly validated technology platform with successfull Ph II study results (in an out-patient<br />
setting) and GMP Ph III manufacturing established.<br />
CORPORATE ALLIANCES<br />
Zosano's lead program ZP-PTH (microneedle delivery of parathyroid hormone) is partnered in Asia. We are seeking partners for the US, EU<br />
and ROW. Collaborations are ongoing around undisclosed mAb and vaccine programs with partners. All partners are currently<br />
undisclosed.<br />
INTELLECTUAL PROPERTY<br />
Zosano has FTO and an extensive IP position around the ZP microneedle patch consisting of 20 patent families with IP protection through<br />
at least 2025<br />
PRODUCTS<br />
Name Phase Indication Milestone<br />
ZP-PTH Microneedle Patch Phase III Severe osteoporosis Initiate Ph III/Seeking US and EU<br />
partner(s)<br />
EPO Preclinical Cancer, delivery of EPO by ZP-Microneedle Patch<br />
Technology<br />
Seeking partner(s)<br />
GCSF Preclinical Cancer, delivery of GCSF by ZP-Microneedle Patch<br />
Technology<br />
FINANCING HISTORY<br />
Seeking partner (s)<br />
Investors: NEA Ventures (0 %) • Phase4 Ventures (0 %) • ProQuest Investments (0 %) • HBM BioVentures (0 %) •<br />
JNJ-ALZA (0 %)<br />
SENIOR MANAGEMENT<br />
Gail Schulze, Chief Executive Officer • Peter Daddona, Chief Scientific Officer • Thorsten von Stein, Chief Medical Officer • John Vuko,<br />
Chief Financial Officer • John Wulf, Business Development<br />
BOARD OF DIRECTORS<br />
Gail Schulze, Zosano Pharma • James Barrett, New Enterprise Associates • John Richard, Phase4 Ventures • Jee Shin, ProQuest<br />
Investments<br />
BIO Business Forum 2011 580 Participating Company <strong>Profiles</strong>
Dr. Surjit Dixit<br />
Chief Technology Officer<br />
#540-1385 West 8th Ave<br />
Vancouver, BC V6H 3V9<br />
Canada<br />
CONFERENCE PARTICIPANTS<br />
Zymeworks Inc<br />
Clinical Foci: Biopharmaceuticals • Drug Development • Immunology<br />
www.zymeworks.com<br />
Phone: 1-604-678-1388<br />
David Poon, PhD, Sr. Manager, External R&D and Business Development<br />
HIGHLIGHTS<br />
Recent Upcoming<br />
Zymeworks successfully achieved novel modulation of the<br />
specificity of the antibody Fc to Fc-gamma receptors leading to the<br />
filing of novel biological IP on functionally differentiated Fc<br />
constructs.<br />
Zymeworks Closes $3.2 Million Round of Financing and Announces<br />
the Addition of Dr. Donald Drakeman (former CEO of Medarex) to<br />
its Board of Directors.<br />
Zymeworks has entered into a research agreement with XOMA<br />
(Nasdaq: XOMA) to optimize an undisclosed antibody using<br />
Zymeworks’ ZymeCAD suite of predictive protein engineering<br />
tools.<br />
Incorporated: 2004<br />
Employees: 30<br />
Ownership: Private<br />
Zymeworks expected to release in vitro and ex vivo results of its<br />
multivalent antibodies based on the proprietary Azymetric Fc<br />
scaffolds in Q3 2011.<br />
Zymeworks expected to release in vitro and ex vivo results of a<br />
novel class of multivalent protein therapeutic in Q3 2011.<br />
Zymeworks expected to close its Series A round of financing in Q3<br />
2011.<br />
CORPORATE MISSION<br />
Zymeworks is seeking to establish strategic collaborations with leading pharmaceutical and biotechnology companies in the design and<br />
development of novel monoclonal antibodies and other classes of protein therapeutics.<br />
Zymeworks is focused on leveraging its proprietary Azymetric IgG1 antibody scaffold in the research and development of multivalent<br />
antibodies. These are designed to have bispecific antigen binding while retaining natural Fc functionalities where specific effector<br />
functions can be customized along with improved serum half-life and stability. In addition, Zymeworks continues to be interested in<br />
partnering on Fc modifications for monospecific antibodies in the areas of effector function, serum half-life, and stability improvements.<br />
Zymeworks is a computational biotechnology company with proprietary structure-guided technologies for the predictive engineering and<br />
optimization of antibodies and protein therapeutics.<br />
PROPRIETARY TECHNOLOGY<br />
Zymeworks has developed a proprietary molecular simulation platform that relates a protein’s function and biophysical characteristics to<br />
its structure. This insight allows Zymeworks to make knowledge-based modifications to the protein that result in new or improved<br />
functional properties leading to more efficacious drugs.<br />
In the design of novel cross-reactive antibodies and the improvement of ADCC, Zymeworks’ platform has the distinctive advantage in the<br />
optimization of multiple interdependent biophysical properties (affinity, selectivity, stability, effector function) on one protein framework.<br />
Zymeworks has the ability to design complex mutations (multiple simultaneous changes) and compensating mutations that take into<br />
account cooperativity and distal effects using the full-length mAb<br />
CORPORATE ALLIANCES<br />
Zymeworks has a collaboration with XOMA for the optimization of an antibody using Zymeworks' structure-guided protein engineering<br />
technology.<br />
Zymeworks has a collaboration with Angelica Therapeutics involving the optimization of a protein therapeutic for the treatment of<br />
mantle cell lymphoma.<br />
Zymeworks has a collaboration with Simon Fraser University for the optimization of a peptide for use as an anti-infective and vaccine.<br />
INTELLECTUAL PROPERTY<br />
Zymeworks has granted and pending patents on both proprietary computational algorithms and functionally differentiated antibody<br />
constructs.<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Seed Round: 01/01/2008 (US $3.50 million)<br />
SENIOR MANAGEMENT<br />
Dr. Surjit Dixit, Chief Technology Officer • Mr. Neil Klompas, Chief Financial Officer • Dr. Ali Tehrani, President & CEO • Mr. David<br />
Tucker, Chief Operating Officer<br />
BIO Business Forum 2011 581 Participating Company <strong>Profiles</strong>
BOARD OF DIRECTORS<br />
Mr. Nick Bedford, Former head of German Equities, UBS Warburg • Dr. Donald Drakeman, Venture Partner, Advent Venture Partners •<br />
Mr. Haig Farris, President, Fractal Capital Corp. • Mr. Kenneth Galbraith, General Partner, Ventures West Management • Mr. Noel<br />
Hall, Former Co-founder & President of Aspreva Pharmaceuticals • Dr. Patrick McCroskey, Principal, TPG Biotech • Dr. Ali Tehrani,<br />
President and CEO, Zymeworks Inc. • Dr. Shermaine Tilley, Partner, CTI Life Sciences Fund • Mr. Amos Michelson, Observer • Dr.<br />
Andrew S. Wright, Observer<br />
SCIENTIFIC ADVISORY BOARD<br />
Michael J. Gresser, PhD (SAB Chairman), CSO, Oxford BioTherapeutics • C. Geoffrey Davis, PhD, President & CEO of Angelica<br />
Therapeutics • Richard Lavery, PhD, Head, Dept. of Molecular Biostructures - Institute de Biologie et Chimie des Proteines • Mihaly<br />
Mezei, PhD, Assoc. Professor and Director of Molecular Modeling Core, Mt. Sinai School of Medicine • Bruce Tidor, PhD, Professor,<br />
Biological Engineering and Computer Science, MIT<br />
BIO Business Forum 2011 582 Participating Company <strong>Profiles</strong>
Peter A. Kiener, DPhil<br />
President & CEO<br />
21 Firstfield Road<br />
Gaithersburg, MD 20878<br />
USA<br />
CONFERENCE PARTICIPANTS<br />
Joseph L. Amprey, MD, PhD<br />
Peter A. Kiener, D.Phil.<br />
Houman Mesghali<br />
Zyngenia, Inc<br />
Clinical Foci: Oncology • Immunology • AutoImmune<br />
www.zyngenia.com<br />
Phone: 1-301-990-4800<br />
Employees: 30<br />
Ownership: Private<br />
CORPORATE MISSION<br />
Zyngenia utilizes proprietary technology to create multi-specific, antibody-like therapeutics called Zybodies. We achieve multi-specificity<br />
by recombinantly fusing short target-binding peptides to the N- and C- termini of the heavy and/or light chains of any conventional mAb.<br />
The resulting Zybodies bivalently bind each of up to 5 distinct targets while retaining the specificity, efficacy, half-life, and effector<br />
functions of the parental mAb.<br />
PROPRIETARY TECHNOLOGY<br />
Traditional mAbs target single antigens whereas diseases are often caused by multiple components or pathways that cannot be fully<br />
addressed through a single specificity. Zyngenia’s solution is to engineer a single molecule therapeutic known as a Zybody, that has the<br />
desired properties of a mAb but is able to simultaneously target several known mediators of a disease and – through this – allow for better<br />
disease intervention with the cost and development paradigm of a single agent.In addition to creating more potent and broadly acting<br />
therapeutics, this technology will allow us to also create exquisitely selective molecules that are able to recognize subsets of cells that<br />
cannot be selectively recognized by conventional mAbs that only have a single specificity.<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Round A: 09/28/2009 (US $25.00 million)<br />
SENIOR MANAGEMENT<br />
Peter A. Kiener, DPhil, President & CEO • Joseph L. Amprey, III, MD, PhD, Chief Business Officer • David Hilbert, PhD, Vice President<br />
BOARD OF DIRECTORS<br />
Dave Mott, NEA • Carlos F. Barbas, III, PhD, Scripps Research Institute • Robert Garland, MD, NEA • Peter A. Kiener, DPhil, Zyngenia<br />
SCIENTIFIC ADVISORY BOARD<br />
William Matsui, MD, The Johns Hopkins University Hospital • Richard McCloskey, MD, Former Chief Medical Officer at Centocor •<br />
David Parkinson, MD, President and CEO, Nodality, Inc. • George Sledge, MD, President, American Society of Clinical Oncology •<br />
Stephan Targan, MD, UCLA School of Medicine • Terry Gerrard, Former Dir. of the FDA Division of Protein Therapeutics<br />
BIO Business Forum 2011 583 Participating Company <strong>Profiles</strong>
Karl Altenhuber<br />
Chief Executive Officer<br />
Stadiongasse 2/13<br />
1010 Wien Vienna<br />
Austria<br />
CONFERENCE PARTICIPANTS<br />
Karl Altenhuber, CEO<br />
Christoph Aufricht<br />
Zytoprotec Gmbh<br />
Clinical Foci: Renal • Drug Discovery • Drug Development<br />
Phone: 43-1406-2002 Ownership: Private<br />
HIGHLIGHTS<br />
Recent<br />
PD-Protec has entered the first clinical phase in the first quarter of 2011.<br />
In March 2011 Zytoprotec has been financed by Quantensprung, an Austrian finance provider.<br />
Zytoprotec's Advisory Board has reorganized itself, among the new members are: Prof A. v. Gabain (Intercell AG), Dr. Peter Rutherford<br />
(Baxter Healthcare SA, Zurich) and Prof. Dr. Achim Jörres (Charité-Universitätsmedizin Berlin).<br />
CORPORATE MISSION<br />
Zytoprotec is a biotech company with focus on "cell protection/cell reparation" founded in 2007. Its current focus is cytoprotection with its<br />
first product "PD-Protec" - an innovative product for renal failure. PD-Protec has entered the clinical phase in the first quarter of 2011.<br />
Further products/research in the field of cytoprotection are planned.<br />
10-year-goal: "To become the leading cell repair company!"<br />
PROPRIETARY TECHNOLOGY<br />
Zytoprotec develops therapies that enhance/restore the cellular stress response mechanism (cytoprotection). Inadequate stress response<br />
and subsequent cell degeneration are important factors in the pathomechanisms of clinically highly relevant diseases, such as diabetes<br />
and hypertension.<br />
CORPORATE ALLIANCES<br />
Zytoprotec currently holds strategic partnerships with the Medical University of Vienna (Department of pediatric and adolescent<br />
medicine) and Universities in Amsterdam and Berlin. It supported by a scientific brain trust (Prof. Dr. Arnold Pollak, Medizinische<br />
Universität Wien; Prof. Dr. Michael Kashgarian, Yale University School of Medicine.<br />
INTELLECTUAL PROPERTY<br />
Zytoprotec has filed for an international patent covering the use of the cytoprotective compound of PD-protec in peritoneal dialysis. The<br />
European patent is expected to be granted soon.<br />
PRODUCTS<br />
Name Phase Indication<br />
PD-Protec Phase I Kidney Failure<br />
FINANCING HISTORY<br />
Most Recent Round: Other<br />
Seed Round: 02/26/2007 (US $2.03 million)<br />
Round A: 11/01/2007 (US $1.09 million)<br />
Investors: H2i-help to innovate GmbH (100 %)<br />
SENIOR MANAGEMENT<br />
Karl Altenhuber, Chief Executive Officer • Prof.Dr.Christoph Aufricht, Chief Scientific Officer<br />
BOARD OF DIRECTORS<br />
Dr. Christian Hoenig, Legal Advisor<br />
Round B: 10/03/2009 (US $1.36 million)<br />
Round C: 03/01/2010 (US $0.54 million)<br />
SCIENTIFIC ADVISORY BOARD<br />
Prof. Dr. Robert H.J. Beelen, Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam •<br />
Professor Dr. Nicholas Topley, Sub-Dean (Operations), Cardiff University, School of Medicine • Dr Peter Rutherford, Medical Director<br />
(Renal) - Europe, Middle East and Africa, Baxter Healthcare SA, Zurich • Prof. Dr. Manuel López-Cabrera, Unidad de Biología Molecular,<br />
Hospital Universitario de la Princesa, Madrid • Prof. Dr. Achim Jörres, Komm. Direktor, Med. Klinik m.S. Nephrologie und internistische<br />
Intensivmedizin, Charité-Universitätsmedizin Berlin Camp • Prof. Dr. Janusz Witowski, Department of Pathophysiology, Poznan<br />
University of Medical Sciences, Collegium Anatomicum, Poland • Univ. Doz. Dr. Bernd Mayer, Managing Partner, emergentec<br />
biodevelopment GmbH, Vienna • Prof. Dr. Piet M. ter Wee, Professor of Nephrology, Department of Nephrology, VU University Medical<br />
Center, Amsterdam • Prof. A. Pollak, Medizinische Universität Wien<br />
BIO Business Forum 2011 584 Participating Company <strong>Profiles</strong>
Change language